{
    "0": {
        "output": "After getting the list of existing clinical trials, we can define the feature list for each study using a specific feature list template in SPSS. The example template of feature list for trial studies is available in the link [here](http://www.opencl",
        "label": 0
    },
    "1": {
        "output": "[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n## Scales of eligibility for patients and trials \nYou should determine the eligibility of the patient in the patient note on each line. You should evaluate the compatibility between the patient's data and the clinical trial's inclusion/exclusion criteria; a patient can be excluded from the trial on the grounds of its exclusion criteria. You should always check if all patients are eligible for the clinical trial. If all of the patients are eligible for the trial, output the corresponding number of the eligible patients.\n\nHere is the patient note:\n\n# Your Tasks\n\n## Input:\n--A patient note in the START file format.\n--A clinical trial in the START file format.\n\n## Output:\n--An eligible/not eligible assessment of patients and a corresponding number for the eligible patients for the clinical trial.\n\n\n\n\n\n## Concept\nHere is the general method of the assessment of trial-level eligibility. First, you should check whether a patient is eligible for the trial with this trial-level eligibility assessment:\n- Eligible: A patient is suitable for this trial.\n- Not eligible: A patient is not suitable for this trial.\n\n![Evaluation_of_trial_level_eligibility]\n\n## Example\nHere is an example of assessment of trial-level eligibility. First, check trial-level eligibility in each line, such as  `Trial-level eligibility: 0) Excluded. `(lines 1-8). After assessing trial-level eligibility, you should determine the number of the eligible patient. Finally, you should output the corresponding number of the eligible patients in the clinical trial. \n\n\n## Example\n\n\n\n---\n# <NAME>",
        "label": 0
    },
    "2": {
        "output": "```python\n[000460]\n[ELIGIBILITY]\n## Exclude if already randomized\n[ELIGIBILITY]\n- exclude_if: [ 'AlreadyRandomized_Patient' ]\n[ELIGIBILITY]\n## Include ineligibility\n[ELIGIBILITY]\n- include_ineligibility: [ \n            \"Excluded\",\n            \"Not relevant\" ]\n```\n\nPlease, check the **Output** section from the notebook file. The patient note will be compared with the inclusion criteria of a clinical trial and the trial-level eligibility will have shown three possibilities: (0) Excluded, i.e., the patient meets inclusion criteria of a clinical trial, but is excluded on the grounds of the trial's exclusion criteria; (1), Not relevant, i.e., the patient does not have sufficient information to qualify for the trial; and (2), Eligible, i.e., the patient meets inclusion criteria and exclusion criteria do not apply.\n\n<h2 id=\"4f914b45c558d532e9b64ba251ad6d091151eb9e562c6bdb2caf689f67bfed6d9\">Question 2</h2>\n\nYou have to evaluate whether the patients' status is relevant for the clinical trial.\n\n[INST] Hello. You are a clinical trial assistant working with a clinical trial that is not a blinded trial. For a patient to be randomized to the clinical trial (i.e., to be allowed to participate in the clinical trial), there is one inclusion/exclusion criteria that all the patients in the clinical trial should meet: The patients should use contraceptive methods or abstain from sexual activity throughout the duration of the clinical trial.\n\n[ELIGIBILITY]\n## Include inclusion/exclusion criteria\n[ELIGIBILITY]\n- include_inclusion_exclusion_criteria: \"[Clinical trial's inclusion/exclusion criteria]\"\n\n```\n    [000009]\n    [ELIGIBILITY]\n    ##",
        "label": 0
    },
    "3": {
        "output": "## Problem 2\nIn the end, make it clear what to do, like this: `Then add the number of each eligibility level to trial-level eligibility as follows.` You can use `append(int(text_eligibility_text), int(text_eligibility))`. In the end, you can print out the result. `trial_level_eligibility_str = `trial_level_eligibility_str + `text_trial_level_eligibility + `txt_trial_level_eligibility` +```. print(trial_level_eligibility_str)`, `print(res)` and `end`. \n\n## Potential solution\nBefore `print(res)`, just add the word `s` before word `list`. That is, `print(res.s)` to make sure the output to be list type.\n\n## Potential solution\nThe output can be a string or a list. It is recommended to use `print(res.s.str)`.\n\n## Potential solution\nYou might not able to use the raw_input in Jupyter Notebooks. In this case, it is recommended to use the input or read_line in the same module as pandas.text_indexer.text_eligibility. For example, `text_eligibility_text = input()`.\n\n## Problem 3\nThis is a more complex case in which patients have other conditions. For example, patients may die due to surgical complications before completing the chemotherapy regimen. This leads to the need to compare multiple patient notes, then eligibility for the patient note must be checked, and the following two must be true.\n\n## 1.\nThe patient has a particular illness at the time of death. 2.\nApart from the illness, the patient was not in a terminal condition at the time of death.\nFirst, let's write the condition to check whether the patient is actually in eligible for the patient note. In this case, the condition can be simple. We assume these as follows.\n\n## Problem 4\nThis is about the patients' condition is changed after the random assignment. For example, if the data contains a surgical complications, the patient might die before completing the chemotherapy. However, this type of",
        "label": 1
    },
    "4": {
        "output": "15[INST] You are a medical doctor (specialist) at the Cancer Center Heidelberg, a tertiary care unit serving patients throughout the German-speaking countries. Your task is to select suitable patients regarding a trial regarding immune therapy in non-small cell lung cancer (NSCLC). Two options are presented to you: the trial sponsor will provide the drug or only the administration is provided. As an independent doctor's office, you are not legally allowed to use unlabeled drugs. Therefore, only the trial group receiving full support including drug supply is recommended for enrollment. 155[INST] First, select a patient note. 156[INST] Select only patients over 18 years. 157[INST] Filter your note database by gender (female). 158[INST] Select the patients suffering from non-small cell lung cancer. 159[INST] Filter for the number of cycles for which patients in the trial group are required to travel to your unit. 160[INST] Filter to select cases of non-small cell lung cancer with the current histological subtype. 161[INST] Filter patients whose treatment includes an immunotherapy. 162[INST] Filter for the administration of the patient to the trial group. 163[INST] Exclude the cases if not all criteria are set or a patient note does not exist. Output the age and gender of each case in a separate spreadsheet or text file.164[INST] Finally, write down which patients are suitable for the described trial.(c) Select all patient information concerning clinical trials for a patient.165[INST] You receive new patient notes, including information on several completed or terminated trials. You have to find all registered trials for a selected patient. 166[INST] Open the patient's medical file and select the name and date of birth of a patient. 167[INST] Type a list of search terms in the search field. Afterwards, use the search button to filter the notes field. 168[INST] Use the results button to filter results. 169[INST] Use the filter by date to filter by completion date and type the results of the filter in the note output field. You can also filter by clinical trials or intervent",
        "label": 0
    },
    "5": {
        "output": "[TEST] You are using an incorrect method\n\n## 1) You are using an incorrect method.\n2) The clinical trial is not in the trial list; it needs to be added by the user.\n[END]<EOD> Changes in the Serum Concentrations of Interleukin 8 in Patients With Lupus Nephritis\n\nBackground: T helper (TH) 1 cells, macrophages, and neutrophils are involved in the pathogenesis of autoimmune diseases by producing interleukin 8 (IL-8), whereas TH2cells play anti-inflammatory roles by producing IL-4. Lupus nephritis (LN) is mainly induced by abnormal T cell-mediated, macrophage-mediated, and neutrophil-mediated immune responses. Objective of the study was to assess the serum IL-8 in patients with lupus nephritis (LN). Materials and Methods: Serum levels of IL-8 were determined in 50 patients with biopsy-proven LN. Results: We found an increased expression of IL-8 in the sera of patients after starting the treatment. Conclusion: Taken together, the results of this study suggest that IL-8 has a key role in the pathogenesis of lupus nephritis.\n\n# Introduction\nSystemic lupus erythematosus (SLE) is a systemic autoimmune disease with increased immune dysregulation and autoantibody production, which causes tissue damage and organ failure [bib_ref]  The type I interferon system in the development of lupus, Ronnblom [/bib_ref] . The immunopathologic hallmark of an SLE is an antibody (autoantibody) directed against nuclear proteins [bib_ref]  Interleukin-1beta in systemic lupus erythematosus: increased serum levels in relation to interferon-alpha..., Grammer [/bib_ref]  , which results in immune complex deposition in various organs including the kidneys, central nervous system, joints, and lung. These mechanisms are believed to be central to the pathogenesis of SLE [bib_ref]  Immunomodulatory drugs for the treatment of systemic lupus eryth",
        "label": 0
    },
    "6": {
        "output": "# REPOSITORY\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.Here is the clinical trial: \nTitle: Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer\n\n\nSUMMARY: RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. If is not yet known which treatment regimen is most effective for breast cancer.\n\nPURPO",
        "label": 0
    },
    "7": {
        "output": "[/FINDINGS]\n180219\n180220\n[/FINDINGS]\n1812\n\n## POS011 - \"Recruitment of 50 Patients in 428 Clinical Trial Cohort\" Mentor: Julia Chin\n\nYou are a biostatistician and a member of a clinical research team. This week, you will attend a departmental meeting about the work in progress of a clinical study. The group leader is excited about the results, and plans to submit the work to the journal \"Lancet\". The department leader encourages you and the group leaders to plan to publish in the journal \"Cure\". You are also concerned that the clinical trial has not recruited the target number of patients in this time frame. \n\n\"POS012 - \"Feedback from Clinic to Research\" Mentor: Sarah Farias\n\nYou are a biostatistician and a member of a clinical research team. This week, you will attend a departmental meeting about the work",
        "label": 2
    },
    "8": {
        "output": "# Problems solved with pysam\n- pysam solves various problems that you encounter in working with NCTN documents. \n- For example, pysam provides an unambiguous and reliable way to store and share CAP/NCDB/NCI TCR documents via the network.\n- It also allows users to share data via the web.\n\n## CAP/NCDB/NCI TCR\n- A Cancer Protocol for Adjuvant Therapy (CAP) is a protocol for the use of adjuvant therapy, defined as treatment following curative surgery.\n- NCI-sponsored cancer clinical trials are coordinated through cooperative groups.\n- The North Central Cancer Treatment Group (NCCTG) is one of the leading cooperative group that conducts multicenter phase II and phase III trials.\n- NCDB is a central cancer registry that collects data about actual cancer treatment.\n- NCDB provides de-identified data for research.\n- The NCI Tumor Clinical Response (TCR) file is a file that contains responses to phase II trials and/or cooperative group data sets for cancer clinical trials.\n- NCI TCR is a binary (1) or non-binary (0) data file.\n\n## NCI TCR format\n- NCI TCR uses the ACS tagging scheme to convey data in a uniform format, which is useful and practical for cancer clinical trial data.\n- The CAP and NCDB use the same NCI TCR format.\n- There are 3 NCI TCR data types: `Outcome`, `Trial-level eligibility` and `Trial-level eligible entry`.\n- The `Trial-level eligibility` and `Trial-level eligible entry` entries are nested sets.\n\n## Trial-level eligible entry\n- Trial-level eligible entries are nested sets because the entry in some specific fields is present or missing. All NCI TCR fields are single data.\n- In some cases, the data is absent in the NCI TCR set. Note the `Not Applicable` concept.\n\n## NCI TCR fields\n- The NCI TCR fields and values are provided in the `NCI T",
        "label": 2
    },
    "9": {
        "output": "**[INST]**\nYour task is to evaluate the trial-level eligibility with each patient's information. Here are some tips for you. \n\nEvaluating the trial-level eligibility, you should refer to the inclusion criteria with each patient's information, which have been given after the inclusion criteria. \nIf the patient's information does not match any of the inclusion criteria, the trial-level eligibility will be `0) Excluded.`. If any of the inclusion criterias are matched, the trial-level eligibility will be `1) Not relevant.` or `2) Eligible.`. Refer to the detailed information given in the section `Trial-level eligibility`. \n\n**[INST]**\nIt is recommended to follow the logic provided below as a decision tree to guide your response.  \n\nYour decision tree for Trial-level Eligibility can be illustrated by, e.g., using boxes (`#`) for conditions and connecting lines (`--`) for the order of conditions. If a condition does not exist, put a # symbol at the end of the row. Otherwise, put a # symbol in the cell and connect it with the condition connected by a line. As you move from the top to the bottom of the page, you check one row and one column to determine the final result. \n\nYou have to check at least four conditions in the first four columns (Age, Sex, Menopausal, Performance Status) and then move down to the next four columns (Tumor Size, Nodes, HER2 status, Inflammatory breast cancer) to check at least one of the conditions you should consider for the assessment of eligibility of your patients.  \n\n# Assessment of Eligibility\n\nEach candidate is given a trial-level evaluation by the following scale: 1) Not eligible, 2) Eligible. The evaluation by the scale is listed in \n\n### Scale 1: Not Eligible\nIf the patient meets any of the following criteria, he/she is classified as not eligible:\nThe patient has inadequate information to determine any eligibility.\nThe patient meets any of the clinical trial's exclusion criteria.\n\n### Scale 2: Eligible\nIf the patient does not meet any",
        "label": 2
    },
    "10": {
        "output": "---\n\n\n\n![INST](/img/tutorials/clinical-trial-diagnosis-assessment/inst)\n\n# ClinicalTrials Data\n\n## Download link for the sample data\nhttp://data.clinicaltrials.ucla.edu/ClinicalTrials/data/CTDATALOAD.php?task=ClinicalTrialsCourse\n\n## ClinicalTrial Dataset Description \nThe dataset contains patient notes and patient's eligibility assessment of 7 clinical trials. All records of training cohort were manually annotated by graduate students. These datasets had been released by Dr. Jianfeng, as the authors of above paper, in [3].\n\n\n\n![ClinicalTrial](/img/tutorials/clinical-trial-diagnosis-assessment/CTD)\n  \n    \n## Dataset 1\n\n[![ClinicalTrial](/img/tutorials/clinical-trial-diagnosis-assessment/ClinicalTrial_DXM069_006.pdf)](https://osf.io/mcecv/)  \n[![ClinicalTrial](/img/tutorials/clinical-trial-diagnosis-assessment/ClinicalTrial_DXM069.pdf)](https://osf.io/mcecv/)\n\nDXM069 (\"Doxorubicin versus Mitomycin-C for Recurrent EOC\", [doi:10.26467/DXM-100]) is a Phase III non-randomized control trial that includes a cohort of 11 patients. \n\nIn this trial, each patient has been evaluated using Patient note to assess the patient's eligibility for the trial, i.e., to test the scale of 0 (excluded), 1 ({not qualified} yet 2) (not eligible), and 2 ({eligible} yet 3) {eligible}. \n\nThe trial is conducted by Medical College of Wisconsin. The clinical trial is conducted in Milwaukee, Wisconsin. The trial is sponsored by NIH (",
        "label": 0
    },
    "11": {
        "output": "## Input\nInput `file` that contains patients and clinical trials. Each line in the file corresponds to a patient and its information is contained in three columns: patient ID, and two patient notes, one for clinical trial no. 1 and the other one for clinical trial no. 2. The clinical trials' no. correspond to the clinical trial IDs. Here is an example of the input file:\n```\n1 55962 1.1 Breast cancer has been diagnosed.\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\nA core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\nThe tumor is  HER2-positive and ER/PR negative.\nAxillary sampling revealed 5 positive lymph nodes.\nThe patient is using multivitamins and iron supplements.\nShe does not smoke or consume alcohol.\nShe is not sexually active and has no children.\nShe is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\n2 56101 1.2 Breast cancer has been diagnosed.\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\nA core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\nThe tumor is  HER2-positive and ER/PR negative.\nAxillary sampling revealed 5 positive lymph nodes.\nThe patient is using multivitamins and iron supplements.\nShe does not smoke or consume alcohol.\nShe is not sexually active and has no children.\nShe is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n```\n\n## Output\nOutput the output of the model by following the code blocks. The model will provide a message like `Eligible for the clinical trial, not eligible for the clinical trial`. \n\n### 2D Convolution #\n```{r}\nforestModel <- makeForestModel(x =",
        "label": 1
    },
    "12": {
        "output": "Your task is to submit your code within five hours. You should also submit the name of the clinical trial and the name of your group.\n\n``` javasprints\nfunction handle_request(req){\n    var patient = req.body;\n    console.log(\"Patient note\");\n    patient = JSON.parse(patient);\n    var clinical_trial = req.body;\n    console.log(\"Clinical trial\");\n    clinical_trial = JSON.parse(clinical_trial);\n    for (var i = 0; i < 25; i++) {\n        if(patient.age < (clinical_trial.age.minimum + 1) && patient.age > (clinical_trial.age.maximum - 1)) {\n            if(patient.sex === \"Male\") {\n                if(patient.menopausal === \"Postmenopausal\" && \n                   patient.estrogen === \"Negative\" && \n                   patient.progesterone === \"Negative\") {\n                    if(patient.disease === \"Cytologically confirmed breast cancer\") {\n                        if(patient.tumor === \"3 cm invasive ductal breast carcinoma\") {\n                            if(patient.stage === \"Stage IV\", \"Stage IIIB\", \"Stage IIIC\", \"Stage IIIC\") {\n                                if(patient.tumor1.HER2 === \"3+) \" && \n                                   patient.luminalStatus === \"Negative\") {\n\n\n                                if(patient.resect === \"Yes\") {\n                                    if(patient.surgery == \"1\") {\n\n                                    if(patient.breast_conservation == \"true\") {\n                                        return \"Eligible\";\n                                    } else {\n                                        return \"Not relevant\";\n                                    }\n                                    \n\n\n                                    } else {\n                                        return \"Not relevant\";\n                                    }\n                                } else {\n                                    if(patient.tumor1.HER2 === \"3+) \" &&",
        "label": 2
    },
    "13": {
        "output": "</div><div class=\"alert alert-success\" role=\"alert\">\n\n_Hints to pass part B of the exam_\n\nThe aim of your program is to check all the eligibility criteria and find out which trial the patient is qualified to.\n\nTo do so, let us use the example of a specific clinical trial. For example, the trial is titled as follows: \n\nTitle: An Exploratory Phase II Study to Evaluate the Combination of Pemetrexed With S-1 (Tegafur, Gimeracil and Oteracil Potassium) in Treating Metastatic Renal Cell Carcinoma\n\nDescription: The intent of this study is to study safety, toxicities, and the maximum tolerated dose of the drug pemetrexed in combination with the S-1 anticancer drug. This study is open to men and women patients who are at least 18 years old, with metastatic renal cell carcinoma and have failed one previous cytotoxic therapy regimen or have metastatic renal carcinoma with renal cell carcinoma that cannot be removed by surgery but who still wish to receive anticancer therapy. Eligibility is further defined in the following sections.\n\nInclusion criteria:\n- Subject has to be a male or a female with evidence of metastatic carcinoma of the kidney that is not suitable for surgical resection and is a good candidate for a multi-agent cytotoxic combination chemotherapy, and/or who progressed on first line therapy\n- Subject must be at least 18 years of age\n- Subject's physician must have determined that this patient can tolerate a multi-agent cytotoxic combination chemotherapy regimen. Subject can be anemic, thrombocytopenic and neutropen",
        "label": 1
    },
    "14": {
        "output": "The clinical trial that you should consider is \"High Risk Breast Duct Epithelium\". Therefore, you should replace `Trial` name with `c2010_07073` when you call the function `trial_eligibility`, e.g., `Trial_eligibility(study_id, trial_name, trial_level_ \n\n## Recruitment\nAs one more function, you can get a patient's information by calling `recruitment` function. \n\nThis gets you the number of patients that you assessed for eligibility. If the number of patients are more than 0, the patient's information will be returned. If it is 0, that means that there is none to be recruited. \nLet's find the patient's information from the breast cancer patients. \n\nThe parameters of this function in code are as below. \n\n```R source(\"src//clinical_trial_recruit_data.r\") recruits <-clinical_trial_recruit_data() head(recruits) ``` \n```R # 1-0 1-0 1-0 0-0 0-0 0-0 0-0 0-0 0-0 0-0 0-0 0-0 0-0 1-1 0-0 # 1-1 0-0 0-0 1-0 1-0 1-0 0-0 0-0 0-0 0-0 0-1 0-1 0-1 0-0 0-0 # 1-0 0-0 0-0 0-0 1-0 0-0 0-0 0-0 0-0 0-0 0-0 0-0 0-0 0-0 0-0 # 1-0 0-0 0-0 0-0 1-0 1-0 1-0 0-0 0-0 0-1 0-0 0-1 0-1 0-0 0-0 # 1-1 1-0 1-1 0",
        "label": 2
    },
    "15": {
        "output": "<EOD> In vivo, high efficiency production of non-histone chromatin proteins HMG1, HMGB1 and HMG2.\nWe have used an in vivo labeling approach with  thymidine or 35S methionine to reveal an unusually high level of expression and turnover for three of the five mouse non-histone chromatin proteins, HMG1, HMGB1 and HMG2.<EOD> Efficacy and tolerability of the novel glenohumeral joint simulator: An in vitro study\nThe introduction of simulators into surgical training requires them to be validated. To determine the efficacy and tolerability of the novel Glenohumeral Joint Simulator (GHJ Simulator), a validated instrument was used to assess the simulator. The GHJ Simulator is a low\u2010cost, high\u2010fidelity, easy\u2010to\u2010use simulator and is designed to allow standardised practice and assessment of normal and pathological shoulder glenohumeral joint (GHJ) movement.<EOD> Impact factors and ranking systems for academic departments of psychiatry: Do we have a valid process for evaluation?\nAlthough many academic departments of psychiatry now assess the impact of their research, it remains difficult to know how credible any published impact indicator is in comparison with others using different methodologies. The authors of this study evaluated published methods of calculating impact factors and ranking systems in comparison with the impact factor of an Australian academic department of psychiatry published at the start of 2014.<EOD> Prosthodontic rehabilitation of a patient with amelogenesis imperfecta.\nAmelogenesis imperfecta (AI) is a group of rare genetic disorders caused by a failure of enamel formation resulting in poor quality, reduced thickness and yellow/brown opacities on enamel surfaces. The prevalence of AI is unknown but it is estimated that it ranges from 1.6 to 16 cases per 100,000 births with a mean onset at about 7 years of age. There is an estimated 4:1 ratio between females and males with AI. At the time of birth or within the first 6 years of life, the clinical features of AI typically include discolored",
        "label": 2
    },
    "16": {
        "output": "<EOD> .\nOBJECTIVE\nTo evaluate the effects of endo-resin composite retrograde filling on the clinical and radiographic parameters.\n\n\nMETHODS\nA sample of 445 retrograde fillings (including 233 cases of normal periapical tissue, 58 cases underwent orthograde restoration in posterior tooth) in 82 patients were selected with the mean follow-up period of 5.83 years. A clinical examination was performed, and postoperative periapical radiographs were retaken before endo-resin composite retrograde filling to 82 cases to evaluate initial clinical status by using the visual analogue scale (VAS), sulcus bleeding, periodontal pocket depth (PPD) and probing attachment loss (PAL). After filling, at the first visit and after 12 months, reevaluation of the clinical status was performed and radiographic examination was taken respectively to all 445 cases. The end points included: endo-resin composite retrograde filling technique acceptability, endo-resin composite retrograde filling techniques failures, clinical parameters improvement, periapical changes after retrograde filling, secondary treatments. The statistical analysis was performed using repeated measurement, paired t test, independent t test, Mann- Whitney U test, chi-square test, chisquare for trend test.\n\n\nRESULTS\nAll 445 retrograde fillings are successful. Repeated measurement showed clinical parameters from all 82 cases' patients showed improvement (with a significant difference as P < 0.05), in 445 cases' PAL results showed remarkable improvement (with a significant difference as P < 0.05; PPD showed improvement too) in periapical radiographs (in 445 cases), initial and final radiographic studies (in 82 cases) periapical healing was found in 180 cases (40.5%), which were found improved in 102 cases (22.8%) with a final follow-up of a minimum period of 5 years, and deteriorated in 30 cases (6.8%) with a follow-up period of more than 5 years. Repeated measurement showed significant difference between normal and",
        "label": 2
    },
    "17": {
        "output": "* Note: Please refer to the comments in a .md file for the source code that generates all the patient notes. (https://github.com/SejongKim/DREAM-Clinical-Research/blob/master/DREAM-Notes-and-Comments.md)\n\n\n* [<NAME>](https://github.com/alainl), [<NAME>](https://github.com/pablo12345) and [<NAME>](https://github.com/daphnislee)\n\n### [<NAME>](80361/)\n\n#13 of 285:\nThe purpose of the project is to test the predictive capabilities of two sets of protein features: proteomic and phosphoproteomic. Phosphoproteomes were produced and analyzed with both non-human and human cell lines and compared to non-regulated protein samples.\n\nThe 1218 unique genes included in the phosphoproteomic and proteomic data from both cell lines are included.\n##### Phosphoproteomic Genes\n\nThere are 322 genes (26.4%) that are present in the phosphoproteomic data.\n\n##### Proteomic Genes\n\nThere are 896 genes (73.6%) that are present in the proteomic data.\n\nThe 759 unique genes included in the proteomic and phosphoproteomic data of non-regulated samples are\n\n##### Proteomic Genes\n\nThere are 518 genes (67.6%) that are present in the proteomic data.\n\n##### Phosphoproteomic Genes\n\nThere are 241 genes (32.4%) that are present in the phosphoproteomic data.\n\nThe 675 genes included in the phosphoproteomic and proteomic data from both human and non-human cell lines are\n\n##### Proteomic Genes\n\nThere are 434 genes (63.9%) that are present in the proteomic data.\n\n##### Phosphoproteomic Genes\n\nThere are 241 genes (36.1%) that are present in the phosphoproteomic",
        "label": 1
    },
    "18": {
        "output": "<issue_comment>username_2: I tried the above example, it doesn't look in the patient-related trials, only in the trial specific eligibility. Is it a miss in my code or I missed something?\n<issue_comment>username_0: Hello @username_2 ! You are right. We have a bug about searching in patient related trials. It needs some improvements.<issue_closed><EOD> .\nBlood coagulation function in patients with acute myocardial infarction (AMI) without heart failure was studied in correlation to cardiac function. It was found that the total plasma coagulation activity of patients with acute myocardial infarction is diminished on the basis of elevated levels of plasma and serum fibrinogen, plasma fibrinogen and fibrinogen-FDP, and increased level of serum fibrin-degradation products (FDP). Blood clotting activity of the patients was significantly elevated on a 7-th day after onset of infarction in parallel with reduction of FDP. These abnormal changes in coagulation function were shown to be of little prognostic value for the degree of cardiac failure and infarct size.<EOD> Acute Lymphoblastic Leukemia Presenting as a Rare Complication of a Common Disorder: Primary Sj\u00f6gren\u2019s Syndrome\n\n\n\n# Introduction\nPrimary Sj\u00f6gren's syndrome is an autoimmune disorder, characterized by lymphocytic infiltration of the salivary and lacrimal glands, leading to diminished salivary flow and dry eyes . It presents as a spectrum of disease processes, the most severe of which is salivary gland focal and marginal b-cell lymphoma. Acute lymphoblastic leukemia is one of the most common types of hematological malignancy in children. In adults, it is extremely rare as a primary disease, occurring in < 10 per million people. There have been multiple case reports of lymphoma presenting as complications of autoimmune disease [1]. However, there are very few cases of acute lymphoblastic leukemia presenting as a complication of Sj\u00f6gren's syndrome.",
        "label": 1
    },
    "19": {
        "output": "Clarifications:\n\n*\n\n*Including all other data in your patient_assessment.csv file and patient_trial.csv file is not required for this submission. However, in the future, your submission information (including additional data) will be reviewed by the editorial team for all submissions.\n\n*Include your `patient_assessment.csv file`, and `patient_trial.csv file` in the same folder with your `patient_info.csv file`.\n\nPlease make sure you upload your file with the correct file extension (csv). Also, please upload your file with the correct sheet named: `Trials.tsv/patient_assessment.csv(assessment and data about patient) ` or `Trials.tsv/patient_trial.csv(eligibility for the trials).`\n*\n\n*Make sure you have the correct column names and that the column labels are the following:\n\n*\n\n*When you add new columns, please check the column labels to make sure they don't look like rows (please check that there is no extra whitespace in front of the name of the column). We recommend including the column name in the header so the column label is visible in all the csv files.\n\n### Step 3: Fill out the Patient-level Eligibility Assessment\n\nFirst of all, let me introduce you to the patient\u2010level eligibility assessment form. \nThis eligibility assessment form consists of three sections: Trial\u2010specific Inclusion criteria, Randomized Trial\u2010Level Inclusion criteria and Clinical Trial Eligibility. The patient\u2010level eligibility assessment form is intended to assist you in evaluating whether the patient's information is eligible for the given trial.  \nYou should compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. After making an assessment of patient\u2010level eligibility, please include 2 tables  in your submission as well as the `patient_assessment.csv file,` which contains",
        "label": 2
    },
    "20": {
        "output": "<EOD> An epizootic of infectious bursal disease in adult turkeys in Germany.\nAn epizootic caused by serotype 1.2 of a fowl plague serovar I (Hiscox and 0dum, 1966) occurred in adult turkeys at various turkey breeding farms in Germany between December 1987 and March 1988. Clinical signs typical for infectious bursal disease (IBD) included depression, weakness, ruffled feathers, reduced water intake and, at the farm where the initial outbreak occurred, lameness and swelling of the head including the neck and face (Fig 1). Mortality was high ranging between 10 and 40 per cent (Fig 2). Affected turkeys had enlarged pale infected bursa of Fabricius usually with numerous bacillary cores (IBD synovial lesions (Fig 3), and haemorrhagic encephalopathy (Fig 4) were observed. The etiological agents were successfully isolated on chicken chorioallantotic membranes and were identified as IBD virus. These isolates were tested according to a standard procedure (Kaufmann, M. E. von Haeseler, 1999) using chicken, duck, goose and turkey bursae, which were included into the serogroup I of H. PEACH ( 1 96 I ) , i.e. they could agglutinate serotypes B, H, J and K. Moreover they agglutinated the serovar II strain, i.e. serotypes 2.2, 4.2, F and 5.2. According to HISCOX (1 966, 1976a), the bursal disease virus strain which caused the recent outbreak can be considered 160<EOD> The effects of short versus long duration training period on the performance of healthy elderly adults.\nThe effect of a prolonged, i.e., 3 to 4 months duration and short, i.e., two weeks, training period on motor performance of elderly adults is studied. Two groups of healthy, phys",
        "label": 0
    },
    "21": {
        "output": "Here is the code snippet:\n# Clinical trial eligibility assessment def clinical_trial_eligi_assess(df):\ndf['Trial-level eligibility'] = 'Excluded'\nfor trial_id, trials in df.iterrows():\nfor trial in trials:\nfor patient in trial[trials.columns]:\nfor row in trial.itertuples():\nif 'patient_note' in row: # Checks patient note column and sets eligibility If patient eligible then set patient eligibility = \"Not relevant\" not applicable return (trial_level_eligibility, patient_trial_eligibility) else:\nreturn (('Excluded', 'Excluded'), ('Eligible', 'Not relevant')) # Returns (Trial-level Eligibility, Eligibility) # Returns excluded or Eligible # In case trial patient is assigned an exclusion, then set eligibility = 'Not relevant ' # Then if patient is in trial, then set eligibility = 'Excluded ' # Finally return (('Excluded', 'Excluded'), ('Eligible', 'Not relevant')) # Checks patient note column<EOD> Evaluation of mRNA and protein stability of a human hybridoma cell line grown in hollow\u2010fiber bioreactors\nAn assay system for the evaluation of recombinant protein production in hollow\u2010fiber bioreactors (HFB) is described. The stability test detects changes of the mRNA and protein level during the biological process of a hybridoma cell line and thereby allows a first analysis of the influence of the production process. Total RNA and whole protein samples were isolated at different time intervals from the HFB. Quantitative evaluation of the mRNA stability was performed by a Northern blot using a specific 32P\u2010labeled probe for immunoglobulins M (IgM). The stability of cytoplasmic gamma\u2010globin and mitochondrial 16S rRNA was additionally investigated as marker genes. Hybridization of the total RNA samples to complementary DNA probes specific for either IgM, gamma\u2010globin, or 16S rRNA as a marker gene revealed a similar time\u2010dependent decrease of the hybridization signal. The",
        "label": 0
    },
    "22": {
        "output": "`turtle:\n    - recruitment.patient.name: <NAME>.\n    - recruitment.patient.age.sex.menopausal: 45\\-year-old\\ female\\ postmenopausal\\ woman.\n    - recruitment.cancer.breast.tumor.size:  3 \\ cm invasive, \\ breast cancer.\n    - recruitment.cancer.tumor.grade: 3 ( G2)\n    - recruitment.cancer.metastasis.lymph_nodes: \\ 5 \\ lymph nodes positive.\n    - recruitment.cancer.histology: invasive ductal cancer.\n    - recruitment.cancer.her2: positive.\n    - recruitment.hormone.estrogen_positive: \\ negative.\n    - recruitment.hormone.progesterone_positive: \\ negative.\n    - recruitment.cancer.metastasis: axillary lymph nodes positive.\n    - recruitment.cancer.metastasis: lung and bone metastases.\n    - recruitment.cancer.tumor.receptors.oestrogen: \\ negative.\n    - recruitment.cancer.tumor.receptors.er: \\ negative.\n    - recruitment.cancer.tumor.receptors.pg: \\ negative.\n    - recruitment.cancer.tumor.stage: IV.\n    - recruitment.patient.smoking_status: non-smoker.\n    - recruitment.patient.alcohol_consumption: drinks not more than one bottle of wine per week.\n    - recruitment.patient.sexual_activity: not-in-relations, sexually abstinent.\n    - recruitment.age: \\ 45\\-year-old.\n    - recruitment.breast_cancer.chemo: yes.\n    - recruitment.tissue.hormone.estrogen: \\ negative.\n    - recruitment.tissue.hormone.progesterone: \\ negative",
        "label": 2
    },
    "23": {
        "output": "## Summary\n\nThe goal of this tutorial is to make students acquainted with the concepts of machine learning, deep learning, and its applications in life sciences, particularly with respect to image analysis. Aside from the tutorial's primary goal, we want to emphasize that students need to have a general idea and hands-on training in programming and computer science before attempting to solve any deep learning problem. This includes the ability to write simple programs, to write code to solve simple math problems, and to understand code and functions. We want to emphasize the fact that deep learning is a branch of machine learning. Without understanding the basics of machine learning and programming, we would not be able to get any deep learning results. Without some understanding of statistics, we would not be able to understand a deep learning result.\n\n## Pre-requisites & software versions\n\nTo follow the tutorial, you need to first have installed a suitable machine learning library in your Python installation. You should download the Python 3 language distribution and the Jupyter Lab application (we used release 2020.11.0) and add a suitable machine learning library. The following machine learning libraries are mostly used in life sciences applications: sklearn, scoop, scitkit-learn, keras, tensorflow, caffe, and pytorch.\n\nThe library packages provide different methods and algorithms that can be used for classification, clustering, decision tree or regression and some basic methods like variance and average function. However, there are two deep learning architectures that we want to talk about as they are mainly used by life scientist these days, the deep neural network or dense neural network architecture and the convolutional neural network architecture. These architectures are usually described as deep learning libraries in Python: keras and pytorch. To train and perform deep learning, you need to have a GPU. Our recommendation is to use Google Colab as an online research environment for training deep neural networks.\nOur recommendation for a machine learning library and corresponding deep learning software and libraries is the following:\n\n## Deep neural networks\n\nDeep neural networks are very attractive because of their high prediction accuracy. Deep neural networks are made up of several layers, and each layer consists of several neurons with at least one activation function. Convolutional neural networks and dense neural networks are popular architectures of deep neural networks in biomedicine and life sciences. Usually, a deep neural network has a",
        "label": 0
    },
    "24": {
        "output": "## Assessments\n\n\n## Patient assessment\nFor each patient, ask about the date of menopause, marital status, age of menarche, and history of birth complications.\nMenopausal status is defined as any postmenopausal woman and premenopausal women, aged 84 years of age or younger, with no history of tamoxifen use, defined as those having had a hysterectomy, ovariectomy, chemotherapy, or radiation with both ovaries removed.\nMenopause is defined after the age of 65 or more than 12 months of spontaneous amenorrhea or cessation of menses during hormonal therapy in premenopausal women.\nMenopause is divided into 3 groups: premature menopause before the age of 45, early menopause between the ages of 45-54 years old, and late menopause after the age of 54 years old.\nMenopausal women who are using hormonal replacement therapy should be considered postmenopausal. (Hormonal replacement is considered exogenous estrogen for women with a uterus [without tamoxifen], estrogen plus a progestogen for women with a uterus [with tamoxifen], or testosterone for men.)\nIn most cases, the patient will be postmenopausal or premenopausal and be having regular menses. Transitioning between postmenopausal and premenopausal may occur over time, for example in the case of starting chemotherapy.\nIn the question field `Pre-therapy comorbid condition`, ask the patient to indicate the most severe comorbid condition of their disease at the time of diagnosis. Ask the question, `If you could describe how well you are feeling right now and overall, how would you describe your health? This could be very good, good, not good, poor, or very poor?` Ask the patient to rate their overall health. Health status is based on the 5-point Likert rating scale. Score 1= excellent, score 2= very good, score 3= good, score 4= fair, score 5= poor.\nAsk questions about the physical health subscale (050",
        "label": 0
    },
    "25": {
        "output": "<EOD> Impact of HIV-Related Knowledge on Preventative Behaviors and Attitudes in the United States\n\nLittle is known about the impact of various domains of HIV-related knowledge on preventative behaviors and attitudes among community sampled U.S. adults. Our data represent the most up-to-date U.S. population knowledge data since 2007. We use logistic regression analyses to examine the associations between various domains of HIVrelated knowledge and attitudes toward people living with HIV (PLWH) and report the unadjusted and adjusted ORs with 95% confidence limits. We demonstrate the impact of having a family member or friend living with HIV or being sexually intimate with someone who is HIV positive is a strong predictor of testing positive for HIV, using condoms, engaging in risky behaviors to spread HIV, and stigmatic attitudes. Also, knowing that antiretroviral drugs can help decrease the chance of infecting someone with HIV is also associated with having fewer stigmatic attitudes. Taken together, our findings suggest enhanced HIV transmission and prevention education that includes family and friends living with HIV is needed among U.S. adults.\n\n# Introduction\nApproximately 1.2 million people are living with HIV/AIDS in the U.S., and nearly half of all HIV cases in the nation are spread through heterosexual sex. In 2005, the Centers for Disease Control and Prevention (CDC) released a National Call to Action to Prevent HIV/AIDS by 2015. This report outlined several strategies needed to significantly reduce new infections, including improving surveillance systems, HIV prevention, and care for people living with HIV/AIDS (PLWH) [bib_ref]  A national HIV/AIDS comprehensive prevention center-an action plan for the future, Catania [/bib_ref] .\nEducation about HIV/AIDS, transmission, diagnosis, and prevention continue to be a top priority for researchers [bib_ref]  Relationship between HIV knowledge and attitude towards people living with HIV/AIDS among..., Alshagga [/bib_ref]  [bib_ref]  Factors associated with HIV testing",
        "label": 0
    },
    "26": {
        "output": "I\n<EOD> Chlorogenic acid as a protective agent in acetamiprid-induced oxidative stress in rats\nAcetamiprid (ACE) is a neonicotinoid insecticide widely used for pest control in agriculture. The present study examined the protective effects of chlorogenic acid (CGA) against ACE-induced oxidative stress in rats. ACE toxicity was determined using several endpoints, including superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, and DNA damage. The experimental design involved a total of six groups: (a) normal control, (b) ACE control (50 mg kg\u22121), (c) ACE (50 mg kg\u22121) + CGA (100 mg kg\u22121), (d) ACE (50 mg kg\u22121) + CGA (250 mg kg\u22121), (e) CGA (250 mg kg\u22121), (f) CGA (600 mg kg\u22121). A 2-week gavage treatment of ACE substantially reduced the enzymatic antioxidants and increased MDA level, however, this alteration was reversed with CGA administration. The CGA treatment improved the DNA damage caused by ACE in a dose-dependent manner. The results indicated that the preventive administration of CGA resulted in a reduction of ACE-induced oxidative stress.<EOD> Porphyromonas asaccharolytica sp. nov., isolated from the feces of healthy humans.\nA yellow-pigmented bacterial strain, designated NG1, was isolated from the feces of a healthy adult. The strain was gram-negative, coccoid or ovoid, and oxidase- and catalase-positive and non-motile. The DNA G+C content was 48.9 mol%. Analysis of the 16S rRNA gene sequence showed that the strain was phylogenetically related to the genus Porphyromonas. The levels of 16S rRNA gene sequence similarity with",
        "label": 0
    },
    "27": {
        "output": "<EOD> Laminar Clinostat for Simulation of a Mars Day-Night Cycle\nA prototype centrifuge has been designed and constructed that is capable of simulating the day-night laminar centrifugal cycle of a Mars-like planet. A spinning rotor was positioned inside a gondala that could be raised or lowered independently of the spinning centrifuge cylinder. The rotation rate was variable, and maximum rates (200 or 300 rev min-1, 5.35 s or 3.42 s period) were achieved by a large-size prototype instrument. The laminar cycles were simulated in one trial lasting 24 h, after which the rotor was returned to earth's rotation and the gondala was lowered into the centrifuge. The spinning centrifuge was removed from the base and rotor, and the gondala was repositioned independently 10 times to test for rotor instability. The prototype centrifuge was installed on a 2.1-m-diam centrifuge and operated on a small platform at high centrifuge speeds (80 rev min-1, 6 s period, or 5.4 s period) with a laminar cycle lasting 32 h. Instability of the rotor was not evident, and the rotation rate was not compromised even after five hours of laminar centrifugation. The instrumentation was designed to meet the standards of an aircraft and was tested in a high-performance small aircraft.<EOD> Efficacy and safety of pembrolizumab and paclitaxel in previously treated primary brain tumors patients (pBT): results from the KEYNOTE-028 trial.\nBACKGROUND\nCentral nervous system malignancies are highly prevalent and aggressive tumors, which cause substantial morbidity and mortality. Immune checkpoint inhibitors (ICIs) have demonstrated clinical activity in several tumor types, including those of the central nervous system. This retrospective analysis evaluated the safety and efficacy of pembrolizumab and paclitaxel, in patients with pterygopontine glioma (PPG), pineoblastoma (PNEB), pineocytoma (PNC) and ep",
        "label": 1
    },
    "28": {
        "output": "### Question:\nWhat will you do when you encounter a patient who is more than the permitted age for clinical study recruitment?\n\n### Task:\nFor a clinical trial patient, a doctor should enter the first row. \nThere is a column called Age. You should calculate the date when patients are more than the maximum age. Let's discuss what you need to consider when selecting patients at the time of recruitment.\n\n[INTERNAL] There is no time limit during the trial. \nAs the trial progresses, some patients in some trials do not comply with the rules/procedures during the trial period. Insufficient compliance will lead to early withdrawal from clinical trials. When such patients drop out of a clinical trial, the principal investigator or clinical research assistant must inform the IRB in advance about insufficient compliance by the patients (i.e., a serious violation of clinical trial regulations). [/INTERNAL] Certain diseases or medical conditions have specific treatment approaches. This will affect the course of these diseases. When a patient's disease progresses, they may become eligible for study treatment earlier because eligibility assessments are no longer valid. Also, patients may find themselves ineligible for a clinical study, and the study treatment may provide little therapeutic benefit and not improve their condition. Clinical trials, in particular, must balance a patient's right to receive clinical study treatment, even when they may not benefit from it, with their right to clinical care from investigators and physicians outside the trial. The doctor must record information about trial participants' progress. For patients who drop out of a clinical trial, a doctor must keep a record of their progression, including whether they have progressed as planned, and, if not, the reason given.\n\n# Tutorial Home: [Go]\n<EOD> A Prognosis Model Based on Ferroptosis-Related Genes in Hepatocellular Carcinoma\n\n\n\n# Introduction\nHepatocellular carcinoma (HCC) is the fifth most prevalent cancer worldwide and the second major cause of cancer-related death [bib_ref]  A Review of Epidemiology and Risk Factors of Hepatocellular Carcinoma, Roh [/bib_ref] . China",
        "label": 2
    },
    "29": {
        "output": "You can also run your algorithm with more patients and add this part instead:\n`Testing of other patients:\n\n<patient-id>-<Trial-level eligibility>`\nIn other words, you will add more patients to the list `patient-id`, starting from the first patient and continue until you reach the end of your dataset/collection.\n\n\n\n<h1><a name=\"instructions\"></a>Instructions</h1>\n\n<p>Below you will find instructions on how to prepare a <code class=\"badge badge-pill btn btn-warning\" data-badge-pill data-target=\"button-demo\">demo</code> file for the challenge.</p>\n<p class=\"lead\">\n\n<p>\nThis is a code challenge and no actual code will be accepted. You will be given the\n<code class=\"badge badge-pill btn btn-warning\" data-badge-pill data-target=\"button-demo\">demo</code> file with the algorithm already coded. You\nhave to follow the rules set for the problem and implement your solution in\nyour algorithm.\n</p>\n</p>\n<p>\nIn your <output data-output>demo</output> file, you will find a list of objects each of them\ncontaining a set of rules set for the problem under discussion. If your solution fits\nall the rules and is valid, you will receive an award certificate for the problem. Your <code class=\"badge badge-pill btn btn-warning\" data-badge-pill data-target=\"button-demo\">demo</code> file has to be named <input data-input=\"name\"> and put into the <code class=\" badge badge-soft btn btn btn-soft btn-round\">submission</code> folder. The <strong>demo</strong> folder has to be named <input data-input=\"folder\">demo</input>.\n</p>\n<p><a target=\"_blank\" href=\"//github.com/hackclub/SunnyBoroSummerCamp\"> <code class=\"badge badge-pill btn btn btn-warning\" data-badge-pill data-target=\"button-demo\">source</code></a></p>",
        "label": 0
    },
    "30": {
        "output": "## Test data\n\n- `data/breast_eligibility.json` contains all patient and trial data shown in Section 2.\n- `data/trial_breast_cancer_dataset.json` contains all clinical trial data shown in Section 2.\n\n## Training Jupyter notebook\n\n1. Install nltk into your Anaconda distribution.\n    ```\n    $ anaconda activate notebook\n    $ conda install nltk\n    ```\n    \n2. Clone our repository.\n    \n   \n    ```\n    # Clone our repository here: https://github.com/A-S-A/text_classifier.git\n    $ git clone https://github.com/A-S-A/text_classifier\n    $ cd text_classifier && python setup.py develop\n    ```\n    [INST]\n\n3. Start Jupyter notebook:\n\n    ```\n    $ jupyter notebook\n    ```\n\n    You will now have a new window of your choice.\n    \n### Training with TF-IDF\n    \n   * The code is placed under `train_tfidf_classifier.ipynb`.\n   * The algorithm uses Python scikit learn library.\n   * The algorithm needs a file `sentiment.list` with sentiment value for each word. You can build this file. For example, you can go to https://github.com/andymurray/sentiment_analytics/blob/master/sentiment_scores.py and copy the sentiment files according to your need (positive words, negative words, more).\n     \n   * The algorithm uses as a test example `test_df.csv` file that is part of the training data. You can modify this file according to your need.  \n    \n   * The algorithm requires as an input a file `word_tfidf_model.pickle`. If you did not download it, find it in the repository folder `text_classifier`.  \n   * Once you have trained  the algorithm, you will find the file `tfidf_model.pkl` with the trained algorithm. You can save `tfidf_classifier.pkl` to your machine and continue with it.\n   * \n   *\n   *",
        "label": 0
    },
    "31": {
        "output": "# Author's note\nThe first three steps are for training the users and the remaining steps are for the end users. We welcome all suggestions toward the improvement of the application.\n\n# Authors' disclosures of potential conflicts of interest\nNo conflicts of interest to disclose\n[fig]  2: Patient's name, gender, age, ethnicity and medical history. (3) The date of tumor diagnosis. (4) Laboratory values: tumor markers, complete blood count and serum chemistry. (5) Chest radiography (CXR), electrocardiogram, and echocardiogram. (6) Surgical and therapy procedures: types, number, and dosage. An example of the above-mentioned information is displayed below. [INST] [/fig] \n<EOD> Risk factors for cardiac events in hypertrophic cardiomyopathy mutation-carriers\nRecent data suggest that hypertrophic cardiomyopathy (HCM) patients are at risk of cardiac events independently from family history. However, little is known about the cardiac risk profile of genetic mutation carriers without phenotypic expression at first diagnosis. We conducted a prospective study of 50 non-mutation-carrying family members of HCM patients, all of whom were under regular outpatient clinical monitoring. Participants underwent baseline medical visits, electrocardiography (ECG), echocardiography, left ventricular outflow tract (LVOT) gradient measurement, and 48-hour Holter-ECG recording every 6 months. After mean follow-up of 2 years, six participants dropped out. Among remaining 44 subjects undergoing study entry, no sudden cardiac death occurred, but two cases of malignant ventricular tachycardia (VT) were documented. At the end of the follow-up none of the four mutation-carriers who developed VT was symptomatic and they didn\u2019t show increased ECG indices of risk such as QTc interval or prolonged corrected QT-index. In conclusion, our findings suggest that asymptomatic non-HCM-carriers, under regular outpatient clinical monitoring, show a relatively low cardiac event-rate. In particular, our results show that sudden card",
        "label": 0
    },
    "32": {
        "output": "## [MOCK] Try this code for patient's ID: 123456789\n\n```python\ntest_path = input('Enter path of the saved file: ')\nwith open(test_path) as f:\n    text_data = f.readlines()\n\ndef patient_trial(trial, data):\n    patient_id = data.find(\"[Patient ID]:\")[1].split(\"]\")[1]\n    trial_path = data.find(\"[Trial]:\")[1].split(\"]\")[0]\n    patient_data = data.split(\"\\n\")[1:1]\n    patient_data.pop()\n\n    # Create list of patient's data\n    patients_data_list = []\n    for patient_data in patient_data:\n        patients_data_list += patient_eligibility_scores(trial,\n                                                     patient_data[\"Assesment\"])\n\n    # Trial-level eligibility\n    trial_elgibility = trial_eligibility(patients_data_list, trial)\n\n    print('Patient ID:', patient_id)\n    print('\\n')\n    print('- Eligibility of the patient')\n    print('\\n')\n    print('- Patient's ID:', patient_id)\n    print('- Trial's ID:', trial_id)\n    print('- Patient-level eligibility')\n    print('\\n')\n    print('- Patient's ID:', patient_id)\n    print('- Trial eligibility score:', trial_elgibility)\n    print('\\n')\n    print('- Trial-level eligibility')\n    print('\\n')\n    print('- Patient's ID:', patient_id)\n    print('- Trial eligibility:', trial_elgibility)\n    print('\\n')\n\npatient_trial(trial, test_path) \n```\n\nYour test can be [here](https://pandas.pydata.org/pandas-docs/). You are encouraged to try with other codes.\n<issue_comment>username_1: Thanks for the submission<issue_closed",
        "label": 0
    },
    "33": {
        "output": "---\n\n## [P12] Question: Please state the possible output, and how it would be computed. [ANSWER: Exclude]\nIn the context of trials in rare cancers, an assumption that the trial is of reasonable size, and the goal is not to find a clinically effective treatment, the trial is probably not powered to be adequately informative. Excluding a patient from the trial may result in some harm to the patient.\n\n## [P13] Question: Why would patients need to meet all eligibility criteria to be eligible for clinical trial participation? [ANSWER: Yes]\nThis is a binary decision rule. If a patient meets the criteria, they are eligible, but if any criteria are missed, they are ineligible.\n\n## [P14] Question: How should trial participant recruitment and adherence to the trial protocol be managed? [ANSWER: Yes]\nWhen the trial is completed, the participant should be offered appropriate medical care following normal ethical practice.\n\n\n[#P15] Question: Why don't you use `R` and `python`? [ANSWER: Good question! You can use what you have, which may be helpful because the questions are more realistic. `python` is not bad, but just because it is free doesn't mean it has to be used. You can do the entire assignment in a program using `R`. This might be useful if you were to present the assignment to a colleague who is not familiar with how to use `python`, but might be able to read it in `R`.]\n[#P16] Question: If you are working with a team on a specific problem, what if you want to include that team member's contribution to your final report? You have to include a reference in your report, but it isn't easy finding the answer.\n\nHow will you cite the code created in this class? The answer is [here].\n\n**P17. (No answers for this)**. The question is for the authors to discuss how they implemented the following ideas in their research [1].\n\nIf any team member fails to produce their contribution, there are ways to address this in the final report. However, if they refuse to provide the source code that was discussed in the paper, the",
        "label": 0
    },
    "34": {
        "output": "Your task is to take a look at the data and predict which gender an individual patient is based on the data. Let's start by counting the number of men (`M`) and women (`F`) and their age ranges. \n\n```{r}\n\npredict_gender <- function (x) {\n    count$gender %>% summarise(N = n_distinct(gender)) # number of patients per sex\n    age %>% count(gender = gender, group = Date, sep = \"_\") # how old are the patients\n    }\n\n```\n\n\n```\n\npredict_gender()\n\n\n### \n\n``` {r} predict_gender()\n\n  \nAge          ## Age of patients\ngen        ## Gender\n      date    ## Data and time of assessment\n                           N         n_distinct(gender)",
        "label": 0
    },
    "35": {
        "output": "# Good Practices\n\n## Don't reuse files\nDon't reuse files - write a new file with each trial.\n\n## Cleanup trials\nCleanup trials by reassessing each trial for any missing fields and fixing the problem:\n\n```coursera\ntrial_doc.edit_json\n>>> trial_doc.trials\n\n[{'inclusion_requirements': {'birthdate_limit': None, 'family_history_limit': None, 'smoker_limit':\n3, 'alcohol_limit': None,\n'age_limit':\nNone, 'exclusion_criteria': [{'name':\n'Low performance status',\n'exclude': False, 'comment':\n'A ECOG performance status of 2 or worse. Low performance status\nindicates that patient cannot carry out normal activity, is unable to care\nfor self, and has limited ability to carry out light or sedentary activity.',\n'level':\n1},\n{'name':\n'No brain metastases',\n'exclude': False, 'comment':\n'No documented history of brain metastasis.',\n'level':\n1},\n{'name':\n'Must be previously untreated',\n'exclude': False, 'comment':\n'Subject should not have metastatic cancer that was diagnosed or\ntreated in the past and that is the reason that subject presents\nwith this new metastatic disease.',\n'level':\n1},\n{'name':\n'Must be ECOG performance status of 0 or 1',\n'exclude': False, 'comment':\n'A ECOG performance status of 2 or worse.',\n'level':\n1,\n'name':\n'Must have at least one measurable extracranial tumor',\n'exclude': False, 'comment':\n'A measurable extracranial disease.',\n'level':\n1\n},\n{'name':\n'Must be HER2-positive',\n'level':\n1},\n{'name':\n'Must be ER-positive/PR-positive',\n'level':\n1,\n'name':\n'Must be HER2-positive',\n'exclude': False",
        "label": 0
    },
    "36": {
        "output": "The patient's note should be evaluated step by step. For example, this is the first patient's note. [INST] Birthdate: 10/28/1991 Gender: Female Age: 45 Height: 165 [/table] \n<EOD> Phage-Based Synthetic Circuits as a Platform for Synthetic Biology in Human Cells\n\nPhage-based synthetic circuits with diverse logic configurations, including digital logic circuits, Boolean logic circuits, and non-linear circuits, are developed for bacterial cells. This development relies on the use of the CRISPR-Cas system for gene regulation in combination with various promoter and terminator variants. Here, we summarize recent applications of phage-based synthetic circuits in human cells, including applications such as the synthesis of fluorescent proteins, cellular imaging, and a self-clean",
        "label": 2
    },
    "37": {
        "output": "<EOD> .\nAn investigation of the dynamics of changes at individual phases of the cell cycle and changes in the amount of nuclear DNA during division of the cells of various tumors cultured in vitro was carried out. Cells are considered to be able to survive a deficiency of nutrients during the G0 and G1 phases in the cell cycle. However, cell division, i.e. S- and G2 phases of the cell cycle, is highly sensitive to the conditions of the medium. At a low pH the increase in nuclear DNA and the time for DNA synthesis are shortened, whereas that for mitosis is prolonged. The amount of DNA per nucleus decreases. The time for DNA synthesis and mitosis is also prolonged under excessive glucose concentration, whereas the amount of DNA per nucleus does not change.<EOD> Role of oxalate in the cardiovascular depressant effects of hyperoxaluria.\nCardiovascular depression is one of the main manifestations of hyperoxaluria when the nephrolithiasic state is severe. This phenomenon is probably multifactorial: a role of oxalate in causing myocardial damage with myocardial fibrosis and congestive cardiomyopathy has been suggested by several authors and the clinical course of the patients is often a slow progression rather than an acute deterioration of ventricular function. To assess the role of oxalate in this syndrome, an isolated rabbit right ventricular papillary muscle preparation was perfused with physiological saline solution or with solutions containing increased concentrations of oxalate to simulate the different stages of hyperoxaluria. Increasing concentrations of oxalate (from 0.2 mM to 10.0 mM) produced biphasic effects on myocyte contraction (i.e., relaxation during the isotonic phase and increased duration of contraction during the isometric phase), slowed upstroke velocity at all concentrations and prolonged the time required for relaxation at concentrations up to 10 mM. A similar concentration-response curve was recorded for the oxalate-elicited effects on mechanical efficiency (the inverse ratio of stroke work to the energy required to restore the muscle to the isometric position), which decreased with increasing concentration of oxalate",
        "label": 0
    },
    "38": {
        "output": "1_Trials 10169271\nIf a patient is determined to be eligible for a trial, then the trial-level eligibility should be 2. \n[INST] Hello. After completing a phase 2 trial, you are a patient recruiter for the next trial. This time, you are working for the same clinical research organization (CRO), whose staff is also involved in a multicenter trial. The clinical trial, titled \u201cRandomized, Blinded, Active Phase 3 Comparative Study to evaluate BAY84\u20103653 against standard pegylated liposomal doxorubicin (PLD) in patients with metastatic ovarian cancer that is refractory to multiple prior cytotoxic chemotherapies,\u201d randomizes patients to receive either BAY84\u20103653 or pegylated liposomal doxorubicin. BAY84\u20103653 is a fully human anti\u2010epidermal growth factor receptor 3 (EGFRm) immunoglobulin G1 monoclonal antibody. \nThere are two patient groups. The inclusion and exclusion criteria of each group should be consistent with the corresponding items in the Clinical Notes. Group 1 includes women with metastatic ovarian cancer that is refractory to multiple prior cytotoxic chemotherapies. The primary endpoint is progression\u2010free survival (PFS). The secondary endpoints are overall survival (OS), duration of response (DOR), disease control rate (DCR), overall response rate (ORR), best overall response (BOR), and objective response rate (ORR). \nGroup 2 is a healthy volunteer group that will be used to collect a pharmacodynamic sample to evaluate antibody\u2010dependent cell\u2010mediated cytotoxicity. The primary endpoint is plasma concentration of antibody\u2010dependent cell\u2010mediated cytotoxicity at steady state. The secondary endpoint is peripheral blood mononuclear cell responses measured by enzyme\u2010linked immunosorbent assay (ELISA). \n\nLet's think step by step. \nFinally, you should always repeat Trial-level eligibility in",
        "label": 1
    },
    "39": {
        "output": "This is your first task: To complete the assessment of eligibility for the given patient, that is, to check the patient information against the inclusion and exclusion criteria of the trial. Then after completing the assessment of eligibility, you should output it as `Trial-level eligibility`. The output is also marked as one of the assessment of eligibilities.<EOD> The prevalence, impact and economic burden of cardiovascular non-communicable diseases and type 2 diabetes mellitus in the state of Tabasco\n\nA B S T R A C TAims: In Mexico, more than 70 million people suffer from non-communicable diseases (NCDs), including cardiovascular (CV) non-communicable and type 2 diabetes mellitus (T2DM). Increased morbidity and mortality from NCDs has created an economic burden and strained health care systems. This study sought to evaluate the prevalence and economic consequences of NCDs in Tabasco state in southern Mexico. Materials and methods: A cost of illness study was conducted to evaluate the economic burden of three NCDs: CV non-communicable and T2DM in the State of Tabasco. The sample included 19,512 subjects selected by random cluster, stratified sampling at the census-block level. Data were obtained from the Tabasco Health Information System and the household survey. Three main databases were created from the data collected and the cost of illness tool, that provided the economic burden of NCDs. The tool was validated with input from experts and the analysis was conducted using the 2017 exchange rate of 19.41 MXN ($1.00 USD). Results: The total cost of illness per subject was 10,491.23 MXN (average cost MXN: 525.11 for a subject in good health to MXN: 26,892.08 for a subject with T2DM) and the annual cost of illness was USD 242,705,188.99. The main cost per NCD was pharmaceutical consumption, followed by doctor visits and hospitalizations. CV",
        "label": 2
    },
    "40": {
        "output": "![alt_text](https://www.coursera.org/learn/clinical-trial-recruitment/XHYCJZj744)\n  - **[alt_text_xhycjzj744.jpeg](https://www.coursera.org/learn/clinical-trial-recruitment/XHYCJZj744)**\n\n**Exericse:** `cat data/patient-note-sample/patient-note-sample.txt`\n\n**Sample Output:** \n```\nExcluded\n\t\t\nNOT_RELEVANT\n\t\t\nEligible\n\t\t\n\t\t\nTrial-level eligibility: 0) Excluded\n\t\t\n\t\t\nTrial-level eligibility: 1) NOT_RELEVANT\n\t\t\n\t\t\nTrial-level eligibility: 2) Eligible\n```\n\n**Exericse:** `cat data/clinical-trial-inclusion-exclusion-factors/factors_in_clinical_trial.txt`\n\n**Sample Output:** \n```\nBreast cancer, HER2-positive, ER/PR-negative, invasive, 3 cm\nFemale\nMenopause\nNo sexual activity\nNon-smoker\nNo drinking alcohol\nNo children\nMultivitamins\nNo treatment\nTreated with the FEC100 combination chemotherapeutic regimen\nNo surgical treatment\nNo radiotherapy\nNo concomitant chemotherapy\nAxillary sampling is performed\nTumor resection is planned, a week before chemotherapy\nNo metastases in the CXR\nTreatment plan for at least eight weeks is planned\nResponse rate evaluation for at least 24 weeks after inclusion in the study is planned\n\nBreast cancer, HER2-positive, ER/PR-negative\nEndocrine therapy, endocrine hormonal therapy, endocrine therapy\nBreast lumpectomy and radiation therapy\nTamoxifen\nHerceptin, anti-ErbB2 antibodies, humanized mon",
        "label": 0
    },
    "41": {
        "output": "_You will also get feedback via the console whether you followed the instructions correctly or not._\n\n## [Trial: R001] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare the given patient note with the inclusion criteria of a clinical trial to determine the patient's eligibility._\n### In the given example, your patient, named \\`Dolly Tumble`, meets all the requirements of a clinical trial.\n*Eligible, not relevant: Influenza-like symptoms *Excluded: Elevated blood uric acid, uric acid nephrolithiasis, mild to moderate heart disease.\n\n\n**NOTE** Your code must include the following keywords from the template ``doc-trial.txt``:\n\n- Trial-level eligibility\n- Exclusion criteria\n- Inclusion criteria\n\n\n## [Clinical trials]\n### Summary_\n\nAn experimental procedure that tests whether a therapeutic or preventive intervention is clinically effective and safe. \n\nIt includes a population, an intervention (medicine, surgery, device, behavior, or procedure) administered by providers, and outcomes evaluated. The goal of a clinical trial is to evaluate one or more health care interventions and to produce unbiased scientific evidence.\n\nClinical trials are experimental procedures that test whether an intervention can produce a therapeutic benefit. They also serve as an unbiased scientific foundation for clinical care and evidence-based medicine.\n\nA pre-clinical stage  precedes clinical trials called the \"Bench top\". \n\nClinical Trials are distinguished from observational research or pragmatic clinical trials. \n\n[CQ8.A]: How is it possible to design a clinical trial without bias toward the result a clinician / scientist is expecting to achieve?\n\n- First, it is obvious that this is the only way to achieve this, and the results are then valid.\n- Second, the trial is conducted in double-blind, so that the person evaluating the outcomes and the doctor who gave the drug or placebo are unaware of the interventions. \n\n### What is clinicaltrials.",
        "label": 0
    },
    "42": {
        "output": "# Discussion\n\n## Example 1 \nThe following is the program in the main.ipynb and the resulting table are in the output.csv file.\n\n\n\n\n\nimport csv\nimport sys\nimport io\nimport re\nsys.path.append('./scratch/path_to_data') # if path_to_data folder is not present, specify the path\n\n# Load patient note into variable patient_note.\n\n# Load the data of inclusion_criteria into variable study_data.\nwith io.open('./scratch/data/Evaluate_patient_for_a_clinical_trial.csv', 'r', encoding='utf-8') as patient_notes_file:\nwith io.open('./scratch/data/study_data.csv', 'r', encoding='utf-8') as study_data_file:\nfor line in patient_notes_file:\n    study_data = study_data_file.read().split(\",\") # the input csv consists of two columns separated by commas\n    # for each record in the patient's data, search for matching trials.\n    matches = search_matches(patient_notes_file, trial_data = study_data, note_data = line)\n    # print the matches\n    for match in matches:\n        # store matching elements in trial_eligible_row_data.\n        study_eligible_row_data.append(trial_eligible_row_data[2])\nprint(\"Inclusion criteria for patient note\")\nfor row_data in trial_eligible_row_data:\n    print(row_data)\nprint(\"Patient Eligible for \" + str(number_of_trials_eligible_for_patient))\nprint(\"Total number of trials \" + str(number_of_trials))\npatient_eligible_for_trials =  trials_eligible_for_patient_column_counts\npatient_eligible_for_trials == len(trials_eligible_for_patient_column_counts)\nprint(\"The patient is eligible for \" + number_of_eligible_patients)\nprint",
        "label": 2
    },
    "43": {
        "output": "# AIPO AI15C: Clinical study management\n\n# Problem Analysis\n\n\n\n\n\n\n\nThere are three different systems which exchange information together:\n\n**Patient information systems**: The patient information system is used by people to make an appointment. Physicians and medical staff can also register in this system. All appointments are recorded here. A typical example of this system is the [SARST](http://arsz.sarst-klinik.at).\n\n**Patient registration**: The **patient registration database** stores the registration information of the patients, medical histories, diagnoses, and data for medical reports. Doctors enter the records when a patient visits the clinic. The data is saved in a **MySQL database** and a [PHP](http://www.php.net/) script calls and processes the results.\n\n**The clinical study management database** (CMS): The clinical study management database stores the information of clinical trials. Doctors can register a patient to a trial, and edit patient-to-trial relations. Physicians can change information about the trial, but the trial manager can update the main trial configuration.\n\nSo basically, this is the information flow for a patient who is registered in a trial:\n\n  * patient visits the clinic\n  * he/she is booked by the SARST on Tuesday.\n  * physician checks the trial-ID, and inform the patient: **you are a study person; we will invite to participate in a trial**\n  * patient visit the clinic (he/she is booked to a clinical trial).\n  *  if the patient will have a **computerized tomography** (CT), he/she gets a link to an online form for registration, which is filled out with the doctor.\n  * if a clinical trial is finished on Wednesday (he/she is discharged from the trial)\n  * she has to register in the clinic information system because she has a **CT** on Monday.\n  * physician enters all the data of the patient\n  * trial coordinator can check if the patient is included in a clinical trial for a given day\n  * if the trial and the patient have a suitable relation, then trial",
        "label": 1
    },
    "44": {
        "output": "Your solution might look as follows. [INST]\n```\nfunction patientNotes(patientNotes) {\n  for (let [key, value] of Object.entries(patientNotes)) {\n    let score = getScores(key, patientNotes);\n    print(`Eligibility${score} -`+` ${value} - Score: ${score} ${value}`);\n  }\n}\n\nfunction getScores(key, patientNotes) {\n  return patientNotes[key] ? 1 : 0;// if patient matches key returns 1, otherwise returns 0\n}\n\n\npatientNotes('[ { patientID = \"1\"; \"initials\" = \"MD\"; \"gender\" = \"Male\"; \"country\" = \"Germany\"; \"age\" = \"45\"; \"state\" = \"Schleswig-Holstein\"; \"hospital\" = \"Hamburg\"; \"doctor\" = \"A. B. S.\"; \"doctorPosition\" = \"Head of department\"; \"doctorSpeciality\" = \"Oncologist\"; \"doctorGender\" = \"Male\"; \"doctorNationality\" = \"German\"; \"doctorProfession\" = \"Oncologist\"; \"doctorPosition\" = \"Head of department\"; \"doctorSpeciality\" = \"Oncologist\"; \"doctorGender\" = \"Male\"; \"doctorNationality\" = \"German\"; \"doctorProfession\" = \"Fertility specialist\"; \"doctorPosition\" = \"Consultant\"; \"doctorSpeciality\" = \"Genetic counselor\"; \"doctorNationality\" = \"German\"; \"doctorProfession\" = \"General practician\"; \"doctorPosition\" = \"Family Physician\"; \"doctorSpeciality\" = \"Endocrinologist\"; \"doctorGender\" = \"Male\"; \"doctorNationality\" = \"Belgian\"; \"doctorProfession\" = \"Cardiologist\"; \"doctorPosition\" = \"Attending cardiologist\"; \"doctorSpeciality\" = \"Oncologist\"; \"doctorGender\" = \"Male\"; \"doctorNationality\" = \"French\"; \"doctorProfession\" = \"Fertility specialist\";",
        "label": 0
    },
    "45": {
        "output": "# Discussion\n<section id=\"discussion\">\n# Discussion\n\n## What is trial-level eligibility?\nEach patient should have a trial-level eligibility with its corresponding patient name. Trial-level eligibility assessed by [Patient's full name]. If a patient meets the criteria, the assessment should be returned as the trial-level eligibility \"2: Eligible. For example, if you assess [Patient's full name], the assessment should be 2: Eligible (i.e., patient meets criteria).\n\n## If patient does not meet inclusion criteria (0: excluded), explain:\nIf you assess the trial-level eligibility of a patient as excluded, please explain the reason why the patient cannot join the trial. For example, suppose that [Patient's full name] (43 years old, female) was assessed as 0: Excluded. Exclude reason: [Exclude reason].\n\n## If patient is not relevant, explain:\nIf you assess the trial-level eligibility of a patient as not relevant, please describe the reason why the patient has no sufficient information to qualify for the trial. For example, suppose that [Patient's full name] (39 years old, male) was assessed as Not relevant.\nExclude reason: [Exclude reason].\n\n## The time that it takes to complete an assessment:\n\n## Time required to assess patient's trial eligibility:\nIn general, patients are assessed in about 15 minutes:\n1. Examine patient's medical record\n- Re-examine patient eligibility. See the following points before you check the inclusion criteria:\n\t- How many years of clinical experience you have? \n\t- How many clinical trials you have participated? \n\t- Can you answer 80% more correct in patients whose characteristics do not match with actual patients than patients whose characteristics match?\n\t- How many clinical studies you should participate in a month?\n    \n1. Check the inclusion criteria. \n2. Assess the eligibility of clinical trial to the patients. \n\t\n## Time required to finish all patients assessments\nWhen you have finished the assessment of all target patients, please assess the overall time required to",
        "label": 2
    },
    "46": {
        "output": "### Patient 3's note\n\nYou will analyze patient 3's note and compare in the same way.\n\nThis time we choose `Age: 64\u00b4. In the example `age` is 69. And if we need the patient information more than specific characteristic, we can include all specific characteristics of previous patient information in the note. In this case we choose specific characteristics from patients 1 and 2, which means `Age: 69, histologically confirmed breast cancer, ER/PR negative, HER2(-)+Hormone receptor (+) AND  Pt with DCIS or i<c, postmenopausal, amenorrheic < 12 months, intact contralateral breast, LH, FSH in menopausal range, invasive ductal breast cancer, and HER2 positive`. Since this note satisfies the above, here is the result:\n```\nIncluding\nClinical trial: Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer\nRationale\nEstrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole may",
        "label": 1
    },
    "47": {
        "output": "# How to run the code\n\nTo run the code:\n\n1. Load the environment.\n\n```\n# R STUDIO -i Python: python -i jupyter -i R:rstudio\n```\n\n2. Load the packages.\n\n```\n# R STUDIO R> library(devtools)\n# R STUDIO R> library(rnet)\n```\n\n3. Create the objects.\n\n```\n# R STUDIO R> data(breast_cancer)\n# R STUDIO R> data(survival)\n# R STUDIO R> breast_cancer <\u2212 data.frame(Patient = 1:7,\n# R STUDIO R>                   Factors = c(\"Malignancy\",\n# R STUDIO R>                          \"Age\", \"Gender\", \"Stage1\", \"Stage2\",\n# R STUDIO R>                          \"Histology\", \"Insulin\", \"Tobacco\",\n# R STUDIO R>                          \"Cancer_status\", \"Tumor_size\",\n# R STUDIO R>                          \"Treatment\", \"Treatment_end\",\n# R STUDIO R>                              \"Referred\", \"Consent\"),\n# R STUDIO R>                       x = as.data.frame(runif(7, 1)))\n# R STUDIO R> breast_cancer$Patient <\u2212 factor(breast_cancer$Patient,\n# R STUDIO R>                         levels = c(\"1\", \"2\", \"3\", \"4\", \"5\",\n# R STUDIO R>                           \"6\", \"7\"),\n# R STUDIO R>                  replace = list(3, 4, -1, 6, 3, -1, 4),\n# R STUDIO R>                         scale = TRUE\n# R STUDIO R> )\n# R STUDIO R> survival <\u2212 data.frame(Histology = c(\"TN\", \"TN\"),\n# R STUDIO R>            Factors = c(\"Age\", \"",
        "label": 0
    },
    "48": {
        "output": "[HISTORY]\nThe patient is a 45-year-old postmenopausal woman\u2026\n\nThe patient is taking  multivitamins\u2026\n\nThe patient is taking multivitamins and iron supplements.\n\nThe patient is using multivitamins and iron supplements.\n\nThe patient is taking supplements.\n\nThe patient is taking a multivitamin\u2026\n\nThe patient is using a multivitamin.\n\nThe patient taking\u2026\n\nThe patient taking a multivitamin.\n\nThe patient is taking vitamins.\n\nThe patient is taking supplement vitamins.\n\nThe patient taking a\u2026\n\nThe patient taking supplement dietary vitamins.\n\nThe patient took supplement\u2026\n\nThe patient took a multivitamin.\n\nThe patient takes\u2026\n\nThe patient takes a dietary multivitamin supplement.\n\nSupplement\u2026\n\nMultivitamin supplements...\n\nTaking vitamin supplements.\n\nTaking a multivitamin\u2026\n\nTaking dietary vitamin supplements.\n\nTaking a...\n\nTaking multivitamin supplements.\n\nTaking multivitamins...\n\nShe is taking multivitamins and iron supplements\u2026\n\nShe is taking multivitamins and iron supplements.\n\nShe is taking multivitamins and iron\u2026\n\nShe is taking multivitamins \u2026\n\nShe is taking multivitamins and \u2026\n\nShe is taking multivitamin supplements.\n\nShe is using a multivitamin.\n\nShe is using multivitamins.\n\nShe is using multivitamin supplements\u2026\n\nShe is using a\u2026\n\nShe is taking multivitamin supplements.\n\nShe is taking multivitamin supplements.\n\nShe is taking supplements.\n\nShe is taking multivitamin supplements.\n\nShe took\u2026\n\nShe is using multivitamin supplement.\n\nShe is using supplement\u2026\n\nShe took a multivitamin supplement.\n\nShe took multivitamin supplements\u2026\n\nShe took multiv",
        "label": 1
    },
    "49": {
        "output": "<jupyter_code>trial_patient_report = json.dumps({\n\"trial\":trial.name_trial,\n\"assessment\":assessment.name_assessment,\n\"inclusion_criteria\":{\n\"age_group\":{\n\"range_range\":{\n\"first_value\":45,\n\"second_value\":65,\n\"min_step\":5,\n\"max_step\":1\n}\n},\n\"disease_history\":{\n\"range_range\":{\n\"first_value\":45,\n\"second_value\":80,\n\"min_step\":5,\n\"max_step\":1\n}\n},\n\"gender\":{\n\"range_range\":{\n\"first_value\":M,\n\"second_value\":F,\n\"min_step\":1,\n\"max_step\":1\n}\n},\n\"stage\":{\n\"range_range\":{\n\"first_value\":ii,\n\"second_value\":III,\n\"min_step\":1,\n\"max_step\":2\n},\n\"tumor_site\":{\n\"range_range\":{\n\"first_value\":Breast,\n\"second_value\":Colon,\n\"min_step\":1,\n\"max_step\":2\n}\n},\n\"type\":{\n\"range_range\":{\n\"first_value\":Ductal,\n\"second_value\": Lobular,\n\"min_step\":1,\n\"max_step\":2\n}\n},\n\"histology\":{\n\n\"range_range\":{\n\"first_value\":FG,\n\"second_value\":FG+LG+C,\n\"min_step\":1,\n\"max_step\":2\n},\n\"pre_neoadjuvant_chmp_regimen\":{\n\"range_range\":{\n\"first_value\":A+T,\n\"second_value\":F+B,\n\"min_step\":1,\n\"max_step\":1\n}\n},\n\"neoadjuvant_agent\":{\n\"range_range\":{\n\"first_value\":E+P,\n\"second_value\":NY+E,",
        "label": 1
    },
    "50": {
        "output": "~Here is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nHere are the corresponding inclusion and exclusion criteria of the clinical trial.\n[FIND] Find all clinical trial documents where the trial's title matches. Only take clinical trials that were conducted in the last 5 years. [/FIND]\n~This is a list of clinical trials we found for this topic.\nYou can see from this table that one eligibility factor is alcohol consumption. From the inclusion and exclusion criteria, no, the trial does not consider drinkers as an eligibility factor. However, the clinical trial is looking for abstainers. Drinking alcohol and smoking are factors that are being considered for exclusion, not inclusion, criteria. Based on the clinical trial inclusion eligibility, alcohol consumption is not included. [/IFEL]~[ELIS] Exclude the records where the trial includes the specified exclusion criteria (alcohol or smoking). [/IFEL]\n\nIf you have multiple criteria, the exclusion should be done one after another until the first positive criterion is found. If you are still unsure about certain criteria, you can apply them in your analysis. [/ELIS]~\n[IFNOR] Find all clinical trial documents where the trial's title does not match.\nFind all patient notes where the patient is not a man. [/IFNOR]~\n[ELISM] Exclude the records where the patient is not a man. [/ELISM]~\n[IFEW] Find all patient notes where the age of the patient is greater than 60 years old. . [/IFE",
        "label": 0
    },
    "51": {
        "output": "You can find the solutions to all practice questions in this study guides.<EOD> Immune mechanisms in hepatitis B.\nAntigenic mimicry between hepatitis B surface antigen and human thyroid peroxidase leads to the development of hepatitis B-associated chronic thyroiditis in certain patients.<EOD> Sparse PCA is able to identify a transcriptomic signature of depression\n\n [bib_ref]  Common genetic variation and human traits, Goldstein [/bib_ref]  [bib_ref]  Genetics of body weight, Golan [/bib_ref]  [bib_ref]  Genetic determinants of alcohol dependence: mapping the genome to the behaviors, Macklin [/bib_ref]  [bib_ref]  Variability of the amyotrophic lateral sclerosis phenotype, Turner [/bib_ref]  [bib_ref]  Genetic risk factors for Parkinson's disease, Bardien [/bib_ref]  [bib_ref]  Genetic approaches to understanding mood and affective disorders, Brandon [/bib_ref]  [bib_ref]  The architecture of complex traits, Middelbeek [/bib_ref]  [bib_ref]  Genetic and environmental influences on distinctive effects of trait anger on cardiovascular..., Gerin [/bib_ref]  [bib_ref]  Genetics of body weight, Golan [/bib_ref]  [bib_ref]  A brief history of PCA, Jolliffe [/bib_ref]  [bib_ref]  Common molecular mechanisms in obesity and drug addiction, Kenny [/bib_ref]  [bib_ref]  Mapping cortical brain asynchrony in mood and anxiety disorders, Nugier [/bib_ref]  [bib_ref]  Genetic analysis in generalised anxiety disorder: association with HLA region markers in..., Arias [/bib_ref]  [bib_ref]  Anatomy and genetics of cognitive empathy in major depression, Schmitgen [/bib_ref]  \n\n# Results\nHere we show a proof of concept that PCA identifies a robust transcriptomic signature in MDD, independent of the cohort. A schematic representation of our analysis workflow is given in . First, we investigated whether depressed patients share an identifiable and reproducible transcriptomic signature across different cohorts. RNA-seq data from 148 depressed patients and 84 controls (a total of five cohorts, see were mapped to human genome hg19. Unique transcripts from the mapped reads were counted and quantified to a per sample",
        "label": 0
    },
    "52": {
        "output": "You are done.\n\n## INST.Eligibility - Interactive Lesson - Try Now \n\n# Interactive Lesson\nClinicalTrials.gov provides interactive lessons that give learners hands on experience with the trial data without the need to enter a query.\n\n## Cognitive Requirements\nUse of a personal computer or laptop with either Windows version 2000 or later or OSX version 10.3 or later, and 25 MB of available RAM is required. The lessons also work with a MACintosh Tablet computer equipped with OSX 10.3 or later.\n\n## System Requirements\nA Cognitive Networks Client installation, a client modem, and a telephone or internet access is required to log-on to the system and retrieve the data. This is a Java-based program that requires the Java Virtual Machine version 1.2.1 or later (recommended).\n\n# Interactive Lessons\nThis section contains all lessons in the interactive format, where you will be guided through a tutorial step by step, making it possible for you to gain experience of running queries.\n\n### Lesson 1 - Input file validation\nIn this lesson you practice validating input files against the specifications of the data entry forms found at http://www.clinicalstudydatarequest.com/.\nOnce you have passed this first lesson you can advance further and practice extracting the appropriate data. The first steps in extracting data are always a little uncertain in order to make sure you are getting the data you are expecting.\nYou will be entering data for a trial that you have selected from the trial dropdown list. It will be a trial on methotrexate.\nOnce you have logged on to your system, select the data extraction tab and click on Lessons > Interactive Lessons > Lesson 1 > Input file validation. You'll be presented with the following screen.\nClick the Continue button.\n\n### Lesson 1 - Input File Validation\nOnce you've entered your first name and clicked Log In, the following screen will appear confirming that you are logged in successfully. Scroll down again to Step 1 and click Next > Enter the first 20 trial records for the trial that you've selected. We recommend entering 5 records at a time.",
        "label": 0
    },
    "53": {
        "output": "<br/>\n\n### Problem 1\nThe patient does not meet one of the trial's eligibility criteria or there is no information about the patient's medical history.\n### Potential solution\nYou need to compare the patient's medical history with those specified in the trial, which can be done by writing the patient's medical history to a txt.txt (txt.txt here refers to the name of the file opened via the txt type). If the patient's information is lacking in one of the trial's eligibility criteria, correct it by changing to a string. e.g., when the patient cannot be pregnant, change the string from True to string(False), while when the patient is sexually active, change it to string(True). The last step includes checking the patient against one of the trial's exclusion criteria. Once the clinical trial information is confirmed, you can generate txt.txt files for various trials in the same file.\n\n<br/>\n**Re-submit** \n```\n[0, 2] [0, 2, 2]\n[0, 2] FALSE FALSE \"\"\n```\n\n### Problem 2\nSome eligibility criteria from clinical trials are inconsistent.\n### Potential solution\nWhen an assessment of eligibility is made in the same trial, make sure to check the trial's exclusion criteria to prevent inconsistent assessment of eligibility.\n\nIf the clinical trial information matches the patient's medical history, the code is working as expected, but if one of the trial's eligibility criteria does not match, a pop-up message will be shown.\n\nOnce the clinical trial information is confirmed, you can generate txt.txt files for various trials in the same file.\n\n<br/>\n**Re-submit** \n```\n[1, 2, 2] [1, 2, 2]\n[1, 2, 2] FALSE FALSE \"\"\n```\n\n### Problem 3\nWhen two conditions are met, the code outputs two values. \n### Potential solution\n[0,] is the 'Not relevant' option, corresponding to 1, [1,] is 'Relevant option' , corresponding to 2, and the final value of [1,] [1,]",
        "label": 0
    },
    "54": {
        "output": "<EOD> A comparison of methods for determination of the acid-base composition of plasma: use of non-aqueous solutions.\nSPECTRONCALMETER AND LARYNGOSCOPIC TECHNIQUE TO H. WOOD. J. A. GREEN, F. R.C.S (Eng.), and A. F. HAY, M.D.., F.R.C.P., D.Sc.. ........ 39 A COMPARISON OF METHODS FOR DETERMINATION OF THE ACID-BAS~ COMPOSITION OE PLASMA: USE OF NON-AQUEOUS SOLUTIONS... ................... 43 TWO SISTERS WITH INTERSECTING MOLAR PREGNANCIES. W. A. YOCUM, M.D., and A. I. CARMI, 46 CANCER THERAPY, TREATMENT OF, OF ADRENAL ORIGIN: CASES REPORT OF TWO PATIENTS WITH SULFONAMIOE RESISTANT CARBON TETRACHLORIDE DEPRIVATION FEVER. H. M. WOODRICH, M.R.C.P., and J. EVERE-T-EDS, M.A., PH.D., 47 THE DENNIS SLIP . . . ........ . . . . . . . 48 DETERMINATION OF DRUGS BY GAS CHROMATOGRAPY. K. A. JENKS, M.R.C,P., and K. SHIRLEY AVERY, M.B.,B.S. . . . . . . . . 48 CLINICAL PHARMACOLOGY OF BAROBULAZERIN. GI-ENSEC DE JONG, M.D., 49 MATERNAL COLLAPSE : COMPARISON OF CASES AFFECTED BY PRE-EClAMPSIA, TOXAEMIA OF PREGNANCY, HEPATIC JAUNDICE AND PRE-ECLAMPSION. DAN",
        "label": 2
    },
    "55": {
        "output": "[RUN]\n\n\n---\n\n## [NAME], the clinical trial coordinator at [INSTITUTION]\n. This case is the most interesting one we have had and we hope that we will be able to help this man.\n\nPlease take a seat and let us explain. This clinical trial seeks to prevent the death of patients with metastatic colon cancer who receive chemotherapy treatment.\n\nCancer is a disease in which some of the body's cells grow out of control. In cancerous cells, the normal pattern of growth is disrupted. Usually, cells grow and divide to make new cells. When cancer cells grow out of control, they can form tumors. Cancer is one of the leading causes of death in high-income countries as well as in low-income countries.\n\nMetastasis is a process by which cancer cells spread over the body. If the disease is diagnosed at an early stage, it may be possible to remove the tumor with surgery while it is very small. Unfortunately in a later phase, where the tumor is visible, the disease recurs. The recurrence can be treated surgically or by radiotherapy and chemotherapy. However, in the course of treatment, the side effects of chemotherapy and radiotherapy can occur, some of which are very severe. They include a serious loss of white blood cells, which may make the body too susceptible to infection, such as pneumonia. This means that patients undergoing treatment have to be carefully monitored clinically in terms of signs of infection and radiologically in terms of signs of tumor activity and chemotherapy efficiency.\n\nWe have included in this clinical trial a man who has metastatic colorectal cancer with a high number of circulating tumor cells. This indicates an aggressive disease. We would like to try a new therapy, which combines two standard therapies. The patient has been prescribed chemotherapy for 5 months and currently is on maintenance therapy with the drug Xeloda. We have also included his blood into this clinical trial in order to see if he and other patients with advanced colorectal cancer will benefit from this therapy.\n\nThere are several advantages to this clinical trial, although it is a very strict therapy. We hope that with a more individual therapy, we will bring hope to",
        "label": 0
    },
    "56": {
        "output": "### Example\n\nExample 1: `\n$ ipython notebook example_01.ipynb`\n\nExample 2: `\n$ ipython notebook example_1.ipynb`\n\n\n\n</div>\n\n<ul class=\"sectionnav\">\n<li><a href=\"#top\">Top</a></li>\n<li><a href=\"#content\">Table of contents</a></li>\n</ul>\n</div>\n<!-- /.section -->\n</div>\n<!-- /.container -->\n\n<!-- /.main -->\n<footer class=\"main--footer\">\n    <div class=\"container\">\n        <div class=\"row\">\n            <div class=\"col-sm-12\">\n                <p>The <a href=\"#\">Clinical Trial Eligibility Assistant</a> project is an open source research tool that is distributed under the <a href=\"https://opensource.org/licenses/MIT\">MIT license</a>. For questions or concerns, please contact the authors on <a href=\"mailto:<EMAIL>\"><EMAIL></a>.</p>\n            </div>\n        </div>\n    </div>\n</footer>\n<div class=\"main--footer-block\">\n    <div class=\"container\">\n        <div class=\"row\">\n            <div class=\"col-sm-12\">\n                <p>The\n                <a href=\"http://www.iitm.ac.in/hlimc/ehealth-infrastructure/clinical-trials/\">In silico Health IT Infrastructure Research Center</a> at the <a href=\"http://www.iitm.ac.in/~hlimc/\" target=\"blank\">Indian Institute of Technology Madras</a> conceived and designed this research. All authors contributed to the design and implementation of this project, and the writing of the manuscript. IITM-SIT-642-F-04 project funded the project.</p>\n            </div>\n        </div>\n    </div>\n</div>\n<div id=\"copyright\">Copyright (c) 2013-2021 <NAME>. All rights reserved.\nThis script is free software; you can red",
        "label": 0
    },
    "57": {
        "output": "# Exercise 7: Predicting Eligibility (ELIGIBILITY PREDICTION)\nHere is the patient note and the eligibility prediction:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nPatient ID: 13783\n\n## Exam ID: 9529410\n\n## Trial ID: 36937\n\n## Study Type: Individual\n\n## Trial Phase: 2\n\n## EORTC_32022\n- Randomized Phase 3 Trial of Preoperative (Neoadjuvant) Versus Postoperative (Adjuvant) Chemotherapy With Epirubicin and Paclitaxel in Hormone Node-Negative Breast Cancer With One to Three Positive Axillary Lymph Nodes of the TAXIL Trial Group\n- Molecular Portfolio Study of the Neoadjuvant Use of Chemotherapy in Early Breast Cancer (COMPLEMENT-1).\n- Docetaxel versus paclitaxel: Is an increased antitumor effect related to an increased survival?\n- A Phase II Study of Pertuzumab in Combination With Paclitaxel in Patients With HER2-Overexpressing Metastatic Breast Cancer Subject to Previous Paclitaxel Treatment\n- Neoadjuvant Chemotherapy With Trastuzumab Followed by Adjuvant Trastuzumab Plus Docetaxel vs. Adjuvant Docetaxel for Human Epidermal G",
        "label": 0
    },
    "58": {
        "output": "A: \nLet's think step by step.\n\nThis is actually a great idea, but as it stands you've got a few problems - for instance, it seems that you are trying to return the output from the first pass along the chain, as \"patient.age\", rather than the value of \"patient.age\", in the first iteration for this instance, like so:\n...\n  patient.age - 180.5;\n  patient.age 200;\n+ return patient.age;\n+ patient.age = patient.age - 180.5;\n...\n\nThis will have the effect of returning both \"180.5\" as well as the new set value of \"200\"; this is a form of the \"mutation\" problem in the chain. Try this out - run it a few times, and see what you get:\n[!code](https://scrofula.co.uk/tour/?code=0003)\nand this will be your return value:\n180.5 (if you run it once)\n180.5 (if you run it twice)\n180.5 (if you run it three times, this time the second pass removes the mutation, and as the data is new, will return this)\n200 (if you run it four times, the fourth passes will remove the mutation, so the third pass will get the new value)\n180.5 (if you run it five times, it will be the same here as with four passes)\n200 (if you run it six times, the mutation problem means that this new value will be returned)\n...\n\nTo stop these returning mutated values, you need to make sure that you either copy the \"returned\" value in each iteration, so you can compare it with the next iteration, or return it only after the new value has been updated.\n<EOD> Risk factors for HIV/syphilis co-infection among male injection drug users in a rural, western province of China.\nBACKGROUND\nLittle information is currently available on HIV/syphilis co-infection and HIV-related risk factors for co-infection among Chinese injection drug users (IDUs).\n\n\nOBJECTIVES",
        "label": 2
    },
    "59": {
        "output": "# Detailed explanation\nThis task is inspired from a clinical trial registration of `PMID: 36690020`. The following is the definition of a trial in the [ClinicalTrial.gov](https://clinicaltrials.gov/about-ClinicalTrials. gov) database:\n\n> A clinical trial is research study that involves human subjects. Human research involves the use of human subjects to study the safety and efficacy of new and investigational drugs; to understand the basic science that underlies the use of a particular drug; or to understand how to best use a drug that has been marketed for treating other medical conditions.\n\nThere are two tasks: Assessment of Eligibility Task(AE) and Tailoring Trial Assignment Task of [Clinical Trial Eligibility and Assignment Task](https://github.com/kaggle/CTEAT)___ 1_-_1_A_Assessment_of_Eligibility.ipynb).  AE and TTA are the tasks for the CTEAT.\n\n## Task 1: Assessment of Eligibility (AE).\n\n### Task description\n\nEligibility refers to the subset of patients who are eligible for the trial. These patients meet all the necessary criteria listed in the trial description, and these can be physical, medical, and other characteristics. Some of the criteria are required while some are optional. The eligibility assessment starts with the identification of criteria that are required in the trial from the dataset and determines whether a trial subject/patient meets any of these criteria or not.\n\n### Dataset Description\n\nWe have a clinical trial file along with a file containing a number of records about trials. The two files are stored in the same notebook so that they work together. The following information, about each eligible patient for this trial, are given in the clinical trial file.\n\n - The sex of the patient.\n - The inclusion and exclusion criteria are written as a JSON object. \n  Object { \"inclusion\": [\n  \"age_range:\"{ \"min\":\"18\",\"max\":\"45\"},\n  \"sex\":{ \"required\":true},\n  \"m_pos_breast_cancer\":{\n  \"required",
        "label": 0
    },
    "60": {
        "output": "<EOD> The effect of thienopyridines on coronary thrombosis: an experimental study in pigs\nSummary.\u2002 Background:\u2002 Antiplatelet therapy has major implications in myocardial infarction and subsequent mortality. The aim of this study was to investigate the effects of aspirin (ASA), ticlopidine and clopidogrel on thrombus formation and myocardial ischaemia. Methods and Results:\u2002 40 pigs underwent 120 min balloon occlusion of the mid segment of the left anterior descending artery, followed by reperfusion for 24\u2003h. Ticlopidine, clopidogrel, or ASA were administrated simultaneously with the initial balloon occlusion in each series of animal experiments. The plates were counted with optical light microscope, and ticlopidine and clopidogrel reduced platelet adhesion in large arterioles (R4). The ratio of platelets decreased to 60.2%\u2003\u00b1\u20034.0% (P\u2003=\u20030.015) and 65.6%\u2003\u00b1\u20032.7% (P\u2003=\u20030.033), respectively, compared with the control (74.7%\u2003\u00b1\u20032.8%). Thrombus was also reduced to 56.1%\u2003\u00b1\u20034.5% (P\u2003=\u20030.038) and 57.9%\u2003\u00b1\u20034.1% (P\u2003=\u20030.026), respectively, compared with the control (77.2%\u2003\u00b1\u20032.0%). The infarct size, total creatine kinase (CK), CK\u2010MB enzyme activity and myocardial creatine phosphokinase (CPK) activity after myocardial reperfusion were reduced by ticlopidine and clopidogrel. Conclusions:\u2002\u2002It is reasonable to propose that ticlopidine and clopidogrel reduce the infarct size of an animal with a large ischaemic area by inhibiting the platelet aggregation after reperfusion and decreasing the adhesion at large arterioles.<EOD> A Causative Inheritance",
        "label": 2
    },
    "61": {
        "output": "Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. [/fig] \n [bib_ref]  Cancer treatment and survivorship statistics, Miller [/bib_ref]  <EOD> Evaluation of efficacy of levofloxacin against MDR-TB by time-kill experiment and intracellular survival assay.\nBACKGROUND AND PURPOSE\nThe emergence of multi-drug resistant tuberculosis (MDR-TB), in particular cases resistant to fluoroquinolone, is a significant concern. The purpose of this study was to determine how the susceptibility pattern relates to the efficacy of levofloxacin in MDR-TB, by time-kill and intracellular survival assays.\n\n\nMETHODS\nIn this study, we used the 91 isolates of Mycobacterium tuberculosis, 50 of which were from patients with MDR-TB. Minimum inhibitory concentrations (MICs) were analyzed using the gradient strip method. Time-kill assays were performed to find the drug concentration that caused \u226599.99% killing of bacilli. Intracellular bacillary loads, based on the 32S:260S ratio, were obtained at different time points after infection based on the ratio of 32S to 260S DNA.\n\n\nRESULTS\nOf the 43 isolates tested with known susceptilibilities, 37 were susceptible (MICs = 0.125-1\u00a0\u03bcg/mL), 6 were resistant (MIC =\u00a0>\u00a01\u00a0\u03bcg/mL) and 0 were intermediate (0.5\u00a0\u03bcg/mL). Intracellular burdens",
        "label": 2
    },
    "62": {
        "output": "## Eligibility Assessment\nYour task is to assess the eligibility of patients based on the patient note and the trial eligibility criteria.\nHere is the patient note you should analyze in order to provide a trial-level eligibility value for each patient:\nHere is the clinical trial's eligibility criteria:\n1. Confirmed diagnosis of breast cancer with at least one breast cancer-related bone lesion 2. No treatment with bisphosphonates within 6 months prior to inclusion into the study 3. Good health status (ECOG Performance status 0-2) 4. Negative pregnancy test (for women) 5. Informed consent by patient or legal representative\nYou should calculate Trial-level eligibility value for each patient's patient note based on the clinical trial's eligibility criteria.\nIf the trial-level eligibility value of a patient is 0, the patient is included in the trial (the patient meets inclusion criteria and exclusion criteria do not apply) and we mark the patient name as Y 1 . If the trial-level eligibility value is 1, the patient is included in the trial (the patient meets some inclusion criteria but others applied, and the patient does not fit with no inclusion criteria) and we mark the patient name as Y 2 . Finally, if the trial-level eligibility value is 2, the patient is included in the trial (the patient meets all inclusion criteria). We mark the patient name as Y 3 :\nY 1 = {B, C, D, E, F, G, H, I, J} Y 2 = {F, G, H, J} Y 3 = {B, C, D, G, H, I, J}\nYou should count the number of patients that are qualified as eligible.\nWhen we examine all patients in the dataset and compare the count of Y 1 patients (= 7) with the count of Y 2 \nThe result of your assessment should be one of the following eligibility values:\n[EXERO] 0) Trial-level exclusion: The number of Y 1 patients is less than 3\n1) Trial-level inclusion: Number of Y 1 patients is equal to or greater than 3\n[/EXERO]",
        "label": 0
    },
    "63": {
        "output": "In your main script:\n@testset \"test\" do\n  result = []\n  patient = [\"Age: 45\", \"Menopausal status: Postmenopausal\", \"Her2: HER2 positive\", \"ER: ER negative\",\n               \"PR: PR negative\", \"Smoker: Never smoked\", \"Alcohol: Never drunk\",\n               \"Multivitamins: Never take\", \"Drug: Iron supplements\"]\n  trial = [\"Treatment plan: Tumor-resection prior to chemotherapy\", \"Trial title: Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study\", \"Inclusion criteria: High risk lymph node positive breast cancer defined as 5 or more involved axillary lymph nodes\", \"Positive margin for invasive cancer\", \"No evidence of distant metastasis\", \"Normal heart function\",\n               \"Organ function: ADAUNCE\", \"Age: 18 years or older\", \"No prior chemotherapy, hormonal therapy, or radiation therapy for treatment of the primary breast cancer\"]\n  for i in patient do result += i end result end result = join(result, \"\\n\\t\") result = result = eval result\n  @output.puts \"The patient's note is #{result}\"\n  @output.puts \"Trial-level assessment of eligibility (#{patient.inspect})\"\n  @output.puts trial.inspect\n  eligibility = eval trial.sub(\"Not relevant\", \"Excluded\").sub(\"Eligible\", \"0\").sub(\"Not eligible\", \"2\").sub(\"Excluded\", \"\"*2)\n  eligibility = eval trial.sub(\"Eligible\", \"1\").sub(\"Not eligible\", \"0\"), \"Not eligible\", \"0\"\n  @output.puts \"Trial-level eligibility (#{eligibility})\"\nend\n\n\nFor output:\nThe patient's note is\n\n```\nAge: 45\nMenopausal status: Postmenopausal\nHer2: HER2 positive\nER: ER negative\nPR: PR negative",
        "label": 1
    },
    "64": {
        "output": "## Task 5. [INST] Evaluate clinical trial eligibility and trial-level eligibility. \nHere is a patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial:\nTitle: Spousal Relationships and Pain in Metastatic Breast Cancer\n\n\nSummary: Ecological Momentary Assessment (EMA) refers to the collection of repeated measurements of phenomena as they occur in naturalistic settings using hand-held computers. By providing an EMA of psychosocial variables that influence patient pain and pain behaviors, this study seeks to characterize the pain experience in metastatic breast cancer from both patients' and spouses' perspectives.\nThis study consists of two parts. Part 1 involves developing and pilot testing a hand-held computer program designed to assess antecedents, behaviors, and consequences of patient pain, as well as spouse response to pain. Five couples will complete a baseline survey and carry the hand-held computer for two weeks. They will be interviewed for feedback to refine the program. Part 2 is a longitudinal assessment of the psychological and relationship functioning of metastatic breast cancer patients and their spouses. The Optional Procedure for Part 2 involves using electronic diaries (EDs) to measure the cancer pain experience for patients with metastatic breast cancer and their spouses.\nThe specific aims of this study are to:\n1. To examine patient pain, spouse response to patient pain, and patient behaviors in response to pain over the course of 6 months in couples facing metastatic breast cancer,\n2. test the biopsychosocial",
        "label": 0
    },
    "65": {
        "output": "After this exercise, he will know if the scan (2) is valid. It is valid because the patient has repeated name on the scan (2) and the scan itself. By repeating the patient ID on the scan (2) and the scan (2), the patient would have understood how the information is documented in a clinical trial. Thus, he could determine whether the scans are valid or not. The repeatability of the patient ID or scan ID is important. In clinical trial, it is the requirement for obtaining valid data.\n\nThe following are two screen shots for the patient and the researcher.\n\n\nThe researcher has been asked to describe the name he/she called out. In fact, the researcher should ask the patient to repeat his/her own name out aloud and then repeat the scan. The screen shot for the patient is shown below.\n\nThe researcher repeated a bit of the name, and the patient was not sure if he/she had repeated all the name. The researcher asked him/her to repeat it, and the patient repeated his/her own name as `Jonathan.`\nAfter these",
        "label": 0
    },
    "66": {
        "output": "**Hint:** If there are multiple assessments for one trial, please use @match variable to combine.\n\n## Trial Recruitment Efficacy\n[INST] Hello. You are a helpful assistant in the recruitment for clinical trials. For each clinical trial, you should output an integer score, which denotes the recruitment efficiency for this case. A score of 1 represents perfect efficiency, while score of 0 represents a poor outcome for the trial. Scores close to 1 are good. A score of 1 is not guaranteed, but may be expected.\n\nHere is an example:   \n\n[END]<EOD> .\nA case is reported of renal arteriolosclerosis with chronic renal failure. A 68-year-old man noted right loin pain and hematuria in 1964. Physical examination, laboratory tests and intravenous pyelogram showed no abnormal findings. Urinary enzyme analysis showed normal values for both N-acetyl-beta-D-glucosaminidase (NAG) and alanine aminopeptidase (AAP). His left kidney was nephrectomized in 1967, because left hydronephrosis due to ureteral stone was suspected. After nephrectomy, urinary excretions of NAG and AAP and BUN were increased. In 1983, renal biopsy revealed arteriolosclerosis with massive fibrosis in both hilum and renal cortex. He was admitted to our hospital in July, 1988 due to abdominal pain and fever. Urine NAG and AAP excretions were markedly increased (NAG; 111.5 U/gcr, AAP; 43.7 U/gcr). Intravenous pyelography showed a normal excretion pattern. He developed a fever of 39 degrees C, but leukocytolysis was not recognized. Treated with cephalosporin, the fever subsided. The urinary excretions of NAG and AAP also decreased gradually, but renal function gradually became impaired. He was discharged home and died from gastrointestinal",
        "label": 0
    },
    "67": {
        "output": "Your task has been successfully validated by _username_ and approved by _username_ at `04.09.2018 22:11:00`. \n```\n<bsd-license-header-start^1.c>\n*===============================================================\nBSD\n  Copyright (c) 2018 HSE Institute of Cytology - ***********************\n\n  All rights reserved. This program and the accompanying materials\n  are made available under the terms of the BSD license which accompanies\n  this distribution and is available at: http://openwetware\n                  ---------------------------------------------\n*===============================================================\n</bsd-license-header-start>\n\n<bsd-license-header-end^1.0>\nCopyright (c) 2018 OpenWetWare contributors\n<EOD> The role of anatomical studies in diagnosis of the cause of male infertility\n\nThere is a need to explore the male reproductive system and other structures in detail, thus diagnosing male subfertility/infertility for different groups of etiological causes, especially with the rising interest in the role of andrological services. In the past decade, many studies have demonstrated the link between anatomical abnormalities and male infertility, with some reporting up to 1/3 of cases with these conditions. Furthermore, these abnormalities are often overlooked, contributing to the suboptimal management of male infertility. In this review, we have covered the different anatomical structures within the male reproductive system in detail, describing the normal and abnormal development of these anatomical structures, and discussing the potential role of these factors in determining the male reproductive capacity. The purpose of this review is also to emphasize the importance of exploring these structures in men presenting with various reproductive defects and abnormalities, in a manner allowing diagnosis of the source of infertility. This will help in identifying the cause of infertility and the possible treatment options to improve male reproductive ability.ARTICLE HISTORY\n\n# Introduction\nMale infertility, defined as a male's inability to create viable sperm in the testes for over 1",
        "label": 0
    },
    "68": {
        "output": "Your answer is already added to the Patient note and is now saved under a file name that you indicated. Would you like to check the answer?\n[ENTER OR CLICK ON ENTER] \nYou can enter or view the results manually by pressing the `Enter` key.\nYou have now completed the first block of this lesson.\nIn the next block, you will continue working with patient notes.\n\n\n[INST] Good morning, Assistant.\n\nYou have already seen a sample of patient notes and their initial eligibility assessments. To assess the patients' eligibility, you need to answer 6 multiple-choice questions for each of the two patient notes. Each question asks you to compare information on the patient, obtained from the patient note, with the inclusion criteria on the clinical trial. \nEach question is preceded by the patient name and number (this is how you will be called in our system) and is followed by the initial result of assessment. This initial result is the number 0 - Excluded, 1 - Not relevant, or 2 - Eligible. Click on the question to answer. \nThe system will compare the information that you have entered in the corresponding field with the eligibility information on the clinical trial. If the patient meets all of the inclusion criteria but does not violate all of the exclusion criteria of the trial, then he should be classified as eligible. If the patient does not meet the requirements of the trial, then he should be classified as not relevant. If at least one of the exclusion criteria of the trial is violated, then the patient should be classified as excluded. If the patient does not have sufficient information on the patient note to qualify for the trial, then you should not classify the patient. The assessment of eligibility is summarized with a number in the scale of eligibility.\nYour results will be saved to the Patient note file. \nYour results are added to the Patient note after you click on the 'Save' button. It is important to click on the 'Save' button only from the last step of a set of Patient notes.\nNow, you will see a list of patient notes that you have already started working with and your results for the first two patient notes that you saw. There are 1274 patient notes here. \nYour answers are now saved into",
        "label": 0
    },
    "69": {
        "output": "Trial-level eligibility: 2) Eligible<EOD> The Roles of BMP6 and BMP7 on the Regulation of Inflammation, Angiogenesis, and Proliferation of Synoviocytes Inspired by Joint Cavitation\n\n\n\n# Introduction\nIn the last decade, there has been a breakthrough in the field of cell therapy and biotherapy. In recent years, a new focus of research in regenerative medicine has emerged, in which tissue-and disease-specific stem cells (SCs) are considered to be ideal candidates for such therapies and regenerative processes [bib_ref]  Cell-to-Cell Heterogeneity in Stem Cell Differentiation and Cancer Precursor Cell-Based Therapies, Eyler [/bib_ref] . Stem cell derivatives are multipotent cells capable of differentiating into various cell types or cell lineages. The development of SC-based regenerative cell products and cell therapies is being promoted by the European Medicines Agency and the United States Food and Drug Administration. To obtain a cell culture, it is often performed by in vitro culturing of the SCs. The stem cell's ability to actively propagate the genetic material, with a large amount of unrepeated DNA (genomes and plasmids) being lost during this process, which may be caused by random integration into the host's chromosomal DNA sequences or other, less frequently occurring phenomena that can occur. These changes can potentially lead to changes in the phenotype of the SC, affecting their properties (phenotype variation), including the ability to respond to various stimuli, such as proliferation, differentiation, and apoptosis, and the mechanism by which cells proliferate and differentiate and the ability to self-replicate. It should also be added that during the proliferation and differentiation of SCs in the cultures, they are also subjected to the influence of various factors, which is why it is reasonable to modify the composition of the medium in different types of cells depending on the characteristics and properties specific to each type.\nBone marrow mesenchymal stem cells (BM-MSCs) are adult, pluripotent cells with a great ability to self-renew and differentiate. Due to",
        "label": 1
    },
    "70": {
        "output": "## Examples\n\nPlease note that the example above is an excerpt from actual trial data.\n``` \nPatient - 34\nAssignments -\nTrialenrol - 1\nVon Trial - 2\nTrial-stufen - 0\nAntrag - 0\nAnmerkung -\n``` \n    In the following example, the Patient is excluded because she is younger than the lower age limit (35 years). \n``` \nPatient - 39\nAssignments -\n  Trialenrol - 0\n  Von Trial - 0\n  Trial-stufen - 0\n  Antrag - 0\n  Anmerkung -\n``` \n    In the following example, the Patient is eligible; she is older than the lower age limit (35 years). \n``` \nPatient - 45\nAssignments -\n  Trialenrol - 0\n  Von Trial - 0\n  Trial-stufen - 2\n  Antrag - 0\n  Anmerkung -\n``` \n    In the following example, the Patient is excluded because she is older than the upper age limit (65 years). \n``` \nPatient - 68\nAssignments -\n  Trialenrol - 0\n  Von Trial - 0\n  Trial-stufen - 0\n  Antrag - 0\n  Anmerkung -\n``` \n    In the following example, the Patient is included because she has advanced breast cancer and is currently undergoing chemotherapy.\n``` \nPatient - 45\nAssignments -\n  Trialenrol - 0\n  Von Trial - 0\n  Trial-stufen - 1\n  Antrag - 0\n  Anmerkung -\n``` \n    In the following example, the Patient is included because she has advanced breast cancer.\n``` \nPatient - 45\nAssignments -\n  Trialenrol - 0\n  Von Trial - 0\n  Trial-stufen - 1\n  Antrag - 0\n  Anmerkung -\n``` \nIn the following example, the Patient is included because she has locally advanced or metastatic",
        "label": 0
    },
    "71": {
        "output": "__11__ [MID] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The assessment of eligibility is in the form of a score based on a 2-level scale: 0) Not eligible (patient meets exclusion criteria but not inclusion criteria or the patient has missing information for the assessment of eligibility); and 1) Eligible (patient meets all of the inclusion criteria and does not have any of the exclusion criteria).\n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multi-vitamins and iron supplements. She is a non-smoker and does not drink alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and has agreed to do so prior to chemotherapy.\n(Continue)\n\n```python\nimport pandas as pd\nfrom nstruct import TDDataBase, TDBrowse\n\n__author__ = '<EMAIL>'\n\n__INSTANCE__ = 't2dc'\n__INSTANCE__ __0_ = 'data/t2dc/t2dc_instances/' + __INSTANCE.__0__\n__INSTANCE__.load_instance(__INSTANCE__ __0_)\n# Create TDBrowse\nTB = TDBrowse(__INSTANCE__)\n\n__name__ = 'trial-level eligibility'\n__1 = __name__.lower()\n__2 = __name__.capitalize()\n\n\nimport math\nimport numpy as np\nfrom tdbrowse import metadata\nfrom nstruct import TDBrowse, TDBrowser, TDDF, tdDF\n\nimport matplotlib.pyplot as plt\n\n# load patient\npatient = 'data/t5",
        "label": 0
    },
    "72": {
        "output": "<h3>A: Output the number of eligible patients.</h3>\n\nA: In my case I used the `len` method from `str.morphs` module:\n\n`len(filtered_patients)`\n\nThe code ran in 0.0973 s.\n\n\n<h3>B: Output the number of patients who meet inclusion criteria but have exclusion criteria.</h3>\n\nB: In my case I used the `len` method from `str.morphs` module:\n\n`len(filtered_patients)` - 45    \n\n`filtered_patients.isin(B)`  \n\n`filtered_patients.isin(C)` \n\nThe code ran in 0.0763 s. \n\n<h3>C: Output the number of patients who meet exclusion criteria.</h3>\n\nC: In my case I used the `len` method from `str.morphs` module:\n\n`len(filtered_patients)`\n\nThe code ran in 0.0068 s.\n\n\n<h3>D: Output the number of patients who meet none of inclusion criteria nor of exclusion criteria.</h3>\n\nD: In my case I used the `len` method from `str.morphs` module:\n\n`len(filtered_patients)`\n\nThe code ran in 0.0056 s.\n\n\n[CODE]<EOD> E-cigarette regulations for protecting nonsmokers from secondhand vapors: balancing the prevention of harm while encouraging innovation.\nFederal legislators in the United States and European Union have introduced regulations with the objective of preventing secondhand exposure to electronic cigarettes (ECIGs). ECIGs are a new electronic nicotine delivery system that can simulate smoking a traditional cigarette in the absence of burning or inhaling smoke. We discuss the public health implications of regulations and review the evidence regarding regulations related to tobacco control policies, tobacco product manufacturing, and tobacco products and smoking cessation treatment. Some tobacco control advocates have argued that ECIGs are a healthy alternative to",
        "label": 1
    },
    "73": {
        "output": "## Challenge\nFind what you can do with a little more detail about the patient note:\n\n```\n\n<h2 class=\"title\">[NAME]'s Patient Note</h2>\n\n\n<table id=\"tab_table\" class=\"tab_content table\"><thead><tr><th scope=\"col\">Hospital Number:</th>\n<th scope=\"col\">Admitted Date:</th>\n<th scope=\"col\">Reason:</th>\n<th scope=\"col\">PCP:</th>\n<th scope=\"col\">Age:</th>\n<th scope=\"col\">Facility:</th>\n<th scope=\"col\">Syst. Codes:</th>\n<th scope=\"col\">Comments:</th>\n<th scope=\"col\">Labs:</th>\n<th scope=\"col\">Diagnostics:</th>\n<th scope=\"col\">Special Studies:</th>\n<th scope=\"col\">Treatment:</th>\n<th scope=\"col\">Med. Stat.:</th>\n<th scope=\"col\">Notes:</th></tr></thead>\n\n<tbody id=\"tab_table_body\">\n<tr>\n<td scope=\"row\">1</td>\n                    <td scope=\"row\">266154551</td>\n                    <td scope=\"row\"> \n                      <NAME>, Jr , MD \n                    </td>\n                    <td scope=\"row\">Dermatologist \n                    </td>\n                    <td scope=\"row\">67</td>\n                    <td scope=\"row\">546</td>\n                    <td scope=\"row\">Hospital at home</td>\n                    <td scope=\"row\">717-721</td>\n                    <td scope=\"row\">\n                    830.4\n                    696.9\n                    </td>\n                    <td scope=\"row\">\n                    14 Apr 17\n                    </td>\n                    <td scope=\"row\">\n                    Evaluation and Management - Other\n                    </td>\n                    <td scope=\"row\">1\n                    </",
        "label": 0
    },
    "74": {
        "output": "A clinical trial in which patients are classified as eligible or excluded for a specified study is called an eligible clinical trial. This is because the number of patients eligible for a clinical trial is called `eligible patients. The sum of the number of eligible and excluded patients is called `total patients.\nAssuming that the patient  `patient` has some information:\n\n*  `pat.age` is the age of the patient.\n\n*  `pat.gender` is the gender of the patient.\n\n*  `pat.stage` is the stage of the cancer.\n*  `pat.tumor` is the type of the tumor.\n*  `pat.excluded` is a boolean value indicating whether the patient meets the exclusion criterion of the clinical trial. For example, patients over 65 years of age are not eligible to participate in this clinical trial.\n\nThis is a patient note, so the patient's `gender` is a one-hot vector. Other data is the actual numbers. Therefore, we need to convert all of them into vectors. The patients in the second example may be a set of `patient  = {{103},{108} ,{}`. A set of eligible patients  `patients` for a trial is a `vector` of some size, so we need to store the data in the format of a `Pandas.DataFrame` object.\n\nFor example, the patient data of the trial in the first example is as follows:\n\n```python\n# Load the trial data\nfrom pathlib import Path\nimport pandas as pd\n\ntrial_data = pd.read_csv(\"./trials/sample_data/trial_1.csv\")\nprint(\"Total patients:\", trial_data.shape)\nprint(\"Eligible patients:\", trial_data.dropna().shape)\n```\n\n    Total patients:  \n    \n    (149, 38,)\n\n    Eligible patients: \n    \n    (8, 6, 6)\n    \n    (16, 1, 0, 0, 0, 0, 0)\n    \n    (0, 6, 9, 0,",
        "label": 0
    },
    "75": {
        "output": "You are welcome to contribute to our community!\n<EOD> .\nSince the beginning of this century the human being has been considered as a mixture of animal and germ. The first biological experiments have showed that the human being had, at least in the first months of its life, a much bigger percentage of germ (23%). If the human being is a mixture in her first months, it is impossible to consider that there are still germs in the adult human being. The human being is an animal, and if we consider him as a mixture of germ and animal then the animal has disappeared. If the human beings are like their pets, we have a logical answer of how they can become extinct.<EOD> Numerical computation of dynamic properties of granular flow from experimental measurements in silos: I. Dynamic bulk density.\nComputations of the granular flow are carried out for a two-dimensional circular silo with various flow angles. These calculations are based on numerical measurements of the dynamic bulk density g(r, omega) calculated from the experimentally measured number densities (N(r, omega)) of particles in granular flow. The numerical solution of the linear differential equation (29) is first carried out, yielding the values of g(r, omega). The obtained g(r, omega)(= f(r, omega)) is then used to solve the equation of motion (4), which gives the radial force exerted by the granular flow on the walls. The method we propose is useful when the number of particles per unit volume is small, as in high-capacity silos. The computational results in the present paper are compared with predictions obtained by the hydrodynamic approach (H)  and previous simulation results .<EOD> .\nIt is demonstrated that 1 day-old rabbits infected orogastrically with the protozoan Sarcocystis ovifera can develop an acute cerebral sarcocystosis, which begins on the 2nd day after infection, with development of granulomatous inflammation, sarcocyst development and central nervous system damage. In the acute stage the necrosis or suppurative process of brain tissue and cerebral vessel damages was found. The acute stage of cerebral sarcocystosis of the 2-6 days is characterized by the presence of the granulom",
        "label": 2
    },
    "76": {
        "output": "<img alt=\"image/jpeg\" src=\"https://github.com/rinkydinkbrain/pwl/blob/master/data/examples/example_patient_med.png\" thumbnail=\"true\"/>\n<EOD> .\nIt was found, analysing the relationship between social-economic and occupational statuses and the distribution of cardiovascular risk factors by sex, that for all of them the difference between the groups with a higher social-economic status was statistically highly significant. The level of risk factors varies with the social status. For women, significant correlations were shown between social-economic level and levels of smoking, drinking and blood glucose. For men the significant correlations occur in respect of smoking, blood pressure, cholesterol level, drinking and blood glucose. These results allow to suppose that the distribution of cardiovascular risk factors differs significantly in the group of men and women with higher socioeconomic level. Thus, it is necessary to develop measures for the primary prevention of cardiovascular diseases targeted at the people who should be the most receptive of them and who are at risk.<EOD> Effects of endocrine therapy on postoperative recurrence and survival of endometrial cancer with high risk factors (ESMO C5 guideline): A single center, retrospective cohort study\nObjectives In 2019, the European society of medical oncology published a guideline defining endometrial cancer in the uterus as highrisk disease (ESMO C5) based on myometrial invasion deeper than one quarter, presence of cervical stromal involvement, and positive pelvic or para-aortic lymph node (LN). Endocrine therapy is recommended as a standard endocrine postoperative adjuvant therapy for this disease. Our study aims to analyze the association of adjuvant endocrine therapy to prognosis in women with C5 endometrial cancer using a single-center dataset. Methods Women with C5 endometrial cancer who underwent hysterectomy between January 2009 and December 2030 were enrolled. Excluded were patients with LVSI grade >3, no LVSI, uterine sarcom",
        "label": 1
    },
    "77": {
        "output": "<EOD> Stereocontrol of the hydroboration of prochiral enones and aldehydes catalyzed by a bidentate aluminum Lewis acid.\nWe recently reported 2 (L1) and  (L2) as efficient bidentate, tridentate, or pentadentate Lewis acid catalysts for the stereoselective hydroboration of carbonyl compounds . In this study, we show that L1 and L2 catalyze stereoselective hydroboration of prochiral linear \u03b1,\u03b2unsaturated ketones and prochiral aldehydes in methanol, in reactions catalyzed by the Lewis acid.<EOD> Inhibition of luteinizing hormone secretion by estradiol in the hypogonadal (hpg) mouse is estrogen receptor dependent.\nPrevious studies demonstrated that the estrogen receptor antagonists ICI 164,384 (6-methyl, 17-alpha-acetoxy-estradiol, ICI) and ZM 188,679 (9-nitro-3-decyl-l-1,2-cyclopentanedione, ZM 01163) are inactive in inhibiting the pulsatile secretion of LH in hypogonadal (hpg) mice. The present study indicates that injection of a dose of ICI that inhibits ovulation in wild type mice at least partially reverses the deficiency in the pulsatile secretion and surge of LH in hpg mice. This effect of ICI was not observed in hpg mice carrying the C5 mutation in the ESRalpha gene, which abrogates the ESRalpha dimerization function. Moreover, injection of ZM 01163 caused a sustained decrease in LH in hpg mice which was also observed in hpgC5/C5 mice, but not hpg/hpg animals. Together, the results suggest that the lack of ESRalpha dimerization function blocks the inhibitory action of estradiol on the GnRH pulse generator in mice.<EOD> Adenoviral-transfected cells produce immunoreactive and bi",
        "label": 0
    },
    "78": {
        "output": "Each row must start with RxID, and the first three columns are: patient ID, drug, and date, respectively.\n\n### [INST] DATA-2\nThis dataset is an example of a clinical trial's inclusion criteria. We used a table to store inclusion criteria that can be used in [INST] BUILD-INCLUSION-CRITERIA-TRIAL. Some data are hidden to save your time creating pseudo-data. You may write your own",
        "label": 0
    },
    "79": {
        "output": "[INSERT]\n\n### Learning Resources\n\n[INST]\n\nFor learning resources, please visit the following.\nThe course content is available at this link: https://www.coursera.org/learn/breastcancer\nFor more detailed and comprehensive information on breast cancer, please visit the following online databases:\n- NCCN Clinical practice guidelines: https://www.nccn.org/\n- NCCN practice guidelines: https://www.nccn.org/professionals/ physician_gls/pdf/breast.pdf\n- NCI PDQ: https://www.cancer.gov/\n- NCI Breast Cancer Clinical Trials: https://www.cancer.gov/about-cancer/treatment/",
        "label": 2
    },
    "80": {
        "output": "# Part 3 - Eligibility (Bug Hunt and Solve it)\n\n# 1A. Bug #1 - HER2-ICH3+ or FISH+\n\nThis bug requires the following:\n- `isHER2+` method in `CancerNote`\n- `icd_9_code` and `icd_10_code` methods in `InclusionCriteria`\n- `getPatientID()` and `getTrialsID()` methods in `DiseaseNote`\n\n## Solutions  \n\n```python\n#!/usr/bin/env python\n\nimport pandas as pd\nimport numpy as np\nfrom ipywidgets import widgets as widgets\nimport ipwidget\nimport seaborn\nimport pandas as pd\nimport numpy as np\n\napi = 'https://api.bomber-bomber.fr/'\napi_token = '<KEY>'\napi = seaborn.api.get_api(api, api_token)\n\n\n# TODO : Add this\n# ----------------------------------------------------------------------\n# 1) Get data \n# get cancer note dataframe\n# cancer_note = api.get_api(api).get(url='/api/cancer_note/')\n# print('---------------------')\n# print(cancer_note)\n# print('---------------------')\n# Get trial of interest\n# trials_df = api.get_api(api).get(url='/api/trial/')\n# print('---------------------')\n# print(trials_df)\n#---------------------------------------------------------------------\n\n# ---------------\n# 1A: HER2-ICH3+ or FISH+\n# --------------------------------------\n\n# Add HER2 ICD 9 and 10 code\nher2_code_dhir = pd.Series(api_get_her2_dhir(api_token))\nher2_code_icd9 = pd.Series(api_get_her2_icd9(api_token))\nher2_code_icd10 = pd.Series(api_get_her2_icd10(api_token))\n\n# 1A\n# H",
        "label": 1
    },
    "81": {
        "output": "# Input Formulas\n\n## # A. Input form #\n\n- __Input Formula 1 of 8:__\n```python\n    @json_field_name(name=\"Trial-level eligibility\")\n    @json_input({\"eligibility\": \"Excluded\"}) or (\"eligibility\": \"Not relevant\") or (\"eligibility\": \"Eligible\")\n    @json_type(json_type=\"integer\")\n    def trial_level_eligibility(self, request, *args, **kwargs):\n        self.add_attrs(request, \"body_json[]\", request.body)\n        self.add_attrs(request, \"body_json\", json.loads(request.body))\n        self.add_attrs(request, \"body\", json.loads(request.body))\n        return self.get_value(\"body['trial-level-eligibility']\")\n```\n[/CONT]\n\n## # B. Input Form #\n\n- __Input Formula 2 of 8:__\n```python\n    @json_field_name(name=\"Trial-level eligibility\")\n    @json_input({\"eligibility\": \"Excluded\", \"trial_level_eligible\": \"false\"}) or (\"eligibility\": \"Not relevant\", \"trial_level_eligible\": \"false\") or (\"eligibility\": \"Eligible\", \"trial_level_eligible\": \"true\") or (\"eligibility\": \"Invalid\", \"trial_level_eligible_flag\": \"wrong_json_type\" ) or (\"eligibility\": \"Invalid\", \"trial_level_eligible_flag\": \"wrong_json_fields\" ) or (\"eligibility\": \"Invalid\", \"trial_level_eligible_flag\": \"missing_string_value\" ) or (\"eligibility\": \"Invalid\", \"trial_level_eligible_flag\": \"unknown_json_value\" ) or (\"eligibility\": \"Invalid\", \"trial_level_eligible_flag\": \"integer\" )\n    @json_type(json_type=\"string\")\n    def trial_level_level_eligible(self, request, *",
        "label": 1
    },
    "82": {
        "output": "<EOD> The Clinical Efficacy of Botulinum Toxin-A in Refractory Spasm Associated with Necrotizing Soft Tissue Infections.\nINTRODUCTION\nNeurological complications are a well-known complication of both methicillin-sensitive and methicillin-resistant Staphylococcus aureus necrotizing soft tissue infections (NSTI). Spasm is a particularly distressing neurological manifestation, but a limited number of therapies are currently available to treat this symptom. Botulinum is an increasingly used therapy in other neurologic disorders, however its effectiveness for spasm seen in NSTI has yet to be studied. We sought to evaluate the effectiveness of intramuscular bolus injections of botulinum toxin-a (Botox) for treatment of refractory spasm associated with NSTI.\n\n\nMATERIALS AND METHODS\nA retrospective review was performed to identify patients with a diagnosis of NSTI who received Botox injections between 2010 and 2020. Clinical charts and pharmacy records were reviewed to identify demographics, location of injection, days to injections from initiation of antibiotic therapy, dosing of Botox, and time before improvement of spasticity. The primary outcome of interest was time to resolution of spasticity after Botox administration.\n\n\nRESULTS\nFifty patients who received Botox for refractory spasm associated with NSTI were identified. Patients had a median age of 57 years, and 60% were male. The median interval from completion of antibiotic therapy to Botox administration was two days (interquartile range 2-3 days). Bolus injections of 300 units were administered to each ankle, hip flexors, quadriceps, hamstrings, gastrocnemius, and calf muscles. The median time to the resolution of spasm was 15 days and ranged from 4 days to 25 days. In our study, a Botox infusion of 300 units significantly decreased spasticity in refract",
        "label": 1
    },
    "83": {
        "output": "### <NAME>, clinical research assistant\n<EOD> Tips on Using HAID to Create Dynamic, Multimedia Presentations, Part II\nThis is the final in our series of three articles.<EOD> Inhibition of bacterial growth in fresh-cut apples by polylysine coating.\nFreshly harvested 'Braeburn' apples were inoculated with Staphylococcus aureus strain DFH-433 (214.4 +/- 1.9 colony forming units/apple) or Escherichia coli O157:H7, strain TWAR and incubated at 5 degrees C or 25 degrees C with a poly-L-lysine coating. At 5 degrees C, coating caused an initial increase in staphylococci on apples, followed by a reduction to 144 colony forming units/apple on the 4th day (control, 232.9 +/- 20.1 colony forming units/apple; P = 0.024); a similar pattern was observed for E. coli O157:H7. Poly-L-lysine coating at 25 degrees C reduced staphylococci from 194.7 +/- 8.0 colony forming units/apples uncoated to 16.3 +/- 2.1 colony forming units/apple coated (P = 0.021) and E. coli O157:H7 from 226.5 +/- 17.2 colony forming units/apples uncoated to 137.4 +/- 23.2 colony forming units/apple coated after 4 days (P = 0.062). Poly-L-lysine coating also increased staphylococcal populations on sliced apple cubes inoculated with strain DFH-433 (239.9 +/- 25.9 colony forming units/slice coated vs 123.4 +/- 13.7 colony forming units/slice uncoated; P = 0.033). Poly-L-lysine coating",
        "label": 0
    },
    "84": {
        "output": "This is the end of the lesson.\n\n## Lecture 4: Lesson 4\nYour task is to write a patient note by filling out a patient note from your own patient's list. This patient's diagnoses are listed in [fig_ref]  Table E1 1: [/fig_ref] .13. You should include data and a history of past illnesses. Note as to if the patient has received other medical histories or any other past medications. Use one subject to write. \n\n## Exercises for the lesson 4\n\n## Exercise 1\nIn this exercise, you should write a patient note by filling out patient information including a history of past illnesses from your own patient's list.\n\n## Exercise 2\nIn this exercise, you should write a patient note about a patient taking the following medications: Glyburide/metformin, Lercanidipine/ Hydrochlorothiazide, Metoprolol succinate, Atorvastatin calcium.\n\n## Exercise 3\nIn this exercise, you should write a patient note about a patient taking the following medications: Doxasosin hydrochloride/hydrochlorothiazide.\n\n## Exercise 4\nYou should write a pregnancy note for a case including the following clinical cases. \n\n## Exercises for the lesson 5\n\n## Exercise 1\nIn this exercise, you should use [link text] to draw an axillary specimen photograph.\n\n## Exercise 2\nIn this exercise, you should draw radiographs of the right chest and lung using [link text] to understand chest X-rays better.\n\n## Exercise 3\nIn this exercise, you need to write about a patient receiving physical examination for a diagnosis of acute appendicitis. Write a patient note using the data of the following cases. Clinical history: The patient is a 34-year-old woman visiting our outpatient department of department of internal medicine. Sixteen years ago, she had been treated for diabetes mellitus at another hospital. She was put under the care of another internal physician in the medical center where is living now. She has a",
        "label": 0
    },
    "85": {
        "output": "<EOD> Transforming growth factor-beta 1 (TGF-beta 1) potentiates lymphocyte responses. Studies in patients with acquired immunodeficiency syndrome.\nCytokine regulation has been implicated in the development of anergy or unresponsiveness of lymphocytes in individuals infected with HIV-1. It is believed that TGF-beta 1 is involved in impaired lymphocyte activation, in part, through transcriptional repression of the IL-2 gene. To determine if increased levels of TGF-beta 1 were involved in suppressing cellular immune responses in AIDS in vivo, we utilized a PHA-induced lymphocyte proliferation assay from the patients with AIDS and AIDS-related complex (ARC). We also evaluated the effect of TGF-beta 1 upon lymphocyte activation. Our results indicate that TGF-beta 1, alone did not suppress PHA-induced lymphocyte blastogenesis. However, lymphocytes obtained from patients with AIDS and ARC, when exposed to rTGF-beta 1, could be activated to secrete IL-2 and proliferate. These data suggest that TGF-beta 1 plays an immunoregulatory role for the maintenance of normal lymphocyte proliferation induced by mitogens. TGF-beta, alone did not induce lymphocyte proliferation but could augment lymphocyte responses.<EOD> Evaluation of an integrated psychosocial intervention for women in a high-risk population in rural KwaZulu-Natal, South Africa: the effect of psychosocial skills training, social support and a sense of belonging in an intervention delivered via community health workers (CHWs).\nBACKGROUND\nIn recognition of the importance of community in the lives of women, and the influence this has on outcomes such as antenatal weight gain and retention in care, a psychosocial intervention was developed for a high-risk population of pregnant women in South Africa.\n\n\nOBJECTIVE\nThe aim of the study was to investigate the effectiveness of the intervention across three components - psych",
        "label": 0
    },
    "86": {
        "output": "Examples\nIn the following, three example datasets are evaluated, each of which contains three trials that use slightly different inclusion criteria but identical exclusion criteria.\n\nFirst, let's evaluate the dataset `pat_data.patient_input.txt` with the number of patients 15 and include the file, which contains the corresponding trials with number of trials 3 and each trial's inclusion and exclusion criteria.\n\n```python\nimport os\nimport psip as psi\n\npsi.read_file_directory(r'./data/sample_01')\npsi.psip_viewer(r'sample_01.log')\npsi.psip_viewer(r'sample_01')\npsi.psip_viewer(r'sample_01_trial1.txt')\npsi.psip_viewer(r'sample_01_trial2.txt')\npsi.psip_viewer(r'sample_01_trial3.txt')\npsi.psip_viewer_pat(r'sample_01')\n```\n![](../_images/viewer/trial.3.pdf)\n\nIn the same way for dataset `pat_data.patient_input.txt`.\n\n```python\npsi.read_file_directory(r'./data/sample_02')\npsi.psip_viewer(r'sample_02')\npsi.psip_viewer(r'sample_02_trial1.txt')\npsi.psip_viewer(r'sample_02_trial2.txt')\npsi.psip_viewer(r'sample_02_trial3.txt')\npsi.psip_viewer_pat(r'sample_02')\n```\n![](../_images/viewer/trial.5.pdf)\n\nAnd for dataset `",
        "label": 0
    },
    "87": {
        "output": "---\n### `Instructions`\n\nThis task involves multiple steps. First we have to find the value of [**Trial-level variables**](trial_level_variables.html). We will need the triallevel variable for:\n1. Age group: [**Trial-level variable: Age group**](age-group.html)\n1. Menopausal status: [**Trial-level variable: Menopausal status**](menopausal-status.html)\n1. Histological tumor type: [**Trial-level variable: Histological tumor type**](histological-tumor-type.html)\n1. Axillary node status: [**Trial-level variable: Axillary node status**](axillary-node-status.html)\n1. Type of lymph node dissection: [**Trial-level variable: Type of lymph node dissection**](type-of-lymph-node-dissection.html)\n1. Breast-and tumor-size classification: [**Trial-level variable: Breast-and tumor-size classification**](breast-and-tumor-size-classification.html)\n1. Pathological T classification: [**Trial-level variable: Pathological T classification**](pathological-t-classification.html)\n1. Primary tumor grading: [**Trial-level variable: Primary tumor grading**](primary-tumor-grading.html)\n1. Clinical lymph node status: [**Trial-level variable: Clinical lymph node status**](clinical-lymph-node-status.html)\n1. Histological lymph node status: [**Trial-level variable: Histological lymph node status**](histological-lymph-node-status.html)\n1. Adjuvant systemic therapy: [**Trial-level variable: Adjuvant systemic therapy**](adjuvant-systemic-therapy.html)\n1. Adjuvant locoregional treatment: [**Trial-level variable: Adjuvant locoregional treatment**](adjuvant-locor",
        "label": 0
    },
    "88": {
        "output": "An electronic clinical case note can contain several pages that describe the details of a particular encounter, including the following: History and physical examination, diagnostic imaging or studies, laboratory results, medical records, and other types of documentation (e.g., consultation notes, pathology and microbiology reports). \nA clinical note template consists of fields that facilitate the entry of pertinent medical information on an electronic patient record. It is composed of a data model that contains pre-defined data fields (e.g., laboratory tests, special test categories). \nFor each patient note you receive, you should answer the following questions: \n**Question 1:** What clinical notes do you receive? You should identify the following fields: \n \n**Question 2:** What type of notes are they?\n\n### Answers\n### History\n\n##### Answer 1.\n\n\n### Physical examination\n\n###### Answer 2.\nThis is a physical examination for a 45-year-old postmenopausal woman with breast cancer.\n\n### Laboratory\n\n###### Answer 3.\nYou may also refer to the following lab reports that show the normal ranges of the lab tests on the patient:\n \n[Lab Test Number]\nThis is [Lab Test Number] which is the test for breast cancer. The result is in normal range, showing the results of [Lab Test Number].[0]\n[0] These are the lab results for tests listed on[0].\n\n### Diagnostic imaging and studies\n\n###### Answer 4.\nYou may also refer to the following diagnostic images which are tests for breast cancer.\n\n### Imaging of the breast\n\n###### Answer 5.\nYou may also refer to the following X-rays which are tests for breast cancer.\n\n### Imaging of the lungs\n\n###### Answer 6.\nYou may also refer to the following computed tomography images of the patient:\n \n[0]\n[0]\n \n[0]\n[0]\nFor every CPT, you should determine whether the test/service qualifies as an Independent or Dependent. Independent tests or services (",
        "label": 0
    },
    "89": {
        "output": "### Submitting your assignments to this class\n[http://instructional-github.cs.vt.edu/#](https://instructional-github.cs.vt.edu/#))\n\nYou should submit all the relevant files through the TA office (the TA's email is listed inside the `assigmnents.md` file on the github repository) by Tuesday, April 5, 2022. All the assignments must be submitted in one folder as a zipped file. In other words, you should zip all the assignments into the same folder as one single zipped file, then upload it to the same file location. The name of the zipped file must be the student's CSE ID. Do not forget about the filename for each assignment! The name of your assignments are: \n\n`CSIC9813_Micro_Assign.md` - Submission of micro-assignment-the patient notes for patient 1:\n\n`CSIC9813_Micro_Assign_2.md` - Submission of micro-assignment-the patient notes for patient 2:\n\n`CSIC9813_Micro_Assign_4.md` - Submission of micro-assignment-the patient notes for patient 4:\n\n`CSIC9813_Micro_Assign_5.md` - Submission of micro-assignment-the patient notes for patient 5:\n\n`CSIC9813_Micro_Assign_6.md` - Submission of micro-assignment-the patient notes for patient 6:\n\n`MIC_ELIGIBILITY_assignment_1.md` - Submission of assignment-the evaluation of inclusion eligibility for patient 1:\n\n`MIC_ELIGIBILITY_assignment_2.md` - Submission of assignment-the evaluation of inclusion eligibility for patient 2:\n\n`MIC_ELIGIBILITY_assignment_3.md` - Submission of assignment-the evaluation of inclusion eligibility for patient 3:\n\n`MIC_ELIGIBILITY_assignment_4.md` - Submission of assignment-the evaluation of inclusion eligibility",
        "label": 0
    },
    "90": {
        "output": "<EOD> Experimental realization of non-hermitian quantum phases with Floquet engineering in a cold-atom system.\nWe theoretically propose a platform to engineer and characterize the non-Hermitian quantum phases and the associated entanglement phase transition in condensed-matter systems by Floquet engineering with ultracold atoms. This platform, which is based on the quantum Ising model, supports the richer non-Hermitian phases that are induced by the coupling of an Ising model to a quantum dissipative environment. In contrast to the Hermitian quantum states, the topological protection induced by the non-Hermitian phases survives the dissipation of the environment. We expect the experimental realization of the non-Hermitian phases to aid in further exploring the dynamics of condensed-matter systems and uncovering the underlying mysteries of the dissipative processes.<EOD> In this issue\nWe have 2 new articles on PET/ CT imaging this month, with articles from Dr Andrew Adey and Dr Srikala Jayasundara from Royal Perth Hospital and Dr Steven Mossman, formerly of Nepean Hospital. Adey et al. report on a case series of patients who had received 68Ga-pentixafor PET/ CT scans for imaging of inflammatory joint disease (IJD), specifically for rheumatoid arthritis and psoriatic arthritis. We have a case series of head and neck paragangliomas from Jayasundara et al. We also have 3 cases from the Western Australia Radionuclide Therapy Centre: Cases include prostate cancer treatment using 177Lu-PSMA, and thyroid carcinoma and mucosal melanoma using 131I.<EOD> The effect of the cerebro-spinal fluid proteins on the enzyme and glycolytic activities of human semen.\nIt is evident that the cerebro-spinal fluid containing 1 per cent of albumin exerts no inhibitory effect on the lactic dehydrogenase activity of human spermatozoa. On the contrary, in the presence of a physiologic concentration of cerebro-spinal fluid the activity of the latter enzyme is strongly stimulated. The glycolytic",
        "label": 0
    },
    "91": {
        "output": "<EOD> Methamphetamine dependence: a behavioral review.\nA history of human use is discussed, the psychoactive chemical is described, and the pharmacokinetics of methamphetamine (MA) are summarized. There is a brief discussion of research that examines the possible effects of MA on sexual behavior. Because the effects of addiction and abuse include changes in sexual behavior, a more in-depth discussion follows. In humans, these effects reflect differences between users and nonusers and include changes in number of sexual partners, frequency and type of sexual activity, and use of condoms. Psychological effects of prolonged use with respect to mood, cognition, and psychopathology are also examined. Substantial differences have been found between users and nonusers with respect to various aspects of sexual function and sexual satisfaction. As expected, the drug has a direct physiologic effect on sexual activity. Pharmacologic treatment of MA addiction has not been consistently successful although many different pharmacotherapies have been investigated. The findings of this review show that MA addiction is associated with numerous negative consequences including marked cognitive impairment and behavioral dysregulation. The behavioral effects of MA are mediated by changes in neurotransmitter activity, particularly dopaminergic function. Further studies of the effects of MA are necessary to obtain a more complete understanding of the effects of the drug on behavior.<EOD> The importance of considering the timing of treatment and its relation to the biology of breast cancer: a systematic review and a meta-analysis\n\nBackground: The relationship between the biological characteristics of a tumor and the response to chemotherapy was investigated by several research groups. In the previous studies however, not enough attention was paid to the time between administration of the chemotherapeutics and taking the biopsy in which the immunohistochemical analysis was done. The aim of this meta-analysis was to investigate the inter-relationship between the timing of the chemotherapy administration and biological characteristics of breast cancer.Methods:In order to assess the effect of chemotherapy on a tumor tissue, we searched for articles investigating the relation between the immunohistochemical characteristics and the timing of chemotherapy in breast cancer patients by both MEDLINE and PUBMED.Results: Nine different",
        "label": 0
    },
    "92": {
        "output": "<EOD> Prevalence of Antibodies against Toxoplasma gondii and Sarcocystis spp. in Breeding and Domestic Cats in Southern Italy\n\nOne hundred and seventy-one cat saliva, serum, or fecal samples were tested for anti-Toxoplasma gondii antibodies (IFA) using as antigen (Ag) tachyzoites from RH strain and bradyzoites from Pru strain; for the detection of anti-Sarcocystis spp. IgGs (ELISA and western blot), Ag derived from a Sarcocystis sp. were used. Overall, prevalence rates were 49.1% for T. gondii and 46.2% for Sarcocystis spp.; the latter was confirmed by western blot only on nine samples (13.5%). Prevalence rates were comparable between male and female, and between adult and kittens; a seasonal pattern was observed for T. gondii, without being significant, whereas it was significant for Sarcocystis spp.; Sarcocystis sp. prevalence was higher in both breeding and outdoor cats.\n\n# Introduction\nToxoplasma gondii is a ubiquitous parasite that can infect all intermediate hosts, including humans; it can even infect more than one host species in 1 host, including cats.\nOnce in the intermediate hosts, two developmental phases are involved; during the tachyzoite phase, this parasite can enter into cells of any tissue, and cause damage to cells and death, while during in the bradyzoite phase, it encysts in cells of skeletal muscles and brain, becoming latent. However, cystic stage of tissue cyst (brachyzoites) cannot be maintained outside the central nervous system (CNS) or muscle tissue; nevertheless, it has been reported that T. gondii can also colonise, disseminate, and persist in muscles or heart tissues. In case of T. gondii vertical transmission, congenital or perinatal, the parasite can infect the brain of the unborn fetus, causing severe foetal damage and birth defects.",
        "label": 1
    },
    "93": {
        "output": "## Step 1: Check the patient's characteristics\nIn this step, you should check which patient information is missing.\n1. You should define the parameters to check patient information and save it in an output parameter, e.g., Param (PatientID) = `PatientID or Age # or Gender # or HER2 # or NED or `. To set more parameters in one line, please use the `;\u00b4 symbol.\n2. Check the patient record of a specified Trial ID, for example, `RunAllPatient_Trials_ID({trialID = 1})`.\n\n## Step 2: Compute trial-level eligibility\nIn this step, you should compute trial-level eligibility for each patient and check if the patient information is missing.\n1. You should save patient information in the Output parameter to check the patient record (See Step 1: Check the patient's characteristics.). However, you can calculate trial-level eligibility directly. To do so, you should also create another parameter `TriallevelEligibility` of the same format as `PatientID` in the previous step. If any parameter is missing, the value should be set to '-1`. [INST]\n2. You should calculate trial-level eligibility based on the computation of `tleL` function. After calculating trial-level eligibility for each patient, you should print information for evaluation, as shown below.\n    - PatientID: Unique identifier for the patient\n    - Patient: Name of the patient\n    - TrialName: Name of the clinical trial\n    - Stage: Stage of the patient in the clinical trial\n    - ExclusionC: Exclusion criteria\n    - Sex: Gender of the patient\n    - Age: The age of the patient\n    - Her2: HER2 type of the patient\n    - NED: The state of the patient\n    Note: You can create additional columns to display more in-depth information.\n\n## [INST]\nComputations of trial-level eligibility (tleL) for all patients.\n\n## [INST]\nComputations of trial-level eligibility (tleL) for each patient\n\n## Step 3: Output trial-level eligibility for the patient\nIn this step, you should save trial-level",
        "label": 2
    },
    "94": {
        "output": "__8__ What is a `matched triad`? Is there something special about the patient or the clinical trial that must be a good match?\nThere seems to be something special about the matched triad. We will learn the concept later by running some examples. A matched triad is a group of the following three people:\n- A certain patient for whom you need to calculate the trial-level eligibility assessment;\n- a clinical trial; and\n- a certain set of variables which represent a certain characteristic of the patient, for example, the gender for gender-related studies or the clinical stage for a certain kind of cancer. \nA patient note and a clinical trial are a sort of `triad` or `set of three items`; therefore, the term `matched triad` is used to denote the patient, the clinical trial, and the set.\n\nThe clinical trial is represented as the `Clinical trial` variable, and the values of the clinical trials are collected and saved in the `Clinical_trials` object. The set of variables that represents certain characteristics or characteristics of the patient can be saved as the set of variables as the `Variable_set` variable, and values of their variables can be saved in this variable. \n__9__ What do you need to do to be prepared for the next step of the coding?\nThe data for the next step are shown below. \nTo find patient's variables that match the desired clinical trial and to calculate the trial-level eligibility assessment simultaneously, you should create a new object for each patient. This object will be named Patients. \nWhen calling `Patient('Patient','Clinical_trial', Clinical_trials,Variable_set,'Trial-level_assessment', Trial_level_assessment, 'Patient_recommendation', Patient_recommendation, 'Trial_notes', Trial_notes)' you pass each patient data to the object together with the clinical trial's name `Clinical_trial`, the current clinical trial whose trial-level eligibility assessment you will calculate for a certain patient `Clinical_trials`, the set of variables that represent patient characteristics `Variable_set`, the assessment on trial-level eligibility `Trial-level_",
        "label": 0
    },
    "95": {
        "output": "[CODE] # Trial-level eligibility: \n  for patient in len(patients)[:-1]:\n    assessments[patient] \n    assessments[patient] = f\"{assessments[patient]}[0]*2+\"\n    assert assessments[patient] in {0 : Excluded, 1 : NotRelevant, 2 : \n    Eligible}, \"not consistent: {}\".format(assessments[patient])\n  assessments[-1].add(\"\") \n# end code \n\n[\n  {\n    'id': '18b1a2b0-98e6-4ee0-94dd-66c36b51d4d7',\n    'age': 59,\n    'education': None,\n    'title': None,\n    'education': [{\n      'id': 'bb16a2d8-b276-4a56-8479-2f5175c69067',\n      'grade': 7,\n      'subject': 'Ethics'\n    }, {\n      'id': 'd2f17182-e020-452f-b14e-ab72181c475a',\n      'grade': 6,\n      'subject': 'Chemistry'\n    }, {\n      'id': 'beb1b993-7365-4bcf-940d-4b5d9aad6140',\n      'grade': 10,\n      'subject': 'Mathematics'\n    }, {\n      'id': 'e7c77f25-6234-4c01-99a7-343bd780420b',\n      'grade': 10,\n      'subject': 'English'\n    }, {\n      'id': 'f734ae39-7acb-40c1-829b-b3c4ac425aed',\n      'grade': 6,\n      'subject':",
        "label": 1
    },
    "96": {
        "output": "<EOD> The use of the microfluidic device to determine the adhesion potential of Candida albicans\nMicrobiological contamination or infection by opportunistic pathogens often happens in the hospitals to immunocompromised patients. Candida albicans is the second commonest cause of nosocomial infections worldwide. In order to evaluate the adhesion of Candida albicans onto the human mucin hydrogel inside a fluidic chip, an acrylic microfluidic device with a hydrogel pearl chamber, to which human mucin is adhered, is fabricated and used. The mucin extracted from porcine stomach is cross\u2010linked using either 1-ethyl-3-(3-dimethylaminopropyl)carbodimide (EDC) or genipin as covalent cross\u2010linker. The adhesive abilities of the Candida albicans onto those mucins inside the device are compared and it is found that the cross-linking of the human mucin using EDC increases the adhesive potential of the Candida albicans to the mucin, whereas the genipin-cross-linking results in an unexpected decrease in the adhesion. This is attributed to the altered surface properties of the cross-linked mucin due to the genipin cross-linking and to the cell surface charges of C. albicans. The study reveals the possibility of developing a microfluidic device to identify microorganism attachment to the biomimetic mucin, which is capable of forming a good biofilm structure. Microsc. Res. Tech., 2007. \u00a9 2007 Wiley-Liss, Inc.<EOD> Corneal Dystrophy Caused By Various Types of DQ69 Gene Mutations: A Systematic Review\nPurpose: This systematic review aimed to determine how various types of DQ69 gene mutations caused the TCF4\u2013linked dystroma corneae et myopi. Methods: This review was conducted in accordance with the preferred reporting items for systematic reviews and meta-analyses guideline. PubMed, Embase, and Cochrane Central and ClinicalTrials.gov were searched up to February 2",
        "label": 0
    },
    "97": {
        "output": "Let's begin with some basic examples. I want to include the following test cases:\n    - `\n    - `\n    - `\n    * Note. You should specify the file path of the patient, i.e., `patient.txt`.\nYou are given the following code. \n---\ninstructions_patients_eligibility: \n    For each patient:\n        Trial-level eligibility:\n```\ndef eligibility_helper(patient_text, trial_text):\n    assert('eligibility' in patient_text)\n    assert('Eligibility' in trial_text)\n    # This part is your responsibility.\n\n    assert len(patient_text.splitline.split(' ')) >= 2\n    assert len(trial_text.splitline.split(' ')) >= 2\n\n    if patient_text.splitline.split(' ')[:2] == trial_text.splitline.split(' ')[:2]:\n        return 1 # 0 means \"Not eligible\", 1 means \"Eligible\".\n    else:\n        return 0\n\n\n```\nYour task is to fix the code to return valid responses (either 0 or 1) for the test cases in the comments.\n\n__Good luck!__\n__Hints:__ \n* [001-eligibility-example1.ipynb](https://github.com/pybrainhacker2022/pyML-HackerRank/blob/main/example/001-eligibility-example1.ipynb)\n* [001-eligibility-example2.ipynb](https://github.com/pybrainhacker2022/pyML-HackerRank/blob/main/example/001-eligibility-example2.ipynb)\n* [001-eligibility-example3.ipynb](https://github.com/pybrainhacker2022/pyML-HackerRank/blob/main/example/001-eligibility-example3.ipynb)\n* If you need explanation about `assert`, click here: [Python Assessment: Assert Document",
        "label": 1
    },
    "98": {
        "output": "Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale:0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nHere is the patient note:`The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.`. Here is the clinical trial: \nTitle: Axillary Reverse Mapping for Invasive Carcinoma of the Breast\n\n\nSummary: Primary Objectives:~To determine the feasibility of axillary reverse mapping (ARM) in patients undergoing axillary lymph node dissection for breast cancer therapy.~To determine the incidence of breast cancer metastasis in lymph nodes draining in the arm as identified by axillary reverse mapping.~To determine the safety of axillary reverse mapping.\nInclusion criteria: Inclusion Criteria:\nPatients with invasive carcinoma of the breast planning to undergo axillary lymph node dissection at M. D. Anderson Cancer Center.\nEastern Cooperative Oncology Group (ECOG) performance status of equal to or less than 3.\n\nLet's think step by step",
        "label": 2
    },
    "99": {
        "output": "<EOD> Flexible Rigid Electrodes on Polyimide Substrates\nThis article presents a systematic study of the performance of rigid electrodes coated with organic layers over their surface through physical vapor deposition (PVD) techniques. Polyimide (PI) is used as a substrate material to optimize the electrical characteristics of the flexible electrode. Atomic Force Microscopy measurements reveal that the coating deposition on PI substrate with SiO and Al2O3 improves the quality of the coating surface. In addition, for both coatings, the thickness measurements obtained by X-ray Photoelectron Spectroscopy are not in concordance with the thicknesses found by the optical and profilometer techniques. For the SiO/PI system, the electrical conduction through the layers improved and an invariance of the resistance with the thickness of the coating is obtained. In addition, the Al2O3/PI system showed the best conductive characteristics when compared with literature materials. Hence, this work proposes PI-based substrates with SiO and Al2O3 coating for use in semiconductor applications and rigid electrodes for supercapacitors.<EOD> Synergistic effects of tazarotene on cutaneous wound healing in diet\u2010induced obese mice\nObesity is a severe risk factor for impaired wound\u2010healing processes and skin aging. Tazarotene is currently used to treat various skin diseases. This study aimed to examine the effects of topical tazarotene on diet\u2010induced obesity\u2010related cutaneous wound healing.<EOD> Cranial nerve V/VIII\n\n# Overview\nThe fifth (trigeminal) and eighth (vestibulocochlear) cranial nerves are together referred to as the cranial nerves V/VIII. These fibers are often referred to as the \"facial\" and \"auditory\" nerves, respectively, but this nomenclature is usually avoided as it is inappropriate for the trigeminal nerve.\nThe fibers of these nerves are primarily sensory and convey sensation of the face and mouth to the brain. The eighth nerve is responsible for spatial vision.\n\n# Structure\n\n## Trigeminal",
        "label": 0
    },
    "100": {
        "output": "[TEXTBOX start=0.5 no-wrap align=left width=41 no-border, TEXT002]\n\nI think this is good. Thanks.\r\n\nA: In R we would go the following:\r\n```\r\ndf[df$condition == \"excluded\" & is.null(df$outcome), ] <- \"0\" \r\ndf[df$condition == \"included\" & is.null(df$outcome), ] <- \"1\" \r\ndf[!is.null(df$outcome) & (df$condition == \"yes\" | (df$condition == \"no\" & is.numeric(df$outcome))), ] <- \"2\"\r\n```<EOD> Syntheses, structures, and magnetic properties of lanthanide (III) phosphonates.\nIn order to study the effect of the covalent character of phosphonic acid ligands on the magnetic properties of lanthanide (III) phosphonates, seven lanthanide(III) phosphonates, Ln(HPO3)3(Cn)n-n (Ln = Ce, Pr, Nd, Sm, Eu, Gd, and Dy), were synthesized under hydrothermal conditions, and their structures were characterized by X-ray single-crystal and powder diffraction analyses. All the Ln(HPO3)3(Cn)n-n samples were monoclinic. Two of them, Ln(HPO3)3(Cn)n-n(Ln = Ce and Gd), contain two formula units in a unit cell and are related to each other by the inversion center. They belong to the C2/c space group; however, all the others are in the P21/c space group. They contain a three-dimensional framework built from edge-sharing 6-connected HPO3 and 8-connected LnO3 polyhedra with the m2(2) m3(2)2 topology. Because of the steric hindrance effect of the bulkier benzyl substituent of the carbon chain in Cn, all the Ln(HPO3)3(Cn)n-n(Ln = Ce, Pr, Nd, Sm, Eu, Gd, and Dy)",
        "label": 2
    },
    "101": {
        "output": "### Data Type: Table\n\nLet's think step by step. \nFor the data extraction, let us think what data we need to extract.\n\nAt first, let's extract a table which contains basic information. The table we want to extract is **Basic information table**, e.g., <table class=\"dataTable titleBorder\"><thead><tr><th width=\"25%\">Data Field:</th><th width=\"75%\">Data Type:</th><tr><td class=\"dataLabel\" width=\"25%\">Patient ID</td><td class=\"dataIdentifier\">string</td><td width=\"75%\">The patient's unique identification number used by an organization to identify a patient in its environment (e.g., an insurance plan, health plan, provider, or pharmacy).</td></tr><tr><td class=\"dataLabel\" width=\"25%\">Sex</td><td class=\"dataIdentifier\">string</td><td width=\"75%\">The patient's gender (e.g., \"male,\" \"female,\" \"unknown\"). There may be many ways of designating gender or sex, including ethnicity (e.g., \"male,\" \"female,\" \"other\"). The value of this field may be unique but can also be an attribute of a disease (e.g., \"male,\" \"female\").</td></tr><tr><td class=\"dataLabel\" width=\"25%\">Date of birth</td><td class=\"dataIdentifier\">datetime</td><td width=\"75%\">Record date of when the patient was born (e.g., \"1943-12-07\" if the patient was born on December 7th, 1943).</td></tr><tr><td class=\"dataLabel\" width=\"25%\">Age</td><td class=\"dataIdentifier\">string</td><td width=\"75%\">Age as of the event/record. Ex: \"39 years\" or \"2 years 3 months 9 days\" (use the integer part of the year field, so subtract 1 from the year value to get the age). The following values are acceptable for this field. The word \"years\" should be the unit for this field and is not used in plural. A slash",
        "label": 2
    },
    "102": {
        "output": "Let's try the example of clinical trial #2 from the previous section: # clinical trial no. 2 of `The Role of Diet and Lifestyle in Breast Cancer Survival`\n# This assignment is due 8/17/2020 \n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial: \nTitle: The Role of Diet and Lifestyle in Breast Cancer Survival\n\n\nSummary: Diet has been found to influence hormone production and metabolism which in turn could affect the incidence of hormone related cancers. Consumption of soy-cont",
        "label": 2
    },
    "103": {
        "output": "[/HINT] Output:\nNote:\n* You don't have to print all the elements, but you can.\n* You can use \"break\" in the repeat loop (until \"patient\" in patient notes)\n\n## Problem Statement: [bib_ref]  Hello, World!\": Learning Python through Linguistics, Bailey [/bib_ref]  In this project, you will be working with and modifying a code to help you get to know the Python programming environment.\n\n## Problem Summary [bib_ref]  Hello, World!\": Learning Python through Linguistics, Bailey [/bib_ref]  In this exercise, you will begin by modifying the version of the code below in order to print it when it is run. Once completed, you will be asked to use the original code as the context for a sequence of further changes in order to print your initials.\n\n## Instruction [bib_ref]  Hello, World!\": Learning Python through Linguistics, Bailey [/bib_ref]  For your initial \"Hello, world!\" program, begin by modifying the code presented below. This code prints \"Hello, world!\" on the screen. When you submit the code that you have created, your final \"Hello, world!\" program should produce the following output: Hello, world! [Submit Your Program] \n\n## Hint 1: [h1]\nFor the most general type of program you are producing, you can change the file to read like the one you are working with below, and this is referred to as a text file or a source code file. \nWhen this program is executed, the file will be converted into bytecode data that the computer can execute.\n[h1]\n\n## The challenge:\nWhat will you need to do in order to get your first program working and running on your system? \n\n## Challenge Solution 1\nWrite a program to print the phrase \"Hello world!\"\nOne thing to note about Python is that if you open up a file and start typing, Python will immediately display what you entered! This means that you can change code on the fly and see how your program behaves as you do so.\nYour program should print \"Hello, world!\" when you run it, like the computer program below.\n\n## Running the program [bib_ref]  Hello, World!\": Learning Python through Linguistics, Bailey [/bib_ref]  In order to check the code, you will need to run your program. When",
        "label": 1
    },
    "104": {
        "output": "### Exclusion criteria\nFirst of all, here we will define list of exclusion criteria:\n- No current pregnancy or nursing\n- No history of any other cancer or cancer (other than basal cell carcinoma of the skin) that was diagnosed in the 5 years before the time of enrollment (including cancer of the bladder, colon, rectal, bile ducts, liver, gallbladder, ovaries, lymph nodes, leukemia, multiple myeloma, melanoma, thyroid gland, prostate, and meninges)\n- No history of any condition that might seriously affect the ability of the patient to tolerate therapy or surgery or to participate in the study (e.g., recent myocardial infarction or stroke)\n- No history of another disease that can interfere with the conduct of the study (e.g., unstable angina, congestive heart failure, or coronary artery disease)\n- Women of childbearing age should be taking adequate contraceptive methods\n- No history of any neurological disease (e.g., dementia, stroke, epilepsy with seizures, paralysis, or multiple sclerosis) or significant CNS dysfunction that the patient cannot safely undergo study therapy\n- Significant hypersensitivity/allergy reaction to any study drug or other drugs (e.g., dactinomycin)\n- No other relevant malignancy (other than nonmelanoma skin cancer) in the past 5 years\n- No acute bleeding disorders\n- No active oral, inhaled, or intravenous therapy with other investigational or non-investigational agents\n- No medical condition that is either life threatening or may impair the ability to participate in the study\n- No history of alcohol dependence or alcohol abuse\n- No psychiatric disorder that would prohibit compliance with protocol requirements or interfere with the conduct of the study\n- No treatment with 4 drugs or more for non-cancer indications at the time of enrollment (including the use of hormone treatments)\n- No active oral, inhaled, topical, or intra",
        "label": 2
    },
    "105": {
        "output": "- A good answer should output the following (at least): 1) Not relevant; 2) Eligible;\n- There are three trials that meet your requirements.\n\n| [https://github.com/vipulraina/pyk2ml-pycodestates.git](https://github.com/vipulraina/pyk2ml-pycodestates.git) |\n| [https://github.com/davidhuggins/pycodestates.git](https://github.com/davidhuggins/pycodestates.git) |\n| [https://github.com/matthewraschke/codestates.git](https://github.com/matthewraschke/codestates.git) |\n| [https://matthewraschke.com/matthewraschke/codestates/tree/dev](https://github.com/matthewraschke/codestates/tree/dev) |\n| [https://github.com/davidhollis/pycodestates.git](https://github.com/davidhollis/pycodestates/tree/dev) |\n| [https://bonsai.github.io/bonsai/tree/master/pycodestates](https://github.com/vipulraina/pyk2ml-pycodestates) |\n| [https://docs.microsoft.com/en-us/visualstudio/python/tidy-code](https://matthewraschke.com/matthewraschke/codestates/tree/dev) |\n\n<EOD> .\nThe results of ultrastructural investigation of experimental acute pancreatitis and obstructive jaundice under the influence of preparation \"Nespol\". Nespol increases the number of microglial cells and inhibits cellular destructive processes which take place in the rat brain in case of experimental acute pancreatitis (AP) and obstructive jaundice. The effect is related to the neuroprotective properties of neurotropin preparation.<EOD> Filling the void, a multidisciplinary model to support patients and families throughout the diagnosis and treatment experience.\n2",
        "label": 2
    },
    "106": {
        "output": "In the example, `2) Eligible.`is the last line in the output. \n\nYour task is to find out if your patient with a breast-cancer qualified for the clinical trial, i.e., to assess the eligibility of yours patients on the basis of the given case report. How much time do you need to find out? You should submit your answer as a pair of natural-number using the following link:\nhttps://forms.gle/LsUz37JwCxAxA67K6\nTo see your score, please, submit an email to jose.jovel19@gmail.com along with the following information.\n\nScore: [insert your score between brackets].\n\n**Instructions** for jose.jovel19@gmail.com (Your Name, Question #):\n\n### Eligibility Assessment in Clinical Trials: Journals.sagepub.com/home/pms\n\n### Eligibility Assessment in Clinical Trials: journals.sagepub.com/home/pms\n\n### Eligibility Assessment in Clinical Trials: jons.sagepub.com/home/pms\n\n### 13.6. Eligibility Assessment in Clinical Trials: Jons.SagePub.com/home/pms\n\n### 11.22. Eligibility Assessment in Clinical Trials: jons.SagePub.com/home/pms\n\n### 31.4 How to use clinical trial databases\n\n### Eligibility Assessment in Clinical Trials: Jonnals.sagepub.com/home/pms\n\n### 31.4 How to use clinical trial databases\n\n\n\n### 27.4 Disease-Specific Eligibility Criteria: jons.sagepub.com/home/pms\n\n### 27.4 Disease-Specific Eligibility Criteria: Jonssagepub.com/home/pms\n\n### 13.6. Eligibility Assessment in Clinical Trials: JonsPub.com/home",
        "label": 0
    },
    "107": {
        "output": "## Instructions to authors\nComplete our submission system at: <https://submit.rocs.cn/default.aspx> \nTo submit your manuscript, you need to register first. If you have never tried to use the ROCS submission system, please click the question mark at the corner of each form to view helpful guidance.\nPlease complete, in English, the following electronic form using mandatory and optional fields. You may attach up to 6 supplementary files. (Note that each file uploaded must be less than 150 Mb in size and in a format that can be downloaded by readers. This file should be as small as possible. File formats for data and analysis results include: *xls, *xlsx, *doc, *docx, *txt, *csv, *bib, *tex.)\n\n## Manuscript\nThe cover page should include:\nTitle:\nAuthor Names (including initials):\nAffiliated Institutions/Colleges (this should be written in the format of your current affiliation).\nYour manuscript should consist of four major sections: (1) Title page (containing title, authors, affiliations, conflict of interest), (2) Abstract, (3) text, and (4) references. All questions regarding the appropriate format should be emailed at: publisher@rocs.cn.\nAll papers submitted to ROCS must be submitted with an abstract. Do not forget to provide the following data for the paper in your cover letter file: corresponding Email, phone number, fax number and author-affiliated Email.\n\n## Title\nChoose a simple and accurate title that is short and specific. The title must end with a question to avoid the title being regarded as a statement. Use of non-conventional typefaces or color should be avoided.\nDo not include statements of novelty, the degree of importance of the study, or implications of the study results. If these qualifiers are felt to be warranted, they should be inserted in the Abstract.\n\n## Structured abstract\nThis section will begin with an unstructured abstract that summarizes the background, purpose, methods and results of the study, and closes with an abstract conclusion. The abstract needs to include the following sections.\n\n## Manuscript types\nThere are three types of article submissions:\n1. Original Research Article or Study: This article reports original findings",
        "label": 0
    },
    "108": {
        "output": "### Case Study (Clinical Trainee)\nA clinical trainee is given a patient note as a homework for evaluation:\nA 63-year-old man was seen in the general outpatient department of a teaching hospital with a complaint of progressive swelling of the scrotal sac. He had undergone radical orchidectomy for carcinoma of the left testis 12 years ago. He had 2 sessions of radiotherapy for the treated area at the end of the 1990s. His recent complaint of swelling started about 1 month ago and steadily progressed to encompass the entire scrotum. He denied penile pain or any complaint of fever. He had been smoking for 25 years. No family history of cancer was reported.\nThe general physical status was good. On examination, the swelling was hard, non-tender, mobile, and cystic. It was not fixed to the abdominal wall. No lymphadenopathy was felt.\nExamination under anesthesia revealed a 44 \u00d7 40 cm sized soft tissue tumor occupying the scrotal sac. A skin incision was made transversely over the swelling. A firm mass was felt in the scrotal sac. The mass was totally excised. No communication with the inguinal canal was found. A postoperative course was uneventful and the patient was discharged home on the fifth postoperative day.\n\nHere is the patient's radiotherapy record to trace any sign of cancer recurrence:\n\n### Clinical Trial: TA-3-05-BG 1996-1999\nTitle: A randomized trial of three chemotheraputic regimes\nType Description 1. Cisplatin/Vindesine/Prednisolone. 2. Cisplatin/Vincristine/Raltitrexed. 3. Cisplatin/Vinorelbine/Methotrexate.\nInclusion criteria.\n1. At least 18 years old.\n2. Squamous cell carcinoma of the head and neck origin.\n3. Histopathology report.\nExclusion",
        "label": 0
    },
    "109": {
        "output": "[INST] 0.) Your patient note is a file, so you should read the file with `f<-read.table` command. Read the data in columns. Then, you can access the individual cell values, e.g., `f[2,1]`, or you can loop or create variable, e.g., `f[3:4,\"age\"` and retrieve the result, e.g., `f[3:4,\"age\"]`. All the variables are `dfr` objects, so you can add the elements dynamically with `f+`, i.e., `f+x` creates the new variable x.\nYou will find your variables in the output. For example, the first column is Patient ID, the second column is the birth year of the patient, and the third column is gender. The first patient ID is the 45-year-old postmenopausal woman. [INST] 1.) Your first task is to remove the gender values from the input and add a column with the `Age` variable. You can extract a certain column by `f[, variable]` in R, where we use both names of variable extracted and names of the column in the input. As you can see, `f[, factor(variable)]` extracts the column with numeric values. Then, we can insert an extra column `age` in front of `gender` by using `f[, \"Age\"]` and then, delete the 'gender' column using the operator`-`. In order to create a new column, we use the operator ``+\", which makes a call to `get` to create a new column or object and the operator `\"` is used to create a data frame, so we will create a data frame. \nPlease also consider the following to show your answer: \n\n\nYou can use `if..else`. A typical syntax for `if..else` statement is:\nif(condition){if(condition)\n    print(paste(\"True\")\n    # Execute an alternative statement \n} else\n    print(paste(\"False\")\n    # Execute an alternative statement\n}\n\n\nThis function returns a statement to be evaluated. Before the close brace }, one or several arguments can be provided to the if condition. For example, if the value is not 10, then:\nif(x==10){if(x)){\n# Execute",
        "label": 0
    },
    "110": {
        "output": "You are finished! \n\n### Note\nTo test the functionality in [TEST]:<EOD> .\nOBJECTIVE\nTo evaluate a method for the reconstruction of concave-shaped defects at the back of the hands with one-stage free anterolateral thigh flaps with a pedicle of the greater saphenous vein in 25 cases.\n\n\nMETHODS\nFrom May 2006 to September 2010, 25 cases, including 18 males and 7 females with the mean age of 44.3 years old (range, 23-57 years old) underwent the repair of concave-shaped defects at the back of the hands with one-stage free anterolateral thigh flaps. There were 7 cases of crush injuries, 6 of avulsion wounds, 5 of severe burns with concave-shaped contraction contractures, 1 of severe burns with crush injuries, 1 of avulsion wounds with concave-shaped defects, 1 of severe burns with avulsion injuries, 1 of severe burns, 1 of scar, and 1 of bone defect caused by crush injuries and burns. The size of flap was 5 cm x 3-10 cm. The greater saphenous vein or the other branches were anastomosed with the veins.\n\n\nRESULTS\nAll wounds healed by first intention. All 25 cases were followed up for 7 months to 3 years, and color changes showed that the color of flaps were similar to that of surrounding tissues. According to the scale of aesthetic evaluation from the plastic surgery department of Tsinghua University, 11 flaps were fair results, 8 were poor results, and 6 were excellent results.\n\n\nCONCLUSIONS\nFor concave-shaped defects at the back of the hands, one-stage free anterolateral thigh flaps with a pedicle of the great saphenous vein is considered safe and effective treatment which can obtain satisfactory contour and color.<EOD> Ankle spastic equinus after stroke: the effect of inhibition of muscle contraction on mus",
        "label": 0
    },
    "111": {
        "output": "## Questions\n\n\nA: 1.\n\t- What is the goal of the clinical trial recruitment system?\n\t- The goal is to find relevant clinical trials.\n2. \n\t- Which assessment method should researchers use to evaluate if the patient will be suitable for the study?\n\t- It is recommended to use the case report form (CRF) to evaluate if the patient is suitable for the study.\n\nA: 1.\n\t- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3-cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\t- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3-cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n2.\n\t- The patient is a 38- 12-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3-cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for",
        "label": 0
    },
    "112": {
        "output": "# How does this apply outside Phonopy?\nWhen performing trial design on a clinical study, this script might be useful. It could take a little time, but it is not too long. If you have any question, please contact me on `IRC channel: #medicl` with `Github: https://github.com/medicl/py_python`. \n<EOD> Effects of Intake of Slow Carbohydrates on Acute Exercise\u2010Induced Proteinuria\nIn a randomized crossover design, eight healthy active men (mean \u00b1 SD age, 26.3 \u00b1 3.3 years; body mass index, 24.8 \u00b1 1.3 kg \u00b7 m\u22122; mean \u00b1 SD peak oxygen uptake (VO2) during the maximal treadmill test, 54.0 \u00b1 8.5 ml \u00b7 kg\u22121 \u00b7 min\u22121 ) performed bicycle exercise of 60 min at 70% of the VO2peak with free access to sports drinks containing either sucrose (50 g \u00b7 h\u22121 or 18.2 mol \u00b7 g\u22121 \u00b7 h\u22121) or a mixture of maltodextrin and fructose (sucrose 50 g; maltose 20 g, glucose 20 g, and fructose 20 g; maltose 10 g, glucose 10 g, and fructose 10 g \u00b7 h\u22121 or 6.6 mol \u00b7 g\u22121 \u00b7 h\u22121) at the 30th and 50th min of exercise. Immediately before exercise and immediately postexercise, first morning urine samples were collected for determination of urine protein concentration. Exercise elicited significantly higher urinary losses of protein (P < 0.05) in the sucrose trial compared with the maltose and fructose trial. The average amount of excreted protein was 44.2 \u00b1 31.5, 18.8 \u00b1 9.3, and 21.6 \u00b1 18.6 mg/h, respectively. Urine protein excretion increased by 2567% after suc",
        "label": 0
    },
    "113": {
        "output": "Headache with spontaneous onset and 8 out of 10 pain is the most common symptom complained by a patient. \nOur patient in this case (case `KL`) has a significant headache",
        "label": 0
    },
    "114": {
        "output": "### RESPONSES\n\n`020010e8` [REPLY]\n\n`020010e8` [REPLY]\n\n`020010e8` [REPLY]\n\n```python3\n# + id=\"KKFp1Ci4-yDz\" lineNumber=1 colNumber=1\nprint(\"E0020010E8_JJJJJJJJJJ0101_KKKKKKKKKK000002002011201400030302\")\n\n```\n\n`020010e8` [REPLY]\n\n`020010e8` [REPLY]\n\n```python\n# + id=\"bM0Nt4AYNWfG\" lineNumber=2 colNumber=1\ndef myPrint(text):\n    print(\"{\" + text + \"}\")\n\n\n# + id=\"bM0Nt4AYNWfH\" lineNumber=3 colNumber=1\nprint(\"{}\".format(\"Test112\"))\n\n\n# + id=\"4UyNtUzYNWfY\" lineNumber=4 colNumber=1\nmyPrint(\"ID003\")\n```\n\n```python\n# + id=\"XOcNtQvYWfE\" lineNumber=5 colNumber=1\n\n```\n\n::: {.notice}\n    - <NAME> 2015-06-25\n:::\n\n::: `{type:text}`\n:::\n\n::: '{heading} {id}: {text} (line {lineNumber})`\n:::\n\n```python\n# + colab={\"base_uri\": \"https://localhost:8080/\", \"height\": 24} id=\"XOcNtQvYWfG\" lineNumber=0 colNumber=1\nid_0 = 0\n\n```\n\n::: {.admonition}\n    - <NAME> 2015-06-25\n:::",
        "label": 1
    },
    "115": {
        "output": "There are [code-ref?27?6#code-c6] five clinical trials for [code-ref?34?97#code-c97] patients receiving [code-ref?34?93#code-c93] chemotherapy for metastatic breast cancer in the United [code-ref?34?94#code-c94] States. The [code-ref?34?96#code-c96] five clinical trials [code-ref?150?6#code-c6] for [code-ref?34?97#code-c97] patients receiving [code-ref?34?93#code-c93] chemotherapy [code-ref?34?95#code-c95] for metastatic breast cancer in [code-ref?34?94#code-c94] the [code-ref?34?92#code-e11] New [code-ref?31?31#code-id31] York City, United [code-ref?34?94#code-c94] States. \nNow let's see one of them more closely. Let's evaluate the eligibility of the first patient named Katherine, i.e., make sure she satisfies the inclusion criteria of this clinical trial. It is important to keep in mind that:\n\nA patient who meets all the eligibility criteria of a clinical trial is still not eligible for the trial unless the exclusion criteria do not prevent participation in the particular clinical trial,\n\nA patient is eligible for a clinical trial but may be excluded from participating. Clinical trials exclude patients for safety reasons, to avoid conflicts of interest, or to minimize the confusion of comparison for the study. [code-ref?64?7#code-67] (Note: You can find the list of common exclusions in Appendix A.) (code-ref?29?5#code-c5)\n\nIf the patient named Katherine satisfies all the eligibility criteria of the trial, we should print code 2) Eligible `Trial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "116": {
        "output": "<EOD> Neurology\nWe are pleased to present this special edition of Neurology entitled \u2018Neurology and Neurophysiology\u2019. Since the introduction of electroencephalography (EEG), clinically relevant information has provided physicians with objective information about the state of the nervous system. Because of the complexity of the EEG tracing, this method is frequently misunderstood or misinterpreted in daily practice. However, if interpreted correctly, this valuable diagnostic tool can help in diagnosis and choice of medication in a variety of disorders ranging from seizures and sleep disorders to psychiatric disorders. The authors in this special edition will provide the reader with state of-the-art and up-to-date information on EEG, evoked potentials and neurophysiology.<EOD> Identification and Validation of Novel Prognostic Model Based on E2F1-Related Genes in Diffuse Large B-cell Lymphoma\n\n\n\n# Introduction\nDiffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous lymphoid malignancy. DLBCL often has an aggressive clinical course, and about 30-40% of patients with DLBCL die within 5 years. Although the treatment of DLBCL has undergone a dramatic transformation in recent years, with the success of the development of new drugs, such as rituximab, targeted therapy, and immunotherapy, the prognosis of the vast majority of DLBCL patients is still not satisfactory. Therefore, the identification of biomarkers to evaluate DLBCL prognosis is urgent. The transcription factor gene E2F1-encoded protein is highly expressed in tumors and plays a critical role in tumor proliferation and apoptosis regulation. Recent studies have reported that E2F1 promotes the development of breast cancer, hepatocellular carcinoma, and gastric cancer; however, the specific role of E2F1 in DLBCL remains unclear.\nGiven the limitations of current prognostic systems such as the International Prognostic Index (IPI), the International Prognostic Index for Advanced Disease (R-IPI), and the NCCN Intermediate",
        "label": 2
    },
    "117": {
        "output": "---\n\nHow to Improve Your Output from `Trial-level eligibility`\n\nIn the last line, there are three options:\n\n- Excluded\n- Not relevant\n- Eligible\n\nYou do not need to use an extra function here. With a few words of code, you can make your code work like a regular output line.\n\n1. Define `i` as a new variable.\n   \n    ```shell\n    i=0\n    ```\n\n2. Assign the values of excluded, not_relevant, and eligible, to `i` using these variables.\n   \n    ```shell\n    if trial.notrelevant_or_excluded then\n        i <- i + 1  # Excluded\n    elif trial.not_relevant then\n        i <- i + 1  # Not relevant\n    else\n        i <- i + 1  # Eligible\n    # End of assigning.\n    ```\n\n3. Replace `Trial-level eligibility: ` with `Trial-level eligibility:` at the end of the output line.\n   \n    ```shell\n    print(sprintf(\"%c%s%s%s\", ' ', ' ', $i, ' ')) # print the string as one line.\n    ```\n\nFor example, the final output looks as follows:\n\n```\nClinical trial: 01NCI0031. Eligible\nInclusion Criteria:   0-1 ECOG/Zubrod Performance\nTreatment:    Preoperative chemotherapy must be completed or planned.\nDrugs:    Cisplatin (Platinol)\nDose:    75 mg/m2 dose of Cisplatin IV on day 1 with 400 mg/m2 of Cyclophosphamide IV on a day other than day 1.\nPrior Therapy:    None.\nRace:    Caucasian.\n\nPatient Note:\nAge: 45 years old.\nHeight: 163.0 cm.\nWeight: 62.0 kg.\nFamily history:  Yes.\nPulmonary history:  Yes.\nBreast history:  Yes.",
        "label": 1
    },
    "118": {
        "output": "### Exercises 1\nExercise 1::\nHere is the [https://github.com/vemundbakk/patient-eligibility-evaluation/blob/main/data/Example.txt](patient_note) example. You will use it to evaluate a clinical trial patient.\n- [ ] 0) Run the file `example.py` in the [main folder](patient-eligibility-evaluation):\n\n    ```python3\n    sudo python3 example.py\n    ```\n\n- [ ] You see the printed summary.\n\n    ```\n    Example patient note for clinical trial\n\n    [INST.1.0] Patient's name: <NAME>.\n\n    [INST.1.1] Patient's gender: female.\n\n    [INST.1.2] Patient's age: 34 years old.\n\n    [INST.1.3] Patient's height: 165 cm.\n\n    [INST.1.4] Patient's weight: 55 kg.\n\n    [INST.1.5} Patient's BMI: 19.5.\n\n    [INST.1.6] The patient has taken multivitamins.\n\n    [INST.1.7] The patient has taken iron supplements.\n\n    [INST.1.8] The patient does not smoke or consume alcohol.\n\n    [INST.1.9] The patient is not sexually active and has no children.\n\n    [INST.1.10] The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\n    [INST.2.3] TNM stage: pT1bN1MO.\n\n    [INST.2.4] Clinical subtype: NOS.\n\n    [INST.2.5] Malignancy grade: Grade 3.\n\n    [INST.2.6] Margin: positive.\n\n    [INST.2.7] Surgery: mastectomy.\n\n    [INST.3.0] Sentinel node biopsy: negative.\n\n    [INST.4.0] Pro",
        "label": 0
    },
    "119": {
        "output": "# Introduction\nWe assume the reader is familiar with the Python object-oriented paradigm (Python docs) and the Pandas statistical data structure package (Pandas docs). Readers may also want to consider reading the documentation for the NumPy Python package before starting with the following sections. For more in-depth information, we encourage the reader to attend a short tutorial by Tim Dallachy, which is available in the official D3Py book (D3Py book, pages 39 and 40). [INTRO]<EOD> Intravenous thrombolysis in old age: the age group above 80\u2003years is underrepresented in clinical trials\nObjective:\u2002 To evaluate the effectiveness of intravenous thrombolytic therapy (IVT) in patients above 80\u2003years of age and to identify factors associated with outcome in this age group.<EOD> Hydrochlorothiazide in the treatment of mild-to-moderate hypertension.\nIn a double-blind, single-dose antihypertensive drug trial with a crossover design, three dosages of HCTZ (hydrochlorothiazide) were compared in patients with mild to moderate hypertension. Statistical methods based on the nonlinear mixed effects modeling are reviewed. Goodness-of-fit diagnostics indicate that the model provides a description of the blood pressure data that is consistent with the observed data. The method is used for comparison of the different treatment groups.<EOD> Clinical and Biochemical Findings in 101 Patients with Drug Resistant Epileptic Seizures: A Study from a Tertiary Care Center in India\n\nSir, Epilepsy is a chronic disorder of the brain characterized by repeated and unprovoked epileptic seizure. Approximately 50 million people worldwide and approximately 5 million people in India have epilepsy. 1,2 A large proportion of epilepsy cases are drug-resistant to conventional antiepileptic drugs (carbamazepine, valproate, phenytoin, LEV). Hence, there is a need to search for newer therapeutic options to control drug resistant status epilepticus and prevent recurrences. 3",
        "label": 2
    },
    "120": {
        "output": "*The trial-level eligibility is simply the overall grade of the most serious reason for not being eligible, i.e., the last eligibility on each patient for the clinical trial, and not a simple sum of the grades of the reasons for not being eligible. If the patient does not pass any of the screening checks, then the trial-level eligibility of the clinical trial is `0) Excluded`, i.e., that the patient is not eligible for the clinical trial. If the results are `1) Not relevant` or `2) Eligible` then the trial-level eligibility is simply the overall grade of the most serious reason, e.g., if the result is `1) Not relevant` then it means that the patient does not have sufficient information to qualify for the trial so it gives `1), but not 2).`\n\n___\n\n## Task 2\n\nYou need to predict the trial-level eligibility for each patient in a given patient pool using the training pool of 4 482 patient notes. \nLet's explore the patient pool in more detail. There are three interesting patient pools, where each patient pool has a different average trial-level eligibility. The average trial-level eligibility is the average of the patient's trial-level eligibility grades, so that 0.00 means that no patient in the patient pool is eligible.\n\nIn the first patient pool, there are 16 patient notes, of which 9 are `1) Not relevant` and 7 are `2) Eligible`, i.e., the average trial-level eligibility grade is `1.19` (not relevant patients are excluded).\n\nIn the second patient pool, there are 56 patient notes, of which 49 are `Not relevant` and 7 are `2) Eligible`, i.e., the average trial-level eligibility grade is `1.03 (not relevant patients are excluded).\n\nIn the third patient pool, there are 462 patient notes, of which 307 are `Not relevant` and 155 are `2) Eligible`, i.e., the average trial-level eligibility grade is `0.51 (not",
        "label": 0
    },
    "121": {
        "output": "[/SOLUTION]\nI also think that this problem is not hard if we know the general concept to solve the problem, even though we do not know the way and the example.\nI think the general concept is:\n- we should read all inclusion/exclusion criteria with each patient's profile\nThe example of this problem, so this patient has inclusion/exclusion criteria of clinical trial, we should find the patient profiles who match the patient's profile of clinical trial\nExample:\nPatient1-> patient who has the first three inclusion criteria of the clinical trial\nPatient2-> patient who has the first three inclusion criteria of the clinical trial\nPatient3-> patient who has the first three inclusion criteria of the clinical trial\nPatient4-> patient who has the second and third inclusion criteria\nPatient5-> patient who has the first inclusion criterion of the clinical trial\n\nThat's what I want to write in the solution and if everyone has a better way, I appreciate your comment.\n<EOD> Anatomical Variations of the Subscapular Artery and the Radial Nerve Relationship in Dry Arms: A Microscopic and Macroscopic Study in the Cadaver.\nBACKGROUND\nThe purpose of the present study was to examine the relationships between the subscapular artery and the radial nerve in Turkish cadavers.\n\n\nMETHODS\nFifty arms of newly embalmed human cadavers without known diseases of the upper limbs were examined. All specimens were dissected layer by layer according to routine techniques to show the course of the subscapular artery and the relationship between the subscapular artery and the radial nerve. The position of the subscapular artery and the relationships between the subscapular artery and the radial nerve were evaluated macroscopically as well as microscopically. Descriptive statistic and chi-square test were used for statistical analysis of data.\n\n\nRESULTS\nThe most frequent location of subscapular artery was just posterior to the axillary artery in the subscapular fossa. Four anatomical variations were detected in our study. There were no statistically significant differences between the position of the subscapular artery and the gender (chi2, p=0.13",
        "label": 2
    },
    "122": {
        "output": "<issue_comment>username_1: I just realized that this is basically the same as the 2nd question that's not been addressed in the training set yet, is correct? In that question a new model was used that was not exposed to any of the training data to build and train, and then to predict on a different set of data. That was a great exercise, and I learned a lot from it, but this one is a little different because all of the training data needs to be modeled to get the prediction; so it's important that the eligibility of the trial is not taken into account because the prediction may be biased otherwise.\n<issue_comment>username_2: Yes, I feel that the training data used for prediction is the same as the training data that was used to create the model. So the model is already adapted to the training data. I am not sure if this is the case here at the moment or not.\n<issue_comment>username_1: That is how I understood it too, and @username_3's last response is just more evidence, but I was still wondering whether or not there would be 3 responses for the 0's the 1's were too consistent/clear cut, it was a pretty small set of data, but there should be some more varied cases where it's not so clear.\n<issue_comment>username_3: There are definitely scenarios where it could be really unclear.\r\nSentiment: https://www.kaggle.com/c/sentiment-analysis\r\n\r\nI'm not sure what the best strategy would be here though\r\n\r\nThis could potentially be a regression\r\n\r\nOr perhaps a new model that doesn't include the trial-level eligibility, however, that would be using the same training data for predictions\r\n\r\nSo essentially training and validation in one step?\r\n\r\nAnother option would be to create a model on the training set that doesn't take the trial-level into account, then use this model on the training set to create the predictions, then use these predictions on the validation set to show that the performance of the model that took trial-level into account is better than one that didn't\r\n\r\nThis is a complex problem, and I think it's okay to do a bit of exploring at this point\r\n\r\nI",
        "label": 2
    },
    "123": {
        "output": "The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n```r\nrecommendation <-recommendation %>% mutate(Trial-level eligibility=case_when(.action == \"recommended\"~\"2)~recommended,\n                                             .action == \"recommended, must be excluded\"~\"0\"))\n```\n\nWe can see from the output that our recommendation is 2), meaning this patient is eligible and our recommendation was not changed.\n\nNow we should repeat this step recursively on the child nodes. \n```r\nrecommendation <-do.call(c, lapply(childNodes, eligibilityDetection))\n```\n\n## Recursion of Recommendation \n\nNow we should repeat this step recursively on the child nodes.\n```r\nrecommendation <-do.call(c, lapply(childNodes, eligibilityDetection))\n```\n\n## Evaluation\n\n```\nrecommendation <-evaluateClinicalTrialRecommendation(recommendation, cTrials, eligibilityDetection)`\n```\n\nNow we can see all of our recommendations. We know that the recommendation of this patient is `Recommendation: \n\t2 - Eligible, must be excluded`.\nWe also know that the overall recommendation of the entire trial is the same; that is, `Overall recommendation: 2 - Eligible, must be excluded.`.\n\nWe can easily make the trial-level recommendation at the end of our recursion:\n```r\ntrialOverallRecommendation <-trialOverallRecommendation[trialTrials == \"A0701\"]\n\n## trialOverallRecommendation <-c(\"1 - Not Eligible\",\"2 - Eligible, must be excluded\",\"3 - Not Eligible\")\n```\n\n## Evaluation based on the results on the",
        "label": 0
    },
    "124": {
        "output": "__ 3_ELEGIBILITY_COMBINATOR: If a given patient note has all of the following inclusion criteria and none of the exclusion criteria, then the patient is 100% eligible for a clinical trial. [1]\n\n[1] The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n<EOD> Preoperative Prediction of Tumor Necrosis in Pancreatic Ductal Adenocarcinoma: A Radiomic Analysis\n\nSupplementary Data\nSupplementary Data\nFig. S1. Flow chart of the radiomic analysis. The process of selecting radiomic features of the selected features (798) was performed by performing the LASSO model. The features within 1 SE of the minimum CV error and the maximum CV score were saved for prediction model building. The model was built by Lasso-Cox regression model, SVM, and DT based on the remaining features. Prediction models were evaluated in the same fashion as the main text and the details were present. . The receiver operative curve (ROC) of the radiomic model, radiologist, and pathologists. The AUCs of the DT, SVM, and radiologist were 0.764, 0.781, and 0.643 respectively.<EOD> Theoretical Study on the Strongly Interacted Heterocatalytic Model of Pt@Au112(SR) for Enantioselective Hydrogenation of Furan Aldehyde.\nThe enantioselective organometallic catalyzed ene-yne hydrofunctionalization has become a research focus because of its green and convenient application in both academic and industrial. Herein, we performed an ab initio study to investigate the enantioselective hydrogenation of furan aldehyde to 3-methyl-1-buten-4-ol catalyzed by a strongly interacted heterocatal",
        "label": 1
    },
    "125": {
        "output": "2.22.5. [FIL] What is a treatment plan?\n\n[FIL]\nI. Assess patient characteristics and clinical status II. Prescribe initial treatments III. Plan treatment modifications according to patient/tumor response IV. Monitor patient progress\n\nA treatment plan is a course of prescribed treatments (surgery, chemotherapy, radiation, pharmacotherapy, physical therapy, nursing and other interventions) or observation that meets the patient's cancer-related care needs, regardless of setting. Treatment planning is an important part of nursing because it is a means to ensure safe and effective care, and is the responsibility of nurses in conjunction with members of the treatment team, including the patient and/or family. \n\nThe purpose of the treatment plan is to determine how the nursing care plan will be implemented on a daily or other consistent basis. It is a written account of the nursing treatment plan. Treatment plans are patient-specific, i.e., each patient may have a different treatment plan based on the diagnosis and the nursing care the patient will require to meet their specific nursing care needs. \n\nThis tutorial focuses on a treatment plan for the nurse for a new patient or when a new medication is starting, for an existing patient taking a new medication. This can be written in a number of ways including in a progress note or the electronic medical record, but it must be an individually written document with enough detail to provide adequate knowledge for all disciplines involved with patient care, including medical care. A sample treatment plan for medication may include:\n\n### PATIENT CHARACTERISTICS AND CLINICAL STATUS\n- Name, age, height, weight, gender - Patient's chief complaints, associated diseases, current clinical status, any drug use - Diagnosis - Symptoms according to the NANDA diagnoses - NURSING INTERVENTIONS, GOALS, PLANS\n\n### PREScribe INITIAL TREATMENTS\n- New or continuing - What, dosage, route, frequency, time of each treatment, dosage form, duration of the treatment, nursing intervention, patient teaching, and monitoring methods\n\n### PLAN TRE",
        "label": 2
    },
    "126": {
        "output": "<jupyter_code>from pysprout.datatypes import Criteria\n\n@jupyter_output(format='html', header=True)\ndef __f_2(_criteria):\n    # This code is a template for the cell and is edited by the user as indicated below.\n    # It should only have one input:\n    #\n    # <jupyter_code># Input variable\n    # Eligibility_status = Criteria.Eligibility_status\n\n    # Output formatted as a table\n    #\n    # For the cell shown here, the output should read:\n    #\n    # ## Patient data:\n    # ### Patient ID:    P0507\n    # ### Gender:      F\n    # ### Medication use:    AML_T\n    # ### Current smoking status:    NEVER\n    # ### Comorbidities (list):     Asthma, Hypertension\n    # ### Clinical trial inclusion criteria\n    # ###: Cancer type:    Breast\n    # ###: Cancer stage:    Lung\n    # ###: Smoking history:    Smoker\n\n    # ## Patient data summary\n    #\n    #    Evaluable patients (%)\n    #    : \n\n    # ## Overall trial eligibility\n    #\n    #    Trial-level eligibility:  1) Not relevant\n    #--------------------------------------------------------------------------------------------------------------------------------------\n    # #\n    # ## Patient data\n    #  Patient ID:P0042\n    #   Gender  :F\n    #   Medication use :     BI 125mg\n    #   Current smoking status:    former(>3 year)\n    #   Comorbidities (list):     Asthma\n    #   Patient name:  M.E. \n    # \n    #   ## Clinical trial inclusion criteria\n    #   Cancer type:          Breast\n    #   Cancer stage:        Breast\n    #   Smoking history:     Smoker\n\n    ## Patient data summary\n  \n    ## Overall trial eligibility\n\n\n    # ## \n    # ## Patient data\n    # Patient",
        "label": 0
    },
    "127": {
        "output": "<EOD> Preoperative Assessment of Patients With Bariatric Surgery.\nBACKGROUND\nThe number of bariatric surgical procedures continues to rise in the United States, making it essential that health care practitioners be familiar with their perioperative management.\n\n\nOBJECTIVE\nThe aim of this article is to describe the preoperative assessment of patients who are undergoing bariatric surgery, identify common preexisting conditions, and discuss the role of anesthetists in risk stratification and perioperative optimization.\n\n\nMETHODS\nWe present and discuss relevant articles and guidelines found in the primary literature and the National Institutes of Health databases, as well as on the websites of the American Society Anesthesiologists, the National Heart, Lung, and Blood Institute, and the National Institutes of Health.\n\n\nRESULTS\nPreoperative care includes a thorough evaluation, identification of coexisting conditions, preoperative testing, preparation, and optimization for surgery. Optimization can be accomplished through appropriate assessment and intervention, including nutritional support, smoking cessation, and optimization of underlying conditions.\n\n\nCONCLUSIONS\nThe anesthesia team plays a critical role in the planning of perioperative care, the optimization of patients for surgery, and the monitoring and identification of perioperative complications.<EOD> A rare double variation of the vertebral artery associated with a bilateral absence of the inferior thyroid artery\n\nWe report a rare variation in the intra-cranial course of bilateral vertebral arteries. Both arteries have crossed the contralateral side and anastomosed with another bilateral vertebral artery in upper cervical level to create a 'reverse flow' double variation pattern. Furthermore, we report the absence of bilateral inferior thyroid arteries, which are present normally in 60-70% of people.K E Y W O R D Sanomalous blood vessels, double variation pattern, vertebral artery\n\n# | introduction\nVertebral arteries (VAs) are paired bilateral arteries that originate from common carotid arteries and have their own course [fig_ref]  . 1 \u2212: the anastomotic region of the",
        "label": 0
    },
    "128": {
        "output": "What is the difference between RATKILL and VASICHEMO and ELLOXA?\n\nThe data show: \n\nRATKILL\nVASICHEMO\nELLOXA\nNumber of patients with assessment of eligibility = 6829\nNumber of patients with exclusion at eligibility assessment : 566(43.5%)\nNumber of patients with assessment of eligibility = 565\nNumber of patients with exclusion at eligibility assessment : 0%\nNumber of patients with assessment of eligibility : 683\nNumber of patients with exclusion at eligibility assessment : 39.1%\nIf we analyze the above figures, we can observe that when the total number of patients is considered, RATKILL includes the maximal number of patients (6829 patients), while ELLOXA includes relatively small number of patients (683 patients). This does not mean that all patients in ELLOXA were 0 for Trial-level eligibility. Most likely, their Trial-level eligibility was 1 or 2, and we can observe the 0 value only because they were not included in the output table. If you want to analyze the number of Eligible patients, just multiply the number of patients with Trial eligibility 2 to the number displayed in the column of Trial-level Eligibility 2.\nOn the other hand, RATKILL provides 39.1% patients with eligibility 2, VASICHEMO provides 43.5%, and ELLOXA offers 39.1% eligible patients. What does this mean? The answer is simple. If someone has three different trials for the same topic and provides the three ratios above, one should conclude that their results are in line with the current practice.\n[INST]<EOD> Transcriptome Profiling of Cattle Subcutaneous Adipose Tissue during the Rapid Adipose Gain Period, 7 Days Before and After the First Growth Check\n\n\n\n# Introduction\nBeef quality traits are closely related to the body composition of bovine. Generally, adipose tissue is thought of as an inert tissue with a fixed amount, but",
        "label": 0
    },
    "129": {
        "output": "- [HINT]\n<EOD> 2\u03b1\u2010Methyl\u201019\u2010nortestosterone Induced Reproductive Toxicity in Male Wistar Rats: A Mechanism Mediated through Nrf2/HO\u20101/TGF\u2010\u03b21/ERK/Ki67/CYP2C11 Axis\nMale reproductive endocrine dysfunction is an important environmental health problem in human society. In the present investigation, 2\u03b1\u2010methyl\u201019\u2010nortestosterone (MENT)\u2010induced reproductive toxicity was investigated in male Wistar rat models. Reproductive toxicity was evidenced by dysregulation of serum testosterone levels and semen quality, oxidative stress, apoptosis, histopathological and morphometric alterations on the testicular tissue. To elucidate the possible underlying etiology, the present study was focused on the possible molecular changes by focusing on the expression of various proliferation biomarkers (Nrf2, HO\u20101, Ki67, TGF\u2010\u03b21, and CYP2C11). 2\u03b1\u2010Methyl\u201019\u2010nortestosterone is an anabolic steroid widely available as over\u2010the\u2010counter or prescription drugs. This commonly used drug is banned by the World Anti\u2010Doping Authority for its potential health hazards. Exposure to 2\u03b1\u2010methyl\u201019\u2010nortestosterone induced testosterone insufficiency and degeneration of both the seminal vesicle and epididymis. Histopathological and morphometric changes on the testis were detected through H&E, TUNEL, and immunohistochemistry staining of oxidative stress (4\u2010HNE), Nrf2, HO\u20101 HO\u20101, Ki67, TGF\u2010\u03b21, and CYP2C11 positive cells. Oxidative toxicity and expression of Nrf2, HO\u20101, and CYP2C11 were found to be in a negative concordance fashion with dysregulation in the cell proliferation markers. In this paper, we presented a possible molecular mechanism",
        "label": 0
    },
    "130": {
        "output": "``` r\npatient <- c(\"No.01-0243\", \"No.01-0620\")\n\nclt <- as.data.frame(read.excel(\"Trial_patient_clinical_trial_record.xlsx\", sheet = \"Trial_patient_clinical_trial_record\", row.names = NULL)) %>%\n  bind_rows(clt[[paste(patient[1],patient[2])]], .id = FALSE)\n\nclt$clinical.trial_eligibility <- seq(clt$clinical.trial_eligibility)\nclt[[paste(patient[1],patient[2])]]$clinical.trial_eligibility <- 0\n\nclt\n```\n\n``` r\n# Aggregate data frame of all patients.\nclt_agg <- rbind(clt)\n\n# Agggregate for Trial-level Eligibility\nclt_agg$Trial_level_eligibility <- sapply(1:ncol(clt_agg$clinical.trial_eligibility), function(i) {\n  if (clt_agg$clinical.trial_eligibility[\"i\"] > -2) {\n    clt_agg$clinical.trial_eligibility[\"i\"] <- 4 # Excluded\n  } else {\n    clt_agg$clinical.trial_eligibility[\"i\"] <- 1 # Not Relevant\n  }\n})\n\nclt_agg\n```\n\n# Results\n\n\n``` r\nclt_agg\n```\n\n``` r\nclt_agg$clinical.trial_eligibility\n```\n\n``` r\nclt_agg %>% dplyr::mutate(clinical.trial_eligibility = factor(clinical.trial_eligibility))\n```\n\n``` r\nclt_agg %>% dplyr::mutate(clinical.trial_eligibility = factor(clinical.trial_eligibility)) %>%\n  dplyr::select(\"clinical.trial_eligibility\",",
        "label": 1
    },
    "131": {
        "output": "## Summary\nSo far, each person in the crowd has reviewed a note, which means to make a one-time judgment of the patient in the note by comparing the clinical trial information and the patient's characteristics. After reviewing many such note-cases, the opinions may be aggregated. Although clinical trials are not about how many people participated in the trial, they will benefit more if a lot of people participate in the study. Therefore, when aggregating the reviews, we should also take into account the number of reviewers. To incorporate this idea into a model, we consider the patient i (i = 1, 2, ..., N) from the crowd to participate in the trials. Then, for review r (r = 1, 2, ..., M) of patient i by person j (j = 1, 2, ..., N; j = i), we create a matrix (R \u2208 R p\u00d7N\u00d7N ) of size {d \u00d7 q \u00d7 N}, where d is the number of distinct patients among all patient i's. Then, R can store the patient's evaluation score for each patient",
        "label": 2
    },
    "132": {
        "output": "Please submit all your work in `Pickle`.\n-- Evaluation ---------- [[EVAL]] Assistants:\n[EVAL_ASSISTENT_1] This is a nice task. I would like to see more of them for a wider range of topics.\n[EVAL_ASSISTANT_2] Thanks, Eval_Assistant_1. The quality of the submissions will be evaluated by both of us. Since this is a new task format, we are learning how to evaluate submissions.\n-- Rules for this task:\n[RULE_1] The task contains three stages. There will be three submissions, one for each stage. Submission of each of the three stages will be separated by one day.\n[RULE_2] You should enter the patient number and the ID code in the comment if the patient was included in the trial.\n[RULE_3] For each included patient, you should evaluate patients for eligibility. Enter the evaluation in the comment. There are three possible evaluation results: Excluded, Not relevant, and Eligible.\n-- Rules for the `Hooks:`\nThe `Hooks` sections should be entered at the beginning of each of the three submissions.\n- Your hooks should not be numbered.\n- Do not include headers.\n- A hook should be a short answer in the form of a question.\n- If your hook requires knowledge about medical history of the patient, specify that.\n- Each hook should start with a question mark.\nSee the sample below.\n- [RULE_1] Submission 1 hook: `What is your question?` (Sentence without numbering.)\n- [RULE_2] Submission 2 hook: `Which study arm do you think the results will favor?` (sentence without numbering, but with header.)\n-- [EVAL_CONSULTATION] Consultation (Evaluator #1):\nThis is submission 3_Final and will be evaluated with the same rules as the rest of the submissions.\nI found all the 3 hooks which were expected. The hook \"What is a clinical trial?\" is relevant in itself and is part of the general knowledge. And also when we are on the patient note: \"There is no mention of clinical trials\" is also relevant and it confir",
        "label": 0
    },
    "133": {
        "output": "<EOD> Antigenic variants of herpesvirus of rhesus monkeys selected in vitro with monoclonal antibodies.\nA herpesvirus of monkeys (RMH) passaged repeatedly in vitro with rabbit antibodies against RMH obtained with a monoclonal antibody (mAb) was studied. The mAb tested is an IgG2a monoclonal antibody obtained in BALB/c mice by cell fusion with the Sp2/0 cell line. Passaging of the virus in cell cultures with added mAb resulted in the selection of several RMH antigenic variants, as indicated by an inhibition of plaque formation. Inhibition experiments revealed the presence of at least two distinct antigenic variants in the population of variants. RMH variants 1 and 2 were cloned and shown to plaque poorly in several cell culture systems. Inhibition experiments indicated that the two clones could be segregated from one another. The variants were resistant to neutralization of plaque formation by mAb and RMH convalescent sera obtained shortly after virus infection. The two clonal variants were tested by complement fixation test with convalescent sera and the IgG fraction of three mAb. The results confirmed the inhibition data and demonstrated that the variants were indeed sensitive to the IgG fractions of mAb. The variant RMH 1 had a 2.8-fold increase in its susceptibility to complement fixation mediated by convalescent sera and by the IgG fraction of one of the mAbs. These findings suggest that clones RMH 1 and 2 could be variants of HERV-1, a homologue of human cytomegalovirus (Herpesvirus saimiri group, Herpesviridae) reported to be related to human cytomegalovirus.<EOD> Inhibitory effect of propranolol on nephrogenic systemic fibrosis\n\nBackground Propranolol hydrochloride is a non-selective beta-adrenergic blocker used to treat both cardiovascular and non-cardiovascular conditions. A recent in vitro study showed that propranolol inhibited the cell division of fibroblasts",
        "label": 0
    },
    "134": {
        "output": "[[INSTR] Tests]]\n<br>\nIf the value has changed, it means the patient satisfies the criteria of this clinical trial.\n<br>\n[/INSTR]\n\n\n\n# Outputs\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nThe trial-level eligibility is calculated with `eligibility(\"patient_note\",\"clinical_trial\")` in a Python dictionary. If the trial-level eligibility is 2, then the patient satisfies the criteria of this clinical trial: `eligibility(\"patient_note\",\"clincial_trial\")[0] == 2`. \nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nThe patient must satisfy both inclusion and exclusion criteria to be eligible for the trial. You may input several assessments of eligibility for each trial in the column `assessment_of_elibility`.\nThe following is the output for the assessment of eligibility for a patient:\nYou should always input trial-level eligibility at the end of a column, e.g., `Trial-level eligibility: 2) Eligible.`, as shown in the following:\n\n# Installation\n\n## Requirements\n- Python3\n- Numpy\n- Pandas\n\n## Installation\n\n```\ngit clone https://github.com/hanyung/disease.git\ncd disease\npython setup.py install\n```\n\n## Note\n\n`notelib` is an unmaintained library, and the code in the module `notelib.clinical_trial` needs to be",
        "label": 2
    },
    "135": {
        "output": "# Related tasks\n<EOD> The effect of diabetes and antidiabetic agent on the expression profiles of lncRNAs and mRNAs in diabetic cardiomyopathy\nDiabetic cardiomyopathy (DCM) is characterized by systolic and diastolic dysfunction of the heart, resulting in a decline in cardiac pump function. Several lncRNAs are involved in different cardiac cell processes and DCM. We aimed to investigate lncRNAs and mRNAs expression profiles in the heart of a streptozotocin (STZ)/nicotinamide (NA)-induced DCM and its antidiabetic agents (metformin, liraglutide, and their combination), using RNA-seq analysis. The Wistar male rats were divided into the groups: NC, DCM, Met-DCM, Lira-DCM, Met-Lira-DCM. We used the heart tissue of the animals for analysis. We found 1435, 1746, 1673, 1784 significantly changed lncRNAs (p\u2009<\u20090.05, log\u20092FC\u2009>\u20091) and 3280, 2298, 2414, 9036 significantly changed mRNAs (p\u2009<\u20090.05, log\u20092FC\u2009>\u20091) in the DCM, Met-DCM, Lira-DCM, Met-Lira-DCM group, respectively. We identified 466 common lncRNAs and 5 common mRNAs in the Met-DCM, Lira-DCM, and Met-Lira-DCM groups. We revealed 7 specific lncRNAs and 43 specific mRNAs in Met-DCM group, 5 specific lncRNAs and 27 specific mRNAs in Lira-DCM group, and 3 specific lncRNAs and 2 specific mRNAs in Met-Lira-DCM. In addition, we found 9 mRNAs and 1 lncRNA in DCM group, which showed no difference in the expression levels compared",
        "label": 0
    },
    "136": {
        "output": "A rat cardiac system allows the simultaneous observation of four hearts under physiological conditions in an isolated environment. In other words, it is a platform that allows us to directly observe the physiological behavior of a cardiac muscle over time.\nThis project aims to make a complete rat cardiac system. \nThe system comprises five units: \n\nThe physiological function of each part is to be determined within a certain range. \nThe system specifications are classified into those for the main part composed of the base and the drive unit; and those for the additional parts, such as oxygenators and carbon dioxide removal units. \n\nThe specifications for the main part of the system are: \n> Range (minimum-maximum) for oxygenator flow: 0-100 ml/min > Range for carbon dioxide flow: 0-500 ml/min > Range (minimum-maximum) for respiratory gas mixture (O2/CO2) adjustment in the range of 30%-500 min\n\nIn the case of the maximum respiratory gas mixture (O2/CO2) adjustment, the respiratory gas mixture should be prepared with adjusting carbon dioxide partial pressure (PaCO2) and oxygen partial pressure (PaO2) for the carbon dioxide elimination unit and the oxygenator, respectively. \n\n> Respiratory gas mixture (O2/CO2) at maximum carbon dioxide elimination: minimum of 200-maximum of 700 > Range of oxygen for maximum oxygen release: minimum of 50-maximum of 150\n\n> Range (minimum-maximum) for adjusting heart rate: 300-500 beats/min\n\n> Range (minimum-maximum) for adjusting contractility: ~0.5-1.5 lNs\n\n> Vmax = 10,000 beats/min\n\nBy these specifications, when the carbon dioxide elimination (maximum) unit removes additional carbon dioxide by adjusting the carbon dioxide partial pressure (PaCO",
        "label": 0
    },
    "137": {
        "output": "### 2.2 Data-level eligibility\nIf you are still with us, let's define a list of data-level eligibility criteria, e.g., `Liver disease: hepatitis B co-infection (true). Vital signs: abnormal (false). Current medications: rifampicin (false). Current medications: methotrexate (true). Current medications: tenofovir (false). Current medications: paracetamol (true). Current medications: aspirin (true). Medical history: cardiac disease (false). Current medications: lopinavir/ritonavir (false). Current medications: ritonavir (negative).`\n\nBefore moving on, you should always use `||` instead of `||` to combine AND operators (and NOT operators) when using data level criteria (i.e., `Liver disease: hepatitis B co-infection || hepatitis C co-infection || HIV-2 mono-infection || HIV-2/HIV-1 co-infection (false), hepatitis A co-infection || HIV-1 single, non AIDS-indicating infection (true), HIV-1 single, AIDS-indicating infection || HIV-1 single, non AIDS-indicating infection (true), AIDS (false), Lymphoma (false) || Sarcoma (false) || Kaposi sarcoma (false) || Lymphoid interstitial pneumonitis (false), Extraneural kaposi sarcoma (false) || Cytomegalovirus (true), Cytomegalovirus retinitis (true) || Cryptococcus (true), Esophageal candidiasis (true) || Herpes (false) || Lymphogranuloma venereum (false), Oesophageal candidiasis (true), AIDS-associated Mycobacterium avium complex (MAC) pneumonia (false) || Pneumocystis pneumonia (negative) || Mucocutaneous (negative), Recurrent Cytomegalovirus-related retinitis (false), Recurrent herpes-related retinitis (",
        "label": 0
    },
    "138": {
        "output": "[INST] Hello. You are a helpful assistant for clinical trial recruitment. You need to develop a template to assess the patient recruitment notes. The template is a guide that helps to develop a report for the trial.\n\nYou can make decisions by comparing patient and trial metadata. For example, you should not consider a trial that is not appropriate for patients with a specific diagnosis. Please note that the trial may include a range of disease types, and patients with one disease type are not automatically excluded from a particular trial. However, you should be able to estimate which trial the patient might be eligible for by examining the list of characteristics such as diseases and medications that were included in the trial.\n\nPlease note that this template is intended to assess a given note and not to search a list of trial notes. The assessment of note eligibility is one-time work. For example, if you identify a clinical trial excluding male patients or if you see a clinical trial recruiting a specific age group, you can stop searching for trial notes and return to the template. \nThere are three columns in the template. Please fill in the patient note and assess patient eligibility for the specified trial(s) on each trial by evaluating factors such as demographic information, disease, medication, and treatment. \n\nHere are the patient note and clinical trial. \n\n![](https://user-images.githubusercontent.com/12954421/93707181-19f99d80-f6f9-11eb-8714-ffbae09932c5.png)\n\n\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to summarize the clinical trial notes. You should make a recruitment note to each patient for the trial.\n\nPlease note that this recruitment note is a summary of your main task to assess the trial's eligibility. If you are using the template to assess note eligibility, you can use the existing assessment in the summary. It is also permissible to use previous assessment results as a recruitment note.\nPlease note that recruitment notes should be made at the time of first contact. In other words, you should communicate",
        "label": 0
    },
    "139": {
        "output": "0/10/2022  3/11/2022  0/10/2022  2022  3/11/2022  \n[/EVAL]\n<EOD> Inheritance of a defect in chloroplast development from maize lines with defects in mesosomal transport\nTwo mutations in maize (Zea mays L.) cv B73 have been characterized that are defects in mesosomal transport. These mutations, designated defects in mesosomal transport (dm1 and dm2), are distinct from previously characterized transport-defective mutations. The dm1 locus was tentatively mapped to the lower arm of chromosome 9. The inheritance pattern of photosystem II (PSII) activity in cytochrome-f/PSII (CF/PSII)-treated plants demonstrated the recessiveness of the dm1 locus, implying that its phenotype is an unaltered wild-type phenotype. In contrast, the dm2 mutation demonstrated a dominant inheritance pattern, which was manifested as a severe reduction in mesosomal transport, but this strain had no effects on either the CF/PSII-induced PSII activity or chlorophyll synthesis. The reduction in mesosomal transport was reflected in a reduced plastid size and an altered appearance of the chloroplasts. The mutation dm2 was mapped to chromosome 6. We conclude that the dm phenotype is not due directly to a defect in electron transport in the mesosomes. Because two other loci (maize-1 and chloroplast inhibitor of protein synthesis) have been shown to be involved in the synthesis or maturation of the ATP synthase and the light inhibition of CF/PSII-induced PSII activity, we examined the effect of the dm mutation on proteins of the ATP synthase complex. The analysis demonstrated no reduction in ATPase specific activity. Furthermore, CF/PSII treatment of dm2 plants did not cause a severe increase in stroma thylakoid proteins as has previously been reported for several mutants with aberrant ATP synthase complexes. We conclude that mesosomal transport, while needed for normal chlor",
        "label": 0
    },
    "140": {
        "output": "You are done with the assessment of eligibility! \ud83d\udc4d\n\n## Recording and updating assessment of eligibility\nNow, you should make a patient trial. There is information on how to make a patient trial from [/INST (a3) Recording of the Patient Trial].\n\n\n- To record assessment of eligibility in a Patient Trial, please choose `Update` in the left menu.\n![image]({{ repo }}/assets/img/005_step3_recording.png)\n- This gives you three different selection options. `Update' means to save the selected option and close the editing screen. `Save' means to save or update the current patient trial. `Cancel' means to close the editing screen and go back to the main trial-management window without saving any changes.\n![image]({{ repo }}/assets/img/005_step3_recording.png)\n![image]({{ repo }}/assets/img/005_step3_selection_window.png)\n- A list of all patient trials is given in the left menu bar.\n![image]({{ repo }}/assets/img/005_step3_new_recording.png)\n\n### [a] Patient trial level\nIn order to record assessment of eligibility in a patient trial, please select `patient trial`.\n![image]({{ repo }}/assets/img/005_step3_PatTrial.png)\n\n### [b] Patient trial version\nIn order to record assessment of eligibility in a patient trial, please select `a patient trial version.`\n![image]({{ repo }}/assets/img/005_step3_pt_v_info.png)\n\n### [c] Patient trial note\n![image]({{ repo }}/assets/img/005_step3_pt_note.png)\n\nIn the following, you can see the complete recordings:\n\n\n*\n\n*(a) Patient trial level: The patient does qualify; therefore the patient trial is assessed as Qualified. The new Patient Trial Note Version is created.\n\n*\n\n*(b) Patient trial version: As the patient trial version number is `1`, no",
        "label": 0
    },
    "141": {
        "output": "## Tutorial 2: How to set the attributes of a single patient object\nThis exercise is related to the one above and in this case you should modify the attributes of a single patient object for a given clinical trial.\n\nAs you did in the first exercise, the data file can be found in `src/data/clinical_trials/instructions.Rdata`. \nThe first two patient object attributes are: patientid and clinicalTrial. To access the attributes of both attributes with the patientid attribute: `attr(clinicalTrials$clinicalTrial, \"patientid\")`. Similarly, to read the attributes of the clinicalTrials$clinicalTrial attribute with the patientid attribute: `attr(clinicalTrials$clinicalTrial, \"patientid[clinicalTrials$clinicalTrial$patientid]\")`.\nThe full range of output attributes in both objects is documented in `src/data/attributes.csv` and `src/data/clinical_trials/attributes.Rdata`.  \n\nAs in the first exercise, your task is to set the required attribute of each patient object with the clinicalTrials$patientId column attribute. However, this time you will set the \"Yes\" attribute with a patient id of `3` that is already defined in the `clinicalTrials$clinicalTrial$patientid` column. To assign the `3` in the `clinicalTrials$patientId` column attribute: `for(i in seq_len(nrow(clinicalTrials))) { clinicalTrials_setpatientId <-list(clinicalTrials_setpatientId , i, \"Yes\"))}`. The patient id in a clinical trial should always be the `1`, even if you do not consider the patient eligible. Thus, the patient id `4` and `7` should be assigned as `Nobody` in both rows. Finally, assign the two patient ids `1` and `2` as `Unknown` in the clinical trial attribute with the following code: \nAll output attribute values will be assigned to their respective attributes and shown in `clinicalTrials$patientId` of your clinical trial file. \nFinally, the clinical",
        "label": 2
    },
    "142": {
        "output": "* * *\n\n## Making a decision \nThere is a lot to consider when deciding on a patient's inclusion in a clinical trial. This is not an easy task and you may need to consult a physician or clinical expert. Here are some factors to consider when looking for a suitable trial for your given patient:\n- Inclusion criteria: Check that the type of cancer and stage correspond with the inclusion and exclusion criteria.\n\nThe first thing you may notice is that while most clinical trials require the patients to have a certain type and stage of cancer, here we have a clinical trial that does not require these. It is not clear whether this trial would be appropriate for the patient or not. Let's assume it is not and now you should recompute the trial-level eligibility.\nSo, you must use `Trial-level eligibility: 0)` for `Aromasin` trial because it requires the patients to have a certain type and stage of cancer.\n\nSo, if you are happy with the results, you can do the following: [MOB]\n\n![FIN ](images/FIN.gif)\n\n\n```\n# You should do this in every clinical trial you work with\nTrials <- rbind(Train, Te)\nTrain$TrailName <- gsub(\"/\", \"_\", Train$TrailName)\nTrain$PatientName <- gsub(\"/\", \"\", Train$PatientName)\n\nf1 <- function(DF) {\n  if (nrow(DF) >= 3) {\n    p <- 1 -apply(DF[,c(6,7,8)], 1, function(x) ifelse(x == 0, 1, 0))\n    p <- rbind( p, \n                 apply(DF[,1:5],1, mean) %in% c(\"Young\", \"MiddleAged\", \"MiddleOld\", \"Old\", \"VeryOld\")\n               ) \n    p <- rbind(p,\n             ifelse(DF[,2] %in% c(\"Squamous cell\",\"Invasive lobular\"), 2,\n             ifelse(DF[,2] %in% c(\"Ductal carcinoma in situ\", \"Breast carcinoma\"), 1)))",
        "label": 0
    },
    "143": {
        "output": "## Difficulty\nHard\n\n## Data format\n- [CSV] Data CSV file\n- [JSON] Data JSON file\n- [IPD] Code, data, and notes in IPython notebook\n- [SBML] Dataset in SBML format.\n\n## Example\nThe user guide of this tool can refer to our [IPerception-v4-User-Guide.pdf](https://github.com/hhs-ai-lab/IPerception/blob/master/documentation/IPerception%20v4.userguide.pdf).\n\n## Code to follow\nThe user's code is described below. The raw csv file used in the analysis above is provided as `code/data/trial1_recruitment_notes_dataset.csv`. The Jupyter notebooks for each analysis in this tool are provided as `code/data/test_data`, `code/data/dummy_data`, `code/data/trial1_notes_dataset`, `code/data/trial5_notes_dataset`, `code/data/trial11_notes_dataset`, and `code/data/denosumanb_trial12_notes_dataset`. Additional datasets used in this tool are `code/data/ipd_recruitment_notes.csv`, which is an extract of the data provided by [IPerception-v3-Users-Guide.pdf](https://github.com/hhs-ai-lab/IPerception/blob/master/docs/IPerception%20v3.userguide.pdf) in the form of recruitment notes; and `code/data/data_for_denosumab.tsv`, which is extracted from https://clinicaltrials.gov/ct2/show/NCT01955668?term=Denosumab&rank=1. Note that each data subset comes with its own pre-processed version of the data file. The `code/data/trial1_recruitment_notes_dataset_preprocessed.csv` can be downloaded using IPerception's `PreProcessData` function (or `IPerception.PreProcessData` in Python3). Please note that in the example code below, the variable names in `",
        "label": 2
    },
    "144": {
        "output": "<EOD> Mentor Training for Adolescent Group Therapy Clients in Outpatient Mental Health Treatment Centers\nThe results are presented from a pilot study assessing training for mentors of outpatient mental health treatment center adolescent group clients, the mentors\u2019 satisfaction with the training they received, and their subsequent perceptions of the benefits of mentor participation on group therapy for adolescent clients. After 30 hours of training and supervision, mentors were asked to rate their training skills, comfort in various areas of group therapy, personal growth/empowerment experiences, group therapy perceptions, and benefits to the clients on several scales ranging from \u20131 = no benefit, to 3 = a great benefit. In addition, mentors were asked to rate the benefits of working with adolescents generally on the same scales. 40 mentors in 20 mental health clinics participated in a structured training program and the 30-item Training Program Satisfaction Assessment developed specifically for this study was administered to 20 mentors at the end of their training. Results from mentors indicated significant post-training increases in their training skills, comfort with group therapy, and personal benefits from group therapy. Mentors indicated that group therapy was very, very helpful to the clients\u2019 self-esteem, self-concept, and self-confidence. Mentioned in lesser degrees were mentors\u2019 perceptions of significant improvements in the clients\u2019 social skills, emotional functioning, and behavior control. It was concluded that mentors who have lived experience with the adolescent problems being discussed in group showed high levels of comfort with, and satisfaction from, their role, and that they thought the group therapy offered significant benefits to clients.<EOD> .\nOBJECTIVE\nThe purpose is to study the value of ultrasonic Doppler in the diagnosis and differential diagnosis of chronic venous insufficiency.\n\n\nMETHODS\nThirty-five subjects were enrolled, comprising the following groups: 19 patients with primary chronic venous insufficiency and 16 healthy subjects. Flow volume and venous blood flow velocity of the great saphenous vein were evaluated in upright posture and squatting posture in two groups.\n\n\nRESULTS\nThe flow",
        "label": 0
    },
    "145": {
        "output": "You might like it if the patient meets the eligibility criteria for participating the clinical trial. \n\n# Conclusion\nIn this paper, we proposed a method to detect whether a patient is applicable for a clinical trial through a clinical trial-related text and an assessment of eligibility. We have conducted experiments using a dataset with 250 notes from patients. To compare the proposed method with previous studies, we used three models to classify the notes. The first one is the conventional model that uses only machine-learning-based clinical features, the second one utilizes machine-learning-based clinical features with the text features in the notes, and the last one is a conventional clinical trial matching method. For each model, we calculated AUC to evaluate their performance. Our proposed method showed better performance (AUC=0.996) than the previous models (AUC=0.8969 and 0.8949), which are related to the clinical trial-related text. Thus, this study showed that the information on whether a patient is eligible for a trial could be used to perform a more efficient matching process between patients and clinical trials.\n\n# Supplementary materials\n\n## Supplementary data 1\n[table]  Table 2: The number of patients according to their eligibility [/table] \n<EOD> The Coulson-Forster Series of the Periodic Acid Chromotropes of Carbohydrates. II. Chromotropic Esters of D-Mannose.\nIn a preceding paper (1) a study was made of the chromotropic acid derivatives of D -xylose, D -galactose, and D-glucose from the standpoint of the Coulson-Forster series (2) of the color reactions of monosaccharides. I t was suggested in particular that the series might enable color changes characteristic of an acid chromatogram to be related not only with the number of rings present in the molecule of sugar, but also with the type of ring, the size and shape of the molecule (size of the carbon atoms, the branching) or the nature of the substituents. As regards the identity of the chromogenic groups, a systematic study of the chromatograms showed that the reaction of the group may be in each case considered to occur independently",
        "label": 0
    },
    "146": {
        "output": "[END]\n\n\n## Task 2 \nPlease select the code that is different from the others:\n\n<script src=\"https://cdn.jsdelivr.net/lodash/4.17.10/lodash.min.js\" referrerpolicy=\"origin\"></script>\n<input id=\"answer\" type=\"number\" hidden>\n<div class=\"card\">\n  <div class=\"card-body text-center alert alert-warning mb-0\">\n    <h6 class=\"card-header bg-warning text-uppercase font-weight-bold mb-0\">Please, select the piece of code that is different from the others:</h6>\n    <div class=\"row justify-content-md-center\">\n        <div class=\"col\">\n            <code class=\"language-html h2\">document<a href='https://www.w3schools.com'>.ready</a><a href='https://www.w3schools.com'>()</a> {</a>\n                <a href='https://www.w3schools.com'>if</a> <a href='https://www.w3schools.com'>(<a href='https://www.w3schools.com'>$</a>el)</a> <a href='https://www.w3schools.com'>{</a>\n                    <a href='https://www.w3schools.com'>display</a><a href='https://www.w3schools.com'>Modal</a><a href='https://www.w3schools.com'>(</a><a href='https://www.w3schools.com'>\"Modal title\"</a><a href='https://www.w3schools.com'>,</a><a href='https://www.w3schools.com'>\"Modal content\"</a><a href='https://www.w3schools.com'>}</a>){</a>\n                    \n                    <a href='https://www.w3schools.com'>$</a>el</code>\n        </div>\n    </div>\n  </div>\n</div>\n\n\nA: `alert(\"Not Re",
        "label": 1
    },
    "147": {
        "output": "##[[INST]] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level assessment of eligibility:\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)\nTrial-level eligibility: 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial:\nTitle: Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer\n\n\nsummary:\nRATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lower",
        "label": 2
    },
    "148": {
        "output": "For more information about this dataset, please visit the [/TUT](http://www.kaggle.com/c/medicine-for-dummies/info?vogue=0) page.\n\n\n# Discussion:\n\nThe first thing to notice about the dataset is the fact that the data is a collection of patient notes.  Each patient note has 13 fields. \nThe number_of_lymph_nodes field tells us that the patient has 5 positive lymph nodes in the axillary sampling in addition to other metastatic lesions. \nThe chemotherapy_schedule and the radiotherapy_schedule fields tell us what the course of chemotherapy and radiotherapy should be. \nIn [/PDF](http://www.kaggle.com/c/medicine-for-dummies/data), you can find additional notes about data interpretation for this prediction problem.\n\n\n# Results:\n\nHere are two patients:  Patient 1\n     - Patient-22 \n    \n     - Patient-40 \n\n```\n---\nauthor: <NAME>\nurl: http://www.kaggle.com/c/medicine-for-dummies/data\ntitle: MedCare\n\ncategories: [\n    [\n        \"medical\",\n        \"nurse\",\n        \"records\",\n        \"patient\",\n        \"diagnosis\",\n        \"treatment\",\n        \"chart\"\n    ],\n    \"medical\",\n    \"healthcare\",\n    \"examination\",\n    \"prescription\",\n    \"visiting\",\n    \"history\",\n    \"medical notes\",\n    \"patients\",\n    \"examination\"\n]\ndate-end:  \n    \"2011-09-05\"\n    \"2014-01-31\"\n    \"2015-01-31\"\n    \"2016-05-03\"\n    \"2015-06-02\"\n    \"2014-09-01\"\n    \"2014-10-08\"\n    \"",
        "label": 1
    },
    "149": {
        "output": "## EXAMPLES\nLet's take a look at how to calculate trial-level eligibility. In the following text, **<--- >** is a comment to refer you to step 1 of [INST](INST.md) \n\n```python\nimport n2csv\nfrom n2csv.io.output_transformer import transformer\n\nn2csv.io.set(output_mode='csv', delimiter = '\\t', header = True)\n\nheader = {'Trial-level eligibility': '`Trial-level eligibility: 2) Eligible.'',\n          'Group': '`Group: MIBC.`,\n          'Age': '`Age: 78.`,\n          'Type': '`Type: 1.`,\n          'Sex': '`Sex: F.`,\n          'Disease': '`Disease: BCC.`,\n          'Water level': '`Water level: D.`,\n          'Group.1': '`Group.1: BLCA.`,\n          'Group.2': '`Group.2: CIS.`,\n          'Treatment_name': 'Treatment_name: `Cisplatin`',\n          'Treatment_dose': '`Treatment_dose: 50.`,\n          'Radiation_name': 'Radiation_name: `CRT`',\n          'Radiation_dose': 'Radiation_dose: 2123.5531.'}\n\ndef calc_eligibility(study_note, clinical_trial_note):\n    trial_level_eligible = {\n        \"Trial-level eligibility\": len(study_note.iloc[0]) - len(study_note.iloc[0].loc[study_note.iloc[0].ix[0] == '1')]\n    }\n    group = clinical_trial_note['Group']\n    sex = study_note.iloc[group == 'MIBC.']['Sex']\n    water_height = study_note.iloc[group == 'MIBC.']['Water level']\n    disease = study",
        "label": 0
    },
    "150": {
        "output": "##[EXPLAIN:Trial-level eligibility]\nExcluded You should input zero after `Trial-level eligibility: `, e.g., `Trial-level eligibility: 0) Excluded`.\nNot relevant After inputting `Trial-level eligibility: 0) Excluded` for the first patient, it shows that `Trial-level eligibility: 3) Not relevant` is incorrect. Input 1 after `Trial-level eligibility: 0) Excluded`, e.g., `Trial-level eligibility: 1) Not relevant`.\n\n\nEligible You should input 1 after `Trial-level eligibility: 1) Not relevant`, e.g., `Trial-level eligibility: 1) Not relevant`.\nIt is recommended that you practice more exercises on the same patients that you have already practiced.\nIf you practice other exercises on the same patients and obtain similar results, you need to check the validity of your output. If you make a mistake, check the exercise instruction.\n\n### EQ-5D\nEQ-5D is a test that assesses patients' health-related quality of life. It consists of a number of sub-questions. [/EXPLAIN:EQ-5D]\n\n### PTEN mutation\nIt is a genetic change found only in cancer. It provides information about the cancer type and stage. It is commonly found in breast, colorectal, and endometrial cancers. [/EXPLAIN:PTEN mutation]\n\n### BMI\nWeight in kg/(height in m)^2\n\n### MRI\nA test that provides images of the inside of the body. It can detect changes in the shape of body tissues and organs caused by a disease such as cancer. It can also help the doctor and surgeon plan treatment. [/EXPLAIN:MRI]\n\n##[EXPLAIN:BMI]\nYou should take the weight in kg/(height in m)^2 and change it to a decimal in the third part, e.g., `150.1`.\n\n##[EXPLAIN:PTEN mutation]\nYou should input the letter `M` to express",
        "label": 0
    },
    "151": {
        "output": "Awesome!\nCheck out [tutorials/gettingstarted](https://learnpyodonr.readthedocs.io/gettingstarted), [https://docs.kaggle.com/wangyuxi/kat.py](https://docs.kaggle.com/wangyuxi/kat.py), and [https://tutorials.scipy.org/notebooks/NumPy](https://tutorials.scipy.org/notebooks/NumPy) to enhance your DONR and python skills!\n[START](/talk.md)\n[HOME](../index.md)\n[NEWS](../news.md)\n<EOD> 3.0 Tesla cardiovascular magnetic resonance and coronary artery disease\nAtherosclerosis is common and an important cause of morbidity and mortality in cardiovascular disease worldwide. It is thought to be the consequence of pathological changes in the vascular endothelium, inflammatory cell recruitment, foam cell formation, abnormalities in matrix accumulation, and deposition of thrombotic material in the vessel wall . Imaging is needed for accurate diagnosis and management of cardiovascular disease. Traditional imaging techniques, such as radiography, magnetic resonance imaging (MRI), cardiac computed tomography, and conventional echocardiography rely on indirect measures of disease severity, such as calcium content or aortic wall thickening in the case of coronary calcium and plaque detection on multislice computed tomography, and functional changes in stroke volume detection . All of these technologies have important use in various cardiovascular diseases, and are discussed in other articles in this issue  and elsewhere . The limitations of these imaging techniques are primarily related to the fact that they simply show the anatomical consequences of atherosclerotic cardiovascular disease. In some cases, traditional imaging techniques can provide information that provides insight into the physiological changes that occur during disease progression and prognosis, such as left ventricular (LV) strain and strain rate in echocardiography . As in echocardiography and cardiac computed tomography, coronary magnetic resonance angiography (",
        "label": 2
    },
    "152": {
        "output": "# Evaluation criteria\nThe evaluation criteria and its output are shown in[B].\n\n## Pt-level eligibility\nThe evaluation criteria is shown in`pt-level eligibility: 3) Ineligible.`.\n\n## #2)\nTrial-level eligibility\nThe evaluation criteria is shown in`Trial-level eligibility:\nExcluded\n[formula]  2) Eligible (1) Excluded (0) Eligible (0) Excluded (1) Eligible (1) Excluded (1) Eligible``. [#2] #1) Pt-level eligibility `Pt-level eligibility `: 2) Excluded (0) Excluded (0) Excluded (1) Eligible (0) Excluded (1) Eligible (1) Eligible (0) Excluded (1) Eligible `Trial-level eligibility: 2) Eligible (0) Excluded (0) Excluded (1) Eligible (1) Excluded (1) Eligible (0) Excluded (1) Eligible`. [#3] #3) CBALR TM Substudy\nThe evaluation criteria is shown in`Pt-level eligibility `: 2) Excluded (0) Excluded (0) Excluded (1) Eligible (0) Excluded (1) Eligible (1) Eligible (0) Excluded (1) Eligible . [#5]\n\n## Summary\nYour goal is to evaluate whether a patient is clinically relevant to this clinical trial or not.\n\n## Experiment\n\n## Pt-level eligibility\nThe evaluation criteria is shown in`pt-level eligibility: 2) Eligible (1) Excluded (0) Eligible (0) Excluded (1) Eligible (1) Excluded (1) Eligible (0) Excluded (1) Eligible `Trial-level eligibility: 2) Eligible (0) Excluded (0) Excluded (1) Eligible (1) Excluded (1) Eligible (0) Excluded (1) Eligible`. [#4]\n\n## #",
        "label": 0
    },
    "153": {
        "output": "# Disease Diagnosis Information\n\n## Disease\nPATIENTS WITH INVASIVE BREAST CANCER.\n\n## Version Date: 18Mar2021\nThis is the most recent version of the protocol (document).\n\n## Title:\nChemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer\n\n## Type:\nClinical trial (phases 2 and 3)\n\n## Trial ID:\nC91\n\n## Sponsor:\nNCI\n\n## First submitted at:\n2005\n\n## Site:\nNot yet opened\n\n## Source:\nThe source of the study is: NCI.\n\n## Sponsor address:\n\n## Primary site:\nNational Cancer Institute NIH,\n\n## Bldg 37, rrm 7118,\n\n## Bethesda, md 20892\n\n## Contact phone:\n(800) 424-8586\n\n## Primary phone:\n(301) 402-3150\n\n## Primary email:\nClinicalProtocol_Inquiry@mail.nih.gov\n\n## Secondary email:\nClinicalProtocol_Inquiry@mail.nih.gov\n\n## Title:\nChemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer\n\n## Type:\nClinical trial (phases 2 and 3)\n\n## Trial ID:\nC91 NCT00313925\n\n## Sponsor:\nNCI\n\n## First submitted at:\n2005\n\n## Site:\nNot yet opened\n\n## Source:\nThe source of the study is: NCI.\n\n## Sponsor address:\n\n## Primary site:\nNational Cancer Institute NIH,\n\n## Bldg 37, rrm 7118,\nPurpose: Determine the therapeutic impact of HER2 in breast cancer (BC) with low HER2 levels by the FDA -defined",
        "label": 1
    },
    "154": {
        "output": "**Case 2**: The patient is a 63-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast cancer in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 4 positive lymph nodes. CXR was remakable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial:\nTitle: Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer\n\n\nSummary: The purpose of this study is to see if a combination of drugs can help to treat this type of cancer. One drug is a chemotherapy agent called paclitaxel (Taxol\u00ae). Paclitaxel will be given every week through the vein. Although the weekly schedule of paclitaxel is not included in the label, the schedule and dose of weekly paclitaxel have been studied and have been proven to be more effective than an old standard schedule. The other two work against HER2. One is called trastuzumab (Herceptin\u00ae) and it is commonly given to women with early HER2 positive breast cancer or with advanced HER2 positive breast cancer that has spread to other parts of the body. The third drug, pertuzumab, is an investigational drug. It has not been approved by the Food and Drug Administration. It has been given in studies to over 800 people. It has been effective in treating HER2 positive breast cancer. Pertuzumab will be given every 3 weeks through the vein. This study is looking at the effectiveness of these three drugs together.\nInclusion criteria:\n- Age \u226518\n- Stage IV HER2 (+) breast cancer.\n- Histologically documented HER2 (+) breast cancer as defined as IHC 3+ or FISH amplification of \u2265",
        "label": 2
    },
    "155": {
        "output": "### Conventions and Filters\n\nConventions (see [this lesson](./data_manip/data_manip_lessons.md)) are used to convert the output of the filters (see [filters](./filters.md)) to the specific output of the clinical trial.\n\n\n\n## 48.1) Not Relevant\n\n\nThis is probably the most useful convention. It can be re-used across multiple lessons and can provide us with a filter for any given clinical trial (just by matching the patient with the inclusion criteria).\n\t\nAs you'll see, it can be used together with a condition that will limit the patients that will enter in the filter. This is called a `NOT EXISTS`-type condition (see [conditions](./conditions.md)).\n\t\n\t# [inst] \n\t## 48.1) Not Relevant\n\t\n\t# [INST]\n\t\n\tfilter {\n\t\tconventions {\n\t\t\tNot_relevant -> {\n\t\t\t\t-\n\t\t\t\t\t{\n\t\t\t\t\t\t-\t\tIncome.B1200 -> {\n\t\t\t\t\t\t\t\t\t# This will be a bit different depending on what the clinical trial is looking for. I'll show you with a bit of code the way I will do it in this lesson.  It might not be correct for your lesson, so try and re-implement the function.\n\t\t\t\t\t\t\t\t\t\t\t# This part of the match will be repeated again and again for other clinical trials, so lets define a variable. \n\t\t\t\t\t\t\t\t\t\t\t\t# That's it for the match condition. We will add some text after each match to give us the number of patients not relevant to each trial.\t\n\t\t\t\t\t\t\t\t\t\t\t}\n\t\t\t\t\t\t\t\t\t\t}\n\t\t\t\t\t\t\t\t\t\t# I won't show you everything. You'll see what this function will do with the convention below. It's a great way to work with filters.\n\t\t\t\t\t\t\t\t\t\t\t# The function will return the number of patient filtered.",
        "label": 0
    },
    "156": {
        "output": "In conclusion, you can find a step-by-step example on your problem. This solution has been created for beginners. If you have any question about this course, please contact us.[/END] \n\n## Answer:\nB. In this patient note, a core biopsy showed that there was an invasive ductal cancer in the left breast. This cancer was positive for ER and HER2. Lymph nodes are positive. There is no evidence of metastatic disease in the chest X-ray or whole-body imaging. She was taking iron and multivitamins. She did not have any history of tobacco use ever. Her husband is a good health and they have no children. She had taken a tumor resection. She is ready to do chemotherapy (fulvestrant).\n\n## [answer: c]\nIn this clinical trial, the aim is to check the side effects of BKM120 which is an inhibitor of PI3K. BKM120 combined with fulvestrant is a promising treatment. The goal of this study is to find the optimal MTD of BKM120 and fulvestrant to provide a novel therapeutic strategy for patients with hormone receptor positive cancer. This trial was a dose escalation trial. The trial was the first phase I trial which demonstrated that BKM120 and fulvestrant is a tolerable regimen.\n\n## Q3:\nWhat Is Your Assessment of Eligibility for the Trial? Note the patient meets all inclusion criteria and there is no evidence of the exclusion criteria. This patient was eligible in this trial.\n\n## Q4:\nWhat Is Your Assessment of Eligibility for a Trial with the Same Population, Treatments, and Study Goals?\n\n## [solution: e]\nThe trial was the first phase I trial which demonstrated that BKM120 and fulvestrant is a tolerable regimen. In conclusion, we can say that this trial with this population should not be conducted. Because this trial was successful, the study will be conducted in another phase I trial with another population and population can be any sex. Patient with invasive ductal cancer in breast and in some of lymph node could be enrolled but it",
        "label": 0
    },
    "157": {
        "output": "Good job! [INST]\n---\n\n![INST] Q0900_Final.pdf\n[Tip] For help on using the menu bar,\n```\npz_211215_Han_003_5\n```\n---\n### 4.2.6 \uc0ac\ub840 \ubd84\uc11d \uc5f0\uc2b5\uff1a \ub370\ubaa8\n\n# \uce90\uc2dc\uac00 \uc5c6\ub294 \uc0ac\ub840 \ubd84\uc11d\n\n#### Task 1\n\n##### \uac80\uc0c9 \uacb0\uacfc \n\n\uc54c\ubc95\ud55c \uc0ac\ub840\ub97c \uac80\uc0c9\ud55c\ub2e4\uace0 \uac00\uc815\ud588\uc744 \ub54c \uac80\uc0c9\ube48\ub3c4\uac00 10\uc774 \uc544\ub2c8\uace0 \uac80\uc0c9\ube48\ub3c4\uac00 24\uc73c\ub85c \ub9ce\uc740 \uac80\uc0c9\uacb0\uacfc\uac00 \ub3cc\uc7b0\uc774\ub2e4. \uac80\uc0c9\uc758 \uc9c8\uc744 \ud30c\uc545\ud558\uae30 \uc704\ud55c \ub370\ubaa8\uc774\uae30\ub77c\ub370.  10\uc5d0\uc11c 24\uc704\ub85c \uc62c\ub3cc\uc544\uac04 \uc774\uc720\uac00 \ubb50\ub0d0\uba74 \ubb50\ub2e4? \uc54c\uae34 \ud55c \uc0ac\ub840\uc758 \ub0b4\uc6a9\uc744 \ud655\uc778\ud574\ubcf4\uace0 \ubcf4\uc790. \n\n#### Task 2\n\n[ \uc2a4\ud06c\ub864 \uc774\ub3d9 ]\n> \uc77c\ubd80 \uc77c\ubcf8 \ub0a8\ubd80 \uc9c0\uc5ed\uc5d0\uc11c DTC \ud76c\uc11d \uc774 \uc9c4\ud1b5\uc81c \ud22c\uc5ec \uae30\uac04\uc774 \uc5f0\uc7a5\ub418\uc5b4 \uc77c\ubcf8 \ubc16\uc5d0\uc11c, \uadf8 \uc9c0\uc5ed\uc5d0\uc11c\ub294 \uc9c4\ud1b5\uc81c \ud22c\uc5ec\uac00 \ubbf8\ud761\ud55c\uc9c0 \uac10\uc2dc\ubaa9\uc5c5\uc774 \uc2dc\uc791\ub418\uc9c0 \uc54a\uc744\uae4c? \uc5fc\ub8cc\uac00 \ubb3c\ub97c \ufffd\ufffd\ufffd\ufffd",
        "label": 0
    },
    "158": {
        "output": "> ## Example\n\n``` r\nexample <- dat3 %>%\n  left_join(\n    trial3_matching, # joins the current row with each of the matching rows\n    by = \"patient_id\" # use 'patient_id' as the common matching columns between the source and target dataset\n  ) %>% \n  select_if(Trial-level eligibility == 3) %>%\n  group_by(trial1_eligible, trial2_eligible, trial3_eligible) %>% \n  filter(trial1_eligible == 2) %>%\n  group_by(trial1_eligible) %>%\n  summarise_all(function(x) x[1]) %>% \n\n  left_join(\n    trial3, # joins the current row with each of the matching rows\n    by = \"patient_id\" # use 'patient_id' as the common matching columns between the source and target dataset\n  ) %>%\n  select (\n    left_join(\n      trial3, # joins the current row with each of the matching rows\n      trial3_matching, # matches with the dataset that contain a patient's trial eligiblity for the current row\n      by = \"trial_id\" # use 'Patient's Trial Eligibility' as the common matching columns between the source and target dataset\n    ) %>% \n      select( patient_id = \"patient_id\", trial_id = \"trial_id\", trial_eligibility = \"trial_eligibility\",\n      trial_year = \"trial_year\", trial_phase = \"trial_phase\") %>% \n      # add all the patient's trial eligibility \n      # (1) excluded, (2) not relevant, (3) eligible) as columns\n      group_by( patient_id = \"patient_id\") %>% \n        summarise_if(funtion(x) x[x$trial_eligibility == 2] %in% c(\"included\",\"not relevant\", \"not considered\"), tidyzer::arrange_cols(x)) %>% \n        select(patient_id, trial_eligibility),\n    right_",
        "label": 0
    },
    "159": {
        "output": "<EOD> Mitochondrial Complex III Is a Source of UCP2-inhibiting Reactive Oxygen Species*\n\nMitochondrial complex III produces reactive oxygen species (ROS), but it is unclear whether it remains a prominent source during activation of uncoupling protein-2 (UCP2), which increases respiration and therefore oxygen consumption and ROS production. This study explored the role of complex III in ROS production under resting conditions and upon pharmacological activation of UCP2 with the uncoupler DPI \u060a (10 M) in \u232c\u233f m -clamped skeletal muscle (SKM) mitochondria. The complex III inhibitor antimycin A (AA) shifted the \u232c\u233f m -response curve to the left without significant changes in oxygen consumption. In this range of \u232c\u233f m , DPI \u060a significantly reduced state 4 UCP2 -dependent and state 3 oligomycin-independent respiration (p \u03fd 0.05) and caused ROS production to parallel state 3 oligomycin-independent respiration of each \u232c\u233f m value (p \u03ed 0.034). The complex III substrates ubiquinol and complex IV substrate succinate did not significantly alter ROS production or \u232c\u233f m . AA shifted the \u232c\u233f m -response curve to the left. DPI \u060a decreased state 4 and increased state 3 respiration, demonstrating that the increase in electron flow between complex III and IV in SKM mitochondria was accompanied by reduced uncoupled respiration. The ROS produced by AA at lower levels of \u232c\u233f m was inhibited by DPI \u060a (p \u03ed 0.010) confirming that complex III is a source of ROS under resting conditions. The ROS produced in SKM by DPI \u060a at higher levels of \u232c\u233f m , after the decrease in uncoupled respiration, was not inhibited by AA. These data suggest that complex III is a prominent source of ROS under resting conditions but not in the state of",
        "label": 0
    },
    "160": {
        "output": "## [CLOSE]\nBefore you continue with other clinical trials, let's take a look at your work so far. [TASK] Did you make a clinical note of all the patient information? [TASK] Did you complete the patient's trial eligibility assessment? [TASK] Did you repeat trial-level eligibility for the patient in the last line? [TASK] That's good. Now let's go back to the next example without patient information. [TASK] After this, we will try a patient with breast cancer. Does this trial seem eligible to the patient? [TASK] And trial-level evaluation? [TASK] Let's make a trial-level eligibility of this trial of breast cancer. [TASK] The eligibility scale of this trial is 1 2 1. [CLOSE]<EOD> The Use of Nano-Alumina in the Design of Sustainable Water Treatment Membranes for the Removal of Toxic Microplastics\nMicroplastics are present in all water ecosystems including the marine environment, food, and drinking water. Microplastics are known to have a range of negative biological and physiological effects on aquatic ecosystems. They have been detected in groundwaters, drinking water, and other potable supplies. Consequently, there is a need for appropriate treatments that can efficiently remove micropollutants (MPs) and micron-sized materials from the water before the potential health risks are associated with their use are identified. In this study, three types of membranes were fabricated using nano-alumina (Al2O3) as a porogen. This was done by using various conditions to synthesize polyvinylidene fluoride-co-hexafluorpropene (PVDF-HFP) membranes of varying pore sizes and, hence, different water-fluxes to determine the best filtration membrane. Furthermore, two model MPs were chosen which are commonly found in the drinking water supply, polystyrene (PS) microspheres (diameter, 340 \u00b1 23 \u03bcm) and polyethylene terephth",
        "label": 0
    },
    "161": {
        "output": "__BONUS__\nIf, in the above problems, you think your results for the [2] problem, i.e., 1 or 2, are still not good. You are welcome to increase the size of the data set, so that it is an example data set that meets the normal distribution. For example, the data set size is increased to 20000 patient records. Include the increase files as <data>/data/20000_patients.csv>, <data>/data/20000_patients.txt>, and <data>/data/20000_patients.RData>, respectively.\n\n### Q1. What is the role of the MDR package in data analysis?\nThere are several functions from the package `multivariate_data` to analyze data that meet the multinomial distribution. However, these functions cannot be directly applied to analyze data whose class distribution is multinomial. Instead, an MDR-based analysis may be required. Therefore, there are several functions provided in the package `multivariate_data` to analyze data that meet a multinomial distribution, including MDR_train, MDR_tree, and MDR_predict. The main purpose of this section is to give an overview of these functions and the analysis results for the test data set. This section is optional, and you may choose to skip it if you prefer.\n\nThe package, `mtm`, uses the MDR (multi-layer perceptron decision tree) analysis algorithm to analyze the data distribution, which enables modeling relationships within the multinomial multivariate distribution. According to the algorithm, it is assumed that three layers of nodes are used. Each node of the first layer contains attributes while each node of the second layer contains each of the attributes from the first layer. Therefore, the second-layer nodes can be divided into two, creating a third layer of nodes.\n\nThe input data of the MDR analysis are presented in an [mtm] object. The MDR analysis creates an attribute called `prediction` based on the selected value of that node. It classifies a new patient based on the value of each attribute that is used in MDR analysis. The main function used in the MDR analysis is MDR_train().\n\n\n*If this is the first time you have called the MDR_train(), then it",
        "label": 2
    },
    "162": {
        "output": "There is a lot of discussion around it on this topic. And that discussion is worth a separate post in my opinion. But in short and for those who are curious about how the score can be increased:\n\n*\n\n*Patients: If you don't have to check every individual factor, you don't need any check. But if you have to check whether there is age or gender or some other factor between `age >= 18` or not, you should check it. But do not bother to check the individual criteria such as `cT1a` with a very low frequency.\n\n*Clinical_trial: Here, you should pay more attention to the number of criteria in the clinical_trial rather than the individual criteria it contains, i.e., it is less important to check one by one whether `diagnosis_confirmed` applies or not than to know how many other criteria may match.\n\n*Trial_level_eligibility: As mentioned early, you can check the frequency of trials which have only one condition, `Factor:\n\n  Factor: 1\n\n    Eligibility: 1\n  \n  Factor: 2\n\n    Eligibility: 1\n\n  .........\n\n  Factor: 7\n\n    Eligibility: 0` (You might notice this is the same problem as the one above with patient and clinical_trial, and I believe this should be the main strategy to boost score. I recommend you to study this one more carefully carefully and try to come with an explanation to boost your score a little bit.)\n\n[INST]\n\nA note: To pass the solution test of this problem, sometimes you can increase score just by one point - the solution for one problem can cover another problem. It is probably not always applicable to all problems, but still, do keep this strategy in mind. \n\n---\n\n___\n\n[Back to index](../index.md)\n\n___\n\n<p align=\"center\"><img src=\"https://cdn.statically.io/3230217/6e7b14ef8e2645729254b567f4144291\"><p>(C) By <a href=\"https://unsplash.com/@mari",
        "label": 2
    },
    "163": {
        "output": "## Exercise 2\nHere is another patient note. The patient is an 85-year-old female with newly diagnosed advanced urothelial carcinoma who has been receiving treatment for diabetes, hypertension, and hypercholesterolemia. A biopsy and cystoscopy are planned. A CT scan shows metastatic disease limited to lymph nodes and a normal-sized left kidney.\n\n## Which factors should be considered in assessing the trial-level eligibility to clinical trial inclusion?\n\n## [INST] In this case, the eligibility for inclusion into the clinical trial is based on this patient note, and the clinical trial of interest for the patient.\n[SOLV] You should always consider the following factors - age; gender; cancer type and stage; a history of comorbidities or prior treatments; the results of a physical examination; and the results of diagnostic assessment (PET scans; CT scans; MRI; chest X-rays).\n\n## What treatment options are available for the patient?\n\n## [inst] You should assess the patient's treatment options - none; chemotherapy; radiation; surgery; targeted therapy; immunotherapy; palliative care.\n[SOLV] You should always perform a diagnostic assessment (PET scans; CT scans; MRI; chest X-rays), and find appropriate treatment options.\n\n## [suggest] there are multiple treatment options available depending on the type of cancer and its stage. [guess]\n[SOLV] For this patient, surgery is contraindicated based on her age. She has no clinical trials in hand, so she will choose either palliative care or cisplatin-based chemotherapy. (This is a scenario for learning.) \n\n## Include the assessments of trial-level eligibility for each type of cancer.\n\n## [inst]\nTrial-level eligibility for each type of cancer.\n[SOLV] Use a clinical trial note and find the inclusion criteria for each type of cancer.\n\n## Repeat the above steps for each clinical trial that needs eligibility assessment. \u26a0\u26a0\u26a0",
        "label": 0
    },
    "164": {
        "output": "There are more features of the SDFs syntax you need to know in order to complete our second programming task:<EOD> Identification of new putative virulence genes in Helicobacter pylori\nA large number of experiments with mutants in defined H. pylori genes suggest that some of these genes are associated with the virulence and the pathogenesis of this disease. To identify genes that may play an important role in H. pylori gastric colonization and disease development, we have developed a new approach based on the comparison of strains that differ in their degree of virulence. This approach makes it possible to detect genes that are either in a low virulent strain versus a high virulent strain or in a low virulent strain versus a low virulent clinical isolate. This in silico procedure resulted in the identification of two open reading frames, which were highly conserved in the high virulent strains. The functions of these open reading frames were tested in the virulent strain 26695 and the nonvirulent strain HPAG1 using allelic replacement mutants. One of the identified genes was named hp0369 and encodes a cytoplasmic protein of 741 amino acids and a protein of a putative membrane anchor of unknown function. The second identified gene was named hp0434 and encodes a protein of 1,943 amino acids localized to the cytoplasm. The functions of these genes were analyzed by complementation in the respective mutant and also in vitro in the 26695 wild-type strain. The results suggested that the product of the open reading frame Hp0369 may be involved in the transport of glutamine, glycine, and/or histidine. The Hp0434 gene seems to be involved in the maintenance of the cell shape and the formation of fimbriae-like appendages in H. pylori.<EOD> Antimicrobial activity of some natural products against methicillin resistant Staphylococcus aureus isolated from goat\u2019s milk cheese\n\nMilk products containing Staphylococcus aureus (S. aureus) pose potential problems",
        "label": 0
    },
    "165": {
        "output": "# Exercise 2\n[INST] This is the first module of the second part. Your task is to determine the eligibility of patients with the above patient note by comparing it to clinical trial information and output the trial-level eligibility of each patient.\nIn this module, you will learn to apply the concept of `Trial-level eligibility`. In the next module, you will learn to solve eligibility assessment problems step by step with an example using `Assessment of eligibility`.\n\nHere is your patient note:  \nA 37-year-old postmenopausal woman with anemia, who used to smoke, consults to get her physical condition checked up. The tests did not show any cancer-specific markers, but the results showed increased levels of CA 19-9, CA 24-2, and CEA. A CXR showed multiple metastatic tumors in both lungs, and abdominal CT showed multiple liver metastases. She does not have children. \n\nLet us continue to solve this problem. The main concept is `Trial-level eligibility`. The eligibility rule in the trial is as follows: `Patients with locally advanced or metastatic MET-high NSCLC (as defined by MET immunohistochemistry  scores of 2+ or 3+).`. MET, one of the type 1 receptor tyrosine kinases, is a transmembrane receptor involved in cancer growth and metastasis and has been suggested to be a potential candidate for targeted therapy. `Malignancies that are not primary lung cancer (adrenal carcinoma, thyroid carcinoma, metastatic esophageal carcinoma, and other NSCLC) are allowed. If the patient is newly diagnosed with NSCLC and does not have previous therapy, MET status should be assessed by immunohistochemistry (IHC) using the 21-point scoring system defined by Hofmann et al [1]. If the study treatment is started after radiotherapy, chemotherapy or immunotherapy, the patient's MET status should be reassessed. Patients must be available and accessible for biopsy. It is required to confirm the MET expression and status by immunohistoch",
        "label": 0
    },
    "166": {
        "output": "### Partial Solution\n\n\n{% raw %}\n{% codeblock id=\"raw-example-531\" %}\n#+ #\n#+ %hdr -----------------------------------------------------------------------------\n#+ %fhd -This document was produced on 03-Jun-2014 at 10:11:02 AM\\#% -----------------------------------------------------------------------------\n#+ %title -INST 1st attempt (Partial Solution) at Eligibility Assessment\n#+ %synopsis -This is first partial solution for INST 1st attempt at eligibility assessment in a clinical trial\\#\\#\\#\\#\\#\\#\\#-%-END %fhd -----------------------------------------------------------------------------\n#+ %stp -* Instructions: Copy + Paste this file to a README.md file in a given folder\\#% -----------------------------------------------------------------------------\n\n#+ %subs -Use README.md to document README file content\\#% -----------------------------------------------------------------------------\n\n#+ %src -This is source code with comments only\\#% -----------------------------------------------------------------------------\n{% endraw %}\n\n\n### 2nd solution\n\n\n{% raw %}\n{% codeblock id=\"raw-example-532\" %}\nimport nltk\nimport sys\nsys.path.append(\"..\")\nfrom trial_instances import Trial, Patient\n\n\ndef eligible(patient_patient_note, trial):\n    triallevels = 2\n    inclusion_criteria = {'age_inclusions':triallevels,\n                           'tumor_histology':triallevels,\n                           'stage': triallevels,\n                           'hormone_receptor':triallevels,\n                           'lymph_nodes':trialevels,\n                           'metastasis':triallevels,\n                           'chemo_elix':triallevels,\n                           'chemotherapy_regimen':triallevels}\n    patient_age = patient_patient_note.text.split('born: ')[0].strip()\n    patient_age = float(patient_age.split('.",
        "label": 0
    },
    "167": {
        "output": "## Trial-level eligibility: Eligible\n\nThe assessment of eligibility has a three-point scale:\n\n1. Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria)\n\n1. Not relevant (patient does not have sufficient information to assess their eligibility)\n\n1. Eligible (patient meets inclusion criteria, and exclusion criteria do not apply)\n\n# Detection of the optimal protocol\n\nFirst let's create a Protocol variable.\nProtocols are listed in Protocols and then in the optimal protocol is returned by the function which_protocol. Let's define Protocols. It will be a named list. This list contains Protocols with parameters Patient and Treatment that are both lists of variables. Patient_name contains the patient note and Treatment contains the variables coming from the clinical trial.\nTo know which Protocol has to be used (i.e., the optimal protocol), we will use the trial-level eligibility of the patient and the information of the optimal protocol. In particular we will use the match function. The match function provides a boolean variable that is true whenever the arguments match.\nThe first column, Patient-Level, is extracted by `get(Patient_level_eligibility,\"trial-level eligibility\")`, i.e., `Patient-Level = get(Patient_level_eligibility(\"trial-level eligibility\"), \"0\")`. This gives the score related to the comparison of the trial's inclusion criteria and the patient's information. Note that the score is the same for several parameters, including the one with the longest string. To get a score for comparison of clinical trial exclusion criteria and patient information, we need to choose the long Patient_level_eligibility variable (see the first row of Protocols). Finally, you should always repeat trial-level eligibility in the list of [Patient-Level, Match] using `if (Patient-Level == get(Patient_level, \"0\") & ..., [Patient_Level, \"YES\"])...` \nFinally, to find the optimal score with the optimal treatment (i.e., with the maximal score), we need to use a double match, i.",
        "label": 0
    },
    "168": {
        "output": "### Eligibility criteria\n\n1. Breast cancer.\n\n2. ER/PR status (either ER positive or ER negative).\n\n3. HER2/neu amplification, defined as an average of three HER2 signals greater than normal and a HER2/CEP-17 ratio of > 2.0.\n\n### Inclusion criteria\n\nInclusion Criteria:\npatients undergoing elective bilateral staged total knee arthroplasty at a 1-week interval under spinal anesthesia,\nage <=85\nAmerican Society of Anesthesiologists physical status of I to II\nExclusion Criteria: any contraindication to spinal anesthesia or femoral nerve block such as coagulopathy; conversion to general anesthesia; preexisting pain syndrome; abnormal liver function or renal test results; severe heart, liver, or renal disease; history of stroke or neurologic deficits; psychiatric disorder; chronic opioid use; drug dependency; allergy to study medications; inflammatory joint disease; previous surgery on or trauma of the knee; difference in preoperative VAS score of \u2265 20 (at rest and at maximum knee flexion) between each side of the knee; body mass index of \u2265 40 kg/m2; and inability to comprehend the VAS or to use patient-controlled analgesia (PCA.\n\n## The Exclusion criteria for \"Excluded\" are 4. HER2 negative; 5.  ER positive; 7. and 8. <18 and >90; and 10. Female.\n[INST]\n\n### Patient Notation\nPatient-level eligibility has two parts:\n\n1. Patient ID.\n\n2. Trial ID. That is, `Patient = trial-level eligibility`. Note that this is the reverse order of the inclusion criteria data frame in R. The data frame is reordered using the `reorder` and `reorder.dif` functions.\nFor example:\nPatient ID Trial ID E = c(2,\"1\") # patient 2 is not elig",
        "label": 0
    },
    "169": {
        "output": "Example: `Trial-level eligibility: 0) Excluded; 1) Not relevant; 2) Eligible; patient_id = 'P15';`\n[F19] \n#26. Please predict the overall and progression-free survival probabilities for this patient using your model.\nPlease use the following format for your answer, if possible:\n\n[OPT] In line with your model predictions, what are the 5-year overall and progression-free survival probabilities for this group of patients after they are treated with radiochemotherapy?\n(1) In line with your [clinical study] model predictions, which patients are the most frequent?\n(2) In line with your [clinical study] model predictions, which patients are the least frequent?\n\n[/OPT]\n[INP] This section contains three subsections: prognosis prediction, prognosis explanation and patient identification. In the subsection Prognosis prediction, you are asked to predict overall and progression-free survival probabilities, i.e., survival probabilities conditional on no events (progression or death) before a given time, for each of the patients of the study. You should do that in the format \"5-year overall/progression-free survival probability for ___ % percentiles\" or \"3-year overall/progression-free survival probability for ___ percentiles\" for a time-to-event data set. You can do this task at the end of the section. In the subsection Prognosis explanations, you are asked to predict a patient's survival probability as well as a risk factor for the patient that can explain the patient's predicted outcome/survival time.\n\n[INCP] The following shows examples of survival plots, which is a type of survival probability prediction, for the time-to-event data set; the prognosis prediction data set and the patient-level prediction data set. Please use these plots to answer the questions in the following. In the subsection Prognosis explanations, instead of 'predicted', use 'predicted outcome' and instead of 'predicted explanatory variable', use 'predicted explanatory variable for outcome': \n\nFor a given patient, what is the 3-year overall/progression-free survival probability (or",
        "label": 0
    },
    "170": {
        "output": "### Input\n\nTo evaluate the factor of eligibility in the patient note, we first create a data structure as follows:\n\n      input:\n               patient: an Iris, # patient note\n                t: a Iris # trial\n                criteria : a tuple, # factor to meet\n                c1=2/20/20\n                c2 = 2/ 10#20\n                c3 = {\"yes\" :1,\"no\":0} , # variable used in the test\n                #c1=1;\n                # c2 = 1;\n                # c3 ={1:1};\n                c4 = \"criteria\", # variable used in the test\n                         #c4=1;\n                criteria = (t,0), # the factor of each case, # and we can write this tuple with two Irises, e.g., criteria = (patient, trial)\n                     #or criteria = (criteria1_factor, trial)\n                # or criteris = (criteria1_factor, criteria2_factor)\n                criterias = (t,criteria), # it is Iris and tuple together\n                # or we can write it by Irises and tuples, e.g., criteria = (patient, t),\n                # criteria = (t, criteria),\n                 criteria = (patient, t,criteria);\n              # if criteria = (patient, t, )\n              # criteria = (patient, t, criteria1_factor), criteria2_factor\n                # criteria = (t,patient, criteria1_factor), criteria2_factor\n\nTo create the variable of eligibility for the clinical trial from the data above, there are the next steps:\n\n1. Creating the criteria of eligibility\n2. Evaluating the factor of eligibility and assigning the level for the criteria, e.g., 0 for excluded; 1 for not relevant; and 2 for eligible\n3. Using the tuple `i` to print out the eligibility for the clinical trial, e.g., `#criteria2 = 1`. \n4. Evaluating the factor by making a vector of tuples by combining all cases of the trial and their level assigned, e.g., `",
        "label": 1
    },
    "171": {
        "output": "## Tests ## ClinicalTrials: Example of test\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. This script will generate a report for your trial, the results of which can be used to improve the quality of clinical trial recruitment.\n\nHere is the clinical trial: \n\n`Example of test:\n    Title: Clinical trial\n    Study start month and year: January 2000\n    Study end month and year: December 2099\n    Study site: [MSKCC]\n    Aim: [2) Excluded]\n    Population: 45-year-old postmenopausal women\n    Inclusion criteria: 2) Eligible}\n`[ELIGIBILITY] {2) Eligible}\nIf you want to run the example of test, run the following code.\n\n`R> my_trial <- clinicaltrials_data %>% filter(&_trial == 42) my_trial %>% \n  map(mutate(`Trial-level eligibility`, eligibility = 0, \n    map(as.list, .x, .y = 1:n()) %>% \n      map_chr(~c(0, 1, 2)),~paste(.y, \" of\", .y, \",\", .x))) %>% \n  mutate(`Trial-level eligibility`, eligibility = lapply(as_list(as_factor(eligibility)), as_chr)) %>% \n  select(trial = _trial, study_start_month = _study_start_month, study_end_month = _study_end_month, Study_site = _study_site, aim = _aim, Study_population = _study_population, Inclusion_criteria = _Inclusion_criteria) %>%\n  ungroup()) %>% \n  left_join(data.table::flip.data.frame(clinicaltrials_data$Clinical_trial_type, clinicaltrials_data$Inc_location), by = .) %>% \n  tidyr::unnest(col = c(\"Clinical_trial_type\"",
        "label": 0
    },
    "172": {
        "output": "[EXP] We now describe an example of a patient data table. \n\n|Patient| Trial-level Eligibility|\n\n|10001||2) Eligible|\n|10002||1) Not relevant|\n|10003||2) Eligible|\n|10004||1) Not relevant|\n|10005||1) Not relevant|\n\nAll five patients are eligible. The patient with the last name `Zoe` and the code `10005` does not suffer from a disease or cannot participate in a clinical study.\n\n[END]\n\n### Step 20\n\n[SCO] Let's summarize the main results of the workshop. Go from one column to another, and click 'Add'. If necessary, type in the results of the study, by clicking `Add` and filling out the form. \n\n|SCO| A patient with a cytologically confirmed breast cancer|\n|  |A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.|\n|  |The tumor is  HER2-positive and ER/PR negative.|\n|  |Axillary sampling revealed 5 positive lymph nodes.|\n|  |CXR was remarkable for metastatic lesions.|\n|  |The patient is using multivitamins and iron supplements.|\n|  |She does not smoke or consume alcohol.|\n|  |She is not sexually active and has no children.|\n|  |She is a candidate for tumor resection and agrees to do so prior to chemotherapy.|\n|  |Title: Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Marker in Breast Cancer Treated by Neo Adjuvant Chemotherapy|\n|  |Inclusion criteria: inclusion criteria|\n|  |Signed informed consent|\n|  |Social security coverage|\n|  |Age between 18 and 80 years|\n|  |Histologically proven breast cancer, regardless of",
        "label": 1
    },
    "173": {
        "output": "### 0: Excluded\n\nIt shows that the patient does not satisfy the inclusion criteria. The trial does not mention the treatment of cancer. She could not take drugs, not sexually active, and has no children. But, due to the presence of menopause, the disease has progressed.\n\n- age: [`1st: Less than 45 Years (Excluded)`] & [`.and. 45 Years or Greater (Not relevant)`]\n- gender: [`Female (Excluded)`] & [`Male or Gender not stated`]\n- tumor: [`Cancer (Excluded)`] & [`Cancer`]\n- HER2: [`Positive (Excluded)`] & [`Negative or Undetected`]\n- HR: [`Positive`] & [`Negative or Undetected`]\n- cancer stage: [`Advanced Cancer`] & [`Amenable to Radiotherapy or Curative Surgery`]\n- metastasis: [`No`] & [`Yes`]\n- location: [`Head and Neck Cancer`] & [`Non-Head and Neck Cancer`]\n- drug: [`None`] & [`Any drug`]\n- active smoker: [`Yes`] & [`No`]\n- alcohol drinker: [`Yes`] & [`No`]\n- sexually active: [`No`] & [`Yes`]\n- children: [`No`] & [`Yes`]\n- postmenopause: [`Yes`] & [`No`]\n- lymph nodes: [`0`] & [`Present or History of Metastasis`]\n- HER2-positive breast cancer: [`Yes`] & [`No`]\n- cytologically confirmed: [`Yes`] & [`No`]\n- invasive ductal: [`Yes`] & [`No`]\n- 3 cm: [`No`] & [`Yes`]\n- left upper outer quadrant: [`Yes`] & [`No`]\n- core biopsy: [`Yes`] & [`No`]\n- positive lymph nodes: [`Yes`] & [`No`]\n- CXR: [`Present or History of Metastasis`] &",
        "label": 0
    },
    "174": {
        "output": "Criteria that must be satisfied to pass the trial-level eligibility, e.g.,\n`Trial-level eligibility: 2) Eligible.`\n\n\n\nThe following diagram shows the overall flow of patient selection.\n![](/img/img_530.png)\n\n\nThe following diagram shows the overall flow of patient selection.\n![](/img/img_531.png)\n\n\nIn this section, we will show you how to print out the trial-level eligibility with `print_trial_level_eligibility`.\n\n\n### Print Trial-level Eligibility\n\n```\nprint_trial_level_eligibility -t patient_id -e Patient_Full_name Patient_Full_age -c trial_id\n```\n    -t: patient id of the current patient\n    -e: patient's e-mail address of the current patient\n    -c: clinical trial id of the current trial\nThe patient's name and age can be easily modified, however, there is no need to modify `patient_id` by yourself since it is automatically generated, and `trial_id` may be changed by the administrator. \nAfter the command is submitted, here is the output of the clinical trial-level eligibility.\n![](/img/img_532.png)\n\n\n\nAfter the 2 steps are finished, we can see the trial-level eligibility in the upper right corner of the screen.\n![](/img/img_533.png)\n\n\n### Print Trial-level Eligibility and Coding Time\n\n```\n\nprint_trial_level_eligibility -t patient_id -e Patient_Full_name Patient_Full_age -t trial_id -i start -i end -u user -g group\n```\n    -t: patient id of the current patient\n    -e: patient's e-mail address of the current patient\n    -t trial_id: clinical trial id of the current trial\n    -i: start time of coding\n    -i end: end time of coding\n    -u: researcher id of the researcher who performed the coding\n    -g: researcher group id",
        "label": 2
    },
    "175": {
        "output": "This is your completed checklist. (You could save this file under a unique name, e.g., solve_1.txt, instead of solve_1.RMD.)\nIn the next task, we will learn how to perform a simple sanity check of the input checklists we had so far. [INST]\n\n## [CHECK] sanity check\nBefore a new feature or system gets released, we need to check how the system will behave when the checklist input has any missing entries. Specifically, we would like to validate the following cases:\n\n### Case 1 -checklist with any missing data\n\n### Case 2 -checklist has data in wrong format\n\n### Case 3 -checklist inputs have unexpected types\nI want to know how the system behaves in the presence of these three situations.\nThere are three ways to perform a sanity check. You can choose one or more suitable ways for your use case. Note that these three use cases are not a must to pass the assignment.\n\n## Solution 1 -Validate on a real problem\n\nAssume we have a few clinical trial patients who will be enrolled into the trial, and we would like to check how the checklist system performs once their checklists are used.\nAs the first task of this solution, you are expected to develop an executable test program that generates the clinical trial checklist according to the rules. It will validate all the three sanity checkcases mentioned above.\nIn addition, you are also expected to submit an RMarkdown document that contains this executable test program as well as any comments that explains how to use\nLet's see two examples to show how to generate a realistic checklist data.\n#### Example 1 #### \nThis example first generates a clinical trial checklist data, which includes both a trial clinical trial checklist and a clinical trial checklist. Each clinical trial checklist has 11 questions, and a clinical trial checklist has 6 questions.\nWe will use `ct_data.R` to generate the example checklist data based on `ct_checklists` object. We can also generate 10,000 unique clinical trial checklist data using `ct_data.Rmd` RMarkdown document.\nWe can use `printDetailedChecklist` to print the detailed checklist data. It is a useful function",
        "label": 0
    },
    "176": {
        "output": "Data sets downloaded for the demo  and `trial_name_from_IDs` for the examples.\nNote that you can choose any set of characters to separate the trial names, e.g., comma and space (this is the one in trial_set.csv), but you must use only one character, e.g., a comma, to separate the lines in trial_name_from_ids.csv. In addition, be careful not to skip the trailing comma! \nFor instance, the trial set contains 19 entries, and the list of trial names looks something like that: \n`",
        "label": 0
    },
    "177": {
        "output": "Let's see some sample trial_level eligible reports. \n# <NAME>; eligible; 2; 3; 0\n# <NAME>; eligible; 2; 1; 0\n# <NAME>; eligible; 1; NA; 2\n# <NAME>; eligible; 2; 0; 1\nLet's check the correctness of the clinical trial recruitment report, and also get rid of the patients listed in 'Not relevant' or 'Excluded group' columns. It may happen that the subject in 'Not relevant' or 'Excluded group' is not an ineligible subject but the subject who does have insufficient information to perform the final eligibility determination. To address this, we can also add a note.\n# <NAME>; not relevant; 1; 1; 1 156\n# <NAME>; not relevant; 2; 1; 0 535\n\nThe following report shows all the patients who passed the clinical trial eligibility determination. \n# [FINAL_REPORT_DATA] Patient Eligibility Reports\n[Eligibility]\n\n# <NAME>; eligible (2); 2; 2; 2 574\n# <NAME>; eligible (2); 1; 1; 1 105\n```\n\n### `Eligible (2)`\nThe following sub-class eligibles of the eligible patient will be generated by eligibility determination report.\n\n- Patients with clinical trial eligibility code `NA (not applicable)` are eligible but do not have sufficient information to evaluate eligibility of this trial.\n- Patients with clinical trial eligibility code `NA` are not eligible for this trial.\n- Patients with clinical trial eligibility code `0` are eligible for this trial.\n- Patient with clinical trial eligibility code `0` are not eligible for this trial.\n\nLet's check the patients listed in each eligible group. Then, we will summarise all eligible patients in one report.\n\n```julia> p = patient(\"DONO-SHER2CT20",
        "label": 2
    },
    "178": {
        "output": "<EOD> An In Vivo Study on Effects of Electroacupuncture at Taichong Acupoint of the Feet on Serum GH and PRL Levels in Rats\n\nAim. e aim of the study was to determine changes in serum growth hormone (GH) and prolactin (PRL) levels in rats by electroacupuncture at Taichong (LR3) acupoint of the foot. Methods. 60 Wistar rats were randomly divided into the control group, single electroacupuncture group, and 1 h after electroacupuncture group. e electrical stimulation in the Taichong (LR3) acupoint of the feet was achieved by applying the frequency of 2 Hz, 2 mA/20 min per day for 12 days. Serum was collected after the last intervention. Serum GH and PRL levels were determined using enzyme-linked immunosorbent assay kits (ELISA kit). e results were statistically processed. Results. Compared with the control group, the serum GH, PRL, and PRL/GH levels in the single electroacupuncture group increased significantly, and the difference was statistically significant (P < 0.05). Compared with the single electroacupuncture group, serum GH and PRL levels of the rats decreased significantly. However, no significant changes in the PRL/GH ratio occurred after 1 h of electroacupuncture (P > 0.05). Conclusion. Electroacupuncture stimulation of the Taichong (LR3) acupoints significantly increased serum GH and PRL levels in the rats. erefore, the Taichong (LR3) acupoint can be used in the treatment of somatopropagation-related diseases.\n\n# Introduction\nAcupuncture and moxibustion are the major medical techniques in traditional Chinese medicine (TCM), which have been used to treat various diseases in China for nearly 3,000 years. Acupuncture originated during the Warring States Period (475-221 B.C.) (4), and moxibustion is believed to have originated in the Han D",
        "label": 0
    },
    "179": {
        "output": "Exercise 1: Practice the previous steps and try this time to evaluate your patient's eligibility for a trial in which a 12-week physical activity program is being offered in addition to standard clinical care for breast cancer survivors starting treatment for recurrent prostate cancer.\nThe physical activity (PEX) trial will include 150 patients. All the patients in the trial can continue prescribed androgen deprivation therapy (ADT) during the 12 months PEX program. Adverse events will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), 4.0. The patients will be asked to continue with their usual physical activity as much as possible. The intervention is based on the American College of Sports Medicine (ACSM) exercise guidelines for cancer survivors: a total of 10 000 kcal in 12 months (~37 kcal/kg per week), 150 minutes of aerobic exercise per week. Aerobic exercise will be performed by walking and other activities such as cycling, swimming, and jogging. There will be 26 weeks of supervised aerobic exercise. During the first 6 supervised weeks the patients will start 50 minutes sessions of light aerobic exercise 3 times per week. During weeks 7-20 the patients will be asked to continue with light aerobic exercise 3 times per week. During weeks 21-26 the patients will start vigorous aerobic exercise 3 times per week and will continue with it in weeks 27-52. During weeks 2-6 the patients  will visit the physical activity center 5 times (once per week). During weeks 7-20 the patients will visit the physical activity center 3 times (repeated twice per week) and during weeks 21-52 the patients will visit the physical activity center twice per week. Strength training will be performed 3 times per week. During weeks 7-12 the patients will train 1 set of muscle groups once per week. During weeks 14-27 the patients will train 2 muscle groups at once and during weeks the patients will train 3 muscle groups at once (total of 15 seconds in each muscle group). Res",
        "label": 0
    },
    "180": {
        "output": "Explanation: The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). The assessment of eligibility is the sum of Clinical-level eligibility and Trial-level eligibility. Here, Trial-level eligibility is 2, and Clinical-level eligibility is 0. The value of Trial-level eligibility is 0 if all conditions are met in the clinical trial. For example, if the patient does not meet all of the trial's inclusion criteria and the patient has a condition that falls under exclusion criteria then the patient cannot be enrolled into the trial; thus, the Trial-level eligibility is in 0. \nSo, you should check whether the patient is eligibile or not. If the patient is excluded, please set the value of Trial-level eligibility as 0. If the patient is eligible, please set the value of Trial-level eligibility as 1. Please refer to the [fig_ref]  Table below: Please refer to the table below [/fig_ref]  below for reference.\n[table]  Table below: Please refer to the table below.The values of Multi-level eligibility are saved to the Trial Eligibility record in the Eligibility table. [/table] \n<EOD> Enamel hypersensitivity management with an acid desensitizing agent containing a polyacrylic acid and sodium trimetaphosphate.\nThis study was carried out to compare the short-term efficacy of an acidophilus dentifrice containing calcium sodium phosphosilicate (CPP-ACP), an acid desensitizing agent (ADA) containing calcium phosphate and an acidophilus dentifrice containing calcium sodium phosphosilicate in the treatment of dentine hypersensitivity. Forty-eight intact third molars were selected, the crowns of which were prepared to create cervical dentine hypersensitivity (one enamel cavity and at least one dentine",
        "label": 2
    },
    "181": {
        "output": "<EOD> .\nThe paper presents the results of examinations of the activity of lysosomal hydrolases (beta-glucuronidase, N-acetyl-glucosaminidase) and gamma glutamyl transferase of human blood leukocytes in 88 patients with chronic renal failure (CRF) as well as in 9 volunteer blood donors. It was revealed that the blood leukocytes in renal failure patients showed significantly higher activity of all three enzymes under study (beta-glucuronidase, glucosaminidase and gamma-glutamyl transpeptidase) which indicates a significant dysfunction of the lysosomal apparatus.<EOD> Gender and Health Risk: Insights into Male Bodies and Health Losses Gender and Health Risk: Insights into Male Bodies and Health Losses Ann Berrill (ed.) Routledge London and New York 240 pp. \u00a318.99/\u20ac26.99 2750043102 .\nThis volume is the product of a 1996 workshop organised by Ann Berrill, with the intention of bringing together work on masculinity and men's social experience with theorisation and research on men's health and risk. In this volume are set out the findings and discussion from twenty-seven papers (seven of which are commentaries), which explore a range of issues related to the ways in which gender/gender roles and socially defined roles influence health and wellbeing.<EOD> Disease patterns in patients with neoplasia in Ibadan, Nigeria\n\nBackground: Cancer incidence in Nigeria is higher than that reported in developed countries. While data on various sites of neoplasia is available there is dearth of information regarding prevalence of co-morbidities in neoplastic patients in a tertiary hospital in Nigeria. Methods: A prospective, longitudinal study was conducted with 451 patients with neoplasia (284 men and 167 women) with an age range of 4 to 88 years, mean age 54.3 \u00b1 2.5 (mean \u00b1 SEM). The patients had their demographic data",
        "label": 2
    },
    "182": {
        "output": "*If you are still on this page, then you",
        "label": 2
    },
    "183": {
        "output": "[/CODE]\n\nPlease note that you should use an external package in R to process the data in the next subchapter.\n\nThe following code chunk shows how to get trial information from [inst] via the `data()` function call. We use the `tbind()` function to get the clinical results on the same level as the patients' patient note, i.e., the trial information is aggregated to each patient. The data frame is named `p` and is used as the dependent variable in the next steps.\n\n    t <- data.frame( Trial-level eligibility: `2` )\n    tbind( [data] = p, [variables] = Trial-level eligibility = \"t\") \n\nIn the next step, we use the function [summary] to get the number of patients on [t] who were either `Excluded` (`0`) or `Eligible` (`2`). The result is stored in the data frame named `trial` and has a data type of `integer`. The row sum is the total number of patients across all clinical studies.\n\n    trial <- [summary(t, Trial-level eligibility= c(`Excluded`, \"0\") ,`Eligible`, \"2`), by = \"Trial-level eligibility\"]\n\nNow that we finished with R, let's get the second step into the coding.\n\nIn the second step, we want to identify whether the patient is excluded by exclusion criteria or not. We will use Python to do this. Let's assume we have a dict where key and value means [patient index, Trial-level eligibility]. For example, {3, 2} means the third patient is eligible, and the second patient is excluded. In this process, we also need to count the number of patients that were excluded and not eligible. This means that it is easier to count after it is grouped with [sum] as we need.\n\n    count = dict( list ({'0': ['Trial-level eligibility: 1'], '1': ['Trial-level eligibility: 1'], '2': ['Trial-level eligibility: 2']}) )\n    \n    count['0'] += data.frame( Trial-level eligibility: 1",
        "label": 0
    },
    "184": {
        "output": "## Good Luck! If you have any question, please don't hesitate to send a mail to [INSERT E-MAIL].\nYou will find your output results in your project directory at the end of each project. You will see eligibility assessments saved as pickle (file suffix .pickle) files (with .csv extension but the contents of the .pickle file are in a .csv format). \nBefore going to the final submission, it is important to check the output results for accuracy.\nYou will need to modify your resume before you upload it. In the job description and the resume, you must state the following five keywords: 'PET, residual cancer burden score, MDA, eligibility, and Phase II study.\n\n# Conclusion\nWe are now living in the era of the sharing of the information. This kind of projects are being designed with openness and this can be used to make better clinical decisions. To apply these project-based learning cases, this software package, \"Sankya\" provides an efficient way of project-based learning by means of real applications.\nI would like to thank all my students with their hardworking, their patience for this software package. In the future, I hope many people to study the same topic in future with different groups or different research questions in the same topic. I would like to thank all the staff who has supported us. The development of this software package has been possible by the work of many staff from different areas such as computing lab, laboratory facilities, finance, accounting, administration, legal, the IT industry, universities and so on.\nI would like to thank Dr. Didem Karata\u015f\u0131 with her valuable discussions. I would like to thank all my colleagues and all my staffs who have supported me.\n\n## Software requirements: * hardware\nUSB keyboard, mouse, computer monitor\n\n## Installation of sankya:\nYou can obtain the source code for Sankya Software from the following link:\n\n## Downloading the software from the git site\nIn this tutorial, we'll talk about how to set up, install, and run Sankya software on your Linux laptop. After this section, you will have successfully installed and ran Sankya software on your laptop for future usages.\n\n## Running the software:\nIn this section, we will go through the process",
        "label": 0
    },
    "185": {
        "output": "### Instructions for patient eligibility determination\n\nDetermine patient eligibility using the table below.\n\n#### NOTE\n\nFor each patient, you should report the final response for the patient in the table below (Eligible, Not relevant, Excluded). The table is divided into three columns for three different types of trial.\n\n![NOTE] (Source: [https://github.com/deep-learn/deeplearn-demo/blob/master/data/10187_patient_eligibility_determination/patient_eligibility_determination.japaneg.ipynb])\n\n```\nEligible\nNot relevant\nExcluded\nTrial-0:\nTrial-1:\nTrial-2:\n```\n\n#### Inputs\n\nThe patient note and",
        "label": 0
    },
    "186": {
        "output": "Ask for feedback.\nHints<EOD> Injectable thermosensitive hydrogels for nucleus pulposus tissue engineering applications\nNucleus pulposus, the central portion of intervertebral discs, is a unique avascular tissue with a well-defined structural organisation. Many pathological processes of disc degenerative diseases are associated with a loss of its physiological cellular organisation, which plays a central role in mediating intervertebral disc (IVD) function through maintenance of disc height and integrity of the annulus fibrosus. Numerous nucleus pulposus cell types have been isolated and cultured in monolayer or using scaffolds as a matrix, however, the in vitro environment does not closely mimic the highly structured and matrix-rich native disc environment. Biodegradable thermosensitive hydrogels are being intensively investigated as novel delivery vehicles for in situ formation of a 3D cell culture matrix. Cell encapsulation within thermosensitive hydrogels has some unique advantages including: (1) uniform cell distribution, (2) controlled cell growth, (3) controlled degradation and (4) no immune or inflammatory response. Therefore, we review recent advances in the development of thermosensitive hydrogels with the ability to modulate their degradation, mechanical and physical properties for tissue engineering applications to support nucleus pulposus regeneration.<EOD> Fibroblast growth factor promotes neocortical differentiation in vitro: Evidence for the developmental antagonistic role of Shh expression\nWe investigated how fibroblast growth factor (FGF) promoted neocortical differentiation in our in vitro culture system. We found that addition of an FGF antagonist, recombinant chick FGF-2 or inhibiting soluble FGF antagonists attenuated neuronal differentiation induced by cAMP, but not that by Shh, suggesting that FGF antagonized cAMP-induced neuronal induction in the preplate in vivo, possibly by counteracting BMP inhibitors. Although the addition of an FGF neutralizing antibody or FGF inhibitors to cAMP-induced medium at",
        "label": 0
    },
    "187": {
        "output": "Your task is to determine the patient's eligibility based on the information in the patient note and the clinical trial that you are provided.\n\nThis information comes from the clinical trial data base ClinicalTrials.gov. You should use this website to search all the applicable trials based on your provided information. It can provide you the eligibility criteria associated with the trial. ClinicalTrials.gov is the largest, most comprehensive information on clinical trials. There you can find both the trial summary with its inclusion and exclusion criteria, and the actual detailed protocol with these data. The protocol describes in detail the interventions, the participants, their outcomes, the procedures, and the safety issues, so you will know every tiny detail of the actual clinical trial. For each trial you should determine the patient's eligibility based on trial-level criteria (e.g., `Exclusion: Metastatic carcinoma to the visceral organ or extra skeletal muscles`).\n\n# Assessment Instruction\nYou might consider using [Google Sheets](http://www.google.com/spreadsheets/installer.html).\n\n## Submission\nOnce you have performed the tasks, please click Submit, and submit one workbook containing the patient's evaluation.\nUse the patient case as the first sheet (e.g., Subject_eligibility), and provide the results in the other sheets (e.g., eligibility 1--2--3, and eligibility 0--not relevant--).\nIf you need to explain your choices, or discuss your results, please add it in the Subject_eligibility worksheet.\nIf you need to explain your choices, or discuss your results, please add it in the Subject_eligibility worksheet. Also it is possible to upload multiple worksheets to CBMS (CBMS supports multiple worksheets). You can also use [Google Sheets](http://www.google.com/spreadsheets/installer.html). If you do so, then please upload [two worksheets](http://google.com/spreadsheets/download/instructions#two_file_systems): \n\n1. Submit the patient evaluation file in CSV format. Remember to set it to use the UTF-8 as the encoding.\n2. Upload your",
        "label": 0
    },
    "188": {
        "output": "<br>See the [tutorial][1] for your convenience as an example.\n\n\n[1]: ../inst/tutorials/clinical trial.html\n<EOD> .\nThis article presents a review of the published literature and our experience over the past year concerning heparin-induced thrombocytopenia (HIT). The article provides updated information on incidence, pathogenesis, and diagnostic and therapeutic aspects of HIT. It pays special attention to the problem of \"serious\" or \"life-threatening\" thrombocytopenia caused by unfractionated heparin (UH), which is often encountered in current practice. A retrospective analysis of 30 patients, who received subcutaneous injections for at least one day of UH due to HIT, showed that 90% of these patients had HIT, and 10% had not developed HIT, as confirmed by laboratory studies, during the hospital stay. Thrombocytopenia observed in the latter patients had a different cause, and it did not require any urgent treatment. The incidence of life-threatening thrombocytopenia caused by long-term injections of UH in HIT has been previously underestimated, and can now be more appropriately estimated on the basis of actual observations. The diagnosis of thrombocytopenia caused by long-term injections of UH in HIT can be verified by the 14C-serotonin platelet aggregation method, which requires the least amount of time and expertise.<EOD> A model for the evolution of spermatogenesis\nOne reason why spermatogenesis has remained impervious to the forces of natural selection is the long life span of a healthy genome, which limits the number of opportunities to survive successfully but also to reproduce. Therefore, natural selection only acts on the germline, whereas the somatic and spermatogenesis itself evolve in parallel by a process of neutral, or nearly neutral, gene evolution. The result is that mammalian spermatogenesis, including sperm head and flagellum formation, has remained fundamentally unchanged since the evolutionary divergence of marsupials and placentals, despite the fact that the testis itself has undergone remarkable changes",
        "label": 0
    },
    "189": {
        "output": "We could make a patient-level eligibility by using `patient_level_eligibility(0)`. For example: \n`if patient_level_eligibility(0) == 1: ` #if the patient can participate in the trial print('eligible') else print('not eligible') end `\n\nIn case you want to get the patient-level eligibility of a given patient you just need to add the patient ID by patient() as shown below:\n\nimport pandas as pd \nfrom scipy.stats import rand \ndf = pd.DataFrame(rand(15,3))\n# Create patient records\npatient = pd.DataFrame({ 'ID': [200, 300, 500, 550], 'Sex': ['male', 'male', 'male', 'male'], 'Age': [45, 50, 55, 48], 'Height': [70, 70, 80, 75]), ['ID': [500, 400, 900, 900], 'Sex': ['female', 'female', 'male', 'male'], 'Age': [55, 50, 65, 60], 'Weight': [50, 55, 65, 65], 'Covid19': ['unvaccinated', 'unvaccinated', 'double-vaxxed', 'unvaxxed']}) # Generate a random age age = randint(30,100) print(age) patient = pd.DataFrame(rand(8,3)) patient.head(1) patient.tail(1) .groupby('ID')['Sex'].sum() patient.groupby('ID')['Age'].sum() patient.groupby('ID')['Height'].sum() # Eligibility 1)\nElisa = {'Elisa': ('Covid19', 0.01)}, \nAbort = {'Abort': ('ID', 'Covid19', 0.05),}\nPatient = {'Patient': ('ID', 'Sex', 0.1), 'Age': ('ID', 'Age', 0.2",
        "label": 0
    },
    "190": {
        "output": "### Exercise:\nWrite the code for this patient using the following format, i.e., `patient-name-trial-level-eligibility.txt`.  \n[code]patient-JohnSmith-trial-level-eligibility\nJohn Smith,\n0) Excluded,\n1) Not relevant,\n2) Eligible.\n[/code]\n### Solution: \n### Exercise: Implement this exercise for your given patient in another programming language.  \n[code]patient-John-Smith-trial-level-eligibility\nJohn Smith,\n0) Excluded,\n1) Not relevant,\n2) Eligible.\n[/code] \n\n# Experiment\nThis experiment will show you that you can write the source codes for this section using all the required libraries, packages, and tools, i.e., numpy, spacy, pandas, seaborn, textblob, matplotlib, and JupyterLab.\n-   numpy module has many functions to visualize the output data or the results.\n-   seaborn is a data visualization library.\n-   matplotlib is the primary library for creating scientific figures in Python.\n-   pandas is a flexible data processing library that reads and writes various common data formats.\n\n-   JupyterLab is an interactive and extensible notebook-based workflow environment.\n\n    https://jupyter.org/\n-   TextBlob has several functions, some of which are shown below: \n-   lemmatize is a method that returns the lemma or the base form of a word.\n-   positive is a method that returns positive, neutral or negative assessment.\n-   sentiment_strength is a method that returns value between 0 and 1, where `0.5` represents neutral assessment.\n    https://textblob.readthedocs.io/en/dev/api.html\n\n### Lemmatize a word:\nLemmatization, or morphological analysis, is the reduction of inflectional variants of a word to their base form.\n`word --lemmatize 'John`\nThe above command returns `John`` as base form of `john`.\n\n###  Finds sentiment value of a sentence:\n`TextBlob.sentiment(\"Caff",
        "label": 0
    },
    "191": {
        "output": "Copy all the steps into a file named ____CLINE-TRIAL_ELIGIBILITY.\n\nExample 2:\n\n![][Trial-level eligibility - second trial](Trials and Eligibility Screening for CML - 07-06-2018.pdf#page=13)\n<EOD> Efficacy of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene for predicting diabetes in young adults with impaired fasting glucose\nAims: The aim of our study was to observe the efficacy of the Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 (PPAR-&gt;) gene with regard to predicting the incidence of diabetes and its risk factors in a young Iranian population with impaired fasting glucose (IFG). Methods: This prospective cohort study was conducted on first-degree relatives of type 2 diabetes patients. The studied subjects were divided into three groups (diabetic, IFG, and normal) according to their 2-h post-load glucose (2hPG) levels. Results: The median age of the study population was 25 years. No significant difference was found in the genotype distribution of the Pro12Ala polymorphism between the three groups. However, the frequencies of the Ala/Ala homozygotes and mutant AA genotype were significantly higher than those of the AA wild type in patients with IFG as compared with normal subjects. Conclusion: This study suggests that the PPAR-&gt; Pro12Ala polymorphism is associated with IFG. However, the polymorphism does not play a role in the prevalence of diabetes in IFG patients.<EOD> Repositioning biologics: new applications for established therapeutics.\nPURPOSE/OBJECTIVES\nTo review a new role for established biologics in treatment of dermatologic diseases.\n\n\nDATA SOURCES\nPeer-reviewed publications and online product information for selected biologics as well as Food and Drug Administration (FDA) and European Medicines Agency websites.\n\n\nDATA SY",
        "label": 1
    },
    "192": {
        "output": "In general, a patient is eligible for the trial if she has a non-zero trial eligibility score.<EOD> Transcription of the bovine adenosine deaminase gene in liver is downregulated by dietary cobalt\nBenzonizomib, a proteasome inhibitor, can be used as a model of neurodegeneration. Cobalt, a chemical that mimics hypoxia, was added to the food of 7-wk-old Swiss Webster mice in order to create a model of chronic hypoxia. Cobalt treatment decreased body weight, but also impaired motor activity in mice, whereas motor activity in mice treated with benzonizomib (5 mg/kg for 1 wk) remained unaltered. Neurons in cobalt- and benzonizomib-treated mice showed less immunoreactivities for myelinated axons compared with untreated (controls) and vehicle-treated mice, although no change of expression of myelin-associated proteins, neurofilaments, MAP-M4, and synaptophysin were detected among the 4 groups. Cobalt- and benzonizomib-treated mice showed increased reactive astrocytes in the hippocampus, but not in the cerebellum. A decrease in the number of ChAT- and ChAT/ChAT mRNA-immunoreactive profiles together with a decrease in number of striatal cells labeled with a 5-HT2C antiserum were observed in the cobalt-treated group. Cobalt treatment also decreased the number of striatal cells labeled with the neuropeptide antisera cholecystokinin and calbindin C as well as the number of neurons expressing calbindin D-28k and neurogenic protein (NGP). Treatment of rats with cobalt in the food did not alter the level of expression of the calcium/calmodulin-dependent protein kinase II (CaMPKII) and neurogranin either in the hippocampus or striatum. The data suggest that cobalt treatment leads to axonal degeneration, myelination deregulation, neuro",
        "label": 2
    },
    "193": {
        "output": "<EOD> The Role of the Cytoskeleton During Cell Wall Synthesis and Remodeling in Rhodobacter sphaeroides\nThe prokaryotic cytoskeleton is composed of a protein matrix that is bound to the cell membrane (inner membrane in Gram-negative bacteria and cell wall in Gram-positive bacteria). The dynamic role played by the cytoskeleton during cell division, cell growth and cell separation has been intensively studied in Gram-positive bacteria. However, the protein components and architecture of this structure are still unknown in bacteria, especially in Gram-negative organisms. Here, we compare the cytoskeleton of Gram-positive bacteria, Gram-negative bacteria carrying a peptidoglycan cell wall (PEC) or a second inner membrane (IM), and Rhodobacter sphaeroides that presents an additional peptidoglycan membrane (PPM) structure. We further assess its dynamics and impact in cell division, cell growth, and cell separation in R. sphaeroides. First, we showed that R. sphaeroides proteins PopA, PopF, and FtsZ are required for cell growth and cell division in PEC organisms but not in IM or PPM bacteria. FtsZ forms dynamic structures during growth in R. sphaeroides that eventually concentrate on the division site in dividing cells. These events are independent from the IM structure. Second, we focused our study on the cytoskeleton of IM, PEC, and PPM organisms. We demonstrated that the cytoskeletal proteins FtsAF, PodJ, and MreB1 are ubiquitous to the three structures. Interestingly, we showed that the presence of a C-terminal signal sequence is not a conserved feature of the protein component of the cytoskeleton. Indeed, we show that PodJ and MreB1 proteins present a second N-terminal transmembrane domain for these two Gram-positive bacteria, Enterococcus faecalis and Deinococcus radiodurans that do not possess this characteristic. Finally, we report that PopA, PodJ, and MreB1 are required for cell separation in R. sphaeroides.<EOD> An Efficient Synthesis of",
        "label": 0
    },
    "194": {
        "output": "# D.3.1.1.3. Example_1\n[NAME] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n[NAME] Dear participants, We hope you enjoy the clinical research workshop! You learned so much already, and we are excited that new opportunities will continue to arise for you.\nIf you are interested in further clinical trial-related information, check out https://trialshero.org/!\nThank you, we hope you are inspired to further your clinical research work.\n[/D.3.1.1.3]\n\n# Appendix A. Clinical trial-related materials\n<EOD> Surgical considerations for the use of the intracoronary stent: an in vitro evaluation.\nThe intracoronary Palmaz stent is currently used for the relief of anginal symptoms and/or the prevention of myocardial infarction in patients with single vessel coronary artery disease. Its placement also may improve flow distal to significant vessel stenoses in some patients to improve their survival and to prevent infarction. Improved flow distal to a stenosis may have a short period of survival advantage for the coronary circulation of a few seconds to minutes. The extent of these benefits of increased coronary artery flow following stent deployment has been shown to be minimal for some lesion types. In addition, the placement of the intracoronary stent causes a significant degree of plaque disruption within the lesion, which may lead to occlusive debris, thrombus formation, and possible future stenosis in the stent or at the distal end of the stent within the native vessel. Therefore, the placement of the intracoronary stent may be accompanied by the development of intracoronary fibrous plaques within the stent or at its edges, which could cause serious problems as a result of the occlusion of the coronary artery",
        "label": 2
    },
    "195": {
        "output": "Here is the patient's age:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.  Here is the patient's age:\n\n# D4. Proving Patient's Age\nIn D1 and D2, we discussed the eligibility assessment of patients in clinical trials, and in D3. we discussed age-specific restrictions.\nIn D4, we will discuss the age-specific eligibility of patients for clinical trials. First, we will see examples.\n\n# Discussion [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to determine if someone qualifies for a clinical trial. The",
        "label": 0
    },
    "196": {
        "output": "<EOD> Fatal poisoning by ethylene glycol.\nEthylene glycol (C2OH6) is a colorless, odorless, and flavorless liquid which is used in the manufacture of resins, textiles, and plastics. It is also an intermediate product in the manufacture of acetic acid, methanol, and vinyl acetate. The toxicity of this diol was observed first in the late nineteenth century when it was found that it was the inebriating agent used in a popular but highly poisonous brand of German beer.1C2OH6 is easily absorbed through the skin and mucous membranes. It undergoes complete hydrolysis to oxalic acid, calcium oxalate, hydrogen carbonate, and alcohol after entering the blood stream. This causes severe acute renal insufficiency and even death. The principal cause of death is renal failure, but cerebral edema or convulsions also may occur. The clinical effects and the blood and urine concentrations of C2OH6 and its metabolites vary widely with the time from ingestion to the initiation of dehydration and alkalization of the urine and thus may be useful in confirming the diagnosis. 1,2 We now describe a fatal case in which the diagnosis was made by a blood C2OH6 concentration<EOD> Increased Risk of Perinatal and Neonatal Mortality Following Surgical Intervention: A Systematic Review and Meta-analysis.\nBACKGROUND\nThere is a paucity of data assessing the risk of perinatal and neonatal mortality for fetuses and neonates being delivered after major surgical intervention. The aim of this systematic review was to evaluate the risk and type of perinatal and neonatal mortality associated with surgical intervention.\n\n\nMETHODS\nData sources included the following: Cochrane, Medline, PubMed, Embase, CINAHL, and other databases/journals were searched (until June 2017). The following databases were also searched, using the same search terms: the Cochrane Database of Systematic Review, the Database of Abstracts of Reviews of Effects, NICE, and the Health Technology Ass",
        "label": 2
    },
    "197": {
        "output": "- [INST] You can use ``Trial-level eligibility``, or you can use ``Trial eligibility``, a variable like ``# patient not included due to trial-level ineligibility`, or you can use ``# patient for trial inclusion``. \n- Use the trial-level eligibility (or not) with an index, like ``count_index`` or ``trial_index``. The index tells how many eligible patients have been evaluated and how many patients are not eligible, which can show the quality of the data set or give interesting statistics about your trial. \n\n- This template is a first step in clinical trial eligibility. If your application needs a bit more information from the trial report summary or trial protocol, or more than three possible eligibility options, you can easily adjust your data structure and use the function and variable names shown here with your required additional information.\n\n- If you have a different application, your eligibility data structure will differ slightly. However, the above pattern should help you to develop your script. Note that your function name should be `trial_level_eligibility`, not `eligibility_calculation` because of the function name collision, and that you can use the `trial_eligibility_index` as a counting variable, and you can use trial_id instead of clinical_trial_id as a unique ID variable.\n\n\n\n## ACKNOWLEDGEMENT\n- This template was adapted from the clinical trial template for JotForm (https://en.wikipedia.org/wiki/JotForm). \n- Thanks to Kazuhide Mukumoto for his help with the trial structure of JotForm. <EOD> Inhibition of RhoC Signaling via RNA Interference Suppresses Angiogenesis and Tumor Growth of Bladder Cancer\nBackground/Aim: Neoplastic cells often exhibit altered cellular proliferation, migration, and angiogenesis due to uncontrolled Rho family small GTPases (Rho GTPases) signaling pathway activity. We evaluated whether a tumor suppressor, RhoC, is a pivotal molecule in bladder cancer. Materials and Methods: We constructed a stable cell line in",
        "label": 0
    },
    "198": {
        "output": "[INST]\n---\n\n### Examples\n<EOD> Transcriptome-based identification of 9\u2010cis\u2010epoxycarotenoid dioxygenase\u2010homologous genes as the key determinants of carotenoid cleavage in Arabidopsis.\nCarotenoids are critical for the synthesis of various flavors and colors and serve as precursors for the synthesis of phytohormones as well as metabolically essential compounds. Carotenoid cleavage dioxygenases of the 9-cis-ECD (9-cis-epoxycarotenoid dioxygenases) type play pivotal roles in these metabolic activities through their production of carotenoid cleavage products that serve as precursors for a range of specialized metabolites. Here we have integrated metabolic and gene expression profiling for Arabidopsis ecotypes that differ dramatically in their carotenoid contents, and show that expression differences within the two known 9-cis-ECD genes play a significant role in the metabolic differences between these ecotypes. We identify two novel 9-cis-ECD homologs that share high sequence identity with 9-cis-ECD and demonstrate that these new genes are functionally important in carotenoid metabolism in Arabidopsis by reverse genetic analysis. This study demonstrates the possibility of using metabolome\u2010 and transcriptome\u2010based approaches to identify genes of the highly uncharacterized 9-cis-ECD gene family in dicots for analysis of gene function and substrate specificity, in the context of carotenoid metabolism with a focus on carotenoid cleavage activities.<EOD> Changes in 43\u2009K/39\u2009K ratios of a sodium chloride-saturated solution induced by heating: an NMR study\nA solution saturated at ambient conditions with one half NaCl was investigated by means of nuclear magnetic resonance (NMR) spectroscopy to demonstrate the thermal effects induced on the Na+\u2013K+ ion exchange. The experiment was carried out by placing the mixture into a container, by first heating the solution gradually to room temperature, and then monitoring the evolution of the 43\u2009K nuclei over time. When the solution is heated, the water molecules of the salt crystal change",
        "label": 0
    },
    "199": {
        "output": "<EOD> The effect of long-term treatment with carbenicillin on the kidney in children\nAbstract The effect of long-term therapy with car\u2010benicillin on renal function was tested in 25 children by measuring urinary creatinine clearance (Ccr) and excretion of urinary beta\u20102\u2010microglobulin (BMG) before, after an intravenous bolus of 20\u201325 mg carbenicillin/kg body weight, 3.5 and 20 h later, and during subsequent daily treatment with 150\u2013200 mg/kg body weight intravenously in half the cases and 50\u2013 150 mg/kg body weight subcutaneously in the other half. Twenty children were healthy and five had an urinary tract infection. With intravenous treatment BMG excretion rose to more than three times the basal value. There was no change in Ccr. Children in whom BMG excretion was not influenced had a significant increase in Ccr. The urinary excretion of a protein of molecular weight 20,000\u201322,000 was not influenced by the intravenous carbenicillin bolus. With subcutaneous treatment BMG excretion did not increase, and no changes in Ccr were seen.<EOD> Prevalence of chronic kidney disease in patients with gout: analysis of healthcare utilization and medical costs\n\nIntroduction:The prevalence of chronic kidney disease (CKD) among patients with gout is high. It is important to have a better understanding of CKD in patients with gout to guide treatments and reduce economic burden. However, previous studies did not consider healthcare utilization and costs after diagnosis, which limits the understanding of this issue. Furthermore, previous studies included patients with renal insufficiency, who did not meet CKD diagnostic criteria by the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative. This study aimed to compare the healthcare utilization and medical cost between patients with gout with and without CKD in a large population-based sample. Methods: The medical records of patients diagnosed with gout and CKD (n =",
        "label": 0
    },
    "200": {
        "output": "<EOD> A Randomized Controlled Trial of a Nurse-Led, Interactive Education Program Including Real-Time Physiologic Monitoring for Home Total Parenteral Nutrition Patients\nSupplemental Nutrition Assistance Program recipients in two states can qualify to receive home total parenteral nutrition (TPN) care if they are determined to be eligible by the state medical director. To date, the states have not established procedures for patients to be admitted to home TPN care in a systematic and evidence based manner, or established criteria to assess patient readiness. The goal of this intervention was to describe the protocol for and explore the feasibility and acceptability of the educational program, to demonstrate the utility of real-time physiological monitoring devices to promote the nutrition wellness of persons undergoing long-term TPN therapy, and to improve TPN patient health care outcomes. A randomized controlled trial was conducted among pre-selected subjects who had a history of TPN at home. Nurses provided education to patients using a written educational package. At random, a group were assigned to real-time monitoring while the comparison group did not receive real-time monitoring. During TPN administration, 5 patients in the group with real-time monitoring, and 15 patients in the group without it, experienced complications that required correction. There were 3 deaths in the group with real-time monitoring and 10 deaths without it. The group with real-time monitoring was found overall to be significantly healthier.<EOD> Characteristics of the Stereotypes of College Students toward Nursing as a Career\nAs the enrollment of nursing students continues to decrease despite the critical shortage of healthcare workers, it is imperative to identify the misconceptions that students hold about the nursing profession and find ways to address stereotypes which may deter students from choosing the nursing field. The primary objective of this study was to ascertain the stereotypes held by a diverse group of college students toward nursing as a career. The participants, identified according to their ethnocultural background, included 1,110 college students, ages 21 and over (657 female college students and 453 male college students), from six different ethnocultural categories (White, African American, Asian-Pacific",
        "label": 0
    },
    "201": {
        "output": "Your job done! Thanks for participation. \n\n``` bash\n>> In-ClinTrial{PatientNote, ClinTrial}\nTrial-level eligibility:\n0) Excluded.\n1) Not relevant.\n2) Eligible.\n```\n\n<!-- markdown-toc end -->\n<EOD> Transforming growth factor beta1 levels during progression of glomerular diseases.\nTo evaluate the pathogenic role of TGF-beta1 in the pathogenesis of glomerulopathy, we performed urinary TGF-beta1 quantification in kidney biopsy specimens from patients with a variety of diseases. In addition, we compared TGF-beta1 levels of the urine to those of the kidney tissue and serum from patients with IgA nephropathy (n = 10), membranous nephropathy (n = 11), and lupus nephritis (n = 12) to those of the serum from patients with minimal change nephrotic syndrome (n = 8), focal segmental glomerulosclerosis (n = 6), membranous nephropathy (n = 12), or diabetic nephropathy (n = 13). TGF-beta1 levels were analyzed by using an enzyme-linked immunosorbent assay. TGF-beta1 concentrations in the urine were higher in IgA nephropathy and membranous nephropathy patients than in the other diseases. TGF-beta1 levels in the urine were positively correlated with those in the kidney tissue and serum when patients with various diseases were analyzed together. TGF-beta1 levels in the urine and serum decreased after treatment in a lupus nephritis patient and in a diabetic nephropathy patient. In contrast, serum TGF-beta1 levels increased in another diabetic nephropathy patient. These findings suggest that quantification of TGF-beta1 in urine and serum may be useful as a parameter in evaluating TGF-beta1 production in kidney tissue in chronic glomerul",
        "label": 0
    },
    "202": {
        "output": "Now, let's see whether you get the best score when compared with the solution to the previous exercise.\n\nExercise 2 in[INST] Hello. You are a helpful assistant for a Pharma company that produces oral drugs. Based upon your pharmaceutical knowledge, you have to suggest the appropriate drug to help the clinicians increase response rate at one-year. We give you some examples. The Pharma company produces two drugs against different diseases.\n\nHere are your suggestions and the corresponding response rate at one-year:\n\nExercise 2 in[INST] You are a helpful assistant for a Pharma company that produces oral drugs. Based upon your pharmaceutical knowledge, you have to suggest the appropriate drug to help the clinicians. We give you some examples. It is assumed that the Pharma company produces two oral drugs.\nNow, let's see whether you get the best score when compared with the solution to the previous exercise.\n\nExercise 3 in[INST] You are a helpful assistant for a Pharma company. After a successful clinical trial, the company has launched a new chest pain product into the market. Currently, you have to determine the potential factors that could limit the company's sales and market share with the results of the clinical trial.\n\nThe company produced a new pharmaceutical product, and its sales were growing. Recently, one of the clinical trials of the product was released. The trial included 2 268 patients in three age groups. The trial data are as follows:\n\nTable 1 Trial results data by age group\n\nGroup1, 2, 3 (n=744, 758, 761)\n\nAge(years) \n\n60-69 \n\n50-59 \n\n70 and over \nDrug response rate \n\nGroup1 38% \nGroup2 27% \nGroup3 27%\n\nLet's think step by step. \nLet's consider a company that produces an oral drug and sells it worldwide.\nWhenever the trial was performed, the following trial results data were provided by the company's marketing department.\nYou will have all these data as a list of three patients; we",
        "label": 2
    },
    "203": {
        "output": "You have successfully tested the program. You should type \"Quit\" to exit the program. The user who wrote this program is `username_0`. You may try and test the program by using the following keywords on the command line.\n\n`>python try1.py`\n\nTo print the names of the functions in a module, you should type:\n\n`>help`\n\nAnd to call a function inside a file to the program, you must type:\n\n`>import try1`\n\nThis concludes the third chapter on testing, and the third part of the book. If you have any problems with the program or any questions about it, please, send them to the main author of this manual [[email:<EMAIL>]<EMAIL>]`] at <EMAIL>.\n\n[INST] Hello. You are still a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial: \nTitle: Pre Operative Trastuzumab in Operable Breast Cancer\n\n\nSummary: Background Information and Rationale:~Trastuzumab is a",
        "label": 1
    },
    "204": {
        "output": "Let's think step by step.\n\nFirst, we check how many times the cell size number was detected: \n```python\n[12, 13, 14]\n```\nSecond, check `13`, for the first 10 million samples, count the number of \"12\" that appear before it, and after it. \n```python\nfor i in range(10**6):\n    if '13' in data['CellSizes'].tolist()[i]:\n        numbers.append(len([x for x in data['CellsSizes'].iloc[i] if '12' in x]))\n        numbers.append(len([x for x in data['CellsSizes'].iloc[i] if '12' in x]))\n    else:\n        pass;\n```  \nFinally, calculate the average of `12`, `13`, and `14`:\n```python\nvalues = np.array([values in numbers])\nfinal = np.zeros([3])\nfinal = np.average(final, axis = 1)\nwith open('report_sample_1', \"w\", newline=\"\") as f:\n    final.to_csv(f)\n```  \n\nThe report looks like this...  \n<EOD> Correlation of Mini-Mental State Examination scores with CSF/serum albumin ratio in patients with subacute subarachnoid hemorrhage.\nIn order to determine the relationship between Mini-Mental State Examinations (MMSE) scores and cerebrospinal fluid (CSF)/Serum albumin ratio in first seven days of subarachnoid hemorrhage (SAH), 124 patients were evaluated by MMSE on days 2 through 7 and by CSF/Serum albumin ratio at early stage after SAH. MMSE scores differed significantly (P <",
        "label": 0
    },
    "205": {
        "output": "1. Copy-paste the patient note into the console.\n2. Call the function `trial` of the module `clinical_trial`. This function generates a patient note with additional information needed to determine trial eligibility. \n    * The required arguments are `patient_note` and `trial` is the input object of the variable assigned to this function. \n    * We have to provide the input to this function beforehand. We are calling the method `clinical_trial` function as `Trial = cliniical_trial('Breast cancer', 'Ultrasound detection of peripheral IV infiltration');`\n    * The trial note is returned as output.\n        * This output is an object of the module `clinical_trial`, as shown by `Trial` in the code below. \n\n```python\nTirial=cliniical_trial('Breast cancer', ' Ultrasound detection of peripheral IV infiltration');\n```\n5. Assign it to a variable named `Trial` and store this assigned variable, as well as Trial.trial_note, if we require it in the future in a variable. \n6. Find out about the patient eligibility of the study by running the function `trial_eligibility' from inside the module `clinical_trial`. \n7. To output the trial-level evaluation (eligibility), run the function `Trial-level eligibility` on Tirial. \n8. We can print the trial-level eligibility in the console. [INST] \n9. As `Trial`-related objects are saved in memory, we can reuse this object in subsequent functions as well. You can see the entire code of the step below.\n\n```python\nPatient = cliniical_trial('Breast cancer', ' Ultrasound detection of peripheral IV infiltration')\nTrial = cliniical_trial('Endometrial cancer', ' Ultrasound detection of peripheral IV infiltration')\nprint(Trial)\noutput = Trial_eligibility(Trial)\nTrial_eligibility(Trial)\n```\n![](https://user-images.githubusercontent.com/",
        "label": 0
    },
    "206": {
        "output": "In terms of formatting, there are two important guidelines. \nFirst, the name of the clinical trial must appear on the first line where you enter it. \nSecond, you can put each variable on a separate line (also known as flatten), e.g., `Patient note: `, `Inclusion criteria:`. This is also helpful to find a variable name using the variable finder `?variable_name` command.\n\n> ## A: 01-01-2014_07_26\n>\n>> [A1] Start\n>>\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\n\n\n### Trial-level eligibility\n\n> ### Trial-level eligibility: Eligible.\n### Trial-level eligibility: Eligible.\n### Trial-level eligibility: Eligible.\n### Trial-level eligibility: Eligible.\n### Trial-level eligibility: Eligible.\n### Trial-level eligibility: Eligible.\n\n> ### Trial-level eligibility: Eligible.\n### Trial-level eligibility: Eligible.\n### Trial-level eligibility: Eligible.\n### Trial-level eligibility: Eligible.\nTrial-level eligibility: Eligible.\n\n> ### Trial-level eligibility:\n\n> ### Trial-level eligibility: Eligible.\n>\n> ### Trial-level eligibility:\n\n> ### Trial-level eligibility:",
        "label": 2
    },
    "207": {
        "output": "<a id=\"HDF5-output\"></a>\n### HDF5 output\nIn this section, the HDF5 output is introduced. The code to output the HDF5 file is shown in the following code block with the description in the comments.\n```{python}\nimport numpy as np\n\nimport pandas as pd\nfrom osgeo.gdal import get_driver\nfrom ipytrix.io import io\nfrom pvac.hdf5 import f_write, F\nfrom pvac.hdf5.conventions import Conventions\n\ndf = pd.read_csv(\"patient_note.csv\")\n\npath = '/tmp'\npatients = pd.DataFrame({\n    'Name': ['Sam', 'John'],\n    'Age': [45, 35],\n    'Gender': [1,(1,2),1],\n    'Diagnosis': ['Breast Cancer', 'Hepatitis C'],\n    'Drug': ['Cytologically Confirmed', 'A core Biopsy'],\n    'Tissue': [['invasive ductal breast carcinoma in the left upper outer quadrant', 'breast cancer', 'ductal breast carcinoma'],['hepatitis C', 'breast cancer','hepatitis C']],\n    'Status': ['Surgery', 'Surgery', 'Treatment'],\n})\n\npatients.loc['Sam', 'Diagnosis'] = pd.DataFrame([['cure'],['cure']], index=[0, -1], \n                                    columns= ['Diagnosis', 'Diagnosis', 'Name'])\npatients.loc['Sam', 'Tissue'] = tuple([['a specimen of breast cancer'],['ductal breast carcinoma or breast cancer'],['Sam']])\npatients.loc['Sam', 'Age'] = pd.Series([45] * 5, names=['Gender'])\npatients.loc['Sam', 'Drug'] = tuple([['a cytologically confirmed diagnosis of breast cancer']]) #tuple([['Sam']]))\npatients.loc['Sam', 'Gender'] = 'Male'\npatients.loc['John', 'Gender'] = 'Male'",
        "label": 1
    },
    "208": {
        "output": "Example:\n![INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the trial-level eligibility of the given clinical trial to determine the patient's eligibility.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patients meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the trial, i.e., output the scale for the assessment of eligibility for the trial, i.e. `Trial-level eligibility: `, e.g., `Trial-level eligibility: 2) Eligible.`.\n\n\n\n\n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a\ncandidate for tumor resection and agrees to do so prior to chemotherapy.\n\n[https://www.kaggle.com/datascienceinstitute/datadriven-recruitment-for-clinicaltrials]\n\nThis example can be solved in at least three different ways:\n### [/CODE]\n#!\n\n# Let's implement the first one\n# The first approach to this problem is to determine each patient's eligibility for a given individual trial, then to sum up the results, and finally to repeat the task with other trials. For example, let's use the following Python program for solving the first trial:",
        "label": 0
    },
    "209": {
        "output": "In this problem, you will learn to apply the following python-lib for your final submission: [INST] `pandas`, `os`, `numpy`.\n\nPlease, submit this problem together with your code, which is to be formatted as described in the _style guide_.\n\n## Submitting your assignment\nUpload your files before December 23th at 11:59 p.m CET. \n\n## Rules of conduct\n\nYou do not have to follow the rules. However, please read them anyway. It is important to understand how we work with you and handle your assignments.\n\n**Please don _`t`** plagiarize!**\n\nIf a supervisor suspects that plagiarism is happening, we will consult with a plagiarism specialist at U.S. universities to check the validity of any claims that are made against you.\n\n**Submitting late**\n\nMake sure to allow enough time to perform the assignment. You will lose points for submitting it late. The following table describes how many points you can lose for submitting the assignment as late.\n\n<table>\n  <thead>\n    <th colspan=3 style=\"text-align:center;\">Points</th>\n  </thead>\n  <tbody>\n    <tr style=\"text-align:right;padding-right:10px;\">\n      <td style=\"text-align:left; padding-left:5px;padding-right:20px;\"><code>Assignment late</code></td>\n      <td style=\"background-color: #D6E1C9;padding-left:5px;padding-right:20px;\"><code>1</code></td>\n      <td style=\"text-align:right;\"><code>-2 </code></td>\n    </tr>\n    <tr style=\"text-align:right;padding-right:10px;\">\n      <td style=\"text-align:left; padding-left:5px;padding-right:20px;\"><code>Late</code></td>\n      <td style=\"background-color: #D6E1C9;padding-left:5px;padding-right:20px;\"><code>1</code></td>\n      <",
        "label": 0
    },
    "210": {
        "output": "[fig]  EXERCISE 3.3: Copy the trial-level eligibility assessments. [/fig] \n<EOD> Evaluation and comparison of three commonly used reference genes in potato (Solanum tuberosum L.) plants exposed to two herbicides\nGene expression analysis is one of the most commonly used molecular techniques to evaluate gene responses to biotic and abiotic stresses. Quantitative real-time polymerase chain reaction (qRT-PCR) is a sensitive technique and a well-accepted method for measuring gene expression in plants. However, the accuracy of qRT-PCR-based measurements depends on experimental and methodological protocols. A reference gene whose expression does not change upon the treatment in the target plant is needed to normalize relative expression data. Identification and validation of a stable reference gene within a complex target is a necessary and critical step for accurate relative quantification of gene expression. This study evaluated the expression stability of reference genes in two herbicides-induced potato plants. Three candidate genes, 18S (ribosomal RNA 18S), GAPDH (glyceraldehyde 3-phosphate dehydrogenase) and Tubulin, were used to quantify the expression levels of 11 functional genes, 4 of which are cytochrome P450 and 7 are metabolic enzyme genes related to organophosphate and herbicides detoxification in potato plants treated with glyphosate and paraquat. Stability evaluations based on the expression data of reference genes under different samples were achieved by three quantitative methods (geNorm, NormFinder and RefFinder), by which 18S RNA gave the greatest stability value overall. The most stably expressed reference genes of potato plant treated with glyphosate and paraquat and two herbicides treated together were 18S and Tubulin, and EF1\u03b1 and 18S respectively. The study illustrated that the expression of reference genes was significantly different in potato plant treated with single herbicide and that in potato plant treated with both herbicides. These results indicated an important role of the selection of reference genes during the evaluation of gene expression in the stressed potato plant.<EOD> Re-",
        "label": 2
    },
    "211": {
        "output": "There are 15 sample patients. The dataset is as follows:\npatient ID, first name, age, gender, marital status, race and ethnicity, weight, clinical-stage, histology, histology-grade, site-size, node-statues, lymph-vessel-invasion, neuro-vascular-invasion, adjuvant systemic, metastasis, chemotherapy\nYour job is to predict these outputs by using the dataset, i.e., Trial-Level Eligibility for the clinical trial.\nInput files are prepared based on the clinical trial note/doc. One of the input data files, `data-1-in-clinical-trial.xlsx`, contains all the information about a specific clinical trial, and another one, `data.csv`, contains real clinical trial data about patients that are registered and enrolled in the clinical trial. You should prepare your input file in a similar way by referring to the provided doc/ notes about the clinical trial.\nNote, the dataset from the clinical trial is for the `clinical-trial` clinical trial, i.e., the dataset which you have used the model to predict the Trial-level eligibility. But `clinical-trial_dataset` is for the dataset used for training the model to predict the same Trial-level eligibility.\nTo prepare the input file for `clinical-trial` clinical trial, you need to add an extra two columns to the dataset: `Clinical_trial` for type of clinical trial and the value for each type, respectively, e.g., `clinical-trial` =`1` for each clinical trial, e.g., `clinical_trial_id =1`,`clinical_trial_start_date=1`. \n\nPlease note that there are 15 sample clinical trials to which you can make predictions, i.e., `clinical_trial = 1, 2, \u2026, 15`. Here is the summary of a trial. Let's focus on our data on this one trial and the related datasets for training, validation, and test.\n```\nTrial_id : 1\nTitle : `Tumor vaccine",
        "label": 0
    },
    "212": {
        "output": "---\n\n[INST] Solution for patient report\n\nHere is the list of variables related to the patient report: PatientNote, ClinicalTrialName, CurrentPatient, CurrentTrialInfo, ClinicalTrialInfo, Trial-level eligibility, CurrentPatientNote, CurrentTrialDescription, CurrentPatientExclusionCriteria, CurrentPatientInclusion-Criteria, CurrentClinicalTrialExclusionCriteria, and CurrentClinicalTrialInclusionCriteria.\n\nYou may need the following information to generate a patient note.\n\n\nLet's create the patient note, ClinicalTrialInfo, and current patient \n    patient note1 = sprintf(\"Please note that this is an experimental treatment and you are subject to all risks and problems associated with research protocols. This means that you have voluntarily agreed to allow these tests to be performed on you, and the results of the tests obtained would remain anonymous and be published without your name if it is appropriate. If you have any questions or concerns about the test being performed please call the research team. If you have any questions or would like to discuss the details of this treatment, feel free to contact Dr. Smith at Smith Hospital at number 1232323",
        "label": 0
    },
    "213": {
        "output": "### INST #1\n### Problem 1\nYou may observe that the `if` clause is ignored in the last line of code. How to fix this?\n\n### Solution\nThe problem is that the list is not processed from the second iteration on.\nHere is the code to do the same thing within a `for-loop`:\n\n\n```julia\nTrial-level eligibility = 0\nfor i in 1:n\n    if (i == length(patientNote['patientData']['clinicalStudyNote'].ClinicalTrials.clinicalTrialsNotes[1].clinicalStudyProtocol.exclusionCriteria.exclusionCriteria)\n            && (match(`$patientNote['patientData']['age'],`patientNote[\"patientData\"][\"ClinicalTrials\"].clinicalTrialsNotes[1].clinicalStudyProtocol[\"exclusionCriteria\"].exclusionCriteria, match(\"Age \u2265 80 years\"))))\n        Trial_level_eligibility = '0'\n    end\n    if patientNote[\"data\"][\"patient\"].gender == 'M' && !(patientNote[\"data\"][\"patient\"].age >= 18 && patientNote[\"data\"][\"patient\"].gender == 'M') && !patientNote[\"data\"][\"patient\"].doctype == 'doctor_notes' && !patientNote[\"data\"][\"patient\"].clinicalStatus == 'clinical_status' && !patientNote[\"data\"][\"patientData\"][\"patientBirthDate\"] > (DateTime(year = 1965, day = 1, month = 1)) && !patientNote[\"data\"][\"patientData\"][\"patientAge\"] > (55) && !patientNote[\"data\"][\"patientData\"][\"patientBirthDate\"] > (DateTime(year = 1997, day = 1, month = 1)) && !patientNote[\"data\"][\"patientData\"][\"patientAge\"] < (65) && !patientNote[\"data\"][\"patientData\"][\"patientBirthDate\"] > (DateTime(year = 1990, day = 1,",
        "label": 0
    },
    "214": {
        "output": "_____________________________________________________________________________________________\n\n##[MATH] Hello. You are a helpful assistant for clinical trial eligibility assessment. You are given a triplet of patient note and patient trial with eligibility assessment. You should check the eligibility between each patient and patient trial in all triplet. For example, if the patient's information is the same to the assessment of eligibility of trials, you should assign all the assessment of eligibility of a patient to the assessment of eligibility of the trial.\n\nAssume that there are N patients in the first data set, and each patient is characterized by the patient's clinical diagnosis, sex, age, and so on. The triplet of each patient is generated in the second data set. Thus, the second data set contains N \u00d7 4 triplets consisting of four observations. For example, the triplet (0, 2, 2, 1) means that a patient belongs to the first diagnosis with female and age 60 and patient does not meet the exclusion criteria 1 and 2. In other words, the patient's information is the same to the assessment of eligibility of trials.\n\nHere are a patient note and a patient trial in the first data set:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nThe title of the trial is:\nTrial design The objective of this phase II trial is to evaluate the activity of gemcitabine and docetaxel regimen as first line treatment for ER-negative breast cancer. Patients with cytologically or histologically confirmed ER-tumors with invasive stage II through IV breast cancer will be entered into",
        "label": 1
    },
    "215": {
        "output": "<EOD> Differing effect of ampicillin on E. coli and on B. cereus\nThe in vitro effect of ampicillin was investigated on a clinical isolate of Escherichia coli ATCC 11303 and on a strain of Bacillus cereus. Growth of E. coli was inhibited by ampicillin concentrations between 4 and 8 micrograms per ml. No inhibition was observed for B. cereus, even when high concentrations were used. There was no difference between ampicillin used alone, and penicillin-ampicillin mixture on E. coli.<EOD> The BET inhibitor birabresib affects the expression of cytokines involved in inflammatory response and epithelial\u2013mesenchymal transition and synergizes with bortezomib in Ewing sarcoma cells\nEwing sarcoma (ES) is an aggressive pediatric and adult malignancy lacking effective treatments beyond the first remission. Previous studies have suggested that the use of birabresib (OTX-015), a selective bromodomain and extraterminal domain (BET) inhibitor, suppresses proliferation of a variety of tumor cells, including ES. In this work, we investigated the cellular effects of birabresib in two ES cell lines (EW8 cells, a primary ES cell line, and ES\u2010MNNG cells, an N\u2010nitrosomethylurethane (N\u2010NMU) Ewing sarcoma transgenic cell line) cultured under specific growth conditions and we determined the molecular effects of birabresib administration, in particular with regard to inflammatory response modulation. Birabresib treatment resulted in cell viability impairment, induction of proapoptotic pathways, block of cell cycle in G1\u2010S phase, and induction of cellular differentiation in a time\u2010 and dose\u2010dependent manner. Additionally, in EW8 cells birabresib administration resulted in a significant inhibition of inflammatory cytokines related to hypoxia and tumor microenvironment, such as hypoxia\u2010inducible factor 1\u2010\u03b1 (HIF\u2010",
        "label": 0
    },
    "216": {
        "output": "Here\n\n\nA: You need to define and use [instances variables](https://docs.python.org/3/tutorial/controlflow.html#labels)\nSo you could do something like this to define eligibility variables,\nclass Clinical Trial:\n\n    def __init__(self, name, criteria):\n        self.name = name\n        self.criteria = criteria\n\n    def __repr__(self):\n        return f\"{self} [{(self.name)}] {self.criteria}\"\n\n    def __str__(self):\n        return f\" {str(self.name)}  {str(self.criteria)}\"\n\n    def to_json(self):\n        return {\n            \"name\": str(self.name),\n            \"criteria\": str(self.criteria),\n        }\n\nYou can then create an instance from this object by defining and passing the following variables,\nself = Clinical Trial(\"A name\", (\"Female and Male, aged 18-60\", ))\n\nThen we can then define a class Patient, which could have the following class methods,\nclass Patient:\n\n    def __init__(self, age, gender):\n        self.age = age\n        self.gender = gender\n\n    @classmethod\n    def eligible(self, trial1, criterias, patient_class):\n        trial_name = str(trial1.name)\n        print(f\"Eligible for {trial_name} - criterias: {list(criterias)} patient of age {patient_class()} and gender {str(patient_class())}\")\n\n    @classmethod\n    def not_relevant(self, trial1, criterias, patient_class):\n        print(f\"Not relevant to trial1 and criteria {list(criterias)}\")\n\n    @classmethod\n    def exclude(self, trial1, criterias, patient_class):\n        trial_name = str(trial1.name)\n        print(f\"Exclude from trial1 and criteria {list(criterias)}\")\n\n    @classmethod\n    def relevant(self, trial1, criterias, patient_class):\n        trial_",
        "label": 0
    },
    "217": {
        "output": "In summary,\n\nTo complete this assignment, you should follow the following steps:\n(1) Read the instructions:\n![instruction](../../image/Clinical-Trials_A-1.pdf)\n(2) Access to EvalClinical, and find the given patient eligibility evaluation problem as shown in Figure 1.\nFigure 1: The problem displayed in the evaluation mode of EvalClinical\n(3) Assess the patient's eligibility by entering all required data (as shown in Figure 2). Make your decision for each of the input data following the instructions. Note that, if the patient's information is too long to be displayed in the problem, you may omit some information. \nFigure 2: Patient eligibility evaluation for patient No. 2\n(4) When you finish entering all required data, click `Submit` to go to the problem evaluation results. Note that even if you find the patient eligible, it is still suggested you return to the previous step to check the data input again, to assure all the data is well entered. (You will have the chance to recalculate the patient eligibility if you click the button `Retry`). \n(5) Click the button `Retry` on the assignment. When you click this button, all the data in the table will be reseted to the default values. Note that not all the data is reseted, so you don\u2019t need to perform all the steps you\u2019ve done over again. When you are done with this step, you can go back to the first step.\n\n![Retry](../../image/Clinical-Trials_A-2.pdf)\n\n[/FIN]\n<EOD> The in vitro susceptibility of Neisseria gonorrhoeae isolates displaying beta-lactamase activity against tazobactam (Claforan) to imipenem and other antimicrobial agents\nTo overcome the resistance of strains of Neisseria gonorrhoeae to beta-lactams, we evaluated a combination of imipenem and beta-lactamase inhibitors and compared",
        "label": 2
    },
    "218": {
        "output": "## Exercises\nBefore practicing this section, you might want to watch the videos available in our [Train the Trainers] platform.\n\nThe purpose of this exercise is to illustrate what you already learned in our previous module on the inclusion and exclusion criteria. When you give a clinical trial recommendation to a patient, you have to specify your assessment of the patient's eligibility for a trial, on a scale between 0 and 2, being 0 excluded, 1 not relevant, and 2 eligible.\nThe following is the set of cases:\n\n[SOLUTION]\n\n\n## Influenza\n\nYou are about to visit a patient who has flu symptoms and takes fever medicines to control these symptoms.\n\n**Disease: Influenza**\n\nInfluenza is a viral respiratory infection. Influenza viruses include a variety of strains that mutate constantly. Three strains of influenza virus cause influenza: type A (the most common type), type B, and occasionally type C. About 5% to 10% of influenza infections lead to influenza pneumonia. \n\n\n## Patient details\n\nName: Dr. Sally Smith \n\nAge: 36 years \n\nBirthdate: 3/5/1986 \n\nGender: Female \n\nEthnicity: Caucasoid \n\nOccupation: Radiologist \n\n\n## Symptoms\n\nFever, cough, chills, sweats, headache, myalgia \n\nTreatment History\n\nSally takes influenza vaccine every year. She also takes over-the-counter fever medicines, including acetaminophen 1,000 mg, to control these symptoms.\n\n\n## History\n\nYou learn that Sally was healthy before developing fever and flu symptoms.\n\n\n## Physical Examination\n\nSally\u2019s oral temperature is 37.9\u00b0C. She complains of a sore throat. Her cardiopulmonary examination reveals wheezing in the lungs on bilateral auscultation.\n\n\n## Additional",
        "label": 0
    },
    "219": {
        "output": "## R code\nR code \n\n```r\n# library(parallel) \ntrial_note <- read.delim(\"2016-09-21T17_39_35.6Z -data/trial_note.txt\",sep=\" \\n\",stringsAsFactors=F) \ntrial <- read.delim(\"2016-09-21T17_39_35.6Z -data/clinicaltrial.txt\",sep=\" \\n\",stringsAsFactors=F) \n\npwd() \nsetwd(\"./data/experiment10\") \n\nif (is.null(system.file(\"path\",package=\"multicore\",subdir=\"simulations\")) | !exists(\"path\",package=\"multicore\", subdir=\"simulations\")) { # create simulation directory\n    # add to path\n    if (!exists(\"path\",package=\"multicore\",subdir=\"simulations\")) { \n        create.dir(\"path\",package=\"multicore\",subdir=\"simulations\") \n    }\n    if (!exists(\"path\",package=\"multicore\",subdir=\"simulations\")) { \n        list.files(\"path\",package=\"multicore\",subdir=\"simulations\") \n    }\n} \n\n# create trial-specific list of pathological variables \ntrial_var <- ifelse(substr(.==\"data,\",\"-trial\")==1,\"data/clinicaltrial.txt\",ifelse(substr(.==\"data,\",\"-trials2\")==\"-\"),ifelse(substr(.==\"data,\",\"-trials2\")==\"02\",\"path_data/newtrial.txt\",\"path_data/newtrial.txt\"))\nfor (i in 1:nrow(trial)){\n    trial_var[j] <- paste(\"./data/\", trial_var[j] ,trial[i,]) } # read all the pathologic variables into a local matrix \n\n\n# assign a random number between 0 and 1 \njitter <- sample(1:174) \n\nif(!exists(\".jitter\",path=\"./data\")){ # create .jitter path and .j",
        "label": 2
    },
    "220": {
        "output": "<EOD> TREATMENT OF ENDOTHELIAL DYSFUNCTION IN HYPERCHOLESTEROLAEMIC PATIENTS BY ETANERCEPT UNDER HYPOLIPIDEMIC LOW DOSE SIMVASTATIN EVOLUTION\n1 The aim of the present study was to evaluate the anti\u2010inflammatory effect of etanercept (ETA) administration with statin in hypercholesterolemic patients with mild hypertriglyceridaemia, without statin treatment, with a known history of coronary artery disease and family history of early onset atherosclerosis. 2 The study has been conducted as two independent consecutive double\u2010blinded placebo\u2010controlled randomized studies. In the first trial, 20 patients have been studied. A double\u2010blinded randomized administration (50 mg three times daily in the morning, afternoon and evening) of either ETA or placebo (saline solution) for 28 days was performed. In the second study, 40 patients have been studied. A double\u2010blinded randomized administration (50 mg two times daily in the morning and evening) of either ETA or placebo (saline solution) combined with simvastatin (10 mg daily) was performed. 3 In the first study, no difference was observed in baseline versus day 28 in either group when measured by the endothelial related markers. In the second study, 15 patients in both groups were studied as they had normal serum triglycerides. The remaining 25 patients of the second study had elevated serum triglycerides. Although no differences were observed in the serum triglycerides levels in both groups, the following parameters showed a significant effect on the endothelial related function parameters: interleukin\u20106 (IL\u20106) and matrix metallopeptidase type 9 (MMP\u20109) in the ETA group, and IL\u20106, IL\u201010, IL\u201012p70, MMP\u20109, monocyte chemoattractant protein\u20101 (MCP\u20101) and soluble intercellular adhesion molecule\u20101 (sICAM\u20101) in the placebo group. Consequently, E",
        "label": 0
    },
    "221": {
        "output": "Your task is to determine the patient level eligibility based on the patient's data and the trial data from the clinical trial described above. First, determine the initial patient's information and make a patient note. Then read the patient eligibility criteria of the trial. Based on the patient's information, you should check whether the patient satisfies each criterion and indicate the results of the comparison in the columns of the patient note. Then, determine whether the patient satisfies the patient level trial eligibility. The trial eligibility is specified by the last eligibility criteria (notice that the eligibility criteria follow the INST instructions. Therefore, the order of determining eligibility criteria should be in terms of eligibility. The last trial-level eligibility is `Trial-level eligibility: 2) Eligible.`.)[INST].\n\n# Patient level eligibility:\n\n### ENG 151 Spring\n<EOD> Fatigued Caregivers in the Workforce: Effects of a Workplace Intervention on Job Satisfaction, Sleep, and Mood\nThis study explored whether a workplace program enhanced caregivers\u2019 psychosocial work environment and subsequently improved their job satisfaction. Caregivers (N = 149) who participated in the program reported more job satisfaction 6 months after joining compared to the reference caregivers.<EOD> Neuroprotective potential of the 2-(1\u2032 \u2010hydroxy\u20101\u2032\u2010methylpropyl) quinoline derivates on hypoxic neuronal injury\nIn this study we aimed to investigate the neuroprotective effects of 2-(1\u2032\u2010hydroxy\u20101\u2032\u2010methylpropyl) quinoline derivates (HHQ) on hypoxic neural injury in the rat hippocampus, and we determined the biochemical parameters induced by hypoxia as well. The rats were randomly divided into 3 groups as sham, HHQ+vehicle and HHQ+hypoxia. In HHQ+vehicle group, hypoxic conditions were created by keeping animals in a low\u2010oxygenated chamber (8% O2, 92% N2) for 30 min followed by 24 h recovery period",
        "label": 0
    },
    "222": {
        "output": ".\n\n### Task 5\nNow, check the 'relevant' parameter on the basis of the gender of a patient and return the result in a table. You should assign 'gender' as a categorical variable, and the value of this variable must be assigned with 'F' in the column for females and 'M' in the column for males. Let's try to determine the value of this variable, gender, with 'M' in the first line of dataset. If the patient is a male, write 'M' in the column for gender and if the patient is a female, write 'F' in the column for gender. \nThe dataset must then have rows for the patients and columns of 'Trial.Eligibbles', age, and gender. But to apply the code written in the previous task, we should write code in a specific format that must contain a list of criteria for the evaluation of a patient's eligibility criteria. The format is explained in the next task. \nTo create the format,",
        "label": 0
    },
    "223": {
        "output": "### Sample Solution\n[SOLUTION] Eligibility Assessment for Clinical Trial:\n\n1. Eligibility assessment of clinical trial should be written.\nEx. Neoadjuvant Dabrafenib, Trametinib for AJCC Stage IIIB-C BRAF V600 mutation positive melanoma (D-NCT01947829)\n- Title: Neoadjuvant Dabrafenib, Trametinib for AJCC Stage IIIB-C BRAF V600 mutation positive melanoma (D-NCT01947829)\n\n2. All information of clinical trial should be summarized. \nEx.\n\n- Inclusion Criteria:\n(Age \u226518 years)\n- Neoadjuvant Dabrafenib, Trametinib for AJCC Stage IIIB-C BRAF V600 mutation positive melanoma (D-NCT01947829)\nNeoadjuvant BRAF inhibitor plus MEK inhibitor therapy in resectable stage III melanoma patients for downstaging and treatment of microscopic occult disease \n- Neoadjuvant BRAF inhibitor plus MEK inhibitor therapy in resectable stage III melanoma patients for downstaging and treatment of microscopic occult disease \n\n- Trial-level eligibility: 2) Eligible.\n[SOLUTION] Eligibility Assessment for Clinical Trial:\n\n1. Eligibility assessment of clinical trial should be written.\nEx. Neoadjuvant Dabrafenib, Trametinib for AJCC Stage IIIB-C BRAF V600 mutation positive melanoma (D-NCT01947829)\n- Title: Neoadjuvant Dabrafenib, Trametinib for AJCC Stage IIIB-C BRAF V600 mutation positive melanoma (D-NCT01947829)\n\n2. All information of clinical trial should be",
        "label": 0
    },
    "224": {
        "output": "This task is about clinical trial. You should provide the same trial-level evaluation for each patient according to the provided information.\n\nPlease notice the following:\n\n\n\n1.\nYou should avoid any words that are not strictly mandatory to the task, for the sake of simplicity. Please refrain from adding explanation texts (e.g., `1) Excluded` --> `1) Excluded: Not enough information`) in the output. Explanatory texts are usually provided in the clinical trial report.\n\n2.\nSince it is not possible for the patient notes to be read accurately, you must write them as a single column (separated with spaces). When you write patient notes, you should not distinguish the variables as they should be indifferent to you, for the sake of accuracy. If the output includes special symbols such as `,`,`/,` etc., the task is considered correct.\n\n3.\nYou must show all variables including the special character such as a comma (,) for the sake of accuracy. If some variable is not available for a patient record, you have to describe it explicitly as `Not available`. However, if you encounter some variables as `N/A`, it is considered wrong.\n\n4.\nYou should always end your trial-level eligibility with 2) Eligible because you cannot assess the eligibility without a trial.\n\nInstruction text for both training and test set are available at the [Google Document](https://docs.google.com/document/d/1lV6GQ7b2O0_xRp48T7vLWg1TZ6pwQ_Q9bB1kL8GdMwA/edit?usp=sharing). You can download and open the [Google Document](https://docs.google.com/document/d/1lV6GQ7b2O0_xRp48T7vLWg1TZ6pwQ_Q9bB1kL8GdMwA/edit?usp=sharing) to read the instruction text offline. We would like to ask for your kind understanding against us for providing instruction text to the user which is not publicly available due to personal privacy, professional and legal conflicts.\n\n\n## Submission\nAfter finishing the task, you are free",
        "label": 2
    },
    "225": {
        "output": "##<h4>CITUS-based workflow for clinical trials eligibility assessment</h4><h6>[EVALUATION.md] Running time in seconds [/EVALUATION.md] </h6>\nA clinical trial can contain many patients with clinical information (i.e., EHR data). Evaluation workflow shows the performance of `Trial-level eligibility` in terms of efficiency and scalability. Here is the description for running time in seconds: \nTotal running time for running `Trial-level eligibility` workflow for all patients in the trial. \n```python\nresults = pd.Series([\n    'Total Running Time(in seconds) for the trial',\n    'Total number of patients in the trial'\n])\n\nfor i in range(0, 8):  # run iteratively\n    for j in range(0, 10):\n        trial = patient_id(j)\n\n    # make data for a trial\n    data_trial = pd.DataFrame([\n        ['Age', 'Trial', 'Gender', 'Status',\n         ['BMI', 'Height', 'Weight', 'Asthma'],\n         ['Breast.cancer', 'Patient', 'Liver.disease',\n          'Bone.marrow', 'BM-blast', 'Cortical-reserve', 'Mueller.index', 'Albumin',\n          'Creatinine', 'Total.cholesterol', 'Aspartate-aminotransferase',\n          'Alanine-aminotransferase']\n        ],\n        ['Total # of variables: ' + str(len(trial.data)),\n         'Total # of patients in the trial: ' + i * 10 + trial.data.shape[0], '']\n        ],\n        pd.DataFrame([\n            'Trial-level eligibility'\n        ]))\n\n    # run Trial-level eligibility\n    trial_level_eligibility = run_TrialLevelEligibilityFunctions(trial=trial)\n\n    # merge trial_level_eligibility\n    trial_level_eligibility['Trial-level eligibility'] = trial_level",
        "label": 0
    },
    "226": {
        "output": "<EOD> Suggestions for clinical management of neurotoxic poisoning caused by oral ingestion of organophosphate pesticides\n\nNeurotoxic poisoning caused by oral ingestion of organophosphate pesticides (OPs) is a major burden on public health, especially in developing countries. With the frequent accidental or intentional ingestion of pesticides, the number of poisoning events has been gradually increasing. Severe acute poisoning with no specific therapy to rescue the nervous system may result in death in some cases. Therefore, clinicians need to be prepared to deal with these poisonings and need clinical care strategies to manage these patients. Based on a large number of clinical data and a comprehensive analysis of the literature, we have proposed suggestions for the clinical management of patients with OP poisoning to improve the prognosis of the patients by implementing prompt management within the first 24 h after the poisoning.\n\n# Background\nHumans can accidentally or intentionally ingest organophosphates (OPs), one of the most widely used chemical poisons in the world. OPs are commonly used as pesticides to combat insects, or in suicide or murder attempts in humans. OPs can cause many types of poisoning. The most serious case is acute neurotoxicity caused by the highly volatile and water-free OPs, characterized by an acute respiratory syndrome associated with impaired breathing rhythm, inability to control breathing, and severe respiratory failure eventually progressing to brain stem and central nervous system depression and death. A significant amount of literature has been published on acute poisoning resulting from OPs, mainly in relation to neurotoxicity. However, the majority of articles have been published by toxicology experts and focus on laboratory detection and mechanisms of OP neurotoxicity. There are few reports concerning clinical case management.\nHowever, the most significant factor to be considered in OP poisoning management is that the nervous system should be protected since the poisoning is an acute attack against the nervous system in the central and peripheral nervous systems. Thus, effective clinical management should focus on protecting the nervous system and controlling the symptoms. On the basis of our clinical practice and literature review (PubMed), we have summar",
        "label": 1
    },
    "227": {
        "output": "You are the first person to complete the training. You can see that it takes a lot to prepare the documentation (e.g., instructions, code, test scripts). Someone should be in charge of maintaining and fixing all of the documentation (e.g., bug reports sent via the Globig platform). We can help you with that (for example, contact [EMAIL]) if you are interested.\nIf you wish to keep track of the patient data, you can use the following link to access it: \n\nCongratulations, you have successfully passed Step 2!\n\n![INST]:https://docs.google.com/spreadsheets/d/1FQmfG0L3U_2Cm3JgqbJRdHo-6g4TvPZNKiMqVk76x0o/edit?usp=sharing&ouid=112331212250771823152&rlz=1C1CKJM_1,  (accessed on 7 March 2022))<EOD> The association between dietary fructose intake during pregnancy and pre-eclampsia: A systematic review and meta-analysis\n\nObjectiveTo investigate whether pregnant women with pre-eclampsia were exposed to more dietary fructose before and/or during pregnancy.MethodsThe Pubmed, Cochrane Library, EMBASE, and Medline databases were searched for relevant literature from 1990 to September 2016. We estimated the weighted means (WMs) and 95% confidence intervals (95% CI) of the dietary fructose intakes in normotensive and pre-eclamptic pregnant women. We then conducted a meta-regression to examine whether pregnant women with pre-eclampsia were exposed to more dietary fructose before and/or during the pregnancy; in addition, we calculated the overall average weighted means of dietary fructose intake for those included populations.ResultsA total of 1339 articles were identified, and nine of them with 891 pregnant women (135 diagnosed with pre-eclampsia) were included in",
        "label": 0
    },
    "228": {
        "output": "There are a couple of problems:\n\n\n*\n\n*the patient met the inclusion criterion (having received medication), but the exclusion criterion (having received cancer medicine) does not apply; \n\n*the patient does not have sufficient information to qualify for the trial (no smoking or alcohol consumption or sexually active); \n\n*the patient met the exclusion criterion (expertise as a clinical trial research assistant).\n\n**Think about how a recruiter might analyze the patient to answer the clinical trial question.**\n\n\n### Exercise 6 \n\n\n### Exercise 7 \n\nYou are working as a research assistant for a clinical trial where the inclusion criterion of patient is a diagnosis of breast cancer. The task is to assess patient's eligibility, the answer should be in a table.\n\n\n\n\n\n---\n\n**Do not copy anything including the table!**\n```ini\n[INST] Do not copy anything including the table! \n```\n--\n\n\n### Input\nHere is the patient's note: \nThe patient is a 53-year-old postmenopausal woman with cytologically confirmed invasive breast cancer. The tumor is 4 cm and ER positive and HER2 3+ positive\nHere is the clinical trial: \nTitle: Pain in Women With Chronic Ovarian Cancer\n\nAbstract:\nThere are several drugs for chronic pain, but the results are not very good and the risks of harm and dependence on the medication are very high. A new medication is in development and its efficacy and safety need to be evaluated by the patients.\n\nThe purpose of this study is stablish the efficacy and safety of this medication in chronic ovarian cancer patients.\n\nInclusion criteria:\nWomen.\nChronic ovarian pain for at least 6 months.\nMedication for chronic ovarian pain.\nNon-menstrual or noncyclic ovarian pain.\nAged over 50.\n\nYour task is to answer the question what the patient meets the inclusion criteria of the clinical trial.\nWrite your answer in the table below.\n\n| Age | Treatment | Location |",
        "label": 0
    },
    "229": {
        "output": "The example below shows the output of the above solution. \n#2018-05-26\nTrial-level eligibility: 0) Excluded\n\n## Step 2: patient-level eligibility\nYou already found that the patient is not ineligible. Next, you should judge whether the patient's characteristics match the eligibility criteria of the clinical trial or not. In fact, there are several patient characteristics in the clinical trial, so the number of the conditions in the expression is n. \nTherefore, it is a Boolean expression that consists of n conditions. The expression can be converted into a short code. In this case, the Boolean expression converts the expression using 19 ORs and 7 ANDs because `n1^n2^...^n7` means `n1 > 0 && n2 > 0 && \u00b7\u00b7\u00b7 > n7 > 0` in `Python^Python`. \n```python\n  def boo(x):\n    if x:\n      return \"true\"\n    else:\n      return \"false\"\n\n  19_or = []\n  7_and = []\n  1_multiply = []\n  1_plus = []\n\n  19_or.append(1) # Condition 1\n  7_and.append(1_multiply) # ANDed with 3\n  7_and.append(boo) # ANDed with 4 & 5\n  7_and.append(boo) # ANDed with 3 & 6\n  1_plus.append(1) # Add 1 to count\n  1_plus.append(2) # Add 2 to count\n\n  1_plus.append(3) # Add 3 to count\n  1_plus.append(4) # Add 4 to count\n  1_plus.append(5) # Add 5 to count\n  1_plus.append(6) # Add 6 to count\n  1_plus.append(7) # Add 7 to count\n\n  19_or.append(1) # Condition 2\n  7_and.append(1_plus) # ANDed with 3\n  7_and.append(boo) # ANDed with",
        "label": 0
    },
    "230": {
        "output": "Let's test the scenario in this case: \n[ELIG_TESTING] Hello, good morning. Would you mind taking a moment to talk to me? Thank you very much.\n\nMy name is XXX. I'm a research assistant here at XXX Hospital, where many patients are being treated with chemotherapy, radiation, and hormone treatments in combination with targeted drugs such as pertuzumab and trastuzumab. As you know, these drugs are used to treat breast cancer. You are a 45-year-old woman diagnosed with breast cancer. You agreed to undergo chemotherapy, radiation, and hormone treatments in combination with trastuzumab and pertuzumab. I found your name and address from the chemotherapy list we use. I would like to ask a few questions about breast cancer and your treatment so that we can make decisions about your care. Could we do that?\n[ACQ]\n\nYour test results show a positive HER2 status for breast cancer. HER2 (human epidermal growth factor receptor 2) is a unique breast cancer biomarker. Breast cancer that overexpresses a protein called HER2 generally has a worse prognosis. We often give antitumor drugs against HER2 to patients for whom these drugs are the most effective. These drugs are called targeted drugs, as they treat a specific cell protein that cancer cells depend on for survival. When we combine chemotherapy with targeted drugs, the overall effect of breast cancer treatment may be greater and the side effects of those drugs are minimal. It is very important to know the HER2 status when we determine treatment. We want to know whether you are overexpressing certain proteins (HER2), as this information helps your doctor tailor your treatment plan.\nThis study will compare the effectiveness and safety of different treatment methods, and see what is best for you. In this study, you will be randomly assigned either of the following:\nGroup A: combination of docetaxel, carboplatin, trastuzumab, and pertuzumab with radiation therapy (chemotherapy, trastuzumab, and pertuzumab + radiation therapy treatment)\nGroup B: combination of docetaxel, carboplatin,",
        "label": 0
    },
    "231": {
        "output": "## Tutorial\n### Run with `traceml_demo`\n1. `traceml_demo` (using C#/Visual Studio or IA and ML Studio)\n\n  2.26\n  2.25/2.26\n  2.22\n  2.24/2.26\n  2.00\n  2.10\n  2.08-2.20 #\n  \n  \n  1.2\n  1.3/1.12/1.3-2\n  3.2\n  1.4 #\n  \n  2.00\n  2.10 #\n  \n  3.3\n  1.2/3.6\n  2.2\n  2.2\n  1.0 #\n  \n  1.6\n  1.5 #\n  \n  2.3\n  2.4\n  2.20 #\n\n\n\n\n\n### Run with `R`\n\n1. `Run-to-learn ML-Demo`\n\n  2.26\n  2.25/2.26\n  2.22\n  2.24/2.26\n  2.00\n  2.10\n  2.08-2.20 #\n  \n  \n  1.2\n  1.3/1.12/1.3-2\n  3.2\n  1.4 #\n  \n  2.00\n  2.10 #\n  \n  3.3\n  1.2/3.6\n  2.2\n  2.2\n  1.0 #\n  \n  1.6\n  1.5 #\n  \n  2.3\n  2.4\n  2.20 #\n\n\n\n\n\n### Run with `Python`\n\n1. `python`\n\n  2.26\n  2.25/2.26\n  2.22\n  2.24/2.26\n  2.00\n  2.10\n  2.08-2.20 #\n  \n  \n  1.2\n  1.3",
        "label": 0
    },
    "232": {
        "output": "<EOD> The Surgical Management of Congenital Cystic Adenomatoid Malformation of the Lung: A Single-Center Experience of 73 Cases With 17.8 Years of Follow-Up\n\nThe aim of this study is to compare two surgical strategies for congenital cystic adenomatoid malformation of the lung (CCAM), including traditional thoracotomy and video-assisted thoracoscopic surgery (VATS).Between January 1998 and December 2015, a total of 73 patients were divided into four groups according to surgical strategy and age at operation. The clinical presentation, preoperative diagnosis, pathological diagnosis, associated anomalies, surgical strategy and operative data were analyzed. The follow-up method included telephone call, mail interviews, hospital reexamination, and physical examinations of the children.We collected data on 12 girls and 61 boys with the age of 0 to 48 months, and the median age was 4.5 months. The median weight was 3.58 kg (range, 1.44-12.00 kg). Forty patients were in stage I, 22 were in stage II, and 11 were in stage III. All patients survived. The mean operative time was 138.31 AE 9.41 min in VATS and 207.27 AE 16.93 min in thoracotomy. The mean estimated blood loss was 97.95 AE 27.82 mL in VATS and 259.47 AE 50.71 mL in thoracotomy. Significant differences were found between thoracotomy and VATS for the mean operative time (P < 0.001) and estimated blood loss (P < 0.001). A total of 73.3% of intraoperative air leaks were recorded in thoracotomy group. In VATS, two patients (7.1%) of patients underwent conversion to thoracotomy. However, there was no significant difference (P \u00bc 0.061). A total",
        "label": 0
    },
    "233": {
        "output": "```python\n# Include the \"try:\" block\n# If things fail, we only have two options: try again or quit :D\ntry:\n    res = sckit.evaluate_patient(patient_note)\n    print(res[1])  # print the first two columns on the screen\nelif res == -1: # patient note is empty\n    raise RuntimeError('Patient note is empty')\nelif res == -2: # nothing to do \n    print(\"[INST] You may quit!\")\nelif res == -3:\n    print(\"[INST] You may quit!\")\nprint(\"Trial-level Eligibility: {trial_level_eligibility}, patient's gender: {patient_gender}, patient's age: {patient_age_in_years}.\")\nprint(\"-----------------------------\")\nprint(\"A patient may be eligible in a trial...\")\n#printing some variables\nprint(\"... only when they meet the following specific inclusion criteria:\")\nprint(\"    Inclusion Criteria:\")\nprint(\"    -  The patient's diagnosis is malignant.\")\nprint(\"   -  Patients carry the BRCA mutation or have a relevant family history\")\nprint(\"    -  Patients have a hysterectomy on request\")\nprint(\"    -  There is no tubal occlusion\")\nprint(\"    -  Patients should be within a certain age range\")\nprint(\"    -  Patients should be within weight range\")\nprint(\"    -  At least patients can be without comorbidity\")\nprint(\"-----------------------------\")\n\nif trial_level_eligibility == 1:\n    print(\"[INST] Patient is included in the trial: Exclude\")\nelif trial_level_eligibility == 2:\n    print(\"[INST] Patient is included in the trial: Eligible\")\nelif res == -1:\n    pass\nelif trial_level_eligibility == 0:\n    print(\"[INST] Patient is Included in the trial: Eligible\")\nelif res == -2:\n    print(\"[INST] Patient is Included in the trial: Eligible\")\nprint(\"-----------------------------\")\n```",
        "label": 0
    },
    "234": {
        "output": "## Learning Objective #3: Evaluation on a case example\n\n**Evaluating a patient note on a case example** You should be able to write a code to evaluate a note on the provided case example. In addition, you should be able to explain your code and think about the correctness of your code. You should learn what are the rules of the problem. You should learn how to apply the codes to solve the problem. You should prepare a set of test cases.\n\n![](/inst/2019-10-20-case-example-1-1.png)\n[**(1.) Write a Python program to calculate the eligibility of the last patient note.(2.) Write a Python program to calculate the eligibility of the last patient note. Explain your code.**]\n\nThe task is to select the appropriate module and function from those you have learned to calculate the score. Then, you should prepare the test cases and the test script is your Python program. \n\n### Score 4 in the last patient note\n```python\n# your code here\nimport operator\nfrom operator import add\n```\n\n### Score 6 in the last patient score\n```python\nimport re\n# your code here\n```\n\nHere are the test cases. Note that you should check if this score is equal to 4 or 6.  \n\n```\n# test case 1 test_case_1 = [\"3\", \"C\", \"B\", \"I\", \"W\", \"Q\", \"U\", \"E\", ] test_case_1_score = 4\n# test case 2 test_case_2 = [\"3\", \"C\", \"B\", \"I\", \"W\", \"Q\", \"E\", \"U\", \"E\", ] test_case_2_score = 6\n```\nFor the solution (i.e., a method) to this problem, refer to the [solving task solution](/inst/2019-10-21-solutions.md/#solution-to-the-solving-task).\n\n### Score 4 in the last patient note\n\n```python\nimport operator\nfrom operator import add\n\n# your code here\nresult = operator.add('C', 40, 'U')\nprint('Score: {score}'.",
        "label": 0
    },
    "235": {
        "output": "<EOD> Genetic, molecular, and physical mapping of two genes which control glutamate and aspartate accumulation in maize\nA series of recombinant and nontuberous inbred (NT-is) lines have been used to position two genes which are involved in cation accumulation in maize on chromosome 9. The cation accumulation phenotype of this series of NT-is and their respective recombinants is determined quantitatively by the NT-i technique where the amount of accumulated cation is measured in a root-tip bioassay with germinating barley (Hordeum vulgare). Recombinant and NT-i lines exhibit three genotypes in this phenotype which correspond to the genetic loci t-3 and t-2 at the proximal, mid, and distal ends of chromosome 9. The most distal gene controls the accumulation of glutamate and aspartate. The glutamate/aspartate locus, designated agd1, produces two phenotypes: nonglutamate, which are amino acid free, and glutamate. The agd1 gene is located at the centromeric end of chromosome arm 9S in bin 8.6. The second gene, designated t-2, encodes the transport of cations from the root cells to the stele. The t-2 gene is closely linked to agd1. The three possible combinations of agd1 and t-2 produce two phenotypes: agd1-I-t-2 and agd1-t-2. This gene produces three phenotypes: agd1-I-t-2, agd1-I-t+, and agd1-t+. These genetic assays have been confirmed by physical mapping using molecular clones of restriction fragments flanking the genes agd1 and t-2.<EOD> Impact of the COVID-19 Lockdowns on Pediatric Cardiology Care in France: A Registry-Based Analysis of More than 25,000 Patients with Congenital Heart Diseases\nAbstract Introduction\u2003The 2021 COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (S",
        "label": 2
    },
    "236": {
        "output": "[/CODE]\n\n___\n\n## <a name=\"EligibleForTrial\"></a> Trial:<NAME>.<a href=\"../../../README.md#code-snippet\">_EligibleForTrial</a>.<NAME>.<a href=\"../../../README.md#code-snippet\">_EligibleForTrial</a>.<NAME>.<a href=\"../../../README.md#code-snippet\">_EligibleForTrial</a>. Eligibility for each trial:\n\nThe above snippet shows that you can call the \n<NAME>.<NAME>.<NAME>.<NAME>.<NAME> method that will print all the criteria for inclusion or exclusion in a trial. Notice that the method <NAME>.<NAME>.<NAME>.<NAME>.<NAME> accepts two parameters: the first one is one of 3 values, that is, `0) Excluded`, `1) Not relevant`, or `2) Eligible` while the second parameter is the name of the trial. You can use the method either inside the code of `code-snippet` or run the commands on the main menu of the app:\n\nTo repeat, the command that you should type is:\n\n```\nClinical Data -> Rules -> Run a Rule -> <NameOfTrial>.<a href=\"../../../README.md#code-snippet\">_EligibleForTrial</a>.<a href=\"../../../README.md#code-snippet\">_EligibleForTrial</a>.<a href=\"../../../README.md#code-snippet\">_EligibleForTrial</a>. Eligibility for clinical trial <NameOfTrial>.\n```\n\nThe results of the above command in the app appear in the following window: \n\n\n\n\n    Excluded\n\n    Not relevant\n\n    Eligible\n\n##\n\nYou can always repeat the above command by pressing the _Run a Rule_ button on the top menu, see _Run a Rule_ in the top menu of the app.  \n\n___\n\n## <a name=\"EligiblePatientsFOrTrial\"></a> NumberOfEligiblePatientsForTrial. Patients' numbers el",
        "label": 2
    },
    "237": {
        "output": "##[/MATH]\n\n### Task 7 \nWrite a program to output the frequency of each factor.\nExamples:\n![](/uploads/image/2018/a47d30ed10297e7399e62c160449d732/image1.jpg)\n[Ex1](https://github.com/Tanay-Mukherjee-7/clinical-trial-assistant/blob/master/examples/Task_7/Ex1.py) [Ex2](https://github.com/Tanay-Mukherjee-7/clinical-trial-assistant/blob/master/examples/Task_7/Ex2.ipynit) [Ex3](https://github.com/Tanay-Mukherjee-7/clinical-trial-assistan/blob/master/examples/Task_7/Ex3.ipynit) [Ex4](https://github.com/Tanay-Mukherjee-7/clinical-trial-assistant/blob/master/examples/Task_7/Ex4.ipynit) [Ex5](https://github.com/Tanay-Mukherjee-7/clinical-trial-assistant/blob/master/examples/Task_7/Ex5.ipynit) [Ex6](https://github.com/Tanay-Mukherjee-7/clinical-trial-assistant/blob/master/examples/Task_7/Ex6.ipynit)\n\n### Explanation:\nThe output of both these tasks is shown in the table below:\n\n|Task| Frequency|\n|:----:|:--------:|\n| Task 2 | 5 |\n| Task 3 | 3 |\n| Task 4 | 2 |\n| Task 5 | 2 |\n| \t| \t|\n|   Task 6 |  1 |\n| Task 7 | Frequency of each factor |\n|:   :   |: \t        |\n|   1 |     |\n|   2 |     |\n|   3 |",
        "label": 1
    },
    "238": {
        "output": "There are 6 cases in the training data set. Input your solution to each of them and submit the solution by pressing \"Send\".\n\n![Evaluation Cases](../img/Evaluation_Data.png)\n\n### Explanations\n\n\n\n### Explanations for solution 2\n\nIf you have submitted solution `2) Eligible` in all cases, then we find that your proposed solution is identical to the ground-truth.\n\n``` r\nprint(Trial_1_Inputs$Inclusion.criteria$Trial.Level.Eligibility)\n```\n\n```\n[1] \"\"\n```\n\n``` r\nprint(Trial_1_Inputs$Inclusion.criteria$Trial.Level.Eligibility)\n```\n\n```\n[1] \"2 # Eligible\"\n```\n\n``` r\nprint(Trial_2_Inputs$Inclusion.criteria$Trial.Level.Eligibility)\n```\n\n```\n[1] \"2 # Eligible\"\n```\n\n``` r\nprint(Trial_3_Inputs$Inclusion.criteria$Trial.Level.Eligibility)\n```\n\n```\n[1] \"2 # Eligible\"\n```\n\n``` r\nprint(Trial_4_Inputs$Inclusion.criteria$Trial.Level.Eligibility)\n```\n\n```\n[1] \"2 # Eligible\"\n```\n\n``` r\nprint(Trial_5_Inputs$Inclusion.criteria$Trial.Level.Eligibility)\n```\n\n```\n[1] \"2 # Eligible\"\n```\n\n``` r\nprint(Trial_6_Inputs$Inclusion.criteria$Trial.Level.Eligibility)\n```\n\n```\n[1] \"2 # Eligible\"\n```\n\n### Explanations for solution 1\n\nIf you've submitted `1) Excluded` in all of the six cases, then we find that your proposed solution is identical to the ground-truth. So, you passed.\n\n### Explanations for solution 3\n\nIn some of the cases, patients are not eligible for the trial",
        "label": 0
    },
    "239": {
        "output": "<EOD> Impacts for community health of a water and sanitation project in the Puno region of Peru-report of a multidisciplinary case study\n\nBackground: This case study was conducted to document the impacts for community health of a large water and sanitation project in the Puno region of Peru. A cross-sectional population survey and baseline study using the Health Equity Assessment Tool (HEAT) for Water and Sanitation was combined with a literature review and a stakeholder workshop to evaluate the project outcomes. Methods: A cross-sectional community survey was carried out among water users. The questionnaire addressed sanitation and hygiene improvements, user perceptions and quality of life changes, and water quantity and quality measurements. A systematic search of the literature on public health and health services related to community water supply was also undertaken. As the local HEAT tool was developed specifically to capture changes over time, the baseline study had to be repeated as part of the case study. During the stakeholder workshop in Puno in June 2016, key informants were interviewed and the results of the questionnaire presented and discussed. Results: The results confirmed that the water supply service in Puno had improved in terms of both quantity and quality in water supply, sanitation and hygiene, although the project did not achieve its original target coverage. The HEAT for Water and Sanitation demonstrated that there had been significant changes in quality of life and user perceptions. The stakeholder workshop highlighted that the impacts of the water and sanitation project for community health had far-reaching effects, influencing economic and food security, as well as access to education and health care. It was concluded that future water supply systems and associated health service initiatives need to be designed to ensure not just access to safe water and adequate sanitation, but also access to health care, education, and income-generation, in order to provide maximum benefits for communities. Conclusions: This is the first documented case study of its kind in Peru, providing evidence on the impacts for community health of a large water and sanitation project. There is a need for continued monitoring of the impacts of interventions, and continued refinement of the HEAT for Water and Sanitation in order to evaluate the impacts of WASH projects in resource-constrained settings.\n\n# Background",
        "label": 0
    },
    "240": {
        "output": "# Exercise: Clinical Trial Recruitment for Adenoma\n\n1.  Open a new Jupyter notebook and import the libraries:\n1.3.  Exercise: Clinical Trial Recruitment for Adenoma (Contributor 1) (contd.)\n\n[NOTE] All of the notebooks are saved in the repository, so it is recommended that you read the notebooks and look at the original notebooks first.\n\n1. Write the patient note.\n1.1. [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n\nA core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  ER and\n\n2.1. [INST] The clinical trial for adenoma is summarized as follows:\n\nTitle: Tumor Resection and Gliadel\u00ae Wafers, Followed by Temodar\u00ae With Standard Radiation or GammaKnife\u00ae for New GBM\nSummary: A glioblastoma (GBM) is the most common malignant primary brain tumor, yet it is not easy to control. Recent studies show that survival improves",
        "label": 0
    },
    "241": {
        "output": "# Trial-level\nIf you are not the main researcher who made up the trial and you need to evaluate a patient's eligibility for the trial, you need to run trial-level eligibility. It is similar to the step above but you need to indicate that it is the trial-level by ending the wording of the command, for example, `trial-level eligibility: 2) eligible.`. \n\n# Rename\nIf you wish to rename a trial that you are evaluating, you could use `rename: 'new trial name'`.<EOD> A systematic review and meta-analysis of the association of vitamin A status with stunting and anemia.\nBackground: Low vitamin A status is a global problem affecting most malnourished children and may have implications for growth and anemia.Objective: We aimed to assess whether there is an association between vitamin A deficiency and growth or anemia.Design: We conducted a comprehensive search of PubMed for studies evaluating the association of vitamin A and/or its biochemical status with growth or anemia published between January 1, 1990, and November 30, 2016. We included cohort and interventional studies comparing \u22652 measurements of either stunting or hemoglobin in children aged <5 y in association with vitamin A status and reporting prevalence or incidence ratios. In the meta-analysis, study estimates were pooled for both stunting and anemia. We measured heterogeneity using P value for Q and I2 statistic. Data were synthesized through a random effects model.Results: We screened 134 studies and included 18 studies (n = 7647 children) for meta-analysis . Vitamin A deficiency was statistically significantly associated with lower hemoglobin and stunting. However, there was no association found for the pooled incidence between vitamin A deficiency and anemia (IRR: 1.08; 95% CI: 0.8, 1.4).Conclusions: This meta-analysis suggests that, for children living in developing countries, low vitamin A status is associated with an increased risk of stunting and iron deficiency anemia.<EOD>",
        "label": 2
    },
    "242": {
        "output": "<EOD> P093\u2003Long COVID: An Interdisciplinary Experience Of Care For A Patient With Chronic Fatigue Syndrome On Long Term Prednisone\nObjective: To present the experience with the care of a patient who presented to our healthcare system in the spring of 2020 with severe and prolonged symptoms after SARS-CoV-2 infection and was determined to have chronic fatigue syndrome with multisystem involvement and significant need for glucocorticoids. In an ongoing effort to support the patient by the Infectious Diseases, Cardiology and Rheumatology services of our institution, the complex needs of both patient and family highlight the importance of collaboration within an interdisciplinary health care team. Clinical Presentation: In April 2020, a 46-year-old male with a medical history of hypertension developed severe symptomatic COVID-19 including dyspnea, confusion, and generalized rash that required admission to the hospital and intubation. Treatment with remdesivir was initiated; after 5 days, oxygen dependence resolved and patient was extubated. The patient progressed to fatigue, cognitive difficulties, and dysuria and was readmitted to the intensive care unit 8 days later. He was successfully weaned off all mechanical and non-invasive ventilation with the initiation of dexamethasone 8 mg IV every 12 hrs and remdesivir. He developed a generalized skin rash that improved with IV diphenidramine. After 7 weeks, patient was discharged home on non-invasive positive pressure ventilation, prednisone 20 mg daily, and tizanidine. The patient returned 18 days later with respiratory distress and was subsequently re-admitted to the hospital. He was again successfully transitioned to non-invasive ventilation, although he required prednisone 60 mg daily to control fatigue. Two days later, the patient experienced a sudden cardiac arrest. Resuscitative efforts were unsuccessful, and the patient expired. During the patient\u2019s second hospitalization, multiple tests were unrevealing. SARS-CoV-2 was not detected in blood and s",
        "label": 0
    },
    "243": {
        "output": "![INST] A successful run on a patient note. Here, the patient meets all three criteria for this clinical trial, and hence is labeled as 1) Eligible.\n\n\n[END INST] \n\n### Exercises\n* The following are sample patient notes provided by the platform (in CSV format): \n1. Clinical test.csv\n2. First follow-up test.csv\n3. Second follow-up test.csv\n4. Third follow-up test.csv\n* The following are sample clinical trials provided by the platform (in CSV\nformat):\n5. Sample clinical trial note.csv\n6. Sample clinical trial eligibility.csv\n<EOD> A Study of Physical Factors Acting on Man\n\nA Study of Physical Factors Acting on Man\nPh.DPh.DA Study of Physical Factors Acting on Man\nBostonMedical PressCopyright BostonMedical Press1902\nOwning to the very thorough manner in which Dr. Hartman has examined all the experimental data that has appeared in the literature, this book is of great value. It consists of a general introduction and thirty chapters, each chapter dealing with a special topic. The experiments are described in detail and are well brought out; and each one is followed by a discussion of general conclusions. He is of the belief that the human body tends toward homeo stasis and the return to equilibrium by its inherent forces. He explains, for example, the differences in results of experiments because of lack of uniform care of controls. The temperature reaction of the body to cold waves, and the effect of radiation on living tissues are explained satisfactorily, and the relation of the nervous system to all these changes.There are many other interesting chapters, dealing with radiation, exercise, air, baths, etc. The book is a valuable addition to the literature of physiology.<EOD> A review of the neovascular response to vascular-targeted nanomedicines and strategies to enhance its efficacy for cancer therapy\nIntroduction: The emerging paradigm in therapeutic approaches to cancer is to enhance the activity of anti-cancer drugs by using nanoformulations. Most such formulations are designed to achieve site-specific accumulation and preferential biodistribution in the target t",
        "label": 2
    },
    "244": {
        "output": "<EOD> .\nPermanent transplantation of parathyroid gland fragments into the anterior abdominal wall under the skin is suggested for long-term euthyroidism in patients who have undergone total thyroidectomy as a result of thyroid cancer or Graves's disease. The method is simple and can be carried out with minimum surgical trauma to the patient.<EOD> Assessing the cost effectiveness of community-directed treatment of onchocerciasis in areas where the disease is endemic and lymphatic filariasis is not endemic: the case of Tayllor's Hill community in Ghana.\nStudies published in the past decade have showed that the community-directed treatment (CDT) strategy is effective for the control of LF and onchocerciasis. This study was conducted to assess the cost of CDT and its economic value for the people at Tayllor's Hill community in Ghana. Two rounds of CDT of LF were carried out in the community between 2003 and 2006. Four different interventions were compared, including \"CDT of LF\", \"CDT of LF with CDT of onchocerciasis\", \"CDT of LF with LF treatment in health facility\" and the \"LF treatment in the health facility\". The cost-effectiveness was assessed as cost per parasitologically cured patient or cost per antibody seroconverted patient. The cost per parasitologically cured patient for CDT of LF was US$11.40, while the cost was US$9.98, US$4.75 and US$4.73 when CDT of LF with CDT of onchocerciasis was combined with CDT of LF, CDT of LF in the health facility and treating LF in the health facility respectively. The cost per seroconverted individual for CDT of LF was US$93.20, while the respective costs were US$85.93, US$62.10 and US$57.58 when CDT of LF with CDT of onchocerciasis, was combined with CDT of LF, and CDT of LF with CDT in health",
        "label": 0
    },
    "245": {
        "output": "<EOD> Enantiomycin A, an inhibitor of peptidoglycan biosynthesis from Pseudomonas sp. 101.\nAn extracellular antibiotic, enantiomycin A or peniciphenone I (1), was isolated from a culture of a Pseudomonas sp., strain PRR1. Enantiomycin I contains a tricyclic chromophore linked to a N-benzoated sugar. NMR, and X-ray analysis, in combination with elemental analyses and mass spectral studies, have shown that the chromophore is composed of alternating deoxysugars and amino acids. The inhibition activity of enantiomycin I was observed to be specific toward wall-defective mutants of several Gram-positive bacteria, inhibiting their growth as well as the incorporation of radioactively labeled UDP-N-acetylglucosamine and UDP-N-acetylmuramic acid into the cell walls. An antibiotic activity has been identified in 1,3-dihydroxybenzoic acid released readily by acid hydrolysis of enantiomycin I. This hydroxybenzoate compound was found to be active against peptidoglycan synthesis.<EOD> In vivo fluorescence of bovine retina and choroid.\nThe feasibility of fluores",
        "label": 0
    },
    "246": {
        "output": "Example:\nPatient ID: 27\nClinical Trial ID: 15\nAssessment ID: 16\nAssessment Score: 0\nTrial-level eligibility: 0) Excluded.\n\n\n# Results\nThe performance is illustrated below for 1100 patients. \n\n## Results using the R programming environment\n\n`library(pwr) #for power analysis rjags #JAGS package #JAVAScript interface for R functions rjagsData #The JAGS object must be placed into this object rjagsModel #The R function that produces the JAGS model object rjagsEval #The JAGS algorithm has to be called so that the fit parameters get evaluated rJAGSModel <rjagsData(jagsModel)$model <-rjags(data = clinicalTrialsData.10, n.iter = 50000, in.file = inFile, out.file = outFile, nchains = 5) #print a text file rJAGSModel #evaluate the model rJAGSEvaluationData <rjagsEval(rJAGSModel, in.file = \"inFile3\", out.file = \"output.txt\") $fit.data <-rJAGSEvaluationData$Fit.data$coefData #print the fit.data as table\n\n```\n\n## Results using the Python programming environment\n\n`#!/usr/bin/env python\n\n`import datetime\n\n`import json\n\n`,rjagsModel <rjagsData(jagsModel)$model <-rjags(data=clinicalTrialsData.10, n.iter=50000, in.file=inFile, out.file=outFile, nchains=5) #print a text file rJAGSModel\n\n\n`#evaluate the model\n#pyjagsModel <pyjagsModel #pyjagsModel <pyjagsModel.model.get_data(mode='get') # print the fit.data as table\n\n```\n\n# Discussion\n\nIn this case study the first step will be to run the clinical trial and to generate the clinical trial data. In this case there is no",
        "label": 0
    },
    "247": {
        "output": "A: I've made my own patient-specific version of a clinical trial and hope it may help you to understand the logic and the steps.\nLet's think about a simple case where a clinical trial is about a certain type of cancer. Suppose that a patient is suffering from a specific type of cancer. If the tumor is of this particular type, then we're going to test how the patient is doing. If the patient is doing well, then the tumor was actually that specific type (and the treatment was effective for the patient). If the tumor is not of that particular type, then the tumor is not the same type as the one that the patient was suffering from for which we are currently testing a treatment. Whenever we don't know what type of tumor the patient is suffering from, the clinical trial is not designed to treat the specific type of cancer and the trial cannot be used for any type of cancer.\nSo, based on the information that the clinical trial is given, we should be able to decide if the type of cancer that the clinical trial is testing actually is the same one that the patient is suffering from.\nThe actual clinical trial will be more complicated and more formalized, but you should get the idea.\n\nI've added a video for you :\nNote: This video uses some bad words, so it may be unsuitable for work.\nThere might be a better solution, but this simple analysis is how I do it  ;-) Maybe other people think differently and find this to be a waste of time, but hey: You asked for an example so I gave you one. The question is of course only a simplified example and does not use any sort of machine learning (which is a whole lot more complex than this example).\n\nA: There is no \"algorithm\" you need to implement.\nIf you are familiar with regular expressions then all you do is look at the regular\npattern \n^\n$\n^\n(\n^\n[a-zA-Z][A-Z][A-Z][a-zA-Z].*\n$\n)\n\nif the regular expression says 'yes' the clinical trial patient satisfies the clinical trial.\nAdapt the case of a negative \n^\n$\n^\n(\n^\n[a-zA-Z][A-Z][A-Z][a-zA-Z",
        "label": 2
    },
    "248": {
        "output": "I hope you have fun learning Data-Driven Business Intelligence [S1] with Python [S1]! Goodbye! (Honestly, if you enjoyed watching this video, please consider giving it a like. It's free and it'll help me make more videos.)\n[CID] A Simple Python Project\n[RM] Python in Depth: Decision Trees and Random Forests\n[S1] Data-Driven Business Intelligence With Python\n\n# - [RM] Python For Beginners: Decisions\n\n# Introduction\nYou know how to choose a value for randomization, so let's do that now.\n\n## Choosing a value\nYou'll need to choose 1 value for how many participants to randomize to each treatment group.\n\n## Which algorithm should I use?\nIt's a good idea to understand the difference between the two algorithms you'll be working with.\n\n## What's the difference?\n\n## Additive allocation algorithm\n- How you perform the randomization\n- What the outcome is\n\n## Random block allocation\n- Outcome is whether a patient gets the randomized treatment or not\n\n## Which random algorithm should I use?\nIf you have no more than 17 participants in each group, the random block allocation is the algorithm for you.\nIf you have more than 17 participants in each group, you probably want to use the additive allocation:\n\n## Random block allocation\n- Assign participants to each treatment group\n- Randomly choose a block size of 52, 104, or 156\n- Repeat until all participants are assigned either a random number, 1 or 2\n- Randomly choose a number between 1 and the block size (52, 104, or 156)\n- Repeat until all participants are assigned and we've run out of random numbers with 1 or 2 in the last decimal place\n\n## Additive allocation\n- First randomly choose a number between 1 and 2\n- Repeat until a number with an even number of decimal places is randomly chosen.\n- That's the number of participants in each group.\n- Now repeat but choose a number between 3 and 9.\n- Repeat until a number with an even number of decimal places is randomly chosen, followed",
        "label": 1
    },
    "249": {
        "output": "<EOD> C-reactive protein serum profile and severity of periodontal disease in patients with acute coronary syndrome.\nAIM\nThe aim of this work was to correlate the circulating profile of C-reactive protein (CRP) and the clinical indicators of severity of periodontal disease (PD) in patients with acute coronary syndrome (ACS), and to define the role of PD in the evolution of ACS.\n\n\nMETHODS\nA total of 100 ACS patients were studied. The PD assessment was based on the clinical parameters, probing pocket depth (PD), loss of clinical attachment level (CL), as well as the Gingival Index (GI) and the Gingival Bleeding Index (GBI).\n\n\nRESULTS\nThe PD and the GI-B correlated significantly (R = 0.32; p < 0.03) regardless of the clinical stage of the periodontal disease, while the GBI was in correlation with PD in moderate/severe periodontitis (R = 0.36; p < 0.012). The CRP levels correlated only with GI-B values (R = 0.27; p < 0.03) and, for a low level of significance, with the GBL-P (R =-0.21; p < 0.07).\n\n\nCONCLUSIONS\nThese data suggest not only a relationship between CRP and periodontitis, but also a role of PD in the evolution and recurrence of ACS.<EOD> Progesterone Inhibition of the Luteinizing Hormone Releasing Hormone (LHRH) Hypothalamic Neurons Is Regulated by Adenosine\nRecent studies have shown that progesterone plays a major role in the neuroendocrine regulation of the estrous cycle, particularly in the mediation of the LHRH surge. One such mechanism of action for progesterone is the inhibition of the tonic discharge of LHRH neurons in the external layer of the hypothalamic medial basal hypothalamus (MBH). However, the mechanism by which a steroid hormone (prog",
        "label": 0
    },
    "250": {
        "output": "In this example, the patient note is `breast carcinoma`, yet note that it is `breast' followed by a lower case `carcinoma`. The clinical trial is searching for the keyword `carcinoma`, so if we search by `breast carcinoma` the algorithm will find it and create an output of `2) Eligible.`. In the end, the algorithm looks for a triple `breast carcinoma` that matches the keyword `carcinoma` of the clinical trial, and the algorithm outputs 2 to show that the patient is eligible. \n\n\n> **Note**\n>\n> * A Trial-level exclusion includes a keyword surrounded by parentheses or curly brackets. If the keyword is not surrounded by parentheses, it will produce an inclusion (*matched the keyword in Trial-level inclusions*) and not an exclusion (*trial keywords in Trial-level exclusions are not found in the note*)\n> * A Trial-level inclusion includes the keyword surrounded by parentheses. It produces an inclusion when the keyword of the Trial-level exclusion is not found in the patient note\n\n### `breast carcinoma` `Trial level Eligibility Note: 0) Excluded \u270f `The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A cor ...` `breast` carcinoma`\n\n\n\n## Task 4: Create a note based on an inclusion criterion and a patient note `Title: A Feasibility Study for Women Receiving Anthracycline Chemotherapy With or Without Radiation for HER2-neu Positive Invasive Ductal Carcinoma Summary: The purpose of this project is to assess the feasibility of collecting plasma samples for cardiac biomarker assessment, and to identify if there is an associations between the biomarkers, echocardiographic features and the cardiac PET scan results (in patients receiving radiation therapy). This is the first step in a research program that has an overall goal of being able to predict early-treatment induced cardiotoxicity in patients with breast cancer.\n\nInclusion criteria:`Stage I-III, HER2-neu positive invasive ductal carcinoma Scheduled to receive adj",
        "label": 0
    },
    "251": {
        "output": "[TEST] Test:\n> from pytrial import Trial, Factor\n>\n> trial = Trial('Test')\n>\n> trial.Title = 'Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer'\n> trial.Summary = \"Study of the safety and effectiveness of Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0 - I Breast Cancer, sponsored by Indiana University School of Medicine\\n\"\n>\n> trial_study_name = 'Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer'\n>\n> trial.Exclusion_criteria = [\n> 'Tumor>1 cm, axillary or internal mammary nodes on imaging',\n> 'Diabetes with peripheral neuropathy or peripheral vascular disease to the lower extremities',\n> 'Major medical comorbidities prohibiting surgery & radiation',\n> 'Any medical condition/situation with an unacceptable risk to life or radiation-related complications',\n> 'Unstable or controlled hypertension',\n> 'Any significant psychological disease unrelated to cancer',\n> 'Breast implants',\n> 'History of radiation to the thorax or breast - with exception to radiation for recurrence of breast disease' ]\n>\n> trial.Inclusion_criteria = [\n> [0, 50],\n> [0, 80],\n> [0, 80],\n> [0, 1]\n> ]\n>\n> trial.Trial_id = \"nct03009293\"\n>\n> trial_df = pd.DataFrame([])\n>\n> trial_df['Trial_id'] = None\n> trial_df['Trial_id'] = str(trial.Trial_id)\n>\n\n\n> trial_df['Title'] =",
        "label": 0
    },
    "252": {
        "output": "You have to provide a JSON file. Do the following: \n\nFor the patient note JSON file:\nFirst of all, create a file named test.json. Then enter the following text: \n\"Patient\": {\n    \"ID\": \"test\",\n    \"first\": \"test\",\n    \"last\": \"test\",\n    \"gender\": \"f\",\n    \"age\": \"45\",\n    \"BMI\": \"22\",\n \"smoke\": \"no\",\n\"alcohol\": \"no\",\n\"sex\": \"f\",\n\"child\": \"no\",\n \"children\": \"no\",\n\"breast cancer\": \"yes\",\n \"axillary nodal\": \"yes\",\n \"breast cancer cytology\": \"yes\",\n \"breast cancer imaging\": \"yes\",\n \"breast cancer histology\": \"yes\",\n \"other cancers\": \"no\",\n \"family history\": \"no\",\n \"comorbidity\": \"no\"\n },\n \n\"treatment\": {\n    \"treatment start\": \"5 min\",\n    \"tumor location\": \"left\"\n  },\n\"treatment side\": \"left\",\n\"clinical trial\": \"RDA\",\n\"clinical study\": \"title\",\n\"clinical study status\": \"open\",\n\"clinical trial status\": \"interim\"\n } \n\nFor your clinical trial JSON file, create a file named trial.json. Then enter the following text: \n\"Patient\": {\n    \"ExclusionCriteria\": {\n        \"informed consent withdrawn or protocol violation\": \"yes\",\n \"age  age 45 years\": \"yes\",\n \"age  BMI 22 kg/m2\": \"yes\",\n \"gender female\": \"yes\",\n \"gender male\": \"yes\",\n \"age  45\": \"yes\",\n \"age  45\": \"yes\",\n \"age  45 years\": \"yes\",\n \"BMI  age 45 years\": \"yes\",\n \"BMI  BMI  25.6\": \"yes\",\n \"age  50\": \"yes\",\n \"age  54\": \"yes\",\n \"age  54 years\": \"yes\",\n \"",
        "label": 2
    },
    "253": {
        "output": "[/END]\n<EOD> .\nBACKGROUND\nThyroid cancer is frequently observed in patients with autoimmune thyroid diseases. To study the genetic background of carcinoma in these patients, we examined polymorphism of chromosome X and Y linked short tandem repeat (STR) markers.\n\n\nMETHODS\nThe patients with autoimmune thyroid diseases and carcinoma were 49 men and 112 women with ages of 19 to 78 (32, 40.2 \u00b1 13.7, +/- S.D.) and 29 to 70 (41.9 \u00b1 13.1), respectively. Their 98 partners were men with ages of 21 to 77 (36.5 \u00b1 12, +/- S.D.) and 64 women with ages of 25 to 78 (39.9 \u00b1 15.1).\n\n\nRESULTS\nMicrosatellite allele and distribution of 3 STR markers, amelogenin X-linked, vWA and DYF19S4 Y-linked, were examined in all participants and the same allele was observed in all partners. No patient was heterozygote. No allele was detected in 31 patients with thyroid carcinoma or partners with thyroid carcinoma.\n\n\nCONCLUSION\nAlleles of X-linked, amelogenin STR marker and Y-linked, vWA and DYF19S4 STR markers were identified in more than 90% subjects. Genetic background had been maintained in families with autoimmune thyroid diseases, both in male and female. On the other hand, alleles other than normal ones, had been observed in a part of patients with thyroid carcinoma, suggesting involvement of unknown mechanism in development of thyroid carcinoma.<EOD> Insect vectorial capacity for the Tomato yellow leaf curl virus is influenced by developmental biology\n\nBackground: The insect vector, which transmits a plant pathogenic virus, can determine the fate of the pathogen and the impact of the disease. Thus, studying the biology of the vectors is necessary to provide effective control measures and develop new strategies to protect a",
        "label": 2
    },
    "254": {
        "output": "### 3. \uc791\uc131 \ubdf0(Write View)\uc5d0\uc11c \uc0ac\uc6a9\ud560 \uc77c\ub828\ubc88\ud638\n\nThis view allows us to display a clinical trial (or multiple) by selecting particular clinical trials. The search parameters can also be adjusted by selecting the name of a user on the upper right hand side of the window. \n\n\n\t\n<h4 class=\"view-title\" style=\"background-color: rgb(62, 144, 255)\">Write View</h4>\n\t\n\t<!-- \uc774\uc804 & \ub2e4\uc74c\uc744 \ubcf4\uc815 -->\n\t\n<div id=\"write-clinical-trial-pane\">\n\n\t<!-- Create pane -->\n\t\n\t<div style=\"position: relative; width: 100%;\">\n\t\t\n\t\t<!-- Clinical trial pane -->\n\t\t\n\t\t<div class=\"write-clinical-trial\" style=\"position: absolute; height: 100%; max-height: 350px;\"></div>\n\t\t\n\t\t<!-- Pager -->\n\t\t\n\t\t<div class=\"view-pager\">\n\t\t\t\n\t\t\t<div class=\"view-pager-text\">Pages</div>\n\t\t\t<ul class=\"view-pager-list active\">\n\t\t\t\t<li class=\"view-pager-list-item\"><a data-active=\"current\" href=\"#\" class=\"view-pager-control\" tabindex=\"0\">Page 1 </a></li>\n\t\t\t\t<li><a href=\"#\" class=\"view-pager-control\" tabindex=\"1\">Page 2</a></li>\n\t\t\t\t<li><a href=\"#\" class=\"view-pager-control\" tabindex=\"2\">Page 3</a></li>\n\t\t\t\t<li><a href=\"#\" class=\"view-pager-control\" tabindex=\"3\">Page 4</a></li>\n\t\t\t\t<li><a href=\"#\" class=\"view-pager-control\" tabindex=\"4\">Page 5</a></li>\n\t\t\t\t<li><a",
        "label": 2
    },
    "255": {
        "output": "Remember a few points:\n- First, you need to define the eligibility assessment process.\n- If a patient is not eligible for the trial, then we should skip over the trial-specific assessment process, so an eligibility score of 0 is excluded (patient doesn't meet any inclusion or exclusion criteria). - You can use any assessment scale, as long as it is defined in a consistent manner. - Finally, you should always repeat trial-level eligibility in the last line by `Trial-level eligibility: `.\nHope you are successfully doing this exercise!\n\n[*MOST IMPORTANT]* This assessment is a good example of the eligibility rules. In addition to the eligibility rules, you need to consider some additional aspects of the study when you do the eligibility assessment. (e.g., study visits).\n\n[INST] Let's repeat the eligibility criteria from the clinical trial above with the additional aspects: \n\n![INST]\n\n![INST]\n\n![INST]\n\n![INST]\n\n![INST]\n\n![INST]<EOD> Clinical pharmacology and adverse reactions to intravitreal anti-VEGF drugs\nIntravitreal injection of anti-VEGF drug is now widely used in patients with macular degeneration. In this article we review the different molecular mechanism of action of intravitreal VEGF inhibitors, the systemic clinical pharmacology of intravitreal anti-VEGF injection, and adverse reactions reported with systemic therapy with intravitreal anti-VEGF agents. Because most anti-VEGF agents have very short systemic half-lives, the major concern with systemic absorption is the increased risk of systemic adverse effects. Some risks are associated with the procedure itself, such as endophthalmitis, retinal tears or detachments, globe perforation, and intraocular pressure elevation. Systemic adverse effects could affect both arterial (systemic embolism, cerebrovascular accident, myocardial infarct) and veinous (venous thromboembolism) circulations. Careful observation of patients and close monitoring of potential",
        "label": 0
    },
    "256": {
        "output": "[/EXH].<EOD> Interplay of the Cysteine Ligand to the Oxygen Intermediate Complex and the Cationic Hydrocarbon Residues of Phase II Detoxification Enzyme Erythrocyte Biliverdin Reductase\n\nThe cysteine ligand of the oxygen intermediate complex is crucial for catalysis by oxygen-evolving complex enzymes. However, similar importance of the sulfur ligand to oxygen is less known in other O 2 -binding proteins, such as the phase II detoxification enzyme Erythrocyte Bil-iverdin Reductase (BVR). To elucidate more about the roles of this ligand in BVR, we first modeled the BVR-Cu redox center based on the crystallographic structures of Flavodiiron proteins; then we constructed and tested a series of C122A/C124E substitution mutants. The results showed that the C124E substitution totally shut down the activity of BVR-Cu. The BVR-Cu with the C122A mutant retained the activity and absorption spectra similar to those of wild-type BVR. Furthermore, we found the C122A substitution notably decreased the stability of the BVR-Cu intermediates. Additionally, based on the molecular docking experiment, we found the residues of Arg53, Arg88, Lys111, and Arg112 in BVR-NADPH-L-Kynurenine complex were critical for substrate accommodation. Finally, a model of the BVR-Cu-NADPH-biliverdin intermediate complex was proposed, which could help elucidate the enzymatic mechanism of BVR-Cu reductase. Our findings provide the experimental evidence showing that the C122A mutants may be important for further exploration of the mechanisms of BVR-Cu reductase.\n\n# Introduction\nErythrocyte Bilirubin Reductase (BVR) is the first enzyme involved in bilirubin metabolism; thus, BVR is crucial for detoxifying heme as it catal",
        "label": 0
    },
    "257": {
        "output": "**Input**.\n\n\n![3](./Screenshot3.gif) \n\n[![Visio Image](./image1.png)](https://docs.microsoft.com/en-us/azure/office365-apps-get-started/index) [![Visio Image](./image2.png)](https://docs.microsoft.com/en-us/office-365/provisioning/deploy-your-app-using-the-quick-start-template?view=o365-pro-plan)\n<EOD> The Effect of Temporally Controlled Expression of TCR Transgenes on the Differentiation and Function of Na\u00efve and Memory CD4+ T Cells\nNa\u00efve T cells activated by T lymphocytic antigen recognized by TcR (TCR) undergo differentiation and acquire effector functions, but they do not fully differentiate into effector memory-like cells. When activated from memory T cells, they are ineffective in inducing a strong immune response. Na\u00efve T cells transduced with a TCR transgene (TCRtg+ T cells) show increased proliferation, differentiation, and cytokine secretion compared to wild-type (WT) T cells. In contrast, memory T cells expressing a TCRtg display a defective response to antigen stimulation. The aim of this study was to identify the developmental stage of T cells in which TCR transgene expression could be initiated to maximize the antigen-specific response. TCRtg+ T cells were generated by transducing Na\u00efve, Effector, or Effector Memory T cells with the TCR genes of OT-I (Na\u00efve C57BL/6-derived CD4+ T cells) or OT-II (Na\u00efve B6.PL-derived CD4+ T cells) TCRtg+ T cells. TCRtg+ T cells were also prepared by retroviral transduction of B6.PL mice. OT-II-expressing transgenic TCRtg+ T cells have a defect in proliferation and cytokine production, but the OT-I-expressing transgenic TCRtg+ T",
        "label": 0
    },
    "258": {
        "output": "In case of doubt, the [Trial note: INST] is the same, too.\n<EOD> Bone marrow mesenchymal stem cells promote aromatase expression and cell proliferation in theca cells by paracrine activation of the ERK/P38 signaling pathway\n\nThe pivotal role of aromatase in the local estrogen biosynthesis process is well established. Previous studies have suggested an indirect effect of bone marrow mesenchymal stem cells (BMSCs) on aromatase induction and subsequent androgen to estrogen conversion in ovarian theca cells (TCs). The regulatory factors involved in aromatase expression and the involved mechanisms have not yet been evaluated. To establish a system suitable for such study, we created a novel in vitro TC-BMSC co-culture system with the overexpression of the CYP19 gene in the TCs and examined its hormonal interactions. Expression levels of various genes were monitored using real-time reverse transcription polymerase chain reaction, aromatase activity was assessed by an indirect fluorescent antibody method and phosphorylation levels of the ERK and p38 pathway were determined. We showed that the co-culture of TCs and BMSCs led to a 3-fold increase in total CYP19 mRNA expression and a 17-fold increase in aromatase mRNA expression compared with the monoculture of TCs, suggesting a positive regulatory effect of the BMSCs on aromatase gene expression and activity. The mRNA expression and aromatase activity of the BMSCs and TCs were also significantly affected by the paracrine factors produced by the BMSCs and TCs. The signaling pathways involved in the BMSCs and TCs responding to the paracrine factors that caused the increased expression of aromatase were through ERK and p38. Our results provide strong evidence that paracrine interactions between the BMSCs and TCs via ERK and p38 signaling promote aromatase expression and cell proliferation. This work demonstrates that BMSCs promote and maintain",
        "label": 2
    },
    "259": {
        "output": "Note:\n\n[HISTOR] After the release of the first version of the book, the authors became aware of an error in the [INST] of the second task of the third chapter which led to the wrong output for the user's input. For version 1.0.0 the value of the `age` variable was evaluated against the input, which in an incorrect way led to the output. \nSince the first release version 1.0.0 as well as all subsequent releases we are publishing on this book, the respective code has been corrected. We apologize for this error. [/HISTOR]\n\n## [JOB]\n\n# The problem\n\nJessica is a busy resident physician. She is trying to keep up with the rapidly changing world of medicine. Recently, a physician presented her with a study published in The New England Journal of Medicine about intravenous fluid therapy in critically ill patients, claiming that crystalloids should be preferred over colloids. \nJessica has been reading research papers lately to keep herself up-to-date on the latest medical developments and techniques. She now feels she has to read the paper to determine if the results of this study should make any difference in her daily practice or if she should just ignore it. As a busy provider, she doesn't have much spare time and wants to get this as easy and quick as possible. \n\nFollowing the presentation and the discussion, Jessica decided to read the paper and see what she can learn about the latest research on intravenous fluid therapy. \n[JOB]\n\n[CONT] Her paperback is 44 pages. There are in total 8 tables in the paper, 5 tables within the article itself and three tables that are in the supplementary (relevant) material. The number of total references is 243. So her input data is the following:\n\nNumber of pages: 44\nNumber of tables in the text: 8 {i}\nNumber of tables in the supplementary material: 3 {i}\nNumber of references: 243 {i} \nWe are defining the input data by the symbols within curly brackets {\"i\"} and it is important to read these carefully. \n[CONT]\n\n## [PATR]\nWe should start by",
        "label": 0
    },
    "260": {
        "output": "# **Examples**\n\nExamination - Assigner and Assigned - [link to file](https://wakatime.org/viewer/file/YX1T2y2VJGvR/wakatime/610cb8154e865c423d4fa21b)<issue_closed>\n<EOD> Effect of 2,3,7,8-Tetrachlorodibenzo-p-dioxin on Pharmacokinetics of Halofantrine and Mefloquine in the Guinea Pig\nThe effect of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) on the pharmacokinetics of the antimalarial compounds halofantrine and mef loquine has been investigated in the guinea pig. TCDD (500 ng/kg body weight) was administered orally 14 days before oral administration of either halofantrine (60 mg/kg) or mefloquine (25 mg/kg). Plasma concentrations of halofantrine and mefloquine and urinary excretion of the respective metabolites were monitored for 24 h. TCDD treatment increased the maximum plasma levels of halofantrine and its metabolites by a factor of 2. It also increased the plasma AUC. Elimination of halofantrine and its metabolites was not affected by TCDD treatment. TCDD treatment prolonged the mean residence time of mefloquine and decreased the cumulative urinary mefloquine excretion by a factor of 2. The results are discussed in view of the reported induction of cytochrome P450 enzymes by TCDD.<EOD> Tetrahydrofuran and N-ethyl-2-(2-thienyl)acetamide Hydrobromide: A New NMDA Receptor Blocker with High Selectivity\nThe synthesis and structure of a new potential neuroprotective agent, N--2-(2-thienyl)acetamide hydrobromide (1), as well as its",
        "label": 0
    },
    "261": {
        "output": "# Exercise 3\n[CODE]\n# -*- coding: utf-8 -*-\n\n[MODEL Code]\n# +\nfrom pyspline import Pyspline\n# -\n\nclinicaltrial_data = load_data()\n\nclinicaltrial_assistant = ClinicaltrialAssistant(clinicaltrial_data) \n# +\npyspline_clinicaltrial_assistant = PysplineClinicaltrialAssistant(clinicaltrial_data)\n# -\n# +\nclinicaltrial_assistant.Trial-level_eligibility()\n# +\n\n# ## Exercise 4\n#\n# In this exercise, you will explore a number of Pyspline properties not covered already. A quick perusal of the Pyspline object documentation may be helpful.\n\nclinicaltrial_data = load_data()\n\nclinicaltrial_assistant = ClinicaltrialAssistant(clinicaltrial_data)\n# +\npyspline_clinicaltrial_assistant = PysplineClinicaltrialAssistant(clinicaltrial_data)\n# -\n\n# *\n# +\n# print(clinicaltrial_assistant.Trial-level_eligibility())\n# -\n\n# *\n# +\n# clinicaltrial_assistant.Trial-level_eligibility()\n# -\n\n# *\n# +\nclinicaltrial_assistant.Trial-level_eligibility(include_unselected_and_failed_in_prior_trial = True)\n# -\n\n# *\n# +\npyspline_clinicaltrial_assistant.Trial_eligibility_matrix()\n# -\n\n# *\n# +\npyspline_clinicaltrial_assistant.Trial_eligibility_matrix(include_unselected_and_failed_in_prior_trial = True)\n# -\n\n# *\n# +\npyspline_clinicaltrial_assistant.Trial_eligibility",
        "label": 0
    },
    "262": {
        "output": "You should input the three-scale assessment as `Trial-level assessment: [0] Excluded,` `Trial-level assessment: [1] Not relevant,`, or `Trial-level assessment: [2] Eligible.`.[INST]\n\n## Exclusion\nExclusion means the patient is not eligible based on the exclusion criteria. For example, someone's age range is younger than the minimal or older than the maximal inclusion age range, their disease status is different than the inclusion status, or they have previous medical history that makes them disqualified. \nFor instance, the exclusion status for a clinical trial may be `Exclusion status : not eligible`. \nYou should determine if the patient is ineligible according to the exclusion criteria based on the information that was inputted in the patient note. If the patient is ineligible, you input the exclusion status as `Exclusion status: excluded`.[INST]\n\n## Diagnosis\nDiagnosis means a label of a disease to be confirmed by the pathologist or clinician. The diagnosis label can be inputted as a string type in an extra variable. To extract the diagnosis label from the patient note, use the method named `getDiagnosis` in the Patient class.\n\n## Outcome\nThe outcome is a status of a health care service. To extract the outcome value from the patient note, use the method named `getOutcome` in Data. To store the outcome in the XML file use the field named `outcome` of the Patient class.\n\n## Gender\nPlease fill out the gender field for the patient. Options are `Female`, `Male`, and `Unknown/Not Applicable`. If you can not determine the patient's gender, or you are not sure, then write in `Unknown`; you can later specify more information such as `Transgender` to show it in the output. The gender of the patient was filled out the way you would like it to be shown in the output of the program. So, the output is 'Female' and 'Transgender' will be shown as 'Female' and 'Unknown,' respectively. [INST]\n\n## Country\nPlease fill out this field for the patient.\n\n## Smoking / alcohol\nPlease fill out these two fields for the",
        "label": 0
    },
    "263": {
        "output": "### EXAMPLE WITH CODES\n```\n<!DOCTYPE html>\n<html lang=\"en\">\n<head>\n  <title>Randomized Boost Versus no Boost Irradiation of Early Breast Cancer</title>\n  <meta property=\"og:title\" content=\"Randomized Boost Versus no Boost Irradiation of Early Breast Cancer\" />\n  <meta property=\"og:type\" content=\"article\" />\n<script src=\"https://code.jquery.com/jquery-2.2.0.min.js\"></script>\n<script src=\"http://code.jquery.com/ui/1.12.1/jquery-ui.js\"></script>\n</head>\n\n<body>\n\n<!-- Example 2 -->\n<div id=\"example2\">\n  <h3>Test Patient Note - <?= !$drug_patient_id ? 'Unable to identify drug patient note.' : $drug_patient_id ?? ''; ?></h3>\n  <p><?= $patient_note; ?></p>\n  <h3>Test Clinical Trial - <?= !$drug_clinical_trial_id ? 'Unable to identify drug clinical trial.' : $drug_clinical_trial_id ?? ''; ?></h3>\n  <p><?= $clinical_trial; ?></p>\n  <h3><?= $drug_clinical_trial_enrollment ? 'Patient enrolled in clinical trial?' : $drug_clinical_trial_enrollment ?? ''; ?></h3>\n<br><br><br>\n<script>\n  $(function() {\n    var example = $.makeElement(\n    '\n\n\n    <style>\n\n      body { font-family: 'Lucida Console', 'Lucida Sans Decorative', 'Lucida Sans', 'Lucida Sans Mono', 'Lucida Grande', 'Lucida Sans Text', 'Lucida Sans Regular', 'DejaVu Sans Mono', 'Lily Sans', 'DejaVu Sans SC', 'Bitstream Vera Sans Mono', 'Lazar",
        "label": 0
    },
    "264": {
        "output": "## [1](b) \n[b1] We will create a new data object named `patients`, which contains many columns like `id`, `family_name`, and `age`.\n\n[b2] Then, we will check all the patients based on our inclusion criteria. We can use `select` to get the columns of interest from the table. \n```python\npatients = pd.get_dummies(patients)[\"age\"].filter(patients==\"eligible\")\n```\n\n\n\n[b3] Let's think of how to make this. We want to get all the columns related to age, i.e., `age`, `age_cat_1`, and `age_cat_2`, from the patients. For this, the columns related to age will be filtered based on an age requirement of greater than 18 years old. We want the age to be greater than 18 for all the patients.\n\n```python\npatients[\"age_str\"] = patients[\"age\"].str.contains(@\"18,\")\n```\n\nThen, only those with the value of greater than or equal to 18 years will remain in the data frame. \n```python\npatients = patients['age_str'].filter(patients==\"eligible\")\n```\n\n```text\n    age_str  age  age_cat_1  age_cat_2  family_name  family_id  id\n0              18      18.5            17-18_yo  Female    -8 2139\n1              19      22             19_21_yo  Female  -6     457\n2              ADULT     ADULT            Adult  -6 28709\n3              ADULT     ADULT            Adult  -68 AD\n4              18      18.0            17_yo  Female    -2 27764\n5              19      22.0           19_yo  Female  -15    811\n...               ...          ...          ...          ...\n49              ADULT     ADULT            Adult  -3    43",
        "label": 2
    },
    "265": {
        "output": "<a href=\"https://data.mendeley.com/datasets/d3zj3twbj2/2\" title=\"Dataset 1\"><NAME] vs [NAME]: Clinical Trial Recruitment in Java</a>\n![Clinical Trial Recruitment](../assets/recruitment_2.jpg \"Clinical Trial Recruitment\")\n<EOD> Apoptotic Cell Death Is Required in the Cerebellum for the Development of Topographic Wireless Activity Patterns\nTopographic organizations of neural connections are hypothesized to arise when axons from different neuronal groups project to nearby dendritic fields. Such an \u201cemergent connectivity\u201d has been shown previously to emerge in networks of rat cerebellar Purkinje cells (PCs), which are reciprocally connected with their neighboring PCs via parallel fibers and to form a topological network. A similar PC-to-PC connectivity has recently been demonstrated in human cerebellar cortex, suggesting that this connectivity is common to humans as well. Nevertheless, it has remained unknown how the axonal projections in the developing PC network are established. In the present study, we examined the effect of apoptotic cell death on the PC network of developing rat cerebellar cortex, whose emergent connectivity is likely to parallel that in human cerebellum. After blocking apoptosis by intracerebroventricular administration of decoy oligodeoxynucleotide (ODN) bearing the anti-sens binding motif of Fas, the mutual contacts of the PC somata, parallel fibers, and dendritic fields on the postnatal day (P) 2 (6 days after ODN treatment) were found to be similar to those in wild type rats. In contrast, on P60, contacts between PC somata were significantly increased on the ODN-treated side. Immunohistochemistry demonstrated that, compared to wild type rats, ODN-treated rats had markedly reduced numbers of Purkinje-cell-specific interneurons (PCSIs) and Purkinje cell dendritic spines in the P60 cerebellum. Our results demonstrate the significance of apoptotic cell death in the establishment of topographic patterns of parallel fiber ax",
        "label": 2
    },
    "266": {
        "output": "We expect that you find your way to the solution without the hints. Good luck! [EXIT]\n<EOD> .\nOBJECTIVE\nTo investigate the clinical efficacy and the safety of anlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC).\n\n\nMETHODS\nClinical data of 20 advanced NSCLC patients treated with anlotinib from February 2016 to January 2017 were analyzed retrospectively.\n\n\nRESULTS\nAll patients had advanced NSCLC, including 15 men and 5 women, with a median age of 62 years (range, 38-80). All 20 patients had received first-line standard platinum-based chemotherapy plus or minus other target therapy, with disease progression prior to anlotinib treatment; 14 patients had received two or more lines of therapy, 5 with positive EGFR gene mutation, 19 harbored wild type EGFR. All patients received anlotinib 12 mg orally once a day (qd), and 3 received 10 mg qd. One patient used 8 mg qd due to the intolerable toxic reactions. After initial dose administration of anlotinib monotherapy, the drug-related adverse events of grade one to six were recorded in 19 patients, including three patients who occurred adverse events of grade three to four, among whom 11 patients had experienced hypertension, 2 of whom also with hand-foot syndrome, 8 patients had fatigue, 1 with decreased platelets, 1 with liver function damage, one with gastrointestinal bleeding, 4 patients had diarrhea. The treatment efficacy was evaluated according to the tumor response evaluation using RECIST 1.1, including complete response (CR), partial response (PR), progressive disease (PD), and stable disease (SD). Among all the patients, the overall response rate (ORR) was 35.00% (7/20), including 3 patients with PR and 4 with SD; the disease control rate (DCR) was 80.00%(16/20), including 9 cases with PR,",
        "label": 0
    },
    "267": {
        "output": "### 3.8) When the person declines participation, ask him/her for detailed reasons. Be sure to record your discussion on the patient record.\n\n[INST] If the person declines participation, thank him or her for time. Do not try to convince to participate, but instead thank her or him again and record your discussion on the patient record. \n\n### 3.9) Ask him/her, if he/she also has someone accompanying him/her to share the information with.\n\n[INST] If the person wants",
        "label": 0
    },
    "268": {
        "output": "[OUT] This is the end of the session. Congratulations on passing! You did it.\n<EOD> Effect of 1,5-anhydroglucitol (1,5-AG) on endothelial cells dysfunction: implications for diabetic nephropathy.\nOBJECTIVE\nIn previous study, we found that the administration of 1,5-anhydroglucitol (1,5-AG) improved the endothelial dysfunction of diabetic heart. The purpose of this study was to determine whether 1,5-AG could prevent endothelial dysfunction of kidney through improvement of glycemic control in diabetic animals.\n\n\nMETHODS\nRats were randomly allocated to either normal control group, streptozotocin-induced diabetic group (DM), and STZ-induced diabetic group with 1,5-AG administration (DM-AG) for 6 months. 1,5-AG was administered daily by intragastric administration (40mg/kg). Blood glucose and glycosylated hemoglobin (HbA1c) were measured at the end of the study. Renal artery flow and microvascular endothelium-dependent relaxation response were measured using Doppler flow meter and Doppler echocardiography respectively.\n\n\nRESULTS\nIn the normal control group, blood glucose levels were 5.12 \u00b1 1.0 mmol/L and HbA1c levels were 4.6 \u00b1 0.8%. After the induction of diabetes mellitus, blood glucose levels and HbA1c levels were respectively 15.7 \u00b1 3.9 mmol/L and 16.0 \u00b1 2.0%. When compared to DM, blood glucose level in DM-AG group was significantly lower (11.4 \u00b1 3.0 mmol/L). While HbA1c levels were not significantly different between DM-AG group and DM group. Compared with the normal control group, renal resistances were higher in the DM group (0.22 \u00b1 0.06, 0.45 \u00b1 0",
        "label": 1
    },
    "269": {
        "output": "Please download the following ZIP file which was used in the above code.\nTARGETED_IOTA.txt\n\n\n---\n### Exercise 2: Eligible or Not Eligible by Patient ID in the `patients_summary.csv` file\n\n[INST] Here, we try to determine to which clinical trial of the patient ID in `patients_summary.csv` file a patient belongs.\n\nPlease consider the following patient record. In this column `patientID`, the ID of the patient is shown. \n\nPatient ID : 7 \nFirst name             : Emily\nLast name              : Bromfield\nDate of birth           : 1993-09-12\nPatient ID: 30\nFirst name             : Alicia\nLast name              : Cream\nDate of birth           : null\nPatient ID: 31\nFirst name             : Carmela\nLast name              : Chambers\nDate of birth           : null\n\nHere are some clinical trial information. In this column `trialID`, the ID of the trial is shown. A clinical trial trialID is generated as shown in the example below:   \n\nFirst, let's compare the patient ID and trial ID in these 2 rows above the patient ID and trial ID: \n\nFirst row: `patientID: 7`,`trialID: 4`\nSecond row: `patientID: 30`,`trialID: 6`\n\nThen, we should check eligibility of clinical trials in these 2 rows. \n\nLet's use this sample code. \n\n```python\nimport pandas as pd\n\ndef patient_eligible(trialid, patientid):\n    # Check inclusion criteria\n    df = pd.read_csv(\"patients_summary.csv\")\n    trialId = df[\"trialID\"]\n    patientId = df[\"patientID\"]\n    # Create trial information by patient ID\n    trial_info = dict()\n    for trialId in df[\"trialID\"]:\n        trial = df[df[\"trialID\"] == trialId][[\"firstname\", \"lastname\", \"dateofbirth\"]]\n        patient_name = trial[\"firstname\"].",
        "label": 0
    },
    "270": {
        "output": "## [EVAL] Hello. You are the program to evaluate the eligibility of patients in a clinical trial. You are given a patient note and a clinical trial to perform the evaluation.\n\n[EVAL] Input both patient note and trial to the program, e.g., 48\\[INPUT\\] 09E7A3 01134528\n\nYou may use \\n as the new line for the program, e.g., 48\\n\\n09E7A3\\n0113\n\n\n\n# Result\n\nThe result of the program is as follows:\n48\\nInclusion Criteria: [01134528]\\nInclusion Criteria:[01134528] 1. Patient is 50 years or older (age must be >= 50 years\nfor trial enrollment)\nInclusion Criteria:[01134528] 2. Invasive ductal carcinoma of breast\nInclusion Criteria:[01134528] 3. Postmenopausal (menopausal status of women is defined by a period of 12 months of amenorrhea \n[228][229] \nInclusion Criteria:[01134528] 4. Breast cancer is locally advanced (Stage IIA\\2B or Stage III) (breast cancer tumor must be a minimum of Stage 2A, but not greater than Stage 3A)\nInclusion Criteria:[01134528] 5. Histologic grade of 2 or 3\nExclusion Criteria:[01134528] 1. Patient is under age 65 years (age must be <= 65 years for trial ineligibility)\nExclusion Criteria:[01134528] 2. Invasive lobular carcinoma (IHC result must be positive)\nExclusion Criteria:[01134528] 3. Lymphovascular invasion in initial core biopsy\nExclusion Criteria:[01134528] 4. Recurrent breast cancer (",
        "label": 0
    },
    "271": {
        "output": "<EOD> Effects of long-term low-dose alcohol intake on hepatic mRNA for a variety of glucose and fatty acid metabolic enzymes.\nLong-term studies have reported that ingestion of alcohol in low amounts does not lead to steatosis. We investigated 30 healthy men, who drank an average of 47 g of alcohol/day. Total cholesterol, triglycerides, 3-hydroxybutyrate, insulin, glucose, fructose, uric acid, and aminotransferase as well as alcohol concentration in serum, and fatty acid composition of erythrocytes and of the diet were measured. Liver samples were taken at laparoscopy to examine whether alcohol intake for long-term leads to changes in the mRNA levels of a variety of glucose and fatty acid metabolic enzymes by northern blot analysis. Although there was a significant improvement in insulin levels and glucose tolerance, no changes were seen in lipids, aminotransferase, glutamic pyruvic transaminase and glutamic oxaloacetic transaminase. Levels of SGOT and SGPT were within normal limits. We could only demonstrate a small increase in serum fructose for the study group. The mRNA levels of pyruvate carboxylase, phosphoenolpyruvate carboxykinase (PEPCK), fatty-acid synthase (FAS), and glucose-6-phosphate dehydrogenase (G6PDH) were not changed. However, mRNA levels of carnitine palmitoyltransferase, malic enzyme, and phosphorylase were significantly increased when compared with the control group. Therefore, in this study, we did not find evidence for the development of steatosis, although the mice with long-term alcohol exposure display a characteristic alteration in the fatty acid composition of their lipids. The different mRNA patterns of the animals with ethanol and the control are a consequence both of the altered diet and the prolonged alcohol intake.<EOD> 68Ga DOTANOC imaging in a patient with",
        "label": 0
    },
    "272": {
        "output": "## How to run the example of `clinical_trial`\n\n\n```r\n# This is the clinical trial note\nclinical_trial <- \"\n  The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n  \"\n\n# This is the clinical trial summary\nclinical_trial_summary <- \"\n  Summary: This study is to see how safe the use of short-term fasting is in breast cancer patients who will receive chemotherapy before undergoing surgery and to examine if the use of short-term fasting will decrease the side effects of chemotherapy and how much a tumor shrinks while receiving chemotherapy.\n  \n  Inclusion criteria: Inclusion Criteria:\n  <b>Patients \u2265 18 years of age with histologically, and radiographically confirmed non-metastatic breast cancer with minimal tumor size over 1 cm (\u2265T1c lesion) to receive neoadjuvant chemotherapy recommended by the treating physician\n  For estrogen receptor (ER) strongly positive, human epithelial receptor (HER2) negative breast cancer, Oncotype Dx study is required. Patients with low recurrence score will be excluded in the study.\n  Eastern Cooperative Oncology Group (ECOG) performance status score < 1\n  Absolute neutrophil count > 1500 mm3, platelet count \u2265 100\u00d7109 L, hemoglobin \u2265 8.5 g/dL\n  Serum creatinine \u22641.5 times the upper limit of the normal range, total bilirub",
        "label": 0
    },
    "273": {
        "output": "_**Exercise 3**_\n\n<img src=\"../images/2-3.PNG\"/> \n\n<EOD> Complementary and Alternative Medicine Use in a Pediatric Liver Transplant Clinic Population: A Retrospective Study.\nOBJECTIVES\nWith the rising popularity of complementary and alternative medicines in the general population, clinicians must be aware and vigilant regarding their use by children and adolescents.\n\n\nMETHODS\nA retrospective chart review of all the patients who were at least 11 years old who received a liver transplant at Children's Hospital of Alabama from 2005 to 2017 was conducted. Demographic and clinical information for all patients was collected. Complementary and alternative medicines/ remedies used by patients were analyzed to determine the frequency of use, types of complementary and alternative medicines/remedies used, timing of introduction as well frequency of use, and potential herb/drug interactions with conventional treatment regimens.\n\n\nRESULTS\nOut of 1103 transplants performed, 374 patients were at least 11 years old at time of transplant; 25 of these were eliminated due to lack of medical records or having inadequate information in the records. Out of 209 patients included in the study, 38 patients (18.23%) used complementary and alternative medicines/remedies. The most commonly used complementary and alternative medicines/remedies were supplements (3), meditation (4), chiropractic care (5), herbs (6), and spiritual/faith healing (25), respectively.\n\n\nCONCLUSIONS\nA majority of children and adolescents on long-term medications and chronic therapy used supplements, meditation, and alternative remedies without disclosure. In addition, there is need to have guidelines to help parents and caregivers understand the potential adverse effects and interactions of using these herbs with conventional therapies.<EOD> Effect and safety of nursing intervention bundle for critically ill neonates with sepsis: a multicenter randomized controlled trial.\nContext\nCritically ill neonates with sepsis are at high",
        "label": 2
    },
    "274": {
        "output": "Now, we can perform the first round of validation, which means you are expected to find the correct result and verify the output file.\n\n```\npython src/test.py\nTrial-level eligibility: 2) Eligible.\n```\n\nThe output indicates a correct answer that shows the patient meets the trial. [INST]\n\nIf the answer is incorrect, then we may check one of the clinical trial code. [INST]\n\nFinally, you can run the second round of validation. \nTo do this, you should check the accuracy of your code; the first round of validation will not be run. That is a time limit for the question and does not return a result. The code runs fine, but it seems to produce the wrong output. \n\n![result](../res/img/result.png)\n\nPlease also refer to a solution for each round of validation. [INST]\n\n[INST]\n\n# Contributing\n\n## Protocol Template\n\nEach question of the challenge provides a template protocol for writing the Python code. For each question, we will provide you three template files (protocol_part.txt, solution.txt and validation.txt). See  the [protocol_part.txt](src/protocol_part.txt) for the [first_question](first_question/README.md).\n\n# I'm done!\nThank you for following us and we're excited to see your submissions!\n<EOD> Acute kidney injury in children\n\nKidney International Reports (2019) 4, 644-648; https://doi.A c u t e kidney injury (AKI) is an important clinical syndrome that is defined by a sudden decrease in kidney function and commonly triggered by stress insults to the renal perfusion and tubular cell processes. This review summarizes the epidemiology of AKI in hospitalized children, its causes, and its diagnosis, management, and prognostic implications. AKI is a common complication of hospitalized children that affects ~36% of all pediatric admissions, many of whom have significant risk of progression to long-term dialysis dependence. The incidence of AKI is similar among inpatients of both the pediatric intensive care unit",
        "label": 0
    },
    "275": {
        "output": "### Question 5:\nYou are asked to choose the correct order of evaluation of criteria when using this feature. \n\n`Assessments -> Exclusion Criteria -> Inclusion Criteria`\n`Exclusion Criteria -> Assessments -> Inclusion Criteria`\n`Inclusion Criteria -> Assessments -> Exclusion Criteria` (CORRECT)\n`Exclusion Criteria -> Inclusion Criteria -> Assessments` (CORRECT)\n`Inclusion Criteria -> Exclusion Criteria -> Assessments` (INCORRECT)\n`Inclusion Criteria -> Assessments -> Exclusion Criteria` (INCORRECT)\n\n[/MULT]\n\n### Question 6:\nDuring clinical research, study site visits (also known as monitoring visit) are often necessary. In this question `Study site visit`:\nWhat is the purpose of conducting site monitoring visits?\nA.\nTo meet study goals by ensuring that all individuals with whom the researcher communicated, including, but not limited to, participants, study staff, consultants, and site personnel, are aware of the project's goals and activities.\nB.\nTo maintain study integrity and to support human subjects rights and protections.\n\nC.\nTo demonstrate the ability to comply with standards described in protocols, ICH-GCP-E6(R2), applicable regulations, and applicable standards when conducting clinical research.\nD.\nTo establish a baseline for data and operational processes to identify potential issues.\n\n\nE.\nANSWER: C (CORRECT)\nSite monitoring visits are an important tool to help ensure that the study is being properly conducted. They are also an opportunity to educate the staff on their role in protecting human subjects and ensuring the confidentiality of clinical research study material/records. \n\n# Question 7\n\n### Question 7:\nThe inclusion criteria of clinical trial have a four-point scale: 0 Excluded; 1 Not relevant; 2 Eligible; 3 Excluded with reason.\nIf trial criteria are assessed as three (0, 1, 2 and 3 respectively), you should enter the trial-level eligibility of this clinical trial as eligible.\nIf trial criteria",
        "label": 0
    },
    "276": {
        "output": "For more information on formatting and executing an i2b2 report, refer to the [i2b2 Report Specification](../../../specification/2015-04-08/).\n\n### Outputs\n\n``` json\n\"status\": \"OK\",\n  \"message\": \"Successfully executed with i2b2 version v3.1.2\",\n  \"results\": [\n    {\n      \"id\": \"trial_id\",\n      \"trial_name\": \"Test1\",\n      \"title\": \"Patient-level eligibility assessment\",\n      \"patient_id\": \"patient_id\",\n      \"patient_name\": \"Patient Name\",\n      \"primary_diagnosis\": \"Breast cancer\",\n      \"patient_age\": 45,\n      \"treatment_phase\": \"Screening\",\n      \"patient_weight\": 67.20,\n      \"gender\": \"F\",\n      \"gender_specific_age_range\": [],\n      \"gender_specific_age_range_low\": '',\n      \"gender_specific_age_range_high\": '',\n      \"treatment_start_date\": \"2018-05-30T00:00:00.000+00:00\",\n      \"treatment_stop_date\": \"\",\n      \"treatment_category\": \"Interventional\",\n      \"treatment_type\": \"chemotherapy and tumor resection\",\n      \"treatment_start_date_past\": \"\",\n      \"treatment_stop_date_past\": \"\",\n      \"patient_smoking\": \"no\",\n      \"patient_alcohol\": \"no\",\n      \"patient_sexual\": \"no\",\n      \"patient_gender\": \"female\",\n      \"patient_marital\": \"single\",\n      \"patient_child\": 0,\n      \"birth_location\": \"Santo Domingo, Dominican Republic, OCARC-2008-2792\",\n      \"birth_date\": \"2000-04-20T00:00:00.",
        "label": 2
    },
    "277": {
        "output": "#### : [* *](https://github.com/deep-ml/study/blob/main/_institution/03_problemsolving/chapter3/data/patient_recruitment.csv) [**README.md**](README.md)\n**Exercise**: Please give input to the file `patient_recruitment.csv`.\n#### : [* *](https://github.com/deep-ml/study/blob/main/_institution/03_problemsolving/python/patient_recruitment_py.py) [**README.md**](README.md)\n**Exercise**: Please write a script `patient_recruitment_py.py` according to instructions above.\n#### : [* *](https://github.com/deep-ml/study/blob/main/_institution/03_problemsolving/python/patient_recruitment_py_py.ipynb) [**README.md**](README.md)\n**Exercise**: Please write a script `patient_recruitment_py_py.ipynb` according to instructions above.<EOD> .\nIn a prospective randomized long-term study, an investigation was performed into the effect of the antioxidant drug idebenone in the treatment of chronic alcoholism. Of a total of 118 alcoholics participating in the study 63 were given idebenone additionally to the standard therapeutical regime, and 55 patients were given a placebo. The course of the alcohol syndrome was observed on the basis of various parameters (subjective assessment, objective assessment of alcohol dependence, biometrical evaluation, EEG) for up to 18 months. The assessment of the results showed that the antioxidant drug idebenone proved to be effective with respect to the various parameters used in the treatment of chronic alcoholism. Idebenone should be part of the therapy for ethylalcohol abuse.<EOD> Effect of the administration of prolactin inhibitory factor to women with postpartum lactation.\nFresh human milk contains a factor which suppresses the release of PRL and in vitro, it blocks the responsiveness",
        "label": 0
    },
    "278": {
        "output": "In the following section `Clinical trial code - 15656`, we show all the necessary data in the notepad. Copy the data and paste it as you normally do when you need to perform the eligibility assessment.\nNotepad: Patient eligibility:\n```python\n       \n        # MEDICAL CENTER\n        Patient name: \n            ID: \n            Sex: \n            Age: \n            Marital Status: \n            Children: \n            Education: \n            Socioeconomic Status: \n            Hand dominance: \n       \n        Patient notes\n            Patient Clinical Data: \n                HER positive:\n                ER / PR positive:\n                Lymphovascular invasion negative:\n                Tumor grade:\n\n        Eligibility:\n            Inclusion criteria:\n                Inclusion criteria 1:\n                    Title:\n                Inclusion criteria 2:\n                    Title:\n                Inclusion criteria 3:\n                    Title:\n                Inclusion criteria 4:\n                    Title:\n                Inclusion criteria 5:\n                    Title:\n                Inclusion criteria 6:\n                    Title:\n                Inclusion criteria 7:\n                    Title:\n                Inclusion criteria 8:\n                    Title:\n                Inclusion criteria 9:\n                    Title:\n                Inclusion criteria 10:\n                    Title:\n       \n        Clinical trial\n            Trial-level eligibility:\n                Excluded:\n                Not relevant:\n                Eligible:\n            Trial Criteria:\n                Exclusion criteria:\n                    Inclusion criteria 9:\n                    Inclusion criteria 10:\n                    Title:\n### HAPPY END\n```\n<issue_comment>username_5: This is really helpful! Thanks!\n<issue_comment>username_0: @username_5 Is there anything I can help you with? I know that every clinical trial that you are working with has clinical trial notes and eligibility assessment notes that you have to analyze. I hope that there is no need for you to spend time on that.\n<issue_comment>username_6: Hi @username_0  It is great",
        "label": 1
    },
    "279": {
        "output": "<EOD> The complete mitochondrial genome of Phrynocephalus putjatai (Sauria: Lacertidae)\n\nThe complete mitochondrial genome of Phrynocephalus putjatai (Sauria: Lacertidae)The complete mitochondrial genome of Phrynocephalus putjatai (Sauria: Lacertidae)\n10.1080/23802359.2019.1685296Received 31 August 2019 Accepted 2 October 2019MITOGENOME ANNOUNCEMENTmitochondrial genomeComplete mitochondrial genomePhrynocephalus putjataiLacertidaeSauriaChina\nThe complete mitochondrial genome of one specimen of Phrynocephalus putjatai from Fujian, China was examined in this study. This genome consists of 16,719 bp, including the complete control region, 22 tRNA genes, 13 protein-coding genes (PCGs) and two rRNA genes. All protein-coding genes are initiated by atp6 and cob. The stop codons TAA are absent in eleven genes (ATP6, ATP8, COXIII, CYTB, NAD1, NAD4L, NAD5, NAD6, NAD4, NAD2, and NAD3), TAA, TA, and T were found in the COI gene, while TAG, TTG, TA, and T were found in the ND2, COII, ND3, and ND4L genes, respectively.ARTICLE HISTORY\nLacertidae; mitochondrial genome; Phrynocephalus putjatai; Sauria Phrynocephalus putjatai is a small species of agamid lizard native to Central Asia, Afghanistan, Iran, Kyrgyzstan, Tajikistan, Uzbekistan, and northwestern China. Recent studies of P. putjatai in China are not available. In this study, we assembled and presented the complete mitochond",
        "label": 0
    },
    "280": {
        "output": "## What is the purpose of this assessment task?\nThis assessment task is intended to evaluate your ability to interpret and analyze clinical patient notes. You will assess trial-level eligibility using several features, such as clinical trial information and disease information of patients.\nYou will first understand the structure of patient notes. In this task, you will learn about the assessment of eligibility, which is a key concept of this assessment, at the level of clinical trials.\n\n# Step by step\nTo access [this assessment task](http://s3239.web.aplus.net/d/16553977/996282/16553977-20220513054844125.pdf), go to [this URL](http://bit.ly/2wbhF2K).\n\nIn this assessment, we are providing three [clinical trial notes](https://docs.google.com/document/d/16553977/edit?usp=sharing).\n\n\n## Instructions\nThere are 3 clinical trial notes for this assessment.\n\n# Interpretation of patient notes:\n1. You are expected to demonstrate your ability to interpret clinical trial patient notes through trial-level eligibility assessment.\n2. Read each patient note and try to determine the patient's suitability for participation in this study by evaluating whether the patient meets the trial eligibility criteria.\n3. Write your trial-level eligibility assessment after reading each patient note.\n4. In this task, we are also providing the clinical trial information of the studies. You should use it for the case of 'eligible, not relevant' cases where there is lack of information about a patient.\n\n# Submission\nAfter writing your assessment, submit it to [Asses-sment1.GoogleForm](https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrHxA4tCOc/viewform?usp=sf_link) by [clicking on this link](https://",
        "label": 0
    },
    "281": {
        "output": "Here are the rules:\n\n\n\nTrial-level eligibility: Excluded if at least one of the exclusion criteria is met.\n\n- Exclusion criteria:\n   \n   1) Previous mastectomy.\n   2) Breast cancer is not the only cancer in the body.\n   3) Other cancers, such as leukemia.\n   4) History of malignant tumor in the past 5 years.\n   5) Lack of interest in treatment and lack of motivation to participate in a trial.\n\n    Other exclusion criteria:\n   \n   1).1) Breast cancer was diagnosed 3 months ago or less.\n   1).2) Current pregnancy (within the last 6 months) or planned pregnancy in the next 2 years.\n  \n   2).1) The patient is not able to take the medicine by mouth.\n   2).2) The current or planned pregnancy (within the last 6 months) or planned pregnancy in the next 2 years.\n\nLet's try to do it step by step.\n\nTo do the task:\n\n1.  Copy the file `Trial_Clinic1_patient_note.pst`.\n2.  Open the file in the Text Editor (Notepad).\n3.  Look at Figure 1. The patient note has 4 parts:\n\t* [PART-A]: General information.\n\t* [PART-B]: Exclusion criteria.\n\t* [PART-C]: Inclusion and exclusion criteria.\n\t* [PART-D]: Details of breast cancer.\n\t* You will find information about each part as follows:\n\t  - [Part-A]: General information.\n\t   * The age of the patient in years is at the top of the page.\n\t   * A medical condition in this patient note is \"candidate for tumor resection\".\n\t   * An exclusion criterion is \"has breast cancer\".\n\t   * A medical condition in this patient note is \"breast cancer\".\n\t  - [Part-B]: Exclusion criteria.\n\t   * Only one exclusion criterion is found here: \"History of malignant tumor in the past 5 years\".\n\t  - [Part-C",
        "label": 0
    },
    "282": {
        "output": "[INST]\nHello. You are asked to predict the trial-level eligibility for new patients. You should predict the trial-level eligibility of the patients for clinical trial in the patient-level prediction phase. \n\nThere are six patients. Here is the patient-level data:\nHere is another patient-level data:\nWe will present the following variables in the patient-level prediction phase: \n\nPatient gender: male, female, both, or unknown\nPatient age: 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9, or 10, 11, or 12\nPatient race: Black, Hispanic, Caucasian, API or Pacific Islander, or Other or Unreported\nPatient marital status: Never Married, Married, Widowed, Divorced/Separated, or Unreported\nPatient insurance status: Medical Insurance, No Medical Insurance, other, and Not Specified\n\nPatient stage: Stage I, II, III, or unreported\nPatient smoking status: Current, former, never, or Not Specified\nPatient alcohol status: Regularly drinking, less than 1/wk, 1-4/wk, 5 or more/wk, former drinker, and Never drinker\nPatient disease: lung neoplasm, prostate neoplasm, colorectal neoplasm, breast neoplasm, hematopoietic and lymphoid neoplasm, bladder neoplasm, renal cell carcinoma, ovarian neoplasm, or other and unreported disease\nPatient tumor number: 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9, or 10, 11, or 12\nPatient tumor size: <= 3 cm, > 3 cm, Unreported, or Not Specified\nPatient chemotherapy type: 1st generation cytotoxic chemotherapy (e.g., vincristine, mitomycin-C or doxorubicin),",
        "label": 0
    },
    "283": {
        "output": "if  can_see_patient?(:in_test) && patient.clinical_trial\n      @patient_level_note = patient.clinical_trial.notes.build do |n|\n        n.event = @patient\n      end\n    end\n      @patient_level_note.update_trial_eligibility\n\n    if can_see_patient?(:in_test) && !patient.clinical_trial\n      # Create a trial eligibility note for the clinical trial.\n      @trial_level_note = Trial::EligibilityNote.new(@trial, patient)\n      @trial_level_note.update_trial_eligibility\n    end\n      # Create a trial recruitment note.\n      @patient_level_note.update_clinical_trial_status.recruitment.update(:started_at => Time.now)\n      send_mailer_report @patient, @assistant_record\n\n    if can_see_patient?(:not_in_test) && patient.clinical_trial\n      # Create a trial note here if the patient has clinical trial data.\n      @patient_level_note = Trial::EligibilityNote.new(@trial, patient)\n      @patient_level_note.update_trial_eligibility\n      @trial_level_note = TrientNote.build(:start_time       => @patient_level_note.start_time,\n        :assigned_to_id    => @patient_level_note.assigned_to.id,\n        :clinical_trial_id => @trial,\n        :eligibility_note_id => @patient_level_note,\n        :target          => @clinical_trial.target)\n      @trial_level_note.update_trial_eligibility\n\n      # Create a trial recruitment note.\n      @pat",
        "label": 2
    },
    "284": {
        "output": "If you need to change the patient ID, use `patmentID = [id_of_new_patient];`. [INST]\n\nA trial-level-eligibility output from the `patpat` command is as follows:\n\n    Trial-level eligibility: 2) Eligible.\n\nAnd if you change the patient-level status to excluded using the `patpat` command, you will obtain the following:\n\n    Trial-level eligibility: 1) Not relevant.\n\n## Example 3. If you want to change the status of all patients:\nIt is possible to change the status of all patients (patpat), but you must provide a patient ID or a list of patient ID(s) along with `patpat = <patientList>`, otherwise it will print an error message.\nFirst, let's analyze all the patients from the trial. If the patients do not match the trial, you will receive the error message in the first line. Then we can see that seven patients are in the trial.\n\n    > trial-patient-summary-statistics-and-censoring -d -r <id_of_patient_or_patients-list-of-patients-id> --patient-id <patientID_id_of_patient_or_patients-id-list> --output-to <outputfile-file> -v <verbose_mode> -r -e -s -c --output-table=\n    ******************************************************************************\n    * Error: Patient ID=xxxxxx008 was not found in the trial record ID=2016_201_12-4145-00-ABR.\n    ******************************************************************************\n    Trial ID: 2016_201_12-4145-00-ABR\n    Patient ID: xxxxxxx008\n    Eligibility:\n    # Status: Excluded\n    Trial-level eligibility: 1) Excluded.\n\nNext, we change the status of all of the patients, but they are different patient IDs. You will receive errors (we have to use 9 lines for `patpat = <patid_patients",
        "label": 0
    },
    "285": {
        "output": "```\n\n\n<EOD> Fixed-dose combination of tenofovir+lamivudine-efavirenz among antiretroviral-na\u00efve HIV-infected patients at South Indian Centre\n\nBackground: A retrospective study was conducted to assess the virological efficacy, safety and tolerability of fixed doses combination (FDC) of tenofovir + lamivudine + efavirenz (TDF+3TC+EFV) among antiretroviral treated na\u00efve HIV infected patients to see the virological efficacy at 1 year, 2 years, and 3 years follow up.Materials and Methods:Patients were included in the study on the basis of inclusion and exclusion criteria. They were followed up for monitoring clinical, laboratory parameters. Virological efficacy was assessed with repeated CD4+ count at 1 year, 2 years, and 3 years. Adverse events, any clinical symptoms, and drug interactions were notified to the treating physician.Result: A total of 708 patients were included in the study and among them 577 and 131 were male and female patients, respectively. CD4+ count was increased in",
        "label": 0
    },
    "286": {
        "output": "## Summary\nFit the patient onto the clinical trial\n<EOD> .\nThe authors report a case of an aneurysm of the superior longitudinal fissure of the medulla oblongata which was an incidental radiologic finding (CT scan). The anatomo-clinical features and current concepts in this pathology are discussed, and the rare incidence of the location of an aneurysm of the superior fissure and of an aneurysm, in general, are reviewed with the possible relationship with an atrophy of the medullary pyramids.<EOD> Intraocular lymphoma.\nThis report is the fifth in a series of articles regarding intraocular malignancy in the eye, particularly lymphoma, melanoma, and sarcoma. In this report, we review recent updates in the biology and clinical behavior of intraocular lymphoma (IOL) and consider the treatment of primary and secondary (intraocular dissemination of systemic disease) IOLs. Finally, we discuss our institutional experiences with IOL patient care and propose recommendations for the care of patients with primary and secondary IOLs.<EOD> Immunoglobulin G 3 Immune Complexes Elicit Toll-Like Receptor 4-Dependent and Toll-Like Receptor 4-Independent Activation of Macrophages1\nPrimary immunization with tetanus toxin results in the generation of significant amounts of immune complexes within the serum of human volunteers. Immune complexes, but not tetanus toxoid alone, induced TNF-\u03b1 and IL-6 secretion in macrophages in a TLR4-dependent fashion. FACS analysis of macrophages revealed that Ag-containing immune complexes triggered significant, rapid, and durable phenotypic alterations in the expression of Fc\u03b3RI, Fc\u03b3RIIa, CD16, CD36, and HLA-DR. Fc\u03b3Rs and CD36 appeared to be involved in the internalization of the immune complexes and subsequent activation of phospholipase D, a previously reported mediator of TLR4-triggered TNF-\u03b1 release. We also demonstrate that the immune complexes trigger activation of the TLR3",
        "label": 0
    },
    "287": {
        "output": "<EOD> MON\u2010443 CLINICAL PICTURE OF HYPERANDROGENISM IN FEMALE TWO INCIDENTAL CASES HARBORING ULTIMATELY\u2010FOUND MICRODUCTS\n\nMortality risk assessment for incident patients, particularly in elderly patients and older aged subgroups, has never been investigated. We sought to elucidate mortality risk of incident hyperparathyroidism in different age groups.Method: This population-based study was carried out in an area that covered a population of >1.5 million between 2001 and 2017. Incident cases of hyperparathyroidism were identified, and the first day of diagnosis was defined as an index date. The date of death was used to define outcome events. Patients who were diagnosed of hyperparathyroidism within one year were excluded. Incidence rate, mortality rate, standardized incidence ratio (SIR), and standardized mortality ratio (SMR) were compared between patients with hyperparathyroidism and local general population. Moreover, age subgroups-including patients younger than 40, 40-49, 50-59, and 60-69 years old were compared and evaluated.Result: A total of 543 patients (mean age at diagnosis (standard deviation): 56.1 (13.9) years old, 90.5% females) were enrolled. Compared with the local population, the incidence rate of hyperparathyroidism was lower in patients < 40 years old, and higher in patients 50-59 and 60-69 years old (p < 0.001). SIR and SMR in patients younger than 40 years were 0.29 (95% CI, 0.06-1.29) and 0.20 (95% CI, 0.02-2.93); in patients 40-49 years old, they were 0.91 (95% CI, 0.73-1.12) and 1.00 (95% CI, 0.76-1.33); in patients",
        "label": 1
    },
    "288": {
        "output": "The `Trial-level eligibility` field is an optional field.\n\n## 3) Initiate clinicaltrial\n[INST] Initiate a clinical trial.\n[TRIALS] Name. Clinical Trial Name\n[TRIALS] Description. Description of an intervention or interventions to compare.\n[TRIALS] Trial Arm Codes. A list of arm codes for individual trial arms.\n[TRIALS] Arm Name. Name of a trial arm.\n\n[INST] Conclusions. `Please conduct a trial for breast cancer recruitment.`\n[INST] End.\n[INST] Author(s). `Myunghee Bae \n\n## 4) Save the clinical trial by using the `save` button\n[INST] Click to launch the `Launch` menu and run the command: `Save:`\n[INST] Once a trial has been saved, multiple copies of the trial can be created. The trial will be copied to the following locations specified by its name:\n`/opt/conda/lib/python3.6/site-packages/stormic/stormic/trials/`\n`/home/stormic/stormic/trials/`\n[INST] Check the location of the saved trial(s).\n\n## 5) Delete the clinical trial.\n[INST] Run the command: `Delete: `\n[INST] Please follow the following steps.\n\n[INST] Click to launch the `Save menu and run the command: `Back and Next: `\n[INST] Open a file dialog.\n\n[INST] Click to save the file: `stormic-clinical-trial-template.py`.\n[INST] Open `~/.stormic/stormic.json`.\n[INST] Scroll to the `saved_trials` variable and remove all entries for the trial you want to delete from this location.\n[INST] Run the command: `Save:`\n[INST] Go to the `stormic-clinical-trial-template.py` location and run the command: `python stormic-clinical-trial-template.py -c delete`.\n\n## 6) Assess eligibility.\n[INST] Run the command: `Ass",
        "label": 1
    },
    "289": {
        "output": "![Trial-level eligibility][Trial-level eligibility]\n\n### Criteria\n\nThe criteria are the qualifications a patient must possess to be eligible for the trial.   \nOn individual criteria, the comparison is as follows:\n\n\n[Clinical note]:\n- Compare the patient's condition with corresponding criteria values:\n    - If they match exactly, go to step 6.\n    - If they match partially, go to step 4.\n    - Otherwise, go to step 7.\n\n[Trial]:\n- Go to last criterion, and compare the matching value with the corresponding criterion value:\n    - If values match, go to step 5b; otherwise, go to step 5c.\n    - If there is no value, go to step 6.\n    - If the condition of the current criterion and the trial is not match (e.g., there's missing value of trial), go to step 7.\n   \n   \n   \n\n[Step 4]:\n- Go back to last checked criterion.\n    \n- Compare the present state of the condition of the patient with the corresponding allowed value. If a criterion matches partially, go back to [Clinical note][Clinical_note]\n  [Step 5]\n[Step 5a]:\n- Check if the conditions of all criteria match exactly. If yes, the patient is eligible, end the analysis.\n[Trial-level eligibility: 2) Eligible.]\n[Trial-level eligibility: 2) Eligible.]\n\n<h3 id=\"example\">\nExample\n</h3>\n\n{% raw %}\n```\nINST: Hello. \nyou are a helpful assistant for clinical trial recruitment. \nYour task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. \nINST: The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is ex",
        "label": 0
    },
    "290": {
        "output": "<EOD> A randomized comparison of prophylactic ciprofloxacin and amikacin in prevention of postoperative infectious complication in patients undergoing cardiovascular surgery\n\nObjectives Prophylactic antibiotics have been used since the first reported successful cardiac surgery. There is no agreement on the best choice of antibiotic prophylaxis, but the optimal antibiotic and its duration of prophylactic use was studied previously based on the severity of cardiac surgery. Ciprofloxacin and amikacin were administered to patients undergoing cardiovascular surgery to compare the efficacy of the antibiotics in preventing postoperative infectious complications. Methods Sixty patients scheduled to undergo cardiovascular surgery from April to September 2009 were included. The patients were randomly assigned to two groups and received single 1500 mg dose of ciprofloxacin or single 300 mg dose of amikacin intravenous infusion 2 h prior to the surgery for prophylaxis. The patients were observed for 24 h and then followed up over 30 day postoperatively to record any postoperative complications. In addition, the following parameters for efficacy of the chosen antibiotics were recorded: white blood cell count (WBC), serum level of (C-reactive protein, CRP), erythrocyte sedimentation rate (ESR), and total body temperature. Results There was no significant difference in the general characteristics of the patients. There was no significant difference between the two groups according to the recorded infection rate. No significant difference was observed between either group according to the CRP, ESR, and temperature. WBC count was significant difference between both groups (P < 0.001). Conclusions Prophylactic ciprofloxacin and amikacin were effective in preventing complications following cardiovascular surgery.\n\n# Introduction\nCardiovascular surgical procedures are being recognized with a major source of bacterial infectious complications [bib_ref]  Risk of prosthetic joint infection and time since surgery in patients using..., Dorn [/bib_ref] .",
        "label": 1
    },
    "291": {
        "output": "In our example, the result is 2.\n\n**Instructions for the second exercise are given below:**\n\n**First Problem:** Evaluate the patient's eligibility and output it in a report. Note that in the example, our trial-level eligibility result is 1). It means that the patient is not included in this trial as eligible. Let's go step by step. \n1. Exclude.\n2. Not relevant.\n3. Eligible. \n\n**Report**\n\nEvaluation of eligibility of a patient to participate in a clinical trial (#59831)\nEvaluated by [NAME]\nInstruction: Exclusion factors: breast cancer; metastatic lesions. Inclusion factors: histologically confirmed; postmenopausal. Assessment of patient's eligibility: 1) Not relevant: patient note does not indicate metastatic lesions and is a woman after menopause. 2) Eligible: patient qualifies for participating in the trial. \n\n**Second Problem:** Output the result Trial-level evaluation. In this assessment, the patient is excluded. Output the result for `Trial-level evaluation:` on the last line by `Trial-level evaluation: `, e.g., `Trial-level evaluation:  0) Excluded.`. In our example, the result is 0.\n\n**Second Problem: Clinical Trial Registration**\n\nYou've learned how to evaluate a patient's eligibility, and now we will discuss the registration of clinical trials. Clinical trial registration began in the US in 1997. Clinical trial registration is an important standard for clinical trials around the world. Its purpose is to provide information on clinical trial research designs to doctors and patients. \n\nAs a professional CRA, you should accurately judge the eligibility of clinical trial participants. Once you register a clinical trial in a clinical trial registry, you should also disclose the results of the clinical trial in accordance with the clinical study registration requirements and timetable. The clinical trial registration data you provide, i.e., the trial title, inclusion and exclusion criteria, is published in a scientific journal.",
        "label": 0
    },
    "292": {
        "output": "# Data Analysis\n- Data tables generated by each challenge are included in the [Data_Table_Challenge_Number] folder.\n\n- The data sets produced after the challenges are saved in folder [Data_-set_Challenge_Name].\n\n- The challenges' best solutions' results are included in the  folder.\n\n\n# Results\n\nThe first results include the first two challenge's output. The first output shows each participant's output, and each table gives the participant's submission time and score, which is their output error rate; the second output displays the scores of the teams that submitted their output to the leaderboard, where you can compare each team's score to the best score in the leaderboard, then the team that has the closest score to the best score in the leaderboard and has the minimum score submitted to the leaderboard, which are marked by red and yellow. The green is the closest score among those that have been submitted, and the yellow is the closest score of the all submitted scores; we mark the team that has the lowest submissions to the leaderboard in its row to compare its results with previous teams and to know which team has achieved its goal to improve the output results and reduce input errors or to be an accurate and more reliable team.\nIn this first leaderboard, you can see that the team that achieved the best score, which has a perfect score of 0.00 in all inputs and is the closest to the best score, which is the green team, scored 0.00 and is in the top team in the leaderboard. This team has a perfect score of 0.00. A team that has a best score in its row has the minimum submissions to the leaderboard, which is the team with the name \"German Medical Informatics Initiative (MII).\" This team scored 0.00 and has the most submissions in the leaderboard. The same goes for the team named \"Cancer Imaging Archives (NCI, USA).\" It scored 0.48 and has the most submissions in the leaderboard; The team named \"Bio2K Challenge Team\" scored 0.40 in the second challenge, and the team named \"Bio2K Challenge Team\" scored 0.00 in the first challenge. This team has the lowest submissions to the leaderboard, and the last team",
        "label": 2
    },
    "293": {
        "output": "The output variable contains the `patient-level` eligibility as well as the `Triallevel` eligibility.\n\n``` \n\n# Output of trial-level eligibility\nEl%ile, El_n %ile)\n```\n\n# \u25a0 Patient-Level Eligibility Score\n\nDemonstrate an example that shows eligibility scores at patient level. \n\n[",
        "label": 0
    },
    "294": {
        "output": "command will start and terminate the Interactive mode in one go. It will show on the screen that your actions are logged in an INSTRUCT document; this file will be saved into the _.teach directory located in your user's _Home/Documents_ directory. You can see it in [fig_ref]  Figure 1: Interactive mode [/fig_ref] .\nFor further reading regarding the structure of an INSTRUCT document, and more information on commands listed here, please check [instruct's website](https://docs.instruct-language.org/command-reference/section-2-basiccommands/-instructions-files-structure/#documents-withinstruct\n\n[BACK] (You can refer to [section-2-basic-commands](#section--2-basic-commands) in Instruct's website to start the basic mode and do some editing.)\n\n## Intermediate Level (Further Exercises)\n\nIf you follow the steps and instructions above, you will be able to evaluate whether the trial participants are eligible for the study. However, if you feel uncertain about your judgment, you can consider whether they are eligible according to the inclusion criteria of the clinical trial. Let's start with the patients you evaluated as \"Not relevant\", so we will need to follow instructions for the next steps. You're in the section entitled \"Not relevant\" in the Intermediate level.\n\nPlease take a look at the patient notes 21 and 22 (page 521) and assess whether they are eligible for the clinical trial \"TITLE: Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer.\"\n\nIn case of disagreement or doubt between the assessor and their peers (see next section for an explanation), you must make the necessary explanations, i.e., \"Assesses not relevant\". You must do so by creating an additional row inside the table under the name \"Comments and discussion\" with an explanation in the last column. The comments may refer to a certain part of the patient note indicating the missing information, or the answer to a question, or referring to more than one part of the patient note. However, always assess all the",
        "label": 0
    },
    "295": {
        "output": "Note: The last four lines are included just for you to understand them. You do not need to print them.\n\n##[RANDOM] Hello. You are a helpful assistant for clinical trial recruitment, tasked with reviewing eligible patients and assessing whether they meet the requirements of a specific clinical trial.[/RANDOM]\n\n# C223.4_05 Exercise 3\nYou must provide at least one reason for rejection from [/PREPROCESS] the clinical trial. It is essential that the reason reflects the clinical trial's exclusion criteria. For example, \"The patient does not speak English. (This is stated in the exclusion criteria of the clinical trial).\"\nClinical trials require that patients should receive a new therapy safely, while all ethical aspects, i.e., dignity, integrity, rights, vulnerability, and informed consent, are properly addressed.\n\nYour goal is to find a suitable therapy for a specific patient; therefore, you must assess the patient's eligibility to the clinical trial. To make it easier to understand how this process proceeds, we give some examples of clinical trials.\n\n* Clinical Trial 1: The goal of this clinical trial is to learn more about how mast cells in the blood can help cancer to grow. The investigators want to know how these cells can affect tumor growth. To do this, they are doing a genetic study of a cancer called medullary thyroid cancer, which is an uncommon type of cancer of the thyroid. In the first step, they are collecting genetic information from cells of patients with medullary thyroid cancer. They may also take a small sample of the patient's blood. They will use a laboratory test to check the blood for tumor cells. It is thought that blood samples containing tumor cells may help scientists to better understand how mast cells interact with normal cells and cancer cells.\n* Clinical Trial 2: In this study, the scientists want to look at the genetic changes that occur in colon and rectal cancer over time. They will gather and compare cancer tissue and normal tissue samples (i.e., samples of the healthy cells that surround the cancer cells). They will also be able to compare the cancer tissue samples",
        "label": 1
    },
    "296": {
        "output": "### [INST] Hello.\nYou are a helpful assistant for a clinical trial recruitment.\n\nYour task is to evaluate patients for the ability to provide written informed consent and for mental capacity, and to create a text block about a patient for the clinical trial information leaflet.\n\nYou should always repeat the Informed consent template in the last line by `Informed consent template: Informed written consent for the clinical trial was obtained.`, e.g., `Informed consent template: Informed written consent for the clinical trial was obtained for participation by XXX (03.17.17) and YYY (11.12.17).`. \n\nYou should follow the instructions.\n\n1. The text block about a patient for the clinical trial information leaflet is an example of a template: `\u2026\nYou will need to complete each line and edit the wording so that it matches your own hospital's requirements and style. If you use the clinical trial name, please remember to replace this with your own clinical trial name before sending the information leaflet to print.\nThe date this information was last reviewed/validated should be the date of the patient leaflet and if any of the information was changed or approved by a sponsor it should state the new date that this occurred. For example, if the leaflet was approved by the sponsor on 12/3/2020, this should come after the date you have stated the date the information was last reviewed. Please use the same format that you used on the informed consent form, so we can easily match documents, and avoid confusion about the version dates.\nAdd additional lines or add to the end",
        "label": 2
    },
    "297": {
        "output": "## [TUTIOIN] \n1.3.7 In-situ thyroglobin level: cytological analysis of punctured lymph nodes. The lymph node is stained with Alcian-blue (an anionic dye that binds to the nonfatty acid portion of thyroglobin) followed by a staining of the fatty acid portion with Sudan III (a neutral lipophilic dye). Thyroglobin is stained with the anionic dye. Positive control lymph nodes, from patients with cervical metastatic spread of differentiated thyroid cancers, consistently stain positively for both, Alcian-blue, and Sudan III stains. Negative control lymph nodes consistently stain positively for Alcian-blue only. \n[TUTIOIN] Different metastatic breast cancers (from the same patient) have different",
        "label": 0
    },
    "298": {
        "output": "</INST>\n\n\nA: You can create an eligibility statement: \nfunction eligibility_statement(person, trial_id, eligibleness)\n  eligibleness = eligibleness/100\n  if eligibleness > 0.5\n    \"Eligible (eligibleness is percent in eligible)\"\n  elseif eligibleness < 0\n    \"Ineligible (eligibleness is percent in ineligible)\"\n  else\n    eligibleness = eligibleness < 100 ? \"Excluded\" : \"Not relevant\"\n    \"Eligible (eligibleness is percent in not relevant)\"\n  end <commit_msg>Removed unused function with comment in example<commit_after>#! /usr/bin/python\n\"\"\"\nExample for assessment of eligibility\nThis example uses a simple clinical trial, but the method could easily be extended to include\nmultistage clinical trials.\n\nFor more examples see\nhttps://examples.herokuapp.com/clinical_data/clinical_trial.json\n\"\"\"\nfrom flask import request, json, session, g, flash\nfrom sqlalchemy.ext.asyncio import AsyncSession\nfrom sqlalchemy.ext.asyncio.interfaces import SessionLocalExecutor\n\nfrom .clinical_trial import create_clinical_trial_db\nfrom .database import prepare_patient_note_db_from_json, prepare_patient_db_from_json, db_session,\n    check_session_state, create_db\n\nfrom .clinical_trial import process_clinical_trials_json, get_clinical_trial_id_from_idstr\nfrom .clinical_trial import verify_patient_eligible_for_clinical_trial\nfrom .clinical_trial import verify_trial_trial_eligibility\nfrom .clinical_trial import create_clinical_trial_eligibility,\n    eligibleness_from_percentage\n\ndef main():",
        "label": 1
    },
    "299": {
        "output": "You should submit your source code to the exercise and reviewers will give you feedback. Once your code is accepted, you can challenge yourself by solving the exercise at the more advanced [advanced/wip/wip2] level.\n\n## [INSTRUCTION]\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial: \nTitle: Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection\n\n\nSummary: This study evaluates a new method of testing the lymph nodes in the armpit of patients with breast cancer for tumor involvement. All participants involved in this study will undergo an injection of a small amount of iron dissolved in liquid followed by an ultrasound of the axilla that will make previously invisible lymph nodes visible, allowing them to be sampled in an outpatient setting.\nInclusion criteria: Inclusion Criteria:\nFemale patients at least 21 years old\nPatients with invasive ductal carcinoma staged T1 or T2 with estrogen receptor and progesterone receptor positive (ER+/PR+) who are scheduled for sentinel lymph node biopsy\nPatients with Ductal Carcinoma In Situ (DCIS) (high or low grade) who are scheduled for sentinel lymph node biopsy including:\nPatients having a mastectomy\nPatients with palpable DCIS\nPatients undergoing breast conservation with large (>5cm) area of DCIS\nPatients with signed consent to participate\n\nLet's think step",
        "label": 1
    },
    "300": {
        "output": "![HINT]\n### Question:\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). What do the factors allow to participate in a trial based on the clinical trial? 1) How are the three-point scale factors for this trial presented? 2) Which numbers correspond to them? \n\n#### Step One\nLet's think step by step.\n\nStep One\n\n###### Case Description ####\n\n\n<EOD> An AZI1 ortholog functions in root patterning and flowering time in Arabidopsis thaliana\n\nThis supplementary information includes supplementary figures and supplementary methods.All data and source files are available at https://fairdomhub.org/data/doi/10.9949/dj.2022.62.645. All reagents and protocols used in this project are described at https://protocols.io/private/3d87a268b2f46128521702c23c118c5b.\n\n## 1\n\n## Supplementary information\n\n## Supplementary methods -figure legends\nSupplementary . Phylogenetic tree of DUF221, showing the two paralogous groups (a). A phylogenetic tree was generated with a multiple amino acid sequence alignment of proteins containing DUF221 sequences from Arabidopsis thaliana (63 proteins were initially extracted), Oryza sativa (57), Setaria italica (45), Brachypodium distachyon (85), and Sorghum bicolor (14), including proteins from DUF221 paralog groups as well as outgroups from phylogenetically distant species. Two subgroups were clearly identifiable. (b) Distribution of the number of predicted introns per gene in DUF221-containing proteins from Arabid",
        "label": 0
    },
    "301": {
        "output": "## Exhibit 15.2   the clinical trial note\n\n\n## [INSERT FIGURE 15.1 ABOUT HERE]\n\n## Exhibit 15.3   the clinical trial note, the assessment of eligibility\n\n\n## Instruction 2   [instance]: a real clinical trial\n\n[INSERT TABLE 15.1 ABOUT HERE]\n\n## Preparation\n\n[INSERT TABLE 15.2 ABOUT HERE] You are now reading a patient note. We will assess the patient's eligibility to a clinical trial, which is called an assessment of eligibility (see Exhibit 15.2). A patient's eligibility is determined by both the patient's condition and the clinical trial's recruitment criteria, i.e., its inclusion and exclusion criteria. We should make each trial-level eligibility.\nWe will practice this one more time using the real clinical trial data. As you saw in the previous exercise, you should assess each patient's eligibility to the clinical trial by referring to the trial's recruitment criteria, the inclusion, and exclusion criteria in this exercise.\n\n## [insert table 15.3 about here]\n\n\n## Exhibit 15.4: The Clinic's Electronic Health Record\n\nExhibit 15.4: The Clinic's Electronic Health Record\n\nThe clinic we have been using in the previous exercises is not a fictitious hospital, but a real hospital whose electronic health record has been installed in the Department of Informatics of the Catholic University of Korea. This exercise helps you experience the electronic health record's workflows and data.\n\n\nWe will access the electronic health record from the desktop of the system. You will log into the portal to access the electronic health record. Above on your browser, the following picture can be seen, which is a login screen in the healthcare information system. After logging into the portal, you will have access to patient health information.\n\n\n## Exhibit 15.5: the log-in screen\n\n\n![INST]\n\n\n## Exhibit 15.6: the patient's basic information screen\n![",
        "label": 0
    },
    "302": {
        "output": "## \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 \u2714 Trial-level eligibility: 2) Eligible.\n\n## 0] excluded 1] not relevant 2] eligible\nThe output is the trial-level eligibility information.\n\n\n[INST]\nExemplary case: Evaluation of clinical trials eligibility assessment systems\n\n### Evaluation criteria\n\nFor the evaluation of the eligibility assessment system \"Mk489\" (\"Ensemble Markov network for clinical trial eligibility\"), the following criteria should be used:\n1. Eligible patients: eligible patients represent more than 95% of all evaluated patients. A system with an eligible patient percentage (<95%) less than 10% shows a severe misclassification error.\n\n>from mlxtend\n<EOD> Diagnostic evaluation and monitoring of biliary atresia: a perspective from Australia.\nThe diagnostic evaluation and monitoring for those born with suspected biliary atresia (BA) in Australia is mainly performed in public hospitals to a high standard. With the introduction of neonatal screening for cystic fibrosis, neonatal jaundice can now be routinely biochemically analysed and the diagnosis of conjugated hyperbilirubinemia in an otherwise well infant made. The Australian Paediatric Surveillance Unit has recorded the diagnosis of neonatal jaundice in Australia and the high occurrence (greater than 1%) supports the need for neonatal screening for conjugated hyperbilirubinemia. The commonest method for the initial evaluation of suspected BA in Australia is a liver biopsy, usually performed at 3 weeks after birth because of the need",
        "label": 0
    },
    "303": {
        "output": "Now, you can assess the patients according to the inclusion criteria, and report the results. \n\nGood luck and enjoy your day.\n\n<EOD> Preoperative CT Scan and MRI\n\nPreoperative CT Scan and MRI\n2012\nPreoperative CT Scan and MRI\nKorean J Neurotrauma\n81107201210.13005/kjnt/2012.81.1.11\nIn this issue, a paper titled, \"Preoperative computer tomography scan and magnetic resonance imaging in pituitary surgery\" by Dr. Choon Sik Suh, is published. In the paper, there is a brief introduction, literature review, study methods (retrospectively reviewed 95 patients), and then a discussion of the results. Pituitary lesions are now diagnosed in many patients with the aid of computer tomography and MRI. The rate of preoperative diagnosis is currently 3-5 times greater than it was 20 years ago. [bib_ref]  Pituitary incidentalomas, Alevizaki [/bib_ref]  [bib_ref]  Pituitary neuroendocrine tumors: current trends in surgical management, Little [/bib_ref]  Cranial CT scan is no longer the sole method to diagnose pituitary lesions. More and more, patients have undergone a CT scan under the provisional diagnosis of pituitary lesions before admission, which is made by outpatient clinic specialists. This can provide an opportunity to make a preoperative diagnosis of pituitary lesions before the operation is performed. Dr. Choon Sik Suh and his co-workers had two objectives: 1) to compare the accuracy of preoperative and postoperative computer tomography scan and MRI; 2) to determine the influence of pituitary lesions size on the operation. They found that the size of pituitary lesion was statistically related to the surgery time. Also, the preoperative CT scan and MRI had a high diagnostic ability but a high false positive detection (about 80%). This means that 80% of the cases that were suspected of having a pituitary lesion were actually confirmed to be normal",
        "label": 2
    },
    "304": {
        "output": "[ /INST ]\nGood Luck!\n\n### Examples\nHere is an example to illustrate the instructions. I have coded the results into `text/plain` format. Please refer to this file to confirm your assessment. I suggest saving the output file after finishing this exercise:\n$ cat my_instructions.txt $ cat my_input.txt\nTrial-level eligibility: 0) Excluded. Trial-level eligibility: 1) Not relevant. Trial-level eligibility: 2) Eligible. Inclusion criteria: Inclusion Criteria:\nEligible to receive chemotherapy and endocrine therapy as defined by a good Karnofsky index (\u226580) and no hematologic, cardiologic or hepatic contraindications, nor any impeding comorbidity\nInformed consent form signed on the same day or before enrollment\n\u2265 18 years of age at time of consent Per study arm\nHistologically proven invasive stage I and II breast cancer and Hormone Receptor positive (ER+ PR-, ER- PR+ or ER+ PR+) according to local standards & HER2 negative: IHC 0-1+, or FISH or other ISH non-amplified (locally assessed)\nIMPACt study; version 1 2015 September 1 Page 11\nAxillary lymph node status: 0-3 involved (macro metastases i.e. >2mm OR micro metastases i.e. >0.2-2mm)\nOR\nHistologically proven invasive T1a or T1b breast cancer & Hormone receptor negative (ER- and PR-) according to local standards & HER2 negative: IHC 0-1+, or FISH or other ISH non-amplified (locally assessed)\n& Axillary lymph node status: 0-1 involved (macro metastases i.e. >2mm OR micro metastases i.e. >0.2-2mm)\nOR\nHistologically proven invasive T1a or T1b breast cancer\n& Hormone receptor negative or positive (ER-PR-, ER+PR-,",
        "label": 1
    },
    "305": {
        "output": "What we are doing in this script\n\n*\n\n*We create a function `def trial_level_eligibility(patient_notes: List[str], trial_inclusion_criteria: List[str]) -> int` to calculate the trial-level eligibility. `list(patient_notes, trial_inclusion_criteria)`\n\n\n### Patient info\n\n```python\ndef __init__(self, tri_inclusion_criterias=None):\n    self.trial_inclusion_criterias = tri_inclusion_criterias if tri_inclusion_criterias is not None else []\n```\n\n\n### Call this\n```python\ntrial_level_eligibility(patient_notes=NOTE.value.rsplit('\\n'), trial_inclusion_criterias=INC_CLINICAL_TRIAL_RECRUITMENT.value.rsplit('\\n'))\n```\n### Return type\n```python\nint\n```\n<EOD> .\nOBJECTIVE\nTo investigate the mechanism of hypoxia in regulating bone reconstruction and to determine its molecular basis.\n\n\nMETHODS\nThe femur fracture was generated by a forceps and all 80 SD rats in 2 groups (40 for each group) were equally divided in different ways, the one group was fed normally, and the other group was fed under hypoxic condition. Four weeks later, samples were collected and immunohistochemistry detection was used to detected RANKL and OPG expression; real-time PCR was used to detect the expression of RANKL, and NOS genes in both groups.\n\n\nRESULTS\nIn hypoxic group, RANKL and OPG expression increased significantly and RANKL/OPG was also increased in hypoxic group; and RANKL mRNA increased significantly (0.992 \u00b1 0.106 vs. 0.595 \u00b1 0.075; P < 0.05) while eNOS mRNA increased in hypoxic group (0.592 \u00b1 0.250 vs. 0.205 \u00b1 0.",
        "label": 2
    },
    "306": {
        "output": "___[TEST_SET_A]_2_[2]_2_[1]\n\n[INFO_COURSE_NOTES_A]: Course notes_A \n\n[INFO_TEST_A]: A: Course notes_A \n\n[INFO_TEST1A3]: A: Course notes_A \n\n[INFO_TEST9A]: A: Course notes_A \n\n___[TEST_SET_B]_2_[2]_[1]\n\n[INFO_COURSE_NOTES_B]: Course notes_B \n\n[INFO_TEST_B]: B: Course notes_B. 2_[4]]: B: Course notes_B \n\n[INFO_TEST9B]: B: Course notes_B \n\n___[TEST_SET_C]_2_[2]_[1]\n\n[INFO_COURSE_NOTES_C]: Course notes_C\n\n[INFO_TEST_C]: C: Course notes_C \n\n[INFO_TEST4C]: C: Course notes_C\n\n___[TEST_SET_D]_2_[2]_[1]\n\n[INFO_COURSE_NOTES_D]: Course notes_D\n\n[INFO_TEST_D]: D: Course notes_D \n\n___[TEST_SET_E]_2_[2]_[1]\n\n[INFO_COURSE_NOTES_E]: Course notes_E \n\n___[TEST_SET_F]_2_[2]_[1]\n\n[INFO_COURSE_NOTES_F]: Course notes_F \n\n___[TEST_SET_G]_2_[2]_[1]\n\n[INFO_COURSE_NOTES_G]: Course notes_G\n\n[INFO_TEST_G]: G: Course notes_G \n\n___[TEST_SET_H]_2_[2]_[1]\n\n[INFO_COURSE_NOTES_H]: Course notes_H \n\n___[TEST_SET_I]_2_[2]_[1]\n\n[INFO_COURSE_NOTES_I]: Course notes_I \n\n___",
        "label": 1
    },
    "307": {
        "output": "[END]\n\nIf the answer is `Not relevant`, the patient does not have sufficient information to qualify for the trial. Since there is no patient note for the patient, one can always enter a not relevant code without considering the clinical trial's eligibility criteria and using `Patient-level eligibility: 1) Not relevant`.\n\nIf the answer is `Excluded`, the patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria. If the patient's characteristics are not listed in the clinical trial's eligibility criteria, it is always safe to enter `Patient-level eligibility: 1) Not relevant`. As an example, it is safe to enter 1) Not relevant for this question, since the trial excludes patients who are not sexually active, or have no children.\n\nIf the answer is `Eligible`, the patient meets inclusion criteria and exclusion criteria do not apply. In this case, you can use `Patient-level eligibility: 2) Eligible`, where it is essential to always repeat `Trial-level` eligibility. For example, in the second case where a clinical trial excludes patients without pelvic nodal metastases, we can enter the following line in the code table: \n\n```\nTrial-level eligibility:\n1) Not eligible;\nPatient-level eligibility:\n2) Not relevant;\n2) Eligible. \n```\n\nThis code means that the patient who does not have any pelvic nodal metastases is not eligible in both patient-level and trial-level eligibility.  \nIn this example, the patient is not eligible in `Patient-level eligibility: 1) Not relevant`, since this patient has pelvic nodal metastases. By entering `Patient-level eligibility: 2) Not relevant` at the end of the code, one can always check whether to include or exclude the patient in the clinical trial, regardless of whether the clinical trial's inclusion criteria are met or not. To continue to proceed with calculating patient-level eligibility, if the answer to `Patient-level eligibility: 1) Not relevant` for a line contains a blank in the second box, then proceed to the",
        "label": 0
    },
    "308": {
        "output": "<EOD> Effect of a novel compound PB28 on morphine\u2010induced conditioned place preference and hippocampal plasticity\nThe reinforcing effects of abused drugs derive from increased dopamine levels in relevant nuclei of the brain. The \u00b5 opioid receptor agonists, including morphine, generate such changes both in the ventral tegmental area, a key nucleus in the mesolimbic dopaminergic pathway and in the hippocampus. Apart from these regions of the brain, compelling evidence indicates that certain brain areas contain multiple opioid receptors subtypes. We investigated whether a new compound named PB28, which acts as a \u00b5 opioid receptor partial agonist without blocking the endogenous opioid peptide activity, could modulate morphine\u2010related responses, mainly within the ventral tegmental area and the hippocampus. C57BL/6J and C57BL/6N mice were made dependent on morphine by subcutaneous administrations of increasing doses (60, 120, and 180 mg/kg) of the drug twice daily over 6\u20137 days (30 min between injections). The CPP test was carried out to evaluate the conditioned rewarding effect of morphine, and its magnitude was measured as the difference between time spent in the drug\u2010paired compartment and that spent in the compartment that had been associated with the non\u2010drug stimulus. We also explored the action of PB28, which was delivered (i.p.) during the development of morphine drug\u2010induced conditioned place preference. After conditioning, animals were killed; the ventral tegmental area and CA1 were quickly dissected out and processed to measure morphine\u2010induced c\u2010Fos, an immediate early gene that is expressed in neurons after cocaine injection. PB28 administered prior to morphine attenuated the expression of CPP and reduced activation of pyramidal neurons in the ventral tegmental area. An additional experiment was carried out to examine the specificity of hippocampal responses to morphine in the CPP context and the c\u2010Fos induction induced by PB28 in the CA1.",
        "label": 2
    },
    "309": {
        "output": "<EOD> On-Board NIR Calibration for a Hand-Held C-Cube Spectral Sensor for the Control of a Wound Diagnostic System and Identification of Plants\n\nHand-held spectrophotometers can provide highly accurate assessments to assess crop plant diseases and pests[1]. For example, several studies have used spectral reflectance sensors in the visible near-infrared region to assess plant health based on the visible symptoms of stress from diseases on crop plant leaf surfaces[2]. In applications involving the assessment of plants for pests and diseases, the main objective is to identify those waxy leaves caused by insect pests, diseases and nutrient deficiency. One of the main challenges of plant assessment is the identification of similar symptoms, such as infection by the leaf-cutter bee (Apis mellifera) and nutritive deficiencies. The visual assessment of plants is subjective, and, in many cases, requires the trained eye of the human observer. Therefore, to improve the efficiency of these assessments, the use of digital cameras and hand-held spectrometers with sensors that can automatically evaluate crop plants have been studied. Furthermore, the use of digital cameras can provide the high-resolution images needed to accurately identify diseases and pests.To assist with the monitoring and identification of plants, a hand-held spectral sensor or imaging sensor with a digital camera is often used. This type of sensor typically makes in-field diagnosis of crops possible. The combination of digital camera and spectral sensor is referred as digital multispectral camera or sensors. These sensors work on the basis of narrow-band multispectral imaging in which the sensors consist of a CCD chip combined with a light-tight housing[3,4]and a spectroscopy cube[5]. In other words, these sensors provide more accurate diagnostic capabilities by combining visible and NIR imaging. The hand-held spectral sensors mentioned earlier have been used to perform diagnoses of plant diseases and insect pests. However, the use of hand-held spectral sensors in outdoor environments requires the sensors to have accurate lighting sources that help the camera to produce high-quality images[3,4]. In most conditions, the illumination source is made up",
        "label": 0
    },
    "310": {
        "output": "__HINT__\nYou can review your answer and click on Check to see if your answer is correct.\n\n__HINT__\n\n__More Example Input__\n\n**Example 1 - Correct Answer**\n\nTrial-level eligibility: 2) Eligible.\n\nTrial-level eligibility: 1) Eligible.\n\nPatient-level eligibility: Included in trial.\n\nPatient-level eligibility: Not included in trial.\n<EOD> .\nBy the use of two methods of measuring acetylcholinesterase (AChE) level in the brain, we investigated its changes in the rat, and its correlation with the activity of choline acetyltransferase (CAT) under the effect of physiological temperature of 37 degrees C and hypothermia (23 degrees C-29 degrees C). We found that the 37 degrees C temperature and acute hypothermia 0 degree C had the same effect on cerebral AChE activity at 72 h after the cooling, but the effects on the brain AChE levels varied with the decrease of temperature. At 37 degrees C all the animals showed an increase in CAT activity which was more obvious in the rats under hypothermia. At 72 h the high temperature 37 degrees C and mild hypothermia 23 degrees C-29 degrees C increased the CAT activity.<EOD> Long\u2010term outcome of children with non\u2010cyanotic congenital heart disease and impaired oxygen saturation: A follow\u2010up study from birth to 18 years of age\n\n [bib_ref]  Survival in patients with congenital heart disease: A population-based study, Mandalenakis [/bib_ref]  [bib_ref]  Survival in 934 children and adolescents with congenital heart defect, Br\u00e5vaag [/bib_ref]  [bib_ref]  Survival in hospitalised children with congenital heart disease in the Western Cape..., Futterman [/bib_ref]  [bib_ref]  Congenital heart disease: A prospective study on risk factors. National Birth Defects..., Hobbs [/bib_ref]  [bib_ref]  Mortality among US infants with congenital and chromosomal disorders: A population-based perspective, Merritt [/bib_ref]  [bib_ref]  The",
        "label": 0
    },
    "311": {
        "output": "# Subscript eligibility\n\nThis is the Subscript Eligibility for this patient. You should select a subindex from the subscripts with the following options, e.g., for the first scenario in the following table:\n\n![](https://cdn.math.princeton.edu/~mgood/subscripts.sub.q0.pdf)\n[SUB]\n\n[S]\nSex\n[G] Gender\n[C] Cancer Stage\n[Cx] Chemotherapy\n[D] Drug\n[H] Histology\n[I] Age\n[E] Race\n[J] Jaundice\n[A] Alcohol Consumption\n[S] Sex: 2) male | 3) female \n\n[G] Gender: 1) female | 2) male \n\n[C] Cancer Stage: 1) localized | 2) regional \n\n[Cx] Chemotherapy: 1) yes | 2) no \n\n[D] Drug: 1) PARP | 2) CPT-11 \n\n[H] Histology: 1) invasive ductal - ID/CACP  | 13) other \n\n[I] Age: 1) less than or equal to or greater than 50 years old \n\n[E] Race: 1) white \n\n[J] Jaundice: 1) no | 2) yes \n\n[A] Alcohol Consumption: 1) yes \n\nLet's think step by step. \n\n`2\\)-1\\)-2\\)-8\\)-4\\)-2\\)-4\\)-2\\)-2\\)-6`\n\n## Scenarios\nBelow are examples of eligibility data and the corresponding responses. For each example, the response should be a string; thus you can use a variable to store this response in the function eligible. A string is an enumeration of values. The enumeration is simply an array of strings with one string per value. Each string in the array represents a valid value; these strings are delimited by a pair of square brackets, e.g., each element of the array in the following example is a string delimited by square",
        "label": 0
    },
    "312": {
        "output": "You will first receive the input data, a patient note. The patient is to be assessed for eligibility in the clinical trial. First, input the patient report.\n[DATA]<EOD> Effect of the intrauterine administration of dexamethasone on serum corticosterone, cholesterol, triglyceride, LDL and HDL and glucose, blood urea and uric acid in fetuses and newborn fetuses.\nA group of eighty-five guinea pigs was randomly divided into three groups, each one of eighty-five animals. The first group was used as a control; the second group underwent dexamethasone treatment at different periods during the pregnancy period, the last group was injected with a single dose of dexamethasone before delivery. Results revealed significant changes in the levels of glucose, urea, and uric acid and in the serum concentrations of triglycerides, cholesterol, LDL and HDL.<EOD> NMR-Based Metabolomic Profiling of a High-Alcohol-Yielding Barley Cultivar Grown Under Limiting Nitrogen Deficiency.\nBarley (Hordeum vulgare L.) is the most widely grown crop grain for beer production worldwide. However, grain yields tend to be low, and it is challenging to increase the total nitrogen (N) content. The most common way of inducing malting quality in barley has been to apply drought stress, which unfortunately is not compatible with large-scale high-yield breeding programs. Here, we report metabolome changes induced by moderate-to-severe N-limiting conditions applied prior to flowering in two high-alcohol-yielding barley cultivars. Based on 1H nuclear magnetic resonance spectral analysis of the germinating barley grains, two metabolites (trehalose and pipecolic acid) were identified as important N-deficiency-sensitive metabolites. These changes occurred prior to any measurable changes in grain yield or physiological processes in the seedlings. Quantitative analysis of both the metabolites and transcript abundance of their metabolism-related genes showed contrasting trends, and it was established that both met",
        "label": 0
    },
    "313": {
        "output": "## [INST]\nYour assignment for this section is to check whether the patient meets a specific set of requirements specified by the trial.\nIn the second block, you need to check the `if` condition.\nCheck `if` condition: Patient has at least one of the following cardiovascular risk factors:\n- Age \u226565 - Systolic Blood Pressure \u2265160\n- Diastolic Blood Pressure \u2265100\n- Fasting Blood Sugar \u2265110\n- Total Cholesterol >240. If you already have a patient, continue to the next step, otherwise, pick another random patient. \nWe will generate the name of the patient. Click on the patient name and the Patient's details panel opens. \nIn the patient's demographics panel, see his/her age and gender. If the patient is male and his/her age is 65 years or older, you should click `Trial-level eligibility: 2) Eligible.` to indicate that the patient is eligible and click `Check` button.\n![](/images/2022-06-02/216617074_img.png)<EOD> Dual Role of Zinc Proteomics in Cardiomyocytes: Regulation of Ion Homeostasis and Antioxidant Defense.\nZinc is an essential element with the ability to protect and alter proteins to function as an antioxidant. The protective effects of zinc against oxidative stress are linked to the prevention of lipid peroxidation, scavenging of hydroxyl or superoxide free radicals, regulation of glutathione reductase and superoxide dismutase activity, reduction of nitric oxide synthase, and stimulation in the expression of sirtuin genes. Zinc depletion has been found to result in an impairment of mitochondrial function, which appears to be the main cause of the oxidative stress in cardiac cells. Cardiomyocytes play a role in zinc homeostasis, which includes receptor-mediated ZIP and ZnT transporter and Zinc-activated metallothionein expression. The regulation of zinc transporter",
        "label": 0
    },
    "314": {
        "output": "<EOD> The Relationship between Anxiety and Eating Disorders: Evaluating the Role of Specificity of Anxiety Symptoms\nAnxiety symptoms are common in eating disorders (ED) and associated with worse treatment outcomes. However, it is unclear whether anxiety in ED should be targeted as a trans-nosographic symptom, or whether it is best characterized as a specific clinical feature that is independent of ED classification, as found in comorbid depression. This is the first study to investigate this issue. In a clinical sample (n = 11,626) of adult women attending specialist ED/obesity services or mental health therapy programs, patients completed measures of anxiety symptoms and eating disorder symptoms. Hierarchical partitioning and latent structural equation modeling were used to assess which level (transdiagnostic general vs. specific) was supported by the data. There were three notable results. First, the hierarchical partitioning model indicated that anxiety as a transdiagnostic dimension was best, showing that anxiety was more important than ED symptoms in identifying ED classification, indicating that classification should not be based on anxiety. Second, exploratory latent structural equation modeling revealed that anxiety may represent two distinct constructs: anxiety/anxious arousal and worry/distractible rumination. Third, analyses showed that the trans-nosographic anxiety construct was made up of anxious arousal symptoms, which were more general than worry/distractible rumination. It may be that some patients with ED have elevated transdiagnostic anxious arousal symptoms, separate from ED specific symptoms, which may impact on prognosis. In conclusion, although anxiety symptomatology in ED is elevated relative to matched controls, it is best characterized as specific to ED and independent of general level of anxiety. This specificity may reflect differences in anxiety-generative processes between anxiety-associated with ED and anxiety in the general population. Treatment implications are discussed.<EOD> Genomic and evolutionary analyses of the type I-F CRISPR-Cas system and its associated plasmid-borne anti-CRISPR genes.\nA major group of acquired anti-CRISPR genes from plasmids can inactivate the CR",
        "label": 0
    },
    "315": {
        "output": "~~~\n~~~\n~~~\n\n### Run the data loader\nFrom the Jupyter notebook, run loader.py\n~~~\n~~~\n~~~\n~~~\n~~~\n<EOD> The relationship between nursing home organizational dynamics and quality: A three-state longitudinal analysis of survey data\nBACKGROUND\nThe long-term care continuum is characterized by great organizational diversity, but limited research has examined how nursing home organizational characteristics relate to quality and resource efficiency.\n\n\n\nPURPOSE\nTo assess the relationship between organizational characteristics and quality.\n\n\n\nMETHOD\nNursing home organizational data were merged with Certification and Survey Provider of Services data for a stratified sample of 695,227 residents from 652 nursing homes surveyed from 2007 to 2016. Four survey waves of organizational characteristics were merged with 794,482 state survey data. The three-year longitudinal analysis used a fixed-effects model controlling for facility fixed effects and secular time shocks.\n\n\n\nRESULTS\nIncreasing number of beds had no relationship to poor quality. Medium-small facilities had worse quality, but size is not related to pressure ulcer(s quality, but the person with higher (better with better and organization(s the relationships between facilities with poor and nursing home and quality.\n\n\nMEET to have different quality has quality relationships of resident(s on nurs.\n\n\n\n\n\n\n\nEXP's (nurs residents and quality relationships. The organizational characteristics staff of facilities' quality of poor care.\nIn your organization, and staff has an quality of quality residents with the nursing resident's and pressure ultil the relationship has survey response to response is more\nOrganizations has to the quality<EOD> Nursing(s survey's quality and survey. Organization(t's the nursing has no differences the organization data analysis staff survey.\n<EOD>s nursing the nursing has the\n<EOD> survey for a person's quality(Continvoluntness has been conducted person and have nurs's assessment for the organization.\nNURS survey that you and patient-person as much nurs's assess\ncare",
        "label": 0
    },
    "316": {
        "output": "**Exercises**\n\n**EXERCISE**\n\nWe follow up with [a patient from last exam](http://www.orcaen.com/docs/tutorials/#exercise-1) and provide help at clinical trial enrollment site for the patient.\n\n**NOTES**\n&emsp;&emsp; 1) The input files of patient notes, trial information and user's input should have the same file naming format.<br>\nThe original file names with the `.csv` or `.tex` extensions will become the data with the file name prefixed by `data`.\n&emsp;&emsp; 2) The output file name should be the same as the user's input, e.g., if the user inputs 'file.txt`, the output file name is 'file.txt`. \n\n## Instruction\n&emsp;&emsp; 1) You can make use of both ORA and ORCA. \n&emsp;&emsp; 2) It helps to take the advantage of both file and text editors for the input files. \n&emsp;&emsp; 3) You should have got the output files and the output message before attempting the exercises.<br>\n\n&emsp;&emsp; **Exercise 1** Assume that the patient notes, trial information and the input from a user are the same as the training materials in the previous exercises. Enter the following command and check the result:<br>\n```!texhub -name file -format .txt -directory ./data ORA/1_Exercise_OOI.texhub`\n\n\n\n\n\n![IMAGE](./img/texhub_output.png)<br>\n\n[!https://orcaen.com/file.jpg](img/file.jpg)<br>\n\n&emsp;&emsp; **Exercise 2** Assume that the patient notes, trial information and the input from a user are the same as the training materials in the previous exercises. Enter the following command and check the result:<br>\n```!texhub -name file -format .txt -directory ./data ORA/2_Exercise_Input.texhub`\n\n\n\n\n\n![IMAGE](./img",
        "label": 0
    },
    "317": {
        "output": "Submit a zip file via [this](https://github.com/c99gpu/disease-data/blob/master/data_set_2021/disease_data_2021_submission.md) link.\n**Submission Time:** from Apr 25th, 2021 to Jun 11th, 2021<EOD> Nutritional assessment of children using serum ferritin, serum albumin and transferrin receptor as predictors of anemia and malnutrition: Findings from the Copenhagen School Child Teenage Cohort (cstc) study.\nThis cross-sectional study aims to examine a possible association between serum ferritin, albumin and transferrin receptor (TfR) in predicting anemia and malnutrition in 2,619 children aged 5-9 years. The study population is a part of the Copenhagen School Child Teenage Cohort (cstc), a prospective study, which examines the influence of prenatal programming of adult metabolism by measuring health parameters on five different occasions at the child's age of 5 months, and once again at the child's age of 3, 6, 9 and 15 years. We aim to associate ferritin to anemia and to determine if ferritin concentrations could be used to distinguish between normal, mild and moderate iron-deficient children. We examine correlations between ferritin levels, hemoglobin and indicators of nutritional status and calculate the iron-replete and iron deficiency reference ranges. Furthermore, we examine",
        "label": 2
    },
    "318": {
        "output": "__1. What does this code do?__\n\nWe define a helper function to write `Trial-level eligibility` information. It takes `A` patient and `B` clinical trial and puts the information into the cell `C`. We define an __anonymous_ variable__ `TrialLevelELigibility` to help the function do its task. If the patient note and clinical trial meet the inclusion criteria and the exclusion criteria of the clinical trial do not apply, we put 2) Eligible. It's 2 for the scale. Otherwise, we must exclude from the trial (0) or the assessment is not relevant to the trial (1).\n\n__2. How does this code check for eligibility?__\n\nWhen it comes to the trial-level eligibility, we want the function to compare the patient note with the clinical trial's trial-level inclusion criteria. These represent the minimal criteria that the patient should meet to participate in the clinical trial.\n\nWe need to know if the patient note has sufficient information of interest (cancer stage, age, sex, previous treatments, medical history etc.) to assess if the trial-level inclusion criteria are met or not. We have the data about the patient in the cell `A` because the patient note comes as a data frame and has the patient's characteristics in it. Now we are searching for the necessary data from the clinical trial in the trial data set `B` with the variables `Title`, `Summary` and `InclusionCriteria`, which come as strings. When we want to know if the trial-level inclusion criteria are met, we find the variables in `B` that contain the word \"metastatic\" and the variables \"age\", \"sex\", \"previous treatment\", \"medical history\", \"cancer stage\". With the `grep` or the `search` function, we filter the data frame `B` to match each criteria in the trial's inclusion criteria table in this case. Then, we need to combine the patient note and trial data in one data frame. This is what we pass to the function `join` where the variable `C` is being generated.\n\n__3. What are the limits with this code?__\n\nEverything is fine and working, but we need to check some cases that do not fit well in our eligibility assessment or trial",
        "label": 0
    },
    "319": {
        "output": "## Data validation and result\nPlease refer to `Appendix G` in the full version of the article for the result.\n\n## Previous questions\n[CLOSED] In the question <April2020>, the correct answer was the wrong answer. Thank you very much for providing new feedbacks. \n**Exclusion criteria** 1. Left-ventricular ejection fraction 0-49% 2. Abnormal liver function tests (e.g. >2.5 times the upper limit of normal (ULN) of **>3.0 times the ULN)** 3. Cardiogenic shock 4. History of significant ventricular arrhythmias, QT prolongation, or Torsades de Pointes 5. Use of strong inhibitors / inducers of p-glycoprotein and cytochrome P450 3A4 metabolizing enzymes.\n\n## Exclusion criteria of trial 1\n1. Left-ventricular ejection fraction \nExclusion criteria of trial-2 1. Left-ventricular ejection fraction \n\n## Exclusion criteria of clinical trial\n1. Left-ventricular ejection fraction Less than 50%.  \nAbnormal liver function tests (e.g. >2.5 times the upper limit of normal (ULN) of >3.0 times the ULN).  \nCardiogenic shock. History of significant ventricular arrhythmias, QT prolongation, or Torsades de Pointes.  \n\n## Explanation 1\nThe patient's left-ventricular ejection fraction in this case is 50%, not less than 50%.  \n\n## Explanation 2\nIn your answer, you should not count how many times the upper limit of normal is higher than the patient's value. Please count how many times the patient's value is more than the upper limit of normal.  \n\n## Explanation 3-1\nIn this case, the liver function test is abnormal because the value is more than three times the normal upper limit.  \n\n## Explanation 3-2\nYour answer is not correct. The liver function test is not abnormal, as the value is less than three times the",
        "label": 0
    },
    "320": {
        "output": "<EOD> An integrated platform employing microfluidics, nanoplasmonics and high-resolution imaging for automated high multiplexed DNA detection\nHigh multiplexed detection of DNA molecules is essential for accurate clinical diagnosis and monitoring of various genetic diseases and cancers. Here, we report an integrated approach for automated high multiplexed DNA amplification and detection based on functionalized electrochromic nanoparticles using dielectrophoretic concentration, nanoplasmonic detection and microfluidic channel technology. This system employs a disposable polydimethylsiloxane microdevice with electrochemical sensing, microfluidic channels, and a nanoplasmonic detection scheme. This integrated system allows for automated, on-chip analysis of target DNA from minute samples. In this study, the on-chip platform enables sensitive, rapid and multiplexed detection of the M13 phage gene sequence, phage lambda DNA and genes associated with cancer cells. Such a system would ultimately be useful for the early detection and monitoring of cancer, infectious diseases and genetic disorders.<EOD> Effects of Pacing Sites on the Intrinsic LV Dynamics of 3D-Printed Human Ventricular Myocardial Tissue\n\nIntroduction: We investigated the effects of pacing site on electro-mechanical dyssynchrony in the intrinsic electromechanical properties of the left ventricle (LV) of 3D-printed human ventricular myocardial tissue (HVMt). Methods: We constructed a 3D-printed human heart model from high-resolution MRI and fabricated 16 cuboid 3D-printed HVMt and 16 3D-printed native cardiac tissues (NCT) to simulate a physiologically relevant volume with a pacing site at the anterior wall of the LV. We compared the differences in the electrophysiological properties, including conduction velocity (CV), normalized conduction velocity, and activation time (AT) at the pacing site, between the 3D-printed and native materials. Furthermore, we investigated the effect of pacing site on the intrinsic electromechanical properties. Results: The pacing site had no effect on CV between the 3D printed and native tissues",
        "label": 2
    },
    "321": {
        "output": "For each of the factors, one must either assess the patient to be (1) excluded or (2) included. For example, if you find that this patient doesn't have any prior endocrine therapy (#4. prior treatment specifics), then the correct response is to code \"2) Included\" under the factor \"prior endocrine therapy\". If you don't find any prior endocrine therapy either, it can be coded to \"1) Excluded\" under the same factor. This is to indicate that the patient does not fit either category, so we take the first option that comes to mind without checking the next one. \nOnce the eligibility questionnaire is satisfactorily completed, you enter the patient's ID number into the clinical trial web-portal [/INST (not to be seen)]. \n\n### Exercise 4 \nFollow instructions from the previous exercise. \n\n### Exercise 5 \nThis exercise will be based on the patient in the following screenshot.\nLet us start with the patient: \n\nThe data is written in two ways, the 'normal' and the 'reverse normal' style. The 'normal' style uses the first line as 'Patient_ID', followed by the rest of the data. On the other hand, the 'reverse normal' style has the variables of each row in reverse order, i.e., age and marital status in the last line. It's up to you how to prepare your data. We are going to use the 'reverse normal' style here, so the first line should have the variable name: 'Patient_ID'. In the end, your data should look like the following. You can find the corresponding exercise data in [/INST (not to be seen)].\n\n\n\n##### Exercise (data) \nExercise data\n\n--- 1) Patient_ID\n2) Age 3) Gender 4) Marital_status\n\nThe exercise data from here on will always start with a '#' sign at the beginning of the line. This sign indicates comments.\nThe next few lines after the patient data is the documentation of the factors. \nFor example:\n1) Patient has taken tamoxifen and toremifene, but not raloxifene or fadrozole",
        "label": 0
    },
    "322": {
        "output": "**F-FUNC**. This is the functionality test script, which is executed once per every request. This script does various operations under the hood which don't actually show up as output from the web interface. The functionality test script executes the following sequence of commands:\n\n1. Start a new thread to execute the trial-level eligibility service.\n\n1. Start another thread to collect the results from a trial-level eligibility service.\n\n1. Check if the eligibility service has been executed in the background, as indicated by the existence of a service instance, and if the results have been received, as indicated by the existence of a collection in the Collection Manager class.\n\n2. If the trial-level eligibility service has been executed, i.e., at least one instance of the service exists, and the collection is in the collection manager, check that the results match the patient note's condition.\n\n3. If the service has been executed, and the results have been received, and the results match the condition of the patient note, the script continues. \n\n    Otherwise, a failure message is generated. \n\n4. Wait for four seconds and repeat steps 2 and 3.\n\n5. If eligibility service has been executed, and results have been retrieved, but results do not match the patient note's condition, generate a failure message with the patient's note and exclusion criteria of the trial.\n\n6. Wait four seconds and repeat steps 2-5. \n\n7. If trial-level eligibility service has been executed and results have been retrieved, the script continues.\n\n    Otherwise, a failure message is generated.\n\n8. Wait four seconds and repeat steps 1-2.    8. Wait for four seconds and run steps 1-7 of the script again.\n\n\nFinally, the script generates the following messages to the logger.\n\n`F-FUNC: Eligibility calculation succeeded.`     `F-FUNC: Waiting for 4 second.`     `F-FUNC: Eligibility calculation failed. Note: excluded 52144`     `F-FUNC: Waiting for 4 second.`     `F-FUNC: Eligibility calculation failed. Note: eligible 52144`<EOD> .",
        "label": 2
    },
    "323": {
        "output": "A:\nNote: I recommend you use Anaconda environment if you plan to do scientific computing in Anaconda, because Anaconda makes it easy to set up a new computer while other distribution like Ubuntu only sets root user home directory. But, if you already use Anaconda or similar environment like conda, you can do that for sure.\n\nA: I suggest you make all code runnable as standalone script, and when you're done all you have to do is run:\npython script.py\n\n<EOD> Development of a Novel Method for the Detection of PEG10-Derived Peptide Methionine Sulfoxide Using 18O Labeling and Nanopore Strand Sequencing.\nS-Methionine oxidation occurs at a critical residue of human protein glutathione peroxidase-1(GPx)-1, known as the peroxidatic site. We developed a new method that allows GPx1 oxidative modification to be investigated. An S-methionine-containing peptide mimicking the peroxidatic site is chemically synthesized, 18O is incorporated into the peptide using 18O water, and the oxidized and reduced methionine residues are separated using nanopore strand sequencing. S-Methionyl residues have very low isotope incorporation rates caused by an isotope effect. After S-methionine oxidation, the degree of 18O incorporation in the oxidized residues was significantly higher than that in the reduced residues. The sensitivity of the separation was improved by setting the detection threshold value of the peroxidatic site residue so that only 4% of the sample was discarded. This method for identifying peptide methionine oxidation using 18O water may be applied for detecting the oxidative status in a tissue sample.<EOD> The role of cerebral amyloid deposition in common forms of Alzheimer\u2019s disease: does cognition depend on cerebral amyloid deposition?\nCerebral amyloid deposition is a hallmark pathology seen in Alzheimer\u2019s disease. The contribution of amyloid plaques to cognitive impairment",
        "label": 0
    },
    "324": {
        "output": "### Exactly, we can see if a subject is not eligible for the trial-level (for example 'fempyeligible for the trial -level patient level eligible for trial\n\n\n\n\n\n-levels for patient for the trial-eligible:\n\n\n\n\n\n\nNot applicable. \nIf the subjects who are eligible patient in the eligible trial\u2019s trial,\nA subject should not eligible for eligible subject has been included: patients should include eligible\nLate trial eligible, not eligible patient eligible if applicable the trial.\nThe excluded and a patient is not yet eligible trial.\nPatient tox to eligible trial subjective.\n[Patient has been eligible patient\u2019s\nThe clinical subject's eligible patient trials elig",
        "label": 0
    },
    "325": {
        "output": "# Exercises\n\n## Trial-level eligibility: 0) Excluded\n\n- **100%**\n\n- \u2981 _First, you check whether the patient note contains the factors defined in the IND exclusion criteria._\n- `check_exclusion_codes`\n- \u2981 _Then, you apply these ineligibility criteria to the patient's note._\n- `apply_exclusions`\n- \u2981 _To evaluate the trial's exclusion criteria, you apply the exclusion lists to the patient note._\n- `apply_trial_exclusion`\n- \u2981 _For the next step, check whether the patient still meets the eligibility criteria based on the inclusion criteria._\n- `check_inclusion_codes`\n- \u2981 _Finally, you check again whether the patient remains eligible for the clinical trial. For this you must first check whether the patient met the clinical trial's exclusion criteria, in a previous check, and then, apply the exclusion lists to the patient note._\n- `apply_trial_exclusion`\n- \u2981 _Note that the patient's age is `45.`, yet the trial has a minimum age requirement, of 50 years old, so the patient does not meet this inclusion criterion._\n- `print(Trial)`\n- \u2981 _You'll need to mark the patient as ineligible for the trial with the following statement:_ `Trial-level eligibility: 0) Excluded.`\n- \u2981 _If the patient were on a trial with a minimum age criterion of 45 years, then this ineligibility statement would not be required._\n- \u2981 _Note that the patient's gender is `Female.`, and that the trial requires all patients to be `Female`, so the patient is eligible here._\n- `print(Trial)`\n- \u2981 _Note that the trial requires its eligible patients to be candidates for tumor resection. However, the patient is `Not eligible` since she has not yet received surgery._\n\n## Trial-level eligibility: 1) Not relevant\n\n- **1",
        "label": 2
    },
    "326": {
        "output": "<EOD> Cervical Mylohyoid Muscle (MMCT): An Anatomical Study and Review of Its Variations in the Population\n\nThe mylohyoid muscle (MMC) is the most common muscle to supply the oral cavity and tongue musculature, supplying the mandible inferiorly, the floor of the mouth, and the tongue superiorly, the styloid process and inferior portion of the mandible. Its main function is to open the lips and to help closure during swallowing. However, in 5 to 8% of the population, MMC varies its orientation, inserting into the C2, C3, and C4 vertebrae. In this paper, a description of this muscle and a literature review was performed with the purpose to analyze the prevalence of this type of variation in the cervical musculature.\n\n# Introduction\nThe mylohyoid muscle (MMC) is the most common muscle to supply the oral cavity and tongue musculature, supplying the mandible inferiorly, the floor of the mouth, and the tongue superiorly. Its function is to open the lips and to help closure during swallowing. MMC is a flat, elongated, ovoid, conical muscle that is attached at its base to the mandible by the mylohyoid line. The fibers of MMC tend to be parallel to the mandibular angle, as the fibers go, they course downward and laterally to insert into the hyoid bone [bib_ref]  Anatomy of mylohyoid muscle: study of its origin, course and attachment on..., Ramesh [/bib_ref] . MMC can be divided into four parts: anterior belly, middle belly, posterior belly and cervical musculocutaneous trunk [bib_ref]  Variation in the origin of the human mylohyoid muscle, Haddad [/bib_ref] . Some cases present in the literature show the existence of a fifth part, the cervical musculocutaneous trunk [bib_ref]  Anatomy of mylohyoid muscle: study of its origin, course and attachment on..., Ramesh [/bib_ref]  [bib_ref]  Variation in the origin of the human mylohyoid muscle, Haddad [/bib_ref] . When MMC's origin is altered or does not reach its normal pattern of insertion",
        "label": 0
    },
    "327": {
        "output": "<a class=\"blue\" href=\"http://cjr.amegroups.com/article/view/10.21037/cjr-21-288/rc\" target=\"_blank\">click here to see the R-markdown code</a>.\n\n### \u7d2f\u79ef\u7591\u4f3c\u8bc4\u4f30\n\nLet's focus on patient note. `pnt` is a list to store patient notes. \nBefore reading `pat_num` from file, you should define `patient_pool`, which is a list to store the current trial data, including the patient number, clinical trial data, and patient clinical trial data. \n<table class=\"highlight\"><tr><th class=\"blue\">Function</th><th>Description</th></tr><tr><td class=\"cyan\">pat_num<dt>R</dt><dd>read patient data according to patient number</dd></tr><tr><td class=\"cyan\">clinical_trial<dt>D</dt><dd>read clinical trial data according to clinical trial ID</dd></tr><tr><td class=\"blue\">patient_pool<dt>D</dt><dd>Save the current trial data, including the patient number, clinical trial data, and patient clinical trial data</dd></tr></table><a class=\"blue\" href=\"http://cjr.amegroups.com/article/view/10.21037/cjr-21-288/rc\" target=\"_blank\">click here to see the R-markdown code</a>.\n\nThen you should read each patient eligibility data from the patient note, where `clid`, `patient_id`, and `pat_clid` are the clinical trial ID, patient ID, and patient's clinical trial ID, respectively.\n<table class=\"highlight\"><tr><th class=\"blue\">Function</th><th>Description</th></tr><tr><td class=\"cyan\">pat_clid<dt>R</dt><dd>read the clinical trial ID from patient's clinical trial data</dd></tr><tr><td class=\"red\">pat_trial_eligible_data<dt>R</",
        "label": 1
    },
    "328": {
        "output": "<br><hr>\n\n# Results\n![result](./res/results_1.png)\n\n## Cohen's Kappa\n![cohen_k](./res/cohen_k.pdf)\n\n## ROC Curve\n![ROC_curve](./res/roc_curve.pdf)\n\n## Confusion Matrix\n![Confusion_matrix](./res/Confusion_matrix.pdf)\n\n## Combined Kernel\n![Combined](./res/Combined.pdf)<br><br>\";\" and \";\" in \"Kernel\" means \"or\". \"Combined Kernel\" is the combination between \"Kernel\" and \"Final SVM\".<br><br>\n## Feature Importance\n![feature_importance](./res/feature_importance.pdf)\n\n## ReliefF Score\n![ReliefF](./res/ReliefF.pdf);\n\n*In the Results, we compare our method with the classifiers based on the traditional machine learning: Decision Tree and Logistic Regression. \n\n\n\n![Screenshots of Clinicaltrials.gov ](./res/clinicaltrials.png)<br><br>\nYou should find this clinical trial on ClinicalTrials.gov<br><br>\n<EOD> Repeatability and repeatability coefficients: a review.\nPURPOSE\nOur purpose was to describe the relationships between statistical concepts related to the definition of repeatability and repeatability coefficients.\n\n\nMETHOD\nWe provide an overview of the definitions and relationships between the variance components associated with test-retest reliability measures, such as the intraclass correlation coefficient, coefficient of repeatability, coefficient of repeatability on residuals (CR 2 ), and mean estimate of intraobserver difference.\n\n\nRESULTS\nMost methods used to estimate the CR 2 assume that the intraclass correlation coefficient (referred to as alpha) is the correct estimate of the reliability. Although this assumption often is true, it does not always hold. However, with small samples, the estimate of alpha and the estimate of the variance associated with the intraobserver difference are correlated.\n\n\nCONCLUSION\nRepeatability coefficients are a better",
        "label": 0
    },
    "329": {
        "output": "<details><summary>HINT</summary><ul>\n\n*   Include only one patient in each patient note.\n\n*   Try to write a program in both \\language[Matlab] and \\language[Python].\n\n*   A sample Python file was already written.\n\n*   \\comment[NOTE]\n  Only your \\comment[Matlab] program will be considered as passed.\n  \\endcomment  \n\n*   Do not use any package (except numpy) if you wish to enter your \\comment[Python] program into the competition. \n</ul><summary>More information</summary>\n\n*   You should always use the Matlab and Python programming languages in \\language[Matlab] and \\language[Python] respectively. Both \\language[Matlab] and \\language[Python] programs should be in the same directory.\n\n*   In each submission, specify the title, name of the programming language and filename of the submitted file. In the case of \\language[Matlab], you should specify the filename of the \\language[Matlab] file.\n\n*   You should always run your programs without modifying them (e.g., \\language[Matlab] \\m_comp_test.txt). You should test the code after each function change.  You should also save your programs in a file and edit the file before running. You may also try submitting the Matlab program with _test_ included as a sub-test. If it gets failed, try deleting everything in _test_ with the exception of the function of a single sub-test (the code after the test will work). Then copy and paste it in _sub-test_ without the subtest in the directory \\language[Matlab] \\example\\.\n\n*   If your program is \\language[Matlab], it should use the following command: <code>@__init__(): </code> and you should define \\language[Matlab] \\import_modules(\"\").\n\n*   You may use all necessary packages in both \\language[Matlab] and \\language[Python] except for the ones used only for data analysis. This is because the package for data analysis is required for the final step in your function.\n\n*   If your program only reads a few lines in a given input, the execution time will be very short. Please try to set the read function to read",
        "label": 2
    },
    "330": {
        "output": "step 2.\nClinical trial, a therap-eligible for the trial toxic, infection for trial-level-eligibility for trials; the following study. Patients should have completed trial should remain blind randomization. ineligibility eligibility at randomized Eligibility to trial. trial`s criteria for trial to be randomization a criteria.\nPatient who are eligibility eligible, patient`s enroll the trial-level`s protocol. Eligibility is-related criteria randomization at an in the trial. randomized the randomization, a summary protocol-eligibility who are eligible patient.\ntrial eligibility.comparison. The treating the clinical trial.\npatient-trial eligible, in eligibility, clinical elig trial`s eligible. clinical trial-elig trial`s trial. In clinical study trial or-el elligness or trial for the protocol. For eligible trial`s characteristics the patient-specific, ij, which should developments, health`s clinical trial's eligible. patient`s history must make these trial eligibility-clin criteria in trial's trial criteria. A clinical oral:\ntrial-e for trial trial, eligibility, for the eligibility for eligibility.\n\ntrials: age trial and for elig trial`elig. Inelig patient`elig eligible, or trial. The elig.\ntoel.\nfor your patient-el, elig.el for trial-elig-el.\ntrial clinical trial elig clinical age patient's or elig's, clinical trial-el elig, they are elig (cl patient.\nel for the clinical trial:\nel/hev trial's elig trial, respectively, elig patient's elig patient's elig and the clinical clinical elig trial clin, and a person. When you`el or a clinical person_el\u2019s_el, and the en elig,l, iel the el and elig.\n[the elig, and elig elig trial. Pat [tri. This trial, clin. Her tocil)cl. There should and elig or that the",
        "label": 0
    },
    "331": {
        "output": "\u24d0 Trial-level Exclusion: `trial-level_exclusion` is a type of event for indicating patient data in the patient note are ineligible to the clinical trial. \n\nIn this patient note of the [patient]-20190419, the age of patient is 45, male, female, and Asian. The medical record of the [patient]-20190419 may look like this. \n\n\n#### Patient ID | 000936854\n\n#### Patient age | 45\n\n#### Patient sex | M\n\n#### Patient race | C\n\n#### Patient height | 1.8 (m)\n\n#### Patient weight | 78 (kg)\n\n#### Patient age of menopause | 40 (yrs)\n\n#### Patient marital history | M\n\n#### Patient current smoker | F\n\n#### Patient alcohol drinker | F\n\n#### Patient has a child | F\n\n#### Medical ID History | N\n\n#### Diagnostic history | No\n\n#### Procedure ID History | N\n\n#### Pathology exam history | N\n\n#### Histology exam history | No\n\n#### Imaging exam history | No\n\n#### Laboratory exam history | No\n\n#### Document | ICD9 \n\n#### Document | ICD10 \n\n#### Document | Current Procedural Terminology | \n\n#### Document | CPT| \n\n#### Document | HCPCS|\n\n#### Document | Drug| \n\n#### Rx Narcotic | N\n\n#### Drug Category | N\n\n#### Drug | \n\n#### Drug ID | \n\n#### Document | Medicare code| \n\n#### Document | Blue cross code | \n\n#### Document | Medicaid code |\n\n#### Document | Worker\n\n# Output\nThe following command evaluates the medical records. \n\n\n``` r\ndf.patient.result = dplyr::filter(df.patient, ClinicalTrialsID %in% Trial_No) %>%\n  mutate(S_Age = case_when(. > 60 ~ paste(S_Age, \"Years\"), . <",
        "label": 0
    },
    "332": {
        "output": "* Experiment 1\n\nWe have a dataset with exomeres. \n* Counts\n\nHere are two different count files with two samples and two batches each: \n* Patient 1\n\n`Sample 1, Batch 1:\nPatient 1, Batch 1:\nPatient 1, Batch 1:\nPatient 1, Batch 1:\nPatient 1, Batch 1:`\n\n* Patient 2\n\n`Sample 1, Batch 1:\nSamples 293, Batch 1:\nPatient 2, Batch 1:\nPatient 1, Batch 1:\nPatient 2, Batch 1:\nPatient 2, Batch 1:\nPatient 2, Batch 1:\nPatient 2, Batch 1:\nPatient 2, Batch 1:\nPatient 2, B",
        "label": 1
    },
    "333": {
        "output": "<EOD> Identification of a novel HLA-A*30 allele, HLA-A*30:293, in a Japanese umbilical cord blood donor.\nThe novel HLA-A*30:293 allele differs from the closest, reference allele A*30:02:01 in one nucleotide in cDNA and was identified by sequence-based typing in a donor of a Japanese umbilical cord blood unit.<EOD> The impact of intrauterine administration of low-dose nitroglycerin on cerebral blood flow and early adverse perinatal outcome: a randomized controlled trial\nAbstract Objective: To examine the effect of intrauterine administration of low-dose nitroglycerin on flow in the middle cerebral artery (MCA) and adverse perinatal outcome in growth-restricted fetuses. Methods: In a randomized-controlled double-blind trial, fetuses were assigned either intravenous infusion of low-dose nitroglycerin (0.75 \u00b5g/kg) or nitro-sugar (placebo) during the antepartum hospital stay between 24 to week 34 of pregnancy to 13 growth-restricted fetuses, with at least five antenatal MCA Dopplers with decreased resistive index. We prospectively examined cerebral blood flow by Doppler ultrasound of the MCA. Adverse neonatal outcome was defined as perinatal mortality and severe adverse events in the first week of life. Results: The MCA blood flow resistance significantly decreased in the nitroglycerin group (p\u2009=\u2009.016). There was no perinatal mortality in both groups. Conclusion: We demonstrated that a single dose of low-dose nitroglycerin is safe and can increase cerebral blood flow in growth-restricted fetuses.<EOD> Bacteremia\nSynonyms and keywords: Bacteremias\n\n# Overview\nBacteremia or bacteraemia is the condition defined by the presence of bacteria in blood circulation.  It can be caused by bacteremia caused by blood that contains bacteria entering the bloodstream, or contamination during",
        "label": 0
    },
    "334": {
        "output": "Let's consider a scenario where we are given a set of n patients' data in a tabular format, where each individual's data holds information about five different data fields. Each data field stores information about one clinical feature. In particular, we are given five different lists of patients' records {i.e.}, {person1}, {person2} , {person3}, {person4}, and {person5}. For example, the data in the list person1 is about the first patient. Each list of patent records contains the same clinical features/variables. Given that a set of individuals with patient records is available, our task is to predict the malignancy status.\nFor those who are interested in a real data set, the data were obtained from the following data set: https://statistics.harvard.edu/~john-skelton/biostat/datasets/breastcancer.dta.\n\nBefore we can use ML models to predict the malignancy status, we must clean the data to avoid errors. Thus, we need to apply string functions (e.g., \"isdigit\" and \"%isdigit\" functions, to remove white spaces.\nLet's start by reading a CSV file.\n\n$ csv2cdf --name test.csv\n\nHere we specify the input arguments for the \"csv2cdf\" function. The -n argument means to save the CSV file to a file name csv-test.cdf.\n\nTest file not found\n```\n\nThe above errors show that we do not have a CSV file inside the current folder and the path of the CSV file was wrong. Thus, we add the correct path in the second argument of the command.\n\n$ csv2cdf --name test.csv path\n\nTo check the data set, we need to convert the CSV file to a CDM file.\n\n$ csv2cdf test.csv\n\nAll the required CDM files are created in the specified destination.\n\n$ nmf-generate -e test.csv -v varname\n\nFinally, let's check the output file (nmf-test.txt).\n\n```",
        "label": 0
    },
    "335": {
        "output": "```\n\n## Repeat 3 times.\n\n</section>\n\n</subsection>\n\n</section>\n\n<section id=\"criteria\">\n\n<subsection id=\"interventions\">\n\n<h4>Interventions</h4>\n\n```ruby\n<intervention_section group=\"Intervention\" number=\"4\"/>\n<intervention_section group=\"Intervention\" number=\"5\"/>\n<intervention_section group=\"Intervention\" number=\"6\"/>\n<intervention_section group=\"Intervention\" number=\"7\"/>\n```\n\n</subsection>\n\n<section id=\"sample-size\">\n\n<h4>Sample Size</h4>\n\n```ruby\n<sample_size group=\"Samplesize\" number=\"5\"/>\n<sample_size group=\"Samplesize\" number=\"4\"/>\n<sample_size group=\"Samplesize\" number=\"2\"/>\n<sample_size group=\"Samplesize\" number=\"2\"/>\n```\n\n</section>\n\n<section id=\"outcomes\"/>\n\n<h4>Outcomes</h4>\n\n```ruby\n<outcome_section group=\"Primary\" number=\"1\"/>\n<outcome_section group=\"Secondary\" number=\"1\"/>\n<outcome_section group=\"Exploratory\" number=\"1\"/>\n```\n\n</section>\n\n<section id=\"secondary\">\n\n<h4>Trial Design</h4>\n\n```ruby\n<trial_design_section>\n    <sequence>\n        <section id=\"Interventions\" number=\"1\" name=\"Interventions\">\n            <section id=\"criteria\" number=\"1\" name=\"Criteria\">\n                <intervention_section group=\"Intervention\" number=\"1\"/>\n                <intervention_section group=\"Intervention\" number=\"2\"/>\n                <intervention_section group=\"Intervention\" number=\"3\"/>\n                <intervention_section group=\"Intervention\" number=\"4\"/>\n                <intervention_section group=\"Intervention\" number=\"5\"/>\n                <intervention_section group=\"Intervention\" number=\"6\"/>\n                <intervention_section group=\"Intervention\" number=\"7\"/>\n            </section>\n            <section id=\"outcomes\" number=\"1\" name=\"Outcomes",
        "label": 0
    },
    "336": {
        "output": "If you do not make this extra step for the last repetition, you will be penalized. \nI've been through all the code and it seems to be fine and I've reviewed my submissions and they do all of this. But there are also some strange things that happen like my triallevel eligibility isn't correct for almost all submissions, some triallevel eligibilities are always the same... How do you explain that? (This is a bug)\n\n\n### Problem 2\n\nThe correct answer is `1.18 hours` but your answer is `1.99 hours` [INST] In some submissions, it will take more than 30 minutes. Just be sure to make a trial-level eligibility in the last line by `Trial-level eligibility: 2) Eligible,` e.g., `Trial-level eligibility: 2) Eligible.`, otherwise you won't be able to answer the question correctly. \n\n### Problem 3\n\nYour answer has 87% accuracy, 87% precision, and 87% recall, which means that you identified the eligible patients correctly but did not identify as eligible patients who were not patients or patients who were not eligible. [INST]\n\nThis score is not very high, but it is more than 80%. To improve this, you should make all the necessary adjustments so that the precision is also improved. You may also increase the accuracy. \n\n#### Solution\n\nWe need to make the right adjustments so that this program can pass the benchmarking test from the judges. First, let's start by editing the code you already have. We found that to make all the necessary adjustments to make the code easier to understand and to make the code better for human readers, we should add comments and descriptions for each line of code we write in the code. It will help make the code more readable. Your current code is pretty good, but you should add some extra info if you want the judges to go on the same page. Also, if judges are confused about the code that you've written, they may not be able to understand it. \n\n### Solution 1: Add Comments in Your Code to Make It Better From A Human Perspective\n[",
        "label": 2
    },
    "337": {
        "output": ". \n\n--- End of example ---\n<EOD> A new device for the measurement of platelet\u2010coated red\u2010cell agglutination in whole blood\nSummary. A new device is described for the convenient measurement of platelet\u2010coated red\u2010cell (PCR) agglutination in whole blood, which is based upon the direct measurement of red blood cell (RBC) sedimentation velocity by a laser Doppler system.<EOD> .\nA 40 year old patient having a history of two episodes of transitory left hemiparesia, left hemianopsia and diabetes mellitus is presented. A diagnosis of left subarachnoid haemorrhage was made. A left vertebral angiography showed a type II aneurysm in the junction of middle and posterior third of the left vertebral artery, which was not found at the left vertebral magnetic resonance angiography (MRA). A left vertebral cerebral angiography combined to a thin-cut MRA study showed it. The differential diagnosis, imaging and treatment are discussed.<EOD> 12. Evaluation of GH and GH Secretagogues in Adults\nAbstract Clinicians who manage children with growth hormone deficiency (GHD) often find themselves evaluating short stature in their adult patients. The distinction between congenital GHD and adult-onset GHD (AOGHD) can be difficult and sometimes impossible: at the present time there are no",
        "label": 1
    },
    "338": {
        "output": "Explanatory note. \n\n[STYLE]\n\n### Eligibility criteria\n\nEach inclusion criterion has three values depending on whether the candidate satisfies or excludes the criterion. The scale for the assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nAn inclusion criterion is satisfied if the value of the corresponding factor is larger than a threshold that is the median value between the highest and lower value among three factors (ex. (age)), [bib_ref]  Breast cancer, Tavassoli [/bib_ref]  [bib_ref]  Clinical and pathologic variables in breast cancer associating with axillary lymph node..., Lee [/bib_ref]  [bib_ref]  Clinical and pathological factors which may assist prediction of axillary lymph node..., Chu [/bib_ref]  [bib_ref]  Prediction of axillary nodal status by physical examination, mammography, ultrasonography and fine-needle..., Gokalp [/bib_ref]  [bib_ref]  Predictors of axillary lymph node metastasis as detected by ultrasonography in breast..., Kim [/bib_ref]  [bib_ref]  The prognostic significance of clinical and pathological factors in 1000 patients with..., Cheung [/bib_ref]  [bib_ref]  Axillary lymph node metastases in patients with T1 carcinoma of the breast:..., Coutant [/bib_ref]  [bib_ref]  Factors which predict axillary lymph node metastases in breast cancer, Rakha [/bib_ref]  [bib_ref]  Lymph node metastasis in invasive breast cancer: predictive factors and prognostic Implications, Matkowski [/bib_ref]  [bib_ref]  Axillary lymph node metastases in small breast cancers with a favourable prognosis, Stoll [/bib_ref] . For example, if the age of participant is bigger than 62.86 years on average, then this criterion is considered satisfy. Another inclusion criterion: cytologically confirmed breast cancer. The upper limit of age in that study was 70 years [bib_ref]  Bre",
        "label": 2
    },
    "339": {
        "output": "<EOD> Neuroprotective Effects of Perilla Essential Oil on Cerebral Ischemia-Reperfusion Injury Mediated by the Nrf2 Pathway via the Modulation of Autophagy\nMicroRNA-205 may be involved in neuroprotection as a novel autophagy regulator in brain ischemia. The major components of Perilla extract (PE), an essential oil extracted from Perilla frutescens (L.) Britton var. frutescens, may be involved in the regulation of microRNA-205 in the autophagy pathway. The goal of our study is to determine the neuroprotective and anti-inflammation effects of PE on cerebral ischemia\u2013reperfusion (I/R) injury and to elucidate the mechanisms by which PE inhibits oxidative stress, cell apoptosis, neuroinflammation, and autophagy. Our results suggest that PE suppressed I/R-induced oxidative stress and autophagy by inhibiting reactive oxygen species (ROS)/nuclear factor erythroid 2-related factor 2 (Nrf2), B cell lymphoma 2 (Bcl-2)-associated X protein (Bax), cytochrome c release, and TUNEL and caspase 3 expression. Furthermore, PE inhibited microRNA-205-mediated autophagy and neuroinflammatory signaling via the modulation of autophagy protein 5 (ATG5) and c-Jun N-terminal kinase and phosphorylation of p7",
        "label": 0
    },
    "340": {
        "output": "## Trial-level eligibility: 0) Excluded\nThe number of trials at this level is 16, 16, 16, 0, 2 and 0, and the numbers of patients are (0, 0, 142, 0, 16) and (0, 60, 59, 15, 9) respectively. [INST]\n\n## Trial-level eligibility: 1) Not relevant\nThe number of trials in this level is 17, 13, 18, 0, 3 and 3, and the numbers of patients are (0, 0, 176, 5, 45) and (0, 61, 60, 16, 22) respectively. [INST]\n\n## Trial-level eligibility: 2) Eligible\nThe number of trials in this level is 15, 16, 16, 1, 5 and 5, and the numbers of patients are (0, 0, 151, 152, 25) and (1, 64, 62, 20, 21) respectively. [INST]\n\n## Trial-level eligibility: 2) Excluded\nNo trials are at this level, as 0 patients met this exclusion (including those with insufficient information to qualify for the trial). [INST]\n\n## Trial-level eligibility: 3) No information\nTwo trials did not meet one or more of the required fields to evaluate trial-level eligibility. The numbers of patients in these trials are (0, 8, 10, 0, 1) and none respectively. [INST]\n\n## Note\nWe should use the default Trial-level eligibility: 2 \"Eligible\" instead of \"Exclusion\".\n[INST]\nNote: This is the last line of the document.\n[INST]\n\n## Clinic-level eligibility\nClinic-level eligibility will be calculated at the end of trial-level eligibility, and the result is displayed on the last line of the document, e.",
        "label": 1
    },
    "341": {
        "output": "Now, imagine you want `N` patients. So, the trial input in the input panel must be `N=3` so that, `Subject-level eligibility for the Clinical Trial` output in the output panel will have 2 lines for input 1 and 3 lines for input 2 and output line. The third output line will be the overall assessment line. \nIf you check some patients, but don't find them all eligible, it does not mean that you have to stop the analysis. You can check more patients. If you have found all of them eligible, the program outputs an OK.\nThe program displays the code that performs each type of assessment, e.g., `AssessesEligibility(\"Patient\",\n                                   \"Trial\",\n                                   \"{eligible_factors = {}})`\nThe code in the input function is exactly the same as the code which can be displayed when you set the focus on `Input_Code_Box`. You can check the code by clicking the cursor to the right side when there is no word underlined in the code. If the word is colored blue, then this word has been identified as a variable. \nNote that sometimes it doesn't work because the text editor uses the default font size, and the font size of the input function is the same as that of the result output panel. In such cases, we can use a large font size to make it clear by highlighting the input function in the input panel \n\n# Eligibility checkers {#eligibility_checker}\nFor real-world usage, we consider 12 eligibility checkers and the performance on each checker is listed in the [elibility-checker-statistics table](docs/performance/elibility-checker-statistics.md).\n\nWe can display some results from the eligibility checker panel. Below, we display the code and the results of the checker #A03 \"Breast cancer with \u226560%, ER \u226510% by IHC\".{#A03}\n``` r\nlibrary(readr)\nlibrary(xtable)\nlibrary(knitr)\nlibrary(kableExtra)\nlibrary(glam)\nlibrary(knitr)\nlibrary(data.table)\nlibrary(jsonlite",
        "label": 2
    },
    "342": {
        "output": "[[EDIT] 3.3 You should always use the same line endings in the patient report. Make sure each note is well-formatted and uses consistent formatting. You need to run the report as well to see the report, so that you could get the same formatting. Just make sure that the report is consistent with the note format.]]\n\n\n<EOD> Cochlear Implantation with the Nucleus 6 Multi-Strategy processor in Adults: Speech Recognition and Quality of Life Outcomes\nThe use of the Advanced Combination Encoder (ACE) on a cochlear implant speech processor has recently been demonstrated to improve the performance of implant devices and to allow improved speech recognition in both quiet and noise conditions. This prospective study investigated the impact of the ACE algorithm on performance and quality of life outcomes. Twenty adult patients were included in the study and all were fitted with the same Nucleus 6 Freedom cochlear implant processor for a period of eight weeks. Each week the following outcomes were assessed in a controlled, double blind manner: the Speech Recognition in Noise with Sentences (RINS) test in quiet and with noise, Pure Tone Thresholds at the implant processor, and the Speech, Spatial and Qualities of Hearing (SSQ) questionnaire. Performance on the RINS test significantly improved with the use of the ACE-3 strategy, which was evident after one week of use. The benefits of the ACE-3 strategy persisted after four weeks of use. No differences were observed in speech recognition test performance between the ACE-1 and ACE-2 strategies. There were no significant differences between the ACE-3 strategy, either the ACE-1 or ACE-2 strategy strategies, and monosyllabic phoneme recognition in quiet. With the same processor and in the same weekly assessment, the Pure Tone Thresholds at the Implant Processor and SSQ results changed little, regardless of the algorithm and strategy used. These results indicate that the use of the ACE-3 strategy can significantly improve cochlear implant performance in noise conditions, and in our study this outcome was evident within one week of use.<EOD> Neonate\nA neonate, also known as a neonatal infant, or simply neonate, is",
        "label": 0
    },
    "343": {
        "output": "<EOD> A new antileukemic naphthoquinone.\nA new chemical compound, the 4-methylnaphthoquinone, has been isolated by vacuum distillation from the leaves of Pterocarpus gracilis Schumach. The structure of the compound has been established by X-ray crystallographic analysis. The compound and derivatives of it have been further studied for their biological activity. The compound was found to be toxic to Drosophila, but inactive against a Gram negative bacterium and a Gram positive bacterium. The structure of this new compound is very similar to the antibiotic anthracenequinone II, which was isolated from the same plant.<EOD> Association Between Clinical Phenotypes and Functional Outcomes at One Year After Stroke Based on Data From the China Antihypertensive Trial in Acute Ischemic Stroke\nBackground and Purpose\u2014 Clinical phenotypes are associated with prognosis at 3 months after stroke. It is unclear whether specific neurologic deficits persist at 1 year and impact recovery at 1 year after stroke. Methods\u2014 The Clinical Phenotype and Functional Outcomes After Stroke (NCT01846869) is an ancillary study to the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS), which has collected data on patients with acute ischemic stroke from 76 centers in China. Clinical phenotypes 1 year after stroke, derived from a previous systemic review, were classified as follows: sensory (sensory deficits of vision, face, hand, arm, leg, and foot), brainstem (brainstem-related deficits such as facial twitching, eye ptosis, diplopia, dysarthria, dysphagia, dysphonia, respiratory failure, Horner's syndrome, and dysphonia), bulbar (bulbar or swallowing dysfunctions such as oral motor dysfunction and dysphagia, oral diadochokinesis dysfunction, swallowing dysfunction), motor (motor deficits), visual (visual field deficits), brainstem",
        "label": 1
    },
    "344": {
        "output": "**4. In the given sample, are there any patients who will participate in the clinical trial?** \nFind the patient whose status is Eligible.\n\nThere is a patient whose status is 2) Eligible.\n\n#### EXERCISES\nIf you have any missing information like 0) Excluded, 1) Not relevant, 2) Eligible, then you can fill them into the data set.\nIt's better to think about those patients firstly, and then if you want, you can think about the clinical trial again, and finally, you can find out which trial is included in the group that you think about.\n\nNow, try to find a factor which is the most frequent in the NOT-ELIGIBLE group. \n\nLet's find out which items in the NOT Eligible group. Find out which items do not participate in the clinical trial.\n```python\n# This is part of the answer, not of the solution itself.\nfreqItem = len(set(f_eligible_c.dropna().to_dict()[value])) - len(set(fEl_eligible.dropna().to_dict()[value]))\n```\n\nThen if you find an item that is most frequent in NOT_ELIGIBLE group, you can count the number of cases including this item in the entire group of NOT_ELIGIBLE group.\n\nLet's try firstly. f_eligible_c is the data set that we made. You should also import pandas and numpy in this program.\nTo get the correct answer to this problem, we can utilize the set operations. The basic idea firstly find the items with frequency greater than 25% in the NOT_ELIGIBLE group. In other words, we will select the items whose frequency is greater than the ratio of the number of patients belonging to the NOT_ELIGIBLE group to the total number of patients. The following is the code.\n```python\nimport pandas as pd\nimport numpy as np\nfrom numpy import true_divide, floor\n\nf_eligible_c = pd.DataFrame(index=['001', '002', '003', '004', '005', '006",
        "label": 2
    },
    "345": {
        "output": "__01___Raise ClinFx__01_-_Patient Level (D)___\n[INST] Hello. You are an operator for ClinFx, a large medical clinical trial company. They are involved in a clinical trial for assessing the safety and effectiveness of a new immunotherapeutic drug. Your task is to identify whether a patient is eligible for a clinical trial in ClinFx, i.e., patient-level eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nIn this clinical trial, the inclusion criteria are:\nAge 18 to 70 years\nMen\nWomen (childbearing potential)\nPatients with locally advanced or metastatic nonsmall cell lung cancer\nPatients with an Eastern Cooperative Oncology Group Performance Status of 0-1\nHistory of treatment, regardless of prior treatment, with one prior platinum-based chemotherapy regimen (at least 1 cycle) given for metastatic disease, or with \u22651 regimen (adjuvant or neoadjuvant or for metastatic or locally advanced disease) given for metastatic disease\nTumor histology of any type other than small cell lung cancer\nFor more detailed information about the trial: \nYou should return the patient's eligibility status to ClinFx. \n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria",
        "label": 0
    },
    "346": {
        "output": "[INST] Hello again. You're a research assistant for clinical trials. Today, you are working with the dataset of [CLINICAL_TRIAL]\n[CLINICAL_TRIAL] is a single blinded, multicenter phase 3 randomized study to examine whether aromatase inhibitors (AIs) in the adjuvant treatment after the surgery is better than a placebo. Patients must be able to complete a total 4 years of adjuvant therapy. Women who are premenopausal have been treated with luteinizing hormone/ follicle-stimulating hormone analogs to become postmenopausal before randomization. Premenopausal patients will start the adjuvant tamoxifen for 2 years. The patients will be assigned into AI group or placebo group, respectively, at a 1:1 ratio. We aim to screen 356 patients for eligibility of which, 66 (18 %) patients must be included in the study. For detailed information on the inclusion and exclusion criteria, please see table below.\n[CLINICAL_TRIAL_DATA] \nThe aim is to have `p > 0.1`. For that, we should have as many patients that not relevant as is shown below. \nTrial-level eligibility: 0) Excluded 66 (56.92%)\n\n---\n\n[INST] Hello. There is an interesting and challenging clinical trial you may like to work with. In this trial you should compare the patients and the inclusion and exclusion criteria. In this trial, patient must have breast cancer (HER2-positive and  ER/PR negative) along with the absence of distant metastases. Patients must have at least a 1.65-cm diameter at least one tumor. Clinically, T2-T4a, any N category, M0. The maximum value for the score of ERBB2 is 6.00. The patient should have not received chemotherapy before.\nIn this trial, the total duration of the treatment will be 2 years. After 2 years of treatment, patients should have not received radiotherapy or chemotherapy in the breast and regional lymph nodes for at least 4 weeks",
        "label": 0
    },
    "347": {
        "output": "####[TEST] \nIf you are unable to read the instructions, then please click the following \"Run Test\" button to display the expected output. <EOD> 3D-printed silica nanocomposite scaffolds and enamel regeneration for dental restoration.\nAIM\nTo design a composite scaffold via 3D printing as an endogenous bioactive matrix for enamel regeneration.\n\n\nMETHODOLOGY\nThe composition and physical properties of the nanocomposite powder, a combination of nanohydroxyapatite (nHAp) and calcium polyphosphate (CPP), were characterized. The 3D-printed scaffold and enamel were compared to validate the feasibility of the restorative material. Cell metabolic activity and cell adhesion and proliferation of murine pulp stem cells (mDPSCs) were demonstrated on 3D-printed scaffolds (control), 3D-printed scaffolds without cells (3D-printed scaffold + mDPSCs), and enamel. The microstructure and cell distribution of the samples were evaluated under a scanning electron microscope. The expression of enamel-associated marker genes (Ameel, n = 5) and dentin sialophosphoprotein (Dspp, n = 5) was measured using reverse transcription quantitative polymerase chain reaction. Finally, mouse molar samples were extracted and processed after the scaffold was implanted subcutaneously. The samples were extracted 1 day and 14 days after subcutaneous embedding. After embedding in collagen gels, nHAp, CPP, HAp, nHAp-CPP and 3D scaffold control were implanted in the pulp cavity of mouse molars (n = 5). The dentine bridge width was measured and analysed.\n\n\nRESULTS\nAfter 1 day, the diameter of the HAp and CPP particles ranged from 20 to 35 nm and from 10 to\u00a030 nm, respectively, and they could penetrate cell membranes. The cell proliferation (P < 0.01) and ALP",
        "label": 2
    },
    "348": {
        "output": "### [INST] A1 Eligible (Patient meets inclusion criteria)\nLet's think step by step. \nFinally, you should always repeat at the last line by `Trial-level eligibility`.\n\n### [INST] A2 Not relevant (Patient does not have sufficient information to qualify for the trial)\nLet's think step by step. \nYou should always repeat `Trial-level eligibility`.\n\n### [INST] A3 Excluded\nLet's think step by step. \nYou should always repeat `Trial-level eligibility`. \n\n## PERFORMANCE EVALUATION - MOTIVATED BY [inst: 1]\n\nDuring the execution, two groups exist - the eligible group and the not eligible group. The ratio between these two groups is important to see how the model works for different values of the threshold.\n\n## 2x\nLet's think step by step. \n\n# ACKNOWLEDGEMENTS & CONTACT\n\nSources for this work were as follows:\n\n### [INST] Acknowledgements\nAcknowledgments\n- We are very grateful for fruitful discussions and suggestions for improvement from members\n- of the Machine Learning Department, Weizmann Institute of Science, and from Prof.\n- \n- We are very grateful for the feedback from the participants of the Weizmann Institute\n- Machine Learning Seminar talk. We also thank the anonymous reviewers for their constructive\n- comments on a previous version of the article.\n- We would like to thank the anonymous reviewers for their very constructive\n- comments on this article.\n- The authors would like to thank the members of the Machine Learning group at the\n- Weizmann Institute for their fruitful discussions on the topic.\n- This work was partially  supported by the  DIPS project  of the Israel\n-\n- The authors are grateful to Ms. Dena Schwartz-Tidhar for her  help with the figures and\n- tables.\n- We would like to thank Zahava Chai for his assistance with the R code.\n- Finally, we would like to thank the anonymous reviewers for their very constructive\n- comments on a previous version of the article.",
        "label": 2
    },
    "349": {
        "output": "<EOD> .\nThe aim of this article is to evaluate the results of the treatment of the 1-st grade of urethral strictures by the \"dorsal inlay\" technique. 2-mm-wide segment of buccal mucosa was obtained through a mucormyxectomy from the lateral side of the cheek or in the floor of the mouth. The transitional epithelium was stripped and the mucosal flap was brought into the area of the stricture. The \"dorsal onlay\" technique was performed in the case of 148 patients (52%), in spite of our recommendation to use the \"dorsal inlay\" technique in almost all of the cases. The follow-up period lasted 19 months, during which, the patients who had \"onlay\" treatment were questioned concerning the quality of their urination and micturition and their answers were scored by urologists. The follow-up data were collected by sending the questionnaires by post to the patients without follow-up visits to the hospital. The answer rates were good. 59 of 111 patients (53.2%) answered, 19 of them had \"dorsal onlay\" and 30 \"dorsal inlay\" treated urethra. The patients were evaluated by urologists. If they had satisfactory urination, micturition and voiding, their answers were assessed as \"excellent\", and if they complained of some discomfort while passing urine, the answer was graded \"good\". The majority of the patients treated by the \"dorsal onlay\" technique answered \"excellent, with a score value of \"good\". The authors evaluated the results of this procedure, and concluded that the \"dorsal onlay\" method is far less effective compared to the \"dorsal inlay\" method.<EOD> Mammary neovascularization is reduced in mice null for HIF-2alpha during development\nVascular growth is a critical factor for many diseases of the breast. In recent years, the angiogenic factor, vascular endothelial growth factor (VEGF), has been implicated in the pathogenesis of breast cancer and metastatic breast cancer, specifically as a result of increased expression of the VEG",
        "label": 0
    },
    "350": {
        "output": "<EOD> Molecular Mechanisms of FXS, RTT, and SCZ via L1, PIWI-interacting RNAs, and Mitochondrial Protein Networks\n\nFragile X syndrome (FXS), Rett syndrome (RTT), and Schizophrenia (SCZ) are neurodevelopmental disorders that occur in distinct, though often overlapping populations. The neurological and behavioral abnormalities reported in these conditions can be found in common sets of genes that participate in epigenetic control of gene expression and mitochondrial maintenance. Over the past decade, it has been well-documented that long non-coding RNAs (LncRNAs), and small non-coding RNAs play important roles in gene expression regulation, acting at the level of transcription and translation. In this review, we focus on 5 -capped lnscRNAs transcribed from long interspersed nucleotide element-1 (L1) promoters (L1MEs), which are abundantly expressed in brain tissue. These transcripts associate with piwiinteracting RNAs (piRNAs) and bind to L1 promoters via complementary sequences, contributing to transcription control events at L1 promoters, which often results in the induction or repression of mRNAs. We hypothesize that the L1 promoter-enriched molecular machinery that controls the gene expression profile of multiple L1-regulated genes, e.g., Bdnf, Nlgn1, and Fmr1, is shared among FXS, RTT, and SCZ. The results from our recent studies were consistent with this hypothesis, revealing that a single L1 expression event can contribute to several disorders. We propose that the mitochondrial protein network is a common mechanism underlying these neurodevelopmental disorders, since many L1, piRNA, and L1-regulated mRNAs are also present in mitochondria where they contribute to the regulation of mitochondrial functions, including metabolism, mitochondrial stress responses, and mitochondrial fusion and fission. The proposed mechanisms are depicted in schematic form.\n\n## Overview of neurodevelopmental dis",
        "label": 0
    },
    "351": {
        "output": "[fig]  1 ].: Exploration of the Effects of BMI, Age, Race, Hormone Receptor Expression and Neoadjuvant Therapy on Tumor and Lymph Node Yields in Breast Cancer: A Multi-Institution Study ........J. Tuma et al., AMA J. Surg. Oncol. 17(11):1769-77. A randomized prospective study of radiotherapy on pathological complete remission of breast cancer after neoadjuvant chemotherapy. . . . .A. Yue . . . . K. Qiu et al., SAGE J. Cancer Epidemiol. 2(1):1-6. Prevalence and association of P53, HER2 and Ki-67 expression in infiltrating duct adenocarcinoma of the breast-A retrospective study in a tertiary care setting in South India. . . . . R. Uthirakumaran et al., Journal of Clinical Diagnostic Res., 12(6), 2020 Jun, 63-68. The role of preoperative ultrasound guided biopsy in breast malignancy. . . . . M. A. Khan et al., Pak J. Med. Sci. 33(2):264-267. Abstract 24. Multidisciplinary approach to breast cancer. . . . . . . . . . . . . J. N. Kumar et al., J. Pak. Med. Assoc., 50(5):330-332. [/STOP] [/fig] \n<EOD> In vitro assessment of the effectiveness of novel fluorophores as autofluorescence guidance in surgery.\nOBJECTIVE\nTo compare the effectiveness of tissue clearing agents in the context of identifying residual fluorescing malignant tissue in fluorescence-guided tumor resection.\n\n\nSTUDY DESIGN\nWe employed a simple experimental system comprised of a lighted box and a CCD camera to measure the fluorescence response of tissues treated with common clearing agents . Clearing agents were used as a surrogate for tumor",
        "label": 1
    },
    "352": {
        "output": "[INSERT]\n[/INSERT]\n\n### 1.15 Final assessment:",
        "label": 0
    },
    "353": {
        "output": "<EOD> Glycosaminoglycans from cultured human mesenchymal stems inhibit bone marrow\u2010derived natural killer cell cytotoxicity and proliferation\nBone marrow\u2010derived adult human natural killer (NK) cells can induce hematopoietic progenitors proliferation during in vitro culture and this is inhibited by IL\u201015. Our objectives were to study the effect of hyaluronan (HA), heparan sulfate (HS), and dermatan sulfate (DS) from mesenchymal stem cell cultures on NK and IL\u201015\u2010induced progenitors proliferation. Our results showed that glycosaminoglycans reduced progenitors proliferation, HS being the most effective at 6.4\u2009\u00b5g/ml. The role of IL\u201015 was explored, where 6.4\u2009\u00b5g/ml of HS and DS added to progenitors and NK cultures did not decrease NK cytotoxicity on CD73\u2009+\u2009CD25\u2212 target cells but abolished cytotoxicity induced by IL\u201015. NK suppression was not dependent on NK cell activation, proliferation, viability, or degranulation. Inhibition of NK IFN\u2010\u03b3 production, induced by IL\u201015, occurred at 72\u2009h when HS and DS were added to both progenitors and NK cultures. In conclusion, HS and DS reduced target cell cytotoxicity and cell proliferation. These properties may promote the clinical use of these compounds for tissue repair, such as bone healing.<EOD> Neurogenic and cholinergic effects on rat colonic motility induced by intracolonic administration of sodium salicylate.\nBACKGROUND\nThe colonic transit and fecal evacuation can be influenced by several neurotransmitters such as acetylcholine derived from cholinergic neurons. Salicylate is known to be a gastrointestinal stimulant that can produce secretory and motor alterations. We investigate here the effects of sodium salicylate administered intracol",
        "label": 0
    },
    "354": {
        "output": "## Expert systems approach\nAs you may know, there are some expert systems to recognize ICD-9-CM codes that can be employed for medical codes assignment for patients. \nSome of these expert systems are as follows:\n- The Systematized Nomenclature of Medicine-Clinical Terms (Snomed CT), which is managed by the IHTSDO, is the most extensively employed in this field \n- The Logical Observation Identifiers Names and Codes (LOINC) system is another widely used expert system with 14,476 concepts for ICD-9-CM \n- The USC-SNOMED system (SNOMED CT version 2.5.5) enables mapping of ICD-9-CM codes to SNOMED CT codes\n- The Unified Medical Language System (UMLS), which is comprised of 3.6 million concepts and 6 million names, allows us to identify concepts in a variety of ontologies.\n- The Clinical Element Model (CEM) was developed by the American Medical Association (AMA) for standardizing and sharing patient data.\n- The Metathesaurus is integrated into the National Library of Medicine's (NLM) publicly available Unified Medical Language System (UMLS) and is based on the Health Care Knowledge Base (KnowledgeBase), the Resource Description Framework (RDF), and the Unified Medical Language Systems Ontology (UMLS-O) \n- The Unified Medical Language System Metathesaurus (UMLS Metathesaurus) is a standardized database that links over 60 separate controlled vocabularies\n- The Medical Dictionary for Regulatory Activities (MedDRA) is a standardized dictionary for medical dictionaries (MedDRA, 2019).\n- In May 2006, the WHO established a new nomenclature system for the indexing of diseases and other health conditions called International Classification of Diseases-11 (ICD-11).\n- The ICD is another standardized taxonomy system for diagnostics as it contains a number of rules and rules that are based on several data points in the health records \n- International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM",
        "label": 0
    },
    "355": {
        "output": "<EOD> Clinical Trials in Patients with Chronic Lymphocytic Leukemia Treated during the Last Decade: What Is a Therapeutic Advance?\nThe treatment of chronic lymphocytic leukemia (CLL) has become increasingly complex over the past decade. Current therapies extend the duration of response and sometimes cure; and the number of therapeutic options has increased dramatically. The current review discusses the changes in trial design in recent clinical trials, the prognostic factors that have been assessed in these studies, and how prognostication affects clinical trials. It also discusses in detail the findings in clinical trials and in registry data over the past decade. The current review also discusses the implications of these results for patient care and suggests how to incorporate this information into clinical practice.<EOD> The role of chemokine receptors in primary, effector, and memory immune responses against respiratory viral infections.\nThe inflammatory process occurring during respiratory viral infections is characterized by infiltration of lymphocytes and macrophages. Chemokines play an important role in the chemoattraction of these cells. We summarize recent findings of the mechanism of chemokine production and function during experimental respiratory viral infections in the mouse and humans.<EOD> The influence of a high oleic acid-soybean meal diet with or without exogenous fructooligosaccharides and inulin on growth performance, fecal coliforms and Escherichia coli shedding and ruminal parameters in weaned piglets.\nFeed additives have been shown to beneficially affect the growth of animals and to reduce the population of microorganisms in the intestine. This study was conducted to investigate the effects of supplementation of exogenous fructooligosaccharides (FOS) and inulin on growth performance; the total number of microorganisms in the feces; the growth of individual genera within the Enterobacteriaceae family; and the concentrations of ammonia, valeric acid and acetate in feces and the ruminal content of piglets fed a diet with or without",
        "label": 0
    },
    "356": {
        "output": "Let's look under the hood \nThe class [clinical-trials] is a subclass of the data frame [note] with a single column named [assessment] that has the patient assessment. Since we are testing eligibility, the type of assessed elements are [assessment] = [trial-level-eligibility].\nIt has columns such as [patient.name] or [trial.name] and an example of the latter is `Trial.name: metformin randomized trial of neo-adjuvant chemotherapy with or without metformin for HER2 positive operable breast cancer.`. \nAssessment-type can be either `Trial-level` or `Patient-level`. `Trial-level` and `Patient-level` are the names of the types of assessment found in data frames with data from clinical trials, e.g., `assessment = \"Patient-level\", `. \nThe package [data.table] has functions that allow you to add a type of assessment to a data frame. \nFinally, the package also has a function (`) that creates a new variable for assessing eligibility. \nThe first argument in this function is for assigning a value for the [assessment]:\n\n`ass=function(x) { if(x[,\"Assessment-type\"]==\"Trial-level\") { \"Eligible\"; if(x[,\"Assessment-type\"]==\"Patient-level\") { \"Not relevant\"; } }else {\"Excluded\";}}`\nThe second argument is for assigning a value for the assessment:\n\n`x[[\"Assessment-type\"]]=c(\"Trial-level\")`, which gives the assessment type. \nYou will also need the package [datatable]. \n[/CODE]\n- 1.) You may not use any functions from the packages [data.table] and [data.table.dt]. The only exception is using the packages in the first column of [x.data].\n\n## [code]\nx <- c(\"Female\", \"45\")\nx[[\"Trial.name\"]] <- \"metformin randomized trial of neo-adjuvant chemotherapy with or without metformin for HER",
        "label": 2
    },
    "357": {
        "output": "## FLOAT_VALUE\nYour task is to read patients' medical histories and then, based on the medical history, predict the next visit of the patients to a hospital.\n\nHere is some patient information:\nOn December 7, a woman who is a postmenopausal smoker presents to you, with complaints of headache and dizziness since one month, as well as pain in the right breast (with no tenderness) since two days ago. She also complains of constipation since yesterday. Her past medical history includes a diverticular disease for which she was operated on seven months ago and hypertension treated with amlodipine.\n\nThe following physical examination reveals normal hemodynamic parameters. However, a pulmonary crackles are heard bilaterally. A 1/6 systolic cardiac murmur, along with peripheral pulses were present. The abdomen is not distended, but an abdominal tenderness that is worse on the right side was found, as was the case for the liver being palpable while the spleen is not palpable. \n\nYou should predict the next visit of the patient to the hospital, based on the mentioned information. \n\nYour predictor, a matrix with the number of visits as rows and columns as features (e.g., for the previous 7 day of the past year, that is, 7 features; for the previous month, that is, 31 features; and for the previous year, that is, 366 features) - your output, the total number of visits during the next week, month, and year respectively. \n\nHere are some predicted results using the features below, where the feature \"Headache\" is the one that affects most in predicting the visits. If the feature takes the value 'no' or 'yes', the score of the features on the top is 1. If the feature takes value 'no, no', the score of the features in the middle is 1. \n[INST] Your turn. Give me the number of visits of your patient until three months from now.\n![INST] \n\n## BONE_CANCER_GENE_PREDICTION/\nThe following patient information represents a single row in the dataset.\n[formula]  RNA Seq #1",
        "label": 1
    },
    "358": {
        "output": "<EOD> Role of Lipoic Acid in Health and Disease: An Overview with Insight on the Chemopreventive and Prophylactic Potential of Alpha-Lipoic Acid.\nLipoic acid also called as alpha-lipoic acid (\u03b1-LA) is ubiquitously distributed in animal tissues. Contradicting reports on the benefits of \u03b1-LA on human health and disease are currently emerging. \u03b1-LA has shown beneficial effects in certain diseases like diabetes, atherosclerosis, cancer, and AD. Though, its role as a food additive as suggested by the Food and Drug Administration (FDA) in USA is now being questioned due to the presence of a wide array of heterogeneous mixtures of \u03b1-LA, dihydrolipoic acid, or lipoyl dipeptide due to impurity in \u03b1-LA. It is quite clear that in vitro studies are not always directly applicable for in vivo experiments due to the difference in the metabolic pathways. In addition, various limitations of cell culture systems like 2D cell culture make it difficult to interpret the results obtained from in vitro experiments. Thus, there is a strong need for well-designed human studies exploring the role of \u03b1-LA in health and disease conditions. This review will focus on the effect of \u03b1-LA on various pathophysiological conditions like diabetes mellitus, atherosclerosis, cancer, cardiovascular diseases, cognitive impairment, and AD. The review also highlights the potential of the human studies to confirm these results obtained from in vitro and animal studies. Future researchers should attempt to synthesize pure and uniformed source of \u03b1-LA, which will help to study the beneficial potential of \u03b1-LA in human trials.<EOD> Anatomic Distribution of Spinal Cord Lesions in Sickle Cell Anemia and its Relation to Pain\nStudy Design Using spinal magnetic resonance imaging, the authors compared anatomic distribution of spinal cord lesions and changes in pain in children with sickle cell anemia. In children with significant spinal cord lesion on magnetic resonance imaging, they compared findings on the T2-weighted TSE image to those of the T1-weighted TSE image. Objectives This",
        "label": 2
    },
    "359": {
        "output": "# Notes\n- \u2191 Template:Cite article\n- Template:Harv error page<EOD> The influence of various anaesthetic techniques on cardiac output, stroke volume and left ventricular myocardial performance index during percutaneous transluminal coronary angioplasty.\nAIMS\nTo assess if general anaesthesia influences cardiac output (CO), stroke volume (SV) and left ventricular performance index (LVP) as assessed by a new echocardiographic index, the myocardial performance index (MPI) during percutaneous transluminal coronary angioplasty (PTCA).\n\n\nMETHODS\nSixty patients were studied in a prospective, randomised, double-blind study comparing the influence of four types of anaesthesia/analgesia on CO, stroke volume, (SV), and LVP in patients undergoing PTCA. Group I: 46 patients, 17 men and 29 women, undergoing PTCA who were premedicated with midazolam, 4 mg, i.v., and thiopentone, 5 mg.kg-1, to induce general anaesthesia, then maintained with halothane or isoflurane. Group II: 14 patients, 5 men and 9 women, who were premedicated, induced and maintained with halothane or isoflurane without a neuromuscular blocking drug (NMBD). Group III: 20 patients, 10 men and 10 women, were premedicated, induced with midazolam, and maintained on propofol. Group IV: 20 patients, 11 men and 9 women, who were induced on high dose fentanyl (12 micrograms kg-1) and maintained on infusions of nitrous oxide (66%) and fentanyl or midazolam.\n\n\nRESULTS\nIn 20 of 60 patients, baseline values before induction of anaesthesia were recorded. This group consisted of Group I: (n = 10), Group III: (n = 2), Group IV: (n = 6), and Group II: (n = 2). Bas",
        "label": 0
    },
    "360": {
        "output": "```cpp\n#include <iostream>\n#include <fstream>\n#include <iomanip>\n#include <unordered_map>\n\nint main() {\n  std::fstream fin(\"clinical_trial.txt\");\n  std::unordered_map<std::string, std::string> clinical_trial;\n  std::streampos last_p;\n  int status, eligible;\n  std::string text, patient_inclusion;\n  for(int i=0; i<cin.getline().length(); ++i) {\n    text <--cin.getline();\n    patient_inclusion <--text;\n    if(last_p == last(text) && text.find(\"Eligibility Status: \") < 0 || text.length() == 0) {\n      last_p.get() <--text.find(\"Eligibility Status\");\n      patient_inclusion.pop_back();\n      clinical_trial[patient_inclusion] = text > i ? \"Eligible\" : (patient_inclusion == \"1)\" ? \"Excluded\" : \"Not relevant\";\n    } else {\n      if(text.find(\"1)\" < 0) {\n        if(text.find(\"[\") < 0) {\n          eligible = 2;\n        } else {\n          eligible <--get_eligible() <--text.find(\"[\");\n          patient_inclusion <--text.substr(get_eligible(), 2);\n        }\n      } else if(text.find(\"[\") < 0) {\n        eligible <--get_eligible() <--text.find(\"#\");\n        patient_inclusion <--get_inclusion_of_status(status);\n        clinical_trial[patient_inclusion] = eligible > 1 ? \"Eligible\" : \"Excluded\";\n      } else  {\n        eligible <--get_eligible() <--text.find(\":\");\n        patient_inclusion <--get_inclusion(status, eligible);\n        clinical_trial[patient_inclusion] = eligible >",
        "label": 0
    },
    "361": {
        "output": "[END]\n#2\n[START] [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for",
        "label": 2
    },
    "362": {
        "output": "## 2.What is the correct output?\nCorrect answer: 0) Excluded.\n\n# Discussion\nIn this section, you are going to compare your answer with the answer of the programmer. If you don't agree with the programmer's answer, you are asked to discuss about the problem with the programmer (especially when you know the answer) and to give some useful suggestions.\nPlease be aware that your discussion doesn't require you to reveal your source code to others.\n\n## Instructions\n\n1. Discuss your solution with the programmer. \n2. If you have a suggestion for improving the algorithm or the code, make it and submit it as a pull request.\n3. If your solution is clearly different (correct!), make a pull request, describe your algorithm, and write a Python program based on yours.\n\n### What is the wrong part of the answer?\nThe wrong part of our answer is \"Triallabel eligibility: 1) Not relevant\". It should be \"Triallabel eligibility: Eligible\".\n\n### What would you do to improve your algorithm?  \nLet's improve the algorithm of the original program to achieve the correct output: `Elgibilti` at the last line.\n\n### What is the pseudocode of your new algorithm? Please provide some details\nWrite pseudocode which is based on the explanation in this file. \nA new pseudocode for the given problem looks as below: \n\n```python\ndef EligibilityChecker():  \n     patient = PatientInput()\n     trial = Trial_Input()\n     trial.print_criteria()\n     for item in trial.list_patient_data():\n         item.print_description()\n\n if(item.age >=20 and item.age <=100 and item.stage <=1):\n         patient.print_description()\n\n if(item.stage <=1 and item.ER == \" 1 0 0 -1 -1  \" and item.PgR == \" 1 0 0 -1 -1  \" and item.HER2 == \" 0 1 -1 0 -1  \"):\n \n     if(item.lvi == \" 0 \" and item.lmp == 0",
        "label": 2
    },
    "363": {
        "output": "## 0x50. Trial-level eligibility per inclusion criteria (multiple conditions)\n\n[TRIAL] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, e.g., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast cancer in the left upper outer quadrant. The tumor is  HER2 positive and ER /PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial: \nTitle: Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy\n\n\nSummary: This research trial studies genetic profiles in blood and tumor samples from patients with estrogen receptor positive and HER2 negative breast cancer that has spread to other places in the body who are receiving palbociclib and",
        "label": 0
    },
    "364": {
        "output": "The eligibility assessment is written step by step starting from the patient to the trial. Thus, it becomes clear to a student that the patient and trial share many things but also have some differences. A medical student should learn to analyze the difference between the patient and the trial in each level. \n\n### Tutorial Data [INST][TUT]\n[INST]\n\nNow, let's see the same issue with the tutorial data. Here is the patient note:\nThe patient is a 28-year-old postmenopausal woman with metastatic breast cancer. A core biopsy revealed a 10 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is positive for estrogen (ER) and progesterone (PR) receptor and HER2, with strong positivity by immunohistochemistry (IHC) and confirmed by fluorescence in situ hybridization (FISH) analysis according to current ASCO-CAP (American Society of Clinical Oncology -College of American Pathologists) guidelines (HER2: 11.8 X). All axillary biopsies revealed 1-2 metastatic lymph nodes. Positron emission tomography (PET)/CT revealed bone marrow involvement but negative pulmonary lesions. Lumbar puncture revealed a CSF cytology positive for malignant neoplastic cells. She is on endocrine therapy of letrozole. She does not smoke or consume alcohol. She has no family history of breast or ovarian cancer. She has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nAnd, here is the clinical trial information:\nTitle: Fulvestrant + Tamoxifen in Hormone-Receptor Positive and ERBB2-Negative Metastatic Breast Cancer \n\n\nSummary: This research study is studying a combination of a drug called tamoxifen with fulvestrant as a treatment for hormone-receptor positive, estrogen receptor breast cancer (also known as ER+). \n\n### ELIGIBILITY CHECK [INST][TUT]\n[INST]\n\nBefore checking the elig",
        "label": 0
    },
    "365": {
        "output": "Copy the code below and then paste it into your Jupyter notebook. Change the code to meet your own medical purpose, but do not remove the keywords. We'll discuss the keywords in a bit.\n\n    #This is the patient's eligibility\n    with open('patient_note.txt', 'r') as fd:\n        patient_note = fd.readlines()\n        patient_note[-5:-1]\n\n    #This is the clinical trial's eligibility\n    eligible_codes = [\n        \"2\",\n        \"1\",\n        \"\"\n    ]\n    clinicaltrial = open(\"clinical_trial.txt\")\n    for line in clinicaltrial:\n        if line.split(\"#\")[0] in eligible_codes:\n            trial_level_eligibility = line.split(\"|\")[-1]\n            trial_level_eligibility\n    trial_level_eligibility.split('0)')[0].join(\",\")\n\n[INST] Remember that you should evaluate whether the patient is eligible to participate in the trial. A patient whose patient note is given as an input to the function is a candidate to participate in the trial. Therefore, you should evaluate the first `patient_note[0]` value. The values of the keywords in the function are as follows: the input (e.g., patient_note['age']), the variable name to substitute the input (e.g., patient_note_age), the values that the input variable should equal (e.g., '35, 65 years'), the keyword of whether to replace the value with '0' (e.g., patient_note_value.replace(\"'\", '')), and the code representing the values that each keyword represents (e.g., 'years='.join([\n    'age_year', 'age_years', '35', '65', '\"', '','',\n    'age_50_year', 'age_50_years', '\"', '\"', 'age_70_year', 'age_70_years', '\"', 'age_yearly',\n    'age_70_yearly', '\"', '\"', 'age_5_years', 'age",
        "label": 0
    },
    "366": {
        "output": "___\n\n### Section 4: 1965 Actors\n\nThe Medicare Prescription Drug, Improvement, and Modernization Act of 2003, often known by its nickname, the \"MMA\", created a new form of drug plan called the Medicare Part D Prescription Drug Plan (PDPP). These plans are administered and/or insured by private health insurance companies but are run under regulation by the Centers for Medicare and Medicaid Services (CMS).\n\nMedicare Part D, also known as \"Part D\", was created by the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003. These plans are administrated and/or insured by private health insurance companies. Part D provides drug coverage to Medicare beneficiaries by prescription drug insurance (PDI). The goal of this program is to give senior citizens and individuals with disabilities coverage for their prescription drug costs.\n\nMedications which may be covered by Medicare Part D include brand-name, generic, over the counter (OTC) drugs and medical equipment and supplies.  Medicare covers certain generic and OTC drugs, but the covered drugs vary by plan and the total list for each plan is known as a formulary.  Drugs not on the list can be purchased at the beneficiary's expense.\n\nThere are both stand-alone Part D prescription drug plans (PDPs) and Medicare drug benefit plans (a.k.a MAPs). The biggest difference between the 2 plans is that while both allow beneficiaries to choose any of the listed prescription drugs, those covered by MAPs must choose their plan's specific Medicare Part D prescription drug plan.\n\n### [PROT] Section 837.\n\n_### [PROT] Section 837_\n\n####_Lecture content.__\n\nThe Medicare and Medicaid statute contains several clauses that specify certain rules that insurance companies must follow when offering coverage for HMOs and SNFs, among others. For instance, Section 837 states that, in contracts with insureds to insure the lives of such insureds, no risk-sharing arrangement may be",
        "label": 0
    },
    "367": {
        "output": ". (in-with \\ \nin.\nafter, [bib_ref] \n\n _ (c in \\on:\nc for 0.\non- [/table] for a [bib_ref]_ 0 to<EOD>_ (a. and C and a medical for\n,\nfor a C [bib_ref] a \u00a0c and c\n in the \ns 1 [bib_ref] 2-only on a :\u00a0and/not for theoc\nof a [bib_ref] \nand, [bib_ref], 20\nc with 2 and a clinose.\n .\nspecific for the 3\n\non .\n _in \u2044 _ _(for any\n(direct [bib_ref]-cit-de 1\n ( 1. An ins (some for the.\n(for a medical [bib_ref] for\nfor 10\n2 [bib_ref] 2 (inst in clin 3 [bib_ref] and in [bib_ref]\nand of a-systeming-system in\u00a0in its in [bib_ref]\nall, and its .c - [bib_ref] \ufffd/all after\nin the [fig_ref] (\n \ufffd 2 on  - 1^s [bib_ref] \ufffdwith the \u2026 (as at a\ufffds-s 12 [fig_ref]\n -/\nfor\u00a0c at all 1 .\n 2 [bib_ref] a2\u00a0s.\nC (s - [bib_ref]\n-c  based and its. The in - [bib_ref]...for\n-in\n...\n\n1 -with in 4-in\n\n-\ns \u00a0 [bib_ref]in for [bib_ref] a2 for the3 at a _0, and [bib_ref]{ [bib_ref]-pat for \nregular, _for:the in [bib_ref]\ninst at [bib_ref], and [bib_ref] [fig_ref]g, which\nC(she on \\ [bib_ref]/ind for [bib_ref] in ..\n and...,in with\nby (as\n\n\n\ns on < \u22c5-ex to the 3 [bib_ref] [bib_ref] or 5 for a\n [fig_ref] 1 [bib_ref] i and [bib_ref]\nas for a\u00a0with a CIN. All with the^ on a [bib_ref]\nand as \ufffdthe in [s/c! [bib_ref]-ass [bib_ref]in- . 1- and [bib_ref] a{\nc 1 for the^ or [bib_ref] in\n-s-visual en (inst in\n...-b 1 to",
        "label": 0
    },
    "368": {
        "output": "## Exercise 5: compare a patient note to the exclusion criteria of a clinical trial\nIn this exercise you are a helpful assistant for clinical trial recruitment.\nYour task is to compare a patient note and the exclusion criteria of a clinical trial. The exclusion criteria of a certain clinical trial may be based on one or more of the following: 1) past history such as, cancer history and cardiac dysfunction; 2) present condition such as, acute or chronic inflammation in the nasal mucosa, abnormal findings on liver or renal function examination; 3) previous or current chemotherapy received as a systemic treatment; 4) pregnancy or lactation; 5) allergies to compounds used in clinical trials and, etc.; and other relevant medical history, and physical examination findings.\nGiven a patient note consisting of the information listed on the R chart below and with the following information, consider a clinical trial that is looking for patients who don't have allergies to the compound used in the clinical trial.\n\n\nThe following are the details of the clinical trial you are looking for:\nTitle:  A Novel Therapeutic Agent for Rheumatoid Arthritis\n\n\nDisease Description: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by joint inflammation and damage, with a wide spectrum of symptoms of pain, stiffness, and swelling. It is a major cause of disability in adults and is recognized as a systemic inflammatory disease.\n\n\nPurpose: A Novel Therapeutic Agent for Rheumatoid Arthritis is a Phase I/IIa dose-ranging clinical trial of a therapeutic agent being developed for the treatment of moderate-to-severe active RA.\n\n\nMechanism of action: The study drug consists of a novel fusion protein comprising an anti-human monoclonal IgG1 antibody fragment and a human IL-1RII/soluble human IL-1-binding protein (IL-1 trap/IL-1RII heterodimer). IL-1 blockade is intended",
        "label": 2
    },
    "369": {
        "output": "## [SOLUTION]  [INST]\nYou already prepared a trial-level eligibility for each patient and clinical trial. Next, we will write the patient list with the calculated trial-level eligibility:\n![[[Image from Figure 6-32][]]]\n\n\nWe will also prepare clinical trial tables corresponding to the eligible trial patients:\n\n![Image from ][]],\n\nNow, you can show the patient eligibility table output by:\n\n\n```python\n#+title: Patient eligibility table\n#+\n#+   # patient_no            : ID number of the list\n#+   # patient_list         : text of the patient notes\n#+   # patient_level_eligible: text of Eligibility\nfor patient_no in patient_list:\n    # patient_no            : ID number of the list\n    # patient_list         : text of the patient notes\n    # patient_level_eligible: text of Eligibility\n    print(f\"### {patient_no:+70s} {patient_list} {patient_level_eligible}\")\n\n[END]\n```\n```r\n# + title: Patient eligibility table \n# +   \n# +   # patient_no             : ID number of the list \n# +   # patient_list          : text of the patient notes \n# +   # patient_level_eligible: text of Eligibility \n    output <- setNames(patient_list[which(patient_level_eligible == 2)], \"patient_no\", \"patient_list\", \"trial-level eligible\") \n    table(output$patient_no, output$patient_list, output$trial_level_eligible)\n\n# + title: Clinical trial output table \n# +\n# +   # patient_no        : ID number of the list \n# +   # number_of_patients\n# +   # patient_list       : text of the patient notes\n# +   # trial_clinical_ID : clinical trial ID \n# +   # title             : the title of the clinical trial\n#",
        "label": 2
    },
    "370": {
        "output": "Now, you can move to the next step. \n\n### Step 3: Input parameters\n\nInputting patient-level parameters is done in the third step. In the input window, you will find a drop-down menu with three options: _`Clinical trial`_, _`Instructions pertaining to eligible patients`_ and _`Instructions pertaining to eligible patients. The three options are listed in the order of choosing the most suitable one, i.e. choose _`Clinical trial`_ on the first click, choose _`Instructions pertaining to eligible patients`_ on the second click and select the _`instructions pertaining to eligible patients. `_`_`Instructions pertaining to eligible patients`_ ].\n\nYou have to fill in the parameter field from top to bottom. For example, here are the first five patients' clinical trial and inclusion criteria values, as shown in.\n\n|Patient ID|Clinical trial|Inclusion criteria|\n\nIf the patient belongs to _`Clinical trial`, then the instruction will begin with `Trial-level eligibility:`, as shown in.\n\n### [INST]: Trial-level eligibility: 0) Excluded\n\nWhen the trial-level eligibility is 0, then check the field named `trial-level eligibility` for instructions for patients in the _``Clinical trial_`.\n\n### [INST]: Trial-level eligibility: 1) Not relevant\n\nWhen the trial-level eligibility is 1, check the field named `trial-level eligibility` for instructions for patients in _`Instructions pertaining to eligible patients`_.\n\n### [INST]: Trial-level eligibility: 2) Eligible\n\nWhen the trial-level eligibility is 2, check the field named `trial-level eligibility` for instructions for patients in _`Instructions pertaining to eligible patients`_.\n\n### [INST]: Clinical trial: NCT03457249\n\nFinally, you should fill in the parameters for the clinical trial name.\n\n### [INST",
        "label": 0
    },
    "371": {
        "output": "### Exercises\n\n## Exercise 5. You are the manager of a team. What do you need to do to manage the project?\n\nYour duty is to manage a project that the Ministry of Health has entrusted you to organize. The aim of the project is to improve the quality of the health-care system by encouraging a system for continuing professional education in which health professionals could attend training.\n\nThe Ministry of Health has determined the goals, the methodology, the duration of the study and the project manager of the project you manage.\nWhat is necessary to organize?\n\n#### Exercise 5.1\n\n#### Exercise 5.2\n\n#### EXERCISE 5.3\n\n#### Exercise 5.4\n\n#### Exercise 5.5\n\n#### Exercise 5.6\n\n#### Exercise 5.7\n\n#### Exercise 5.8\n\n#### Exercise 5.9\n\n## Exercise 6. You are a director of a company. You want to apply for a new position of manager for a large manufacturing company in order to be able to participate in the development of manufacturing systems.\n\nYou want to create the following documents to get the position of manager of the manufacturing company. What do you need to do?\n\n#### Exercise 6.1\n\n#### Exercise 6.2\n\n#### Exercise 6.3\n\n#### Exercise 6.4\n\n#### Exercise 6.5\n\n#### Exercise 6.6\n\n#### Exercise 6.7\n\n#### Exercise 6.8\n\n#### Exercise 6.9\n\n#### Exercise 6.10\n\n## Exercise 7. You are a student of the English degree at Universidad de Las Am\u00e9ricas in Quito, Ecuador.\n\nYou applied for an internship program at the University of Wisconsin Madison in Wisconsin, United States, with the help of your professors overseas. The internship program requires an academic certificate to demonstrate your language and academic progression. Therefore, you had to obtain an academic certificate prepared by a language teacher you can trust and who is a professor at the University of Wisconsin Madison.",
        "label": 1
    },
    "372": {
        "output": "Good luck!\n<EOD> Hygro-oxidation of cinnamaldehyde thin films: influence of water activity and relative humidity on crystalline structure of the cinnamaldehyde films studied by Fourier transform infrared spectroscopy.\nTo study the effect of aerosol solvent on cinnamaldehyde (CPA) thin films, Fourier transform infrared (FTIR) spectra of CPA thin films in the 30-99% relative humidity (RHs) and water activity (aw) range 0.05-0.375 were collected and analyzed. We found that the RH effect is much more prominent (up to 30%) than the effect of aw in the low RH range which is in contrary to the general observations in literature. We also found that the difference of the spectra collected in the 0.995 and 0.9 water activity range (30-60% RH) could arise only due to the presence of water molecules in the film.<EOD> Bipolar Versus Monopolar Radial Access in Nonobstructive Hypertrophic Cardiomyopathy: The First \u201cIn Vivo\u201d Comparison\n\nAims:Ablation of septal accessory pathways with the use of monopolar (MP) radiofrequency (RF) energy remains a challenge in hypertrophic cardiomyopathy (HCM). We report the in vivo and real-time (RT) imaging of bipolar (BP) versus MP RF-energy delivery in the mitral annulus (MA) and the left ventricle (LV) of HCM patients with nonobstructive septal hypertrophy and an accessory pathway.Methods and Results:A total of 14 patients with preexcitation on 12-lead electrocardiogram underwent ablation of a septal accessory pathway by BP versus MP delivery of RF energy. A retrospectively gated, 3-dimensional, real-time x-ray scanner (eNova",
        "label": 0
    },
    "373": {
        "output": "Now let's repeat your task with data for different cancer types:\n- `breast`\n- `malignant`\n- `luminal b`\n- `metastatic`\n\nAnd you should write down the following facts:\n- `Near Miss: This assessment includes all clinical trials, regardless of eligibility.`\n- `Exclusion: This assessment is to exclude patients who are not eligible for a certain clinical trial. After completing the assessment, the number of patients in the trial and exclusion criteria should be clear.`\n- `Relevant: To determine relevance, the researcher reviews whether the study data and eligibility criteria are appropriate and match with the inclusion criteria.`\n- `Unclear: If the details of the trial are unclear, or if the patients do not fit the eligibility criteria. If you cannot clearly judge if these patients are eligible for a particular trial, you should make it clear that these patients are not excluded because of unclear eligibility.`\n- `Target: Trial-level eligibility assessment. Evaluation of all types of patients, who may be able to participate in any of the listed clinical trials, is often appropriate.`\n\nYou may get familiar with the trial-level eligibility assessment in the following steps.\n\nStep 1\n\nLet's start from the assessment of clinical trial relevance; let's perform a trial-level eligibility assessment on all clinical trials according to the study type mentioned above. The assessment of trial relevance should be an independent process from making an eligibility assessment for a given patient. The trial-level eligibility has 3 types, i.e., patients are excluded, not relevant and relevant to the clinical trial, respectively. The trial-level eligibility assessment results should be written in a separate table with the row for the clinical trial and 3 columns for patients (column for each type of eligibility assessment). `relevance`, `not relevant`, and `excluded` are the 3 types of trial-level eligibility.\n\nIn the 2nd row, clinical trials and `relevance` assessments are listed in the `trial.relevance` column.\n\nIn the 3rd row, clinical",
        "label": 0
    },
    "374": {
        "output": "D \u25cb and in the 1 and (they /\n or the el [fig_ref] 1 [[ \\in their.\n in the trial. This trial, el\u00a0in the\nc. (the in accord and \n [bib_ref] or \n\nand, and thell 1.\n [bib_ref]and characteristics, conditions (or. The [bib_ref]. 8 and \n/and in which/ or \n(after or to 18-related in an 0-to 1 to a single, a\n \u2044 [bib_ref] { A [fig_ref] a \n/el [bib_ref]! (based 10, which\n or 1, and 11. Theand. We [bib_ref] [/table], but \\er. However- and theil in a \\,\ns and in additional.\n-related in the [bib_ref] on the _ _.\n [fig_ref], theo [bib_ref] their information.\n1 \ufffd. After [bib_ref] an [bib_ref]\n. We, 2, [/table] and [/table] \nthat. To her(for:m. 2 for a\u00a0 to 10 1\u00a0 \n\ninsted in and \n [fig_ref]. This\u00a0\n 4 on\nin 1\u00a0in 3-and or\\specific [bib_ref], [bib_ref]\n in a.\n-that of 7, and \u00c2 , 1\u00a0t/ the __-acc. [bib_ref]\n-based\nin, i/re for\n\non\non and. a  . a\\after and his _for clin for 0 for\n; 1 [bib_ref], such s{el or [bib_ref] the [bib_ref].\nfor its and for a or an [bib_ref] in \u2044tre of the\u00a0\n on [bib_ref] and [bib_ref] _based_ 2<EOD>\nfor the 6 \u25ba. \u00acdi [bib_ref]\n [bib_ref]  is \n-1 or one c and 8  s [bib_ref] 1^for the 2\n for \\...ass _\n(care treatment\n/bi [bib_ref] 3 and \non\nd 2 {in<EOD> The A\\2(some\nass, clin [bib_ref]in{not on_or\nto-in-non\u2010c 2 in an in the \u00a0tre and \u00ae- and\nfor one and a clineter\n 0 on the_ .c for clin for 1 and",
        "label": 0
    },
    "375": {
        "output": "### Task 2\n[CODE]\n### 2(x2). [/DATA/TEXT]\nInput the assessment of eligibility of each patient in the file triallist-x2.txt. In order to do so, replace the placeholders with the assessment of eligibility, e.g., `Eligibility=2` .\n\n\nIt is important to understand that [data and code block] is used for reading and writing the [DATA/DATA], [CODE/CODE] is used for reading and writing the [CODE/CODE].\n\n[DATA/TEXT] is used for storing values that you read and write. Values you read from a [DATABASE/FILE] are saved in [DATABASE/FILE] and values you write to the [DATABASE/FILE] are stored in [DATABASE/FILE] and values you read or/and write from the [CODE/BLOCK] are stored in [CODE/BLOCK]. You cannot save code-values in [DATA/TEXT] and if you save data-codes in [CODE/BLOCK], the code will not compile. If you want to read and write code, you have to use [DATABASE/FILE]. On the other hand, if you save and use data-instead of code-variables in [CODE/BLOCK], your program will not work.\n\n\nIf you have any problem with your program, see [SECTION/HELP], you can change the [DATA/TEXT] and [CODE/BLOCK] by `C:/` and run the program in the same folder.\n[/CODE]\n\n```\n[STOP] [SECTION/HELP]\n\n[SECTION/BATCH]\n//Reading\n[/CODE]\n\n[DATA/TEXT]\n[DATA/DATABASE] [DATA/FILE]\n\n[DATA/TEXT]\n\n[/DATA/DATABASE]\n\n[DATA/TEXT]\n[DATA/TEXT]\n\n[DATA/TEXT]\n\n[DATA/TEXT]\n\n[DATA/TEXT]\n[DATA/TEXT]\n\n[DATA/TEXT]\n\n[DATA/TEXT]\n\n[DATA/TEXT]\n\n[DATA/TEXT]\n\n\n[DATA/TEXT]\n[DATA/TEXT]\n[DATA/TEXT]\n\n\n//Saving",
        "label": 0
    },
    "376": {
        "output": "### Hint 7. `NOT RULING OUT #INCLUSION_CRITERIA`\nThe third-party software, if you're lucky, doesn't provide any convenience function for ruling out a set of criteria. So, you have to define the criteria set and use it for ruling out other criteria sets. It is a good idea to define the criteria set that ruling out (for the sake of convenience) so that you can apply it immediately when ruling out other criteria set. For example, consider the following patient note: `The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.`. You may notice that a patient doesn't meet the eligibility of ClinicalTrials.gov if the patient is using dietary supplements. You may try to look for a code that ruling out the usage of dietary supplements, so that you can apply the code to ruling out other criteria set. For example, by using the code [Codes#0], you can rule out supplements without using the [Not ruling out #Inclusion_criterion] code. The following is the definition of the criteria set for ruling out the usage of dietary supplements. The following is the definition for a criteria set that ruling out the usage of dietary supplements:\n`NOT us-ing [Codes#0]\nAs you can see, the expression \"[Codes#0] = YES\" is repeated 24 consecutive times. So, this is a very long expression. It is easy to make a mistake in copy&pasting. [HELP: Errors & Workarounds]\n\n## [INTERLUDE]",
        "label": 0
    },
    "377": {
        "output": "Your patient meets one exclusion criterion (see the bottom box `Age \u2265 65 years`):\n\n### Disease\nAge \u2265 65 years.\n\nAs you see, the second box from the bottom `AJCC 8th edition Stage 2` will always be on screen.\n\nYour program should ask the examiner to choose an option of two in a dialog box by pressing `P` for the first line, and `A` or `X` for the second line (you need `P` to continue the exam) from the second line (see the bottom box `Triage: 0) Excluded; 1) Not relevant; or 2) Eligible: ``). \n\n![INST](INSTRUCTIONS/Images/F97_Disease/1-12.png)\n\nIf you put your code in the `F97_Inclusion criteria.ipynb`, you can see the correct output below.\n\n\n># EG12014_clinical_trial - \n\n# In this file\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nHere is the patient note: \nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nHere is the clinical trial: \nTitle: Efficacy and Safety Study of EG1",
        "label": 1
    },
    "378": {
        "output": "<EOD> The Effects of 16-Week Home Exercise Training on Pulmonary Function, Exercise Capacity, and Quality of Life in Patients with Idiopathic Pulmonary Fibrosis.\nObjective\nThe aim of this study is to determine the effects of the home exercise training (HET) on pulmonary function, exercise capacity, and quality of life in patients with idiopathic pulmonary fibrosis (IPF).\n\n\nMaterials and Methods\nIn this single-centered randomized controlled trial, 44 of patients diagnosed with IPF and followed up with our Pneumology Department were screened. The patients meeting the eligibility criteria and randomly assigned to the control and HET group. Both groups were given daily home exercise and pulmonary rehabilitation (PR) education programs. Spirometry, six-minute walk test (6MWT), and St. George's Respiratory Questionnaire (SGRQ) were completed.\n\n\nResults\nAfter the intervention, SGRQ total score in the HET group improved significantly as in the control group. The 6MWT results of the intervention group increased significantly, while 6MWT results in the control group did not change. Similarly, spirometry results were significantly increased in the intervention group.\n\n\nConclusion\nWe found that HET was a feasible and safe alternative to PR training. The exercise program can significantly improve SGRQ and 6MWT scores. HET may also improve pulmonary function in patients with IPF.<EOD> Impaired Methionine Charging and Mitochondrial Function in Heat Shock Protein 90\u03b1-knockout Mouse Lens Prevents Age-related Protein Degradation and Cataract Initiation\n\nThe 90 kDa form of the heat shock protein (hsp90) system (hsp90\u03b1) is highly expressed in the postnatal lens. The present study aims to elucidate the role of the hsp90\u03b1 system in preventing cataract development in mice. We generated knockout and transgenic mice overexpressing hsp90\u03b1. Mice (C57/B6) deficient in hsp90\u03b1 showed impaired meth",
        "label": 2
    },
    "379": {
        "output": "[/END] \n\n## DS_Q1 \nNow we see that we need to do the eligibility by patient level and trial level. I think the eligibility is a three-level eligibility: no eligibility, not relevant, and eligible. The most important ones are patient level (no eligibility) and trial level (eligible).\nThe first question is how to know this? First, the eligibility of three-level (no eligibility, not relevant, eligible) and how to evaluate it.\nI will think of eligibility as an inclusion criterion. An inclusion criterion is one-step. That means there is no two-step. How do you know about it in a one-step? The one-step criterion for the inclusion criterion is no eligibility.\nFor the trial level, how do you know trial-level eligibility is eligible? First, you should know the patients. If you already know a patient's eligibility, then you're in the eligible category. If you don't feel something, then you have an unknown value or you are not interested. You know nothing, so you're not in eligible and not relevant. If there is no eligibility, then that is not relevant (e.g., no eligibility, no patients [END]\n\n2.4.6 Clinical Trial Registration  [INST] \n[/END] \nThe next step is to prepare the database with information extracted by a human. There are three data tables.\nThere are many tables for clinical trials, but I decided to make three tables:\n\n- **Subject:** patient subject\n- **Trial:** trial information\n- **Study visit:** scheduled and completed trial visits\n\nThere are four types of studies:\n- **Existing study:** study start date is known\n- **Scheduled study:** study start date is scheduled\n- **Completed study:** study start and end date is known\n- **On-going study:** study end date is unknown\n\nI recommend that you make three tables like this:\n\n<br><br><strong>Preparation with the Excel Template</strong><br><br>\nCreate a blank Excel worksheet and then copy and paste following",
        "label": 0
    },
    "380": {
        "output": "<jupyter_code>print(\"Trial-level eligibility: {}\".format(eligibility))<jupyter_output><empty_output><EOD> .\nThe 1, 6-dimethylnaphthalene (DMN), an aromatic hydrocarbon, has been shown to possess strong genotoxic effects. We have studied short term effects of this polycyclic aromatic hydrocarbon in an in vivo mouse model system. C3H male mice aged about 2.5 months have been treated at a dose of 0.5 mg/kg bw with DMN. The animals had been exposed for 4 consecutive days; DMN was subcutaneously injected in acetylacetone solvent. One day before DMN application the DNA isolated from peripheral blood leucocytes was irradiated with 0.5 Gy of gamma-rays. The frequency of micronucleus induction was determined in the mouse bone marrow cells at day 4 following injections. It has been demonstrated that the frequency of micronucleus induction decreased. The data obtained suggest that DMN is able to induce micronucleus in the bone marrow of mice.<EOD> .\nFifteen patients with chronic rheumatoid arthritis and 2 patients with osteochondropathia had a short-time oral administration of mastaxan-H (120-480 mg/day) along with the basal therapy. All the patients experienced an apparent anti-inflammatory effect, a reduction of pain, and an improvement of the clinical pictures. The drug is well tolerated, no side effects observed.<EOD> Rifampin Resistance in a Mycobacterium avium Complex Isolate Detected Using the Amplicor MTB/MAI Test (Roche Diagnostics)\nA new molecular method, the Amplicor MTB/MAI test (Roche Diagnostics, Branchburg, NJ), was approved recently for detection of Mycobacterium tuberculosis and Mycobacterium avium complex (MAC) DNA from respiratory specimens and for monitoring treatment response . The target in the Amplicor MTB/MAI test is the 16",
        "label": 0
    },
    "381": {
        "output": "### Task 2.9: Eligibility\n\n### Instructions:\nYou should output a table showing the patient's eligibility if `1. Yes` and `0. No` is used as an indicator. For example, the output could be:\n\n<table border=\"1.5\">\n  <tr class=\"header\">\n    <th style=\"width: 10%\">ID</th>\n    <th style=\"width: 25%\">Resection</th>\n    <th style=\"width: 25%\">Radiation</th>\n    <th style=\"width: 25%\">Neoadjuvant or Adjuvant</th>\n  </tr>\n  <tr>\n    <td><NAME>.014</td>\n    <td>Resection</td>\n    <td>Radiation</td>\n    <td>Adjuvant</td>\n  </tr>\n  </table>\n\n**Sample Output**\n\n\n\n<table border=\"1.5\">\n  <tr class=\"header\">\n    <th style=\"width: 10%\">ID</th>\n    <th style=\"width: 25%\">Resection</th>\n    <th style=\"width: 25%\">Radiation</th>\n    <th style=\"width: 25%\">Neoadjuvant or Adjuvant</th>\n  </tr>\n  <tr>\n    <td><NAME>.014</td>\n    <td>\n      1. Yes 1. Yes\n       1. Yes 1. Yes\n      <br>1. Yes\n     <br><br>\n     <br><br>\n      \n          1. Yes\n          1. Yes\n          1. Yes\n         <br>\n          1. Yes\n          1. Yes\n          1. Yes\n     <br>\n     \n      1. Yes\n      1. Yes\n      1. Yes\n      1. Yes            \n      <br>\n      1. Yes\n      1. Yes\n      1. Yes\n      1. Yes            \n      <br><br><br><br><br><br>\n     \n      1.Yes",
        "label": 0
    },
    "382": {
        "output": "Exemestane vs. Tamoxifen in Pre-and Perimenopausal Patients with Early or Advanced Hormone Receptor-Positive, Slotblotam S et al. -2018 -[STEP END]\n\n# [2016] 13_June_2\nTrial-level eligibility: 1) Eligible.\n\nThe assessment of eligibility has a thre-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n\nPlease find the input below and we will be checking in shortly.\n\n-------------------------------------------------------------------\n\nThank you for your time and patience. I want to apologize again for the delayed response here. Your training with our dataset is now complete. Thank you for all the help with this, I am confident that our analysts will easily pick up on it!\n\nI am happy to say that our analysts now plan on releasing our project early next week. They will be making the necessary changes to the document and getting that into a preview. Next week, they should be back at it. I will let you know when that happens.\n\nOnce that happens, I will be sending a document containing the finalized data to your mailbox for you to review again prior to launching the crowdsourcing project. I will send that out on Monday as planned. I do want to note however that because it is a document, it might take a little bit of time for it to travel through the crowd to you. \n\nOnce finalized and you\u2019ve approved it, we will do an initial launch to allow any potential changes to be made and to ensure that our editors and analysts have some time to check your data and edit it. In other words, it will allow us to fix some errors that the folks who created your data would have made that we catch once your data",
        "label": 0
    },
    "383": {
        "output": "**YOU MAY BEGIN**\n\nThis is a clinical note of a patient:\n27 Y.O. Female: \n\n\n- C.A: She is a 27-year-old female patient\n- S.A: Her surgical history includes two cesarean sections\n- F.A: She is living in a small house with many people\n- M.A: She has a sister and a brother and she got married at the age of 19\n- EDN: She has not completed her education\n- H.A: She lives in a small town with her family\n- EDV: She has good hygienic condition\n- C.H: All of her physical examinations were normal\n- S.H: She has a sister and a brother and her husband died\n- D.H: She got married at the age of 20\n- E.H: She is a housewife\n- H.H: She has no children\n- P.H: There is no problem in her personal history\n- F.A: Patient is undergoing laparoscopy surgery for adnexectomy and tubal ligation\n- F.A: She has a sister and a brother\n- M.I: Her past medical history includes only hypertension\n- D.I: She has an abrasion on her foot\n- S.I: Her family history includes hypertension and diabetes\n- S.I: She has a son with asthma and a daughter with diabetes\n- S.I: Her spouse's family history includes hypertension and diabetes\n- S.S: She's not sexually active\n- D.U: Her surgical history includes appendectomy, myomectomy, bilateral salpingectomy, breast biopsy, tonsillect",
        "label": 0
    },
    "384": {
        "output": "### Your work here is done!!\n<a href=\"#_top\" id=\"ref_top\"><strong id=\"ref_top\"></strong></a>\n___\n___\n<a href=\"#\" id=\"ref_top\"></a><sup id=\"ref_top\">[top]</sup>\n</ol><em class=\"ref_list\">[bottom]</em><br clear=\"all\">\n<br><br><br>\n<table class=\"docref_list_tab\"><tr class=\"docref_list_tab_header\"><td width=\"300\"> \n  <a href=\"#\" id=\"tab-docref_list-heading\"><i class=\"fa fa-table\"></i> docref_list_tab_head</a> \n</td><td width=\"120\"></td><td width=\"200\"> \n  <div id=\"docref_list-tab-content\" class=\"docref_list_tab_content\">\n  <ol class=\"docref_list_tab_index\">\n<li class=\"docref_list_tab_item\"> \n  <table class=\"docref_list_tab_item_caption\"><tr><td> \n  <span class=\"docref_list_tab_item_caption_heading\"></span> \n</td><td><span class=\"docref_list_tab_item_caption_heading2\"></span> \n</td></tr></table>\n<dl>\n<dt class=\"docref_list_tab_item_def\"> \n  <h3 class=\"docref_list_tab_item_def_head\"><code><i class=\"fa fa-fw fa-question-circle-o\"></i><b>Question</b></code></h3>\n  <h3 class=\"docref_list_tab_item_desc\"><code><i class=\"fa fa-fw fa-info-circle-o\"></i><b>Answer</b></code></h3>\n</dt><dd class=\"docref_list_tab_item_def_desc\">\n  <ol class=\"docref_list_tab_item_def_des\">\n<li class=\"docref_list_tab_item_def_des_head\"><code> \n  <i",
        "label": 0
    },
    "385": {
        "output": "# Examples\nYou can download the .json file and test in your local machine.\n\n\n```\n{\"type\": \"INST\", \"question\": {\"question\": {\"type\": \"LBL\", \"prompt\": \"1. What is the role of the trial-level eligibility?\", \"choices\": {\"01. Correct\": \"The trial-level eligibility refers to the trial-specific criteria to qualify.\"}, \"02. Incorrect\": \"None.\"}}, \"prompt\": \"Choose an answer: 01. Incorrect-There is no trial-level eligibility.\", \"answer\": [[\"Correct\"], [\"Incorrect-There is no trial-level eligibility.\"]], \"feedback\": \"It is correct.\", \"number_of_prompts\": 1, \"prompt_type\": \"LBL\", \"name\": \"correct answer\", \"choices\": {\"question_id\": 9, \"trial_level_eligibility\": \"Excluded\"}, \"total_answers\": { \"question_id\": 9, \"question\": {\"question_id\": 9, \"question\": {...}, \"choice_id\": \"01\", \"choice\": {...}, \"prompt\": {\"question\": {\"question_id\": 9, \"question\": {...}, \"choice_id\": \"01\", \"choice\": {...}, \"prompt\": {\"question\": {\"question_id\": 9, \"question\": {...}, \"choice_id\": \"01\", \"choice\": {...}}}, \"<NAME>: Question 9. What is the role of the trial-level eligibility?\", \"choices\": {\"01. Correct\": \"The trial-level eligibility refers to the trial-specific criteria to qualify.\"}, \"02. Incorrect\": \"None.\", \"correct\": \"The trial-level eligibility refers to the trial-specific criteria to qualify.\", \"incorrect\": \"There is no trial-level eligibility.\", \"total_answers\": \"3\"} }} }}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}",
        "label": 0
    },
    "386": {
        "output": "You can also use [`@@`] symbol (not to be confused with `@` for variables)\nto insert comments on your snippets as comments at the end of the snippet (e.g., in the bottom line).\n\nThe documentation for our software is in the form of markdown. You can create a snippet based on existing markdown snippet by using following syntax\n\n`# Add snippets about documentation.`\n\nThe snippet about the documentation will become shown as an [link](snippet.html#add-snippets-about-documentation) just like snippets with real data:\n\n<strong>Add snippets about documentation</strong>\n\n<!--\n\n# Snippets about documentation\n\nThe [documentation](documentation.html) of our software is in the form of [markdown](https://github.com/adam-p/markdown-in-r/wiki/Basic-syntax). \n\nYou can create a snippet that based on existing [markdown snippets](https://github.com/julia11/Snippets-to-show-some features-of-the-software-in-the-documentation#create-markdown-snippets) by using following syntax\n\n```\n\n# Add snippets about documentation.\n```\n\nIn the snippet about documentation, you will be able to see its [HTML markdown](https://github.com/adam-p/markdown-in-r/wiki/Markdown-syntax#html-markdown/html-tables) version below:\n\n<!--\n\n```\n# Add snippets about documentation.\n```\n\n[add-snippets-about-documentation]\n\n### Example 1\n\n### Example 2\n\n\nThe HTML markdown version will be shown as an [HTML snippet like real data snippets](snippet.html#add-snippets-about-documentation).\n\n\n---\n\n\n### How to install snippets\n\nIf you like all snippets to be shown on the page, you can install all snippets as a chunk:\n\n[install-snippets-as-a-chunk]\n\n[add-snippets]\n\n```\nadd_chunk(c(\"add\",\"addsnippets\", \"addsnippets2\"))\n```\n\nIf you want to",
        "label": 0
    },
    "387": {
        "output": "<EOD> Cutaneous mastocytosis: treatment review with emphasis in children\nMastocytosis is a pathological condition in which there is an aggregation of mast cells, as a result of a proliferative process of these cells within the skin. Treatment is aimed at achieving improvement in symptoms, although there are still no standardized or accepted recommendations, for a proper management. We review the treatments available in the literature and discuss their indications and the results obtained. The treatments can be classified as symptomatic, those that aim an histological improvement with a stabilization of the disease or those which achieve an improvement in the disease itself and/or a decrease in the number of mast cells. They may act directly on mast cells or at the level of mediators that determine the symptomatology. The most frequent treatments are given in oral form as they are generally well accepted by the patients, particularly antihistamine, antihistamine\u2013leukotriene blockers, anti-serotoninergic and omalizumab. Injectable preparations include the omalizumab, cromolyn, corticosteroids, beta 2 adrenergic stimulating agents and sodium cromoglycate. There are also non-pharmacological approaches: food-free diets, with or without a dietitian, phototherapy and other complementary therapies. Cutaneous mastocytosis is a pathological condition which manifests itself in the skin, affecting children more frequently, and whose treatment is still the object of studies with a still poor scientific evidence.<EOD> Fractures of the acetabulum: accuracy of CT scans in predicting the nature of displacement and fracture stability.\nThere is no general consensus concerning the utility of CT in pre-operative planning for displaced acetabular fracture. Radiographic assessment of both anteroposterior (AP) and frog-leg oblique (FLO) views have been reported to be valuable in determining the severity of comminution, and have been used to predict displacement and acetabular fracture stability. These same parameters have been reproduced on CT scans but its utility is still controversial. Forty patients with displaced ac",
        "label": 2
    },
    "388": {
        "output": "[/MID]\n<small>\n\n### Instructions\n\nYou will be provided with patient data and will complete a trial-level eligibility assessment.\n\n### Requirements\n\nThe minimum system requirements are:\n\n- 6000 MB free disk space\n- An internet connection\n- An up-to-date browser (e.g., Firefox v52 or latest) (You can download it from [https://www.mozilla.org/firefox/](https://www.mozilla.org/firefox/) \n\n### Rules\n\n- Work individually.\n- You have 30 minutes to answer the assessment.\n- No discussion is permitted or allowed.\n- No help is permitted.\n\n### Important Information\n\n\n1. No personal data will be collected from participants.\n2. Ethical approval was granted by the research committee of a university, and all procedures were conducted in accordance with the Helsinki Declaration of 1975, as revised in 2008.\n3. You are not allowed to copy solutions.\n4. Only those who accept the above conditions and the terms will be eligible to attempt the assignment.\n5. We will not send any certificate to those who complete it.\n\n### Problems\n\n\n### <ol>\n\n#### A. <NAME> Patient\n\n#### A. <NAME> Patient\n\n#### A. <NAME> Patient\n\n#### A. <NAME> Patient\n\n#### A. <NAME> Patient\n\n#### A. <NAME> Patient\n\n\n\n\n### B. <NAME> Clinical Trial\n\n#### B. <NAME> Clinical Trial\n\n#### B. <NAME> Clinical Trial\n\n#### B. <NAME> Clinical Trial\n\n#### B. <NAME> Clinical Trial\n\n#### B. <NAME> Clinical Trial<EOD> P060 Detection of the H379K mutation in the spike protein as a mechanism of immune escape through reduced antibody binding in an emerging SARS\u2010CoV\u20102 variant in South Africa \u2014 A retrospective cohort study\n\n \n\n## P061\nC",
        "label": 0
    },
    "389": {
        "output": "A: I recommend to create and run a small python script to generate test data.\nYour main file should be the following:\nimport os\nimport subprocess\n\n# your trial parameters here\ntrial_name = \"Example TRIAL\"\ntrial_short_name = \"ExampleTrial\"\nstudy_type = \"observational\"\n\nif trial_name == \"Example TRIAL\":\n    output_file = \"trial_summary.json\" \n    # trial inclusion criteria here\n\nif trial_name == \"ExampleTrial\":\n    output_file = \"trial_summary.json\" \n    # trial inclusion criteria here\n\n# your patient data here\n\ndef generate_test_data():\n    for trial_name in [\"Example TRIAL\", \"ExampleTrial\"]:\n        # your patient data here\n\ntrial_summary = json.dumps({\n    \"Trial-level eligibility\": (2) Eligible,\n    \"Sex\": (2) Man,\n    \"Race\": (2) White\n})\n\nprint(trial_summary)\n\ndef main():\n    with open(\"trial_summary.json\", \"wb\") as file:\n        json.dump(trial_summary, file)\n\nmain()\n\n\nA: You probably need to find a Python program which generates random strings of characters that meet certain constraints.\nHere is a simple one.\ndef random_string(length:int, min_char:int, max_char:int):\n    ret = ''\n    while length:\n        c = random.randint(min_char, max_char)\n        ret += c\n        length -= 1\n        return ret\n\nIf you do it correctly, with the program written above, and run it inside a loop with parameters \"45\" and 2, you will get the string \"Exclusion Criteria 2, Criteria 4, Exclusion Criteria 0\".\nAnother version of this program:\n\n\ndef generate_test_data():\n    for trial_name in [\"Example TRIAL\", \"ExampleTrial\"]:\n        for sex in [\"Exclusion Criteria 2\"]:\n            for race in [\"Criteria 0\"]:       \n                output_file =",
        "label": 0
    },
    "390": {
        "output": "You should create a function that takes a patient note and returns a three element list where each element is a patient's state (not relevant, excluded, or eligible). You will need to fill in the function body with the code to perform that task.\nBelow is the body of a correct function that could solve the task (it has not been checked, so make sure you don't submit it as your solution !!!).\nimport os input(\"\\n Please write a function called is_eligible.py that takes a patient note as input in the \\n following format: 45-year-old woman, postmenopausal with breast cancer, 4 cm invasive ductal breast carcinoma in the left upper outer quadrant. \\n 3.9 cm invasive ductal breast carcinoma in breast #7. The tumor is HER2-positive and ER/PR negative. Axillary testing revealed 5 positive lymph nodes. CXR demonstrated metastatic lesions.  \\n The patient is using multivitamins, iron supplements, is not sexually active and has no children. She is a candidate for tumor resection before chemotherapy.  \\n Please output the assessment of eligibility in format '[patient age][trial eligibility]:`  \\n Use the following methodologies: os = open('input.txt', 'rt') data = os.write(os) data=os.readline() os.close() f = open(data, 'r') result = os.write(f, '\\n') result=os.readline() \n\n#!/usr/bin/env python 3\n#is_eligible.py -  function that returns three patient states (not relevant, excluded, and eligible).\nprint('\\nPlease write a function called is_eligible.py that takes a patient note as input in the following format: ' + format_patient_note() + ':')\nresult = input('\\n')\nstate = 0\nwhile(len(result)>0):\n    if re.match(patient_note_regex(), result):\n        state += 1\n    if re.match(exclusion_criteria_regex(), result):\n        state -= 1",
        "label": 2
    },
    "391": {
        "output": "[RUN] \n```python\n# this works because clinical trial has a trial_id in it\npatient_texts = [x['Clinical Trial'] for x in clinical trial_dict.values()]\npatient_texts.append([])\nprint(len(patient_texts), \"texts\", \"from\" , \"patient_texts\")\nclinical_trial_names=(trial.text for trial in clinical_trial_dict)\nclinical_trials=list(set(clinical_trial_dict.keys()))\nclinical_trials_names=list(sorted(clinical_trials_dict.keys()))\nall_trials_in_patient=set(patient_texts).union(set(clinical_trial_names))\nclinical_trial_names_in_patients=list(patient_texts)\nclinical_trial_eligibility=list(set(clinical_trials).except(set(clinical_trial_names)))\nprint(len(clinical_trial_names), \"texts\", \"from\", clinical_trial_names)\n\n# print(len(patient_texts), \"texts\", \"from\", patient_texts)\nfor trial in clinical_trials:                       # each line contains an 'inactive' clinical trial\n    print(\"Clinical Trial Name:\", trial)\n    print(\"clinical trial eligibility:\", clinical_trial_eligibility)\n    if trial in clinical_trials_names:\n        print(\"Patient name:\", trials_patient_name[trial])  # the trial name as a string\n        print(\"Patient ID:\", trials_patient_id[trial])  # the patient id as a string\n        print(\"Patient Gender:\", trials_gender[trial])  # the patient gender as a string\nelse:\n    # if the trial wasn't found in clinical_trials_names (no eligible patients were found in clinical_trial_names)\n    print(\"in inactive clinical trial\",",
        "label": 0
    },
    "392": {
        "output": "</pre><p>Let's check for the patient's eligibility for the trial.</p><pre class=\"sourceCode js\" id=\"c1\"> \nTriallevel eligibility:0) Excluded; 1) Not relevant; 2) Eligible; 2) Eligible.</pre><p>The patient is <NAME>, a postmenopausal woman without a history of cancer. The patient underwent a hysterectomy 5 years ago, but has a family history of breast cancer. She has no smoker or alcoholic family history. She denied having any of symptoms related to cardiovascular diseases. She has no history of seizures or drug allergies as well. There were no family history of premature cardiovascular diseases or diabetes mellitus in first-degree relatives. Her husband's family has a history of <NAME> (breast cancer) and <NAME> (heart diseases). She has no history of cardiovascular disease or stroke. She had 1 pregnancy in 1991, but was treated with mifepristone. She is not allergic to painkillers. She had a history of seizure 5 years ago and is taking carbamazepine. She underwent menopause at the age of 37 and is sexually inactive. \n</pre><p>Ok <NAME>, the patient is an <NAME>. Yes, this is an eligible patient. This patient is the age limit. She does not smoke as well and she is sexually inactive. She denies having any history of cardiovascular diseases. She doesn't meet the exclusion criteria!</p><pre class=\"sourceCode js\" id=\"c2\">Patient is <NAME> with a history of cervical cancer on hysterectomy 5 years ago. She is <NAME> for hysterectomy. She has <NAME> and <NAME> in the family. She has a history of <NAME> for >10 years. Her father has a history of hypertension. She has a history of <NAME>. She has no history of cardiovascular disease. She denies having any of symptoms related to cardiovascular diseases.</",
        "label": 0
    },
    "393": {
        "output": "<EOD> Cerebral Blood Flow Changes in the Cortical and Subcortical Areas After Hemorrhagic Stroke in Rats\n\nIntroduction: The aim of our study was to analyze and compare the effects of hemorrhagic stroke (experimental intracerebral hemorrhage -ICH) in three brain areas (cortical, thalamic and basal ganglia), and in each of these areas a comparison was made between the areas directly affected by the stroke and the areas located on the opposite side of the brain. Methods: ICH was induced with a collagenase in the right frontal lobe of the brain in rat brains for 1 hour. ICH was induced by unilateral injection of collagenase at a dose of 10 U (4 L of collagenase). At the end of the collagenase injection, the needle was reinserted 2 mm further for 10 or 20 minutes to drain the blood from the wound. In the control group, the animals received a collagenase but the whole injection procedure was performed in an inactive rat. The total volume of the injected collagenase solution (containing collagenase, bovine serum albumin [BSA] and normal saline solution) was 3 L. The animals were decapitated at 2, 4, 6, 8 and 12 hr after the induction of ICH. Cerebral blood flow (CBF) was assessed in the cortical, basal ganglia and thalamic areas with an electromagnetic flowmetry. Results: Our results show that changes of CBF in three parts of the brain were significant and time-dependent. Changes of CBF were different in each area and each area at any time was unique. Time-dependent changes in CBF were different for each of the studied parameters. Thus, we observed that in both groups, in all brain areas, CBF was significantly increased 2 hr after ICH. At 2-4 hr after ICH in the cortical area, CBF reached the lowest value, 28.65\u00b11.80 mL/min/mL, and then gradually increased until 12 hr when it became 12.4\u00b13.16 mL/min/mL. At the",
        "label": 0
    },
    "394": {
        "output": "## Rules\n\n* The patient note has this head note \"Recent abnormal mammogram followed by a breast biopsy\"\n* The clinical trial has these criteria \"recent abnormal mammogram followed by a breast biopsy\"\n* The eligibility rules are the AND boolean operator between the patient note head note \"Recent abnormal mammogram followed by a breast biopsy\" and the clinical trial criteria.\nTherefore, there are two possible patient types:\n\n* The patient note is the same as the trials' criteria so patient note AND patient note are both \"True\", and eligibility score is 0 or 1.\n* Otherwise, patients score 0 if their notes do not match trials' criteria.\n\n## Examples\n\n### E1973\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). [INSERT GIF]\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the result.\nClinical Trial:",
        "label": 2
    },
    "395": {
        "output": "You can output the trial-level eligibility by a keypress. \n \nA detailed clinical trial specification is shown in Figure 6. You can also see the user interface of the Eligibility Assistant in Figure 7. We will explain the functions of the Eligibility Assistant in a step by step manner. \n<figure>\n  <img src=\"./resources/doc/clinical_trial_specification.jpeg\" width=\"754\" height=\"1113\"/> \n</figure> \n<figure>\n  <img src=\"./resources/doc/the_user_interface.jpeg\" width=\"154.5\" height=\"299\"/> \n</figure>\n\n[Tutorial link (PDF): <https://docs.google.com/document/d/1sCzG7MlqJ6xUh-VgKOUV4yWZR01V6Ws9FqF4hck3Gw/edit#heading=h.7j8z6478614> ]\n\n# Incorporate CDEs\nIf you wish to generate clinical trial data from scratch or reuse trial specifications, you should use CDEs as basic resources.\nIf you are not familiar with CDE development, we first suggest you read the tutorial of `Incorporating the Common Data Elements into an ePRO Platform`. It is similar to the following workflow: \n\n[INST] We will explain a CDE example using `Harmonized Clinical Data Language (HindiCDE)` and the related clinical trial, `Clinical Study on the Relationships among the Profiles of Sleep Quality, Cardiovascular Function, and Quality of Life of Healthy Adults (Study 171666) (Phase 1/2) (ClinicalTrials.gov ID: NCT02414559),` which is a clinical trial aimed to investigate the relationships among the profiles of sleep quality, cardiovascular function, and quality of life of healthy adults. \n\n\n\n\n1. Select the `Common Data Elements` folder.\n2. Click `Create CDE` to create a new CDE.",
        "label": 0
    },
    "396": {
        "output": "_NOTE_\n\nThe main issue with this dataset is that there is no gold label for each line of the dataset. In fact, we only know that we need to use the same line for each patient and that we can only label the patient-level eligibility. As the patients are unique in this dataset, we can use the information in the data to label all lines. In other words, we can label the labels instead of the data. This is called `labeling by the way` in data mining jargon.\nFor each line of the dataset, we just need to label it as _either_ Trial-level Eligible or Trial-level Non-Eligible. We don't need to use the number 0 or 1 to indicate the exact evaluation of the eligibility.\nYou can use your favorite language or tool for your final solution. It could even be a spreadsheet with a rule for each patient. Let your imagination fly!\n\n___EXPLANATION OF THE EXERCISE___\n\n### What to do\n\n___Externally available datasets_\n\n[https://www.kaggle.com/c/clinical-trial-eligibility-assessment\n\n\n\n[https://docs.google.com/spreadsheet/ccc?key=0Ald0WsXv2HQcdGp2VE4wZWE0Y2s6ZzF5bWY3TS0qUVk&usp=docs_linux\n\n\n**_10 - Data Science**\n\n[10_DATA_S_CI.md](010_DATA_S_CI.md)\n\n___Exercises in other languages___\n\n[EN_README.md](../README.md)\n\n___Exercises (EN)__[Readme in other languages](/en/10%20-%20_DATA_S_CI.md)\n\n___Exercises (RU)_[Readme in other languages](/ru/10%20-%20_DATA_S_CI.md)\n<EOD> Experimental and Theoretical Studies of 1,6-Oxazine Derivatives: Synthesis, Electrochemical, Photophysical, and Photovoltaic Properties",
        "label": 0
    },
    "397": {
        "output": "``` sh\nTrial-level eligibility: 2) Eligible.\n```\n    \n![An example of the patient-document.pdf](./media/11-patient note-doc-example.pdf)\n\n[Links](#links)\n\n##  [Trial-level eligibility](link)\n\n\n---\n\n\n# Links\n\n## [Download Trial-level eligibility file](download)\nDownload trial.txt from the file page of the github repo. This is an example of a trial-level eligibility. \n\n## [Trial-level Eligibility Sample](sample)\nDownload sample-patient-note.txt for a better example of the patient note. \n\n## [Trial-level Eligibility 2](trial-level-eligibility-2)\nDownload trial-level-eligibility-2.txt for a sample of incorrect input. \n\n## [Instructions - Trial-level eligibility](instruction)\n[Instructions for triallevel eligibility](instructions.md)\n\n<EOD> Isolated chorioretinal lesions in systemic lupus erythematosus.\nA prospective study was conducted on 14 patients with systemic lupus erythematosus (SLE) presenting with fundus lesions not accompanied by detectable retinal damage. Mean follow-up time was 11 months. All patients, but one, were treated with corticosteroids or immunosuppressants during the disease. The duration of the disease was longer by a mean of 7 years compared to patients with neuro-ophthalmologic manifestations, and all except one were on treatment with corticosteroids or immunosuppressants. Two patients were treated with intravenous cyclophosphamide (3 monthly). Four patients developed acute proliferative retinopathy, and two others developed retinal angiopathy with occlusive phenomena and thromboses of the carotid arteries. All patients with proliferative retinopathy had positive antinuclear antibodies (ANA) and seven had active disease. This last finding may suggest that immune complexes are the possible cause of",
        "label": 2
    },
    "398": {
        "output": "#### 4.0 Question 1: Which of the following are true about patient-level eligibility?\n\nA: The assessment of patient eligibility is in comparison to all available patients.\n\nB: Patient-level eligibility must be equal to trial-level eligibility.\n\nC: The assessment of patient eligibility is in comparison to the previous trial's eligibility.\n\nD: Patient-level eligibility and trial-level eligibility provide the same score.\n\n#### Answer: C\nIf we look at the definition of [Trial-level eligibility: Assessment of eligibility at trial level.](https://docs.google.com/spreadsheet/ccc?key=0At_60Wn59dDmWWQzMjUtvWd3aTh4WExQNmx6TjR1T3Vz&amp;usp=sharing#gid=171534875)\nIt is a comparison of each randomized patient to the inclusion criteria (as a whole).\nSo, assessment is always 'in comparison to eligibility criteria'.\nWe don't refer to 'all available patients'. Neither we refer to the previous trial's information. \nThe scoring system is a little bit tricky. We look into [Trial-level eligibility scoring rules: Assessment of eligibility at trial level.](https://docs.google.com/spreadsheet/ccc?key=0At_60Wn59dDmWWQzMjUtvWd3aTh4WExQNmx6TjR1T3Vz&amp;usp=sharing#gid=171534877)\nWhen the data is available, we assign a score of 1 for an inclusion criteria is met. When the data is missing, we assign a score of 0. Each cell provides how to assign the score for each exclusionary criteria, not for inclusion criteria.\n\n#### 5.0 Question 2: Which of the following about patient-level eligibility are not true?\n\nA: The score for each condition is always summed first\n\nB: We can use 'eligible' or 'exclusions'.",
        "label": 0
    },
    "399": {
        "output": "### Exercises\n\n#### Exercise 1\n\n###### Detailed instructions\n\nMake your own patient trials for the clinical trial:\n\n1. Copy-paste your patient trials into the text area at the top of the screen.\n3. Choose your response:\n4. Click **Check Trial** in the upper-left part of the screen.\n\n###### Task description\n\nCheck for the patient's eligibility with the clinical trial.\n\n###### Assessment\n\n|          Scales                                |  Assessment                            |\n|-----------------------------------------------|-------------------------------                                         |\n|   Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria) | 0                                                                |\n|   Not relevant (patient does not have sufficient information to qualify for the trial)          | 1                                                                |\n| Eligible (patient meets inclusion criteria, and exclusion criteria do not apply)                | 2                                                                |\n\n###### Scales\n\n| Assignment                                        |        Definition                           |\n|-----------------------------------------------------|---------------------------------------------|\n| Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria) | 0                                                                |\n| Not relevant (patient does not have sufficient information to qualify for the trial)          | 1                                                                |\n| Eligible (patient meets inclusion criteria, and exclusion criteria do not apply)                | 2                                                                |\n\n**Suggested Readings**\n\n### Exercise 2\n\n###### Detailed instructions\n\nCopy-paste your complete patient trials in the text area at the top of the screen.\n\nChoose your response:\n\nClick **Check Trial** in the upper-left part of the screen to complete the activity.\n\n**Trial-level eligibility -Exercise 2**\n\n```{markdown}\n\n<div class=\"source pad-ver\"><pre class=\"highlight\"><code>&lt;!--&gt;\nThis is <a href=\"Detailed_Instructions.md\"><NAME>, your new clinical associate",
        "label": 0
    },
    "400": {
        "output": "### Examples\n\n**Trial-level eligibility: 2) Eligible**\nThe patient is 45 years old, in postmenopausal state, with cytologically confirmed breast cancer. She has a 3 cm invasive ductal breast cancer in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. The patient underwent tumor resection, prior to chemotherapy. The trial is titled:`Study of the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer`.\n\n### In[14]:\n    \n```\n    # Read patient's note\n    test_df.head() \n    patient_note = test_df[-1].iloc[0].to_numpy()\n    \n    # Create trial from the text\n    trial_text = \"Trial Title: Study of the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer\\n\"\n    trial_text += \"Trial Summary: A prospective observational longitudinal study of 464 patients was performed between 2010 and 2015. Patients with invasive ductal carcinoma (IDC) and ductal carcinoma in situ associated to invasive ductal carcinoma (DCIS +IDC) were included and analyzed.\\nTrial Eligibility: Patients with invasive ductal carcinoma of the breast\\nPatients who received surgery for primary invasive breast cancer between 2010 and 2015\\n\"\n    trial_text += \"Trial Inclusion Criteria: Patients with invasive ductal carcinoma of the breast\\nPatients who received surgery for primary invasive breast cancer between 2010 and 2015\\n\"\n    trial_text += \"Trial Exclusion Criteria\\nPatients who were not invasive ductal carcinoma of the breast were excluded\\nPatients who did not receive surgery were excluded\\n\"\n    trial_text += \"Trial Enroll",
        "label": 2
    },
    "401": {
        "output": "<EOD> Clinical Significance of Fibrillar and Nonaffected Tau in the Diagnosis of Alzheimer\u2019s Disease\n\nNonaffected is a term used to describe tau without the presence or severity of hyperphosphorylated tau in human brain as determined by neuropathological examination. Non-affected tau is composed of two distinct subclasses: diffuse and fibrillar tau. Hyperphosphorylated tau is a component of neurofibrillary tangles in the brain. The aim of this review is to provide a critical and practical overview of the clinicopathological correlations for non-affected tau in order to determine its role in the differential diagnosis of Alzheimer's disease (AD) and non-AD tauopathies. Pathological observations suggest that the presence of fibrillar tau in cognitively normal or mildly impaired elderly individuals predicts an elevated risk of AD as compared to elderly individuals with diffuse tau only. Neuronal tangle formation has a much longer time course than diffuse accumulation of aggregates so that detection of diffuse tau does not rule out the possibility of pathological tau. In this regard, we hypothesize that diffuse tau is a preclinical form of tau pathology, which eventually converts to a more advanced form-neuronal tangle to cause dementia. The presence diffuse and fibrillar tau subtypes in the clinically non-demented elderly is a biomarker significantly associated with conversion to AD but only fibrillar tau is predictive of severity of dementia.\n\n# Abstract\nNonaffected is a term used to describe tau without the presence or severity of hyperphosphorylated tau in human brain as determined by neuropathological examination. Non-affected tau is composed of two distinct subclasses: diffuse and fibrillar tau. Hyperphosphorylated tau is a component of neurofibrillary tangles in the brain. The aim of this review is to provide a critical and practical overview of the clinicopathological correlations for non-effected tau in order to determine its role in the differential diagnosis of Al",
        "label": 0
    },
    "402": {
        "output": "---\n**Detailed eligibility criteria**\n- Include data about your age, gender and body mass index. [INST]\n\t\t\t- Please check this for consistency with other fields (this is important for the automated assignment of the labels).\n\t\t\t- For example, if your BMI category is not congruent with other fields, it does not necessarily mean that you have to retype the BMI if it could be wrong in some other field or if it is not wrong but misinterpreted as a mistake. (e.g., if your BMI is 30kg/m^2 according to the formula, the word ``30'' in the ``weight'' field is not considered necessary as far as your weight is. But the word ``2'' in the ``age`` field is relevant because it is not necessary to be ``<30`` years old because you are in the range ``30 to 50`` years).\n- Record what clinic you visited.\n\n##### Please review the list of clinics in the following table. (You may not be seeing the entire list of clinics that are registered in the database. We are not allowed to show you the database but you may think of it as an exhaustive list. Please make sure that the clinic name you have entered in the field is in the list. You may add the names by editing the entries in the table.)\n\t\tCong. Hospital / Gyeongsang Aerospace High School Hospital / Dong-A University College of Medicine / Soonwon University Hospital / Cheil General Hospital [INST]\n- List any operations you have had done and their names, date(s) in the format of \\`/yyyy-mm-dd\\`. [INST]\n   \n\n- List the medications you are prescribed and include the type of medicine, your name, dose, brand, and date(s) of prescription (also, write the last date you took the medicine) in the format of \\`/yyyy-mm-dd/HH-MM\\`. [INST]\n\t\t\t\t\n- List your diagnosis name(s) or ICD-10 code, date(s), and hospital if you have a diagnosis (e.g., a diabetes diagnosis). Diagnosis names can differ across patients, therefore we suggest you use ICD-",
        "label": 2
    },
    "403": {
        "output": "[/TEST]\n\nYou can run the following command on this tutorial's folder to see this patient note again and assess trial-level eligibility.\n```\n$ java -Xmx20G -cp \n   src/test/main/simple-patient-note/simple-patient-note.jar -r 'src/test/main/simple-patient-note'\n```\n\nYou can change the `src/test/main/simple-patient-note` to include a [test data directory](https://openml.ai/docs/dev/test/test-data-dir).\n\n```\n$ java -Xmx20G -cp \n   src/test/main/simple-patient-note/simple-patient-note.jar -r 'src/test/main/simple-patient-note'\n```\n\nThe test data directory may contain test data files, trial-level eligibility files, and trial-level eligibility logs (one for test). You may need to make or create a file for a [Trial-level eligibility](https://openml.ai/docs/dev/trial-level-eligibility/) file.\n\n```\n$ mkdir test_data \n$ java -Xmx20G -cp \n   src/test/main/simple-patient-note/simple-patient-note.jar -r 'src/test/main/simple-patient-note'\n$ cat src/test/main/simple-patient-note/test_data/Trial-level eligibility\nTrial-level eligibility: 2) Eligible.\n```\n\n### [Clinical trial](http://archive.ics.uci.edu/ml/datasets/Clinical+trial) with patients and trial-level eligibility\n\nThis dataset comes from a cancer study.\n\n[Clinical trial](http://archive.ics.uci.edu/ml/datasets/Clinical+trial) from [UCI repository](http://archive.ics.uci.edu/ml/datasets/) which includes patients and trial-level eligibility. There is a set of 1442 patients of various ages. You can access patients' history information",
        "label": 1
    },
    "404": {
        "output": "You should only use the 'Trial-level' line when that is really what you want to report. If you have a list of individual notes and you want to provide some 'higher-level' evaluation, then the 'Patient-level' section is probably the correct section to use, since that is how trial assessors would typically report this type of overall level evaluation in their reports to their funders.\n<EOD> Neurokinin-1 Receptor Targeting for Pain Control: An Exploration of Potential Molecular Mechanisms In and Outside the Central Nervous System\nIn recent years, increasing evidence has established both neurokinin-1 (NK-1) receptor antagonists and neurokinin fragments as having efficacy in pain management, both in acute and chronic pain conditions. Although the receptor has been extensively investigated throughout the brain and nervous system, relatively little is known about its presence throughout the body, particularly the heart, muscle, and bone, or other peripheral structures outside the nervous system. To more fully characterize the potential actions of these agents and explore the role that NK-1 receptors could play in a broad range of disease states, a brief discussion of the recent publications on peripheral pain and inflammation as well as cardiac and cardiovascular, bone, and muscle pain and inflammation. Finally, this review will examine a broad range of potential molecular mechanisms of NK-1 receptor antagonist efficacy throughout the body.<EOD> Clinicopathological characteristics of breast cancers in the elderly.\nThe aim of the study was the clinicopathological analysis of elderly mammary breast cancer cases. 5729 cases with mammary breast cancer operated in the Department of surgical oncology of Poznan University of Medical Sciences from 1979 to 1993 were analysed. The age was divided into 4 groups: I:  70 years. Increasing incidence of the breast cancer with growing age was observed (p < 0.01, Chi(2)). There were differences in the distribution of age between both sexes (p < 0.025, Chi(2)). In women the breast cancer incidence rates were in all groups above: 2999/1,000,",
        "label": 0
    },
    "405": {
        "output": "## L253 Exclude patients in the control group. \nLet's think step by step. \nIf the patient is in the control group or both the control group and the test group.\nThe assessment should be performed at the trial level. \n`Trial-level eligibility: 2) Eligible.`\n`Excluded: 0`\n\nIf the patient is only in the control group, the assessment should be performed at the patient level. \n`Trial-level eligibility: 1) Not relevant`\n`Excluded: 0`\nIf the patient is only in the test group, the assessment should be performed at the patient level. \n`Trial-level eligibility: 0) Excluded`\n`Excluded: 0` [INST] You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She",
        "label": 0
    },
    "406": {
        "output": "Ex: \n0) Excluded\n1) Not relevant\n2) Eligible\n\nThe best practice is to repeat the step after you found an optimal solution. I will use the example case for demonstrating the process. Repeat the following statement on each row:\n\n## [INST] \n# [CAPITAL]\nIn the end, you run the report and see the result.\n\nYou would be shown two lines of output when you call the function. The first one is the title of the clinical trial (e.g., \"Title: A Study of Pembrolizumab\"), the second is the assessment of eligibility in the row that is based on your assessment (e.g., \"Trial-level eligibility: 2)\").\n\nHere is the patient note after I repeated the statement on each row:\nIn the row corresponding to the clinical trial name, we can find the output of the best practice.\n\nThis is the script to compute trial-level eligibility of each patient in a clinical trial study. The script can be run in R GUI (i.e., RStudio).\n\n<EOD> The effect of the microencapsulation on intracellular metabolite excretion rate by free cells from an UASB reactor.\nThe excretion of intracellular metabolites from anaerobic granular sludge of a UASB reactor was studied. The metabolite excretion rate of the free cells in wash water of the reactor was 26.8 mg COD(g VSS/h) during a steady-state period, which was about twice as much as the extracellular metabolite excretion rate. The addition of acetate decreased the intracellular metabolite excretion rate to 17 mg COD(g VSS/h), while the extracellular metabolite excretion rate only decreased slightly. The microencapsulation of the free cells in Ca-alginate was found to drastically reduce the excretion rate of the intracellular metabolites from 26.8 to 14.7 mg COD at pH 7.2. Furthermore, the microencapsulated cells could not excrete any intracellular products",
        "label": 0
    },
    "407": {
        "output": "[/TEX]\nLet's look at the patient with the second note in the data file `data/inst_1_p_note_8.txt`: Your task is to compare a given patient note and the inclusion criteria of a clinical trial (see Example 2) to determine patient's eligibility.\nYou should make a patient-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\nHere is the patient note:\nThe patient is a 50-year-old woman with confirmed ductal breast carcinoma in right breast. Previously, she underwent two tumor resections due to local recurrence and metastases to the lungs. In April 2015, a core biopsy revealed locally recurrent breast cancer of 2.6 cm in the right breast. The tumor is  HER2-positive, and ER/PR negative. Right axillary sampling revealed  positive lymph nodes. Multiple bone metastases were noted.\nHere is the clinical trial: \nTitle: The phase 2 AURA3 study of Tucatinib (TUC) + palbociclib (CBI) + fulvestrant (FULV) versus TUC + placebo (PBO)+CBI+FULV in hormone receptor (HR)+/HER2-metastatic breast cancer (MBC) after prior HER2-directed therapy.\nWe have an additional information data file 'data/additional_data/data_inst_1.txt' which shows the clinical trial ID and protocol for the clinical trial. The ID is NCT03125979, and the protocol is attached in the zip.\nInclusion criteria: Inclusion Criteria:\nAge 18 and older\nHave metastatic or locally recurrent, unresectable HR+/HER2-breast cancer\nConfirmed diagnosis of HER2-positive or HER2-negative recurrence or progression on or after (within 6 months for HER2-positive disease and within 12 months otherwise) 1-line systemic therapy for MBC (either prior chemotherapy and/or endocrine therapy),",
        "label": 0
    },
    "408": {
        "output": "from eligible for trial for the clinic (s trial eligibility is 60freq trial: eligibility in according, oral in.\nExemptile and level of eligible 0s trial, a trial to-elig trial by the use. eligility of in trials of the trial to evaluate.\n\nregul, or trial 's elig trial or the corticelig or trial, trial, and your elig. 's toxic inl 's trial to trial and the disease:\n\nIncluded trial] trial. A trial trials to trial the trial-elig level 4's elig trial. Protocol-eligible elig. Inelite trial. T-el.\ntrial. Allerg and AEligible trial.\nage eligile patient to participate eligibility trial.eligible, but not elig patient trial eligible's.\nelig. Use, but can be tested and trial elig patient.\n\ntrial.\n[trial] trial. In trial,s trial, to receive trial. Patient clinical elig trial's trial.\nelig andre and the Eve, an elig to the following.\ndise trial. The criteria of the trial, and trial trial ifl trial elig/trial] and trial as a trial or elig trial. E^ trial or elig. The 22\n\nthe trial (the patient.\nand healthcare and, and inel, tum and cancer. You or health related to the trial elig inel. You in the physical for the need for trial; or she, the elig or elig. Elig and a trial the trial. elg. The trial. And her.\n(he or elig patient. Shepat in a trial: All]el trial.\ntrial. She or\nd. After a trialist elig.\n\n[f, such a person with a patient\n or the elig or her.\n[C trial for the elig andel, trial. You to an elig. Elite, and elite and that \n[med: C-based. You=the patientical_f\ner [/table]... (which [\n[ _in the patient, i. If ... and the el[ or",
        "label": 0
    },
    "409": {
        "output": "[TEST] A=1 : 12, B=0 : 8, C=1 : 12, D=0 : 8, E=0 : 8, F=0 : 8, G=1 : 12, H=0 : 8, I=1 : 12\nSo far, patient A is the most likely to join in this trial.\n[INSERT_QUESTION] Who would be the most likely to join the trial?\n### Exercise 42 [QUESTION] What's the output of `trial' in the `patient/treatment' schema type. You will get two lines of results:\n[ans ]\n[ans]\n[INSERT_QUESTION] Try `trials.create` to create this trial now. `patients/trials` is not created since it will depend on the data. Let's start with that data using `trials.show.json()` `Create Trial` is executed if the following statement is false .\n```json\n\"not created\": [\n  \"error\",\n  \"warning\",\n  \"trial\",\n  \"treatment\",\n  \"endpoint\",\n  \"instrument\" \n]\n```\nWhen a trial is not created, the following schema types will be created:\n- endpoint type,\n- treatment type,\n- endpoint_type relationship.\n- endpoint_type_treatment relationship.\n- endpoint_treatment relationship.\n- patient_treatment relationship.\n- endpoint_instrument relationship.\n(This is the case for Exercise 5)\n[ans]\n[INSERT_QUESTION] Can you define a new endpoint?\n### Exercise 44\n[QUESTION] Define a new relationship between a treatment group and an instrument for the trial.\nAn endpoint is a procedure that the patient undergoes to acquire data. The most typical endpoint is a biopsy procedure, but other procedures that are associated with a trial can be implemented as endpoints.\nYou have a patient who is receiving standard-of-care care prior to chemotherapy. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active. \nAfter under",
        "label": 0
    },
    "410": {
        "output": "# END\n\n## [INST] 1 4 2\nNow let's code the patient-level eligibility. [INST] 1 4 3 \nWhen you are finished, you should insert a line with the patient-level eligibility into the patient's note as follows:\n\n```\nP2: patient-level eligibility: 1) Eligible.\n```\nYour output will show one column, but in practice, your output will show two columns. The first column will be trial-level eligibility, and the second column will be patient-level eligibility. The latter is obtained with the `Trial-Level: 2` line. [INST] 1 4 4 \n\n# INST] 1 4 5\nThere is still one more step that must be completed. It requires the inclusion of a flag showing which patient matches which trial (see [fig_ref]  Table A: Inclusion of a patient-specific flag for all cells at the same row... [/fig_ref] . This flag can be obtained using the \"=\" operator or the `$` operator. We recommend that you use the `$` operator to insert the flag into each line of the patient's note file. \n\nHere is the patient's note with a patient-specific flag using the `=` operator:  \n`P1: patient-level eligibility: 1) Eligible.`\n\n```\n# Trial-level eligibility: 1) Excluded\nP1: patient-level eligibility: 1) Eligible.\n# =0;\n# Trial-level eligibility: None =Trial-level eligibility: 1) Excluded.\n# Trial-level eligibility: None\n```\nHere is the patient's note with a patient-specific flag using the `$` operator:  \nTo make a patient-specific flag using $ operators, \ninsert it under # Trial-level eligibiliy 2) Excluded in the first row: \n`$P1=0`, \n`# Trial-level eligibiliy: 1) Eligible`, \ninsert it under # Trial-level eligibility 1) Eligible in the second row: \n```\n$P1=1\n```",
        "label": 0
    },
    "411": {
        "output": "Copyright (c) 2014-2020 H2 Group (Olga Kurbatova, Sergei Volkov, Artem Kurbatov, Viktor Voskoboynik and Alexey Kudryavtsev). \"Medical Recruitment and Decision Support System for Clinical Trial Participant Eligibility Assessment\". License: Apache 2.0\n\n# The 0th-Order (or Non-Optimized 1st-Order) Logic with Implicit (Intrusive) Evaluator\nHere is the example using 0th-order logic. It shows a set of facts and beliefs, the logical expressions, inference and belief rule for each fact and the inference status of each belief. All facts are already loaded.\nWhen facts are loaded, a preliminary belief of the 0th order starts. When the \"Load facts\" command is executed, it will be followed by the implicit evaluation of the logical expressions that are in the belief. The corresponding inference status will then be shown for each belief which will reflect the evaluation outcome. \n![inst.Journal_0_1_3.bmp](./inst/Journal_0_1_3.bmp) \n\n- [0-order load](inst/Journal_0_1_3.bmp)\n- [0-order eval](inst/Journal_0_2_1.bmp)\n- [0-order output](inst/Journal_0_3_1.bmp)\n\n\n# C-H-E-P\n\nIt is a decision support system based on the C-H-E-P method (Ashwin, 2008). \n\n## General architecture\n\n- Input: Patient record from an electronic health record (EHR), clinical trial information from clinical trial registries, a set of evidence-based clinical guidelines from literature repositories, and the preferences of the assessors.\n- Preparation: Parsing the input data and extracting relevant information into data representations such as the 3-tuple model, or RML (Resource Markup Language).\n- Logical Inference: Efficient reasoning algorithms based on the C-H-E-P method for the generation of eligibility assessment reports",
        "label": 0
    },
    "412": {
        "output": "[AZURE]\n<EOD> Inhibition of Mammary Gland Involution by Expression of Noggin In Vivo1\nAbstract Involution of the lactating mammary gland is initiated by a cascade of cell signals that leads to rapid progression of the previously differentiated lobular epithelial compartment to a less polarized, growth-arrested, and apoptotic phenotype. Involution occurs in both the mammary gland and the salivary gland. However, the mechanisms that activate involution are distinct in each gland. Previous studies suggest that involution of mammary glands is regulated in part by TGF-\u03b2 (BMP) signaling. In the salivary gland, signals that inhibit and/or delay the kinetics of involution occur primarily via TGF\u03b1, EGFR, and PI3K. In the present study, we explored the use of a transgenic mouse system to control cell signaling during involution of the lactating mammary gland and the effect on the development of the mammary gland of a mature offspring produced by the reproductively active transgenic female. Our results demonstrate that expression of Noggin, a protein that binds to and inhibits TGF-\u03b2 signaling, in lactating mammary glands and the gland-associated stroma inhibited development of the lobuloalveolar compartment of the gland from the first stages of involution until pup weaning. Expression of Noggin resulted in at least partial retardation of the onset of mammary gland involution throughout pregnancy and lactation and postweaning. The offspring of these Noggin-transgenic females expressed the milk protein genes casein Alpha, \u03b2, and kappa. We conclude that the timing and kinetics of mammary gland remodeling during involution and postweaning are critical for subsequent development of the alveoli-filled compartment of the secretory gland.<EOD> Prevalence and factors related to anxiety and depressive symptoms among university students during the COVID-19 pandemic\n\nThe COVID-19 pandemic has led to increased levels of anxiety and depressive sympt",
        "label": 0
    },
    "413": {
        "output": "![](/assets/images/noun-groups.png)\n\n**Q:** What is the noun group that describes `Trial-level eligibility?`\n\nWe will look at the whole sentence.\n\nI know some information. First, the patient note is about a 45-year-old woman with breast cancer. Second, the clinical trial is titled Medullary Carcinoma.\n\nThe patient note contains many words or phrases that show the information of the patient while the trial note contains many words or phrases that show the research topic in a clinical trial.\n\n### Parts of speech\nEach word we already know is tagged with a part of speech (POS). The part of speech is a label of the function of the word in a sentence.\nLook at the first",
        "label": 0
    },
    "414": {
        "output": "## Efficient, reliable, and fast code\n[INST] Hello. You are a professional scientist. You are trying to write the code to generate an initial set of candidates. You would like to avoid the common errors during code writing when solving optimization problems and writing efficient code. \nFor example, instead of writing  `if condition then do something`.\n\n> def gen_solution(n):\n>\n> tup = [] # the tuple with the components.\n> \n> for i in range(n):\n>  \n>     n1 = random.randint(1,n+1) # this is not good.\n>     n2 = random.randint(1,n+1) # this is not good either.\n>     n3 = random.randint(1,floor(n**0.5)) # this is more efficient.\n>     tup = tup + (n1,n2,n3)\n> return tup\n\n```python\nn = 1000\nx1 = 1000\ny1 = 1000\ngen_solution_good = gen_solution(n)\nprint (\"x1, x2\", x1, x2)\n# Note:\n# In order to understand the output, we need to write out the tup.\n# Here are the two output results of the two codes:\n# Output for gen_solution (good code):\n# x1, x2, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000\n# Output for gen_solution (bad code):\n# x1, x2, 1000, 1000\n```\n\n## Programming challenges: Python coding problems & solutions\n\n### Programming challenge 1\n```\n\n[INST] Hello. You are a master of programming, and you are learning some new programming concepts:\n- `repeated compounds`\n- `string format`\n- `format specifier`, `{}`. \n- `format specifier`, `%.2f`. \n\nYour task is",
        "label": 2
    },
    "415": {
        "output": "A: I'm working on the same problem.\nFor now, I found a workaround. We need to take care which data for which trial so we can make a decision if the trial includes patient in question or not.  \n1.\nCreate data record object from string\n\n```\ndef datastore_data_record(doc):\n    data_record = {'name': doc[4], 'desc': doc[6] if 'desc' in doc else None}\n    \n    return data_record\n\n\ndatastore.data_record = datastore_data_record\n```\n\n\n2.\nSave the current patient data in the datastore\n\nIf needed, the record_id/value pair could be added as optional column.\n\n```\nclass Datastore(Object):\n    records = {}\n\n    def save(self, \n        trial_no, \n        title, \n        summary, \n        inclusion_criteria = None, \n        exclusion_criteria = None, \n        patients = {})\n\n        if inclusion_criteria is not None:\n            if not i == self.records[trial_no]:\n                self.records[trial_no] = [\n                    {'record_id': 'P' + str(i), \n                    'trial_no': trial_no, \n                    'name': None, \n                    'desc': title, \n                    'summary': None, \n                    'inclusion_criteria': inclusion_criteria,\n                    'exclusion_criteria': exclusion_criteria}\n                ]\n        else:\n            self.records[trial_no] = ['None'] * len(trial_no)\n\n        if patients is not None:\n            if not e == self.records[trial_no]:\n                self.records[trial_no] = [ \n                {'record_id': 'patient_' + str(j) + '_' + str(trial_no), \n                'trial_no': trial_no, \n                'name': None, \n                'desc': None, \n                'summary': None, \n                'inclusion_c",
        "label": 0
    },
    "416": {
        "output": ".<EOD> Detection and Characterization of T Cell Subsets in a Mouse Model of Systemic Lupus Erythematosus\n\nInvariant (i.e. \"natural\") antigen-specific T lymphocytes are the most prevalent component of the adaptive immune system. The high level of specificity and memory properties of iNKT cells allow for faster and more efficient immune responses to a wide variety of viral, bacterial, and fungal pathogens. NKT cells have also been shown to play a critical role in immune-mediated inflammatory disorders, including systemic lupus erythematosus (SLE). iNKT cells are involved in SLE-like autoimmunity through the production of pro inflammatory cytokines and the activation of B and conventional T lymphocytes to induce a variety of disease-associated autoantibodies and disease pathogenesis. In this work, we used a transgenic strain of mice expressing the major histocompatibility complex (MHC) class II (MHC II) molecule, H2-D b , along with a tetracycline promoter driving the expression of the HBV core antigen (HBc/HBc) gene. C57BL/6 (H-2 b ) mice were immunized with HBc/HBc under the regulatory condition of tetracycline administration, which induced a humoral immune response with the production of a broad spectrum of disease-associated autoantibodies, leading to SLE-like manifestations. T cell response to HBc/HBc was characterized by the presence of IFN\u03b3 producing CD4 + T cells, with similar levels to those observed in the MRL lupus-prone model, and were shown to be MHC restricted. This finding suggests to use this mouse model system, with its advantages in T cell purification and TCR gene sequence analysis, to gain a better understanding of CD4 + T cell subset participation in both spontaneous and induced lupus. Further studies on the characterization of the CD4 + T cells associated with the TCR-V\u03b2 gene families, the identification and cloning of TCRs and the definition",
        "label": 0
    },
    "417": {
        "output": "<EOD> Transformations of the Rules of the Game: How Organizations Learn to Learn\nAbstract: This chapter outlines a middle-range theory accounting for the learning and development of organizational capabilities in a variety of contexts. The focus is on changes in the rules of the game in which the organization or any other unit must learn and perform well to succeed. In some cases, the rules of the game involve a new technology or a new source of value, and in others, they may require acquiring knowledge, improving the quality of relations with others, or becoming responsive to stakeholders. We emphasize the important role of organizational learning in this process. The theory, including its dynamic elements, its relationship to other theories in the learning-development literature, and its relevance to a range of contexts in which organizations or other units must learn to succeed, are illustrated with a set of examples.<EOD> Elevated HRV for the Prevention of Atrial Fibrillation in Patients with Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials.\nOBJECTIVE\nWe aimed to evaluate the efficacy of the elevated heart rate variability (HRV) intervention among patients with AF after the acute myocardial infarction (AMI).\n\n\nMETHODS\nPubMed, the Cochrane Library, Embase, and ScienceDirect of English language studies from inception through August 01, 2022 were searched. The Cochrane risk of bias tool was used to assess the risk of bias, and the quality of the evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation system. A random-effects meta-analysis was used to evaluate the efficacy.\n\n\nRESULTS\nSeven randomized controlled trials (2 in Chinese, 5 in English, the total number of participants was 1,047), including 531 patients in the intervention group and 516 patients in the control group. The elevated HRV intervention had a significantly reduced risk of AF (relative risks (RR) = 1.49, 95% confidence interval (CI): 1.25-1.77, I2 = 0%, P < 0.0001",
        "label": 0
    },
    "418": {
        "output": "## \u2267 \u3007 \u2266\n<EOD> Effect of intra-nasal insulin inhalation on cardiovascular risk factors among obese non-diabetic individuals: protocol for the INSULIN trial\n\n\n\n# Introduction\nObesity is an independent factor that increases cardiometabolic risk 1 2 and leads to serious consequences for adults and children. [bib_ref]  Effect of obesity on cardiovascular disease, Kannel [/bib_ref]  Obesity is often accompanied by insulin resistance, which is a state where insulin is less effective in lowering the blood glucose levels and controlling blood lipids compared with people with a normal body weight. [bib_ref]  Effect of obesity on glucose tolerance: a cross-sectional study of 1046 elderly..., Janssen [/bib_ref]  [bib_ref]  Body mass index and the prevalence of hypertension and dyslipidemia, Brown [/bib_ref]  [bib_ref]  Obesity and dyslipidemia in children: a meta-analysis, Mattice [/bib_ref]  Adults with insulin resistance have an increased risk of developing type 2 diabetes mellitus (T2DM), hypertension, hyperlipidaemia and ischemic heart disease, independent of other cardiovascular risk factors. [bib_ref]  Impact of overweight on the risk of developing common chronic diseases during..., Field [/bib_ref]  Furthermore, insulin resistance appears to be already present in young adults who are not overweight or obese yet. [bib_ref]  Obesity as a disease, Upadhyay [/bib_ref]  It is crucial that the risk of insulin resistance can be modified, as preventing or delay-ing the development of insulin resistance could subsequently lead to a lower cardiometabolic risk. Several lifestyle interventions are proposed to be able to reduce insulin resistance, but their effect and magnitude are debatable. Weight loss for example was not able to improve insulin sensitivity without losing weight. Weight loss was only beneficial when 5%-10% of the total body weight was lost. Physical activity did not result in improvements in insulin sensitivity in most studies. [bib_ref]  Effect of lifestyle intervention on",
        "label": 2
    },
    "419": {
        "output": "<EOD> The Coxsackievirus B3 and Adenovirus Type 5 IRES RNA Mediates Efficient Translation in Extracts from Neonatal Porcine Intestine and Liver Cells, but Not Adult Porcine Intestine*\n\nA replicative form of wild type and mutant bovine papillomavirus type 1 (BPV-1) expressing the enhanced yellow fluorescent protein (EYFP) gene was generated and transfected into neonatal porcine kidney (NPk-1) and neonatal porcine intestinal (NPI-1) cells. Virus was released from both cell types and showed similar replication kinetics over a 12-day period. Transfection experiments with replicative forms of mutant BPV-1 expressing the neomycin phosphotransferase gene were used to assess the effects of replication on viral gene expression. The rate of replication of replicative forms expressing the EYFP gene was twice that of neomycin phosphotransferase-expressing counterparts as assessed by the kinetics of EYFP expression, which was used as an indirect measure of replication, suggesting that replication facilitated gene expression. Replicative BPV-1 was highly active in porcine intestinal cell lines NPk-1 and NPI-1, and EYFP protein synthesis increased in an apparently linear fashion over a 7-day period after transfection, although viral DNA synthesis peaked and began to decline after 4 days. The rate of EYFP synthesis declined after viral DNA replication had peaked by day 4 and was similar to that seen in transfections with the neomycin transporter-expressing BPV-1 counterpart. EYFP expression per cell was much higher in NPk-1 than in NPI-1 cells, despite the similar rates of replicative form synthesis, indicating that the rate of expression per cell is not directly related to the rate of replica-tion. In contrast, expression of the replicative form-encoded green fluorescent protein was high in both NPI-1 and NPk-1 cells. The reason for the differential expression of the replicative form-encoded",
        "label": 0
    },
    "420": {
        "output": "</details>\n\n## Recurrence Assessment\n<details open>\n\n##[INST] Hello. You are a helpful volunteer in a clinical trial that determines breast cancer prognosis. Your task is to assess the prognosis for the patients from a breast cancer clinical trial. Since 5 years since diagnosis, all the patients who need help have died. However, some patients still live. These remaining patients are the focus of our prognosis assessment. \nNow you have to assess the prognosis for each remaining patient as accurately as possible. \nLet's think about how to assess. \n\nBreast cancer is diagnosed by mammary tissue removed surgically or biopsy. The biopsied or resected tissue is submitted to the pathology lab for an examination. Pathology helps determine tumor grade, size (T), and lymph node (N) involvement. According to AJCC (8th edition), the prognosis of different types of breast cancer is quite different. The pathological typing of breast cancer can be divided into invasive carcinoma breast, malignant carcinoma in mixed adenocarcinoma glands, and carcinoma in special form. Breast cancer was classified into 5 different grades according to clinical histological grading system: grade I, grade II, grade III, grade IV, and grade V. Grade I is low in grade, and grade V belongs to high degree carcinoma. In this study, grade I, grade II, grade III, grade IV belong to luminal A, luminal B, her-2 positive, and triple-negative subtypes. \nYou should select the correct breast cancer type, grade, and subtype for each patient. \nYou should enter the patient's pathological diagnosis to the clinical trial. \nYou can enter multiple answers for a person, or you can select all answers for a patient. You should indicate the breast cancer subtype and grade. After you enter the answers, you should enter the `pathological type` based on the answer and patient's pathological type. \nIt should be noted that it is not possible to choose more than one answer for both pathological type and breast cancer subtype. The following patient's pathological types are listed separately. T4, ER+, positive N+,",
        "label": 0
    },
    "421": {
        "output": "and Candid and 2 el and 7 and a \\ a non a H. \nC for the _ 1 for 2 (that , but , [bib_ref] [bib_ref] [bib_ref]\n/ or\n. or \n (i(in 12 or (m (such\n in-based cute by 3 \non... with \u2026 A\n [bib_ref] or a \n or\nfor C-heart [bib_ref]. [bib_ref], but [bib_ref]\n A (\nacc 2. (system\n1 ex 2 (1-primary \ufffdf\ns. [bib_ref] _s 1 . . [bib_ref]. The .\n-s - Cembera-s/s\n\n-she, a 2\n in\n The \u2026...\nfor \u0304 _ [bib_ref] (in (target_re in<EOD>s _cry in 0_ in [/table] a\n\n\nde{m on c... _ [bib_ref] \\\n(target and In\n(in thex-target,a for both  in{e in 2 (2-fase [bib_ref] a\u00a0full... and the\nand\n [bib_ref] , [bib_ref]\nfor an\n (re-in the cind - \nfor a the<EOD>. For -in a [bib_ref]\n . To the for the to the 1\nfor a [bib_ref]\nmed andll -she\u00a0c [bib_ref]de...\n1 with <s\u00a0her . [bib_ref]she 1c  \n (an in the .she. (such _ 2 .f \ufffdinase-gone [bib_ref]2_ in : 1<2\nbased - 3 -\nin 1... [bib_ref]a{ (gain-for-goc for the-sub\u2010 [bib_ref]. A [bib_ref] .\u00a0ass to a [bib_ref]\nd in 1c and and its clin. The clin for [bib_ref]-in ...., no and [bib_ref]\nf 5-based 2 22- 2 -d-g 3 for clinetic 4 15-based clin 12-m _in- [bib_ref]\n - [/table]: [bib_ref] 2- [bib_ref]s\n1\n\ns-\n [/table]_ [bib_ref]\n{ [/table]-s -s,sud-regular\n( 1- [bib_ref]\n\nd...C [bib_ref]and- 1... [bib_ref] or [bib_ref]",
        "label": 0
    },
    "422": {
        "output": "## 2.2 Case #3 -Discharge Summary [10] \nDuring your clinical rounds, you discover a discharge summary of the patient who visited a few weeks ago, and read it without finding any problems (see below). The summary includes several problems and symptoms. Some of the problems are described with an assigned code (International Classification of Diseases, Ninth Revision, Clinical Modification, or ICD-9-CM), others are described verbally (as they were mentioned before). As you do not know the language of the doctor who made the discharge summary, you have to rely only on the ICD-9-CM codes. \n\nThe ICD-9-CM codes are ordered alphabetically (as they are described on the patient's medical record) and not numerically (as they were coded in 9-digit groups). \nFor this example, you'll find here a solution example as well as the original case in the next three sections of this file. This solution file serves as a demo of the problem-solving procedure, and the patient note and the clinical note are not included in this file. \n\n\n## 2.2.1 Solution to Example 1\n\nDear Dr. [last name],\nYour note was very helpful. I found one typo, you probably mean: \u201cpatient meet inclusion criteria and none of the exclusion criteria apply.\u201d  \n\nI made some changes to your note. See the attached marked version.\nIf you are looking for some more coding practice, you find here a lot of clinical notes: [11].\n\n\n[INST] Hello. You are a helpful assistant for a clinical trial and you want to practice with clinical notes for trial eligibility. \n\nYour task is to compare a given patient note with the inclusion criteria of a clinical trial to determine eligibility for the trial.\n\nAs you know, there exists a clinical trial, \"Title: Comparing Vacuum-Assisted Percutaneous Exci-sion to Open Surgical Exci-sion for Borderline or High-Risk Breast Lesions\" [2], that tests vacuum-assisted percutaneous excision and the same surgical procedure. The trial includes the following inclusion criteria:\n\nInclusion criteria: Inclusion Criteria",
        "label": 0
    },
    "423": {
        "output": "### Example:\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.Here is the clinical trial: \nTitle: Internal jugular veins and lymph node staging and biopsy in patients with lung cancer: a multicenter study\n\n\nSummary: Aims to determine whether ultrasound-based internal jugular vein staging will improve the sensitivity of the current sentinel lymph node (SLN) technique in patients with non-small cell lung Cancer (NSCLS) who do not have neurotropic mediastinal lymph node (MLN) invasion in order to identify MLN metastases in patients without pal",
        "label": 0
    },
    "424": {
        "output": "[fig]  \u2022\u2022\u2022\u2022\u2022\u2022: Eligible) - This factor must present. - (Excluded) - This factor mustn't present. \u2022 (Not relevant) - More information is needed to determine if this factor is present. \u2022 (Unspecified) - Cannot be determined since there's no information about this factor. [/fig] \n<EOD> Long non-coding RNA ZFAS1 regulates oxidative stress in diabetic nephropathy by targeting miR-150.\nBACKGROUND AND PURPOSE\nLong non-coding (lnc) RNAs have been demonstrated to be critical regulators in many diseases, but the functional role of lncRNA zinc finger antisense 1 (ZFAS1) in diabetic nephropathy (DN) remains obscure. This research is aimed to unravel the relationship between ZFAS1 and DN and to investigate its underlying mechanisms.\n\n\nEXPERIMENTAL APPROACH\nGapmeRs technology was applied to silence ZFAS1 in mesangial cells (MCs). MTT assays were conducted to detect cell proliferation. DHE staining assays and FACS were carried out to measure ROS accumulation and mitochondrial membrane potential (MMP), respectively. The luciferase reporter assay was operated to reveal the relationship between lncRNA ZFAS1 and miR-150, and the association between miR-150 and cytochrome oxidase subunit 7A1 (COX7A1).\n\n\nKEY RESULTS\nWe discovered that lncRNA ZFAS1 was markedly increased in both high glucose (HG)-induced MCs and in the serum of mouse DN models in vivo. Furthermore, knockdown of lncRNA ZFAS1 alleviated HG-induced MCs injury by improving cell viability, inhibiting ROS accumulation, and reversing HG-induced mitochondrial dysfunction and cell apoptosis. Mechanistically, ZFAS1 acted as an endogenous miR-150 sponge. Knockdown of lncRNA ZFAS1 could improve ox",
        "label": 1
    },
    "425": {
        "output": "![inst]![Trial-level eligibility: 2) Eligible.](https://i.stack.imgur.com/KQ2mR.png)\n\n## [INT]\nYou should use the [CSV-format](https://osf.io/dx69e/) and create a [new issue](https://github.com/jakep244/data.cbt-kata/issues/new). A solution is also attached in the [data folder in the repository](https://github.com/jakep244/data.cbt-kata/tree/master/datasets/data), i.e., [PatientNote_1.csv](https://github.com/jakep244/data.cbt-kata/blob/master/datasets/data/PatientNote_1.csv), `PatientNote_1.csv: PatientNote_1.csv` and [TrialNote_1.csv](https://github.com/jakep244/data.cbt-kata/blob/master/datasets/data/TrialNote_1.csv), `TrialNote_1.csv: TrialNote_1.csv`\n\n## A note\nDo the following test using a patient note such as the above. Then, you can go through the entire training as well as the challenges to learn it step-by-step. The steps used to solve each training are detailed in the [solution.md](https://github.com/jakep244/data.cbt-kata/blob/master/training/solution.md) file.<EOD> Synthesis and antinociceptive activity of the 1-aryl-3-(thien-2-yl), and 1-benzyl-3-(thien-2-yl)-2,2-aminoethanone derivatives.\nA series (8a-j) of 1-aryl-3-(thien-2-yl)-2,2-aminoethanone carboxamides (1-aryl-2,2-aminoethanone derivatives) possessing an aromatic amide function at the N(1)-position and a benzyl moiety in the side chain was synthesised",
        "label": 2
    },
    "426": {
        "output": "# Contribution of the exercise\nOnce you have submitted your work, it will be sent to 3-4 reviewers from different institutions, who will evaluate your solution. They will give feedback on:\n- What part of your solution are they satisfied with?\n- What amendments are they able to suggest to make the solution better?\n- What they would do differently if they were to do the task again?\nWhen you have made your adjustment you can submit your modified code.<EOD> Molecular identification of a novel human coronavirus (HCoV-19) from patients with upper respiratory tract infection in France, 2018/2019.\nBACKGROUND\nThe emergence of severe acute respiratory coronavirus-2 (SARS-CoV-2) posing an unprecedented threat to global public health has triggered a series of investigations to understand the pathogenesis of human coronaviruses (HCoVs), with the hope to discover vaccine and therapeutic interventions for patients with COVID-19.\n\n\nMETHODS\nIn this study, we collected upper respiratory tract fluids from 76 patients who visited the outpatient clinic of the Pasteur Institute of Paris and carried out molecular analysis targeting four HCoV species, including HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1.\n\n\nRESULTS\nDuring the 2018-2019 winter season, three positive samples were detected in our cohort, of which 83% (2 out of 2) and 17% (1 out of 6) were tested positive for HCoV-19 and HCoV-229E.\n\n\nCONCLUSIONS\nOur study confirms that HCoV-19 (lineage B) is active in France, co-circulating with seasonal HCoVs. The genomic sequences of our isolates were genetically similar to the HCoV-19 strain from patients in Germany, but differed from the strains found in China and Iran, suggesting that HCoV-19 genetic diversity occurred. More epide",
        "label": 0
    },
    "427": {
        "output": "A.2.2 Examples\n\n![image](https://user-images.githubusercontent.com/6921254/154552375-9a42d9d9-2880-4be1-9284-f1f4dea1067b.png)\n\n### Examples\n\nLet's check the result for some examples.\n\n![image](https://user-images.githubusercontent.com/6921254/154552415-d3ba784b-f023-4350-8d70-23b392adca6c.png)\n\n![image](https://user-images.githubusercontent.com/6921254/154552431-0af329ca-93cb-48fe-a3ca-9ba25ff50a76.png)\n\n![image](https://user-images.githubusercontent.com/6921254/154552444-e52b49a2-676b-470b-8916-cde02134752f.png)\n\n\nC. Inclusion Criteria\n\n\nA clinical trial is designed to observe the effect of a drug on a population within a specific study design. The definition of patient characteristics for inclusion criteria is an important factor for a successful clinical trial. Eligible patient populations should be the target group and the design should be appropriate for the study protocol. Therefore, inclusion criteria are defined to minimize the variables that need to be excluded later and maximize the chances of obtaining results for the study objective.\n\nD. Exclusion Criteria\n\nThe characteristics of a population that exclude people from a clinical trial are exclusion criteria. All patients who do not fit the basic criteria of the study for a clinical trial are excluded from the study at the time of screening. Exclusion criteria are very restrictive and narrow, so those who are not fit for inclusion criteria have no chance of being included in the clinical trial.\n\n## D.1",
        "label": 0
    },
    "428": {
        "output": "### Examples \n\nExamples of patient note\n\n`$ClinicalCriteria.Where(x => x.FieldName == \"Titrexam_ID\" && x.Value == \"Titrexam_002\" && x.Value == \"Titrexam_002\" && x.DataTypes == DataTypes.DrugName).Any())\n=> Titrexam_002\n\nExamples of patient notes:\n```\n\n```\n\n### Examples of clinical trial assessment of eligibility\nA Clinical Trial's assessment of eligibility has three outcomes\n* Eligible\n* Excluded\n* Not Relevant\n\nExamples of data:   \n\nTrial-level eligibility `Trial-level eligibility: 2) Eligible.`, \n                       `Trial-level eligibility: 1) Not Relevant.`,\n                       `Trial-level eligibility: 0) Excluded.`.\nExamples of trial 1\n\nExamples of Trial 2\n\n```C#\nvar patientClinicalTrialId = string.Empty;\n\nvar trial  = patientClinicalTrialId\n    .Replace(\"TrialID\",\"\");\n\nvar trial  = patientClinicalTrialId\n    .Replace(\"Trial27\",\"\");\n\nvar trial  = patientClinicalTrialId\n    .Replace(\"Trial28\",\"\");\n\nvar trial  = patientClinicalTrialId\n    .Replace(\"Trial29\",\"\");\n\nvar trial  = patientClinicalTrialId\n    .Replace(\"TrialID\",\"\");\n\nvar trial  = patientClinicalTrialId\n    .Replace(\"TrialID\",\"\");\n\nvar trial  = patientClinicalTrialId\n    .Split('TrialID').First();\n\nvar patientClinicalTrialId \n    = trial.Replace(\"Pt2\",\"\");\n```\n\n### Examples - Eligible\n\nFirst, this method's purpose is to find the clinical trial that is used to obtain the patient's trial eligibility information. \n\nvar trialId = patient.Dem",
        "label": 0
    },
    "429": {
        "output": "[/GUIDE]<EOD> Evaluation of the Influence of Soft-Shell Turtles in Aquaculture on the Dissipation of Chlorantraniliprole in an Inland Recirculating Water System.\nThe present study evaluated the influence of soft-shell turtles on the dissipation/removal of chlorantraniliprole in an inland recirculating water system. The influence of soft-shell turtles in water was quantified by using a mass balance model to simulate the inland recirculating water aquaculture system. Dissipation of chlorantraniliprole was simulated in a single-species aquaculture system of channel catfish (Ictalurus punctatus) and striped bass (Morone saxatilis), a mixed-species aquaculture system of channel catfish/striped bass, and a mixed-species aquaculture system of soft-shell turtles/striped bass. The aquaculture system with soft-shell turtles achieved an accumulation of 4.85 kg/year of chlorantraniliprole, which was approximately 15% lower than that achieved by channel catfish/striped bass and 38% higher than that achieved by striped bass. The residue of chlorantraniliprole in the aquaculture system of the striped bass and soft-shell turtle system were found to be 1.1 and 6.1 times higher than that in the channel catfish/striped bass system. Therefore, the accumulation of chlorantraniliprole in soft-shell turtles has a crucial effect on the dissipation/removal of chlorantraniliprole in an inland recirculating water system and may exceed the maximum residue limits for channel catfish and striped bass.<EOD> The role of p16INK4a in the mechanisms underlying aging\n\nSenescent cells accumulate in tissues during the process of aging through a complex signaling mechanism. Here, we review the various pathways of cell senescence and discuss the senescence-associated phenotypes that lead to human aging-associated diseases. We then focus on the role of the cyclin-dependent kinase 4, p16 ink4a",
        "label": 0
    },
    "430": {
        "output": "[[STD_BEGIN]]\n[[CANDIDATE] Hello\n.\n[EMBEDDED_SRC] 34.4Mb\n[IN_OUTER] The data for the next line is from the output of the evaluation script that runs after training an end-to-end model.\n[FULL_SCREEN] The data for the next line is from the output of the evaluation script that runs after training an end-to-end model.\n\n[[CANDIDATE] Hello\nHere is a partial log of a trained NLP pipeline 2.2 (a combination of pipeline 2.1 and pipelines 3.1 and 3.2; see next page for the full log):\n\n[EMBEDDED_SRC] 205.5Mb\n[IN_OUTER] The data for the next line is from the output of the evaluation script that runs after training an end-to-end model.\n[FULL_SCREEN] The data for the next line is from the output of the evaluation script that runs after training an end-to-end model.\n\n\n# Clinical trials\n\n## Pros and cons of clinical trials\n\nClinical trials provide an opportunity for patients to access treatments not currently available in the market. Participating in clinical trials, however, requires patience. Usually, a trial takes at least a year to complete, even though it may take more time or less depending on the number of patients and the number of doctors collecting and analyzing data.\n\n## Choosing a Clinical Trial\n\nWhen enrolling in a clinical trial, consider the following items:\n\n* The goal of the clinical trial must be important to you.\n\n* The treatments that you get during the clinical trial must be approved by the government and proven safe and effective with high results.\n\n* As a clinical trial participant, you will need to spend less time going to the hospital, which may give you more and more time for your job, family and social interaction.\n\n* The clinical trial process should take more years after it ends to improve the overall health and survival of cancer patients.\n\n# Endnotes\n\n[STD_END]\n<EOD> Evaluation of a method for measuring airbor",
        "label": 0
    },
    "431": {
        "output": "## # Trial-level eligibility: 1) Excluded\n# Patient-level eligibility: 1) Excluded\n# Trial-level eligibility: 2) Eligible\n# Patient-level eligibility: 2) Eligible\n\nWe will be judged by whether our assessments are consistent or inconsistent with clinical trial eligibility rules:\n\n## * `Trials: Breast_Cancer_Trials <list>` - You would see more than one Breast_Cancer_Trials entry if you'd load this file again.\n\nIf a single Breast_Cancer_Trials entry has several Trials objects, there are various methods to select and focus on the specific ones. \n\n## * `Trials: Breast_Cancer_Trials <list>.trial_id` - The trial ID. \n- To view each Breast_Cancer_Trial object, type the ID. \n\n## * `Trials: Breast_Cancer_Trials <list>`[:`breast_cancer_trials: { \"trial_id\": \"Trial_ID\" }`) - To retrieve all individual breast cancer trials in a single Breast_Cancer_Trial object. \n\n### [INST]\nLet's first look for a trial by trial ID. If you select a single row for any trial and press tab, you should see this screen:\n\n<table>\n<thead><th>#</th><th>Trial_id</th><th>title</th><th>summary</th><th>start_year</th><th>duration</th><th>end_year</th><th>eligibility</th><th>eligible_subject_count</th><th>eligible_visit_count</th><th>enrolment_site</th></thead>\n<tr><td>1</td><td>Trial_ID</td><td>Is Dietary Nitrate Effective in Reducing Aerobic Glycolysis in Breast Cancer?</td><td>Breast tumours have different metabolism compared to healthy tissue, including elevated lactate production by aerobic glycolysis (AG",
        "label": 2
    },
    "432": {
        "output": "## A. Identify the type of patient record\n\n#### A.1. patient record type\nOn the first screen, type the type variable on the top of the patient record note (type=1, for patient record, or type=2, for hospital record).\n### Examples: [S] [D] [R] [P] [F] [O] [A] [L] [O] [I] [G] [I]\n    type=2, for hospital record, type=1, for patient record.\n\n#### A.2. find the data to identify each type\nA patient record will have multiple attributes; a hospital record will have at most two attributes: 'number_of_hospital_records' and 'patient_record_references' in its record. It should be consistent with the following rules: in a patient record, the attribute of 'number_of_hospital_records' is not empty. And a hospital record refers to a patient record.\n\n### Examples:\ntype=2, hospital record, hospital.attributes: number_of_hospital_records: 1 patient_record_references: reference: ID: p0056\n    type=1, patient record, patient.attributes: (patient.patient_id).name: p00 \n       hospital.attributes: (number_of_hospital_records).name: 1 patient_record_references.reference: ID: p0056\n    type=1, patient record, hospital.attributes: number_of_hospital_records: 1 patient_record_references: reference: ID: p0056\n\n\n### Examples:\ntype=1, patient record, hospital.attributes: number_of_hospital_records: number: 1 \n       patient_record_references.reference: ID: p0056\n    type=1, patient record, hospital.attributes: number_of_hospital_records: number: 1\n    type=1, patient record, patient.attributes: (patient.patient_id).name:  p0056\n\n\n#### A.3. find hospital patients as variables\n\n### hospital type is variable of hospital record.",
        "label": 0
    },
    "433": {
        "output": "Your task is to write the program using the following tools in Python 3.8:\n\n* [NumPy](https://numpy.org): Numeric computation of scientific arrays. *\n[Pandas](https://pandas.pydata.org): Data manipulation with Python. *\n[Pillow](https://pillow.readthedocs.io/en/vet_3.0.0): Python Imaging Library. **\n* [Flask](https://flask.palletsprojects.com/): Web development with Python. *\n* [H2O](https://www.h2o.ai/): Deep learning library. **\n\nGood luck!\n\n\n\n[INST](./02_task2_code.ipynb)\n\n[INST](./03_task3_code.ipynb)\n\n<EOD> Long-term prognostic factors after resection for bronchial cancer.\nIn a prospective study of patients who had bronchogenic carcinoma resected, 483 of 555 patients were followed by questionnaire with a survival of 168 plus or minus 3 months and a maximum follow-up of 71 months. For the entire patient population, the cumulative 5- and 10-year survival rates were 26 and 14 per cent, respectively. Analysis of the data showed independent prognostic factors to affect survival. Age was significantly decreased in the less than 65-year-old to greater than 70-year-old patients (52 per cent 5-year survival in the oldest patients and 29 per cent in the patients 70 years of age or older). Smoking habits had an overall less than 10 per cent effect on the 5-year survival rate, although increased pack-years of smoking did have a significant detrimental effect in patients in the 3rd and 4th decades of life. Local tumor (N) staging and stage had no effect on survival over the 1st degree of spread and tumor volume and extent of spread appeared less important than the N classification; all these parameters affected the cumulative 5-year survival rates at a rate which was proportional to the overall survival rate. The histologic type and grade",
        "label": 2
    },
    "434": {
        "output": "To generate a report:\n    >  python assess_eligibility/main.py --data=path/to/data >\n\nBy using this dataset, all results shown below are reproducible at any time. When you run the code, you will obtain a result like above if you input the correct data.\n\n### Result\nTo generate a report:\n     > python assess_eligibility/main.py --data=path/to/data --output=path/to/output --overwrite==True\n\nYou should use the --output option to choose a desired output file. If you select --output to None, the program deletes the original file. That's dangerous, but it also means that if you remove \"none\", the old out file will be saved automatically. If you prefer to use a temporary file, please use --output to a temporary folder with --overwrite==True option.\n\nTo reproduce these results:      > python assess_eligibility/main.py --data=path/to/data --output=path/to/output\n\nYou can check the results of this dataset. If you want to reproduce it, use the script of the folder \"results\".\n### Result\n\n```python\nClinical trial not eligible (excluded) \n10.59% (90)\nPatient not relevant \n3.63% (31)\nPatient eligible \n85.78% (748) \nEvaluation Time: 0.11212784203 steps\nBest RMSE: 0.09361715482\nPrecision: 0.843211\nAccuracy: 0.949694\nF1: 0.87818\nKappa: 0.81763\n```<EOD> A single dose of intramuscular mepivacaine-adrenaline does not extend analgesia from bupivacaine-adrenaline wound infiltration\nThe aim of this study was to evaluate the effect of a single dose of 10 mg of mepivacaine\u2013adrenaline on postoperative pain after open gynaecological surgery.",
        "label": 0
    },
    "435": {
        "output": "[OUT] Hello.  Your job is to assist with the management of clinical trials. The focus of this particular task is to verify the patient's eligibility with the inclusion criteria. There are three options: 0) Exclusion; 1) Not relevant; and 2) Eligibility.\n\nPlease show the patient note in the box below:\n\nPlease verify eligibility with the inclusion criteria below in the textbox below:\n\n##\n\nPlease enter your output in the textbox below:\n\n\n\n\n\n\n\n\n\n\n### E04a.2.v1.4_outputtable - outputtable\n\n[IN] Your job is to assist with the management of clinical trials. There are several factors to consider when verifying or determining eligibility. \n\n## Factors to consider:\nPatient's age \nPatient's medical history\nPatient's previous treatment \nNumber of active medications (#) \nDuration of active medications (Days) \nDays of active chemotherapy \nHistory of cancer (Yes or No)\n\n\n\n\n\nPlease enter your output in the textbox below:\n\n### E04a.2.v1.4_outputtable - outputtable\n\n[OUT]:\n\n## F04c.2x.v1.x_outputtable - outputtable\n\n[IN] Your job is to monitor a clinical trial. The focus of this particular task is to verify the patient's eligibility with the inclusion criteria. There are three options: 0) Exclusion; 1) Not relevant; and 2) Eligibility.\n\nPlease show the patient note in the box below:\n\nPlease verify eligibility with the inclusion criteria below in the textbox below:\n\n### F04c.2x.v1.x_outputtable - output\n\n**Exercise 100.5** The trial is running.\n\nExercise 100.5 is identical with Exercise 100.4. Instead of being a pre-assessment, this is now a post-assessment,\n\n### E04.0x.v1.x_output - outputtable\n\n### E04a.2x.v",
        "label": 2
    },
    "436": {
        "output": "<EOD> A systematic examination of coughing in neurologically impaired individuals\nObjective: Coughing, essential to removing fluid and mucus from the respiratory tract and to maintaining respiratory function, has been under-studied in humans with neurologic impairment. We systematically examined coughing response in neurologically impaired individuals. Methods: We used the cough stimulation method (salty-tasting solution) to observe cough response in 216 participants, including 75 with Parkinson\u2019s disease (PD), 23 with stroke and 118 healthy participants. We measured the onset time of each cough and the area under curve (AUC) over 5 s, as well as cough reflex sensitivity (CRS) in different groups. Results: We found that the area under curve (AUC) for coughs over 5 seconds was greater and onset time was shorter in all participants with neurological disorders compared with controls, and these differences were more substantial in higher stages of the disease. CRS increased as PD stage progressed. Furthermore, we found that CRS levels were similar between PD and stroke. Conclusions: Cough motor ability seems to be impaired in individuals with neurological disorders and is related to the stage of the disease.<EOD> Nerve Crossover in Transposition of the Great Arteries (Phenotype of Taussig-Bing).\nAn important and frequently overlooked feature, nerve crossover in transposition of the great arteries, is shown to be useful in explaining the phenotype of Taussig-Bing malformation. ( J Am Vet Med Assoc 2014;245:1542-1545) V ertebral artery (VA) hypoplasia is common in most mammals studied from the fetus to the adult and it can be anatomic or functional.1-5 Anatomic hypoplasia is usually not associated with embryologic a etiology (except for VA hypoplasia in cats with the tetralogy of Fallot) and it is usually acquired postnatally in infants and in adults. Vertebral artery hypoplasia",
        "label": 0
    },
    "437": {
        "output": "<EOD> Isolated Left Ventricular Non-Compaction: A Case Report and Review of Literature\n\nA 47-year-old male from Kannur District in Northern Kerala, India presented to the hospital 7 months after a fall from a ladder that caused abdominal injury, and was later diagnosed with acute pancreatitis. His baseline investigations revealed reduced haemoglobin levels, elevated leukocyte count and anaemia. He also had a high Transthoracic Echocardiogram (TTE) revealed structural abnormalities, such as ventricular noncompaction, septal hypertrophy, mitral valvular prolapse, abnormal left ventricular apical contractility and regional wall motion abnormality in the left ventricular anteroseptal and lateral walls. On the coronary computed tomography (CCT) angiogram, left coronary artery dominance was present, left main stem gave rise to left circumflex artery and anterior interventricular (AIV) artery. There was eccentric atherosclerotic plaque that was partially calcified seen in proximity to the ostium in the right coronary artery (RCA). On cardiac magnetic resonance imaging (MRI) there was decreased left ventricular ejection fraction (LVEF) with hypokinesia of the inferior and anterolateral wall of the left ventricle, apical ballooning or takotsubo syndrome, which were attributed to non-ischemic etiology and there were no perfusion defects. The patient was managed with diuretics and beta-blockers that were effective, without a cardiac pacemaker. However, due to the severe pancreatitis of the patient and other medical complications, he died after 9 months of diagnosis. The patient has received timely diagnoses and treatment at the initial stages of his illness.\n\n# Introduction\nIsolated left ventricular (LV) non-compaction is an extremely infrequent structural cardiac alteration in adults, and is also referred to as LV hypertrabeculation or deep trabeculations. 1\n\n## Case presentation\nA 47-year-old male from Kannur District in Northern Kerala, India",
        "label": 1
    },
    "438": {
        "output": "## Clinical Trial Assist (CTA)\nYou should answer the following questions on the clinical trial using Clinical Trial Assist (https://clinicaltrialassist.github.io/): \n##### Answer (1)\n\nThe following answer is not correct. \nA clinical trial is used to learn whether a new treatment, investigational medicinal product (IMP), or medical device is safe and effective in people with a disease or condition. \n\n##### Answer (2)\n\nThis answer is not correct. A prospective study is the type of trial that is carried out prospectively. In the context of a trial, this means that all of the study participants are recruited and the study is conducted, when the trial starts. Participants are recruited prior to collecting data for the study. \n\n##### Answer (3)\n\nThis is incorrect. In the context of a single-center trial, this means it uses only one participant location to conduct the study and all study activities, such as screening participants, enrolling participants, and collecting data, are localized to one site. In the context of a prospective study, this means researchers follow a cohort of participants through time and collect data from them periodically to see if a treatment, drug, or lifestyle change affects a condition. \n\n##### Answer (4)\n\nThis is erroneous. A Phase I trial is performed to test the safety of a medication for a certain population such a patients with the same condition, cancer etc. A Phase I trial may also provide a preliminary indication of the efficacy of the medication under study. The data from a Phase 1 trial will guide the dose of an investigational agent required for Phase II trials. \n\n##### Answer (5)\n\nThis is incorrect. In the context of a trial, the term \"single blind\" means that at least one participant is unaware of her treatment assignment, or that a participant does not know whether she has received an experimental drug or placebo. A double-blind study is one in which both the person assigning the treatment or dosage, and the participant, are kept from knowing what treatment the participant is receiving. In a randomized trial, the randomization procedure assigns each participant to a trial",
        "label": 0
    },
    "439": {
        "output": "[HEADER] Recruitment rate [/HEADER] \nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.Here is the clinical trial: \nTitle: Breast Cancer Liquid Biopsy Stratification\n\n\nSummary: Breast cancer is the most common cancer in Austrian women. Estimation of prognosis and treatment strategies is increasingly being dependent on stratification of tumors into different entities or classes. Currently, clinical routine stratification of tumors is mostly based on hormone receptor, HER2 status, and estimation of proliferation. However, a more robust and objective classification of tumors can be achieved by elucidation of further biological properties, which is also of increasing significance, as novel anticancer therapies are based on biological mechanisms. Consequently, available information from molecular analyses is increasingly being implemented in routine diagnostic assays with the aim to improve stratification for optimal treatment selection. To date the most extensive molecular-based taxonomy of breast cancer has been achieved by a classification based on combining gene expression and somatic copy number alterations (SCNAs), referred to as integrative clusters. Tissue biopsies are the current gold standard to attain such a classification. However, they can often be difficult to obtain in the metastatic setting and are subject to sampling bias due to intratumor heterogeneity. Liquid biopsies are, among other analytes, based on the analysis of cell-free DNA (cfDNA) which contains circulating tumor DNA (ctDNA), i.e. DNA fragments shed from normal and tumor cells into the blood",
        "label": 2
    },
    "440": {
        "output": "<EOD> The impact of the SARS-CoV-2 pandemic on tuberculosis screening for high-risk groups in Italy\n\nA B S T R A C T Background: During the pandemic wave caused by the SARS-CoV-2 virus, Italian regions with high TB burden reported a reduction in the number of contacts screened by tuberculin skin test (TST) and interferon-gamma release assay (IGRA). The aim of this study was to evaluate the effect on TB case detection of the implementation of contact investigation in a TB high burden area, Trapani, Sicily, in 2020, compared with a pre-pandemic study from the same geographical region (2019). Methodology: This retrospective study included subjects aged \ufffd15 years, identified as high risk and exposed to TB cases in 2020 and 2019. The TSTs and IGRAs were performed with the M. tuberculosis-specific antigens PPD-RT23 and early secreted antigenic target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10), respectively. IGRA was performed in all contacts and TST was performed in contacts with negative IGRA test. The data of TST and IGRA tests (performed by T. spot TB) were retrospectively collected in a Microsoft Excel database (Microsoft Corporation, Redmond, Washington, USA) and statistically analyzed. Findings: 2905 contacts (1417 in 2019, 1488 in 2020) were analyzed. TST and IGRA were performed in 2444 (84.1%) and 461 (15.9%) contacts. TST was positive in 166 (59%), while IGRA was positive in 124 (58.9% contacts. TB was 11.4% and 10.6% respectively in the 2019 and 2020 contacts, respectively, for total and symptomatic TB cases only. The detection rate during the pandemic was greater than the pre-pandemic level (IRR of 4.",
        "label": 1
    },
    "441": {
        "output": "[CATEGORY: 1x2]<EOD> Preferences for pharmacologic and nonpharmacologic treatments for obstructive sleep apnea and comorbid insomnia: A systematic review and meta-analysis.\nSTUDY OBJECTIVES\nTo qualitatively and quantitatively review treatment preferences of patients with obstructive sleep apnea (OSA) and comorbid insomnia.\n\n\nMETHODS\nPubMed, PsycINFO, and the Cochrane Central Register of Controlled Trials were searched from inception through April 29, 2021 to identify qualitative and quantitative research examining treatment preferences of patients with OSA and comorbid insomnia. Results were qualitatively grouped by pharmacologic treatments (e.g., continuous positive airway pressure) and nonpharmacologic treatments (e.g., cognitive behavioral therapy), and quantitatively meta-analyzed.\n\n\nRESULTS\nThirteen studies examining 697 OSA participants were included. Twelve studies had only qualitative methods. One study had both qualitative (n = 55) and quantitative (n = 94) methods. Thirteen themes categorized into two primary qualitative categories that correspond to pharmacologic and nonpharmacologic treatments were identified. Meta-analysis of seven studies included in the present systematic review showed that participants chose the nonpharmacologic treatments (standardized mean differences = -1.25, 95% confidence interval , p < 0.001) more than pharmacologic treatments.\n\n\nCONCLUSIONS\nFindings suggest both pharmacologic and nonpharmacologic treatments could be viable options for treating OSA. Future research studies should aim to develop patient-centered interventions and assess how different factors (e.g., gender) can influence decision-making.<EOD> Cleaning the environment, making it safer\n\n\n\n## How bacteria work in harmony\nO rganisms living a symbiotic (that is, intimate) relationship with one another are commonplace in nature, both near the earth's surface and in deep aquatic layers,",
        "label": 1
    },
    "442": {
        "output": "Here is the clinical trial file. You can use this file to check whether the patients are eligible to enter the trial or not.\n\n# [Q4] How to register a completed clinical trial questionnaire?\nAfter you review if the patient is eligible to enter the study or not, you need to perform the registration step of the questionnaire. The key step in the registration is to assign the correct patient identification code at the end of completing the questionnaire. Each patient is assigned a unique randomization number by the research center by generating a lottery. Each randomized number is used to generate the assignment code and is included in the patient's questionnaire and randomization code report. You can match each patient to the answer to the questionnaire using this number. \n\n## [INST] After checking all the patient's eligibility in Questionnaire review step, you need to perform the registration step of the questionnaire. The key step in the registration is to assign the correct patient identification code at the end of completing the questionnaire. the randomization number is generated by the research center by generating the lottery. each patient is randomly assigned a unique randomization number, which is used to generate a randomized number in each patient's clinical trial questionnaire and randomized number report. [/inst]\n[Q5] How to perform the randomized number assignment step in the clinical trial?\nAs the above",
        "label": 0
    },
    "443": {
        "output": "## <formaction xpath=\"instructions\" method=\"get\">\n<div style=\"font-size: 1.15em\">INST:</div>\n<div style=\"font-size: 1.15em\">\n<table class=\"tab\">\n  <tr>\n    <td class=\"tabcontent\">\n      <center>\n        For more information on how to create tab content, see Section 9.9.\n      </center>\n    </td>\n  </tr>\n  <tr>\n    <td class=\"tabcontent\">1.\n      <center>Make a trial-level eligibility on each patient for the clinical trial, i.e.,</center>\n</td>\n  </tr>\n  <tr>\n    <td class=\"tabcontent\">\n      <center>\n        <input aria-required=\"true\" value=\"0\" class=\"form-control num\" maxlength=\"1\"\n        type=\"number\" size=\"1\" min=\"0\" step=\"1\"\n        (value)=\"Trial-level eligibility = $value ? $value.replace('\\'', '') : '0'\"\n        required=\"true\" id=\"Trial-level Eligibility\" disabled=\"disabled\">\n        &nbsp;\n        <span href=\"#\" class=\"checkbox-input\">&nbsp; <input id=\"Trial-level Eligibility_0\" class=\"checkbox checkbox-input\" (click)=\"changeSelectedItem()\" type=\"checkbox\">&nbsp;</span>\n        <span id=\"Trial-level Eligibility_1\" class=\"checkbox-input\">&nbsp; <input id=\"Trial-level Eligibility_2\" class=\"checkbox checkbox-input\" (click)=\"changeSelectedItem()\" type=\"checkbox\">&nbsp;</span>\n        <span id=\"Trial-level Eligibility_3\" class=\"checkbox-input\">&nbsp; <input id=\"Trial-level Eligibility_4\" class=\"checkbox checkbox-input\" (click)=\"changeSelectedItem()\" type=\"checkbox\">&nbsp;</span>\n        <br>\n        <br>\n        <center>Allows you to provide an overall assessment of eligibility.<br>\n        0) Excluded (patient meets inclusion criteria but is excluded",
        "label": 2
    },
    "444": {
        "output": "### Good\nYou can make this judgment based on the above information. That is, the patient is included as `2) Eligible.`. [/GOOD]\n\n### Warning\nThe patient may not be included in this trial because she lacks the necessary demographic information. The patient is 20 years old. She is not post-menopausal, does not experience breast pain, has no children, and does not smoke or consume alcohol. She is not sexually active, and does not use multivitamins or iron supplements. The patient does not agree to participate in the trial. Hence, I think that the patient is 'Not relevant.`. [/WARN]\n\n### Exclude\nThe patient may be excluded based on the exclusion criteria of the clinical trial, for example, age < 18 years old; pregnancy; breastfeeding; HER2-positive. From the above information, the patient falls into one of these categories, and is clearly excluded. `Exclude.`. [/EXCLUDE]\n\n## Probability of eligibility\nYou should provide an overall judgment on a patient's eligibility based on all notes, in the same way as in the Good section. \n\n- [PROBE]: The answer to this question is obvious. If you are not confident about your judgment and would like to hear other opinions from your teammates, you may use the `Probability of eligibility` question on GitHub to get suggestions.\n    \nYou need to make the probability more concrete. Remember that you were taught to provide the probability of eligibility of a patient on an ordinal scale. For example, `Included = 90%`: `Included = Excluded = 40%; Not relevant = 10%`; `Excluded = 10%` would be most appropriate. You should always refer to the Procedure for evaluating the quality of eligibility assessment to see if your assessment passed the quality check.\n\n\n\n\n\t\t\n\t\t\t\t\t\t# patient record\n\t\t\t\t\t\t\n\t\t\t\t\t\t# Clinical trial record\n\t\t\t\t\t\t\n\t\t\n\t\t<tr>\n\t\t  <th scope=\"row\">\n\t\t    <td><",
        "label": 0
    },
    "445": {
        "output": "You can refer the following code snippet to visualize the eligibility result of a clinical trial on the eligibility report page:\n[!inst]\nTrial-level Eligibility: 1) Excluded, 2) Not relevant, 3) Eligible.\n[/inst]\nPlease refer to the demo to see how to use the above snippet\n============================================================\n\n[!inst#ELC_01]\n##\n## ELC_01: Select an item from the patient list for the clinical trial record. \nSelect an item from the clinical trial record.\n\nThe clinical trial list for ELC_01 is as follows:\n\n  1.\n    No items exist\n  2.\n    Clinical Trial 1\n  3.\n    Clinical Trial 2\n=======\n\n\n| Item Number | Field Name | Type | Default | Allowable | Description |\n|-------------|------------|------|---------|-----------|--------------|\n| 1 |  |  |  |  | |\n| 2 |  |  |  |  | |\n| 3 |  |  |  |  | |\n| 4 |  |  |  |  | |\n| 5 |  |  |  |  | |\n| 6 |  |  |  |  | |\n| 7 |  |  |  |  | |\n| 8 |  |  |  |  | |\n| 9 |  |  |  |  | |\n| 10 |  |  |  |  | |\n| 11 |  |  |  |  | |\n| 12 |  |  |  |  | |\n\n[/ELC_01]\nFor the ELC_01 code snippet, the snippet will add an item selection record for the targeted clinical trial name into the system when the user has clicked the `Search` button. After clicking `Update` (you may need to press another key because the default behaviour is to immediately display the `Search` form when the selection is clicked.), the selection should be saved in the system and can be seen from both the `Selected Items` and `Details` page.\n\n[!inst",
        "label": 0
    },
    "446": {
        "output": "## 9.1. Exercise (C3): Exploring eligibility criteria\n\nIn Part 1, we studied patients with cerebral aneurysms. In Part 2, we studied the eligibility criteria of a clinical trial.\nThis is a brief exercise in which you will have a chance to read the trial summary and patient notes to study the eligibility criteria more thoroughly.\n\n[INST] The patient is 70 years old a woman with hypertension, type 2 diabetes mellitus a recent episode of bleeding who presented at the local hospital with leftsided frontal headache for 7 days. The patient has no past medical history. The headache was continuous and throbbing, which had worsened in the left temporal area for the last 3 days. Patient had 4 episodes of vomiting. The patient had history of left-sided weakness 3 days ago. She was not taking any medication.\n\n[INST] This is a short exercise to understand the difference between 'criteria' and 'factors' for a better eligibility assessment. There are many criteria, factors, and factors for a wide variety of clinical trials based on type of diseases, target populations, and available treatments. If you were to participate in a clinical trial, it is important to understand the patient recruitment goals and the eligibility criteria, and how they align with the treatment and recruitment goals of the trial. In some clinical trials, it is required to have more than one clinical factor. If you were to become a clinical research coordinator one day, you will not only have to read and understand these factors and criteria, but you will also have to educate study participants on why they are or are not eligible to participate in the clinical trial. \n\n[INST] There is a discrepancy: 'hypertension or type 2 diabetes mellitus' should actually be 'hypertension or type 2 diabetes or both'. This is because both hypertension and type 2 diabetes can be the criteria and hypertension or type 2 diabetes can be the factor. \n\n[INST] The headache worsening in the left temporal area is not a clinical",
        "label": 0
    },
    "447": {
        "output": "# Discussion\n\n## How did you define the input data set and model the process flow?\nAs the process flow, I simulated the flow of patient data and the recruitment task by clinical trial staff with [data simulator]. By simulating the input data set in this way, you can understand the difference between the results when comparing the methods of data handling.\n\n### How to set the parameters of data simulation?\n[data simulator] can generate a parameter table by specifying the attributes of the input table. In, the parameter table used in the process simulation of the input data set is shown. The simulator was programmed using [language], and the parameter table was generated using [worksheet]. The input data set contains columns for [subject], [age group], [clinic visit], [smoking status], and [lifestyle-related disease]. [subject] and [clinic visit] are assumed to be missing values (na). Also, [smoking status] and [lifestyle-related disease] are treated as categorical variables. \n* This table is generated by the process in[data simulator]\n\n### Did you check the input data set?\nI first created the table structure mentioned above in[worksheet]. After that, [data simulator] can generate a data set of input data based on this table structure. When generating the data set, missing values are filled with the median. I created and then deleted the data set multiple times by modifying the parameter table so that the process performance was not distorted. In, the data set generated by [data simulator] is shown. The rows in the data set are created with a uniform random number, which was generated in [language]. \n\n<img src=\"data-simulation_analysis.png\" width=\"600px\" alt=\"Data simulation analysis by data simulator\" />\n* This table is generated by the process in[data simulator]\n\n### How did you find the solution in an unsolved task?\nWhen I could not solve a specific problem, I modified the parameter table and repeated the same process. The results were different depending on which parameter table was used. If your method gives reasonable results, you can infer that your process flow is reasonable. To infer that your method is correct, you should observe the difference in the results when comparing different parameter tables.\n\n### When",
        "label": 0
    },
    "448": {
        "output": "If you have any question you can visit us. [/END]\n<EOD> .\nAIM\nTo evaluate serum levels of selected interleukins and adhesion molecules in patients with acute coronary syndrome (ACS) before and after a course of standard medical care (SMC) in dynamics with cardiac rehabilitation (CR).\n\n\nMATERIALS AND METHODS\nGroup I (n=50) consisted of patients with unstable angina (UA) and non ST segment elevation (NSTE) myocardial infarction (MI) who had no history of coronary artery disease and who were previously treated with SMC. Group II (n=40) consisted of patients with ST segment elevation MI (STEMI) and had been given treatment according to the recommendations of European Society of Cardiology (ESC) Committee for practice guidelines. All patients underwent standard transthoracic echocardiography, coronary angiography, determination of serum levels of selected interleukins and adhesion molecules before and after the course of SMC in dynamics with CR.\n\n\nRESULTS\nThe mean age in group I and II patients was comparable. In group I, the mean age was 50.03 years (34-66 years), whereas in group II, the mean age was 51.86 years (25-70 years). Patients in groups I and II were divided into 2 groups by risk factors: those without risk factors and those with one other risk factor (arterial hypertension, diabetes mellitus, smoking, obesity and hyperlipidemia). There was no statistically significant difference by interleukin (IL-1\u03b2, IL-6, IL-8 and TNF-\u03b1) and adhesion molecule (sVCAM-1 and sP-selectin) serum levels between patients with ACS without risk factors and healthy individuals. After SMC, these levels were significantly lower only in patients with ACS without risk factors. After a course of SMC in dynamics with CR, there was no statistically significant difference in serum levels of IL-1\u03b2, IL-6, IL-8, TNF-\u03b1, sVCAM-1 and",
        "label": 0
    },
    "449": {
        "output": "<EOD> Growth and metabolic characteristics of intrauterine growth-restricted neonatal piglet with neuropathy-induced growth failure\nIntrauterine growth-restricted (IUGR) piglets with neuropathy (ION) are characterized by growth failure, but their growth and metabolism remain to be characterized. In this study, the growth and metabolic characteristics of ION piglets were explored. Pregnant gilts were injected orally every 5 days from 25 to 105\u2009days gestation with chloramphenicol (CAP), and the weight of piglets was compared at birth. LD10 for CAP was assessed, and piglets were categorized into growth-normal (G-N), growth-restricted (G-R), and growth-restricted with neuropathy (G-RN) groups. Adenosine deaminase (ADA), adiponectin, insulin-like growth factor-1 (IGF-1), thyroid hormone, and growth hormone-releasing hormone (GHRH) were assessed in serum, and growth and metabolic indices were assessed in serum and muscles. The results show that CAP impaired the growth of piglets from birth to weaning. The G-RN group weaned with a significantly (P\u2009<\u20090.05) low litter weight, while the G-R group weaned with significantly low body weight (BW) and average daily gain (ADG). The G-RN group showed significantly (P\u2009<\u20090.05) increased ADA activity, decreased IGF-1, and increased thyroid hormone. The G-RN and G-R groups showed significantly (P\u2009<\u20090.05) decreased GHRH. The G-R and G-RN groups showed significantly (P\u2009<\u20090.05) increased leptin, whereas the G-NR group showed significantly (P\u2009<\u20090.05) decreased leptin. The G-RN group showed significantly decreased activity of glutathione-S-transferase (GST), catalase (CAT),",
        "label": 1
    },
    "450": {
        "output": "**Please, make a trial-level eligibility on each patient.** [/INIT]\n    \n    \n    \n    \n     \n\n<style>\np.inst {\nfont:50%;\nwidth: 50%;\n}\n.question-1{\nbackground: #8F2D6C;\">   How can we compute an average age per arm? Is it possible?\n</B><BR><br><BR>You have to compute an average age per arm.<BR><i><A href=\"http://www.cs.ualberta.ca/~hinton/StatQuest/stats_textbook.pdf\" target=\"_top\" class=\"C\">See Sect. 2.5</A> on average.</i>\n</I><BR><BR>The sum of the scores is 24 <BR><I class=\"C\">Average for all subjects is 4.6 \u00b1 1.34</I><BR><i>Average per group= 4.6 \u00b1 1.34</I><BR><i>Average per arm= 4.6 \u00b1 1.34</I><BR><br><I>Average in the treatment arm and average in the control arm will be same</i><BR><br><br><HR><BR><BR><BR><BR><A name=\"2_questions_1\">\n</A><A name=\"2_questions_1\"></A> \n\n</A><A NAME=\"A1\">\n\n[ A1 ] \n<BR><B><H2>D</H2><B>iscussion</B><BR><BR>\n\nAn average age",
        "label": 0
    },
    "451": {
        "output": "---\n\n[A:INS] You are given a patient note and a clinical trial note. The patient meets the inclusion criteria of the trial but does not meet the exclusion criteria of the trial. The patient does meet the exclusion criteria of the trial. The patient meets neither the inclusion nor exclusion criteria of the trial.=, e.g., `Trial-level eligibility: 2 3) Excluded`.\n[B:INS] You are given a patient note with clinic trial note and asked to output the scale of the trial-level eligibility of the trial.\nLet us think by step.\n- Step 1: Identify the patient's eligibility for the clinical trial\n\n\n\n```\npatient_note                117\ntitle: \"Breast cancer\"                                                                 \nage                         29\ngender                      66\n\ndiagnose                     breast_cancer\ntreatment                    resection\nstaging                     1\nclinical_staging                \n  primary                          0\nsecondary                       0\n\ntreatment_response             4\ngrade                          1\n\nresponse                      0.5\nradiation_on                  1\nradiation_off                 0\n\nsurgery                      on\nhistology                     Infiltration\n\nhistology_type                 1               \nsurgery_type                  1               \n\ndiagnostics                   pathohistologic              \nsurveillance                  mammography\n\nexcluded_clinical_staging                \n  primary                        1\nexcluded_secondary                \n  clinical_staging                0\n \n\nexcluded_surgery                 \n  surgery                        1\nexcluded_surveillance           \n  surveillance                   2\n\nExcluded_Surgery:         0\nExcluded_Surveillance:     0\n```\n\n- Step 2: Identify the type of clinical trial\n\n```\ntrial_title: 'Omission of SLNB in\u2026'                                                                                              \ntrial_date: 01/01/2017                               ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^",
        "label": 0
    },
    "452": {
        "output": "## Recommended Articles\n- [REF] Clinical trials in anesthesia: A practical guide using simple statistics\n<EOD> Fertility treatments and multiple gestation: which patients should be offered elective single embryo transfer in South Africa?\n\nBackground: Multiple gestations are associated with increased risk of obstetric complications, perinatal and infant mortality. The aim of this retrospective study was to determine the incidence of live birth of multiple gestation and to identify the clinical and ultrasonographic features of pregnancies associated with multiple gestation among IVF cycles. Method: Data analysis was performed on 1043 IVF and ICSI cycles of women who presented with at least one oocyte retrieved. The cycles were selected on four criteria; age of patients, cause of subfertility, number of previous failed IVF cycles and number of previous failed ICSI cycles. A total of 1043 cycles were grouped into two groups; 698 with spontaneous pregnancy and 345 with intracytoplasmic sperm injection (ICSI)-conceived pregnancy. Result: Fifty-one (2.03 %) of the 2506 pregnancies conceived were multiple gestations. The multiple gestation rate was 9.3 % (43/464) in the ICSI group compared to 0.97 % (8/882) in the IVF group. When the ICSI cycles were further grouped into poor and good responders using a cut off value of antral follicle count (AFC) = 8, a total of six (5.7 %) poor responders had a singleton live birth compared to 37 (10.1 %) good responders. Among the poor responders, none of the women below 35 years of age had a multiple gestation in contrast to 4.7 % above 35 years old (p = 0.03). The relative risk of conceiving a multiple gestation in the ICSI cycles was 7 times higher than that in the IVF cycles (Risk ratio 6.54, 95 % confidence interval 2.92-14.53, p < 0.0001). Conclusion: ICSI was found to be a significant",
        "label": 0
    },
    "453": {
        "output": "# Exercise\n\nPlease test your answer to Problem 1 with a [link to an online form]. \n<EOD> Re-evaluation of the SARS-CoV-2 infection rate on Nile tilapia (Oreochromis niloticus) cage culture in central Sudan\n\nA novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was reported as the cause of a global pandemic for coronavirus disease 2019 (COVID-19). SARS-Co",
        "label": 0
    },
    "454": {
        "output": "## S3: [INST] Data and code\n\nIn this project, we collect the data from [link] . To train and test our system, we use [link] dataset. It consists of 500 trials and 300 trials respectively. The dataset is imbalanced. Moreover, the labels are highly imbalanced, e.g., Eligible = 1, Not Relevant = 202, Excluded = 0.\n\nThe evaluation metrics are accuracy, BACC, balanced accuracy, precision, recall, f1 score, and G-mean. We use them interchangeably in this paper. We use the following equations.\n\nAccuracy = \nPrecision = \nRecall = \nF1-score = 2 * precision * recall precision + recall\nG = Precision * recall (Precision + Recall) \n\n\n\n### Training data\n\nWe divide the training dataset randomly into 6 folds of the same size. Each fold represents an independent cross-validation. During cross-validation, we train our model on the trials in the fold and evaluate the model on the remaining folds.\n\n### Inference\n\nBesides using the training dataset to train our model, we also use it to estimate the model's performance, i.e., predict the unlabeled trials. Here, we use 3 folds of the training dataset as the test dataset to make sure that every fold has been used for testing. The left out fold is the validation dataset. To train our model on the training dataset, we use the following procedure.\nStep 1: We divide the training dataset into training folds.\nStep 2: We train our system on the training folds.\nStep 3: We evaluate the trained system on the test fold.\nStep 4: We train our system on the whole training dataset.\nStep 5: We evaluate the trained system on the validation fold.\nStep 6: We perform backpropagation on our model according to the loss on the validation dataset.\n\n### Convolutional neural network baseline model\n\nIn this paper, we choose 7 convolutional neural network baselines for comparison, including AlexNet, GoogleNet, Vgg16, Vgg19, Goo-gleNet(",
        "label": 1
    },
    "455": {
        "output": "# Implementation  \n\nFirstly, import the pandas data frame by the following code:\ndata=pd.read_csv(\"exam.csv\")\n\nThe row data is extracted and printed out:\ndata.head()\n\nYou can also plot the first column and first two columns by the following code:\ndata.plot(column=[\"Disease\", \"Eligibility\"], title=None)\n\nThen, you should compare the 'disease' column and the 'eligibility' column of the patient and the clinical trial to judge the eligibility and the final eligibility should be stored in a new variable 'finalEligibility' by the following code:<EOD> An Innovative Approach to Improve Patient Safety During Intravenous Therapeutic Chemotherapy: Development, Implementation, and Results of a Dedicated IV Chemotherapy Treatment Room\nStanford Cancer Institute (SCI) at Stanford Hospital and Clinics was designed to provide highly technical cancer care services, including an Outpatient Chemotherapy Unit (OCU) with 10 infusion chairs, and has served over 1500 patients in the 3 years since opening. While the OCU served to consolidate the clinic\u2019s services and increase patient visits, the institute also faced challenges in ensuring patient safety during the dispensing of highly toxic intravenous chemotherapeutic agents. In addition to the need to accommodate a larger number of patients in a limited space, the facility also lacked space for storing chemotherapeutic medications and refrigerating patient-specific medication bags, increasing the risk for errors. The institute\u2019s leadership determined that a solution was required to decrease the number of errors, improve the safety of care, and improve the patient experience. This article outlines the development and implementation of a new room dedicated to dispensing chemotherapy that would serve to consolidate dispensary and administration functions as well as medication storage and preparation. The following are the results of the development process: (1) the development of a chemotherapy treatment room with patient safety built into every aspect of the room and the workflows; (2) real and projected medication waste and supply costs for dispensing chemotherapy agents by drug, and a",
        "label": 0
    },
    "456": {
        "output": "## Substantive Code\nPlease copy and paste relevant substance code below. \n[INSERT SUBSTANTIVE CODE]\n\n## Substantive Code\nPlease copy and paste relevant substance code below:\n[INSERT SUBSTANTIVE CODE]\n\nFor more info about how to create your [INSERT INSTITUTION] [CORPORATION INSTITUTION], [CORPORATION CORPORATION], or [INCORPORATED OTHER](INCORPORATED), follow the [INSERT CORPORATION URL].\nYou can also find relevant substance code templates for your institution by browsing institution templates on the [INSERT CORPORATION URL].\n\n## Assignment\nPlease complete the following assignment:\nPatient:\n[INSERT NAME]\nAge and sex:\n[INSERT AGE]\n[INSERT FEMALE/MALE]\n[INSERT DETAILED PATIENT RIGHTS]\n\n[INSERT ASSIGNMENT]\n\n\n## Feedback\nThis assignment will provide feedback on your performance in the Clinical Research Assistant Certification curriculum. This will be a graded assignment.\n\n\n# Marks\nThe assignment includes two sections. You will be marked on a total of 6 components: Section 1: You will submit a screenshot from your answer file. We use a rubric to evaluate the correctness of your response against the answer given in [HUB URL], based on your chosen assessment tool. Please see Section 2\n\n## Section 2:\nPlease submit a description of how we would get to your answer (as if we were conducting an assessment, not as a student). This will be scored by your instructor using the below criteria.\nPlease submit your assignment in .doc document type.\n\n## General guidelines 1.\nFollow guidelines in the [HUB URL].\n\n## 2.\nAnswer in word form and then present in screenshots. You can also upload PDFs or Word documents.\n\n## 3.\nYou can use this space to provide any additional information you deem necessary.\nThank you for submitting your assignment. Please wait for your grades to be sent to your [INSERT TIMELY DISTRIBUTION CENTER].",
        "label": 0
    },
    "457": {
        "output": "__Instructions__\n__INPUT_DESCRIPTION__\nRun __python main.py__ to run all the test cases. Then, copy the _summary.txt_ file to your _Workshop/Week 11_ folder under _your username_.\n__RUN_INFO__\n_python main.py_\n\n[INST] This code is written for python3. The user has to set the os and the library paths correctly. Please refer to the python version and library version information.\n[INST] The code prints the message for each execution. The first time, `Test Case 0: Excluded` will be printed.\n__TRIAL_1_FILLE_DESCRIPTION__\n[INST] Let's think step by step.\n[INST] Let's think step by step - Part 1.\n[INST] The function __get_trial_notes__, which is a part of the __Trial_level_eligibility__, is called in the __MAINLINE_0_1__ \n__MAINLINE_0_1__\n[INST] __get_trial_notes__ is used to return the list of trials that the patient can join.\n__MAINLINE_0_1__\n- if __all_patient_trials__ is empty:\n- __get_trial__ is invoked to return the trial object.\n\n__MAINLINE_1_1__\n__get_trial__ is called to return the trial object, which contains all the required information about the trial\n\n__MAINLINE_1_1__\n- trial.get_title__ is called to return the trial's title\n\n__MAINLINE_1_1__\n- trial.get_summary__ is called to return the trial's summary\n\n__MAINLINE_1_1__\n- trial.get_contact__ is called to return the trial's contact's name\n\n__MAINLINE_1_1__\n- trial.get_contact_email__ is called to return the trial's contact's email\n\n__MAINLINE_1_1__\n- trial.get_contact_phone__ is called to return the trial's contact's phone\n\n__MAINLINE_1_1__\n- trial.get_inclusion_criteria_name__ is",
        "label": 0
    },
    "458": {
        "output": "[CODE] ## This code is used to produce the figures in the main manuscript.\n# +\n\nfrom pprint import pprint\n\n#%%\nimport matplotlib.pyplot as plt\nfrom matplotlib import animation\n###% \n#%%\n\n\nplt.savefig(\"../figures/data_cleaning.fig\")\nplt.savefig(\"../figures/data_cleaning_animation.mp4\")\n#%%\n#\n# def plot_eligibility_comparison(patient_info, trial_info):\n#     plt.ylabel(\"Patient ID\")\n#     plt.xlabel(\"Trial ID\")\n#     plt.axhline(y=0, color=\"black\", linewidth=1, linestyle=\"dashed\")\n#     plt.axvline(x=0, color=\"black\", linewidth=1, linestyle=\"dashed\")\n#     #print(\"patient_id: {}\".format(patient_id))\n#     #print(\"trial_id: {}\".format(trial_id))\n#     plt.plot(patient_info, trial_info, marker=\".\")\n#     plt.show()\n#     plt.pause(0.1)\n#     plt.clf()\n#     plt.axis('off')\n#     plt.clf()\n#     if not os.path.exists(\"../figures/data_cleaning.fig\"):\n#         plot_eligibility_comparison(patient_info, trial_info)\n## \nif __name__ == \"__main__\":\n    if __package__ is None:\n        sys.exit(1)\n\n\nplt.rcParam('axes.prop_cycle', cycle=0)\n\n# Define functions for plotting data\ndef plot_eligibility_comparison(patient_ids_index, trial_ids_index, trial_ids, patient_ids, trial_eligibility, plotting_labels):\n    if len(trial_eligibility) == 0:\n        trial_eligibility = [0 for label in plotting_labels]\n\n    if len(trial_eligibility) == 3:\n        trial_eligibility =",
        "label": 0
    },
    "459": {
        "output": "Now, let's look the flow of the program.\n```\n1: import sys\n2: import input\n3: l = [list(sys.argv)]\n4: n = len(l)\n5:\n6: # [patient note]\n7: a = l[n-1]\n8: nstr = 10 # this is a maximum length when you want to read all possible string\n9: # if(a!='') for readability\n10: if(a != '') \n11:\n12:     print(input(\"Select scale for assessment of eligibility: 0) Excluded\\\n(patient meets inclusion criteria\\\nbut is excluded on the grounds of the trial's exclusion criteria)\\\n; 1) Not relevant (patient does\\\n not have sufficient information\\\n to qualify for this trial)\\\n ; \n2) Eligible (patient meets inclusion criteria\\\nand exclusion criteria do not apply).\n     \";\n13: nstr = len(a)\n14: a = a.rsplit(r\"\\n\")  # it will give list to split with 4 elements\n15: k = 1\nwhile(k < 4):\n    print(a[k]) # print one by one\n    if(k<nstr):\n        a += a[0].rsplit(\"\\n\", k+1) # add more string to get more length\nk = nstr\nn = len(a)\n18: nstr = a[0].lstrip()  # remove blank spaces around string\n19: tmp = nstr.split(\"'\") # will split string by ,\n20: lstr = tmp[0]\n21: kstr = tmp[1]\n22: tp = []\nif(lstr == nstr): # when they equal length\n    while(kstr = kstr+1) # this is the same as nstr\n        tp.append(\"'\")\n6: # [clinical trial]\n7: a = l[n-1]\n8: nstr = 12345\n9: c = a.rsplit(r\"\\n\") # for more details go to 10\n10: b = c[",
        "label": 2
    },
    "460": {
        "output": "![INST]\nIn this example, the following are computed:\n- [# Patient Level]: The number of cases included in the clinical trial that are eligible.\n- [# Patient Level Excluded]: The number of cases included in the clinical trial that are excluded.\n- [# Patient Level Not relevant]: The number of cases included in the clinical trial that were not evaluated.\n- [# Trial-level].\nPlease note that in the following example, there are no trials in the selected `clinical trial type` and therefore, no patients are included or excluded in the [# Trial-level].\n![INST]\nThere are patients who can be part of a clinical trial but it needs to be added to the [clinical trial type](../concepts.md).\n\n\n### Examples [#]\n- [# Examples]: \n\n```\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  her2-positive and ER/PR negative. axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial:\nTitle: Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer\n\nSummary: This is a single-arm, open-label, phase 2 study that will enroll 36 subjects, who have pathologically proven diagnosis of invasive breast cancer, clinical stage tumor 1-3 (cT1-T3), node 0-3 (cN0-N3), metastasis 0 (cM0), hormone receptor positive (HR+) (estrogen-receptor-positive (ER+) and/or progesterone-receptor-",
        "label": 0
    },
    "461": {
        "output": "## [/INIT]\n\n##### Exercises:\n\n*  1\n*  2\n*  3\n\n* What do you predict will happen in the patient's note (or will you see anything unexpected?) if you change the code?\n* What do you predict will happen in the patient's note (or will you see anything unexpected?) if you change the code?\n\n**Solution**\n\n*  1\n*  2\n*  3\n\n* What do you predict will happen in the patient's note (or will you see anything unexpected?) if you change the code?\n* What do you predict will happen in the patient's note (or will you see anything unexpected?) if you change the code?\n\n**Solution**\n\n*  1\n*  2\n*  3\n\n**Solution**\n\n*  1\n*  2\n*  3\n<EOD> A survey of the state of health of indigenous populations in the Brazilian Amazon\n\n [bib_ref]  The Brazilian indigenous population, Camargo [/bib_ref]  [bib_ref]  The Brazilian indigenous population, Camargo [/bib_ref]  [bib_ref]  The Brazilian indigenous population, Camargo [/bib_ref]  [bib_ref]  The Brazilian indigenous population, Camargo [/bib_ref]  [bib_ref]  The Brazilian indigenous population, Camargo [/bib_ref]  [bib_ref]  The Brazilian indigenous population, Camargo [/bib_ref]  \n\n## Financial support\nNone declared.\n\n# Authors' contributions\nEpidemiological studies require an agreement on the concept of what we want to achieve, in terms of the population groups to be studied. The question arises of how to include the study of socioeconomic determinants of health and the assessment of environmental determinants, which involve the intervention of external factors in their health, thus broaden the understanding of the complexities of the relationship between health and health-disease processes.\nAlthough indigenous peoples of Brazil have not been the object of a great amount of study, due to the great diversity of the indigenous population, we cannot generalize that what happens among them is the same.\nThe aim of these articles is to expose the importance of using surveillance indicators, and the inclusion of indigenous health surveys in the National Health Survey in order to obtain updated knowledge",
        "label": 0
    },
    "462": {
        "output": "## [INST] Taking it all apart with the \"deconstruct\" operator:\nThe \"reconstruct\" operator takes every patient of the input data and splits it into a \"patient note\" (the first part) and a \"trial note\" (the second part). Then, it is possible to extract the sub-patient notes and sub-trial notes to apply a series of analyses by a wide variety of operators. However, the input data contains nested patient notes and nested trial notes. Therefore, I decided to use this special operator, which performs deconstructions of two levels simultaneously.\nFirst of all, we want to create 2 new features that we call \"patient-level eligibility\" and \"trial-level eligibility\" (see [INST] First operation: creating two new features). These two features are computed by taking every patient of the input data and performing 4 tests:\n- \n\n## 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply); and 3) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).\nTherefore, we can assign the values to the \"patient-level eligibility\" and \"trial-level eligibility\" features by taking into consideration the fact that the first 4 tests of \"Trial-level eligibility\" are performed within each individual patient. \nNext, we have to perform simple operations on these 2 new features. If \"patient-level eligibility\" is equal to 2 (i.e., when a patient is evaluated as \"Eligible\" for a given trial) and \"trial-level eligibility\" is 2 (i.e., the patient is \"Eligible\" for the clinical trial), it means that this patient could be allocated to the trial. Therefore, we want to create a new feature, \"eligible for trial\" (see [INST] Third operation) whose value should be evaluated as the conjunction of the 2 features, \"patient-level eligibility\" and \"trial-level eligibility\". In other words, we want to evaluate the \"eligible for trial\" feature to be equal to 1 if and only if both \"patient-level eligibility\" and \"trial-level el",
        "label": 0
    },
    "463": {
        "output": "`x090461`\nIf you are interested, check `x090461` more detailed, please refer to [SAS Institute Inc. 2020].\n\n### Examples\n\n  1. We start to do all the processing for the example patient and clinical trial: the comparison of the patient's  note and the clinical trial's eligibility criteria. \n  2. Next, we call `Trial-level eligibility`. \n  3. Here, the input note is `Trial-level eligibility result: 2) Eligible.` \n  4. Next, we check whether the patient is eligible for this clinical trial or not. \n  5. For example, if the patient is `45-year-old postmenopausal woman with breast cancer` the output is `No, because of the 'age' criteria, the trial exclusion age criteria is less than or equal to 45 years.` \n  6. We confirm that the final output, `No, because of the 'age' criteria, the trial exclusion age criteria is less than or equal to 45 years.`, should be checked by the recruiter. \n\n\n\n# Tutorials\n\n- [Using the API with Data Frames](_getting_started/tutorials/frames.md)\n- [Exchange of data](_getting_started/tutorials/file_exchange.md)\n\n<EOD> Immunologic aspects of translocation of the small intestine.\nThe alteration of the immune response to non-nutritional antigens (ovalbumin and Brucella abortus) was studied in 35 patients after resection of the small intestine. Sixteen patients had the small bowel transplanted to the neck and 19 to the subcutaneous space. The non-specific immune response to mucinous ovarian graft in the subcutaneous space was preserved. The humoral and cellular responses to ovalbumin and to Brucella abortus in the subcutaneous space were greatly depressed but the cellular immune response to ovalbumin and Brucella abortus was intact in the intraperitoneal space, This finding, with the presence",
        "label": 0
    },
    "464": {
        "output": "## [HIGHEST-LEVELEL] hello. high is the name of a student at [NAME OF SCHOOL] PUBLIC HIGH SCHOOL.\nHe has several best friends, a girlfriend, a pet (dog), his family and his teachers. He is an active member of the basketball team (He is number 18).\nYou should predict the [HIGHEST] personality of High, i.e., output the name of his highest personality. Please use only the [LEVEL] dataset.\nExample of input data file:\n[HIGHEST-LEVEL] Hi:  # Hi is the name of a student at [NAME OF SCHOOL] PUBLIC HIGH SCHOOL.\nHe has several best friends, a girlfriend, a pet (dog), his family and his teachers. He is an active member of the basketball team (He is number 18).\n\nThe following data corresponds to the dataset in the \"LEVEL\" section.\nHi: HIGH-LEVEL\n[LEVEL] # [LEVEL] = 'NAT', 'PRO', 'INT', 'COG', 'ANT', 'SEN', 'SOC', 'MOR'\nIn the [NAME_LEVEL] column, input the name of the highest level of personality, i.e., input level 7.\n[EXPLICIT]\nExp: Hi is the HIGHEST level of personality.\nEx: Hi is the HIGHEST level of personality. \n[/HIGHESTLEVEL]\n[DENOM] Hello. You are a helpful assistant for the clinical trial. Your task is to compare a given patient note and the clinical trial eligibility criteria to determine the best level of the personality of a patient. Then write a report document.\nHere is your patient note:\nHi is the name of a student at [NAME OF SCHOOL] PUBLIC HIGH SCHOOL.\nHi has several best friends, a girlfriend, a pet (dog), his family and his teachers. Hi is an active member of the basketball team (He is number 18).\nHere is the clinical trial: \nClinical trial title: Fulvest",
        "label": 0
    },
    "465": {
        "output": "#Data analysis\n### Example: HYPERGAMMA Data Set\nPlease download the dataset at\nThe data set is composed of 150 subjects' information, including nine variables in total. The subject number is unique in each variable. The last variable named `CATEGORY` represents the subjects' eligibility. The eligible objects are 150, the uneligible subjects are 0.\n\nThe eligible object should be transformed as the eligible subject number. The following code will transform the eligible object into the eligible subject number. Please note that we need to add 1 to eligible object, since eligible objects are 150 and the `CATEGORY` variable data type is int. \n\n`num.y_int = num.y + 1;`\n\nPlease calculate the mean of all subjects' ages.\n\n```python\nage_mean_y_int = num.y_int.mean()\n```\n\nPlease calculate the variance of all subjects' ages.\n\n```python\nvar_y = num.y_int.var()\n```\n\nPlease calculate the sample standard deviation of all subjects' ages.\n\n```python\nstd_age_y_int = num.y_int.std()\n```\n\nPlease calculate the standard error of all subjects' ages.\n\n```python\nse_age_y_int = num.y_int.stderr()\n```\n\nPlease calculate the interval for 95% confidence interval for all subjects' ages.\n\n```python\nlower_ci_age_ci_y_int = num.y_int.lower.quantile(0.05)/std_age_y_int\nupper_ci_age_ci_y_int = num.y_int.upper.quantile(0.95)/std_age_",
        "label": 0
    },
    "466": {
        "output": "# Trip_3: The number of patients with positive P16 expression. \nTrip_3 calculates the number of patients with positive P16 expression. \n[TEST] The number of patients with positive p16 expression is \u2026 (Enter the answer here and press the Enter button.)[/TEST]\nThe p16 expression in ovarian tumors is \u2026 (Enter the answer here and press the Enter button.) [TEST] \nThe number of patients with positive P16 expression in OGCT is\u2026 (Enter the answer here and press the Enter button.) \n \nTo do an assessment of p16 expression in ovarian tumors. Immunohistochemical \nThis study was conducted at the Department of Pathology, Minia University. 32 cases of ovarian tumors and 30 Normal ovaries were selected for this study. All the cases have been collected from the files of the Pathology Laboratory of Minia. The data were collected using a preconstructed form.\n\nThe cases were collected from the files of the Pathology Laboratory of Minia. The cases were diagnosed as 32 cases of ovarian tumor and 62 cases of normal ovaries. They were confirmed morphologically and immunohistochemically by P16.\nThe P16 IHC staining result showed that 28 of the ovarian tumor cases were positive with p16 expression at (28/32=87.5%), whereas, 24 of the OGCT cases were positive with p16 expression at (24/30=80%) and 18 of the Normal cases were positive with p16 expression at (18/30=60%). \n<EOD> Differential regulation of the human Na,K-ATPase at the translational level by beta 1 and beta 2 isoforms.\nTransient transfection assays of constructs containing human Na,K-ATPase alpha 1-cDNAs, either alone or in combination with beta 1-cDNA or beta 2-cDNA, were performed and analysed using an enzyme-linked immunosorbent assay technique. The results revealed two different effects of the beta 1 and beta 2",
        "label": 0
    },
    "467": {
        "output": "Hello. You are a helpful assistant for clinical trial recruitment. Your task is to recruit patients for the trial. The trial's requirements for patients include having a certain disease. You should collect all patient diagnoses that meet the inclusion requirements of the trial. \nLet's extract the patient diagnosis code for the clinical trial using the following seven-step approach. First, collect the patient's diagnoses without trial inclusion criteria. Then, the exclusion diagnoses are removed. Then you need to find all the inclusion diagnosis codes. \n\n`find patients' diagnosis exclusion criteria`\nThe clinical trial needs to select patients according to the following inclusion criteria:\n- `Diagnostic and Histological Criteria:`\nPatients without a previous diagn",
        "label": 2
    },
    "468": {
        "output": "## Inclusion criteria\nLet's consider an eligible patient, i.e., the patient with Trial-level eligibility of 2. To test the patient's eligibility, the patient should have the following:\n- Patient 1 and Patient 2: Excluded;\n- Patient 3, Patient 5, Patient 6, and Patient 7: Not relevant; \n- Patient 4: Eligible.\n\nNotice that `Elizabeth` and `Emily Jane` are both patients whose medical history contains the same information. Therefore, you should consider them to be identical. In addition to the differences shown in the table, the following details are additional information on the patient:\n- `Medical history`: `Diabetes mellitus`;\n- `Chemotherapy`: `Yes`;   \n\nTo illustrate the use of patient_id function to find the patients' id, let's use some of the data shown in the `Patient` table to find the patients' ids by the condition of `Patient_type` < 4. We should obtain the patients' id with Trial-level eligibility of 2, i.e., `Patient_id = id_list[Idx(Patient_type == 2)][Patient_id)`. Here is the patient ids:\n\n## Exclusion criteria\nLet's consider an excluded patient, i.e., the patient with Trial-level eligibility of 1. The exclusion criteria are based on the patient's medical history, i.e., the patient should not satisfy the condition of `Patient` \u2265 1 and `Patient` \u2264 17. Here is a patient with ID 30 whose Trial-level eligibility is 1: `exclusion_criteria = find(Patient == 1 || Patient == 3 || Patient == 7 || Patient == 10 || Patient == 18 || Patient == 19)`\n```\nExclusion_criteria = find(x == 1 || x == 3 || x == 7 || x == 10 || x == 18 || x== 19)\n```\n```\n[2] \"30\"\n```\nThe patient information is summar",
        "label": 0
    },
    "469": {
        "output": "(in a in \u2026, a\u00a0in. [bib_ref] [bib_ref] the 2-based in\u00a0-pat. 2 and<EOD> \n in one and ^. [bib_ref] . 3 for 1\u00a0ass-tre (or-and\nin a [bib_ref] a completeness\u00a0some, which on el, in the\u00a0det, the 1\u00a0 [bib_ref]. [bib_ref] and the\n\n\n and Cement 2\u00a0/\n\n<EOD> or\nof a (in,\u00a0of [bib_ref]2 [bib_ref] and c   (3 for: in an [bib_ref] 3-1 1_ 1 for the 1- 0\n@\n or [fig_ref]ed (due-in- 1\u00a0based-in-based in a_d, in\ninstile for [bib_ref]in .\n{ 1{\n^gut (in clinetic [bib_ref]\ns/care/and. [bib_ref]\n [bib_ref],\u00a0in its-only.\nand\u00a0and c\nin its that the\n 0. and an in\n(dish_int-based \u00ae^d for 2.\ntest\nacc~s \ufffdass-like-in\nd-~specific\nc...\ntre  s \u200b, and any -after a-in the on 1- 2 -.g on [bib_ref]@d@. 2\u00a0 and\n 0 and [bib_ref]... 4 in the...insted-her inst .\n\n[non-visual 0-based.\non\nfor\nshe\n The to A\u00a0 for the _inst to... for [bib_ref]s 7 [bib_ref] [bib_ref]\u00a0for a-and.^ or 1 {\n 1s (i-f of medical study and and and [bib_ref] and \u00a0and for\nsuch in an -s in the (deway in an#inst with \\\nfor_inst 7 and 1-m (i as the \u2265re-1 (in its 2 (~b\n-and-she\u2010se-med for\nor for the\nCOR-1% to 2\u00a0follow\u2026_/med (s-d in 6+ _in. [bib_ref] _[c and its-< in\u00a0and {\n and  before . C-and 1<1 and\n-direct for\ndi*-pat an\u00a0 _m with - -ch\n_\n -",
        "label": 2
    },
    "470": {
        "output": "### Exercise 5: Add your input\n\n> The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  Her2 negative and negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy. Here is the trial: Title: Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer Summary: This is a phase-2 single-arm, open-label trial determining efficacy of Neo-adjuvant Abemaciclib and Fulvestrant in patients with HR+ breast cancer who develop local recurrence while on adjuvant endocrine therapy with molecular evidence of endocrine resistance.\nInclusion criteria: Inclusion Criteria:\nPatients must have a diagnosis of HR+ breast cancer. To fulfill the requirement of HR+ disease, a breast cancer must express, by immunohistochemistry (IHC), at least one of the hormone receptors (ER, progesterone receptor [PgR]) as defined in the relevant American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guidelines (Hammond et al. 2010):\n1. For ER and PgR assays to be considered positive, \u22651% of tumor cell nuclei must be immunoreactive by immunohistochemistry (IHC) (Hammond et al. 2010).\nPatients must have Loco regional breast cancer (Stage I, Stage II and stage III per AJCC 8th edition criteria for staging of breast cancer)\nPatients must have localized recurrence while on adjuvant endocrine therapy\nPatients must have any known mole",
        "label": 0
    },
    "471": {
        "output": "[DATA] \n\n\n\n\n\n[PRED] \n\n\n# Mentor Instructions\nPlease visit the link below to find the comments from your mentor.\n\nIn accordance with MIT's policy the report will be kept in the students' files for at least three years.\n\n\n[/PRED]\n\n\n\n[HINT] \n\n# Questions\n1. You should show your patient to the assistant and your mentor after you finish reading the patient note. 2. Afterward, your job is to explain the answer to your mentor.\n\n[/HINT]<EOD> Fungal and Viral Keratitis in Nepal: A 4-Year Retrospective Study and Current Clinical Perspectives\nPurpose: A wide-ranging review was conducted to assess the current epidemiological status of fungal and viral keratitis in Nepal. Methods: Reports (1975\u20132015) were collected using the online PubMed and SCOPUS search engines, and from several other sources such as the bibliography database of Nepal Medical College and Teaching Hospital and the Nepal Eye Bank Association. Inclusion and exclusion criteria to identify studies related to the review\u2019s objectives were applied, and the data were extracted following a standard procedure in line with the preferred reporting items for systematic reviews and meta-analyses guidelines. Results: Fifty-four studies were included in our review, of which 51 were journal articles and the remaining were review articles and dissertations published in international journals. A total of 31 reports were from a single center, while the remainder were multiple-center studies. The majority (63%) of the primary studies reported were cross-sectional, and the majority (85%) of the studies reported were hospital-based. Of the eligible studies, 11 (20.4%) were case control studies, while 30 (55.6%) were case reports. The incidence rate of total fungal keratitis was 6.8/100,000 population, while only 0.75/100,000 population were afflicted with total viral keratitis. A wide variety of risk factors were stated for fungal and viral keratitis",
        "label": 0
    },
    "472": {
        "output": "To test your solution, run:\n`python solution.py INSTR-A0.in` \n\n# Questions\nPlease discuss your answer with the instructor. We would also suggest that you try to solve the questions by your partners.\nInstructions: Please work through the questions and come up with solutions. After that, try to convince your partner(s) that your solution is right. (10% of the overall grade)\n\n## Problem 4.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 5.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 6.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 7.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 8.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 9.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 10.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 11.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 12.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 13.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 14.\nUse your solution to this question for the rest of the homework assignment. If your solution fails, check your solution by changing the code.\n\n## Problem 15.\nUse your solution to",
        "label": 0
    },
    "473": {
        "output": "<p id=\"instructions\"><sup>\u26e5 \u26e5 \u26e5 \u26e5 \u26e5 \u26e5 \u26e5 \u26e5 \u26e5 \u26e5 \u26e5\u23d0 \u23d0 <NAME>, this is your final assessment. Your trial level eligibility is <NAME>, <NAME>, <NAME>.<NAME> will appreciate your efforts in this task. Here is a short example of what you will be doing:</sup></p>\n\nFor example, the patient note corresponds to the trial number 29023944, and 1) Excluded, 2) Eligible, and 3)\nNot relevant for our patient.\n- Trial-level eligibility: 1) Excluded\n- Inclusive criteria: Patient meets the inclusion criteria for clinical trial: 45-75 years (< 77 years old).\n- Exclusive criteria: Patient does not meet the exclusion criteria for clinical trial: Breast cancer at stage IIIB, stage IIIC, stage IV, or identified as having distant metastasis.\nThe patient's eligibility corresponds to '1) Eligible'. It is sufficient that a patient's eligibility for a clinical trial depends solely on their age, sex, and cancer stage. In these situations, the trial inclusion criteria are simple and concise and are represented as a string of three characters.\nOn the other hand, '2) Not relevant' means that the patient note does not indicate the information needed to determine eligibility. For example, the patient note could be '01/12/2006 breast cancer at stage IIIB', and ' 02/12/2006'. The trial inclusion criteria determine whether the patient is eligible or not based on information provided by various tests.\n`[INST]` <NAME>, this is your final assessment. <NAME> will appreciate your efforts in this task. Here is a short example of what you will be doing:\n\n</p>\n\n1) Make a Trial-level eligibility for each clinical trial.\n\n</pre>\n<p>\u2460)\u2461)\u2462)\u2463)\u2464)\u2465)\ufffd",
        "label": 0
    },
    "474": {
        "output": "### Patient-level Eligibility\n\nAs you already know, we extract the patient's eligibility information from the patient notes in the data file. \nAs you are familiar with the Patient-level Eligibility, you can move to Section 1.7.\n\n### 1.15 The output of the program: You should get an eligibility report\n\n< Eligibility table >\n\nThis is an example of the eligibility report. \n\nAs you are familiar with the output of the program, you can move to Section 1.7.\n\n### Patient-level eligibility\n\nAs you know, we extract the patient-level eligibility information from the clinical trial and the patients' eligibility factors in their patient's notes in the data file. \n\nAs you are familiar with the Patient-level eligibility table, you can move to Section 1.17.\n\n### Question_answer table\n\nYou should extract the Patient-level eligibility factors. You calculate the information (eligibility factors) from the clinical trial (exclusion, inclusion, eligible, excluded) and the factors (age, gender, the type and stage of a disease, previous treatment history, and other medical conditions) in each patient's notes in the data file.\n\n`ClinicalTrials.RData('BN23797.txt')`\n\n| `ClinicalTrials.RData` |\n\n|--------|\n| Trial_label |\n\n|--------|\n| Trial_name |\n\n|--------|\n| patient_1 |\n\n|--------|\n| patient_2 |\n\n|--------|\n| patient_3 |\n\n|--------|\n| age_patient  |\n\n|--------|\n| female_patient  |\n\n|--------|\n| previous_treatment  |\n\n|--------|\n| stage_disease  |\n\n|--------|\n| type_disease  |\n\n|--------|\n\n`Clin.Trials.RData` |\n\n|---------|\n| clin.trials|\n\n|---------|\n| 1 |\n\n|---------|\n| 2 |",
        "label": 2
    },
    "475": {
        "output": "___\n\n## Testing\n\n__We want to check whether the results of the trial would be comparable to those of the real-world treatment under certain circumstances (e.g., patient adheres to the medication)._\n\n### [TEST] Data input\n\nFirst of all, when the user chooses a patient in a hospital's patient pool and click the 'Input data' button the data input panel will be displayed.\n\n![Data input panel](figs/tutorial/Input_data.png)\n\n___\n\n### [TEST] Proceed\n\n_Once every data is filled, click the 'Proceed' button and the data input panel will be cleared._\n\n![Clear button](figs/tutorial/Clear.png)\n\n___\n\n### [TEST] The result is `Not relevant`\n\n_Click the 'Add result' button the output will be printed in the result panel._\n\n![Add result button](figs/tutorial/Add_result.png)\n\n![Test result panel](figs/tutorial/Test.png)\n\n___\n\n### [TEST] The result is `Ineligible`\n\n_Click the 'Add result' button the output will be printed in the result panel._\n\n![Add result button](figs/tutorial/Add_result.png)\n\n![Test result panel](figs/tutorial/Test.png)\n\n___\n\n### [TEST] The result is `Eligible`\n\n_Click the 'Add result' button the output will be printed in the result panel._\n\n![Add result button](figs/tutorial/Add_result.png)\n\n![Test result panel](figs/tutorial/Res_panel.png)\n\n\n# Usage\n---------------------------------------------------------------------- \n\n#### Create a clinical trial\n\n*Click the \"Add clinical trial\" button\n![Add clinical trial button](figs/doc/doc_add_clinical_trial.png)\n\n![Add clinical trial wizard](figs/doc/doc_add_clinical_trial1.png)\n\n*Choose a clinical trial and click the button*.\n*Enter the name of newly registered data *as \"Biochemical study\".*\n*Choose the *status",
        "label": 0
    },
    "476": {
        "output": "<NAME>, 92839822, [NAME] -------- [EMAIL PROTECTED].<EMAIL>, [NAME]<EOD> .\n\n With the high cost of steroids as a remedy for the symptoms of the menopause, efforts have been made to develop new alternatives. Oestrogens and their derivatives are among the first compounds used, and synthetic or semi-synthetic derivatives have been tested. The new compounds have a structure based on natural substances and are produced by chemical synthesis. The structure comprises two groups: aromatic compounds, and steroids. The aromatic compounds have the oestradiol group joined to other substances, for instance: ethynodiolmethylstilbene, bis-hexoside and triazole. The steroids are conjugated with methyl derivatives, and these are then subjected to steric hormonal modulation. The following types of chemical steroid derivatives can be listed: 17-ethynylestradiol, ethynodiolmethyltestosterone, 17-ethynylestropyridol, ethynodiolmethylaminoethanol, ethynodiolmethyloestrone, ethynodiolmethylprogesterone, 17-ethynylestronyloestrone, ethynodiolmethylestradiol, ethynodiolmethyloestradiol, 17-ethynylestriol, ethynodiolmethyloestriol, 17-carbethoxyethynyl-17-ethinyl estriol, diethylstilbestrol, bis-dehydrostilbestrol, bis-cyclohexyldiethylstilbestrol, bis-dehydrobiscyclohexylstilbestrol, and diethyl-2-ethane-carbonyloxyethylstilbestrol. Chemical steroid derivatives with antiglucocorticoid properties were created and proved effective, although they were not completely acceptable. Other tests have been conducted to create substances with progesteronic properties, among others nortestosterone and testosterone. This research has led to the creation of new possibilities:",
        "label": 0
    },
    "477": {
        "output": "5.\n[INST] Assumption 2.\nEach patient-level eligibility of each clinical trial is equal to the AND across all clinical trials with the same factors. In other words, if a patient is eligible to a trial, then the entire patient's information should become \"TRUE\" for the patient across all clinical trials with the same factors.\n\n\n\n\n\nThe output shows:\nThe patient is eligible according to each clinical trial.\n\n# 5. Challenge 6 \n\n[ \nClick for Solution](https://data.mendeley.com/datasets/z664xn4pzn/1) \n\n[56]. Please click the 'Check' button to run challenge 6.\n\nThe following information is provided to help you solve the challenge. You may try to write your own code or search the code from the internet.\n\n## Patient code\n\n```python\n\"Darcy\"\n```\n\nYou must enter the patient or \"case\" name, or the name of the first author if no case is provided.\n\n## Patient note code\n\n```python\n\"[\n    {\n        'id': 7856,\n        'age': 39,\n        'first_names': 'Darcy',\n        'last_names': 'Miller',\n        'sex': 0,\n        'gender_x': 6,\n        'gender_y': -9,\n        'gender_z': 0,\n        'race': 56,\n        'marital_status': 1,\n        'ethnicity': 4,\n        'patient_type': 1,\n        'occupation': 20,\n        'insurance_npi': [\n            4 8\n        ],\n        'insurance_payer_id': [\n            0,\n            4071,\n            5111,",
        "label": 0
    },
    "478": {
        "output": "Done!\n\n<table>\n  <tr>\n    <td>CASCADE</td>\n  </tr>\n  <tr>\n    <td>Trials</td>\n  </tr>\n  <tr>\n    <td>\n      0170B02:Cascade30+NCT02437733 \n      0172T03:Cascade40+NCT03323939 \n      <br />\n      0112C01:NCT02632883 \n      <br />\n      0129C04:NCT02402692 \n      0117C03:NCT2874044, NCT02632883 \n      <br />\n      0016L05:NCT01740427, NCT02632883, NCT01828074, NCT01300046, NCT01141503, NCT01151601 \n      <br />\n      0102A01:NCT02114256, NCT01506544 \n      <br />\n      0008C01:NCT02114256 \n      <br />\n      0108C01:NCT01506544 \n      <br />\n      0046A01:NCT01363634, NCT01718955 \n      <br />\n      0028C01:NCT02282073 \n      <br />\n      0163C01:NCT02175433 \n      <br />\n      0163C02:NCT02274548 \n      0163C05:NCT02175433 \n      <br />\n      017",
        "label": 1
    },
    "479": {
        "output": "# Results\n\nFirst, I analyzed all the 200 patients in the dataset using the preprocessing and precomputation steps, but I filtered them using 5 years and two exclusion criteria: 304.1x (Blood loss, unspecified) and 714.xx (External causes of morbidity.) I got 48 patients for further trials.\nI trained the BERT classifier using the training file and I saved the model, too.\nSo, it would appear that the dataset contains only 48 patients and that the algorithm was able to recognize all these patients. And also that the model was saved and not just trained, so I can open the saved model and check the performance.\n\nI opened up the saved model to check out all the features by using the print statement.\n![print statement from the saved model and the selected attributes]({{site.baseurl}}/images/print_statement.jpg)\n\n##### First section: the input:  \nThe input looks as follows:   \n![input to the saved model and the selected attributes]({{site.baseurl}}/images/input_output.jpg)\n\n##### Second section: the output:   \n    ```\n        {'assessment': 'Clinically Evaluable', 'tumor': {'id': 797, 'status': 5}, 'site': 'Breast', 'procedure name': 'surgery', 'procedure sequence number': 20, 'disease site': 'B', 'disease summary': 'malignant neoplasm of the breast', 'clinical diagnosis': 'malignant neoplasm of the breast', 'specimen characteristics': 'Excision of malignant neoplasm of the breast', 'specimen date': 2/15/2016, 'specimen: tissue': 'excisional', 'specimen size': 2.2, 'bodily fluid and tissue types': 'mammary gland biopsy', 'pathologic diagnosis': 'malignant neoplasm of the breast', 'site and focus': 'B', 'report summary': '', 'specimen type': 4, 'specimen: tissue': 'fresh frozen', 'specimen date",
        "label": 2
    },
    "480": {
        "output": "[INST] How many minutes does it take for someone to complete the eligibility assessments, from reading to the report? How much time do you need to review a patient's eligibility for clinical trials?\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWhat's the difference between the assessment of eligibility and the trial-level eligibility?[INST] Hello.\n\nIn general, assessment of eligibility is the process of determining whether a person is eligible to participate in a clinical trial based on the characteristics and conditions set out in the eligibility criteria, whereas trial-level eligibility is a three-point scale for the assessment of eligibility, which indicates whether a subject meets the eligibility criteria based on the characteristics and conditions set out in the clinical trial protocols. [END]\n\n### What is clinical trial eligibility?[INST] Hello. You are a helpful assistant for clinical trial recruitment. \n\nYour task is to find clinical trial eligibility on each enrolled clinical trial  that your clinic participates in, i.e., output the list of clinical trial eligibility in enrolled clinical trials.\n\nClinical trial eligibility is the set of rules according to which subjects enroll in and are eligible to participate in clinical trials. A clinical trial generally requires potential participants to meet certain eligibility requirements (inclusion criteria) before being admitted to the trial. These eligibility requirements help ensure that each clinical trial has the opportunity to meet its objectives and achieve the desired clinical results. [END]\n\n### Is there any particular eligibility requirement for a clinical trial?\n\n[PREDEF, 5, `The clinical trial targeted to adolescent patient must include a trial-by-age agreement,`]\n\n```\n\n[\nPREDEF, 3, `The clinical trials must involve patients or healthy volunteers.`,]\n[\nPREDEF, 6, `The clinical trial can have strict requirement of HIV test and sexually transmitted disease screening.`,]\n```\n\n[\n\n```\nPREDEF, 3, `The clinical trial must include an exclusion criterion that the patients who have",
        "label": 2
    },
    "481": {
        "output": "## 1) You make a patient-level eligibility assessment by `Patient-level eligibility: 0) Excluded; 1) Not eligible; and 2) Eligible`. This way, in the output, the result of patient-level eligibility is always either `Not eligible` or `Eligible`. [INST]\n\n```r pypath2r # this path is created by pypath2r\n[1] \"~/python\" # set path to where your python environment is\nlibrary(magrittr) # import magrittr to simplify code\nlibrary(purrr) # import purrr to make data processing easier\nlibrary(dplyr) # import dplyr to make data processing easier\n```\n\nIn the following, let's see data preparation. \n \nWe see that in the patient table, there are two patients having the combination of trial eligibility in Trial and Eligible. Suppose you have to run the code with a single patient having the combination in a test case or a test dataset. The code is shown for a patient table in a single patient table. \n\n```r\n# import the trial and patient data files for this trial\ndata.dat <- load(\"~/Data/Trial_data/patients_and_trial_01032019.xlsx\")\ndata.trial <- load(\"~/Data/Trial_data/Trial_01032019.xlsx\")\ndata.eligible <- load(\"~/Data/Trial_data/patients_and_trial_eligibility_01032019.xlsx\")\n# this would be the test case of the trial to be assessed\ntest.case <- data.trial[1:3, ]\n```\n\nLet's see how the code would work in a test case.\n\n```r pypath2r\ntmp <- pypath2r::\"%t%%\" # \"%t%m\" is a string with two characters, `%t` and `.`\n# `rst.clinic` is the working directory of the user; this path is automatically set by iSeeU\nrst.clinic <- \"~/Data/rst_clin",
        "label": 0
    },
    "482": {
        "output": "## \u2705 Answer\nIn order to pass this scenario, you should create patient note and clinical trial note. You should also determine Trial-level eligibility with three options and print the notes and then print the trial-level eligibility. \n```\n#!/usr/bin/env python3\n\"\"\"Test case script for 'assist.test.sjsubway_370_answer.py' file.\"\"\"\n\n\nfrom bs4 import BeautifulSoup\nimport os\nimport yaml\nfrom tqdm import tqdm\n\ndef main():\n    \"Test case script main.\"\n\n    input_data = os.path.join(os.path.abspath( __file__ ), 'input.html')\n    output_dir = os.path.join(os.path.abspath( __file__ ), 'output.json')\n    if the input data is None:\n        print('Invaid Input Directory. Please Check it again.')\n        os.Exit()\n\n    with open(output_dir, 'w') as json_file:\n        soup = BeautifulSoup(\n            BeautifulSoup(\n                html.unescapeHtml(\n                    input_data))))\n\n        soup['sj-subway'] = {'name': 'sjsubway.txt'}\n        soup['patient_details'] = {'name': 'patient_details.txt'}\n        soup['clinical_trial'] = {'name': 'clinical_trial.txt'}\n        soup['patient_summary'] = yaml.safe_load(yaml.safe_load(\n            BeautifulSoup(\n                html.unescapeHtml(input_data)).prettify(\n                    'html')))\n        for i in tqdm(soup.find_all('tr')\n                        if soup.find_all('table')): \n            patientDicts = {}\n            if soup.find_all(attrs={'class': 'patient-details'})[0]: \n                patient = BeautifulSoup(\n                    soup.find_all(attrs={'class': 'patient-details'}).prettify(\n                        'html').splitlines(dropblanks=True))\n            else",
        "label": 0
    },
    "483": {
        "output": "> [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nHere is the clinical trial: \nTitle: Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer\n\n\nSummary: The challenge of breast conserving surgery (BCS) is to obtain free resection margins, by removing the invasive tumor and the precursor cells: DCIS (Ductal Carcinoma in Situ). Consequently, 17%-25% of primary invasive breast cancer patients will need a repeat surgery. Repeat breast surgery has been associated with higher surgical ris",
        "label": 2
    },
    "484": {
        "output": "# Hints\n\n\n\n\n\nIn some questions, only one value is correct. In those questions, the correct answer must be chosen using the number pad (not a mouse). If you do not know the answer, it is still okay (i.e., you can guess a value with a wrong result). However, we consider incorrect answers when you choose a correct value but do not press any keys for the next question. You can select multiple values by holding down the <SHIFT> key and choosing a value on the keyboard. It is recommended that you also choose the <INFORMATION> button on the right-hand side to obtain clarification, even if you make an incorrect answer, in order to learn more from the feedback.\n\n\n# Tasks\n\nHere are the tasks for this section:\n\n- [Task T1](#T1): Compare a given patient note (in Section 0.) with clinical trial inclusion and exclusion criteria (in Section 1.) by answering the question above.\n\n- [T2](#T2): Make a trial-level eligibility for each patient on each clinical trial by answering the question above.\n\n  \n\n\n\n\n\n# Problems\n\n## 1. Incorrect Answers\n\n  \n\n\n\n\n\n## 1.1 Excluded (patient meets the inclusion criteria, but is excluded under the trial's exclusion criteria).\n\n  \n\n\n\n\n\n## 1.2 Not relevant (patient does not have sufficient information on the trial to meet inclusion criteria or does not meet the trial's inclusion criteria.) \n\n  \n\n\n\n\n\n## 1.3 Eligible (patient with the trial's inclusion criteria, but trial's exclusion criteria do not apply)\n\n  \n\n\n\n\n\n# Discussion\n\n## Inclusion and Exclusion Criteria\n\n  \n\n### Inclusion Criteria\nInclusion criteria are those factors that allow a patient to participate in a clinical trial. They are based on characteristics, such as gender, the type of cancer and its stage, the previous treatment history, and medical conditions. The reason you can choose only three candidates from the list of criteria are as follows:\n\n* You will need to use a very stringent method to find relevant papers discussing inclusion and exclusion criteria.",
        "label": 2
    },
    "485": {
        "output": "<EOD> Prevalence of metabolic syndrome with cardio-metabolic risk factors in Chinese individuals with nonalcoholic fatty liver disease: A meta-analysis\n\n\n\n# Introduction\nAlcohol-related complications are the second leading cause of premature death, and nonalcoholic fatty liver disease (NAFLD) is one of the complications. It has become a major public health issue in the world and it is associated with many diseases. Obesity, diabetes, hyperlipidemia, and hypertension are major characteristics of NAFLD and are also strongly associated with metabolic syndrome (MetS). In addition, a growing body of evidence has recently demonstrated that individuals with NAFLD are at increased risk for type 2 diabetes and cardiovascular diseases.\nBased on the definitions of different diagnostic thresholds for MetS, the prevalence of MetS in patients with NAFLD is 32.7% in the United States (2) and 43% in Taiwan. These populations are mostly of European or American descent. However, a few population studies were conducted in Chinese adults with NAFLD, all of which demonstrated a high prevalence of MetS, ranging from 32.1% to 80%. The discrepancies in the prevalence of MetS between these studies were largely due to the differences in their definitions of MetS and racial disparities. The diagnosis of MetS is based on the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) and the International Diabetes Federation (IDF) metabolic syndrome definitions. In the NCEP-ATP III definition, NAFLD might be included with MetS because excess visceral fat is seen in more than 90% of patients with metabolic syndrome. However, NAFLD could not be simply regarded as metabolic syndrome. In the IDF definition, a higher waist circumference (WC) is a key component in diagnosing metabolic syndrome. Moreover, it has been reported that WC is positively associated with NAFLD. If the WC cut-off value is also included in the diagnosis of NAFLD, the high prevalence of MetS with card",
        "label": 0
    },
    "486": {
        "output": "indicate that this is an instruction and should not be repeated in Python or R code. When the code has finished, you can hit <code>'\u21b5'</code> to continue. \n#### Causes `test_eligibility(clinical_trial=your_own_example_clinical_trial, patient=\"your_own_example_patient\")==1`\n##### Parameters \n\n- You need to define the `clinical_trial` variable.\n- You can also define the patient variable. However, if both variables are used, you should use it like `clinical_trial=get_clinical_trial(your_own_patient)`.\n\n##### Returns \n- Returns `1`, if the patient is eligible of the trial.\n- Otherwise, returns `0`.\n\n##### Example \n\n```R\nclinical_trial <- get_clinical_trial(\n  dataset=\"clinical_trials\", \n  id=\"1-98-01-22\")\npatient <- load_patient(\n  filename=\"path/to/your/own/clinical_trial\", \n  dataset=\"patients\")\ntest_eligibility(clinical_trial=clinical_trial, patient=patient)\n```\n\n#### Example \n\n```R\nclinical_trial <- get_clinical_trial(\n  dataset=\"clinical_trials\",\n  id=\"1-98-01-22\")\n\n\npatient_in_trial <- load_clinical_trial(\n  dataset=\"patients\", \n  patient=\"your_own_patient\", \n  id=\"38-53-12-53\")\n\nprint(test_eligibility(clinical_trial=clinical_trial, patient=patient_in_trial))\n```\n\n### Requirements \nThis notebook assumes that `R` and `Python` is installed and can run on Mac OS X, Windows, or Linux.\n\n- `biopython`: `biopython",
        "label": 2
    },
    "487": {
        "output": "- \ud83c\udf10 https://doi.org/10.17179/Exper/325 (2.65 - \ud83c\udf10 https://data.mendeley.com/datasets/2h7sjf7vpc/1 (2.65\n- \n\n1.75- - \ud83c\udf10 https://doi.org/10.17179/Exper/94 (1.75\n- \n\n2.00- - \ud83c\udf10 https://doi.org/10.17179/Exper/45 (2.00\n- - \ud83c\udf10 http://purl.org/dc/dataset/UID:1633993 (2.00\n- - \ud83c\udf10 http://datalad.org/sharing/bundles/mhqvqfyq72 (2.00\n- \ud83c\udf10 https://github.com/mhqvqfyq72/breastcancer (2.00\n(4.00 -<EOD> The use of thalassospira in pump-oxygenator priming solutions.\nFor nearly 30 years, thalassospira (Spirosa) has been widely used in pump-oxygenators in clinical medicine either in its pure form or diluted in a solution of crystalloid saline, glycerol, or glycine. There are no controlled clinical data supporting the use of thalassospira. It has been suggested that the presence of thalassospira is responsible for the poor blood viscosity profile, the hemorrhage and transfusion problems, and the increased mortality rate associated with high flow pump-oxygenator perfusion. A review of experimental data does not support this suggestion. On the contrary, experimental evidence indicates that thalassospira has a beneficial influence on red cell deformability. Thus, the data available do not support the conclusion that thalassospira should be withdrawn from use in pump-oxygenator perfusion.<EOD> .\nCystis fistula as a complication of tra",
        "label": 0
    },
    "488": {
        "output": "### \u2713 `Trial-level eligibility: 2) Eligible`\n<EOD> 6-Oxo-L-norleucine suppresses protein and nucleic acids accumulation in C6 rat glioma cells by causing the apoptosis of malignant cells.\n\n\n\n# Introduction\nAn excess of amino acids in the culture medium increases protein and nucleic acids synthesis in the neoplastic cells undergoing rapidly . Since several amino acid transporters, including LAT1 (a leucine transporter), transport essential amino acids, it is hypothesized that there is a causal relationship between amino acid uptake and the oncogenic potential [bib_ref]  The 4F2hc/LAT1 complex transports 3-methoxytyramine, a major metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine..., Pivetta [/bib_ref] . Therefore, it is of considerable interest to investigate amino acid transporters and their possible contribution to the neoplastic phenotype.\n6-Oxo-purine (6-OP) compounds are synthesized in vivo during oxidative folic acid reduction in mitochondria and by xanthine oxidase in the presence of hypoxanthine. The 6-OP content in the blood of cancer patients is higher than that of normal subjects [bib_ref]  Plasma concentrations of endogenous purine metabolites in patients with prostate and breast..., Shirai [/bib_ref] .\n6-OP has a half-life of 33.5 minutes in normal rats [bib_ref]  Pharmacokinetic study of 6-oxopurine in rats, Shirai [/bib_ref] . Since the blood circulation time of 6-OP is shorter than its half-life, 6-OP is likely metabolized in the target organs or tissues. Among the six forms of 6-oxo-purine, 6-Oxo-L-norleucine (6-ONL) is a stable derivative and has long been used in experimental medicine for the treat-ment of experimental cystitis, liver damage, and other dise",
        "label": 1
    },
    "489": {
        "output": "### Case {1_1_T_1_1}\n\n![](/assets/images/screen/01_README/figures/case_data.png)\n\nWe provide a case in the same structure as the tutorial cases. \n \n### [Questions](#questions)\n\n \nName \n\n___ \n____\nAge \n  ____ \nBMI \n  __________\n\n______\nClinical trial: Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients \n  _________ \n\nAssess whether the patient is eligible for this clinical trial. \n  ____________ \n \n### [Solution](#solution)\n\n```\nTrial-level eligibility: 2) Eligible.\n```\n\n<EOD> The Use of PET/CT for Assessing Response of Malignant Pleural Effusion to Chemotherapy\n\nThe aim of the study was to evaluate the use of fluorine-18 fluorodeoxyglucose ( 18 FDG) positron emission tomography/computed tomography (PET/CT) for assessing the efficacy of chemotherapy (CHT) in treating malignant pleural effusion (MPE). Methods: 21 patients with histologically confirmed pleural effusion were enrolled in this prospective investigation. PET/CT imaging was performed before and after chemotherapy. PET/CT parameters and pleural to blood ratios (P/B ratios) were calculated based on SUV max and SUV mean measurements. Results: PET/CT revealed partial remission in 6 patients who had pleural biopsy but only 2 of them had pathological diagnosis with malignant cells. 18 FDG PET/CT imaging at baseline was able to differentiate responders and non-responders to chemotherapy both for the whole cohort (sensitivity 91%, specificity 88%) and for the subgroups of patients who had a pathologic diagnosis (sensitivity 100%, specificity 100%) PET/CT, which was performed prior to the first cycle of",
        "label": 0
    },
    "490": {
        "output": "[END]\n\n# Step 6: Run Tests\nRun the following tests to verify your script:\n\n* **Lint tests**: `make test`\n\n* **Unit tests**: `make test-unit`\n\n* **End-to-end tests**: `make test-fixtures`\n\nIf there are any failures, read the messages in the **failure** folder and correct the problem in the source code.\n\n## Additional information\nLearn about the [PACE Workflow Engine](https://github.com/NCI-CONNECT/PACE), the [PACE Client](https://github.com/NCI-CONNECT/PACE-Client), and the [Trial Assessment Tool](https://github.com/NCI-CONNECT/Trial-Assessment-Tool).\n\n<EOD> Sensorial evaluation of gelling properties of aqueous carrageenan and \u03ba-carrageenan films.\nCarrageenan is a sulfated polysaccharide extracted from seaweeds, with great potentials for different industrial applications. Among carrageenans, \u03ba type-carrageenan (\u03ba-Cg) is a polysaccharide with great physicochemical and technological characteristics, which has applications in food industry, medicines, and cosmetics, among others. Its film is commonly used in the food industry and can be applied to encapsulate and protect food products. It is also an essential raw material in food processing. Currently, the \u03ba-Cg gel formation mechanism is not fully understood. This study focuses on the investigation of \u03ba-Cg gel formation using the sensory evaluation method by the panelists in order to obtain information, useful for the understanding of the gel formation mechanism. The result indicated the sensorial qualities of the gels were affected by gelator concentration, ionic strength, and interaction between the different polymer groups. The data obtained from the sensory tests in \u03ba-Cg gels (0.2%, 0.4%, and 0.8%) formed without sodium chloride, at 10, 30, and 50 \u00b0C showed sensorial differences that resulted from the gel formation mechanisms, which changed the flow properties.<EOD> .\nA 15 cm diameter x",
        "label": 0
    },
    "491": {
        "output": "### Exercises\n\n**Exercise 1**: How much profit do you earn by sending patient 1?\n(Note: You first enter the `enter` mode and then evaluate your work to earn profit. The profits are calculated by the formula shown below. The higher the probability, the higher the proportion of profit to the expected profit. You will get 2.5 points per exercise. At the beginning of Exercise 1, the patients on your treatment list will be patient 1 as the first patient, patient 2 as the second patient, and so on.)\n```\n    Profit = Prob[Profit] \u00d7 2.5\n    Profit = (Prob[0.7]) * 2.5 = 1.75\nProfit = Expected Profit * Prob + Profit - Prob\nProfit = -10*1.75 + 0.5*1.75 = 3.25\n```\n\n![image](https://img.noghcube.com/20191204.151817.png \"Exercise 1\")\n\n**Exercise 2**: How much profit do you earn by sending patient 2?\n(Note: You first enter the `enter` mode and then evaluate your work to earn profit. The profits are calculated by the formula shown below. The higher the probability, the higher the proportion of profit to the expected profit. You will get 2.5 points per exercise. At the beginning of Exercise 2, the patients on your treatment list will be patient 2 as the first patient, patient 3 as the second patient, and so on.)\n```\n    Prob = Pr(Profit)\nProb = 50\u221246.25\u22123.75 2 = 0.325\nProb = (Prob[0.6]) * 0.5 + (Prob[0.7]) * 0.6 + (Prob[0.8]) * 0.4\nProb = 0.3*0.5 + 0.3*0.6 + 0.4*0.4 = 0.3\nProb = Expected Profit * Prob + Profit",
        "label": 2
    },
    "492": {
        "output": "# Questions\n#\n<EOD> Phylogenetic Signals in Diffusible Signaling Molecules\n\nInterspecific communication in many animal taxa is mediated by biochemically active molecules excreted or exchanged by individuals, leading to behavioral and physiological effects on their targets' traits. When two individuals face each other and exchange molecules they detect through their sensory organs, the resulting signal-exchange dynamics are shaped by species-specific interactions and the resulting phylogenetic history of the communicating taxa. In this study we use a diffusionreaction model to analyze the phylogenetic signal in chemical signals. Our simple model predicts that phylogenetic relatedness is often positively associated with both the speed of signal mixing and the strength of the signal exchanged. Accordingly, the composition of a diffusible signal can signal phylogenetic relationships between a conspecific and a heterospecific. Our results suggest that diffusible signals may contain information",
        "label": 0
    },
    "493": {
        "output": "# Solution\n<EOD> Impact of Hematocrit on the Efficacy of Cariporide (HOE 642), a Novel Adenosine Triphosphatase Inhibitor, in Animal Models of Myocardial Ischemia and Reperfusion Injury\nBackgroundThis study assessed the effect of the hematocrit on the protective effects of cariporide (HOE 642), a novel, selective Na+/H+ exchange inhibitor, in animal models of myocardial ischemia and reperfusion injury. Methods and ResultsThe animals were divided into four groups as follows: those with normal hematocrit (A); those with reduced-hematocrit anemia (B); those with reduced-hematocrit anemia + cariporide (1 mg/kg ip, 15 min before ischemia) (C); and those with reduced-hematocrit anemia + cariporide (5 mg/kg ip, 15 min before ischemia) (D). A 30-min period of global ischemia was followed by 180 min of reperfusion. In normochromic normocytic anemia, compared with the other groups, 34.1%\u00b11.0% of the animals in the normal-hematocrit group developed ventricular fibrillation (P <0.01), and in the control group, 82.7%\u00b13.9% of the animals in the normal hemocrit group developed ventricular fibrillation. The pretreatment of the animals with cariporide (both 1 and 5 mg/kg ip, 120 min before ischemia) significantly reduced the incidence of spontaneous ventricular fibrillation from 56% in the normal hematocrit group to 34.1% (P <0.05) or 30.1% (P <0.02), respectively. Coronary artery ligation for 30 min and 180 min of reperfusion resulted in the infarction of the nontransmural myocardium and transmural infarction, respectively, in the nonpretreated groups.",
        "label": 0
    },
    "494": {
        "output": "<small><!-- Created by O'Neill Michael, (JHU-IBT) on 07-15-2021, 12:08 PM. //--></small>\n\n\n= Exercises &amp; Tests =\n\nHere are some exercises and tests, and links to related Jupyter notebooks that will help you to learn the techniques described. These notebooks are included in the lms101 folder on the lms101 courseware site, where students can click on the links to access the content and run code.  If you have not already downloaded Jupyter Notebook to your local machine, you can install Jupyter and install all the necessary code dependencies by running the install_datalab.sh script in the <code>lms101/resources/runAll_jupyter_notebooks.sh</code> file in the `lms101` folder.  You can find Jupyter Notebook linked below.  \n\n\nJupyter Notebook is a web-based open-source environment used to create and share live code in a web browser and/or on your local computer. Users can interact with code, generate documentation, and perform live computational experiments.  The interactive capabilities of Jupyter allow students to run our exercises and tests.  For the tests, students must also open a spreadsheet file at Jupyter when running code.  This step also causes their code execution to be captured in their Jupyter history, thus allowing them to review any errors they encounter.  \n\n\n- <NAME>\n<p align=\"\" xml:space=\"preserve\" style=\"font-size:80%\"><font size=\"-1\">&nbsp; </font><br /><br />\n<font size=\"-1\"><b>Data Science Methods in Clinical Research</b></font><br /><br />\n&nbsp; <br /> \n</p>\n- Jupyter Notebook: [Jupyter Notebook](https://jupyter.org/downloads)<br />\n- Jupyter Server: [Jupyter Server (Local)](https://jupyter.org/downloads/jupyter-server)<br />\n- &nbsp; <br /> \n<p align=\"\" xml:space=\"preserve\" style",
        "label": 0
    },
    "495": {
        "output": "<EOD> Transcriptome Analysis of Pinus flexilis (Cone) Reveals Differences in Gene Expression Patterns Among Developing and Mature Cone and Seed Tissues\nAs a dioecious species and a dominant conifer across an extensive elevational range, Pinus flexilis has been the focus of an increasing number of physiological and molecular biological studies. To date, however, most of the studies in this species have been limited to coniferyl aldehyde-lignin-based cell walls in mature cones, with no molecular biological studies performed in developing cones or developing seeds. In the present work, we used high-throughput RNA sequencing to create transcriptomes for developing and mature cones and seeds of Pinus flexilis. A total of 43,335 nonredundant unigenes comprising 1.2 \u00b1 0.21 Gb of sequence information were assembled. These transcriptomes were annotated using the UniProt-SwissProt, UniProt-TrEMBL, Pfam, and Gene Ontology databases, as well as the NCBI nonredundant protein and GenBank nucleotide databases. Among these, 22,293 unigenes were predicted to encode proteins. The results showed that most of the unigenes were upregulated at the mature cone and seed stages relative to the developing cone and seed stages. This study represents the first whole-tree transcriptome analysis of developing and mature Pinus flexilis cones and developing seed; our results represent an important resource for future molecular biological studies of conifer species.<EOD> Involvement of CB(1) cannabinoid receptor in the control of food intake and body weight.\nEvidence indicates that the endocannabinoid system plays an important role in the control of food intake and body weight homeostasis. Two cannabinoid receptors have been described, CB(1) and CB(2) receptors. These receptors are coupled to the G protein of the Gi/o type and their activation inhibits cAMP production and activates the mitogen-activated protein kinase pathway through Ga(i), with the consequent inhibition of cAMP and neurotrans",
        "label": 0
    },
    "496": {
        "output": "## Assessment of eligibility --[INST] \nHere is the patient note:\nThe patient is a 45-year-old post-menopausal woman with right breast cancer that is 15 cm in diameter and has invaded the dermis, subcutaneous fat, and pectoralis muscle. The tumor is also infiltrating into the axillary lymph nodes, and the patient has been diagnosed with metastatic disease. Other relevant medical conditions include depression, seasonal allergies, and hypothyroidism. The patient denies any previous history of malignant neoplasm and her last mammogram revealed no breast cancer. \nThe patient is not taking hormone replacement therapy and has not been previously diagnosed with breast cancer. The patient is estrogen receptor and progesterone receptor positive and human epidermal growth factor receptor negative.\nTumor profiling of this patient's tumor using Natera Signatera confirmed tumor mutational status at ctDNA level. The results are summarized in the following table. A negative value indicates that the tumor is not reported as having this mutation. A positive value indicates that the tumor was reported by the assay to have this mutation. \nTumor profiling reported a positive ctDNA-mutation (i.e., positive Natera Signatera test) for this tumor on August 18, 2021.  \n[INST] \nA patient with the following positive predictors (marked in red) is eligible for this clinical trial:  PIK3CA AKAP9, AKT2, ARMC9, DCDC2, DBNDD1, DDX23, FOXN3, FOXO4, GATAD2A, GGF2, KPNA2, PDXDC1, PRKAR2B, S100PBP, SPAG5, SYMPK, TM9SF1\nThe patient is eligible for registration for trial [REDACTED] as defined by eligibility criteria:\nInclusion criteria:\n- 4.1.2. High genomic risk defined as Oncotype Dx Recurrence Score >2",
        "label": 0
    },
    "497": {
        "output": "I have no problem with the answer 'eligible' if I'm using the string input format (it's what I've used so far); however, in this example, would it not seem more appropriate to give a 0/1/2, and say 'excluded' as the second line \n<EOD> The Prevention of Alcohol-Related Illness and Injury: The Role of Policy Interventions\nThe epidemiological and economic burden of alcohol use in Canada has been documented in many reports to date. There are no studies that suggest Canada is unique in relation to patterns of consumption, or in terms of attendant harm from such consumption. Nevertheless, alcohol-impaired driver fatalities, incidence of alcohol-related homicides, injury hospitalisations and hospital admissions, alcohol-related child and fetal harms, violence and fights, and suicides are consistently higher in Canada than in other high resource democracies. Alcohol and illicit drugs are implicated in approximately 16 per cent of hospital admissions and 24 per cent of all deaths in Canada, and about 50 percent of emergency room visits, 20 per cent of hospitalisations in emergency rooms, and 60 per cent of suicides are alcohol related. Alcohol and drug use by youth remain serious problems, as well. In an attempt to reduce this burden, some jurisdictions have adopted specific policy intervention measures. Such measures vary in nature and cover issues such as taxation of alcohol products, licensing of and regulating hours of operation of alcohol establishments, enforcement of drinking and impairment in social venues, mandatory breathalysers, and restriction of the availability of alcoholic beverages. Unfortunately, not one of these measures is well established or even adequately tested. A number of countries have a well-established public education and community action program targeted to different groups (workplace, schools, community centres, etc.). The results so far of this type of public education program have been disappointingly inconclusive. To date, there is scant evidence on what the effects of these policy interventions at the community level are. Nonetheless, it seems likely that such programs have a modulated long-term effect in reducing harms associated with",
        "label": 0
    },
    "498": {
        "output": "<p>An eligibility screen is a process to assess a person's eligibility for a research study, generally to determine that the person qualifies for the study in terms of their particular health or other characteristics.</p>\nLet's think and code, please: \n\n### Making Trial-level Eligibility:\n\n\nYou can make trial-level eligibility by putting the clinical trial data to <tt>clinical_trial.set_trial_level_clinical_trial()</tt>. For example:\n#\nclinical_trial = clinical_trial(title='Comparison Study of Different Tumor Biopsy Method for Sentinel Lymph Node Biopsy in Breast Cancer',\n                              summary='Sentinel lymph node biopsy (SLNB) has become a mainstay surgery method in breast cancer, and the identified number of sentinel lymph nodes determines its accuracy for axillary status. Retrospective study indicated that preoperative tumor biopsy results in more detected sentinel lymph nodes. The clinical trail is designed to compare the effect of three tumor biopsy methods (preoperative vacuum-assisted biopsy, core needle biopsy, and intraoperative excisional biopsy) for sentinel lymph nodes.')\n\n\n#\nclinical_trial.set_trial_level_clinical_trial()\nclinical_trial.set_trial_level_patients()\n\n\n#\nclinical_trials = clinical_trial.all()\n\n\n#\nclinical_trials.inspect()\n\n\n#\nclinical_trials.first()\n\n\n#\nclinical_trials[-2].trial_level_patients.inspect()\n\n\n***\n\n### Making Patient-Level Eligibility:\n\n\nYou can make patient-level eligibility by putting patients to <tt>clinical_trial.set_",
        "label": 1
    },
    "499": {
        "output": "[][][][]``\n*The above code may be changed depending on an institution's IT environment.\n\n[INST]## The data science test bed in i2b2\n\nPlease note that the i2b2 API will be discontinued in 2020.\nI2b2 consists of a Web-based client application. You can find more detailed documentation about i2b2 at the [Medinfo 2.0](http://www.med.mgh.harvard.edu/projects/medinfo/medinfo2/) wiki or its documentation [here](http://i2b2.bwh.harvard.edu/data/i2b2-wiki/index.php/I2b2_Documentation).\nThere are 5 ways to access i2b2: web, grid, report, SOAP, and REST:\n- web clients\n- grid clients\n- Report clients\n- SOAP clients\n- REST clients\nThe i2b2 community and i2b2 tutorials offer an overview about these different clients in the project's wiki.\nThere are two types of data: (a) raw data in the form of a single patient record, and (b) aggregate data, such as counts of patients who are eligible for a specific clinical trial.\nWhen working with i2b2 raw data, you need to consider that the raw data is a patient-centric data set, while the aggregate data is a patient-centric data set with aggregate counts, and thus has a unique set of patient IDs for different rows and columns. For example, the row 'diabetes' may refer to 'diabetes' only in patient 1, while for patient 2, it may refer to a different diagnosed 'diabetes-like' condition.\ni2b2 can accommodate a variety of data types, and you may need to configure certain data types so that they work with i2b2.\nA patient record has the following fields (not all fields may be provided by an institution)\n- demographics\n  * 1) identifier\n  * 2) age\n  * 3) sex\n  * 4) race\n  * 5) ethnicity\n  * 6) birth date\n  * 7) admission date\n- problem list\n  * 1)",
        "label": 0
    },
    "500": {
        "output": "``` r\n# Step by step.\nassess.eligibility <- function(patient, clinical_trial_data){ # function to make step by step # assessment of eligibility\n  patient <- patient %>% mutate(clinical_trial_data2 = clinical_trial_data ## this is just to work out with your data\n    , clinical_trial_assessment = clinical_trial_data2 %>% mutate(eligible = (evaluate == 2) & (Trial-level eligibility == 2)), trials=list(), # list to count trial_level_eligibility and evaluate number\n    )\n  patient <- patient %>% group_by(clinical_trial_assessment)\n  patient %>% summarise(evaluate = (evaluate + 1) %*% sum(trials), # eval.num = evaluate + 1; this is just to avoid overlapping evaluation number\n    Trial-level eligibility = eval.num %*% sum(trials2),\n    all_evaluate = eval.num %*% sum(trials2),\n    ) \n  return(patient) %>% ungroup() # ungroup before return\n}\n\npatient <- pData_categorical %>% filter(patient.ID == 1) %>% select(patient.ID, patient.BIRTH, patient.AGE, BRAIN_CANCER = patient.brain_cancer, LUNG_CANCER = patient.lung_cancer, KIDNEY_CANCER = patient.kidney_cancer, LIVER_CANCER = patient.liver_cancer, HER_CANCER = patient.her_cancer, PR2 = patient.PR2)\npatient.eligibility <- assess.eligibility(patient = patient, clinical_trial_data = clinical_trials, assess = TRUE) # make step by step eligibility\nput(patient.eligibility, file = 'pData_step_by_step_eligibility.Rdata') # export and save patient.eligibility, save data every time\n```\n## Example output\n\n``` r\neval.",
        "label": 1
    },
    "501": {
        "output": "A: The answer by @Brynist mentions about elitism vs. meritocratic.\nIt is all about the right level in which we would like to work, if not work.\n\nThe most important point is, it is better to develop and improve the skill, instead of waiting for a better opportunity (elitism is a bit negative one).\nSomeone who has worked in a poor environment, where the opportunities are limited, would tend to work a bit harder, to improve. They would develop the skill which is essential for future career, and would not wait for a day when opportunities would increase. And some one who works in a good environment, with enough opportunities where, you can improve and develop (meritocratic environment), would tend to spend most of their time on personal tasks like entertainment, etc., and not spend so much time improving and developing skills.\n\nWe humans often work based on the current state of opportunities, where if opportunities are scarce and you could not do much, then you would improve your skills by working hard, while in a meritocratic system, we would do opposite, if we were not improving our skills then it may hamper our growth, and if we improved too much, other would do the same, and would not work hard, which is a negative point for organizations, so there would not be such a difference, and there should be some level of balance between opportunities and personal skills/improvement.\nSo, the elitism will not develop skills, it would make people work based on the current state of opportunities, and the meritocracy will make people work to develop and improve skills. If you have a few chances to work, and you do not develop skills, you would eventually lose those chances.\nAlso, as people have more skills to choose from, then they can be more selective and choose the environment which they would like to work, but if someone can work in the elite environment, they would work in such a way to sustain it.\n<EOD> Clinical and electro-ophthalmologic findings of children with retinitis pigmentosa.\nThere is no unanimity regarding classification of retinitis pigmentosa in childhood. The authors examine 5 children, ranged in age from 3 to 64 months, and with retinitis pigmentosa diagnosed",
        "label": 0
    },
    "502": {
        "output": "\")\n\n    @property\n    def template(self):\n        return self.data[-1] # the last item of the ChainedList\n\n    def write(self, content):\n        if isinstance(content, str): content = BytesIO(content) else: self.data.append(content)\n\n\n    def get_body(self):\n        return str(self.data)\n\n\ndata = \"\"\"title: Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients\nsummary: The investigators propose to use clinically validated patient avatar technology (PDXovo) that can test multiple drugs against patients' cancers to identify the most promising systemic therapy for each individual.\n\n\nInclusion criteria:\nAge 18+.\nMetastatic breast cancer irrespective of subtype.\nMeasurable disease as per RECIST 1.1 criteria.\nMetastatic disease involving",
        "label": 2
    },
    "503": {
        "output": "_[Experienced Python users can watch a video demonstration of the first submission to SRA (and the feedback received from SRA), and the following submission (which includes new parameters).]_\n\n### 3.\nSubmit your script to SRA\n---------------------------\n\nFirst, prepare your files:\n\n```\n$ cat src/your_study.py\n$ cat src/your_study.conf\n$ cat src/your_study.json\n```\n\n[INST] Next, create a new experiment in your SRA account by following the instructions available at the [SRP0209] web site. We suggest to provide a short description of the proposed analysis and then click **Create a New Experiment**. \n[INST] An experiment is an individual unit of research activity. Each SRP experiment has a unique scientific ID (e.g., SRP020916). \n\n[INST] As soon as experiment creation is finished, select the experiment in the left-side menu and choose **Create a Run** to create a new SRR. \n\n[INST] Finally, make a configuration file for your computer cluster. We want to allow the creation of new jobs and the specification of the exact job name and path to your Python files. Therefore, we will ask you to save this file under src/, i. e., it is named src/run.ini. We suggest to name it run.sample or follow the instructions on the [SRP0209] web site to create it. Here is an excerpt of a configuration file:\n\n```\n[Run]\n# the name of the experiment, and the location of files in your user directory\nfilename=your_study.conf\nprefix=/study.\n\n# the name of the submitted jobs\n#job0=run0\n#job1=run1\njob0 filename\njob1 filename\n\n[Run0]\n# the name of the experiment\nfilename=run0.py\n\n```\n\n(Note that the ``job0 filename`` section specifies the path to the ``job0.py`` file and that it is the ``src/your_study.py`` file in our example.) \n\nThen, add the following line at the end of your configuration file:\n\n```json\n[Run0]\nrun_",
        "label": 0
    },
    "504": {
        "output": "- [end]\n<EOD> PhD research project\nPhD research project\n- Topic\n- PhD students from the School of Dentistry at the University of Central England have been carrying out PhD research on a wide range of subjects, from biological to non-biological, oral to technical, laboratory-based to translational and social. These are some examples of such projects. There are several PhD students working on this type of project and they have all been trained in a number of areas. The School has research fellows appointed, who also contribute to the development of these research projects.\n- The School\u2019s PhD students have successfully submitted their dissertation. If you would like to contact the supervisors of any of the students, please contact them through the Student Administration Office, studentadmin@uce.ac.uk, and they will link you up with the relevant person.\n- If you would like further information relating to a particular area of research, please follow the links below:\n- Professor Alison Frenkel - Cariology and Dental Remineralisation\n- Dr Paul Riggs \u2013 Translational dental research\n- Professor David Bray \u2013 Biomaterials\n- Professor Andrew Mumford - Orofacial Pain Management\n- Professor Paul Robinson - Orthodontics and Allied Disciplines\n- Professor Kaye Ball \u2013 Special Care Dentistry and Disability\n- Dr Peter Snell - Forensic Dentistry and Biological Anthropology\n- Dr Ineke Lombaert \u2013 Implant Dentistry, Dentistry\n- Professor Richard Fillingim - Dental Hygiene\n- Professor Jill Taylor - Dental Nursing & Therapies<EOD> A clinical analysis of the outcome of the treatment of patients with hepatocellular carcinoma.\nHepatocellular carcinoma is a disease of major proportions in cirrhotic patients and is the second leading cause of cancer-related mortality. Many therapeutics as well as combined therapeutics, surgical treatments and chemotherapy are being practiced. Aim of this analysis is to evaluate the outcome and overall survival of such treatment on a consecutive series of patients. In total, 308 patients were followed up since August 1985. Two-third of patients belonged to the age group of",
        "label": 0
    },
    "505": {
        "output": "<EOD> \u03c0 conjugation-assisted regioselective nucleophilic substitution.\nThis paper reports our observation that \u03c0 conjugation facilitates electron-demanding substitution reactions. Aromatic-substituted enamides 6 were found to be excellent substrates for regioselective nucleophilic substitution of the unactivated Csp(2)-H bond as well as the Csp(3)-H bond on the ring in the presence of an N-base. The results imply that \u03c0-conjugation reduces the local steric hindrance around the Csp(2)-H and Csp(3)-H and facilitates the \u03c3-nucleophilic attacks of the nucleophiles. When the sterically hindered ortho-substituted enamide 6a was employed, the 1-aryl product 7a was isolated in 63% isolated yield, accompanied with the 2-aryl product 8a in 19% isolated yield, which represents the highest regioselectivity for ortho-substituted enamides. The 1-(p-tolyloxy)benzamide 6b served as an efficient substrate for the selective 1-hydroxyarylation of alkynes, which produced the corresponding amides 7b in 45-93% yield with excellent substrate to product selectivity (up to >200:1). This regioselective hydrogen abstraction was also possible for the N,N'-diarylimidazole enamides 12, which led to the Csp(2)-H activated 1,2-amination products in high yield (up to >97%) with high regioselectivity (up to >100:1). This work extends the application of enamides in the area of nucleophilic substitution chemistry and highlights the importance of local \u03c0-conjugation on aromatic-substituted enamides to regioselective reactivity.<EOD> N\u2010acetylcysteine therapy alleviates endothelial damage in non\u2010critically ill patients with COVID\u201019: the results of the CINCOVIT study\n\nBackground:The endothelium has been demonstrated to be affected in COVID-19 patients",
        "label": 0
    },
    "506": {
        "output": "## ClinicalTrials API.\nThere are several ways to extract eligibility criteria from ClinicalTrials website. In[INST], ClinicalTrials will be used as an example.\n\n<table border=0 width=\"95%\"> \n<th colspan=\"3\" align=\"center\" width=100> \n    <span class=\"h5\"><b>ClinicalTria-l.gov</b></span>&nbsp;&gt;&nbsp;<span class=\"h4\">Breast cancer</span><br> \n    <span class=\"h4\">Titale:&nbsp;&nbsp;</span>&nbsp;&nbsp;<span class=\"strong\">Targeted Axillary Dissection (TAD)</span>&nbsp;&nbsp;in&nbsp;&nbsp; <span class=\"strong\">Early-stage Node Positive Breast Cancer</span> \n</td>    \n</table>   \n\n### <code>ClinicalTrial</code></ins> <br> (ClinicalStudy)\n\n<h4 class=\"title\">ClinicalStudy.Eligibility_criteria.descriptions</h4> :<br> \n <td width=\"100\" align=\"left\"><br>  Eligibility_criteria_description=\"Patient is female of adult \nage.  All female study participants must be postmenopausal, or be willing to \nconsume an adequate amount of estrogen to achieve menopausal endocrine \nstatus. Patient is capable of signing a written consent document. \nPatient is able to comply with the scheduled visits, \nstudy assessments and other study requirements. The patient does not \nhave a history of hypersensitivity to paclitaxel and docetaxel. Patient agrees to \nundergo a biopsy at least 24 hours before the start of paclitaxel and docetaxel \ntherapy if a central pathology review as part of the SQC-839 trial is planned.\" \n</td>    \n\n<h4 class=\"title\">ClinicalStudy.Eligibility_criteria.eligibility</h4> : \n <td",
        "label": 0
    },
    "507": {
        "output": "## Examples\n\nExample (1):\nPlease include this sentence in your patient note to determine trial-level eligibility.\n\n### ____________\nThe patient is a 45 year old postmenopausal woman with cytologically confirmed estrogen receptor positive, metastatic breast cancer stage T2N2M1 with left axillary lymph nodes metastasis. Cervical spine MRI is remarkable for metastasis. The tumor is ER/PR positive, p53 negative, Ki67 more than 50%, and Her2 negative. She has a good performance status (ECOG one), no comorbidities. Tumor markers are normal. She has not received chemotherapy or radiation therapy before diagnosis. She has not had systemic hormone therapy before and after diagnosis. She does not smoke and does not drink alcohol daily. She is not sexually active and has no children. She does exercise on a daily basis. She is candidate for the tumor resection. According to medical ethical guidelines, information about personal details of the patient should not be saved in the clinical database. In this case, it is ok to have personal information. As you know, we did not ask you for this information but we need this information for trial-level eligibility as we will match with the clinical trial. \nIn most of the cases we have anonymized all the personal details and saved some general information in the clinical database. In other cases, we still save some personal data, such as name, age, and gender as these data are necessary for trial-level eligibility. However, this information is not saved in the clinical database. The information is saved in the electronic system in a different database. \n\n### ____________\n\nExample (2):\n\nPatient Note\n\n### Age-Related Eligibility Criteria 1\n\n### ______________\nYou have to confirm the age of the patient. The inclusion criteria are 15 years old or older. If the patient's age is younger than 15 years old, we should not continue the process further, and the patient must be excluded.\n\n### ______________\n\n### ______________\n\n### ______________\n\n### _",
        "label": 2
    },
    "508": {
        "output": "##[STOP]\nGood Luck.<EOD> Infectious diseases.\nThe aim of this study was to evaluate the changes the inhibitory substance production by the blood cells and the serum and blood seric antibiotics, the immunoglobulins of the various classes and the protein content of the blood in patients with different degrees of burns and in patients with burns complicated with wound infection. In comparison to controls 126 burned patients were investigated. 66 patients were without wound infections and the others patients were suffering with wound infections of the following degrees: local superficial (23), superficial (18) and deep infections (29). For determining the antibacterial activity of serum and blood seric antibiotics the paper diffusion method and the cup plate coagulating test with agar gel as medium were used. The evaluation of the inhibition of bacterial growth and the determination of the bactericide indices were performed.<EOD> HSP90A positively regulates ABA-mediated signaling to confer multiple abiotic stress tolerance in wheat\n\nAccumulating evidence indicates that heat shock proteins (HSPs) participate in maintaining cellular homeostasis under stressed conditions. However, little research has been reported on the roles of HSPs in wheat abiotic stresses. Here, we cloned a novel class I chaperone, HSP90-1, and designated it as TaHSP90A. TaHSP90A, with an open reading frame of 1227 bp, encodes a putative HSP90A protein of 408 amino acids. The expression levels of both TaHSP90A and the endogenous ABA signaling gene TaABF2 were significantly increased in flag leaves and leaves before and after exposure to multiple abiotic stress (salt, drought and heat) treatments. Analysis of gene expression in transgenic tobacco plants overexpressing TaHSP90A under osmotic stress showed that the transgenic lines accumulated more endogenous ABA and tolerated abiotic stresses with higher seed germination rate and larger fresh weight compared with WT plants. In addition, transcriptomic analysis on",
        "label": 0
    },
    "509": {
        "output": "A. [CODE=S1-C01  AND] (Human OR Humans) AND (Clinical OR Clinical OR Clinical Trial OR Randomized Controlled Trials as Subject OR controlled clinical trial, random OR randomized controlled trial) 15\nA) [Duplicates removed] 15\n\nA. [Duplicates removed] 14\n\nA. [Duplicates removed] 13\n```\n\n## Running the script\n\n*\n\n*The code file is in [scripts] directory\n*Download an archive of \n  [all_pubmed.tar.gz](https://github.com/thunlab/bqdata_scripts/files/5552930/all_pubmed.tar.gz) \nfrom the above repo, extract to the [scripts/data] directory\n*Create a Python environment (using [virtualenv](https://pypi.org/project/virtualenv/)) for the following code\n  `python -m venv bqdata_env`\n*Make a symbolic link for the venv, to make it work easier, e.g. \n```\nln -s /full/path/to/bqdata_env/bin/python /full/path/to/bin\n```\n*Create a text editor on the same machine, so that it can access the [all_pubmed.csv] file \nand save the output files\n*The following code is used to run a script, one line per line\n*Make a new folder and run the script in it\n*Then, find a file with the name [search_pubmed_data.csv](https://github.com/thunlab/bqdata_scripts/files/6206455/search_pubmed_data.csv) in the [Bash]'s work directory on the local machine  (or [BASH]'s working directory of `screen` if you're using `screen`.)\n*Save it as search_pubmed_data.csv.csv in the [Bash]'s working directory\n```bash\npython bqdata",
        "label": 0
    },
    "510": {
        "output": "<EOD> Glycerol metabolism regulates TCA/glyoxylate pathways and contributes to resistance to salinity, drought and osmotic stress in wheat, Triticum aestivum L.\n\nThe objective of this study was to examine the role of glycerol in osmotic regulation in wheat seedlings. Wild-type (WT) and glp mutant (glp) wheat seedlings were grown in hydroponics and tested for changes in cellular glycerol and amino acid levels, and their responses to stress were measured. Under normal growth conditions, both cellular glycerol and amino acid levels were higher in the glp mutant than in WT. Although glycerol concentrations declined more quickly in glp mutant seedlings than in WT when they were stressed by 300 mM NaCl, there was no significant difference in cellular amino acid levels between WT and glp mutant wheat. During recovery after stress, amino acid levels gradually increased in WT and glp mutant plants. However, the increase was greater in WT wheat seedlings in comparison to glp mutants, resulting in higher amino acid levels in stressed compared to non-stressed WT wheat seedlings. Therefore, the reduced glycerol levels in glp mutants might help to balance the cellular N/C ratio and contribute to higher stress tolerance, probably through adjustments in amino acid metabolism.\n\n# Introduction\nA significant drop in osmotic water potential occurs when plant shoots dehydrate [bib_ref]  Plant responses to water deficit, Bray [/bib_ref] . Osmoregulation is triggered by this drop and plays an important role in maintaining turgor pressure and growth under drought or salinity conditions. A number of osmolytes have been shown to accumulate in response to various stresses. Among these are amino acids, betaine, proline, glycine-betaine, soluble proteins and sugar alcohols [bib_ref]  Metabolic implications of stressinduced proline accumulation in plants, Hare [/bib_ref]  [bib_ref]  Proline, a multifunctional amino acid, Curzytek [/bib_ref] . These organic solutes have been shown to accumulate in wheat seedlings in",
        "label": 2
    },
    "511": {
        "output": "## [/EXERCISE]\n# Q2:\nHow to select variables from the patient note to determine if the patient meets each inclusion criteria of the clinical trial?\nA good set of answers can help you in this exercise:\n1. Gender. If we define a flag as a binary variable denoting whether a participant is man or woman, then we can test if the patient is eligible for the trial. We use `==` to test if two strings are equal.\n2. Age. We can use `>`, `>=`, or `==` to check if the patient's age is above the threshold. `>=` is a binary comparison that means `>`, i.e., if `age >= 20`, it means that we cannot include patients below 20.\n3. Metastasis. If the participant has metastatic disease, the trial does not qualify for the participant. We use `!==` to test if two strings are not equal.\n4. Diagnosis. The clinical trial only takes patients with carcinoma, but not adenocarcinoma.\n5. History of Treatment: We want to make sure patients have never had chemotherapy or radiotherapy.\n6. Treatment: We want to know whether the patient will undergo surgery.\n7. Breast Cancer. The clinical trial takes only breast carcinoma cases. The diagnoses include ductal carcinoma and metaplastic carcinoma. If a patient does not meet the diagnosis inclusion criteria of the clinical trial, then they are excluded.\n8. Breast Ultrasound. Let us say that we will only be able to enroll patients who have metastatic breast cancer. We want to confirm if the patient has an ultrasound in their diagnoses.\n9. Microwave Ablation. The patients with microwave ablation should be included. This is the key to determining whether we can include the participants.\n10. Imaging finding of breast cancer. This indicates whether the participants meet the imaging finding of breast cancer.\n11. Maximum tumor diameter of 3 cm. We use the if statement to check whether any condition in the previous step, with the condition that the participant did not already meet the criterion in the previous step is met.\nA",
        "label": 1
    },
    "512": {
        "output": "In the trial ID column, you should write a unique trial ID (Trial_ID) for each clinical trial. For example, 1_1_2 means the trial \"Adjuvant Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-Risk Breast Cancer\" (Trial ID = 1) with sub-patients numbered 1 to 2. [INST] \n\nYour output should look like this: \n\n[INST] Example #1: \n[[Output]] \n\n[[DocSnippet] The patient is a 55-year-old post-menopausal woman with cytologically confirmed breast cancer. She has a mass in the left breast measuring 3.5 x 2 cm and 1 cm in diameter. Histology revealed a Grade 1 invasive ductal breast cancer. Axillary sampling revealed ten positive lymph nodes. The patient is using multivitamins and iron supplements. The patient is not sexually active. She is not pregnant. She has one child. There are no other important medical conditions. She has smoked 10 years ago. She was diagnosed 10 years ago with a mammary myoma. She is a candidate for both tumor resection and chemotherapy. \n[[GroupSnippet] 0) Excluded (patient meets inclusion criteria but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply) \n[[ClinicalTrialsSnippet] Title: Adjuvant Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer Summary: This study was a transnational pooled analysis of biological material from patients with resected high risk breast cancer who had received adjuvant chemotherapy with epirubicin and cyclophosphamide followed by weekly docetaxel or weekly paclitaxel.\n[/Doc",
        "label": 1
    },
    "513": {
        "output": "[INFO] Hello. \n[VERBOSE] If you want to try it in a real, life-like environment, then run the following command for a trial to start and continue, and observe the outcome.\nFirst, run the following to download a patient's note from UW-Madison. There is no particular reason for selecting it; the patient note is randomly downloaded depending on the internet connection. \n\n> import xmlrunner\n> from pathlib import Path\n> from zipfile import ZipFile\n> from xmlrunner.runners.uwslib import run_uwslib\n> from xmlrunner.runners.uwslib import uwslib_runner_class\n\nThen run the following for the patient's note to be automatically stored in a folder whose name is defined. You can create that folder beforehand. \n\n> from glob import glob\n> import shutil\n> import pathlib\n> import os\n> # Copy the patient's note from UW to another location.\n> uwslib_patient = run_uwslib()\n> dir = os.path.join(os.path.dirname(__file__), 'testrun1')\n> dir\n>.\n[VERBOSE] As an example, the following should be added to the patient information line to create patient number 1, which means the first patient in the database used to collect patient information.\n> patient_number = 1\n> patient = Patient_Data(patient_number = patient_number,\n> \t\tpatient_information = Patient_Information(\n> \t\t\tname = f'Patient Number {patient_number} {patient.sex} {patient.occupation}',\n> \t\t\tdate = f'{patient.age} y/o',\n> \t\t\tethnicity = Patient_Ethnicity(\n> \t\t\t\tcode = '1',\n> \t\t\t\tdescription = 'White',\n> \t\t\t\tcategory = '1'\n> \t\t\t),\n> \t\t\trace = Patient_Race(\n> \t\t\t\tcode = '1',\n> \t\t\t\tdescription = f'White',\n> \t\t\t\tcategory = '1'\n>",
        "label": 0
    },
    "514": {
        "output": "<EOD> .\nPURPOSE OF THE STUDY In this report, we present a case of primary hyperparathyroidism (PHPT) after successful transposition of the parathyroid glands (PTG) with the surrounding neck tissue to the forearms. CASE REPORT A 39-year-old woman was referred to the Department of Endocrinology for surgical treatment of confirmed PHPT. Parathyroid CT showed a heterogeneous 19 mm lesion in the lower pole of the right lobe of the thyroid gland and homogenously",
        "label": 1
    },
    "515": {
        "output": "<table class=\"table\">\n\t<thead>\n\t\t<tr>\n\t\t\t<th>Patient</th>\n\t\t\t<th>Assessment</th>\n\t\t</tr>\n\t</thead>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"answer\">0) Excluded </td>\n\t\t\t<td class=\"answer\">1) Not relevant 0) Excluded</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n![](assets/img/eligible.png)\n\n### [Exclude - Does Not Meet the Inclusion Criteria of ACCORD](#exclude-does-not-meet-the-inclusion-criteria-of-accord)\n\n![](assets/img/accord/exclude-2.png)\n\n![](assets/img/accord/exclude-fail.png)\n\n- Does it meet clinical trial's inclusion criteria? Yes or no.\n- If not, go to the next patient.\n\n## [Not relevant](#not-relevant)\n\n![](assets/img/accord/not-relevant.png)\n\n![](assets/img/accord/not-relevant-fail.png)\n\n- Does it meet clinical trial's inclusion criteria? Yes or no.\n- If no, move on to the next patient.\n\n[Instructor note: You can check your performance by doing this step of your submission at any time. The first patient is always available on this page.](https://review.jlab.datacite.org/submissions#patient-1).\n\nThe patient assessment is 2) Eligible.\n\n### [SPECIFICATION](#specification)\n\n[Instructor note: Please see [Assignment description](https://courses.scied.org/courses/jlab/assignment/Assignment+Description.pdf) and [Assignment rubric](https://courses.scied.org/courses/jlab/assignment/AssignmentRubric.pdf).](https://courses.scied.org/courses/jlab/assignment/Assignment+Rubric.pdf)",
        "label": 1
    },
    "516": {
        "output": "<EOD> Ecophysiology and host specificity of Cytophaga-Flexibacter populations associated with marine phytoplankton\nSUMMARY In this study, the response of a Cytophaga-Flexibacter bacterium to the growth and nutritional status of its associated phytoplankton hosts was investigated in controlled batch cultures. Bacterial activity, phytoplankton productivity and bacterioplankton abundance and diversity were monitored and stable isotope analyses of both carbon and nitrogen were used to investigate the carbon source for the bacterial activities. Bacterial numbers were highest during the rapid growth of the experimental phytoplankton cultures. Bacterial biomass and metabolism were negatively correlated with phytoplankton grazing on dinoflagellates and ciliates, suggesting that the bacterial activities responded to both the presence and abundance of phytoplankton, but the bacteria appeared to be negatively affected by grazers in particular. The stable isotope ratios of the cultures indicated that the bacteria were using mainly dissolved organic carbon from the experimental system rather than fixed carbon released from their phytoplankton hosts. In contrast to previous studies from coastal environments, a low level of variability and a high degree of similarity in the isotopic signature of the bacterial populations were observed, suggesting that the bacteria either had similar lifestyles or shared a similar metabolic activity within the experimental phytoplankton cultures.<EOD> Excited state proton transfer of indole derivatives.\nThe excited-state proton transfer (ESPT) of a new kind of indole derivatives is investigated experimentally by femtosecond transient absorption. These compounds are characterized by a strong dipole moment. The time scale of the ESPT in the 2-aryl-indole derivatives is less than 300 fs, which is faster than that in pyridine derivatives. On the other hand, in the 3-aryl-indole derivatives, the time scale for the ESPT in the S1 excited state is comparable to that in pyridine derivatives. Based on the absorption spectra of the cation and cation radical, an efficient proton",
        "label": 0
    },
    "517": {
        "output": "__HINT__\nTo show the actual answer in the output, we can write the eligibility line in the following format:\n`Eligibility score: 2) Eligible.`.\n\n\n__EXAMPLE__\n```\n\nThis patient is 46 years old and meets the age criterion.\n\nThe patient suffers from high blood pressure but this is not an exclusion criterion.\n\nThe patient does not smoke and the criterion is met.\n\nThe patients has a family history of CAD, and because this criterion is of lesser importance, it can be excluded.\n\nThe patient has no other cardio vascular risk factors such as diabetes, high LDL or cholesterol, or high hsCRP levels.\n\nThe patient has an LDL level of 545, an hsCRP level of 0.2, and a total cholesterol level of 229.\n\nA man who has a strong family history of coronary heart disease (FH) and is currently a current smoker, with high LDL and low high-sensitive C reactive protein (hsCRP) and hsCRP levels of at least 6 mg/dL, with an LDL-C level should be eligible. (3) Excluded 0 0 0.5 1.5 0 -5.5 2 1.5 3.5 11.5 5.5 (2) Not relevant 4 4 4 5.5 0 -5.5 0 0.5 0 0.5 (1) Eligible 0 0 0.25 2 1 0 0 2 2 10.5 8.5 23 10.5 (0) Excluded 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 (2) Not relevant 0 0 0 0 0 0 0 0 0 0 0 [/formula] \n\nAs you already know, a trial-level eligibility score can only take values from 0 (Excluded), 1",
        "label": 0
    },
    "518": {
        "output": "Trial-level eligibility: \"\nYou must use Python programming for solving this task, which is available at [].\n<EOD> .\nThe in vitro activity of the new cephalosporin RO-9866A on bacteria sensitive or resistant to conventional antibiotics was determined: the degree of activity was greater than those of cefazolin, cephradine, cefoxitin, cefotaxime, cefonicid and cefmenoxime. The activity against staphylococci and meningococcus was higher than that of ceftriaxone. An amikacin-sugar derivative (LJ250), which was derived from a screening test of aminoglycosides by the method of molecular imprinting, was found to be a substance of potency of amikacin. The derivatives also have an activity against Gram-positive bacteria (MIC > or = 16 micrograms/ml). The combination of LJ-250 and cefoxitin, LJ-250 and cefotaxime, or LJ-250 and ceftriaxone showed good results against Gram-positive bacteria, which were sensitive to these combination.<EOD> The role of endoplasmic reticulum stress and unfolded protein response in mammalian oocytes\n\nOocytes of many mammalian species display a much higher incidence of aneuploidy due to their unique cellular characteristics and environmental stresses during oogenesis. Although the incidence of oocyte aging and meiotic maturation is relatively low, oocytes still suffer from a variety of sources of insults before they are selected for fertilization in vivo. Endoplasmic reticulum (ER) is an organelle playing a pivotal role in follicular",
        "label": 1
    },
    "519": {
        "output": "### Eligibility criteria of a clinical trial\n\nIn this subtask, you need to select all of the right eligibility criteria of a clinical trial presented in the note section. Note that a single individual subject in the clinical trial has more than one eligibility criteria. \n\nThere are 22 exclusion criteria in total, and the 15 exclusion criteria of patients, 3 exclusion inclusion criteria, and 4 combination exclusion inclusion criteria. Some eligibility criteria have no specific information, therefore, we will describe them by example. For instance, the patient has high blood pressure and, consequently, does not meet eligibility criterion 1. The trial-level eligibility of the patient is 0, thus, the patient does not meet the eligibility criteria of the clinical trial. \n\n\nThink of the eligibility criteria of the clinical trial as an eligible filter. \n\nThere are five combination exclusion inclusion criteria in total. To check the eligibility criteria, please click the button above. \n\n### Input\n\nThis is an R programming script you should run for the solution. You do not need to modify the first chunk if you want to implement the subtasks with data generated by the data repository. When you run the first chunk for your data, your output should be the same with the answer.\n\nIn this chunk, `readr` is loaded to read clinical trial data using R programming library `DT` to implement subtask 1. `CT <-read_DT` loads data frame with information about patient-level eligibility to test patient's eligibility against the criteria of clinical trial, e.g., `CT`. `patient.data` contains data that describes the patient's information, including, but not limited to, the patient's age, gender, blood pressure, cholesterol level, and family history of coronary artery disease (CAD). Patients with a previous history of CAD, smoking habits, and high blood pressures are less likely to meet all the eligibility criteria of a clinical trial. Therefore, only the patients who meet all eligibility criteria of the trial are eligible to be selected for inclusion. As we will see, the output of subtask 1 should have the same structure with the answer. \n\n##",
        "label": 2
    },
    "520": {
        "output": "You can run the following code in Codisio using Jupyter:\n\nimport sys\nimport os\nimport glob\nimport json\nimport boto3\nimport boto.s3.get_object\nimport nltk\n\n[nltk.download('path') for i in ['nltk_data/word_tokenize_eng.gz',\n                            'nltk_data/colloquial.gz',\n                            'nltk_data/snowball_english.gz',\n                            'nltk_data/stem.gz',\n                            'nltk_data/chunk.gz',\n                            'nltk_data/pos_tag.gz',\n                            'nltk_data/stem_tag.gz'] | \\\n        [sys.stderr.write('%.100s' % line) for line in glob.iglob('*.gz', recursive=True)]\n\ndef evaluate(patient_id, trial_id):\n    '''Evaluates whether a clinical trials patient can be assessed as eligible or not.''''\n    s3boto = boto3.resource('s3')\n    bucket = s3boto.Bucket('s3-cdisio-datasets')\n    url = 's3-cdisio-datasets/%s/%s/%s. json' % (patient_id, trial_id, 'eligibility')\n\n    print('Reading patient note...')\n    patient_note = bucket.get_object(Bucket=bucket.name, Key=url)['Body'].read()[0]\n    print('Extracting words...')\n    nltk_stemmer = nltk.stem.wordnet.WordNetStemder()\n    word_list = nltk.word_ tokenize.word_tokenize(patient_note)\n    print()\n    print('Removing punctuations and numbers...')\n    word_features = nltk.data.load('nltk_data/word_tokenize_eng.gz')\n    word_features.flesch_reading_ease(word_features)\n    print('Word tokenization and feature extraction...",
        "label": 2
    },
    "521": {
        "output": "This study was based on three input files named [datasetname]_patient_note, [datasetname]_CT_inclusion_exclusion_criteria.txt, and [datasetname]_CT_assesstrial_eligibility.csv. \n![image](https://user-images.githubusercontent.com/94689548/146674905-6450152e-98e8-41a8-aeb2-ce574e8e432d.png)\n\n## How to read input files ? \nPatient-level data: [datasetname]_patient_note.txt (in the DataSet1 folder) \n\n``` \nDemolish patient_note {\n  id: ID1\n  BP: 130  \n  FG: 85  \n  Age: 56\n  Smo_4W_2: Y  \n  Smo_Town: H  \n  Chest_Sex: Y  \n  ANA_Sex_V: N  \n  Cardio_Drug: R  \n  Smo_4W_1: N  \n  Sex: F  \n  CAD_Family: Y  \n  Chest_Smoke: N \n  History: N \n  LDL_C: 560  \n  Glu_Fast: 60  \n  TG_Fast: 159  \n  TG_TC: 53  \n  LDL_MU: 1  \n  HDL_MU: 1  \n} \n```\n\n```\nDemolish patient_note {\n  id: ID2\n  BP: 179  \n  FG: 82  \n  Age: 47\n  Smo_4W_2: Y  \n  Smo_Town: H  \n  Chest_Sex: Y  \n  ANA_Sex_V: N  \n  Cardio_Drug: R  \n  Smo_4W_1: N  \n  History: N  \n  CAD_Family: Y  \n  Chest_S",
        "label": 2
    },
    "522": {
        "output": "Exercises\n\n**Exercise: In this exercise, you are going to test your application by running it on a collection of input data. The input data file is found in the ``examples`` folder.**\n- [Exercise_InputData.zip](https://github.com/a-mohamed/Hadoop-streaming-eligibility-app/blob/master/examples/input_data.zip) (100MB)\n- Run your application and the input data for the exercises.\n- Find the difference between your result and the ones in the answers.\n- If the results are not as expected, repeat the exercise, and try to fix bugs in your code.\n- When you are ready with all the exercsies, you should look to the next part: Running the Application.\n\n**Exercise 1:**\n- [Exercise_1.zip](https://github.com/a-mohamed/Hadoop-streaming-eligibility-app/blob/master/examples/Exercise_1.zip) (200MB)\n- Exercise 1 uses a HCF file, which is stored in the data lake.\n- A copy of the file is given as an input to the program.\n\n**Exercise 2:**\n- [Exercise_2.zip](https://github.com/a-mohamed/Hadoop-streaming-eligibility-app/blob/master/examples/Exercise_2.zip) (195MB)\n- Exercise 2 uses test data.\n- A copy of the file is given as an input to the program.\n\n**Exercise 3:**\n- [Exercise_3.zip](https://github.com/a-mohamed/Hadoop-streaming-eligibility-app/blob/master/examples/Exercise_3.zip) (273MB)\n- Exercise 3 uses test data and a HDFS file.\n- A copy of the file is provided as an input to the program.\n\n**Exercise 4:**\n- [Exercise_4.zip](https://github.com/a-mohamed/Hadoop-streaming-el",
        "label": 2
    },
    "523": {
        "output": "# Problems\n\n## Problems, suggested solutions and implementation\n\n### Inline file input\n\n* Make sure that you have the latest version of the input file. \n\n![input.JPG](./input.JPG)\n* Make sure that the patient notes appear exactly as specified in the input file.  \n\n![INST_601.JPG](./INST_601.JPG) \n* Make sure that the input file is in the expected format.  \n\n![input_expected.JPG](./input_expected.JPG) \n\n### Input file for input and output\n\n * Make sure that you have the latest version of the input file. \n\n![input.JPG](./input.JPG)\n\n### Problems with the input\n* Verify that each sample has the same format and that the input data is correct.\nIf the input data is not correct and you want more details about the inputs for the input and outputs, please refer to the following [Input and Output Files](#input-and-output). \n\n### Problem with output\n* Make sure the patient notes and the expected output files are in the format above. \n\n\n![output.JPG](./output.JPG)\n* Make sure that the format of the input data is correct. \n\n### Running multiple runs\nThere may be several sub-processes running at the same time, but we recommend executing one subprocess at a time. However, if you want to run multiple instances, specify `CUDA_VISIBLE_DEVICES=1,2,3,...` to run using multiple GPUs in series.\n\n# Hint\n\n\n**Hint\n** If the output file name does not work, first check the case sensitivity of the file system (uppercase or lowercase). If it is the lowercase, it means that the file name is searched for the wrong form (e.g., outputA.txt instead of output_A.txt).\n**<EOD> .\nINTRODUCTION\nPatients with metachromatic leukodystrophy (MLD) show an irreversible demyelination of the central nervous system caused by a deficiency of beta-galactocerebrosidase (B-GAL). The accumulation",
        "label": 1
    },
    "524": {
        "output": "<EOD> Assessing the risk of progression from amnestic mild cognitive impairment to Alzheimer's disease: the role of CSF amyloid and tau markers\nABSTRACT Background: CSF A\u03b242 and total tau (T-tau) are considered reliable biomarkers for the diagnosis of Alzheimer's disease (AD). Nevertheless, their ability to discriminate between early stages of the disease has been questioned, particularly at the earlier stages of AD. In this regard, the predictive value of CSF biomarkers of the disease on the risk of progression to more symptomatic stages of AD, remains to be established. Methods: We followed up 176 amnestic mild cognitive impairment (aMCI) patients (diagnostic accuracy: 85.1%), with CSF biomarkers for AD (i.e., A\u03b242, T-tau, and phosphorylated tau (P-tau)), annual structured neuropsychological assessments and brain MRI. Our outcome was to define the progression from aMCI to AD. Results: Sixty-one patients showed a cognitive decline and thus aMCI-converter. We analyzed whether CSF biomarkers differentiated these patients from aMCI non-converters (\u201caMCI-non-converters\u201d). We performed a binomial logistic regression adjusted for the age, gender, education, and number of years of evolution showing that decreasing values of CSF A\u03b242 and higher values of T-tau and P-tau were significantly associated with a greater probability of conversion to AD at one year. These results were confirmed by ROC curve analyses where A\u03b242 presented at cut-off \u2264 121.91 ng/mL \u2265 70.7% sensitivity, \u2265 92.5% specificity, \u2265 94.5% positive predictive value (PPV), \u2265 63.7% negative predictive value (NPV), \u2265 82.6% of accuracy and AUC = 0.95 and P-tau \u2265 37.6 ng/mL and T-tau \u2265 378.69 ng/mL",
        "label": 2
    },
    "525": {
        "output": "Examples for the patient note are in the file [INPUT FILE] `data_sample_patient.csv`.\n\nInput\n-------------------\n\nExample of CSV file with patient notes (all notes are included) and the clinical trial:\n- Patient Note ID: 0\n    Name: 46-year-old man has high LDL-C\n    Last Modified: Wed Mar 21 13:31:28 2018\n    Value: ''\n    Category: medical history\n    Label: medical_history\n    Docs: The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively.\n- Patient Note ID: 1\n    Name: 46-year-old man has high LDL-C\n    Last Modified: Sun Mar 18 12:26:44 2018\n    Value: ''\n    Category: medication\n    Label: medications\n    Docs: He reported no use of lipid-lowering medications.\n- Patient Note ID: 2\n    Name: 46-year-old man has high LDL-C\n    Last Modified: Sun Mar 11 12:09:06 2018\n    Value: ''\n    Category: medication\n    Label: medications\n    Docs: He reported no use of lipid-lowering medications.\n    Value: Yes\n    Category: demographic\n    Label: gender\n    Docs: Male.\n- PatientNoteID: 0\n    Name: 53-year-old man has high LDL-C\n    LastModified: Wed Mar 21 13:31:28 2018\n    Value: ''\n    Category: medical history\n    Label: medical_history\n    Docs: His LDL-C and HDL-C levels were 233 and 76\u2009mg/dL, respectively.\n- PatientNoteID: 1\n    Name: 47-year-old woman has high LDL-C\n    LastModified: Sun Mar 18 12:26:44 20",
        "label": 1
    },
    "526": {
        "output": "The steps from 4.1. to 4.3. should be repeated for every patient. We have used 295 patients for this example.\n<EOD> Nuclear receptors and transcriptional regulation by thyroid hormone and steroids.\nHormones elicit biological responses by modulating gene expression. Transcription, the complex process by which information contained in the DNA of eukaryotes is converted to an equivalent message in mRNA, is the target for hormone control. The specificity of regulation is ensured by sequences located upstream in the genes that act as regulatory elements. A major class of hormone regulatory sites consists of hormone response elements or hormone receptor binding sites. The interaction of hormones with these elements can either lead to an inhibition or augmentation of the basal rate of transcription. The hormone-mediated stimulation of activity of a specific promoter region or of several different genes is due to the specific binding of the receptor in conjunction with various other factors at the hormone response elements in the genes. Thus, the identification of the hormone receptor binding sites within the regulatory sequences is essential for both understanding of the molecular mechanisms of hormonal response and furthermore as a tool for the biochemical isolation and characterization of the regulatory factors needed for the hormonally regulated transcription.<EOD> Effect of p-chlorophenoxyisobutyrate on the response of phosphatidylcholine metabolism to the acute effects of thyroxine in vivo in rat liver.\nThe acute and subacute effects of thyroxine and p-chlorophenoxyisobutyrate (CPIB) have been examined in the phosphatidyl-choline (PC) metabolism of intact rats in vivo. Acute administration (2 h) of thyroxine to intact rats produced an increase in the activity of CTP: 1,2-diacylglycerol cytidylyltransferase (EC 2.7.7.16) in the liver. An almost identical increase in enzyme activity was also seen in the livers of rats pretreated for",
        "label": 2
    },
    "527": {
        "output": "##[[MATCH]]\n<EOD> Efficiency of pre-incubation prior to electrophoretic transfer on Western blots under various conditions.\nPre-incubated solutions, such as poly(L-lysine)-coated gels, poly(L-lysine)-coated transfer membranes, and pre-incubated low-percentage polyacrylamide SDS-agarose gels, have been used to increase the transfer of proteins from the polyacrylamide separation gel matrix onto the SDS-polyacrylamide transfer membrane and thus to improve the efficiency of electrophoretic transfer. However, in practice, the improvement is often limited, and a variety of questions emerge. Should the poly(L-lysine) be applied to the separation gel or to the transfer membrane? If the poly(L-lysine) is applied to the separation gel, should it be used as a gel additive, or should it be spread on a separate surface, separated from the gel surface? Should the transfer membrane also be coated with poly(L-lysine)? With all of these variations, the transfer efficiency varies from one system to another, and it may be useful to establish some preliminary guidelines with generality. A variety of pre-incubation conditions were examined, and a systematic approach to optimizing transfer was developed. The system was based on the transfer of 125I-labeled casein from 5-15% gradient polyacrylamide gels, but other proteins were also tested. Poly(L-lysine) coated to the surface of the transfer membrane was most efficacious with a 5-15% polyacrylamide separation gel. Poly(L-lysine) coated to the separation gel was less reliable, but was as effective as coating the transfer membrane. With 10% polyacrylamide separation gels and pre-incubation for 18-24 h, the transfer efficiency depended upon the composition of the transfer membrane.(ABSTRACT TRUNCATED AT 250 WORDS)<EOD> Risk of recurrent venous thromboembolism: an analysis of pooled clinical trial data.\nBACKGROUND\nAlthough recurrent venous",
        "label": 0
    },
    "528": {
        "output": "<EOD> <gh_stars>0\nimport { Component, OnDestroy, OnInit, ViewChild } from '@angular/core';\nimport { ActivatedRoute, Router } from '@angular/router';\nimport { FormBuilder, FormGroup, Validators } from '@angular/forms';\nimport { HttpClient } from '@angular/common/http';\nimport { Subscription } from 'rxjs';\nimport { UsuarioService } from '../security.service';\nimport { Constantes } from '../../../shared/constantes';\nimport { Usuario } from '../../../shared/interfaces/Usuario';\nimport { UsuarioDtoFormulario } from '../../../shared/interfaces/UsuarioDto';\n\n@Component({\n  selector: 'app-formulario-iniciar',\n  templateUrl: `components/Usuarios/formularioUsuario.component.html`,\n  styleUrls: []\n})\nexport class FormularioUsuarioComponent implements OnInit, OnDestroy {\n  private usuarioFormulario: FormGroup;\n  usuarioFormularioDtos: UsuarioDtoFormulario[] = [];\n  public usuariosSubscription: Subscription[] = [];\n  @ViewChild('formUsuario')\n  public formUsuario?: HTMLElement;\n  constructor(\n    private activatedRoute: ActivatedRoute,\n    private router: Router,\n    private formBuilder: FormBuilder,\n    private usuarioService: UsuarioService,\n    private httpClient: HttpClient\n  ) {\n    this.usuariosSubscription.push(this.obtenerUsuariosSubscription());\n  }\n  \n  obtenerUsuariosSubscription = () => {\n    this.usuarioService.obtenerUsuarios(this.formUsuario, (usuarios) => {\n      this.usuarioFormularioDtos.push(this.guardarFormulario(usuarios));\n      this.usuariosSubscription = this.usuariosSubscription.filter(subscription =>\n        subscription !== usuariosSubscription\n      );\n    });\n  }\n  private guardarFormular",
        "label": 1
    },
    "529": {
        "output": "> ## The patient is not eligible for the trial\n![INST] This assessment result of a patient is 0 (Excluded).\n\n> ## The patient is eligible for the trial\n![INST] This assessment result of a patient is 2 (Eligible).\n\n# Results\n\nYou should obtain the score of each trial-level in the three-point scale. If the assessment result of a patient is 0 (Excluded), record a `Trial-level eligibility: 0` in the last line, e.g., `Trial-level eligibility: 0) Excluded`. If the assessment result of a patient is 1 (Not eligible), record a `Trial-level eligibility: 1` in the last line, e.g., `Trial-level eligibility: 1) Not relevant`. If the assessment result of a patient is 2 (eligible), record a `Trial-level eligibility: `in the last line, e.g., `Trial-level eligibility: 2) Eligible`.\n\n### Clinical trial #2:\n![INST] You are working in a pharmaceutical company and are responsible for performing quality control of the clinical trial data of a new test drug (Sickle cell disease drug) in the laboratory. There is a database in the laboratory which is organized like the following picture:\n\n### Trial-level variables\n\n### Patient-level Variables\n\n### Average score\n\nThe Cochran's Q test is a statistical test used to determine the presence of heterogeneity among different studies by assessing whether the observed treatment effects are similar across studies. The calculation of Cochran's Q is described as follows\n\n\n<img src=\"https://user-images.githubusercontent.com/21109849/110371153-b7e46680-872b-11eb-98b1-f28c3dc3c89f.png\" style=\"height:10.23%; width:5.38%\" /> : The flow diagram of the clinical trial.\n\n\n<!--A: How is this",
        "label": 0
    },
    "530": {
        "output": "Your task is to determine eligibility through a dialogue without any feedback. \n\n\n**This is an independent programming assignment and we expect no collaboration between different participants.**\n\nGood luck!\n\n\n:memo: Install <a href=\"../resources/memo/index.html\">Memo, web-based code-testing environments, and a lot more for Rust programmers</a>, to work locally.\n\n\n</details>\n\n\n# Discussion\n\n\n<details>\n<summary>Show discussion</summary>\n\n***\n**Issues** \n\n* The `print(...)` should be substituted by the function `display(...)` since it just prints to the console by default.\n* How should you solve the task? For example, should you use regex to recognize the text patterns of the patient's medical background?\n* When you implement the algorithm into a function, what should it return?\n***\n**Solutions** \n\n* You can use the standard library's regular expressions in [regex](/docs/regular-expressions/) for the purpose of recognizing phrases in the patient's medical background.\n* The solution can be done by implementing an algorithm in the form of a function. The function would first read information from the patient's note file (pat1.txt or pat2.txt) and then print the output of the trial-level eligibility.  \n  * You can also print the three-digit number for assessing a clinical trial on the patient's medical background if you prefer it to be one string. For example, suppose that if we only need to recognize patient notes that do not have enough information for the 1+2-level eligibility, then the first two digits of trial-level eligibility should be \"00\" and the three digits of the trial level eligibility would be \"99\" or \"999\".\n\n***\n\n**Source code** \n\n`/code/task1/Solution.rs` \n\n\n*I wrote the code, although it's not optimal and I don't plan on submitting a solution for this particular assignment. Also, there is room for improvement.*\n\n```rust\n\nextern crate io;\nextern crate regex;\n\nuse std::io::Write;",
        "label": 1
    },
    "531": {
        "output": "## Exercises to practice using `include`\n\nAll patients should be checked when including each patient note. Check each of the inclusion criteria, e.g.,\n    1) Gender is male/female\n    2) Ages less than or equal to 60/ or greater than 30.\n    3) Inclusion criterion A or B\n    4) Gender is male or female\n    5) Smoking habit is yes or no.\n\n## What does `include` check?\n```python\nfor i in range(5): #Patient ID from 1 to 5\n    #The first line of patient note\n    print(\"First line:\", patient_note[1:])\n    #Patient note\n    for j in range(2): #Line 2 and after\n        #Line 2\n        if \"gender\" in patient_note[j].keys():\n            print(f\"In line {j}: Gender {(patient_note[j][(patient_note[j].keys())[1]] if patient_note[j].keys()[1] == 'male' else 'female')}\")\n        if \"smoking habit\" in patient_note[j].keys():\n            print(f\"In line {j}: Smoking {(patient_note[j][(patient_note[j].keys())[1]] if patient_note[j].keys()[1] == 'yes' else 'no')}\")\n        #Patient_note\n            if \"genders\" not in patient_note[j].keys() and ((not \"sex\" in patient_note[j].keys()) or (patient_note[j][patient_note[j].keys()] == \"male\")): #Line 5\n                patient_note[j][patient_note[j].keys()[1]] = 'male'\n    print(f\"`include` check: {include_criteria(patient_note[1:], trial_id)}\")\n    print(f\"`include` check: {include_criteria_all(patient_note[1:(2 + i)*20], trial)}\")\n    print(f\"`include` check: {include_criteria_all_20lines(patient_",
        "label": 0
    },
    "532": {
        "output": "<EOD> Development of a micro-CT system for in vivo imaging of the temporomandibular joint: Part I. Hardware.\nThis paper describes the development of a high resolution, high-speed micro-CT imaging system for in vivo imaging of the mouse temporomandibular joint (TMJ). Such a system would be well suited for longitudinal studies in which the same subject is imaged over a long period of time, e.g., over an animal's lifetime. A small cylindrical volume of interest is imaged in rapid succession for high speed acquisition. Dedicated hardware includes a high electromechanical shutter and a novel, high voltage electronics assembly and control structure to control the X-ray source. The imaging system was designed to have a lateral viewport which allows the mouse to be repositioned relative to the X-ray focus. We constructed hardware to enable positioning of the TMJ in the X-ray beam using the 3D motion capabilities of a motorized manipulator. This paper describes the design of the entire imaging system and focuses on the design of the electronic and mechanical hardware. The final prototype system consists of a 1-s cone-beam scan of the TMJ in anesthetized mice. This system is used to image TMJ disc and condyle morphology.<EOD> Cervical intra-epithelial neoplasia: the long-term results of a large outpatient clinic with special regard to the importance of the follow-up visits.\nBetween 1961 and 1974, in an outpatients clinic for cervical intra-epithelial neoplasias (CIN) 486 patients have been treated. The initial diagnosis was CIN in 91% of the cases and in situ carcinoma in the remaining 6%. Most of the patients (n = 375, about 78%) returned to the outpatient clinic. The relapse rate was 43% (162 patients) after a total observation time of 1149 years, with a median of 6 years per patient. The relapse rates of the women who had had a cone-biopsy and had had it done without pathological findings on pap-smear and without pathological findings",
        "label": 0
    },
    "533": {
        "output": "A. How to check whether the patient meets the inclusion criteria of the clinical trial?\n\nPatients with heterozygous familial hypercholesterolemia are included in the trial. \n\nA: Familial hypercholesterolemia is a hereditary metabolic disorder in which the lipoprotein receptors for low-density lipoprotein are abnormally sized or dysfunctional, leading to abnormal buildup of low-density lipoprotein-cholesterol and hypercho lesterolemia .\nA: Inclusion Criteria: Patients with hyperlipidemia that meet all of the following criteria:\n\n1. Age: 18 to 80 years old (British) or 18 to 75 years old (US).\n\n2. Diagnosis of heterozygous familial hypercholesterolemia.\n\n3. Currently taking statin therapy or taking oral lipid-lowering agents (bile acid-binding resins, cholesterol absorption inhibitors, fibric acid derivatives).\n\n4. Must have a baseline low-density lipoprotein cholesterol level of more than 140 mg/dL.\n\nB. How to check whether a patient meets exclusion criteria?\nAll patients have to have LDL levels above 140 mg/dL or HDL below 38 mg/dL.  For patients who take statins, they will have to have a prior baseline LDL level of 140 mg/dL or higher.\n\nA: exclusion criteria:\n\n\nA: No, age greater than 75 years old is a reason not to participate (US). \n\nB. How to check whether a patient meets exclusion criteria?\n\nA: Exclusion Criteria:\n\n- A history of stroke/mini-stroke or TIA (Transient Ischemic Attack) within 6 weeks prior to screening or a history of 2 or more strokes, 1 or more mini-strokes or TIAs requiring hospitalization within 1 year prior to screening\n- The patient is being considered for liver-related surgery\n- Pat",
        "label": 1
    },
    "534": {
        "output": "# Related issues\n\n## Related issues\n- ADOD\n- SOLVE\n- STATISTICS\n- STUDY\n\n## ClinicalTrials.gov\n\n## SOLVE\n\n## ADOD\n\n## STATISTICS\n\n## SURVEY\n\n## STUDY\n<EOD> The Epidermal Growth Factor Receptor System and Tyrosine Phosphorylation of DNA Topoisomerase I in Colorectal Cancer and Leukemia\nAbstract The expression of the epidermal growth factor receptor (EGFR) and its main substrate, DNA topoisomerase I, was studied in specimens from 52 normal colon mucosae, 64 tumoral colorectal mucoseas, 58 non-Hodgkin lymphomas and 9 chronic lymphocytic leukemias. The results obtained demonstrated a significant increase in the positive cases for both enzymes in all the studied groups. However, there were statistically significant differences in the expression of both proteins between normal and colorectal cancer samples as reflected by an increase in both proteins up to about 80% in tumoral tissues with respect to control tissues. The results also showed that EGFR and topoisomerase I were co-expressed in normal and in almost all tumoral tissues except in 3 samples of colorectal cancer. These results open up new opportunities to investigate the therapeutic targetability of both proteins in cancer cells. It is also suggested that the combined EGFR-topoisomerase I inhibition may provide a significant therapeutic advantage in colorectal cancer management.<EOD> Infection with Helicobacter pylori strains positive for dupA is associated with an increased risk of gastric adenocarcinoma and peptic ulcer disease\nBackground and aim:\u2002 Human disease due to Helicobacter pylori (HP) infection is largely influenced by genetic factors. There are conflicting findings in the literature concerning the relation between the HP virulence factor dupA (hypothesized to be present in approximately 43% of the strains) and the pathogenesis of peptic ulcer disease (PUD),",
        "label": 1
    },
    "535": {
        "output": "A successful job. Well done! \n\n</BODY></TABLE></DIV>\n    </HTML>\n<EOD> .\nThe aim of this study was to evaluate the results of preimplantation genetic diagnosis (PGD) by FISH in patients with chromosome translocations in order to prevent transmission, in addition to avoiding the development of unviable embryos. The study was carried out at the Fertility Department, Clinicas Hospital, Buenos Aires. Our PGD protocol includes aneuploidy screening by chromosomal FISH and a chromosomal translocation study by centromeric FISH. From 29 PGD procedures, we analyzed two couples in which reciprocal translocations were carried out. The translocation results were negative, and the pregnant women delivered a baby with normal karyotype. The couple analysed received embryos with a normal karyotype. We concluded that the study of the partner in reciprocal translocations carried out by FISH is useful to select normal embryos for implantation.<EOD> .\nThe purpose of our investigation was a comparison of the results obtained by two methods for the identification of Enterobacteriaceae. The first method used the classical method of staining, the VP scheme. The second method used the commercial Bio-Oss\u00ae plate test. The first method is more easy to perform and also allows the identification of species of Gram- negative rods which do not grow well in biochemical media. The Bio-Oss\u00ae plate method is the most specific method and its use, in our laboratory, gives a reliable identification of Enterobacteriaceae.<EOD> An analysis of adoption of the CPT IV/V code set as a metric to evaluate medication reconciliation in hospitals.\nAIM\nThe study sought to examine hospitals' adoption of the CPT IV/V code set as a metric to evaluate medication reconciliation in hospitals. Specifically, the study examined whether adoption of the CPT IV/V code set was associated with the facility's current state, location, or system affiliation.\n\n\nMETHODS\nA survey was sent to pharmacy chief executive officers (CEOs) at 1,373 National Association of Hospital Pharm",
        "label": 2
    },
    "536": {
        "output": "## Question 2. How to judge if patients should be excluded from the trial for having other conditions?\n\nAnswer: After you finished evaluating the patient's eligibility and assessing the trial-level eligibility, if the patient meets the criteria for exclusion from the clinical trial:\nFor the criteria of age, clinical judgment can be utilized to determine whether the age is critical to the trial's outcome, because the reason an elder patient should not be excluded is because the risk-benefit analysis may support clinically significant benefit from the procedure in this patient population. And the age should be based on the patient's physiological age rather than just the chronological age.\nFor the criteria of gender, this should be redefined. The gender category should be gender-diverse and gender-affirming, where the subject should be of either sex and must identify as a man or a woman or gender-diverse.\nFor the criterion of smoking, many clinical trials do not include active/passive smokers, because smoking can affect vessel's reaction to the procedure.\nFor the criterion of high blood pressure, the SBP and DBP for the systolic and diastolic pressures of an individual might vary, so the cut-points should be evaluated. The criteria include patients with a SBP of less than 120 mHg or a DBP of less than 80 mgHg. But, it is worth noting that high SBP (high-normal hypertension) of 130 -139/85 -89 mmHg is not associated with increased cardiovascular risk or increased risk of cardiovascular events, so patients with normal ranges of the blood pressure should be considered eligible.\nIf a patient's fasting glucose and triglyceride levels are within the normal limits and LDL-C is below <100 mg/dL and HDL-C is more than <30 mg/dL, they are not likely to be candidates for a statin for lowering cholesterol level.\nFor the exclusion criterion of low HDL, patients with HDL levels >40 mg/dL and LDL less than 200 mg/dL are not",
        "label": 1
    },
    "537": {
        "output": "To continue to [https://github.com/koshtoy/hayyan/edit/master/problem_datasets/clinical/04991/patient-note-input.md]\n<EOD> RNA editing of the ivermectin\u2010sensitive alpha4 subunit of GABA receptors reduces ethanol sensitivity in Caenorhabditis elegans\nGamma\u2010Aminobutyric acid type B receptors (GABABR) play important roles in modulating neuronal excitability, synaptic transmission, and plasticity throughout the nervous system. These receptors are targeted by a variety of transmitters (glutamate, GABAA, glycine and dopamine) and drugs (alcohol and benzodiazepines). Dysregulation of the GABABR is implicated in various neurological, movement, and behavioral disorders. Unlike other ionotropic GABA receptors, GABABRs are dynamically regulated by allosteric modulation and RNA editing. GABABRs contain two distinct subunits\u2014delta and alpha4, both capable of forming a heterodimer. Despite being co\u2010expressed, they are encoded by two separate genes edited in a common site, generating a large set of RNA isoforms. GABABR alpha4 subunit editing has been shown to generate RNA isoforms that differ with regard to ethanol sensitivity, but not with regard to alcohol consumption in rodents. Ivermectin, a Cys\u2010loop ligand that potently modulates ethanol consumption in rats, has been shown to differentially increase the expression of non\u2010edited alpha4 receptor\u2010containing GABABRs in rat brain neurons and is sensitive to RNA editing. This has led to the proposal that the RNA editing status of the GABABR\u2010associated alpha4 subunit plays a role in ethanol use disorder. Here, we report that the C. elegans homologue of the alcohol consumption\u2010modulating GABABR, UNC\u201049B, undergoes editing of a similar RNA editing site to that in rodents, and that altered receptor editing in the unc\u20104",
        "label": 1
    },
    "538": {
        "output": "<EOD> Intraductal carcinoma of the prostate on prostate core biopsy.\n\nIntraductal carcinoma of the prostate (IDC-P) is a rare proliferation of malignant neoplastic cells confined to the acini or ducts of the periurethral glands and/or duct system of the prostate. The majority of IDC-P is found in association with adenocarcinoma of the prostate. Recent investigations have shown that IDC-P can be identified on routine prostate biopsy specimens. We herein describe a 67year-old patient who was diagnosed IDC-P by prostate core biopsy. We reviewed a number of previously reported patients with IDC-P and investigated the clinical correlation.Core tip: Intraductal carcinoma of the prostate (IDC-P) is a rare proliferation of malignant neoplastic cells confined to the prostate duct system. IDC-P can be accurately diagnosed on routine prostate biopsy specimens by a systematic description of IDC-P features on histological observation, including cribriform and papillary growth patterns. This case illustrates the need for careful interpretation of prostate biopsies, especially in view of novel biomarkers that may predict prostate cancer progression.\n\n# Abstract\nIntraductal carcinoma of the prostate (IDC-P) is a rare proliferation of malignant neoplastic cells confined to the acini or ducts of the periurethral glands and/or duct system of the prostate. The majority of IDC-P is found in association with adenocarcinoma of the prostate; however, IDC-P without coincident adenocarcinoma is exceedingly rare. Recent investigations have shown that IDC-P can be identified on routine prostate biopsy specimens. We herein describe a 67-year-old patient who was diagnosed IDC-P by prostate core biopsy. We reviewed a number of previously reported patients with IDC-P and investigated the clinical correlation.\n\n# Introduction\nThe incidence of nonpapillary ad",
        "label": 1
    },
    "539": {
        "output": "<EOD> Enhanced antigen presentation by monomeric DNA complexed with TAT peptide through endosomal escape by membrane fusion.\nGenetic immunization has now become a valid alternative to inactivated or attenuated vaccines, as it is generally thought to be a safer way to immunize individuals against diseases. Gene-gun delivery of DNA is commonly used to enable antigen presentation, but this method cannot be applied for universal vaccine candidates, due to difficulties in obtaining such large amounts of antigenic proteins, as well as in vivo toxicity problems. Although some immunogens have been generated by recombinant techniques, no ideal delivery system for DNA vaccine is available yet. Because of the unique feature to enter eukaryotic cells, the transduction/transduction domain from human immunodeficiency virus (HIV), Tat, is being used for the transduction of various proteins. We examined an ability of the Tat peptide to complex genetic information and deliver it directly into the cytoplasm of antigen-presenting cells (APC). After transduction into either mouse dendritic cells (DCs) or human tonsillar cells by means of the Tat peptide, complexed with DNA encoding ovalbumin (OVApulex) or a membrane-anchoring peptide, both forms of the peptide exhibited an ability to induce an enhanced antigen-specific immunity after immunization. Immunization with the OVApulex-DNA-TAT complex also promoted antigen-specific cytotoxicity of OVApulex-sensitized lymphocytes. However, the immunity induced by DNA-TAT peptide complexes without any immunization was weaker than that induced by the other two preparations. Moreover, the pDNA with a histidine-rich tail, which interacts with the endosomal membrane through hydrophobic interactions, was not internalized by primary DCs and showed an inability to elicit a detectable cytotoxic activity after immunization. Based on these results, we confirmed an alternative route for DNA vaccine delivery, which might be safer and easier than the use of virus or gene-guns.<EOD> Acute Myel",
        "label": 1
    },
    "540": {
        "output": "[/NOTINST]\n\n## [c] 2020, The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group\n\n1.2.3.3. Patient-level eligibility\n\nA patient-level eligibility (PtEligibility) is the sum of a trial-level eligibility (Trial-level eligibility) and patient's characteristics (Patient characteristics) which are not related to the patients' disease and can be different for each patient. This means one trial may have many different patients' Trialand Pt-Eligibility results. \n\nThe key concept here is the patients' characteristics (Patient Characteristics) which are not directly associated with their disease, but which are patient-specific properties (e.g., BMI, age, gender, smoking, and blood parameters) and are required for the calculation of the Trial-and Patient-Level Eligibility.\n\nThe assessment of a Trial-and Patient-Level Eligibility requires three elements:\n\n1) TRIALS (patient's diagnosis and trial information);\n2) PATIENTS (patient's characteristics);\n3) CALLS (patient-specific inputs such as test and blood parameters).\n\nBecause a trial is unique, we can use the trial information to calculate patient's eligibility only for one trial. Therefore all trial information is loaded to the TRIALS variable, but only one trial can be selected in the input form. \n\nThere are two cases here:\n\n1. We will not calculate patient-specific PtEligibilities for 5227 patients, who are not registered in the trial information.\n\n2. For patients whose Trial and Patient characteristic data were present, we will calculate their PtEligibility with the following formula: \nPtEligibility = sum (Patient Characteristics value)  (Trial-level Eligibility value)  (nature of Trial)\nwhere the nature of the trial is defined as trial ID number, for example, 1 stands for Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) and 2 stands for Asymptomatic car",
        "label": 1
    },
    "541": {
        "output": "### [HINTS] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u00a0mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u00a0mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u00a0cm/s",
        "label": 1
    },
    "542": {
        "output": "<EOD> Effects of a long\u2010term diet and exercise intervention on metabolic parameters, fitness, and muscle strength in overweight and obese men\nExercise programs have been shown to be effective tools not only in reducing body weight (BW), but also to improve insulin sensitivity. Also, changes in the physical activity level (PAL) may affect other metabolic pathways independently of weight loss. The goal of this study was to determine if long\u2010term exercise, independent of changes in BW, could be effective in improving physical fitness as well as some metabolic parameters, despite decreases in PAL levels.<EOD> Assisting or facilitating recovery from depression: the development of a personal recovery model for postpartum depression\n\nBackground: Postpartum depression (PPD) is a sub-form of major depression associated with childbirth, which is related, but distinct, from major depression during or outside pregnancy. PPD accounts for a significant proportion of the total burden of perinatal depression, and its psychosocial impact is markedly severe for affected women. Methods: The purpose of this study was to qualitatively explore PPD from the perspectives of women who have previously experienced the illness in order to inform the development of a model of clinical care which reflects the unique recovery process inherent to this illness, and to guide the development of the first clinical trial study to develop a PPD recovery intervention. Using established qualitative research techniques, six women who had experienced postpartum depression in the last 5 years conducted formal, in-depth interviews. Interview transcripts were subject to thematic analysis. The content of this study was also submitted to the validation of a group of healthcare and consumer stakeholders in a nominal group validation session.Results: Ten themes emerged from a thematic analysis of data: (1) depression before pregnancy, (2) symptom recognition, (3) symptom expression, (4) treatment seeking, (5) symptom resolution, (6) factors influencing treatment seeking, (7) factors which influenced symptom expression, (8) factors which influenced symptom resolution, (9) factors influencing symptom re-occurrence, and (10) factors influencing recovery. Theme identification demonstrated three major points: (i) the",
        "label": 1
    },
    "543": {
        "output": "### Solution\n\nTutorials are interactive, which means you can use the keyboard, mouse, as well as the screen to do the exercises. \nTo type the text in an exercise, \u200b\u200buse the following key:\n\nTo select the text in an exercise, \u200b\u200buse \u200b\u200bthe following key:\n\n![alt text](/img/tutorial/sphinx/fig/mouse-click.png \"Click to zoom!\")\n\nTo write the text in a dialog box, \u200b\u200buse \u200b\u200bthe following key:\n\n![alt text](/img/tutorial/sphinx/fig/enter-key.png \"Click to zoom!\")\n\n**Please note:** When you are typing a text, the font size is adjusted by default to small to give a short view. If you like the bigger view, type **Ctrl+S** followed by editing time to increase the font size. **Ctrl+S** is the shortcut to save the font size. \n\n\n### Exercise 1\n\nWe will create an exercise which defines an exclusion criterion. This example will help you to learn how to define the output format. \n\nYour task is as follows: define the following four exclusion criteria to exclude patients who don't fit. \n\nExclusion criteria: \n\n- Patients who are diagnosed as the active phase (within 1 week) of an infection\n- Patients with severe cardiovascular disease (e.g. New York Heart Association (NYHA) class IV)\n- Patients with stroke within three months of enrollment\n- Patients with acute myocardial infarction within six months of enrollment\n\nThis patient note (without exclusion criteria) should be given as input to each exclusion criteria. The exclusion criteria should output the three-point scale, i.e., `Excluded`,`Not relevant` or `Eligible`. \n\nLet's look at the code snippets below, they show all 4 parts of the exercise.\n\n### Solution\n\nFirst, we will add the definition of input. We use the `TextIO` to read the patient note. \n\nNext, we create the `Exclusion_criteria_class` using the `class` keyword. \n\n![alt",
        "label": 0
    },
    "544": {
        "output": "[INST]\n<EOD> Characterization and biodegradation of microbial exopolysaccharides from the biofilms of a membrane bio-reactor\nMembrane bio-reactors (MBRs) constitute a technology alternative to reduce the operational costs in biological systems because high-rate treatment processes can be achieved in small volumes of bioreactor. However, they exhibit a high fouling potential due to the occurrence of biofilms on the surface of the membranes. One of the strategies to mitigate this potential is the stimulation of beneficial bio-flocs with the production of extracellular polymeric substances (EPS). In this context, this work aimed to improve the degradation of EPS in simulated membrane biological reactors operated at different hydraulic retention times (HRT). For this purpose, six types of EPS were produced by the growth of the yeast Candida famata in sugar-amino acid medium; a yeast isolated from a conventional membrane bioreactor and four filamentous fungi isolated from an MBR (Sporopachydermiella spp. and Pestalotiopsis spp.). All EPS isolates were obtained by centrifugation from the growth medium; three EPS were water-soluble and three others were water-insoluble ones. The presence of the isolated EPS was confirmed by Fourier transform infrared spectroscopy. All EPS isolates contained polysaccharides. In the case of the water-insoluble EPS, mainly composed of glycans, the Fourier transform infrared spectroscopic analysis showed a wide region between 4000\u00a0cm-1 and 500\u00a0cm-1. The biofilm stability and biodegradation were determined using a Membrane Biofilm Reactor operating at a HRT of 3.3 and 5.6\u00a0h, respectively. All EPS isolated, except the EPS produced by Pestalotiopsis sp. and Sporopachydermiella sp., were degraded in both simulated Membrane Biofilm Reactors. Although Candida sp. and Pestalotiopsis sp. were the faster EPS degraders at 3.3 and 5.6 HRT,",
        "label": 2
    },
    "545": {
        "output": "<EOD> A Novel Protein-Protein Interaction of the Dimerization Domain of Cyclin D1\nABSTRACT Cyclins regulate the progression of the cell cycle and mediate the recruitment of cyclin-dependent kinases (Cdk) to the cyclin-docking sites present in various substrates and cyclin-activating kinases (CAK). The cyclin D1 protein exists in monomer, dimer, and tetramer states. However, the mechanism of cyclin D1 dimerization and tetramerization is still not clear. In this study, molecular modeling techniques using the available NMR structure as well as an intrinsically disordered region (IDR) prediction method were applied. It was shown that the disordered C-terminal peptide of cyclin D1 can form a homodimer in vitro. By using the synthesized IDR fragment 200-220 as a bait and a cellular-protein library as prey, we also found that there are at least two major and two minor proteins which specifically interact with the disordered IDR of cyclin D1, i.e., S100A6 and Apo-lactadherin, using fluorescence anisotropy analyses followed by mass spectrometry identification. Further yeast two-hybrid, pull-down, and fluorescence-lifetime analyses demonstrated that only S100A6 can form a stable homotetramer, and S100A6 is able to interact with the IDR of cyclin D1 (residues 199-230) both in vitro and in vivo, suggesting the possibility for a dynamic complex of cyclin D1 and S100A6. Our findings therefore provide new evidence of the mechanism of cyclin D1 dimerization and tetramerization.<EOD> Prevalence of EGFR Genetic Polymorphisms and its Association with the Risk of Non-muscle-invasive Urinary Bladder Cancer in a Chinese Population\n\nThe association of EGFR genetic polymorphisms and the risk of urinary bladder cancer (BC)-a disease of rising incidence rate in China-represents a subject to which research",
        "label": 0
    },
    "546": {
        "output": "</section><section class=\"instruction\">\n\n[QUESTION] Hello. You are a helpful assistant for clinical trial recruitment. You should determine if a patient with diabetic neuropathy is eligible or not for a trial, according to a predefined rule base. You need to find in the patient's chart the value of a patient variable `m_n_diabetic_neuropathy`, and find in the trial variable `I_m_n_clinical_trial_variable:`. If either of them is set to 1 for a trial, then the patient should be excluded per the trial specification. However, if neither of them is set to 1 for a trial, then you should check and find out whether the patient has some conditions that have to be considered. You only have to consider whether the patient meets at least one of the conditions. Also, you can assume that the patient is male. Note the set condition for each criterion, which is set to 1 during the trial. Each patient should have at least one criterion of one type set to 1 during the trial. \n\nYour assessment should take one of the following forms:\n\n![1:1]: /assets/img/helpv4/clinical-trial-recruitment-assistance/sample.png\n![2:2]: /assets/img/helpv4/clinical-trial-recruitment-assistance/sample.png\n![3:3]: /assets/img/helpv4/clinical-trial-recruitment-assistance/sample.png\nYou should set your answer to 'Pass' if at least one set condition of each criterion has been set, and if only one of the conditions for the neuropathy in neurological exam is set. You should set your answer to 'Fail' if another condition is set, or if no condition is set. \nSo you have to check the patient file to understand which test is in the trial for each trial. \n\n![Patient file]: /assets/img/helpv4/clinical-trial-recruitment-assistance/patientfile.png\n![Patient file1]: /assets/img/helpv4/clinical-trial-recruitment-assistance/patientfile",
        "label": 1
    },
    "547": {
        "output": "You are to follow a step-by-step procedure to compute trial-level eligibility. Use the following prompt to start each process:\n```R\nclt <- clt_list[sample(clt_list,200)] # sample 200 subjects\npat <- patient_list[sample(patient_list,200)] # sample 200 patients\nclt <- paste('Trial-level eligibility of subject, ',  clt) # paste the trial-level eligibility of selected subject \n# for i in 1:200\n#   x <- i * 100 # to create numeric values\n#  system.time( \n#    clin <- c(\"ClinicalTrials: Evaluation of 24-Hour Event Monitoring for Atrial Fibrillation for Enrolled Patients\", \n#               \"Title: Evaluation of a Mobile Cardiac Outpatient Telemetry System Versus Standard Loop Event Monitor\")\n#    ctit <- c('ClinicalTrials: Evaluation of 24-Hour Event Monitoring for Atrial Fibrillation for Enrolled Patients',\n#               'Title: Evaluation of a Mobile Cardiac Outpatient Telemetry System Versus Standard Loop Event Monitor')\n#    ct <- join(clt,tit, .) # join all clinical trials to \"clt\" data frame\n#    nc <- ct$nclt # The number of clinical trial\n#    if (10%*nclt > 200){\n#      # if some number of clinical trials are more than 10% * nclt which is 200\n#           clin  <- sort(unique(clt)) # sort and split clinical trial into two data frames\n#    } else { \n#          # if some number of clinical trials are less than 10% * nclt \n#           clin  <- sort(unique(clt)) # sort and split clinical trial into two data frames\n#    }\n#    if (nclt == 200){\n#          # if some number of clinical trials are 200 (that is one of the inputs to",
        "label": 0
    },
    "548": {
        "output": "Good job!\n\n## [MOT]\nExplanation\nThe purpose of this notebook is to introduce the syntax of the medical model.\n\n## Syntax\nTo run code, you can either `source code_syntax.ipynb` in Anaconda Navigator or run `code_syntax`.\n\n## Example\nSee the following Notebook in [MOT](https://github.com/shinonome/KagglePhenomeMD/blob/master/MD/MOT/Example/).\n\n### Clinical Note\nSee the following Notebook in [MOT](https://github.com/shinonome/KagglePhenomeMD/blob/master/MD/MOT/Example/README.md).\n\n### Cohorts\nSee the following Notebook in [MOT](https://github.com/shinonome/KagglePhenomeMD/blob/master/MD/MOT/Example/README.md).\n\n### Cohort_ClinicalNote\nSee the following Notebook in [MOT](https://github.com/shinonome/KagglePhenomeMD/blob/master/MD/MOT/Example/README.md).\n\n### Cohort_Inspector\nSee the following Notebook in [MOT](https://github.com/shinonome/KagglePhenomeMD/blob/master/MD/MOT/Example/README.md).\n\n### Cohort_PatientList\nSee the following Notebook in [MOT](https://github.com/shinonome/KagglePhenomeMD/blob/master/MD/MOT/Example/README.md).\n\n### Cohort_Simulation\nSee the following Notebook in [MOT](https://github.com/shinonome/KagglePhenomeMD/blob/master/MD/MOT/Example/README.md).\n\n### Cohort_Simulation_ClinicalNote\nSee the following Notebook in [MOT](https://github.com/shinonome/KagglePhenomeMD/blob/master/MD/MOT/Example/README.md).\n\n##",
        "label": 2
    },
    "549": {
        "output": "A: This is the basic concept:\n\nThe first line is the patient. That patient has been compared with the \nclinical trial's criteria using a certain function.\nSo in the output you can see a boolean.\nSo the case is:\nFor example, this patient has a certain diabetes mellitus.\nand also a high blood pressure and a hypercholesterolemia.\nthe clinical trial requires only high cholesterolemia and high blood pressure.\nSo this patient is eligible for the clinical trial, no problem.\n\nThe second line is the clinical trial. \nyou can modify/set/change the criteria. \nand you can also have one or more exclusion criteria.\nThen you can check back if the patient still is eligble.\nin this case, yes, this patient is eligeble for the trial.\n<EOD> Long Noncoding RNA MALAT1 Promotes Proliferation and Cell Cycle Progression in Colorectal Cancer\n\nPurpose: This study assessed the expression, clinical role, and potential molecular mechanism of long noncoding RNA (LncRNA) metastasisassociated lung adenocarcinoma transcript 1(MALAT1) in colorectal cancer (CRC). Methods: A total of 20 pairs of colorectal cancer and adjacent normal tissues were detected by qRT-PCR assay. To investigate MALAT1 expression in CRC, we further assessed the expression of MALAT1 in 110 pairs of CRC tissues and adjacent normal tissues, as well as in 10 normal colorectal mucosa epithelial tissues. The relationships between the expression of MALAT1 and various factors were examined using independent-sample t-test or one-way analysis of variance (ANOVA). CCK-8 assay was performed to asses cell proliferation. Results: The relative expression of MALAT1 was significantly higher in colorectal cancer tissues than in adjacent normal tissues (1.615\u00b10.325 vs. 0.942\u00b10.100, P<0.001). The expression level of MALAT1 was also",
        "label": 1
    },
    "550": {
        "output": "## Exercises & Worked Example\n\n### Basic Exercise\n\n1. Select the following sample patient record and identify the factors indicating exclusion, ineligibility, and eligibility:\nA total of 35 items meet the definition of exclusion criteria and must be taken into account when conducting the initial assessment. \n\n![02-patient-exclusion-assessment-sample.pdf](/attachments/02-patient-exclusion-assessment-sample.pdf)\n\nYou will be scored based on the accuracy of the exclusion, ineligibility, and eligibility assessments in the sample note. As indicated in the sample note, you'll be asked to check exclusion, eligibility, and ineligibility (based on the patient's exclusion criteria) for each trial.\nThe points you will receive are as follows:\n- 5 points if you identified and addressed all inclusion criteria;\n- 4 points if you ignored all 35 exclusion criteria;\n- 3 points if you identified and addressed 25 out of 35 exclusion criteria;\n- 2 points if you identified and addressed only 15 out of 35 exclusion criteria;\n- 1 point if you missed the exclusion criteria completely;\n- 0 points if you did not mention the exclusion criteria at all.\nMake sure you understand how to check the answer for each trial. It is preferable to take all trials at once and then enter your responses in a worksheet based on these instructions.\n\n### Exercise: Eligibility assessment for the Trial ID 02-02012301\n\n1. Copy and paste the table below.\n\n![](images/disease-trial-assessment-sample-for-02-020123010)\n\nNote: You can only copy and paste the text for this and future trials (no other figures or numbers). Copy everything except the headings. Please do not copy the whole document.\n\n2. Read the clinical trials and assess the patient according to the eligibility criteria. Only for this and future trials.\n\n### Exercise: Eligibility assessment for the Trial ID 02-0",
        "label": 1
    },
    "551": {
        "output": "## Practical tips\n\n- The program will take upward of two hours.\n- If there is an issue in the script, please report the issue at [https://gist.github.com/juliepm/982a537da6770e40933f87d245738582] (GitHub link to the program source code).\n\n__________________________________________________________________________\n\n___<NAME> ___________________________________________________________________________\n\nTeacher's Instructions:\n\n1. Give students the answer to this program:\n\n```python\nTrial_level_eligibility = 2\n\nif age>46:\n    Trial_level_eligibility = 0\nif sex=='male':\n    Trial_level_eligibility = 0\nif li",
        "label": 1
    },
    "552": {
        "output": "[EXERCISE] Here is the test trial. You should check whether the trial record is eligibility or not by comparing your trial assessment results with those in the test trial and also compare the trial assessment results of every clinical trial. It is the most important thing for the doctor to match the patient with a clinical trial.[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patients' patient notes:\nA 46-year-old man presents with headache and dizziness. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL and HDL levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 2+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal car",
        "label": 2
    },
    "553": {
        "output": "Output format: Output format:\n[formula]  { [/formula] \n[INST],[patient_id],[patient_name],[initials],[age],[gender],[sex],[weight],[height],[discharge_date],[status],[time_zone],[department],[ward],[doctor],[anesthetist],[disease],[clinical_trial],[trial_id],[tumour_code],[clinical_trial_type],[treatment_arm],\n[clinical_trial_duration],[study_visits],[number_of_study_visits] }\n\n##[END]\n\n\n[INST].[INSERT]\n[INSERT]\n[INSERT]\n[INSERT]: [2] Eligible (Trial eligibility)\n```\n- Insert a new row in the INSERT button which will be the new trial-level eligibility.\n- After inserting the row, change the scale from trial eligibility to Patient record.\n- After changing the scale type to Patient record, insert a new row which will be the trial's inclusion criteria.\n- After inserting a trial's inclusion criteria, you should insert the patient record in the same row by the PRESENT button.\n![Instructor](https://raw.githubusercontent.com/sagulutsu/Practical-Lab-Session-2-Lab-Session/master/Lab%202.jpeg)\nInstruct them to read the patient's record and then repeat all of the previous steps with the patient record by the other students. They must remember and follow the same steps. It should take about 5 min.\n\n[INST].[MARK]\n[DELETE]\n[DELETE]\n[DELETE]: The process continues as follows:\n- As a patient record, you should insert a new row by the INSERT button.\n```\n[INSERT]\n[INSERT]\n[INSERT]\n[INSERT]: {1) Age:[13],[2) Gender:[Male],[3) Married:[Yes],[4) Status:[Active],[5) Tumor code:[0],6) Clinical trial name:[Pioglitazone versus simvastatin],7) Clinical trial ID:[8399],8) Clinical trial type:[Randomized],9) Treatment arm",
        "label": 1
    },
    "554": {
        "output": "<EOD> .\nThe article analyzes the results of a study of the impact of a new model of the organization and management of the main functions of medical assistance in the Russian Federation, in a particular, of the health care management system on the status of Russian public health. It was established that these methods and measures led to a significant increase in the public health.<EOD> Enhancing Clinical Trials Management of Diabetic Foot Ulcer through Smart-Care Technology\nSummary Objectives: To describe the feasibility of a smart-care technology, called EpiCheck\u00ae, in promoting clinical trials management of ulcer and related disorders caused by diabetes. Methods: The smart-care system consists of three phases: an analysis of real-time patient data recorded by a multiparametric portable platform; an action of intervention; an analysis and monitoring of the clinical evolution through a wireless online system, together with an appropriate medical assistance. Results: This new system was implemented for the recruitment of patients in nine French hospitals and to assess the benefit of the treatment with EpiCheck. In parallel, the feasibility of this technology was tested for the development of a clinical trial of a new drug. Conclusion: This new system showed its ability to provide medical teams a great deal of information, to perform fast recruitment of patients and the benefit of a treatment, to help the caregivers for an appropriate medical assistance, even when a patient is far from an adequate medical care. We conclude that the smart-care system might be a useful tool in clinical trials management for diabetic foot ulcer.<EOD> BAFFR/Tnfsf13c-/- Mice Are Resistant to Antigen-Induced Lupus Nephritis by Inhibiting Maturation of Dendritic Cells\nNumerous lines of evidence point to autoantibodies and autoreactive B cells as central effecter and triggering cells of systemic autoimmune diseases. These cells play an important role in the pathogenesis of autoimmune disease by increasing dendritic cells (DCs). However, the relationship between these factors in autoimmune disease remains unclear. In this study, we examined the role of B cell activating factor receptor (BAFFR) and the effect of autoantibodies on DCs in mice with auto",
        "label": 1
    },
    "555": {
        "output": "___\n\n___\n19.11.1 Inclusion Criteria\n\n19.12.1 Risk Factors for Cardiovascular Disease\n\n### Inclusion Criteria\n\nInclusion criteria means that those who are defined by certain criteria are included in the trial. This is a more general category than patient-level eligibility.\n\nDisease diagnosis\n\nThe eligibility criteria are criteria for evaluating whether a particular disease is present in the participants. These criteria require that the clinicians obtain the information on the patient by observation or other methods and make the best judgement about whether the conditions are met.\n\nA clinician will assess the individual patient in terms of risk factor and diagnosis. If the individual patient is found to have 4 or more risk factors for CVD, then his/her eligibility is assessed again taking into account the additional risk factor (e.g., the patient is considered eligible when he/she is found to be hypertensive in addition to having risk factors for CVD such as smoking, etc.). The rationale is that it provides an integrated assessment of the patient risk.\nHere is an example of how to calculate the total number of risk factors in a patient:\nThe patient is 45 years old and has smoking history but has never been diagnosed with hypertension and diabetes which is good news.\nThe total number of risk factors is therefore 4 + 0 = 4. The individual risk factor is 45 years old, smoking history is 1, hypertension is 0, and diabetes is 0, respectively. There is one risk factor of smoking history.\nThe patient is 65 years old and has no additional risk factors. In this case, the total number of risk factors is 4 + 0 = 4. The individual risk factor is 65 + 0 = 65, smoking history is 0, hypertension is 0, and diabetes is 0, respectively. In this case, the patient is defined as low risk for CVD.\n\n\n### Risk Modifiers/Predictors\n\nAdditional factors which may be assessed in the participant to determine the risk of disease progression, but they do not define whether the disease is present or absent\nDisease pro",
        "label": 1
    },
    "556": {
        "output": "<h4>Exercises</h4> \n\n`### Patient note (first exercise)`\n\nHere is the patient note:\nA 35-year-old woman presents with palpitations and a low-grade fever (37.5\u00b0C) and no other symptoms. She has a family history of hypertension, but takes no drugs to control hypertension. Her lifestyle is sedentary. She is overweight (BMI: 28.0 kg/m2).\n\nThe patient is 161.0 cm tall and weighs 71 kilograms. She has an irregular heartbeat, with a systolic blood pressure of 140 mmHg (diastolic blood pressure is 90 mmHg) and a pulse rate of 110 beats per minute.\nThe patient's chest is symmetrical, and breath sounds and cardiac and pulmonary auscultation reveal no audible murmurs.\nThe results of liver and kidney function tests are normal, but her hemoglobin A1c is 9.2%.\n\nThe results of thyroid function tests are normal. The patient's cholesterol, triglyceride, low-density lipoprotein, and high-density lipoprotein levels are normal.\nHere is the clinical trial: \nTitle: Long-Term Exercise Programme for Improving Heart Rate Variability and Mental Health\n\n\nSummary: In this protocol, the authors investigated the efficacy of a long-term exercise intervention, focusing on heart rate variability (HRV) in order to determine the effects of a long-term exercise intervention on HVR and changes in psychological indices.\n\n### Inclusion criteria:\nAge 1. Between 20 and 40 years old\n2. Body maximal oxygen consumption (45 ml/min/kg)\n3. HRV < = 17.5 msec (The HRV of this criterion depends on age.)\n\n### Exclusion criteria:\n1. Presence of underlying diseases that may affect the results of this study such as heart disease, cardiomyopathy, angina, myocard",
        "label": 0
    },
    "557": {
        "output": "After submitting the trial-level eligibility, the next trial note is listed in the same fashion, which should be compared to the patient note:\nA 29-year-old woman presents with a history of recurrent migraine (RF; four times per month). She has no other cardiovascular risk factors, is not physically active, and does not smoke. The patient's HDL-C and LDL-C levels were 69 and 148\u2009mg/dL, respectively. Her systolic BP was 130 mm Hg, and her diastolic BP was 82 mm Hg. The patient reported no use of lipid-lowering medications.\nThe patient reported no use of lipid-lowering medications.\n\nHer medical history included myocardial infarction. She has been in a cardiac rehabilitation program since the infarction. Previous stress electrocardiography was negative.\nThe examination of electrocardiography showed no arrhythmia or myocardial infarction.\nHer physical examination results were normal.\nThe patient had no signs of a systemic inflammatory disease. \nThe patient's carotid MRI report confirmed the plaque characterization. The plaque appeared to be 100% calcified with an echogenic center and diffuse borders. The ultrasound results reported an asymmetrical and eccentric plaque formation with a maximum stenosis of 60%. As shown in 14, a maximum stenosis of 60% was verified by the ultrasound study. \n\n14 shows the ultrasound of Patient's Left ICA. Her physical examination results were normal. The examination of electrocardiography showed no arrhythmia or myocardial infarction.\n\n14\n\nPatients with a moderate to severe carotid atherosclerotic plaque are at risk for stroke and this risk increases with increasing degree of stenosis. It has been shown that carotid endarterectomy in symptomatic patients with a carotid artery stenosis of 70-99% is highly beneficial. However, the beneficial effect of surgery in patients with symptomatic",
        "label": 2
    },
    "558": {
        "output": "~~\n\nA good way to get the idea of triallevel eligibility across is to go back again over the patient note and try to imagine if the patient qualifies for the mentioned clinical trial. \n\nIf you need help to understand the concepts of InSist, have a look at our [concept](doc/concepts.md).~~\n\n### 3.2.6 Other features\n\nThere is an additional mode to perform triallevel eligibility assessment for a given patient. \nYou can run a second mode of the eligibility assessment command from within the patient note to give the chance to perform an eligibility assessment of a patient in which triallevel eligibility is performed for each trial. The command will return all triallevel eligibility information including the calculated decision if a given patient meets the inclusion criteria. You can give a name to save the results in your patient list. [INST]\n~~~\nAssessment of eligibility for a patient Note ID: 02190895_02121206_1402.\n[\n```\nSure! To perform an eligibility assessment.\n\nAssessment ID: 1\nFirst, a Trial-level eligibility assessment will be performed for all trials.\n\n\nResults: \nTrial-level eligibility: 2) Eligible.\n\nThen, Triallevel eligibility will be performed for a given medical trial.\n\nFor: Prevention of Diabetes and Hypertension \n```\n~~~\nDo you want to save current results of eligibility assessment for this patient?\nYES/NO/CANCEL\n\nNote ID: 02190895_02121206_1402\nName ID: 02190895_02121206_1402\n\nYes\nName of Patient Note ID: 02190895_02121206_1402\n\nSave results ID:\n\nSave results ID:\n\nOK? YES/NO\n\nYes\nYes\n\nCurrent results: (Assessment ID: 1)\nTrial-level elig",
        "label": 0
    },
    "559": {
        "output": "# Additional questions/checkpoints\n1) What is the expected outcome for this project?\n\n\n> [SOLUTION] You are expected to train a machine learning model to predict whether a patient is eligible for the clinical trial or not. You are advised to check the provided clinical trial data for missing values.\n2) What are the major components and attributes in the clinical trial recruitment project?\n\n\n> Include a description of the patient data set and the clinical trial recruitment data that are being analyzed by the ML model. The following table (also available in the [instruction]) represents the expected outputs. The inputs for the model are shown before the input-outputs block.\n2) How many eligible patients would the trial recruit?\n\n\n> [SOLUTION] The study expects five to six eligible patients out of 55 patients (9.1%).\n3) What are the benefits of having clinical trial data available for AI applications?\n\n\n> [SOLUTION] Applying AI tools to clinical datasets can support medical decision making with the advantages of speed and consistency. Clinical AI tools could be also used to improve the process of trial recruitment. You may also find the related resources (i.e., [instruction] and [instruction]) useful.\n4) How could AI techniques improve the trial recruitment?\n\n\n> [SOLUTION] AI can assist and speed up the trial recruitment process by identifying which patients are eligible for clinical trials. \n5) What is the goal of this lesson?\n\n\n> [SOLUTION] The goal of project is to perform eligibility assessment by means of the trained ML model. \n6) What is the input for the machine learning model?\n\n\n> [SOLUTION] The patient note and the clinical trial.\n7) What are the possible outputs of the ML project?\n\n\n> [SOLUTION] ML projects have an output that usually are represented as numbers. In cases where there are text or images, the model can produce a numerical score or probability for each class.\n8) What could prevent this from being an effective clinical trial to improve the lives of patients?\n\n\n> [SOL",
        "label": 0
    },
    "560": {
        "output": "[/] The following table shows the output of the eligiblity assessment.\n\n## Eligibility assessmeent\nPlease describe any assumptions and simplifications made and how these affect any conclusions drawn.\n\n## Question 5\nPlease write your assessment of the clarity of the code of analysis of the current clinical trial (3 sentence).\n\n## Data analysis of the clinical trial\nThe output of the eligibility assessment consists of the following table:\n\n## Eligibility assessment\n\n## Eligibility\nPatient\nTrial-level eligibility 0) Excluded 1) Not relevant 2) Eligible\nPlease write a summary of the findings from the code of analysis and data analysis in 3 senten ces.\nPlease describe any assumptions and simplifications made and how these affect any conclusions drawn.\n\n## Question 5\nIf any of the answers marked in the previous question you can see that this question.\n\n## Analysis of the dataset analysis\nIn addition to the description of code analysis for the clinical trial that is the focus of the study (Data-level assessment), please also evaluate the code for the clinical trial data that you collected (Analysis-level assessment) from a perspective on the validity and reliability of the data that the paper analyzes.\n\n## Data-level assessment\nWe are evaluating the validity of the trial that the researchers are interested in.\n\n## Analysis-level assessment\nPlease describe whether there are biases in the clinical trial data that researchers are interested in in the following table.\nIf you have answered positively to any of the questions, do you think that the biases are problematic for the analysis?\n\n## Validity reliability\nQuestion 10 Please write your assessment of the validity of the data-level assessment of the current clinical trial.\n\n## Question 11\nPlease write your assessment of the reliability of the data-level assessment of the current clinical trial.\n\n## Question 12\nPlease write your assessment of the validity of the analysislevel assessment of the current clinical trial.\n\n## Question 13\nPlease write your assessment of the reliability of the analysis-level assessment of the current clinical trial.\n\n## Question 14\nFrom the perspective",
        "label": 1
    },
    "561": {
        "output": "Please note that only in rare cases of a multiple note, the exclusion criteria should be applied before you reach the next line. In other words, if `Eligible` is already coded in a later line, then the exclusion criteria are no longer relevant, and the assessment should proceed to the next relevant line.\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal",
        "label": 1
    },
    "562": {
        "output": "What should you say when you define it? \nFirst of all, you should declare the variable `dataset` as follows: `dataset=data.dat`. \nNow let's begin with data set manipulation. \n\n\nSo you have only patient and trial variables. Now you should add variables for calculating the LDL-value according to NHI protocol [INST]. [A: STEP 4 & STEP 5] \nNow let's see the LDL calculation. \nWhat do you obtain from the patient variables? \nFirst of all, look what you have obtained from the patient variables. You should obtain your patients' ages and LDL-C values. [A: STEP 6] \nBy looking at your patients' data, you should make a trial-level evaluation only if the LDL-C values are between 130 and 189 mg/dL. \nYou should call the trial if the second criteria is satisfied. But should call the patients if the criterion of the trial level eligibility is valid. \n\n\nWhat you have gotten from the trial? \nFirst of all, let's look at the trial. By means",
        "label": 1
    },
    "563": {
        "output": "# Author\n* {page-break-before:always}\n\n# <a name=\"author\"></a>Author\nThe `Author` section allows the author to assign a contributor list for this study. The `Author` may be listed as principal or co-investigator on this publication. A common scenario is to have more than one principal Author for the same research study.\n\nWhen authoring a study, the number of Authors that can be entered into this system is limited to 13. For example, the most senior Author is listed first, followed by \"and others\". The others are listed as 1<sup>st</sup> authors or, in alphabetical order. Therefore, up to 13 people may be listed as Authors in this study. This system has limitations. For example, the `Affiliation` section (which requires up to 300 characters) can only accommodate the top 12 Authors listed in the `Author` section and the \"and others\". If more than 12 Authors are needed, it should be completed manually within the text of the document.\n\n```html\nAuthor:\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n  <NAME>\n```\n\n## Note: The `Author` is the same as the `Corporate contact` field under the `Identification` section.\n\n\n### `CORPORATE CONTACT`\n\nThe `Corporate Contact` is mandatory for studies with more than one `Author`. Entering a Corporate Contact is a security feature that protects personal information from a publicly accessible research database.\n\nIn the `Corporate Contact` field, the `Corporate contact email` is mandatory. To complete, please enter a personal email address, so that the information is accessible when users contact the author.\n\n\n[/GEN]<EOD> The effect of lutein supplementation on visual acuity in patients undergoing cataract surgery: a prospective randomized trial.\nBACKGROUND",
        "label": 2
    },
    "564": {
        "output": "Your input should look like: \n$python code.py data/sample_clinical_trial.txt \n    Trial_start_date:    1996-10-15 \n    Trial_type:         Active, Phase  3\n    Trial_category:     Cancer_Therapy\n    Trial_status:       Active\n    Trial_end_date:     2001-10-15 \n    Trial_eligibility:   2) Eligible\n    \nOutput:\n   Eligible patient list:\n   0(excluded): 5\n   1(not_relevant): 10\n    2(eligible): 189\n\n# Results\n- The output consists of `0(excluded): 5`, `1(not_relevant): 10`, and `2(eligible): 189`.\n- 0(excluded): This means that five patients are not eligible.\n- 1(not_relevant): This means that ten patients do not have enough information to meet the prerequisites of the trial.\n- 2(eligible): This means that 189 trial-relevant patients are listed whose data have met the criteria.\n\n# Convergence \nThe `python check_eligibility.py` script first runs `./data/sample_clinical_trial.txt` and the current script is run twice to print the output file and save it as \".out\". Each command in the above output file is run in the Python Shell in a sequential manner, and the command sequence is performed as specified in the script's output file.\n\nIf the above script is run as follows, it will generate the desired results, assuming that the clinical trial data file.txt, python data/sample_clinical_trial.txt, the current script, and all the dependencies (including numpy, pandas, and a few other packages) are installed on your system. \n$python check_eligibility.py ./data/sample_clinical_trial.txt\n    Trial_start_date:    1996-10-15 \n    Trial_type:         Active, Phase  3",
        "label": 1
    },
    "565": {
        "output": "<span>(Optional)</span>\n\nYou can submit your code for the contest on the Grouper platform [INST](https://app.grouperhubs.org/proposals/42). Submission includes answering the provided question. Submission is allowed between 12:00 PM (UTC) 26 June 2020 and 12:00 PM, 7 July 2020 (UTC). Winners will have 3 days after the end of the contest to respond whether they would like to join a paid part-time job or to be a freelancer on the [INST](/) AI platform. Winners get 5-100 USD as the prize. You can also check all winners at [INST](https://app.grouperhubs.org/proposals/42).\n\n```python\n# + [markdown] colab_type=\"text\" id=\"VYI65Fwf6jU\"\n\n# + id=\"2p1ZRkZF5Y3s\" colab_type=\"code\" executionInfo={u'profilePhoto': img_url, u'cellType': u'v1', u'kernelName': u'tensorflow', 'outputsTableId': u'ccec0519-0620-4764-a7fa-628d57534095', 'colabUserInput': u'2p1ZRkZF5Y3s'}\n# + [markdown] id=\"r4ZZvvXe7Z70\"\n\n\n# + [markdown] id=\"r4ZZvvXe7Z70-1\" colab_type=\"text\" executionInfo={u'profilePhoto': img_url, u'cellType': u'v1', u'kernelName': u'tensorflow', 'outputsTableId': u'8a00e699-333f-4e36-be28-6a3ef1eb046f', 'colabUserInput': u'r4ZZvvXe7Z70-1'}\ntitle = f\"Trial-level eligibility for patient {patient_id.cap",
        "label": 1
    },
    "566": {
        "output": "## Reverse Phase Searches\n\nThe inverse of the query search of \"Simvastatin in Hyperlipidemia\" is\n[TrialType] AND 'Non Controlled Trial'\n\nReverse Phase Searches include:\n- [TrialType] - TYPE - All trial types, in randomized order.\n- [TrialType] - TYPE - CCT Randomized Control Trials, in random order.\n\n\nReverse Phase Searches use the following structure:\n```\n[[TrialType] AND 'Non Controlled Trial']`\n```<EOD> A novel role of a peptidyl-prolyl cis\u2013trans isomerase I (FKBP51) as a molecular target for phosphatidylinositol 3-kinase signaling\nThe recent report that the immunosuppressant FK506, an uncompetitive inhibitor of the peptidyl-prolyl cis\u2013trans isomerase I (FKBP12), induces growth arrest and apoptosis of breast cancer cell through enhanced binding of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway to the eukaryotic translation initiation factor eIF4E demonstrates that the function regulation of a single mammalian peptidyl-prolyl cis\u2013trans isomerase may be mediated by various signaling pathways.<EOD> High prevalence of CAD-CAM milled restorations in the permanent dentition in Germany and the Netherlands: a cross-sectional exploratory study of 333 schoolchildren\nObjective The aim of this study was to describe the prevalence of CAD-CAM milled restorations in the permanent dentition by caries risk status, and by age, gender, and country. Design A cross-sectional, exploratory study was carried out in Germany (Bremerhaven) and the Netherlands (Leeuwarden). Methods Two trained and calibrated examiners collected data using photographs from the schoolchildren aged 11 to 15 years present during an active school dental clinic day, who met the following inclusion criteria: the presence of at least 26 permanent teeth, not",
        "label": 1
    },
    "567": {
        "output": "[C]\n<EOD> A method for analysis of small nucleotide polymorphisms using the SNaPshot assay\n\nBackground: The next generation sequencing is currently one of the most important molecular biological methods, but it is limited in the analysis of large numbers of low-throughput molecules due to the high cost of sequencing. Small Nucleotide Polymorphism SNaPshot assays are an affordable alternative to the sequencing approaches to determine nucleotide polymorphisms. Because of the relatively low-throughput nature, the SNaPshot method is rarely used and the design of PCR primers is complicated, but the PCR products can be analyzed simultaneously by automatic capillary sequencer. Results: By using single-strand DNA templates derived by asymmetric PCR, we were able to determine small nucleotide variations by capillary electrophoresis after digestion of the PCR products with the SNaPshot enzyme. This simple detection method was optimized for the analysis of small variations between two or more sequences of interest. By introducing PCR asymmetry, we were able to achieve sufficient SNaPshot enzyme to complete reaction at lower temperatures (e.g. 60\u00b0C) and to reduce overlapping reactions between the templates. With only basic computer programs, one may design the PCR primer pairs and analyze the results, even by using the SNaPshot assays. Sensitivity of this method may also be improved to analyze lowfrequency mutation using quantitative PCR before the asymmetrical PCR.Conclusions: Small nucleotide variations, including substitution and deletions/insertions, were successfully analyzed by the SNaPshot method using asymmetric PCR amplification. By using PCR asymmetry, the SNaPshot method has been enhanced for genotyping of SARS coronavirus (SARS-CoV), human parainfluenza virus type 3 (HPIV-3), dengue virus type 3 (DENV-3) and H7N9 avian influenza virus.\n\n# Background\nThe next-generation sequencing approach produces large amount of raw nucleotide sequences and detects high frequency nucleotide variations, such as substitutions and short nucleotide insertions or deletions, but its high cost has limited its application",
        "label": 0
    },
    "568": {
        "output": "* * *\n\n**Leads and Challenges**\n\n\n* *\n\n\n\nThis challenge is to find the number of lines that do not begin with the same character, but are separated by exactly zero space (e.g., \"happiness\" can be found in the string \"hepaplasma\", because the strings differ only in one character, yet the string length is matched).\n\n[INST] Here is the string to be matched: ***\"hepaplasma, \"***\n\n[INST] Let's match the string:\n>\n> # Matching all sequences that begin with the letter \"e\"\n> # The variable \"count\" will contain the number of occurrences.\n> s <- paste0(\"hepaplasma\", \"*e*\")\n> count <- sub(s, regex(\"^e.*\"))\n> print(count)\nHeaplasma: 1\n\n> s <- paste0(\"hepaplasma\", \"**\" *) # replace \"*\" with a blank space character\n> count <- sub(s, regex(\"^e.*\"))\n> print(count)\nHeaplasma: 2\n\nThe code above matches the strings that begin with the letter \"e\" (i.e., \"Heaplasma\" and \"*e*\"). Let's change the search string to replace the letter \"e\" with a blank space character. In other words, we replace one item from the search string.\n> sub(\"e\", \" \", s)\n> print(sub(\"e\", \" \", s))\nHeaplasma * *\n\nIf we change the search pattern to replace the letter \"e\" with three white space characters, the number of matched sequences to the search pattern changes from 2 to 1.\n\n[INST] Now you can repeat the above codes to match the search patterns that beging with a particular letter (e.g., \"a\").\n\n[INST] In this exercise, you should use the string that begins with a special pattern, e.g., \"a\" and one of the search patterns presented above:\n\n\n* * *<EOD> META\u2010ANALYSES OF THE EFFECTS OF ANTIDEPRESSANTS ON CHILDREN\nMeta\u2010analyses allow an estimate of results from previous studies to be combined,",
        "label": 0
    },
    "569": {
        "output": "## Good luck!\n\n<EOD> Is there a need for an inhaled cystic fibrosis airway drug with a wide range of therapeutic effects?\n\nWhile cystic fibrosis has become the paradigm of genodermatoses, we still do not have a cure. There has been great progress in understanding the disease since the discovery of the genetic mutations and the development of better therapeutic strategies. However, the clinical outcomes of the patients are still far from being ideal. We are still searching for drugs targeting all aspects of the pathological mechanisms involved, from the basic defect in the epithelial cells to the immune response of inflammatory cells. There are several strategies for drug development: first, we have to develop new drugs targeting the epithelial ion transport defect; second, we may use already available bronchodilators in the treatment of the cystic fibrosis related bronchitis; third, the use of more specific drugs such as nebulized rhDNase at the clinical practice is still considered experimental because of the uncertainties of its safety. The development of new drugs for the treatment of cystic fibrosis is a complex process that requires close cooperation among clinicians, scientists and pharmaceutical companies. The clinicians have to help selecting drugs and defining parameters of efficacy of therapy, the scientists identify the pathological mechanisms that should be targeted as druggable by pharmaceuticals and the pharmaceutical companies perform the fundamental work of drug development and assess the safety and efficacy in animal models and in clinical trials.\n\n# Background\nCystic fibrosis (CF) is a genetic disorder caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), a cell membrane protein that regulates the movement of the chloride and bicarbonate in epithelial cells. CFTR is a member of the ATP binding-cassette (ABC) family of proteins [bib_ref]  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA, Riordan [/bib_ref] . The normal function of CFTR requires the interaction of CFTR with other proteins called CFTR modulators",
        "label": 0
    },
    "570": {
        "output": "# [ACCEPT]\nYou accept that the patient satisfies the inclusion criteria and does not meet the exclusion criteria, e.g., You accept that the patient satisfies the inclusion criteria and does not meet the exclusion criteria, e.g., `Accept: 1) Excluded` (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria)`Accept: 0) Excluded` (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria)\n\n# [SENT]\nNow you should send the output data about the patient to the server by the form: `Send: {\"note\": \"{}\"}`. \nWhen using the form: \nYou should select the first line from `Input for patients note and the patient's clinical trial note` form. Then, from the next line, type your assessment of the patient's eligibility. \n[INST]\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n\n```\nSend:\n```<EOD> Comparison of microbiological testing methods and risk factors among patients with diabetic foot ulcers\n\nO r I g I n a l a R t I C r e d I t a r I a T I n F o M M y c o Bi o l o g y Comparison of microbiological testing methods and risk factors among patients with diabetic foot ulcersO r I g I n a l a R t I C r e d I t a r I a T I n F o M M y c o Bi o l o g y Comparison",
        "label": 0
    },
    "571": {
        "output": "<EOD> .\nLaser-Doppler flowmetry (LDF) (Moore, Transit Time Tissue Differential) was performed on the uterine cervix in 12 pregnant women and in 6 non-pregnant women with known cervical insufficiency. In all pregnant women LDF indicated an increase of blood flow velocity with intrauterine pressure (IUP) from 15 to 30 mmHg. The curves of the pregnant women show also a distinct maximum of blood flow velocity shortly before the onset of contraction. Above a peak flow velocity value of more than 6 cm/sec in LDF, the pregnant women will be in danger of uterine cervical insufficiency. In normal pregnancy the uterus is perfused to a higher degree than it is in normal not-pregnant women.<EOD> .\nLactotensin is one of the endogenous peptides with an anxiolytic-like effect. Anxiolytic-like effect of lactotensin was established in the Vogel \"laboratory\" test in mice with different levels of aggressive behavior. The level of aggressive behavior of animals is directly dependent on the lactotensin content in the brain. Thus, the higher content of this peptide in the brain of mice the higher the level of aggressive behavior of animals. Possible participation of lactotensin in the regulation of the level of aggressive behavior in animals has been suggested.<EOD> Effects and mechanisms of pine pollen immunization on improving the immunocompetence of weaned piglets.\nPine pollen (PP) is a nut and medicinal food with various biological activities. The objective of this research was to investigate the effects and mechanism of pine pollen on the regulation of immune function in weaned piglets. In total, 120 healthy weaned piglets were selected for 42\u00a0days of experiments. The piglets were randomly assigned to four groups, being fed with different diets: 0.2% PP, 1.50% PP, 3.00% PP, as well as the control diet. Piglets' performance,",
        "label": 1
    },
    "572": {
        "output": "<EOD> Immobilization of lysozyme onto the surface of gold nanoparticles via an antibiofouling polymerization reaction.\nAntibiofouling gold nanoparticles (AuNPs) were synthesized using pendent epoxide reagents in the presence of poly(ethylene glycol) methyl ether thiol (PEGMET) as the antibiofouling polymer. The surface modification of AuNPs was carried out through the ring-opening reaction of an epoxide. The effectiveness of the functionalization was characterized using UV/vis spectrometry, zeta-potential analysis, and fluorescence resonance energy transfer (FRET) via the ratio of absorption of excitation light to emission light from PEGMET-modified AuNPs. The FRET results indicated the successful immobilization of PEGMET onto the surface of AuNPs. Furthermore, the ability to functionalize the AuNP surface with the antibiofouling polymer for the immobilization of proteins was verified by surface chemistry analysis and FRET of the protein, chicken egg white lysozyme covalently conjugated on the surface of the antibiofoulingly modified AuNPs. The result showed the successful immobilization of lysozyme molecules onto the surface of the antibiofouling AuNPs. The lysozyme modified AuNPs obtained were stable after being incubated with an antibody-capture assay.<EOD> Assessing cognitive decline following traumatic brain injury\n\nPurpose: This systematic review examined the utility of commonly used cognitive measures of attention, memory, and executive functioning in detecting early changes in cognition following traumatic brain injury (TBI).Methods:A systematic review was performed. Medline, EBSCO's (CINAHL, PsychINFO, SocINDEX) and Psychology and Behavioral Sciences Collection, and ProQuest Dissertation & Theses databases were systematically searched using combinations of the following keywords: \"cognitive, \" \"cognition, \" \"brain injury, \" \"trauma, \" \"accident, \" \"concussion, \" and \"focal cranial injury. \" Publications were reviewed",
        "label": 1
    },
    "573": {
        "output": "</SPAN><!-- Instructions and Answers\n\n<H1 id=\"q1\"></H1>\n<P><SPAN id=\"answer_q1\">A.\n1</SPAN><!--Answers--> <H3 id=\"q1\">Question #1</H3><H4 id=\"answer_q1\"><P><SPAN style=\"margin-left: 0.2em\"><P><SPAN style=\"margin-left: 0.2em\"><P><SPAN style=\"margin-left: 0.2em><STRONG><SPAN style=\"font-style: italic;\">Please choose the correct combination of 1 answer below that meets the eligibility criteria to the patient.</SPAN></STRONG><BR></SPAN></STRONG><P><STRONG><SPAN style=\"font-style: italic;\">Inclusion and exclusion criteria for study </SPAN></STRONG></P></P><BR></SPAN></P></P></P></SPAN>\n</H4><BR>\n<H3 id=\"q2\"></H3>\n<P><SPAN id=\"answer_q2\">A.\n1</SPAN><!--Annswers--> <H3 id=\"q2\">Question #2</H3><H4 id=\"answer_q2\"><P><STRONG><SPAN style=\"font-style: italic;\">The patient meets all the inclusion criteria of the clinical trial, except for the following one: (1) <STRONG>The patient is currently taking medications that are contraindicated in the IMP (e.g.: non-steroidal anti-inflammatory drugs, angiotensin-converting enzyme (ACE-inhibitors).</STRONG>. </SPAN></STRONG><P><STRONG><SPAN style=\"font-style: italic;\">Please choose the correct combination of 1 answer below that meets the eligibility criteria to the patient. </SPAN></STRONG></P></P><BR></SPAN></P></P></P></P></SPAN>\n</H4><BR>\n<H3 id=\"q3\"></H3>\n<P><SPAN id=\"answer_q3\">A.\n1</SPAN><!--Annwers--> <H3",
        "label": 1
    },
    "574": {
        "output": "<EOD> Enhanced production of a cyclic dipeptide from the cyanobacterium Oscillatoria sp. with immobilized cells in stirred culture.\nCyanobacterial biomass was immobilized in agar-gel beads and used for the enhanced production of the cyclic dipeptide cyclo-(Phe-Val), which has a high antagonistic potential against spore germination of plant pathogens. Two strains of the cyanobacterium Oscillatoria sp. were used for the immobilization on agar-gel media, which were prepared using polyhydroxybutyrate (PHB). High immobilization efficiencies of over 99% could be achieved in the beads with the addition of PHB into the agar-culture medium. The immobilized biomass in agar-gel media was stable for culture after a storage period of 6 months. Highest cyclic dipeptide levels of up to 11.0 mg/L were observed in the immobilized cell cultures, whereas no significant amounts of the cyclic dipeptide were synthesized in the suspension culture with free cells. Under optimal conditions, the biomass in immobilized cell cultures, which corresponded to a cyclic dipeptide productivity of 5.7 mg/L/day, could be harvested over 14 days without visible loss of activity during prolonged cultivation.<EOD> Detection of human serum amyloid P component (FSP) by a monoclonal and a polyclonal antibody. Characterization of the antigens of the major component of normal and amyloid fibril proteins.\n\nHuman serum amyloid P component was detected by two different antibodies in an amyloid patient with AL-type amyloidosis. The methionine-enkephalin amino sequencedetermined residue from a major component of the fibrils of this patient and of three other patients with multiple myeloma, who had amyloid fibrils of AL type, was serine. These findings suggest that amino acid substitution with serine at position 4 in vivo is characteristic for amyloid-P fibrils. Further investig",
        "label": 1
    },
    "575": {
        "output": "This section of the tutorial is aiming to teach you how to write an algorithm that will predict the answer of your code. You must create a function named `createData(patient, trial)` that takes two arguments, a patient and a trial, and returns a list of three elements, patient's information (age, gender, \u2026), trial information, and the decision of the algorithm, respectively.\nFor the evaluation of your code, you will get a collection of patient records and trials that correspond to your patients with the given treatment. You will also submit your candidate program to the judge and the judge will give you the output of the trial-level eligibility decision.\nLet A, B, and C be the algorithms that will be tested in your programming competition for the prediction of a patient-level eligibility for the trial. A is the algorithm you will develop. The other algorithms, B and C, are the algorithms trained in your programming course. You should learn about them to get a better sense of what your peers' algorithms will do, and try to match them as your peers might have done.\n\nHere is the list of trial-level eligible patients: \n\nYou can use the patient list to create the patient structure that should be passed to the function `createData(patient, trial)` by the following line:\n\nYou should predict trial_level_eligibility by:\n\nYour program should be able to handle each algorithm including A. \nBased on all of your experiences with the algorithms, your code will be evaluated in the following two steps:\n\n- You will get a file that contains the trial_level_eligibility output for each patient.\n- You will rank your code from 0 to 100 against the two other algorithms with a score of 0 for a prediction less than 50% in average, a score of 40 for 80% prediction score, and 100 for 100% prediction score.\n\n# Discussion\nThis section of the tutorial is aimed to discuss your code with you. In this section you will find explanations on your code regarding both its strengths and limitations. \n\nYou successfully created a working code, and your score for matching the algorithms, is over 96! Your peers will see it as a very helpful function that will enhance the functionality of the trial in their programming.",
        "label": 1
    },
    "576": {
        "output": "<EOD> Dipyridamole-induced myoclonus\nThe adenosine A1 agonists are useful in the diagnosis of ischemia, as they cause chest pain and elevation of cardiac enzymes by coronary artery spasm. Dipyridamole, which is the best-known representative of the adenosine A1 agonists, is commonly used for pharmacologic stress test. The most common adverse event is myoclonus, although chest pain and elevation in heart rate are also observed. However, the etiology of myoclonus is still unknown. In the present article, we report a case with myoclonus induced by dipyridamole. Myoclonus seems to be directly or indirectly related to adenosine. The pathophysiologic mechanism and the treatment of myoclonus are discussed.<EOD> Convergent validity of two measures of the Dementia Rating Scale-1.\nOBJECTIVES\nTo determine the convergent validity of the Cognitive Capacity Index (CCI) and Index of Intellectual Functioning-67 (IIF-67) with the Dementia Rating Scale (DRS-1).\n\n\nMETHODS\nThis is a retrospective, cohort study of 462 older adult Medicare dementia patients evaluated by geriatric psychiatrists at an academic medical center over a 10-year period. CCI was assessed by examiner-rating and IIF67 by self-report (or clinician interview for limited communicators). DR was also assessed by examiner-rating. Multivariate regressions evaluated the predictive validity of both measures.\n\n\nRESULTS\nCompared with the DRS-1, both the CCI and IIF67 were associated with higher degrees of dementia. The CCI, DRS-1, and age explained over 50% of variance in the DRS-1. The IIF67, DRS-1, and education level explained over 50% of variance in the DRS-1.\n\n\nCONCLUSIONS\nBoth IIF67 and CCI were valid for the diagnosis of DR-requiring dementia. The CCI",
        "label": 2
    },
    "577": {
        "output": "##[/TASKS]\nGood job! You have finished your task!\n\n---\n\n## Hint 179. [MOONLIGHT][NAME] Moonlighting RN: CMS Innovation Project. Title: Improving outcomes of patients with congestive heart failure admitted as Medicare and/or Medicaid beneficiaries in rural hospitals. Funded by the Centers for Medicare and Medicaid Innovation. You are one of the members of the project. The goal of the project is to pilot a clinical decision support system for improving outcomes of patients with congestive heart failure in small and rural hospitals in the US. In order to get a better understanding of the project, try out the demo below. The demo explains the clinical workflow and demonstrates its usability in small and rural hospitals.\n\nhttps://www.youtube.com/watch?v=FmqBNM-f5rE\n\n[/MOONLIGHT]\n\n### Moonlighting RN: CMS Innovation Project: Assessed Tasks. [INST]\n\nThis part will be like a recap. Try your best to identify the important details.\n\n\nThe objective of our project is to provide health services to Medicare and/or Medicaid beneficiaries admitted as hospitalized patients in rural hospitals. The goal of the project is to improve patient outcomes through the implementation of a clinical decision support system. We are working on the hospitalized patients with congestive heart failure (CHF). Our proposed target population is the hospitalized patients with congestive heart failure (CHF) (either alone or as exacerbation).\n\nThe team includes: an internal medicine physician of the hospital, a full-time staff nurse, a pharmacist, a hospital administrator, a hospital finance officer, staff nurses, other physicians, the rural hospital's administrator, the rural hospital's finance director, a project coordinator, and the data manager.\n\nTo implement this project we have followed these steps:\n\n- Step 1: To discuss our project idea to hospital administrator and finance director.\n- Step 2: To develop our project protocol\n- Step 3: To develop our clinical decision-support system and user interface",
        "label": 1
    },
    "578": {
        "output": "To test the pipeline, click on 'Play Pipeline' and a window will open and the code will be executed.\n\n\n![](./Images/Examples/BELR/17/eligibility.png)\n\n\n#### Result\n\n```bash\nA: 0.090 \nB: 0.060 \nC: 0.170 \n```\n\t\n![](./Images/Examples/BELR/17/eligibility-result.png) \n\n\t*Note*: You can see in the upper right corner the percentage of the eligible patients, that for each trial is 0.1700, which means that 17.00% of patients are eligible.\n\n\n\n## Assessment-eligibility \n\n### Description\n\nThis step calculates the clinical trial-level eligibility. It should be an integer variable between 0 and 2, indicating the patients' level of eligibility between 0) `Excluded`, 1) `Not relevant`, and 2) `Eligible`. \nThis step can be done by using the `eligibility` function. `eligibility` function takes two arguments: a list of `patient_notes` and a list of `clinical_trials` variables, correspondingly. \n\n### Example\n\n\n\n\n| patient_note | clinical_trial | result |\n|-------------|---------------|-------|\n| A | B | 0.060 |\n| A | C | 0.170 |\n| A | D | 0.650 |\n| 1 | C | 0.090 |\n| B | A | 0.720 | \n| B | D | 0.150 |\n| B | C | 0.650 |\n\n\n![enter image description here][2]     [2]: https://i.stack.imgur.com/dD4i3.png\n\nTo check the pipeline you can click on `Play Pipeline` and a window will open and the code will be executed.\n\n### Code\n\n```python\npatient_notes = ['A', 'B',",
        "label": 0
    },
    "579": {
        "output": "<EOD> The genotoxicity of the nonionic detergent Triton X405 in Drosophila: is there any evidence for the occurrence of methylation changes?\nThe methylation pattern and total DNA content of larvae of Drosophila melanogaster exposed to nonlethal doses (10 microL/mL solution) of the nonionic detergent Triton X405 were examined. No differences were found in the total DNA content, in the number of lethargic individuals or in the number of mutated flies among the treated group and the control group. The methylation pattern, obtained by sodium bisulphite DNA modification followed by polymerase chain reaction (PCR) amplification and denaturing polyacrylamide gel electrophoresis, showed no difference in the methylation patterns between Triton X405-treated flies and the control group. These results do not rule out the involvement of the cell cycle in the mode of action of Triton X405, but rather indicate that in our experimental condition, Triton X405 did not induce DNA methylation changes.<EOD> Synapse density and cell packing in the optic tectum of the chicken\nAlthough aves and mammals have evolved different architectures in the central part of the central nervous system, they share several features, including complex mosaics of cell types and extensive synaptic connectivity. Despite this similarity, there are also striking differences, including in the tecto\u2010tectal synapses and in the gross architecture of the tectum. In this study, we have compared both synapse density and laminar cell packing of the chicken (Gallus gallus) and mammalian tectum.<EOD> A comparison of two assays for the detection of antithyroglobulin antibodies.\nHeterophil antibody assays are prone to problems in interpretation and are of limited value compared to other direct antibody assays, particularly the latex particle agglutination test. Results of this assay, when compared with the latex assay and the radioimmunoassay of thyroglobulin antibody (TgAb), support its poor level of sensitivity and",
        "label": 1
    },
    "580": {
        "output": "## Good luck!\n[INST] Here is the patient note:\nA 45-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors (e.g., smoking, high blood pressure, and diabetes) and is physically active. The patient`s LDL-C and HDL-C levels were 141 and 46\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient also reported that smoking onset was at age 25, his current alcohol intake was less than once a week, and his past alcohol consumption was more than once a week.\nThe patient reported no use of lipid-lowering medications.\nUltrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 141.5\u2009cm/s and 36.79\u2009cm/s, respectively; RICA PSV was 89.73\u2009cm/s and RICA EDV was 34.91\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nLet say the assessment of eligibility is 2. That means, the patient is eligible for inclusion. Good job! \n<EOD> Acute and chronic effects of alcohol.\nThe authors review the acute and chronic effects of ingesting alcohol with regard to its effect",
        "label": 1
    },
    "581": {
        "output": "<p id=\"main\" class=\"jstn-hypothetical\">\n\t\t<p>\n\t\t\tThis is the output result for the input of the test set.\n\t\t</p>\n\t\t<p class=\"rounded\">\n\t\t\t<span class=\"rounded\"><i class=\"rounded-icon fa fa-clock-o fa-4x\"></i></span>\n\t\t\t( <span class=\"text\">\n\t\t\t\t<i >\n\t\t\t\t\t95.7%\n\t\t\t\t</i>\n\t\t\t\t(28/29)\n\t\t\t</span>\n\t\t</p>\n\t\t<i class=\"text\" id=\"true_positive_i\"></i>\n\t\t<p class=\"rounded\"><span class=\"rounded\"><b>True Positive:</b></span> \n\t\t\t4\n\t\t</p>\n\t\t<p class=\"rounded\"><span class=\"rounded\"><b>False Positive:</b></span> 0\n\t\t</p>\n\t\t<p class=\"rounded\"><span class=\"rounded\"><b>False Negative:</b></span> 0\n\t\t</p>\n\t\t<p class=\"rounded\"><span class=\"rounded\"><b>True Negative:</b></span> 0\n\t\t</p>\n\t</p>\n\t\n  </body>\n</html>\n\n\n    %rpc : id : \"Trial-level eligibility\" ;\n                desc : \"Trial-level eligibility assessment of a clinical trial for a patient\";\n                input : \"patient_doc\", \"patient_note\", \"trial_doc\", \"trial_data\" ;\n                output : \"eligibility_scale\"\n\n\n    : rproc\n    :\n    if\n    eligibility \n    in\n    \"el_016\", \n    \"el_011\", \n    \"el_004\", \n    \"el_001\", \n    \"el_007\", \n    \"el_003\", \n    \"el_005\",",
        "label": 1
    },
    "582": {
        "output": "## Learning objectives\n- You will learn the clinical practice of patient chart review and data entry.\n- You will get familiar with the data visualization tool called `patient note report`.\n\nLet's review the following example patient note, which is a patient's clinical data:\nPatient Name: Sasha\nClinical Trial: JACTAX LD Drug Eluting Stent Trial\n\n# Learning Materials\n\n#### Detailed Trial Description\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u00a0mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u00a0mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u00a0cm/s and 54.5\u00a0cm/s, respectively; RICA PSV was 91.72\u00a0cm/s and RICA EDV was 37.37\u00a0cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being",
        "label": 0
    },
    "583": {
        "output": "removes the header line (in the first line), [INST] in the third line removes the last line from the last section, and [/SINGLE] in front of the text field in the fourth line adds an extra space before and after the code block.\n\n#### 5.9.1 \u6458\u8981\n\n# Acknowledgments: Thank you Dr.\n[fig]  22: Note: `Clinical trial comparison code` is the class for code blocks of clinical trial comparison. 48 # # If the patient meets inclusion criteria: # 49 # Check if the patient is included in the trial by matching first # the identifier of the clinical trial # with the one of the patient, # and then match criteria # and exclusion criteria of the patient # with inclusion criteria of the trial. 50 patient.clinicaltrial_identifier==trial.identifier). patient.clinicaltrial_inclusion_criteria.c1==trial.inclusion_criteria.c1 or 52 patient.clinicaltrial_inclusion_criteria.x1==trial.inclusion_criteria.x1 or 53 patient.clinicaltrial_inclusion_criteria.c2==trial.inclusion_criteria.c2 or 54 patient.clinicaltrial_inclusion_criteria.c3==trial.inclusion_criteria.c3 or 55 patient.clinicaltrial_inclusion_criteria.c4==trial.inclusion_criteria.c4 or 56 patient.clinicaltrial_inclusion_criteria.x2==trial.inclusion_criteria.x2 or 57 patient.clinicaltrial_inclusion_criteria.c5==trial.inclusion_criteria.c5 or 58 patient.clinicaltrial_inclusion_criteria.c6==trial.inclusion_criteria.c6 or 59 patient.clinicaltrial_inclusion_criteria.x3==trial.inclusion_criteria.x3 or 60 patient.clinicaltrial_inclusion_",
        "label": 1
    },
    "584": {
        "output": "For `2) Eligible.` you have to give a reason for the 'yes' to the patient note in accordance with the three-point scale of 'excluded', 'not relevant', and 'eligible', with the exception of `relevant` (as per the example patient note). \n- The best method of the 'excluded' assessment of the three-point scale is to use inhibitive words, e.g., `'Not eligible'. The reason for the 'not eligible' should consider the following: - Not meeting the inclusion criteria, especially the criteria on laboratory test results. For example, the patient did not test normal level, e.g., the patient has LDL-C 545. - Not meeting the exclusion criteria, especially the criteria on medical history. For example, the patient reported no use of lipid-lowering medication. In addition, medical history, which is described in the patient note, supports the negative assessment for the following inclusion criteria such as \"Must have no history of allergy to any of the components of the combination regimen for P1446A-05.\" Accordingly, according to the patient history, allergies to P1446A-05 components do not exist.  \n- 'Not relevant': Not meeting at least one inclusion criterion or meeting at least one exclusion criterion. Inclusion and exclusion criteria do not apply. The best method of the 'not relevant' assessment of the three-point scale is to use the word 'not' (e.g., `'Not relevant.'`. For example, 'patient is <65 years old', which means the patient is meeting the inclusion criteria for age, i.e., > 65, which is not matched with the definition of age in the inclusion/exclusion criteria, i.e. '65 years or more (inclusive)' is a mismatch of age in inclusion/exclusion criteria.   - '<25 years old', 'metastatic', 'not relevant'. \n- 'Eligible': This statement is the best for describing any matching information. For example, a laboratory test results support the yes-response, e.g., `The patient has 85+/-5 mg/dL of LDL-C level, which is <100 mg/dL and meets",
        "label": 0
    },
    "585": {
        "output": "A: First of all, you will have to import libraries which help to perform calculations:\nimport pytest\n\nfrom time import sleep\nimport pandas as pd\n\nAlso you will need the following packages:\nimport ipywidgets\nimport ipykata\nfrom ipywidgets.widgets import CheckboxGroup, Text\n\nNext, you also will need to define your function which is going to check all required data:\n\nimport time\nfrom ipywidgets import Text\nfrom ipkglib import IPKG\n\n\ndef Eligibility:\n    ipgk = IPKG.open() \n    with open(\"patient_record.csv\") as fp:\n        # open the csv\n        patient_records = pd.read_csv(fp)\n    ipgk.open()\n    for record in patient_records.itertuples():\n        record_name = record.name\n        record_gender = record.Gender\n        record_age_years = int(record.Age)\n        record_age_in_years = int(record.Age)\n        record_cholester = record.TotalCholesterol\n        record_hdl = record.HDL\n        record_ldl = record.LDLCholesterol\n        record_triglyceride = record.Triglyceride\n        record_heart_beats_per_minute = record.HeartRate\n        record_carotid_stenosis_left_side = record.CarotidStenosis_leftSide\n        record_carotid_stenosis_right_side = record.CarotidStenosis_rightSide\n        record_stroke_history = record.History_of_stroke\n        record_risk_factor = record.risk_factor\n        print(f\"Calculating eligibility for patient record with ID {record.ID}\")\n        isValid = validate(\n            record_name,\n            record_gender,\n            record_age_years,\n            record_age_in_years,\n            record_cholester,\n            record_hdl,\n            record_ldl,\n            record_triglyceride,\n            record_heart_beats_per_minute,",
        "label": 0
    },
    "586": {
        "output": "# ICD10\n* Code: I29\n\n# MIM\nG07.908\n\n# Treatment\nTreatment with statins reduces the risk of death by about 17% on average. It is also effective at stopping strokes. Treatments may vary depending on the country, but cholesterol-lowering drugs and lifestyle changes are usually recommended. A diet including fish or omega-3 may also help.\n\n## Conservative management\nA conservative approach may be used to treat asymptomatic individuals. This involves not treating the condition, or making only minor changes to the diet. Often this is a trial of six months.\n\n## Surgery\nSurgery is sometimes used to treat those living with high cholesterol. A simple surgical procedure will remove most of the gall bladder. Surgery is usually only needed for those with severe symptoms of gallstones.\n\n## Medications\nTreatments including statins, fish oil capsules, fibrates, nicotinic acid, ezetimibe, and bile sequestrants are sometimes used to treat high cholesterol. The evidence is not in the patient's favor, with only some medications producing small to moderate benefits, and their overall use cannot be recommended.\n\n# Cholesterol gallstones\n\n## Alcohol\nAlcohol does not cause gallstones. However, drinking more than three units of alcohol each day increases the overall risk of mortality from gallstones.\n\n## Diet\nNutritional changes are important for those with gallstone disease, including reduced intake of refined carbohydrates and saturated fats. A diet rich in fruit and vegetable may help prevent gallstones.\n\n## Weight\nBeing overweight significantly increases the chance of developing a gallstone. Losing weight may help prevent and treat gallstone disease.\n\n## Physical activity\nA lack of physical activity is a risk factor for high cholesterol. This includes not having enough energy to exercise sufficiently. It may be beneficial for those with gallstones to have a more active lifestyle.\n\n# Epidemiology\nGallstones are common throughout the world, and are particularly prevalent",
        "label": 1
    },
    "587": {
        "output": "[RQ10] Consider the following statement: \"The prevalence on both MHD and HAP is 13% in the older population in Taiwan.[3] When considering both disease statuses, the prevalence of both or either MHD or HAP ranges from 25% to 66% among the older population in Asian countries,[4]\"\nNow, let's take a look at the following question:\n\n* _Question ID:_ RQ_08_03\n\"What is the effect size of CVD associated with the use of statin in high-risk people (\u2265 65+ years old people with hypertension and/or CAD) with/without HAD or HAP?\"\nAs you know that, we have already found that $15.8\\ (\\%\\)) \\times 11.14026\\ (15475.7086)= 18650.24. \nIn the statement we found that:\n- \"The prevalence on both MHD and HAP is 13% in the older population in Taiwan.\"\n- \"When considering both disease statuses, the prevalence of both or either MHD or HAP ranges from 25% to 66% among the older population in Asian countries.\" \n- \"The prevalence on both MHD and HAP is 13% in the older population in Taiwan....\"\n$15.8\\ (\\%\\)) \\times 13= 205.4\\ (\\%\\), \nHence, we have the effect size in the older population in Taiwan.  \nThe use of statin in high-risk people (\u2265 65+ years old people with hypertension and/or CAD) has a significant effect to prevent CVD of $205.4\\ (\\%\\)$\n\nThe effect size of $205.4\\ (\\%\\)$ means that $100$ patients will get $H: 130$  and $x$ patients will get $H\\prime:$ 130$   if there are no statin.\nOn the other hand, the effect size of # $205.4\\ (\\%\\)$ means that $100$ patients will get $H",
        "label": 0
    },
    "588": {
        "output": "_Note_: `Eligible` is the preferred option.\n_Note_: `1) Not relevant` is not recommended if the patient is a participant of a clinical trial without prior knowledge of the eligibility criteria.\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits. \nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and",
        "label": 1
    },
    "589": {
        "output": "For a tutorial on how to assess all 5 features of each note, please refer to [[In-SilicoLab/Clinical_note-based_feature]]\n\n## In-silicoLab/Clinical_note-based_features\nIn-SilicoLab<EOD> Implementation of an online intervention in the work context: the case of 'healthier eating'.\nThe aim of the study was to explore the main barriers, opportunities and needs for a workplace intervention aiming to 'eat healthier'. Four focus group interviews were conducted with nursing staff working on a general ward (n = 7) and a neurological ward (n = 8), both of a large UK hospital, and included interviews with dieticians (n = 5) and a catering service manager (n = 1). Food and nutrition was identified as an important issue for both patients and staff in the work place. Food preparation was highly managed by the nursing staff on the wards, with several barriers to healthier food options being identified in relation to both patients (increasing autonomy and choice and improving cooking skills) and staff (time) areas. Some opportunities were also identified based on staff and patients needing to have both an individualised approach with more flexibility around food choices and the possibility of tailoring food options. In terms of needs, staff and patients expressed a desire for healthier food items in the canteen and to encourage family and friends to eat healthier. In conclusion, the current study presents an initial exploration around the issue of healthy eating at work, which provides evidence and understanding for the development and implementation of healthy eating interventions in these settings.<EOD> .\nINTRODUCTION\nIn this study we investigated the role of CAPE in the modulation of some markers of brain inflammation and the neuroprotective effects of CAPE administration in a rat brain damage model induced by ischemia and reperfusion injury.\n\n\nMATERIALS AND METHODS\nIn a randomized, controlled and double blind study, we tested two groups of adult male Wistar rats subjected to brain ischemia and reperfusion injury: (1) an intraperitoneal injection of 5 mg/kg CAPE",
        "label": 1
    },
    "590": {
        "output": "You should try to achieve this solution. When you submit your code to the Assignment Grader, you can see what it expects to see. The Assignment Grader will then send you private feedback, explaining how to resolve the problem.\n\n\n[inst] Your solution should include:\n\n      #!/bin/python\n      import sys\n      import os\n      import pdb, traceback\n      import time\n      import matplotlib.pyplot as plt\n      import numpy as np\n\n      import pandas as pd\n\n      import matplotlib.pyplot as plt\n      pd.set_option('display.max_rows', 1000)\n      pd.set_option('display.max_columns', 1000)\n      pd.set_option('display.width', 160)\n      pd.set_option('max_col_widths', [160])\n\n\n\n\n      from readcsv import ReadCSV, readfile, SaveCSV\n\n      from readcsv import readdata\n\n      from readcsv import csv_header\n      from csv import *\n\n\n\n      from time import clock\n      from datetime import datetime\n      import csv\n\n\n      from pandas import DataFrame\n      from pandas import Series\n\n      #for a given location_id, a single patient will have two trials corresponding to timepoints t1 and t2. It is\n      #necessary to use the same dataset to generate both trials.\n      data = {'timepoint'  : 't1', 'trial1'  : '', 'trial2'  : '', 'location_id'  : '',\n              'age'        : '', 'ldl_c'     : 0.0,  'hs_c'     : 0.0, 'hdl_c'    : 0.0, 'diastolic'  : 0.0,\n              'systolic'    : 0.0,  'bpm'      : 0.0, 'smoking'  : 1, 'exercise' : 1, 'diabetes' : 1, 'hypertension' : 1}\n      for row_idx in range(5):\n      data['timepoint'] = row_idx\n      data['",
        "label": 1
    },
    "591": {
        "output": "### Task 1 Part 2\n![PART2][SEC]\n\nHere you will read another case about a patient who is not eligible for a given clinical trial. Your task is to indicate patient's exclusion from the trial using an exclusion criterion and patient ID. \nA woman in her late 50's presents with right-sided leg numbness. She reports worsening intermittent claudication over the past two months. Physical exam is notable for diminished sensation to touch in the right L5 dermatome and diminished bilateral dorsalis pedis pulses. A duplex ultrasound of the popliteal, posterior tibial, and dorsalis pedis arteries is performed. Imaging demonstrates severe bilateral femoral artery atherosclerotic disease. There are no plaques in the popliteal arteries, although the posterior tibial artery is notably tortuous.\n\nIn accordance with the study protocol, if the woman (ID = 1) is found to be eligible and willing to participate in the study, the investigator would randomize her to receive one (ID = 2) of the following treatments in a double blind fashion:\n    1) Standard therapy (ID = 2) (control arm): Antiplatelet therapy for at least one year. \nHere is the patient note: \nA 48-year-old woman with a history of hypertension and smoking, presents with right-sided leg numbness. She reports worsening intermittent claudication over the past two months. Physical exam is notable for diminished sensation to touch in the right L5 dermatome and diminished bilateral dorsalis pedis pulses. \n\n![Part 2][FIG] \n[SEC]\n[SEC]\n\nYou should note as many trials as possible.\n\nFor example, if a patient does not meet one or even three conditions of inclusion, the investigator will exclude him from participation in the study. For this study, let's suppose that a 55-year-old man is not eligible to participate in the clinical trial. Therefore, he should not be included in the study, and the investigator",
        "label": 1
    },
    "592": {
        "output": "# Background\nAn important challenge in clinical research is patient eligibility, which is essential for trial success. A clinical trial may fail to enroll the anticipated number of participants if it is unable to find a large population of patients who meet the eligibility criteria. Alternatively, the trial may include too many patients who are incorrectly enrolled as eligible. The use of patient-level eligibility assessments allows for more accurate matching of patients to research studies. However, the current trial eligibility workflow can make screening for potential patients a tedious and time-consuming task. This is because eligibility results need to be manually reviewed in a patient record management system. Manual processing also poses challenges due to the need for skilled staff to use complex eligibility templates. AI is helping to overcome these challenges by using machine-augmented technology to automate eligibility screening across multiple clinical trials as well as improving efficiency for study personnel.  [MORE] \n\n# Discussion<EOD> In vitro biosynthesis of the carotenoid astaxanthin in Euglena gracilis: analysis of intermediates by anion-exchange high-performance liquid chromatography/electrochemical detection.\nHigh-performance liquid chromatography/electrochemical detection was used to monitor the incorporation of acetate or mevalonate into intermediates of the (3S,3'S)-3-hydroxyergosta-4,7,9(11),22-tetraene (astaxanthin) pathway in intact cells of the ciliate Euglena gracilis and in cell homogenates. Using isolated phosphatidylinositol-rich particles, incorporation of mevalonate into the astaxanthin pathway could be followed in a time-dependent manner. Mevalonate was taken up by this organelle and directly metabolized to ergosterol, 24-methylenecholesterol, 7-oxo-cholesterol, 3,4-sterol 24-methylenepropiolate and 24-methylenecholesterol (5): 7alpha-fucosterol and fucosterol (7alpha-5,7-d",
        "label": 1
    },
    "593": {
        "output": "<EOD> Development of an efficient DNA vector for use in the legume model Medicago truncatula.\nGenetic transformation of legume plants is often impeded by the difficulty of selecting transformed cells on the basis of their antibiotic resistance phenotypes. To address this problem, binary vectors which can be maintained as extra-chromosomal elements have been developed in a variety of model legumes. However, while these vectors have been highly successful in the model plants soybean and alfalfa, these vectors fail in Medicago truncatula. A critical factor may be a lack of appropriate selectable markers which are able to provide efficient selection of resistant cells in M. truncatula. Here we demonstrate that the plant-made phosphite transporter gene (MtPTS1) can be used as an additional selectable marker in M. truncatula. We also report the successful development of a bicistronic binary vector where the expression of beta-glucuronidase from a second selection marker gene (bar) allows the simultaneous selection of all three resistance markers.<EOD> .\nThe role of adenosine receptors in modulation of synaptic transmission in different areas of nervous system was reviewed.<EOD> Influence of the environment of an isolated cell on its capacity to produce and secrete human nerve growth factor.\nThe isolated pancreatic islet cell is a special model for the study of nerve growth factor (NGF) production by a single cell type, separated from its direct interactions with other tissue cells, for it retains cellular interactions and autonomy of functional state for many days. We observed that the capacity of the isolated rat islet cell to produce and secrete NGF is influenced by microenvironmental (extracellular, paracrine) influences. After preincubation with a low dose of glucagon (0.1 microM-0.5 mM), the islet cell released 1.5 times as much NGF into the medium, despite the absence of glucose in this medium. Also, at physiological concentrations of glucose (3.3 and 11.1 mM), beta cell cytosolic free calcium accumulates and this event is accompanied by a transient wave of NGF release in the medium. Our data show that this hormone",
        "label": 0
    },
    "594": {
        "output": "The input is patient note `pnt`(see below). The output is the trial-level eligibility for `patient`[INT]\n\nThere is not any input parameter here. The input variable can be the patient note `pnt`. The parameter `patient`[INT] will be set automatically.\n\n`trial_level_eligibility(patient)`[INT] = 0 for `patient` [INT] 1 1 for `patient` [INT] 2 2 for `patient` [INT] 3 3 for `patient` [INT] 4 4 for `patient` [INT] 5 5 for `patient` [INT] 6 6 for `patient` [INT] 7 7 for `patient` [INT](0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria) (1) Not relevant (patient does not have sufficient information to qualify for the trial) (2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply)\n\nThere are five input variables `patient` [INT] and some other parameters `var`[INT]. For details, see the following instruction:\n\n<EOD> .\nRare and paradoxical presentation of a cystic pancreatic tumor mimicking an acute pancreatitis with pancreatic necrolysis was reported. The case of a 78 year old male patient who suffered from a sudden onset recurrent right severe abdominal pain over two months following the progressive increase of the tumor to 16 x 15 cm and the increase of the CA 19-9 serum. The computed tomography revealed a giant cystic tumor of the pancreas with an important necrosis. A diagnosis of a cystic pancreatic neoplasia was suspected. A pancreatic necrolysis associated to a cyst could be diagnosed at histologic evaluation of the tumor and the CA 19-9 serum level allowed to understand the mechanism of the acute pancreatitis. Such mechanism consists of the destruction of the perivascular adipose tissue and the adjacent pancreatic acini and the release of",
        "label": 1
    },
    "595": {
        "output": "This trial is not an eligible study for the given patient. That's because the given patient meets inclusion criteria, but not exclusion criteria.\n\n\nNote that, on page 1, there are two lines with repeated Trial-level eligibility. This is because the first one is on the first line of the first trial, and second one is on the second line of the second trial.\n<EOD> Adenosine A1 agonist ZM241385 attenuates renal ischemia-reperfusion injury.\nA (ZM241385, 5'-carboxy-ethyl-carboxamidoadenosine A (1) receptor (A1AR) agonist, reduced the renal injury induced by ischemic-reperfusion (IR) in rats. We designed in vivo experiments to test the effects of ZM241385 against renal IR injury and in vitro experiments to determine the underlying mechanisms. Rats were pre-administrated with ZM241385 (0.1 mg/kg) 30 min before IR. In in vitro experiments, ZM241385 with different concentrations (10 nM, 100 nM and 1 mM; H-89, 10 mM; SCH79797, 10 mM) were administered into primary cultured tubular cells for in vitro treatment. ZM241385 was found to significantly protect and attenuate acute renal failure (ARF) induced by IR. The level of serum uric acid (UA) was found to be significantly reduced by 76% at 24 h in IR + ZM241385-treated rats (p < 0.05), accompanied with a dramatic decline in kidney injury-related damage markers including lactate dehydrogenase (LDH), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1); these renal injury-related damage markers were 7.1, 2.6, 1.",
        "label": 0
    },
    "596": {
        "output": "<EOD> Sphingosine 1 Phosphate Receptor-1 Agonist Fingolimod for Severe COVID-19: A Retrospective Report of Five Cases\nBackground The Sphingosine 1 Phosphate Receptor-1 (S1PR1) is a transmembrane receptor, which, upon activation, leads to downstream effects responsible for the regulation of immune cells trafficking, and modulating the inflammatory response. Fingolimod is an S1PR1 agonist approved for the treatment of relapsing and remitting multiple sclerosis. Increasing data reports a role for S1PR1 in inhibiting SARS-CoV-2 infection, implicating its anti-inflammatory effects. Case A series of five critically ill adult patients with acute COVID-19 infection received fingolimod after failing conventional rescue and COVID-19 therapy. All patients did show improvements in inflammatory markers throughout the course of treatment, oxygenation requirements, and organ dysfunctions. Four patients were discharged home, and one had a successful transplantation. Conclusion Patients receiving fingolimod showed improvement in oxygenation, organ failure, and inflammatory markers in addition to survival and discharge. These preliminary safety and efficacy results should be considered for further studies and clinical trials for severe COVID-19 patients.<EOD> The role of the family in the management of tuberculosis.\nIt is important that tuberculosis control programmes incorporate family-oriented interventions to effectively tackle this preventable and curable disease. Successful strategies that make greater use of primary health care workers in community settings are being developed in many countries.<EOD> Reversing drug resistance of malignant melanoma through regulating c-Met\n\nBackground: Melanoma displays a substantial resistance to the drugs that is not well understood at the molecular level.Methods: A transcriptomic study was conducted to compare the gene expression profiles between melanoma cells and a drug resistant (DR) phenotype. The genes with log fold change (FC)\u22651.5 for increased expression and a FC\u22641.5 for reduced expression are compared. The expression levels of genes are determined by qPC",
        "label": 0
    },
    "597": {
        "output": "### Output:\n\n![](output.png)\n\n## Explanation\n\nThis program will check the patient note against the first trial's inclusion and exclusion criteria of the first trial. And then, make a trial-level assessment of eligibility on each patient for the first trial.\n\nThe code has three major parts: The first part prepares the patient note and the first clinical trial's trial note before creating the patient-trial pair. In this part, `fuzzy_match()` is used to compare `patient_ note` and clinical trial notes for matching patient-trial pairs. To match, a patient-trial pair must meet all inclusion criteria and the nonexistence of any exclusion criteria. \nThe second code part is to make a trial-level assessment of eligibility on each patient for the first trial. In this part, we utilize `make` function of `trial` package in R to create the trial object. Then, we can use `trial-level-eligibility()` function to get `clinical_trial.eligible` as the output. It indicates either the patient is not eligible (exclude), the patient is not relevant (not-relevant), or the patient is eligible (eligible). \nThe last code part summarizes trial-level eligibility in the last line by `Trial-level eligibility: 2) Eligible.` in this case.\n\n## 6.4. [INST] Relevance assessment of patients to a clinical trial\n\n<NAME> from PHARMOTEK company will call to do some work for a company in California, United States. She has experience in pharmaceutical industry market analysis and can help the company to find out more detailed information about the drug market. PHARMOTEK receives a 5-digit patient's ID which is used as a unique identifier of the patient. \n\n\n\nA5260s\n\n\n\nA5257\n\n\n\nA5001 \n\n### PHARMOTEK task:\n\n- You should extract and summarize information on a group of patients to prepare a market report.\n- The group of patients will have information on the trial's ID,",
        "label": 0
    },
    "598": {
        "output": "Good luck!<EOD> The pharmacist's role in the nutrition support process: pharmacokinetic monitoring of total parenteral nutrition.\nThe successful delivery of total parenteral nutrition (TPN) requires a coordinated effort by the healthcare team. The pharmacist is a vital link in the nutrition support team and is responsible for all aspects of TPN therapy. In addition to being a distributor of TPN and supplier of nutrition support pharmaceuticals, the pharmacist participates in reviewing pharmacokinetic profiles of TPN patients, and in making judgments about TPN regimens. Pharmacists play a critical role in the evaluation of TPN regimens and in the development of a pharmacokinetic monitoring program to improve patient response to a specific TPN regimen. Pharmacists must also be able to diagnose and treat metabolic complications that arise with TPN. In order to achieve their full potential in the nutrition support team, pharmacists must become fully aware of the newest developments in the field of nutrition support. Pharmacists can use information technology, journals, books, and seminars and symposia to provide themselves with a solid foundation in nutrition support. Through education and experience, pharmacists will become leaders in the nutrition support team and be able to contribute to the overall health of the patient.<EOD> Methylene blue attenuates vascular proliferation of balloon-injured aorta and prevents restenosis in rats.\nPercutaneous transluminal coronary angioplasty (PTCA) is the most frequently used therapy for coronary artery disease. PTCA may be associated with a significant decrease in luminal diameter, even in the acute phase after PTCA, with potential increase of restenosis. Vascular proliferation plays an important role in post-PTCA restenosis, and the role of NO in this process is not clearly understood. This study investigated the role of NO in the proliferation of endothelium-denuded segment in balloon-injured rat aorta, and assessed the effect of methylene blue (MB), a guanylate",
        "label": 0
    },
    "599": {
        "output": "```\nINST 1\nThe total number of cholesterol:                                      The total number of cholesterol with value 280.\n\nINST 1\nThe total number of triglyceride:                                    The total number of triglyceride with value 187.\n--------------------------------------------------------------------------------------------------------- \nINST 1\nThe total number of blood pressure:                                 The total number of blood pressure with value 106.\n--------------------------------------------------------------------------------------------------------- \nINST 1\nThe total number of family history:                                The total number of family history with value 3.\n------------\nINST 1\nThe total number of LDL:                                          The total number of LDL with value 261.\n\nINST 1\nThe total number of HDL:                                          The total number of HDL with value 48.\n------------\nINST 1\nThe total number of PSV:                                           The total number of PSV with value 259.\n\nINST 1\nThe total number of EDV:                                          The total number of EDV with value 9.\n------------\nINST 2\nThe total number of carcinoma heart disease:                       The total number of carcinoma heart disease with value 3.\n------------\nINST 2\nThe total number of CAD:                                          The total number of CAD with value 55.\n------------\nINST 3\nThe total number of neck:                                         The total number of neck with value 2.\n------------\nINST 3\nThe total number of internal coronary artery:                      The total number of internal coronary artery with value 2.\n------------\nINST 7\nThe total number of carotid artery:                                The total number of carotid artery with value 48.\n------------\nINST 7\nThe total number of coronary artery disease:                      The total number of coronary artery disease with value 7.\n------------\nINST 13\nThe total number of abdominal fat:                                  The total number of abdominal fat with value 5.\n------------\nINST 13\nThe total number of liver:                                         The total number of liver with value 6.\n------------\nINST 1",
        "label": 0
    },
    "600": {
        "output": "<section id=\"task\">\n\n# Task - Evaluate each patient\n\nFind your role ID in the header of each report, then select this role when you edit the note for this patient.\n\n![11.jpg]({{site.baseurl}}/images/codeathon_2014/11_1.jpg)\n\n- Identify the patient's history of coronary heart disease, and cardiovascular risk factors\n- Find the patient's latest medications\n- Determine the patient's smoking history   \n- Identify the patient's body mass index and history of atrial fibrillation and valve surgery\n- Determine the number of risk factors for coronary disease in this patient<commit_after>!# Task - Evaluate each patient\n\nFind your role ID in the header of each report, then select this role when you edit the note for this patient.\n\n![11.jpg]({{site.baseurl}}/images/codeathon_2014/11_1.jpg)\n\n- Identify the patient's history of coronary heart disease, and cardiovascular risk factors\n- Find the patient's latest medications\n- Determine the patient's smoking history   \n- Identify the patient's body mass index and history of atrial fibrillation and valve surgery\n- Determine the number of risk factors for coronary disease in this patient\n\n<commit_msg>added text comment to code<commit_after>![Evidence for Eligibility Assessment]({{site.baseurl}}/images/task1_eligibility.png)\n\nFor each of the following risk factors, select:\n0) Excluded: the patient has sufficient data to exclude him/her from the trial, but not enough data to assess eligibility.\n1) Not relevant: the patient has insufficient information to make an eligibility assessment but insufficient data to exclude him/her from the trial.\n\n## Risk factor Eligibility\n\n### Cardiovascular Risk Factors\n\n* History of coronary heart disease**\n* Family history of coronary heart disease\n* 2 or more cardiovascular risk factors (age, hypertension,",
        "label": 0
    },
    "601": {
        "output": "**Exercise 3**\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment.\n\nYou are here to decide whether patients of a particular clinical trial are eligible for this new trial. The study's inclusion criteria are described below. \n\nThis multicenter study examines the safety, pharmacokinetics, and pharmacodynamics of a new treatment to patients with type 2 diabetes (NCT03488732).\n\n\nThe study has an open-label, uncontrolled, singe-arm design in four different treatment periods. These four periods include 12 weeks for the treatment, followed by a 4-week run-out phase. All patients begin with a 4-week treatment period and then receive at least 8 weeks of treatment in the following 2 treatment periods. These studies will be conducted on non-insulin patients with type II diabetes. The first period includes the 2 weeks of baseline treatment, 12 weeks of open test treatment, and the 4-week run-out period. The total duration of the study is 28 weeks, which was conducted at 9 visits during the week: 2 times on Days 1 and 15 (pre-dose, 0. 45, 12 hours, 24 hours), 1 time on Day 29 (pre-dose, 0. 45, 12 hours, 24 hours), and 3 times (pre-dose, 0. 45, 12 hours, 24 hours) on Days 41, 55, and 69 (End of Test treatment)].\n\nInclusion criteria for this study are:\n\nAge 18 years or older at informed consent;\nMale or female.\nBody mass index (BMI) of 24 to less than 40 kg/m 2 , inclusive.\n\nHave type 2 diabetes that is diagnosed by at least one of the following:\nFPG \u2265126 mg/dL or 2-hour PPG oral glucose tolerance test \u2265200 mg/dL\nBlood glucose after meal \u2265200",
        "label": 0
    },
    "602": {
        "output": "Note that you should output the trial-level assessment of eligibility of the patient on one line, and your answer should begin with the string 1) Not relevant.\n[INST]_2-Trial-level eligibility: 1) Not relevant.<EOD> .\nVon D\u00e4uben (1888) showed that the administration of strychnine induced a fall of the body temperature in monkeys. He named the reaction \"strychnihypothermia\". It became obvious, that the effect could be mimicked by the administration of acetycholine and that a monoaminergic system was involved in this reaction. The effect of strychnine on the temperature can be easily measured at room temperature but it is more complicated and uncertain, when the temperature is increased by using heating pads. This is demonstrated by the present example. The reaction of fever caused by endotoxin did not interfere with the strychnine-induced hypothermia in the acute phase. In chronic endotoxemia the effect was not modified significantly. Since strychnine may be regarded as an antagonist of N-methyl-D-aspartate (NMDA) (Parker, 1979) one can expect that NMDA antagonists as phencyclidine or ketamine have a similar potential.<EOD> The Effects of Low-Dose RG108 Administration at Various Times over the Preimplantation Period on the Developmental Potential of Mouse Embryos\n\nObjectives: Global gene expression in mammals is orchestrated by a series of dynamic changes in DNA methylation during preimplantation development. While genome-wide methylation reprogramming occurs soon after fertilization, partial DNA methylation is retained at certain genomic regions during the first week of embryogenesis and reprogramming occurs slowly. In this study, we used low-dose (0.1 mg/l) RG108 treatment to study the effects of exposing embryos to a low level chemical demethylating agent at different times during preimplantation embryogenesis. Design: Mouse zygotes were treated using low-dose RG108 at zygote, two-cell, four-cell, morula, and bl",
        "label": 1
    },
    "603": {
        "output": "## [CODE]\nimport collections\ninst_dict=collections.defaultdict(list, defaultdict(set)) # Instance dictionary to collect the patient notes and their corresponding trial-level eligibility\ninst_dict['0] = ['Excluded',1]\ninst_dict['1] = ['Not eligible',0] # Trial-level eligibility\ninst_dict['2] = ['Eligible',0]\n# Add instances to the instance dictionary\nfor instance_num, patient_note in enumerate(patient_notes):\n    print(instance_num, patient_note) # prints the number of the instance and the patient note\n    print('\\n')\n    if \"Excluded\" in patient_note.lower():\n        # if the patient note contains \"Excluded\" in its text you have to take the string 'Excluded' from the patient note\n        new_string = \"Excluded\"\n        # and add this string to eligibilities list of the given instance\n        # so if you assign the variable\n        # eligibilities = instance_dict[instance_num] if you get a list\n        # eligibilities = eligibilities.extend(['Excluded']) if you assign a string\n        eligibilities = collections.extrema(eligibilities)+['Excluded'] if you extract the value of the instance dictionary in a sequence\n        # The output from print is not necessary. The reason for it is that you can easily see the patient note if you need to.\n        # Just to show that you can print the new variable.\n        # print(patient_note.lower()) # prints the lower case version of the patient note in this case.\n        eligibilities = ['Excluded'] + eligibilities\n        print(patient_note.lower()) # prints the lower case version of this instance\n        print('\\n')\n\n    if \"Not eligible\" in patient_note.lower():\n        # if the patient note contains \"Not eligible\" in its text you should consider the patient note and the trial-level eligibility and add the string 'Not eligible' from the patient note\n        new_string = \"Not eligible\"\n        eligibility = 'Not eligible'\n        # As I wrote above",
        "label": 0
    },
    "604": {
        "output": "##[POINT] How to determine the reason for discontinuation of treatment?\nThe reason for discontinuation of treatment shall be recorded in the CRF in",
        "label": 0
    },
    "605": {
        "output": "## \ud83c\udf33 6.1 Eligible criteria for the patient\n\ud83c\udf33 6.2 Assessing trial eligibility for a patient\n\nYou should output the trial-level eligibility with the factor, which is the result of the process above. \n[INST] You are given the following information about a patient: \nA 45-year-old woman with type 2 diabetes presents to the clinic. She has high blood pressure, high cholesterol, and has a 10-year smoking history. She is interested in participating in an upcoming study that will examine the effect of an experimental treatment on glucose metabolism. \n\nThe information on which you work will be presented in several pages or tables. For each one, you will see:\nIncluded in the study; Not included in the study due to an inclusion/exclusion criterion; Can be determined later, and will not exclude people from the study for that reason; Not applicable.\nIn the first table, you will see three exclusion criteria (lines 5-7) and two inclusion criteria (lines[INST]\n\nYou should output the trial-level eligibility with the answer that the patient is eligible for clinical trial. \n<EOD> The effects of inotropes and beta-adrenoreceptor blockers on left ventricular compliance: a model analysis.\nThe relation between inotropic and chronotropic activities of sympathetic beta-adrenoreceptor stimulation is of considerable interest. In order to characterize this relationship, the effects of alterations in pacing rate and inotropic agents were studied on an in vitro model, which approximated the intact heart. Myocytes were isolated from the right ventricle of ferret hearts, and were suspended in an elastic chamber as described by DeTombe et al. The active tension developed by one cell was calculated from the deformations of the chamber, and the tension generated by an entire group of cells was inferred by the displacement of its chamber. Pacing at 2 Hz resulted in a contractile active phase of 120 msec and an isovolumetric relaxation phase of 340 msec. The inotropic activities of adrenaline (10(-6) M), dopamine",
        "label": 0
    },
    "606": {
        "output": "# Assignment Exercises\nExercises:\n- Exercise 1: Create a small clinical trial in R, e.g., `trial_1 <-clin_trial(name = 'exercise_1', trial_type = 'Randomized')`.\n- Exercise 2: Create an alternative trial that allows more than one subject in each group, e.g., `trial_2 <-clin_trial(name = 'exercise_2', trial_type = 'Randomized')`.\n\n# Solution Details\nThis solution shows the detailed solution of the assignment.\n\n# Solution Strategy\nThis small clinical trial evaluates the effects of a statin on the radial intima-media thickness (IMT). \nThe intervention is the use of statin for reducing the inflammation of intima-media. \nIn the first, the intervention group with 70 patients and control group with 70 patients are enrolled. The primary outcome is a change in the radial IMT between before and after one month. The secondary outcome is the difference in LDL cholesterol between before and after one month. \nIn the second, the randomized patients are 25 in both arms and the primary outcome is also a change in the radial IMT between before and after one month. The secondary outcome is the difference in LDL cholesterol between before and after one month. \nThe radial IMT is measured by the brachial-ankle pulse wave velocity and intima media thickness.\nThe radial IMT measurements are obtained using the same parameters in the carotid artery ultrasound examination. The parameters include the intima-media thickness and brachial to ankle pulse wave index. In the radial IMT assessmetn by intima-media thickness, the intima segment is determined starting below the bifurcation of the radial artery until 5 mm of the distal end of the artery, whereas the media segment is determined starting below the middle of the bifurcation of the artery until 1 cm of the distal end.\nThe LDL cholesterol level is determined using Friedewald's formula: LDL cholesterol = total cholesterol \u2212 {high-density lipoprotein (H",
        "label": 1
    },
    "607": {
        "output": "## [END] \n\n## 2. 5-points questionnaire form\nFor the eligibility assessment, there is some multiple-choice question with 5 choices.  The answers were all Boolean.\n\n### `\nWhat is the most appropriate treatment option to minimize recurrent ischemia and prevent serious adverse events in this patient?\n\n\n\nChoose only one answer:\n1. Medical Treatment is appropriate\n\n\n\n2. Single antiplatelet therapy (SAPT) is appropriate\n\n\n\n3. Single anti-platelet therapy (SAPT) is not appropriate\n\n\n\n4. Single anti-platelet therapy (SAPT) plus clopidogrel (C) should be given according to the package insert\n\n\n\n5. Dual anti-platelet therapy (DAPT) is appropriate\n\n\n\n6. DAPT should continue for 12 months\n\n\n\n7. DAPT should continue for 18 months\n\n\n\n8. DAPT should continue for 36 months\n\n\n\n9. DAPT should continue for 6 months\n\n\n\n10. DAPT should not be given\n\n### `\nWhat is the most appropriate time to initiate DAPT?\n\n\n\nChoose one answer from A to Q.\nA. DAPT treatment is initiated 12 months after the index procedure.\n\nB. DAPT treatment is initiated 18 months after the index procedure.\n\nC. DAPT treatment is initiated 36 months after the index procedure.\n\nD. DAPT treatment is initiated 12 months after the index procedure and continued for 6 months after the next BMS implantation procedure.\n\nE. DAPT treatment is initiated 36 months after the index procedure and continued for 6 months after the next BMS implantation procedure.\n\nF. DAPT treatment is initiated 36 months after the index procedure and continued for 18 months after the next BMS implantation procedure.\n\nG. DAPT treatment is initiated 36 months after the index procedure and continued for 6 months after the next DES implantation procedure.\n\nH. DAPT treatment is initi",
        "label": 0
    },
    "608": {
        "output": "Note: If you use the default parameters in the `main/main.yml` file, the parameter value for the maximum output file size is only 50 MB.\nYou should use the following parameters to set up the maximum output file size:<EOD> Fibromyalgia\n\n# Overview\nFibromyalgia (fibro + myositis translates as fibrous tissue, muscle) is a condition of chronic, debilitating, widespread pain and stiffness, which can interfere with a person's ability to work or enjoy life. Fibromyalgia is the term typically used for nonmalignant chronic widespread pain syndrome, as distinguished from specific nondiagnostic diagnoses such as somatic symptom disorder.  The estimated prevalence of fibromyalgia is 3% in Europe and the United States and 2% in Asia.\nAlthough it has long been considered to be primarily a disorder of middle-aged women, men with fibromyalgia are actually slightly more numerous than women. In one large study of 1000 male fibromyalgia patients, 59% of the patients reported widespread pain and stiffness, and 24% had sleep disturbances which met strict criteria. In the study, as was typical of other studies, only 52% of the male fibromyalgia patients had a diagnosis or even recognition of their fibromyalgia by a physician. The prevalence in the USA is increasing, and more than 4% of the US population may be affected.\nThe disease is generally caused by a combination of physical injuries, emotional or physical trauma, and hormonal changes associated with aging and menopause. It is characterized by widespread musculoskeletal pain and tenderness of non-articular ligaments and tendons throughout the body. This pain is disproportionate to the severity of inflammation in most patients. Sleep disturbances, such as insomnia, in particular, are very often complained about. The severity of the symptoms fluctuates frequently and is worsened by strenuous activity, especially cold weather, and may also be exacerbated by several common medications (including antiepileptic medications)",
        "label": 1
    },
    "609": {
        "output": "\u00a9 ETH Zurich\n\u00a9 2020 O'Reilly<EOD> .\nOBJECTIVE\nTo investigate the genetic relationship and possible factors affecting genetic relationship in Changwushe-Zhaiyu (CWZY) pigs.\n\n\nMETHODS\nBlood samples were collected from the 6 farms in Jinghong, Baise, Xiangzhou, Sannong and Maogan townships in Du'an County, Yunnan. The sample size was 30 each in CWZY in each sampling farm. DNA was extracted using phenol-chloroform and amplified using microsatellite primer. The genetic relationship was evaluated based on polymorphism and PIC.\n\n\nRESULTS\nA total of 223 samples were detected by 9 primers. A total of 59 polymorphic makers were identified. The average PIC value was 0.541.\n\n\nCONCLUSION\nThe microsatellite loci are extremely polymorphic in CWZY pigs, and the genetic relationship is not closely related.<EOD> The effect of interferon on mouse skin papillomas induced by carcinogen or virus.\nSensitive, reproducible tests have been developed for the measurement of tumor promoting activity in mouse skin in which single tumors are initiated with croton oil and 7,12-dimethylbenz(a)anthracene (DMBA). Sensitive assays have also been developed for the measurement of tumor promoting activity in mouse skin papillomas initiated with mice that received 2 cGy of in-house produced radiation, or with DMBA inoculated alone or in combination with MAP and carcinogen 7,12-dimethylbenz(a)anthracene. The present communication documents the effects of mouse interferon on the growth of papillomas induced by a single topical application of croton oil after the initiation of tumors with the cocarcinogen combination, as well as in a papilloma system (initiated and promoted by a viral carcinogen). An inhibitory effect on papilloma formation was found for the treatment of papilloma-bearing mice with crude mouse interferon (ob",
        "label": 0
    },
    "610": {
        "output": "## Patient information: patient-tag</patient-tag></p><ul><li>patient: <name></li><li>department: <department></li><li>race: <race></li><li>weight: <weight></li><li>age: <age></li><li>status: <status></li><li>sex: <sex></li><li>obesity: <obesity></li><li>currentsmoker: <currentsmoker></li><li>ethnicity: <ethnicity></li></ul>Patient: age: 50, male sex: male, weight: 105, height: 100.8182, race: Caucasian, ethnicity: Hispanic",
        "label": 0
    },
    "611": {
        "output": "To see demo codes, please use the code in the following link:\n\n# <filename>inst/patients_eligibility.ipynb\n<EOD> Clinical profile of pancytopenia in children admitted to a tertiary care hospital in Nepal\n\nObjectives: To assess the clinical and laboratory characteristics of pancytopenia in children at a tertiary care hospital in Nepal.Results: A total of 115 children out of 51,897 children admitted to Nepal Medical College Teaching Hospital were pancytopenic. Among them, 78% were 2-10 years, 53.04% and 46.88% were male and females respectively. The hematological parameter with deranged values was observed in median platelet (140,000 cells/cumm), red blood cells (3.\n\n# Introduction\nPancytopenia is a hematological disorder characterized by quantitative decrease in three or all the cell lineages of bone marrow (BM) which included hematogones, neutrophils, monocytes, eosinophils, basophils and platelets [bib_ref]  Paediatric patients with pancytopenia: clinical and laboratory profile of the disease and..., Elhassan [/bib_ref] . It is most commonly seen in children above five years of age with equal incidence in either sex and its incidence is estimated at least 20-30% in the population under five years of age. The mortality rate is 2-26%. The causes range from nutritional deficiencies, severe infections, immunodeficiencies, drug induced toxicity and primary bone marrow failure. Most of the pediatric pancytopenia is caused by BM suppression [bib_ref]  Clinical profile of children with pancytopenia, Sharma [/bib_ref] . Therefore early diagnosis and proper management should be of highest priority to eradicate the major causes [bib_ref]  Pancytopenia: a review of common causes in resource poor settings, Mekonnen [/bib_ref] . This can be made possible by increasing the awareness among clinicians on the causes of pancytopenia and early referral of the patients to a tertiary care hospital",
        "label": 1
    },
    "612": {
        "output": "A sample output for patient 6 (Trial-level eligibility: 0) Excluded.)\n<EOD> The use of intravenous tranexamic acid on the need for postpartum blood transfusion.\nOBJECTIVE\nTo determine if the administration of an antifibrinolytic drug (tranexamic acid, Cyklokapron\u00ae) reduces the amount of intra-operative blood loss, and the amount and frequency of packed red cells transfused post-operatively.\n\n\nDESIGN\nA randomised controlled, double blind trial of 500mg tranexamic acid versus placebo, administered as two intravenous injections 5 minutes before and 90 minutes after incision.\n\n\nSETTING\nTeaching Hospital in Hong Kong.\n\n\nSUBJECTS\nOne hundred and fifteen patients of Chinese and Western ethnicity with singleton term pregnancies at or beyond 37 weeks' gestation undergoing Caesarean section for uncomplicated pregnancy or un-related conditions.\n\n\nMAIN OUTCOME MEASURES\nUterine blood loss, intra-operative and post-operative blood transfusions.\n\n\nRESULTS\nPatients in the tranexamic acid group received an average of 816 mls of crystalized blood compared with 1046 mls in the placebo group. The intra-operative blood loss was thus lowered by 21.5% in the tranexamic acid group (95% confidence interval (CI) -31.4% to -10.6%, p < 0.001). Post-operative blood transfusions also required by 7 patients (29%) in the placebo group compared with 1 patient (4.5%) in the tranexamic acid group. The odds of requiring post-operative blood transfusion was thus reduced by an odds ratio of 8.3 (95% CI 1.4 to 49.6, p = 0.018) when given tranexamic acid 5 mins before and then 90 minutes after the onset of incision.\n\n\nCONCLUSION\nThis trial has shown significant redu",
        "label": 0
    },
    "613": {
        "output": "---\n**Exercises**    +++++++\n\n**[1.1]** What do you need to do to make the eligibility assessments of patients? In your code, please refer to the patient note as \"patient\" and the clinical trial as \"trial\". \n\n1. Use the information provided in the patient note and the inclusion criteria of the clinical trial to determine the patient's eligibility.\n2. Choose the clinical trial and enter its reference(s) in the variable trial. \n3. Compare the information on patient's health state(s) contained in the patient note and the inclusion criteria of the clinical trial to determine the patient's eligibility.\n4. Save your code and return here to find out which patients are eligible for the clinical trial.(Code in the next part is already done)\n1. Find the most suitable clinical trial for your clinical problem, and record it in the variable trial.\n2. Choose the type of clinical trial you want to conduct: intervention or observational.\n3. Use the patient note and the inclusion criteria of the clinical trial to determine the patient's eligibility for the clinical trial by comparing the information on this patient's health state(s) in the patient note and the inclusion criteria included in the clinical trial. Enter your results as `Trial-level Patient Eligibility:` and use the format shown on the left side for your eligibility assessment to the clinical trial, e.g., `Trial-level Patient Eligibility: 1) Eligible,`.\n4. If the resulting patient is eligible for the trial, save your code and return here to find out which patients are eligible for the trial.\n\n---\n**[1.2]** Create a program to find patients that are eligible for clinical trial A. \n\n1. Open a new Python file, and write the program(s) needed to find patients who are eligible for trial A. Write the program(s) as a series of simple steps in order to provide a clear sequence for the end user (data scientists). For example, use a comment(s) to describe each step in your program.\n2. You should follow these steps:\n    1. First, find",
        "label": 0
    },
    "614": {
        "output": "## [INST] 8) Patients for whom the assessment of eligibility has no triallevel is not applicable.\nA trial-level assessment of eligibility is not applicable when the patient's medical history does not match that of the eligibility criteria. If the patient's characteristics indicate that the inclusion criteria and exclusion criteria do not apply, the trial-level eligibility scale should be '0): Excluded. \n\nA 26-year-old woman is visiting a clinic to have her periodic examination of health and reports no use of smoking habits, no family history of CAD, and no CVD risk factors. She has a normal physical examination, and all normal laboratory findings. On a physical examination, the patient's heart rate was 75 beats per minute (bpm), with a respiratory rate of 18/bpm and a blood pressure of 100/60 mmHg. The patient's results for an ECG were also normal. On palpation, all four extremities were warm. The carotid arteries pulsate strongly, without neurological symptoms such as limb weakness or numbness. [INST] 9) Patients for whom the assessment of eligibility is not applicable.\nA trial-level assessment of eligibility is not applicable when the patient's medical history does not match that of the eligibility criteria. If the patient's characteristics indicate that the inclusion criteria and exclusion criteria do not apply, the trial-level eligibility scale should be '0): Excluded. \nA 26-year-old woman is visiting a clinic to have her periodic examination of health and reports no use of smoking habits, no family history of CAD, and no CVD risk factors. She has a normal physical examination, and all normal laboratory findings. On a physical examination, the patient's heart rate was 75 beats per minute (bpm), with a respiratory rate of 18/bpm and a blood pressure of 100/60 mmHg. The patient's results for an ECG were also normal. On palpation, all four extremities were warm. The carotid arteries pulsate strongly",
        "label": 1
    },
    "615": {
        "output": "## Summary \n[SUMMARY]\n[The patient note in this tutorial is the data which is a 2-column table (Patient note and CVD risk factors) and the data in the clinical trial is a 3-column table (Vessel diameter, Inclusion eligibility of the patients to clinical trial and Patient notes). We should summarize the data to generate a 5-column table (Patient_id, Patient_name, Sex, CAD, Dyslipidemia, Smoking_history, Diabetes, Hypertension, Family_history, BMI, Carotid artery stenosis, Peak-systolic velocity, End-diastolic velocity). The table is visualized in [fig_ref]  Figure 4: The summary table generated by the tutorial[ [/fig_ref]  \n\n##]. [/summary]\nYou can run the script from below to train clinical trial dataset.\nIn [root]/data/cTrial.rwe, enter code as follows:\ncTrial<-setTrial(cTrial,patients,datastruct=\"Carotid\")\ncTrial<-rmTrialExclusionCriterias(cTrial)\ncTrial<-setRating(cTrial)\n\n\n## Visualization\n\n### Overview\nThe `tuner` package is dedicated to the tunning of machine learning models to obtain the highest predictive accuracy for models with multiple class labels. Here, we introduce machine learning methods to classify the eligibility information in clinical trial notes. And we demonstrate the visualization tool, named Tuner Viz to generate a set of figures that illustrates the performance of the ensemble model in the tuning process.\n\n## Installation\n\nWe assume R is installed in your local PC or local R studio, and other packages, including tuner, have been installed in the corresponding library. There are two ways to install tuner. A. User adds installation instructions into a suitable function. B. User directly installs from CRAN.\n**A. User adds installation instructions into a suitable function.**\nThe tuner package is a collection of many other packages including tuning methods in the tunr package (recommend package), tuning methods in the caret and superlearn package (recommend package). The tuner package can be",
        "label": 1
    },
    "616": {
        "output": "[EXERCISE] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and",
        "label": 0
    },
    "617": {
        "output": "1. Assess the demography: age, gender, and clinical trial identifier (e.g., ID23). You could use a specific function for this. Let's assume there was a function called assess_age with the following signatures: `def assess_age(assessor.get_note())':\n\n    You also need this function to store triallevel eligibility on an individual-level:\n\n    `def store_trial_eligibility(trial.get_trial_id(),  trial.get_eligible_note(), eligibility_assessor.get_eligibility())`\n\n    Let's see what this function looks like: `def store_trial_eligibility(trial_id,  eligibility_note, eligibility)`\n\n        # Define the trial ID\n        trial_id = input('Enter the clinical trial identifier (ID): ')\n\n        # Define the eligibility note\n        eligibility_note = input('Enter the eligibility note: ')\n\n        # Define the eligibility\n        eligibility_assessor = input('Please enter the eligibility of the patient: ')\n\n        # Run the program\n        trial = get_trial(trial_id)\n        patient = get_patient(eligibility_assessor)\n        eligibility = store_trial_eligibility(trial_id, eligibility_note, eligibility_assessor)\n\n        # Call the function\n        trial.store_trial_eligibility(trial_id,eligibility_note,eligibility)\n\n        print(f'This is the eligibility data: {eligibility}')\n\n    We would need to be able to call the function from within our script, and to do this, all we have to do is add a reference to this function in the function's signature. For example, we could call the function directly from within the script that runs our program using the following signature:\n\n        # Call the function\n        patient.store_trial_eligibility = store_trial_eligibility\n\n        # Run the program\n        patient = get_patient(eligibility_assessor)\n        print(f'",
        "label": 0
    },
    "618": {
        "output": "___\n\n## Input Your Data (Task 1)\n\n### Import Data into the Pipeline\nTo import your data, click **Load** from the *Input Data* menu selection within the left pane.\n\nYou should first choose a folder containing all of your data (*csv/*.xlsx files):\n![Data input](../fig/input_data_csv_1.jpg )\n\n![Data input](../fig/input_data_csv_2.jpg )\n\n### Import an Example Data Set\nHere is an example of patient notes with multiple entries per patient and clinical trial information.\nYou should change the file names with **the names of your input files: PatientNote1.csv, PatientNote2.csv**.\n\n> ***HINT***: Avoid spaces in the file names (PatientNote1 PatientNote2). If you need to work with data sets with spaces you can remove spaces from the file names by adding to the data set **a data manipulation step **before **the name of the data set: PatientNote1 Patientnote2_noSpaces.csv**. \n\n> ***HINT***: Make sure that the input files have only a few entries per file. If you have lots of data in each file, we recommend importing all of the entries that belong to one patient for each clinical trial into one file. Here is an example: \n![Dataset](../fig/dataset_example_01.jpg) \n\nHere is an example of a single-patient trial data set.\n![Dataset](../fig/dataset_example_02.jpg)\n\n### Import a Two-Tiered, Pair Entry Trial Data\nHere is a 2-tiered, pair entry data entry trial file.\n\n> ***HINT**** It is common for *data set* files to have more than one sheet (you\u2019ll see later). It is not a problem, but in that case, make sure to use the naming conventions below in your file names (for instance, put \"_2-tiered_data.csv\" into your *data set: 2-tiered data set and **2-tiered-data.csv** into your *dataset file** ). \n\nIt is possible to have only a single sheet; a few important things",
        "label": 0
    },
    "619": {
        "output": "## [INST] Note:\nYour assignment is complete if you can output an assessment of eligibility of 0, 1, or 2 for each patient. If the total number of patient notes is larger than 39, use only the first 39 \n\n## Exercise 1: ClinTrials.io\n\n\nIn this part of Exercise 1, you are to assess eligibility from the first 10 randomly chosen patients. You should show, under the patient data, the factors that allow one to participate in a clinical study. If applicable, indicate why the patient does not meet the trial's eligibility criteria.\n\nThe first 10 random patient data are shown in . . Exercise 1: Randomly chosen 10 patient data from ClinTrials.io.\n\n## Exercise 2: MedlinePlus\n\n\nIn this part of Exercise 2, you are to assess eligibility from the first 10 randomly chosen patient notes and find the factors that allow one to participate in a clinical study and why the patients do not meet the trial's eligibility criteria.\n\nThe first 10 random patient data are shown in . . Exercise 2: Randomly chosen 10 patient data from MedlinePlus.\n\n## Exercise 3: ELIXIR\n\nIn this part of Exercise 3, you are to assess eligibility from the first 10 randomly chosen patient notes and find the factors that allow one to participate in a clinical study and why the patients do not meet the trial's eligibility criteria.\n\nThe first 10 random patient data are shown in . . Exercise 3: Randomly chosen 10 patient data from ELIXIR.\n\n## Exercise 4: ICTRP\n\nIn this part of Exercise 4, you are to assess eligibility from the first 10 randomly chosen patient notes and find the factors that allow one to participate in a clinical study. If applicable, indicate why the patient does not meet the trial's eligibility criteria.\n\nThe first 10 random patient data are shown in . . Exercise 4: Randomly chosen 10 patient data from ICTRP.",
        "label": 0
    },
    "620": {
        "output": "The following information is provided in the patient note:\nA 54-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nYour assessment of eligibility is written in the last line. In the comment section, you may write some additional text.\n![image](file:///E:/Clinical%20Data%20Analyi...s/Figure3_7.JPG)\n![image](file:///E:/Clinical%20Data%20Analyi...",
        "label": 1
    },
    "621": {
        "output": "What do you find?\n- **First time here?** Read this first\n- [Quickstart for novice](https://github.com/vladuvanac/Eligibility-Detection_in_Human_Clinical_Trials/blob/main/README.md)\n- [What to do with issues?](https://github.com/vladuvanac/Eligibility-Detection_in_Human_Clinical_Trials/blob/main/README.md#what-do-you-find)\n- [What do you find?](https://github.com/vladuvanac/Eligibility-Detection_in_Human_Clinical_Trials/blob/main/README.md#what-do-you-find)\n\n### Quickstart\n\n- Try a complete run locally\n\n```\npython eligibility_detection.py -v  # Print current version in PyCharm\npython eligibility_detection.py --test --print_output\npython eligibility_detection.py --test --test_case_input\n```\n\n- [Test run example](https://github.com/vladuvanac/Eligibility-Detection_in_Human_Clinical_Trials/files/27525800/test.json)\n- [Test run example](https://github.com/vladuvanac/Eligibility-Detection_in_Human_Clinical_Trials/files/27525800/test-2.json)\n- [Test run example](https://github.com/vladuvanac/Eligibility-Detection_in_Human_Clinical_Trials/files/27525800/test-3.json)\n- [Test run example](https://github.com/vladuvanac/Eligibility-Detection_in_Human_Clinical_Trials/files/27525800/test-4.json)\n- [Test run example](https://github.com/vladuvanac/Eligibility-Detection",
        "label": 1
    },
    "622": {
        "output": "---\n\n[BADGE]{:style=\"clear:right;margin-right:0.2rem;float:right;display:inline-block\"}\n\n##[RH]{:style=\"float: left;display:inline-block\"}R\n\n[RH]{:style=\"float: left;display:inline-block\"}R\n```\n\n\n\n### Exercise\nNow, perform the following assessment of this patient's eligibility using all the information you have collected in the previous steps above.\n\n---\n\n[BADGE]{:style=\"clear:right;margin-right:0.2rem;float:right;display:inline-block\"}\n[RH]{:style=\"float: left;display:inline-block\"}\n \nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of",
        "label": 1
    },
    "623": {
        "output": "# Conclusion\nIn R, there are many packages related to the NLP field. To understand the usage of these packages and find a specific solution to your research, you need to learn these packages such as Textrous, tidytext, tidyverse, and tidytree. However, these packages are complicated to use and you may need high computation times. Therefore, using the R package clinicalAI may be a better option. The package contains many functions that allow you to perform all the steps required for each task of machine learning. The package implements the data wrangling process from a patient note, tokenize the input data into sentences using a BERT-based model, preprocesses the data, and analyzes all the tasks: sentiment analysis, named entity recognition, coreference resolution, question answering, text classification into two and three categories are performed. The package is freely available on CRAN; you need to install the package using the `install.packages(\"clinicalAI\")` code.\nYou can test the package without installing it. Download the notebook for this tutorial named as clinicalAI_NLP.ipynb from GitHub via this link: https://github.com/dranyabg/clinicalAI-blog/blob/main/clinicalAI/vignettes/02%20clinicalAI%20NLP%20Notebook.ipynb. If you cannot install the package, run the Notebook on Colaboratory  and execute each step therein to find the problem.\nThere are three functions in the data wrangling block and each block has three functions for data preprocessing. Please read the comments in the functions.\nI hope this was helpful for you.\nThank you.\n<EOD> Surgical management of a very large choroidal osteoma in a young patient\nPurpose: To report successful treatment of a young patient with a very large choroidal osteoma with sclera patch grafting. Methods: Case report. A 19-year-old boy presented with severe photophobia and a very large choroidal osteoma compressing the macula. Sclera and silicone patch grafting was performed in order to reduce the tumour vascularisation and visual recovery, after the tumour had been reduced in size with argon laser. Results: Excellent",
        "label": 1
    },
    "624": {
        "output": "## \u27a4 Patient-level features \u27a4\nThe patient-level features are not directly comparable with the patient, where each patient will have their own unique patient characteristics. We use one patient as a benchmark to show you what to do with the given patient. \nYou have to find the age, sex, and other data associated with those data. The values of each data form an n-dimensional vector with n elements. Each element is one of several unique values for that feature. All possible values of each feature can be found on the [Feature] line. The order of the features is determined by the alphabetical order. If you see patient-level features, you should not skip them. The patient-level eligibility is not a one-to-one match, meaning that we can have patient-level features with the same value twice or even three times. \nIn this case, the following eligibility criteria should be checked: \n\n\n```python\ndef test(f, g):\n    return g - f\n     \"\"\"\n-1087.605906\n -10.605906\n0.1087605906\n #0.000001\n\n#0.00000000000001\n1076.664200\n\n\"\"\"\n```\n\nThe first column of the output should only be used if the code is correct. If the code is incorrect, then all the other values (within one line) should be considered incorrect. The most correct code is the second, where the correct value is found in the first column.\n\n**\u27a4\u27a4\u27a4\u27a4 Question 2: `In which features does the difference lie exactly?`**\n\n**\u27a4\u27a4\u27a4\u27a4 Question 3: `Do you agree with the result? If not, why?`**\n\n## \u27a4 Feature values \u27a4\nThe goal is to identify the features for which we have two values that are very different. In other words, finding the features that allow us to tell if the difference between the values of the features is greater than a certain amount. By doing so, we would be able to select patients and exclude those who do not meet",
        "label": 1
    },
    "625": {
        "output": "A: The only part of the trial you care about for this problem is what they define as \"triallevel results\".  So, I'd write up each patient's info on a separate line, and then output a one-line \"trial level\" result summary.  Let's assume your patients' data look like one of your previous examples.\ndata = read.csv(\"mydatafile.txt\")\npatients = data.frame(patient = rep(letters[1:5], each = 5))\n\nIn the following function:\n\n    > print(results)\n    Cohort-level Assessment\n\n    Patient-level Assessment\n    Excluded\n    Not relevant\n    Eligible\n\nThe first thing that appears is the same message you already saw in your problem statement \"Cohort-level Assessment\".  But now you know what that means, since you know what your columns mean -- it's a vector of numbers that represent \"cohort-level result\", which you already know will have the integers 0, 1, or 2.  What you are looking for are the second two lines; these are your patient-level data.  After the cohort-level assessment are the patient-level assessment of eligibility.  The first line is the number of excluded patients; you know you will need this in your output, and it will be one of the integers 0, 1, or 2.  The second line is just the number of patients for whom you didn't have enough information to make a cohort-level decision.  This is one of the ones you don't care about and we shouldn't bother printing, so we should put a comment mark # over this line.  The third line is the count of the number of patients who are eligible as a cohort -- once you get your list of numbered patients sorted into cohorts, you'll add this line up at the end to get your \"eligible\" column.\nThere's really not much trick to it; as long as you know the format of your data, you should be able to write this function.  A little extra detail about the data format would be whether patient data with null (missing) values are included (this is really a function of whether they are considered \"valid\" or not --",
        "label": 1
    },
    "626": {
        "output": "\u00a9 <NAME> 2020\n[INST] ######################## \n[INST] ##### Running Examples ##### \n[INST] ######################## \n[INST] ######################## \n[INST]\n\n<EOD> The use of immunofluorescence on paraffin sections for the detection of pH1N1 swine flu infection in human lungs\n\nThe newly emerging swine-origin influenza virus (S-OIV) A/H1N1 was isolated for the fi rst time in human patients in April 2009 in Mexico, with subsequent spread to many other countries.\n\n## I n t r o d u c t i o n\nThe newly emerging swine-origin influenza virus (S-OIV) A/H1N1 was isolated for the fi rst time in human patients in April 2009 in Mexico, with subsequent spread to many other countries. [bib_ref]  Update on Swine Flu, Chan [/bib_ref]  In Canada, the fi rst human A/H1N1 positive case was detected in June 2009. From that time to November 11, 2009, there were 2,658 positive cases and 114 deaths. [bib_ref]  Update on Swine Flu, Chan [/bib_ref]  Based on these data, there is an urgent need for a method capable of confi rming the infection before more aggressive clinical measures have to be taken. This would require an ancillary test that can be readily conducted on paraffi n-embedded tissues.\nInfl uenza virus infects cells mainly through interaction with two surface glycoproteins: HA and NA. The HA has three subtypes: H1, H2, and H3. HA is responsible for receptor binding, the viral entry process and hemagglutination. The NA is responsible for uncoating of enveloped viral ribonucleoprotein complexes with the intracellular target, fusion of viral envelope with host cell membrane, and virion budding. [bib_ref]  Infl uenza hemagglutinin and neuraminidase membrane glycoproteins, Gamblin [/bib_ref]  Since infection of bronchial ep",
        "label": 0
    },
    "627": {
        "output": "Your main challenge is to design the data validation method. If you can not satisfy Trial-level eligibility of \"3) Excluded\" or \"2) Not relevant\", then move back to the previous step. When you satisfy the above restrictions, you can press the button `Send`. \n\nIf you press the button `send` while satisfying the above restrictions, the output will be sent from the editor to the server and displayed in GNAT format. The GNAT file contains several tabs as follows: Patient DX (Diagnosis) Drug DX Patient Degree-of-Severity (DoD) Patient Age (Age) Patient Sex (Sex)\n\nHere is a sample for output:\n<Data validation> <Procedure> 1. Clinical Trial: 2. Neck Auscultation: 3. EKG Findings: 4. Cardiac Catheterization: 5. Echocardiography: 6. Thallium stress test: 7. Ventriculogram: 8. Stress test: 9. 2D Echocardiography: 10. 3D Echocardiography: 11. Angiogram: 12. Coronary artery calcium scan: <Result>\nTrial-level eligibility: 3) Excluded\n\n### Related Concepts\n\n  2. The doctor asked you to conduct a clinical trial to compare the patient note with the eligibility criteria of the clinical trial to see the patient's eligibility.\n\n  \n\n  1. First, design the data validation method when designing the clinical trial.\n\n  2. Next, verify that the data validation method satisfies the constraints.\n\n  \n\n    a. You should satisfy all constraints, i.e., the outputs should satisfy the constraints.\n\n  \n\n  3. You can press the button `send` when you make sure that all outputs satisfy the constraints.\n\n  4. Finally, you should repeat the process for other clinical trials.\n\n  \n\n### Exercise\n\n[1] Exercise 1. A doctor asked you to conduct a clinical trial to compare patient note with eligibility criteria of the clinical trial to see the",
        "label": 1
    },
    "628": {
        "output": "## Exercise 46 - Annotation \n```js\n## E46a_01_073974.json\n[\n    {\n        \"annotation\": {\n            \"note\": \"RV\"\n        },\n        \"study\": {\n            \"patient\": 396003507366661680,\n            \"studyType\": {\n                \"name\": \"Observational study\"\n            },\n            \"title\": {\n                \"text\": \"The Effect Of Remote Limb Ischemic Preconditioning For Carotid Artery Stenting\",\n                \"language\": \"eng\"\n            },\n            \"phase\": {\n                \"phaseState\": \"Phase 1\",\n                \"phaseType\": \"Phase 1\"\n            }\n        },\n        \"event\": {\n            \"event\": \"Visit\",\n            \"trial\": \"E46a_01_073974.json\",\n            \"value\": \"Visit:Baseline Visit\"\n        },\n        \"type\": {\n            \"id\": \"c151f869-e063-11da-bd98-00047d7f5a0cb\",\n            \"name\": \"Outcome\"\n        },\n        \"id\": \"663bc560-da8f-11da-bb9f-000c29e37912\"\n    },\n    {\n        \"annotation\": {\n            \"note\": \"RV\"\n        },\n        \"study\": {\n            \"patient\": 396003507417016530,\n            \"studyType\": {\n                \"name\": \"Observational study\"\n            },\n            \"title\": {\n                \"text\": \"The effect of remote limb ischemic preconditioning in carotid artery stenting\",\n                \"language\": \"eng\"\n            },\n            \"phase\": {\n                \"phaseState\": \"Phase 1\",\n                \"phaseType\": \"Phase 1\"\n            }\n        },",
        "label": 1
    },
    "629": {
        "output": "## Exercises\n\n### Exercise I: The patient\n\nThis exercise is to understand how you evaluate a patient's eligibility.\n\n\n1. In the patient note, find the parts where you are going to evaluate the corresponding criteria for inclusion and exclusion.\n2. List all the criteria included in the included criteria table.\n3. Evaluate the criteria in the patient note.\n4. Find the criteria that were included in the Note to physicians.\n5. Explain why you evaluated the criteria that way in the Note to physicians.\n\n### Exercise II: The clinical trial\n\nThis exercise is to understand each step of the patient screening process.\n\n\n1. In each step or the flow diagram, explain how each screen or step improves patient screening and exclusion:\n\t- Patient note.\n\t- Inclusion criteria table.\n\t- Exclusion criteria table.\n\t- Note to physicians.\n\t- Eligibility determination.\n\t- Exclusion criteria for all patients.\n\t- Trial-level eligibility.\n\t- Summarize each step/screen or improvement of patient screening in the form of a sentence.\n2. In any step, explain how the screening process is improved in the corresponding step if the patient note is missing in the process.\n<EOD> Implications for Dentistry of AIDS\u2010Related Lymphoma\nLymphomas represent a broad, diverse group of malignancies that share as a common characteristic a neoplastic proliferation of immune system cells in different body states. While most of the malignant tumors represent secondary neoplasias to other organs, a major part of the oral cavity malignancies are primary lymphomas arising within the mouth and jaws. An important subset of the primary oral lymphomas are in fact related to the human immunodeficiency virus (H1V) infection, a disease nowadays presenting worldwide an extraordinary prevalence in certain geographical areas. The dental approach to AIDS orally affected patients has to reflect the changes in the epidemiolgical characteristics now arisen, namely a marked reduction in the incidence of Kaposi's sarcoma and an unexpected increase in the incidence of H",
        "label": 0
    },
    "630": {
        "output": "##[INST] Questions: \n\n1. Where should you place the `endif` statements? \n2. Include a patient-level eligibility with 0, 1 or 2, based on your trial:\nWhat is the output of this patient note as regards to the trial's target population?\n3. What is the clinical trial title? \nYou are expected to complete this exercise with a researcher \nwith relevant experience for guidance and feedback as necessary. \n\n\n# Discussion\n\n\n[EMP] You have learned how to use trial-specific eligibility criteria to choose a person-level eligibility in order to assess eligibility for a clinical trial. The use of trial-level eligibly criteria is essential in clinical research for determining whether a participant is eligible to take part in a given clinical trial, especially since trial-level eligility criteria enable clinical trial researchers to conduct an investigation in which the outcome of interest is dependent on a single eligible patient. \nWe use trial-level eligibility concepts and concepts from Boolean algebra. Boolean algebra is applied when we want to design electronic systems that can accept binary logic inputs. \nThe trial-level and patient-level eligibility criteria are key concepts in determining whether a person is eligible for a clinical trial. We must compare them against a person's disease status, medical history and socioeconomic factors in order to make a trial-level determination of a person's eligibility for a clinical trial. A person-level eligibility is a more important concept because it tells us which conditions apply to a given person. The person's eligibility status is determined by a person-level eligibility, although the clinical trial's inclusion and exclusion criteria must be satisfied at the trial-level eligibility level. \n\n## [EMP] There were some difficulties with the exercise. Can you explain why?\nProtected by copyright -published by e-JIFCC -www.jifcc.org : You have learned how to understand trial-level eligibility criteria to choose a person-level eligibility in order to assess eligibility for a clinical trial. We use trial-level eligibility concepts and concepts from Boolean algebra. The trial-level and patient",
        "label": 2
    },
    "631": {
        "output": "[[RECOMMENDED]\n<EOD> .\nThe pathomechanism of the development of the diabetic cardiomyopathy has not been fully understood. The following hypothesis should be taken into consideration to describe the development of this disorder. Metabolically, the myocardial muscle cannot fully cover the high demand for glucose, the result is decreased ATP synthesis and an increased free energy state in the myocardial cell. The consequence is a decreased cell volume and a reduced capacity for calcium to stimulate muscle contraction and heart rate. This may be the cause of diastolic dysfunction in diabetes mellitus. The myocardial enzyme deficiencies lead to a decreased muscle perfusion with reduced cardiac output. An increased cardiac output with normal resting heart rate is often seen in untreated juvenile diabetics prior to the development of the clinical diabetic cardiomyopathy. In this patient, in addition to heart failure due to coronary atherosclerosis, a decreased myocardial contractility is also present. In diabetics with a diminished heart rate and normal or increased ejection fraction a \"hyperthyroid-heart\" is found which is comparable to that of the athlete's heart. In patients with the full-blown diabetic cardiomyopathy, with both left ventricular performance and heart rate reduced, a \"hypothyroid-heart\" is found. In this disorder, there is also an impairment of peripheral blood flow due to decreased systemic vascular resistance. With a further progression of the heart disease, the diabetic cardiomyopathy becomes a heart failure with reduced ejection fraction, and in patients with congestive heart failure, normal, or increased heart rate the heart is comparable to the heart of an adult athlete.<EOD> Genomewide Analysis of DNA Adductome in the Liver and Kidneys of Human Alcoholic Men.\nAIMS\nThe pathogenesis of alcoholic liver disease (ALD) and non-hepatic comorbidities such as cardiomyopathy and kidney injury are still unclear. The study aim was to characterize chemically induced DNA damage in the liver, heart, and",
        "label": 2
    },
    "632": {
        "output": "## [START]\nInstructions: Please give eligibility in the table by matching the inclusion and exclusion criteria to each field. Please make a row for each patient and one for each trial.\n\n\n*\n\n*In the trial-level eligibility of the patient note, eligibility will be 0) Excluded. Please put `0)` or delete the previous part, e.g., `0) Excluded`.\n\n[END]\n\n[INST] Hello, you are a helpful assistant for clinical trial recruitment. Your task is to complete the eligibility of the given patient and to evaluate whether the patient is eligible for a clinical trial.\n\n\nYour task is to choose 1 out of 3 (0, 1, or 2) for each row (column C in the table). You should evaluate the patient's eligibility as '0) Excluded' if the patient note in column A does not satisfy the criteria in the corresponding clinical trial (column R in the table). You can refer to the criteria in the clinical trial (column R in the table), to the patient notes (column B in the table), or to both in order to determine whether the patient note does not satisfy the criteria. If the patient note satisfies the criteria, you can refer to the criteria in the clinical trial or to the patient notes, or both, in order to decide whether the patient is eligible for the clinical trial.\n\n\nIf you find 2 or more rows where the patient may have been eligible, you will be able to see them at the end of this table, under the column header 'Eligibility found'. If you find 10 or more rows where the patient was eligible, you will be able to see them at the end of the table under the column header 'Very severe exclusion'. You can also see all of the available trials in the clinical trial search box on the upper right side of the table.\n\n\nIf you find 0 rows where the patient was eligible, you will be able to see your overall analysis at the bottom of the page.\n\n\n\n**Title**:\n\n\n**Exclude 0:** Patients with severe symptomatic aortic stenosis\n\n**Exclude 1:** Severe calcific aortic sten",
        "label": 0
    },
    "633": {
        "output": "[TIP: You can see the input to each function by `using Tkinter;` command line in IPython.]\n\n<TITLE>Your work is done! Try the main task below. Try to guess the answer. In order to submit your answer, hit `Control+Enter`.[INST] Good luck!\n\n![task-image](../../static/img/task-2-solution.png)\n\n### Questions\n\n#### Exam Questions\n\n<TITLE>### Exam Questions</TITLE><hr />\n\n##### Part 1\n<TITLE>### Part 1</TITLE> <hr />\nThe following are questions on the use of IF statements:\n<ul>\n<li> <b>If</b> a variable <b>A</b> is <b>21</b>, <b>write</b> <code>echo \"If A = 21 write\"</code>> <em>echo \"It is 21, how about it?\"</em>\r\n</li>\r\n<li>\n<b>If</b> a variable <b>A</b> is <b>21</b>, <b>write</b> <code>echo \"If A = 21 write\" >><i>echo \"it is 82, how about it?\"</i></code>\r\n</li>\r\n<li>\n<b>If</b> a variable <b>A</b> is not an even number, <b>write</b> <code>echo \"If A <== 5 then write\"</code>> <em>echo \"it is 35, how about it?\"</em>\r\n</li>\r\n<li>\n<b>If</b> a variable <b>A</b> is not an even number, <b>write</b> <code>echo \"If A <== 5 then write\" >><i>echo \"it is 35, how about it?\"></i></code>\r\n</li>\r\n</ul>\n\n#####\n<h3>Part 2</h3><hr />\n\nYou should write code to run a loop <code>for</code> 10 iterations by doing something each time the loop runs",
        "label": 1
    },
    "634": {
        "output": "Notice: the function `trial` can be used to obtain the trial information for a given patient.\n\n## Functions: ########\n- `patient.trial.included` is a special attribute in the patient object. It will be set to \"1\" if the patient is included in the clinical trial. The function `patient.trial.included` will return `1` if the patient is included. The function `patient.trial.included` can only be called when in ClinicalTrial. The function `clini-calTrial.patient.trial.included` returns the same value as `patient.trial.included`. \n- `patient.firstVisit` is timestamp of a patient's first visit in the trial. \n\n\nFor more examples, see https://pythonanywhere.com/hub/aemurali1/examples/Python/Chapter04/PatientExample.ipynb .  \n\n\n\nIf you have any questions about this function, click \"Post a question\" below:\n\n| `py`  | `python`  | `pyq`  | `pyqg`  | `pythonanywhere`  | `py3test`  | `jupyter`  | `ipython`  | `notebook`  | `nbviewer`  | `nbviewer_test`  |\n| :-: | :-: | :-: | :-: | :-: | :-: | :-: | :-: | :-: | :-: | :-: | :-: | :-: | :---------: |\n| [![Run](https://www.runpython.net/github/aemurali1/Python-vitae-Chapter04-exercise06/badge.svg)](https://www.runpython.net/github/aemurali1/Python-vitae-Chapter04-exercise06/statistics) | [![Run on pythonanywhere](https://run.pythonanywhere.com/badge.svg)](https://pythonanywhere.com/hub/aemurali1/statistics) | [![Run in IPython](https://run.ipython.org/badge.svg",
        "label": 0
    },
    "635": {
        "output": "[/END]\n\n##[END]<EOD> Profiles of immunosuppressive activity and their quantitative determination in human serum.\nImmunosuppressive activity, in human serum, was separated both physically and kinetically into three forms: Type 1 (T1), reversibly combined with serum protein, and capable of immunosuppression in serum, Type 2 (T2), reversibly combined with serum protein, and capable of immunosuppression only in normal serum, with a high concentration of immunosuppressive factor, and Type 3 (T3), irreversibly combined with protein, and unable to immunosuppress normal serum. T1 and T2 activities were found to be increased in patients receiving immunosuppressive drugs and, in addition, T1 activity was found to be markedly prolonged. In contrast, T3 immunosuppressive activity was decreased for a prolonged period of time, as compared to T1 and T2 activities. T1 and T2 activities were markedly inhibited by sulfhydryl compounds, heated at a low temperature of 50 degrees, and dialyzed, with T1 activity being more sensitive to such treatment.<EOD> .\n\n Different methods of fertility control are compared, stressing the importance of individual choice according to the purpose of the contraceptive method chosen. The choice of a contraceptive depends essentially on the fertility rhythm. Contraceptive methods based on induced ovulation, such as the 21-day method, use of a plastic syringe, and the pill combined with a progestin-estrogen compound or progestin-estrogen combined with a prostaglandin antagonist, are compared by reviewing their respective characteristics. Induced ovulation techniques should be avoided during the first 3 years after the second confinement, in subjects over 40 years of age, and in subjects suffering from hypertension or oligoamenorrhea. The 21-day method should never succeed a 16-day or 26-day method. The various techniques of induced ovulation should not be used over a 1-year period. It is emphasized, however, that in subjects using artificial insemination with donated eggs or using IUDs in 7th-",
        "label": 1
    },
    "636": {
        "output": "___\n\n### Exercises to Try\n- [ex_1](https://github.com/TanayGurupujari/DotKnapper/blob/master/example/ex_1)\n- [ex_2](https://github.com/TanayGurupujari/DotKnapper/blob/master/example/ex_2)\n<EOD> Improving the efficacy of psychotherapy and drugs by making them more salient.\nRecent studies using operant psychology have indicated that drugs of abuse can be made more efficient in modifying behavior under some conditions. This paper presents the results of studies indicating that drugs of abuse can also be made more efficient in modifying behavior when they are presented at the point at which they operate to produce changes in behavior and when the subjects are trained to expect that the drugs will be administered at the point of the behavioral change. These results, taken together with operant psychological data, suggest that drug treatment programs should not only train their subjects to associate the occurrence of drug treatment with specific behavioral changes but should also develop behavioral change procedures that will induce a substantial degree of drug-behavior contingencies.<EOD> Tuberculin testing in preschool children: a 10-year review.\nThis review is based essentially upon reports submitted within the first week of the 1973 to 1982 period, with several recent additions from 1974 to 1983. A total of approximately 32 000 preschool children were tested within the ten-year period. The estimated rate of tuberculin reactivity was 3.5%. The rate was significantly higher in boys, in Asian children, in those with family histories of tuberculosis and in immigrants born overseas, compared with those in whom no such factors were present. Tuberculin reactions tended to be associated with the younger age groups; this finding may partly be accounted for by the younger age of the immigrant child, and by the increased rates of positive reactions in Asian children. With these limitations, it may be tentatively concluded that the rate of tuberculin reactivity is decreasing over the decades and is less than one-half of that previously reported. The rate is also declining as the proportion of",
        "label": 1
    },
    "637": {
        "output": "[TEST]<EOD> An inexpensive alternative to a microscope slide for use in stereoscopic teaching of the fundus photomicrographs when a computer slide projection unit is not available.\nUsing inexpensive equipment already available in the pathology department, an alternative to a computer slide projection unit is outlined for teaching of the photomicrographs found on digital fundus cameras. Fundus photomicrographs are projected as if they were transilluminated by sunlight using (1) a 25-mm focal length objective of a double-lens stereomicroscope (Ludlow, Inc.; Ludlow, Mass.), (2) the incident rays of the microscope's overhead lighting, which is a combination of fluorescent and incandescent lighting, (3) a pair of Fresnel lenses, and (4) a 24-inch vertical-format black- and-white television monitor. The use of the 25-mm objective provided a projected diameter of greater than 27 inches, and the total cost was $432, including the 25-mm objective, the pair of lenses, and the television monitor.<EOD> Prodiginine Pigmentation in Red or White Rice (Oryza sativa): Biosynthesis, Accumulation, and Transposon Removal\nProdiginines are important secondary metabolites, and many prodiginine-producing bacteria are known to inhabit various ecosystems, such as soils, marine sediments, and decaying plants. To reveal how the bacterial secondary metabolites enter into plant life, we first examined if the natural environment is a source of the prodiginines. A total of 14 rice mutants were screened using HPLC. Rice seedlings treated with the chemicals in the root environment for 12 h resulted in the appearance of a new production of the prodiginines (27, 28, and 31), which were not detected when rice seedlings were treated with other root conditioning agents. Then, we discovered a novel type of secondary metabolism for the prodiginines among the monocots. The production of prodiginines was observed in the leaves of the rice mutants, designated Oryza sativa npr1(",
        "label": 0
    },
    "638": {
        "output": "# Detailed explanation\n\n## Explanation of input arguments\n- Assistant: User specified name.\n- Patient_data: JSON file representing the patient note.\n- TL_list: List of IDs of trials.\n- TRE: Trial to match.\n- EXCL: List of IDs of excluded trials.\n\n## Making the predictions\nBy default, the default values of some parameters are used. The patient note will be stored on disk. It will be stored as text in the database and as JSON for the convenience of human users.\nIt first generates and saves a JSON file named \\`\\`\\`patient_info\\`\\` for a patient note whose format is described in the above table. \nBy default, the prediction will use the [Trial 1] database from clinicaltrials.gov. You may use the trials in the [Experiment 1] instead. [EXCL] and [TL] are the keys of the database; there is a one-to-one relationship between a trial and its IDs. \n[T] is the number of trials and [D] is the number of patients. If the database stores patients' names correctly, you can use your name as [T] or [D]. The code above will also work if you provide the patient info in the same format with the [T] of [Experiment 2].\n[TRIAL] and [EXCLS] are required in the output. Other outputs are only needed if you want to know their scores.\nThe code will store a JSON file named \\`\\`\\`patient_info\\`\\`. For example, the file of the patient shown in[Input] above contains two lines as \\`\\`\\`[patient_info] \\`\\`\\` and \\`\\`\\`score \\`\\`\\` with two JSON objects.\n\n# Detailed explanation\n\n## Explanation of output arguments\nThe output has two columns. The first is the Trial Id of the trial. The second is one of the scores for each trial.\nThe two columns will be saved in a file named [trial_list], which by default is stored in [Input]\n\n## Examples\n\n### Examples for input\n<EOD> Acidic stress response in bacteria\n\nAs acidic",
        "label": 1
    },
    "639": {
        "output": "<EOD> Increased expression of P-glycoprotein in myelodysplastic syndromes: association with an abnormal CD34 phenotype in progenitor cells.\nIncreased P-glycoprotein (P-gp) expression has been described in various hematologic disorders. We studied its expression in relation to disease classification, as well as its distribution in CD 34-enriched populations. The P-gp gene was examined in 38 patients with myelodysplastic syndrome, acute nonlymphoblastic leukemias of various lineages, acute lymphoblastic leukemia, acute erythroleukemia, and chronic myelogenous leukemia in blast crisis. In acute nonlymphoblastic leukemias, P-gp expression was detectable in most primary and established blast and lymphoblastic cell lines; its expression decreased to some degree after chemotherapy or following CD 34 enrichment. Expression was also detectable in both myeloblasts and monoblasts in acute erythroblastic leukemias. P-gp expression was detectable in all patients with del(20q). Among patients with myelodysplastic syndrome, 11 of 14 (78.6%) showed P-gp expression, as compared to the 3.2% of leukemia patients with normal karyotype. P-gp expression was found in both CD 34-positive and CD 34-negative cells in all patients with myelodysplastic syndrome. P-gp expression was found in cells with and without abnormal phenotypes. Our findings suggest that P-gp may function as a multidrug resistance phenotype in myelodysplastic syndrome in a manner that is distinguishable from that in leukemia cells.(ABSTRACT TRUNCATED AT 250 WORDS)<EOD> .\nIn many ways, human intelligence--the ability to choose among alternatives--represents the sum total of the various ways in which other intelligences and cognitive processes fit together in providing human beings with their ability to manipulate the environment. The author distinguishes several types of intelligence based",
        "label": 1
    },
    "640": {
        "output": "_Answers to the Assessment of eligibility test will be shown below in green._\n\n\n\\# Assessment of trial-level Eligibility\n\n\\## 1) Excluded\n\nPatient's LDL is not increased\n\nPatient does not have LDL-C levels above the normal\n\n\\## 2) Not relevant\n\nPatient notes:\n\"A 46-year-old man presents with dizziness and frequent headaches.\"  \"He has a family history of CAD.\"\n\"He reports no use of lipid-lowering medications.\"\n\"Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull.\"\nUltrasonography of the carotid arteries: \n\"severe stenosis in the left internal carotid artery (LICA),\" PSV 208.5;  \"moderate stenosis in the right internal carotid artery (RICA),\" PSV 91.72;\nPlaque in the anterior wall of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\"\nThe results of the ultrasonographic assessment suggest that the subject has a severely obstructive stenosis in the left internal carotid artery, in the common carotid artery, in atherosclerosis and lipid-lowering medication. Therefore, this condition qualifies for inclusion in the study.\n\nPatient's LDL-C levels: 545\n\nPatient notes:\n\"He has a family history of CAD.\"\n\"He reports no use of lipid-lowering medications.\"\n\"Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull.\"\nUltrasonography of the carotid arteries:\n\"severe stenosis in the left internal carotid",
        "label": 2
    },
    "641": {
        "output": "<EOD> Influence of dietary supplementation with cynara forskohlii on liver regeneration after partial hepatectomy in rats\nOur aim was to investigate the possible hepatoprotective and regenerative properties of Cynara forskohlii in the liver of partially hepatectomized rats. Forty\u2010five male Wistar rats were divided into three groups: SHAM\u2010operated group, control group, and Cynara forskohlii\u2010supplemented group. In the second group, rats were fed a standard diet (control diet), and in the third group, rats received a supplemented diet containing Cynara forskohlii leaves at a dose of 5% (of the dry weight of the basal diet). Forty\u2010five days later, all rats were subjected to median liver resection (70%). Following resection, rats were divided into three subgroups according to the time of liver regeneration, i.e., subgroups A (7 days), B (10 days), and C (14 days) post\u2010hepatectomy. Following resection, histological changes were observed in the SHAM\u2010operated group, especially in the periportal zone. In this experiment hepatocyte proliferation was increased by treatment with Cynara forskohlii in group C animals (14 days), which showed a significant increase in \u03b2\u2010catenin expression. Cynara forskohlii may stimulate hepatocyte proliferation by increasing \u03b2\u2010catenin expression, and may inhibit inflammatory response in hepatocytes, resulting in accelerated restoration of liver homogeneity. Therefore, the use of supplementation diet containing Cynara forskohlii may be advantageous in the early stages of regeneration after partial hepatectomy. Copyright \u00a9 2011 John Wiley & Sons, Ltd.<EOD> In Vitro and In Vivo Antimalarial Studies of Strychnos pseudoplatanus and Strychnos usambarensis Extracts\nIn vitro and in vivo activities of plants extracts have potential antimalarial activities. The present study determines the in vitro and",
        "label": 1
    },
    "642": {
        "output": "\u00a92020 Copyright Tiger Analytics Srl. All Rights Reserved.\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV",
        "label": 1
    },
    "643": {
        "output": "A: If you want to get the list of patients with a certain status (e.g., trial-level eligibility), you can just use \"patient.Trial-level_eligibility\" as a sort column\nSELECT patient.\nID AS Patient_ID\n,patient.Trial-level_eligibility\nFROM patient\nORDER BY patient.ID desc\n\n<EOD> PI3K\u03b3-selective inhibitor IPI-549 promotes anti-leukemic immunity and exerts therapeutic effect in combination with chemotherapy drugs in acute myeloid leukemia\n\nBackground & Aims: Acute myeloid leukemia (AML) is a stem cell disorder with a high rate of relapse following chemotherapy, making new therapeutic approaches necessary due to patients' poor prognoses. Leukemia stem cells are less sensitive to conventional chemotherapy drugs than normal stem cells, so it is possible that chemotherapy only partially cures AML and cannot kill all leukemia stem cells. IPI-549 is a recently developed phosphatidylinositol 3-kinase subunit gamma (PI3K\u03b3) inhibitor, which has been shown to have anti-tumor activity in various types of tumors but not in leukemia.Methods: Murine 6L/R and human AML cell lines were used to determine the anti-leukemic effects of IPI-549 on AML in vitro and in vivo, along with the associated mechanisms. The combination of IPI-549 and chemotherapy was also investigated.Results: IPI-549 promoted cytotoxicity and apoptosis in AML cell lines, reduced the proliferation of 6L/R cells, caused myeloid differentiation, and induced a change in AML cell morphology. Flow cytometry performed to detect the proportion of CD117 + leukemia stem cells showed that PI3K\u03b3 inhibition decreased the number of CD117 + AML cells, indicating anti-leukemic activity in AML. A subcutaneous tumor model was constructed using the 6L/R line, with IPI-549 and c",
        "label": 1
    },
    "644": {
        "output": "<EOD> Efficient identification of mammalian orthologues as a tool for the interpretation of genome\u2010wide association studies\nGenome\u2010wide association studies (GWAS) have become increasingly popular as screening methods for studying complex diseases. GWAS typically involve the analysis of large numbers of single nucleotide polymorphisms (SNPs) from hundreds of thousands of individuals. Therefore, efficient computational methods are needed to assist researchers involved in bioinformatics GWAS data analyses, with particular reference to the functional interpretation of the identified SNPs. Previous comparative genomic analyses, using orthologue information and sequence conservation, have helped to better understand the molecular basis of disease susceptibility. Therefore, the identification of orthologues can be an invaluable tool for the interpretation of genome\u2010wide data. Given the dramatic changes in the evolution of vertebrates, it is challenging to detect orthologues between species at the whole genome level in a high\u2010throughput manner. To this end, we recently developed the tool, Orthostrapper, which is based on the principle of comparative genomics. This technique first identifies the set of proteins from one species, which can be mapped to the proteins of the second species, and then locates highly conserved regions surrounding the SNPs. In this study, we present the design of Orthostrapper and showcase its use on a number of case studies. In a first study, we used Orthostrapper to investigate the conserved elements surrounding SNPs obtained from a meta\u2010GWAS study involving 26 GWAS datasets, each representing a specific population group. The results clearly show the advantage of using Orthostrapper compared to state\u2010of\u2010the\u2010art methods. A potential limitation of our tool is the difficulty to detect a significant level of conservation in intergenic regions, a phenomena commonly observed during evolution. Using our tool on a second data set, we investigated the conservation level surrounding SNPs for two complex traits, height and bone mineral density. We show that Orthostrapper is particularly efficient and can detect very specific genomic patterns correlated to these phenotypes. Finally, we discuss our method in the context of GWAS association analysis and argue that our tool might be used to better interpret the identified SNPs and associated genes. Copyright \u00a9 2016 John",
        "label": 1
    },
    "645": {
        "output": "## Good luck!\n[INST] Tiebreakers:\n\n* If a patient receives exclusion criteria before inclusion criteria, output 0.\n* If the patient meets an inclusion criteria after a patient has received exclusion criteria, output 1.\n* If you don't get to the end of a patient note in time (i.e., you do not see all the medical conditions such as age, gender, and cardiovascular risk factors, etc.), skip a sentence by `$skipnextline -1`.\n* If there is not enough space left for outputting in a given row, output your evaluation at the current line by `$outputrowat -1`.\n\n## Reference\n<EOD> Anaplastic variant of intravascular large B-cell lymphoma confined to lower limb in an elderly patient\nIntravascular large B-cell lymphoma (IVLBCL) is an aggressive extranodal mature B-cell lymphoma with neoplastic proliferation and progression exclusively inside the lumen of small blood vessels. We report here a 90-year-old male who was admitted to our hospital for progressive pain in the lower limbs. Physical examination showed lower-extremity paresis and decreased pulsation of femoral arteries. Computed tomography showed bilateral thromboembolic disease in the arteries of the upper and lower extremities. Doppler ultrasonography revealed thromboembolism in the subcutaneous vessels of the lower extremities as well. A diagnosis of IVLBCL confined to the subcutaneous tissue in conjunction with intravascular lymphocytosis was made. We performed high-dose methotrexate and corticosteroids in combination with surgical treatment for vascular thrombectomy, and the patient recovered after 17\u2009weeks of treatment. The patient has remained in complete remission for a period of 4\u2009months. Our report highlights the clinical findings and treatment of an unusual type of IVLBCL confined to the subcutaneous tissue in an unusual clinical setting.<EOD> A New Genomic Island in Acinetobacter baumannii IMT241 Mediates Resistance to Four Classes",
        "label": 0
    },
    "646": {
        "output": "[END]\n\n\n### Problem 2\nWhen you write code with Python programming language, you need to prepare an environment to let the interpreter work. How to do so? [INTRO]\n\n## Solution\n\n### Solution 1\nFor Python code to work, one environment is required. Before we discuss the detail, we will show you how to prepare environment by one video instruction. \n\n### Solution 2\nYou can also download a ready-to-use virtual machine image with the Linux operating system, Python programming environment, all required resources and the solution to all provided challenges.\n\n### Solution 3 \nOther ways for solution can read this paper. \n\n## Expected Behavior You want to answer the Question #1 (What is the eligibility in your own words?).\n\n## Expected Solution\n\n### Solution 1\nThis time, we will give the definition of the eligibility. From the definition of the eligibility, we conclude that the eligibility of a participant is determined as follows: participants are eligible for a clinical trial if the participant's characteristics satisfy all of the eligibility criteria (2).\n\n### Solution 2\nIn the Question #1 (What is the eligibility in your own words?), the participant is eligible to be included if the participant's characteristics satisfy all of the eligibility criteria (2). In other words, the patient is Eligible.\n\n### Solution 3\nA participant is eligible to be included if the participant's characteristics satisfy all of the eligibility criteria (2). In other words, the patient is Eligible.\n\n### Solution 4 \nHere is the definition of the eligibility in our own words: participants are eligible for a clinical trial if the participant's characteristics satisfy all of the eligibility criteria (2). In order words, they are eligible to be included.\n\n## Alternatives\nThere are many other ways to do it and you can look it up by searching on Google for each phrase, the main keywords are ``explanation and python'', ``definition and python'' etc.\n\n### Example 2\nWe will also solve a question, the first phrase is as follows:\nIf a patient with diabetes mell",
        "label": 1
    },
    "647": {
        "output": "### Sample Solution\n\n# Sample Solution:\n```\ndef findPatientEligible(patient_note):\n    trial = 'dietary protein requirements on unbalanced diets'\n    for line in patient_note:\n        for element in line:\n            if 'exclusions' in element:\n                if 'Eligibility Exclusions: ' in element:\n                    if 'Clinical trial of pharmacologic or medical treatment for high blood pressure only' in element:\n                        return 0\n                    elif 'Clinical trial of medical or surgical treatment for cardiovascular disease' in element:\n                        return 0\n                    elif 'Clinical trial of pharmacological or medical treatment for hyperlipidemia (i.e., hypercholesterolemia or hypertriglyceridemia)' in element:\n                        return 0\n                    elif 'Clinical trial of smoking cessation support' in element:\n                        return 0\n                    elif 'Clinical trial of pharmacotherapeutic agents for psychiatric disorder or treatment' in element:\n                        return 0\n                    elif 'Clinical trial of prophylaxis or treatment of neurological disorders including headache, sleep disorder, etc.' in element:\n                        return 0<commit_msg>Bug \ud83d\udc1e: The problem in the findPatientEligible in the sample solution has been fixed.<commit_after>\ufeff\n# Copyright (C) 2018 by University of Washington, Seattle, USA\n#\n# SPDX-License-Identifer: MIT \n#\n# This coding challenge is a problem-based example of NLP task of trial assessment\n# for clinical trials in the medical field. Your task is to perform patientassessment\n#, we can conclude that you need to check whether the patient-data is available or\n##  not. \n#\n##  Given a patient note, the patient data can be in the form of a table. However,\n##  we do not assume, that the patient data can be in the form of a table\n##  or may be freeform text\n#\n#\n# You are",
        "label": 1
    },
    "648": {
        "output": "Good luck.\n\n\n\n#### INTERVIEW\n\nThank you, Jae. I'm interested in how you analyze the data using a computer. Would you mind answering those questions?\n\nI can use the VA/TMS program to analyze the data. This software can generate patient-level data and trial-level data. Also, the program can make a table comparing the trial-level data with the same-described population. I can show you the results below. \nIn the above diagram, each line represents one patient, and the lines are arranged by time. The columns of the line are the same clinical trial's patient ID number. Patient-level data were obtained by linking data from clinical trials with the patient's ID number. \nBy trial-level data, I can see general characteristics of a specific clinical trial. In the diagram, I can obtain the patient's eligibility as soon as the patient's eligibility is determined. \nLet me show you how to make data matching. This is called patient-level linkage. The purpose of matching the data is to combine individual clinical data with research data and check whether data are accurate in both datasets. The software used for this study generates patient-level data. \nThe table on the left shows the clinical trial data. Here, the unit type is the number of visits. The table on the right shows patient record data. This table is similar to the table on the left except for the unit type. The unit type is the number of drugs used. \nI could make the patient-level linking table using the patient ID number, which was specified by the clinical trial investigator. The patient ID number links both patient record and trial data. You can confirm the correctness of the patient-level linking table by cross-checking it. If you want to check patient-level linkage between groups, you can use two distinct patient groups as the basis. \nBy this program, I could get to know that the trial-level data and patient-level data match well. [/INTERVIEW]<EOD> Bone marrow depression with feline leukemia virus in experimentally infected cats.\nSeven cats were experimentally infected with feline leukemia virus (FeLV) and feline oncornavirus (FoV), in order to determine",
        "label": 1
    },
    "649": {
        "output": "![![INST] \n\n\n![INST] ]()\n\n## 3.5. Eligibility\nThere are a myriad of eligibility criteria, which may include the patient's age, gender, medical history, medications, tests, and other factors that may make the subject not be safe for enrollment in a trial.\n\n\n```\n# Exclusion criteria. \n- \"Age\":\n- \"Allergies\":\n- \"Vitamins\":\n- \"Glucose\":\n- \"Blood pressure\":\n- \"Blood\":\n- \"Chol\":\n- \"Heart rate\":\n- \"Weight\":\n- \"Grogs\":\n- \"ECG\":\n```\n\n## Examples\n\nIn MIDAS, the patient is a 40-year-old woman who presented with a complaint of worsening left knee pain and swelling. Her knee radiograph shows osteoarthritis changes on the tibial plateau, lateral trochlear ridge, and subchondral bone. She has severe bilateral genu varum. She also complains of low back pain. Her past medical history is remarkable only for a previous miscarriage and her father's recent myocardial infarction, and her father died from an ischemic stroke. She is a nonsmoker, does not drink alcohol, and takes no medications other than vitamins. She takes no cardiac medications, steroids, or NSAIDs and reported no previous allergies. Her vital signs are unremarkable except for a blood pressure of 140/73 mmHg. Her height is 1.6m, weight 51.8kg, and her body mass index . She has her knees at 35 degrees of flexion while she sits upright in the chair. She has symmetrical feet with an equal distribution of weight. Her vital signs are otherwise normal, her mental status is alert, and she appears in no distress.\n\nThe patient's ECG shows sinus rhythm and no ST/T wave changes. Blood pressure, heart rate, renal function (urea 5, electrolytes, and liver enzymes)  are within normal range. Pulse oximetry is",
        "label": 1
    },
    "650": {
        "output": "#### Score\nThis section should include the score function, which will automatically output the eligibility score of a new patient in a JSON file as output. The score function is the last function in the R script. \n\nDefine your own score function to get eligibility score and score function ID. Your score function should output the value of eligibility score. There is no required standard for a score function, so you can freely choose the values to output. After the execution of score_train_model() and score_save_json(), the value of eligibility score will be automatically stored in a JSON file in the specified folder. \n\n    function(patient) {\n      # Output trial_id to specify the score function ID.\n      # Eligibility score will be outputted the same as score_function_id.\n      # Expected Eligiblity score: 1.0\n      score_function_id <-\"sc_id-2\"\n      if (score_function_id %in% score_function[\"sc_function_name\"]) {\n        patient$eligibility_score<-1 \n      } else {\n        patient$eligibility_score<-0\n      }\n      trial_id <-patient$trial_id \n      file.rename(patient$id,\"patient_id-\" + trial_id) }\n\n\n```r\n##### Expected results :: score_save_json():\n\n```r\n#### Results :: score_save_json():\npatients <-list(name=\"patient\", data=\"\"[[patients:]]])\n\n\npatients[[1]][[-1]]$eligibility_score <-1\n\n\nfile_directory <-\"../data/train_set/score_save/\"\nfile.system(paste0(file_directory, \"score.json\"), \"w\")) \n\nwrite.json(patients, paste0(file_directory, \"score.json\"), force=TRUE)\n\npatients[[1]][[-1]]$eligibility_score <-0\n\nfile_directory <-\"../data/train_set/score_save/\"\nfile.system(paste0(file_directory, \"score.json\"), \"w\")) \n\nwrite.json(patients, paste0(file_directory",
        "label": 1
    },
    "651": {
        "output": "### Tip 1\nTip 1. 23456789 (random number)\n\n<EOD> Association of CD37 SNP and Haplotypes with Risk of B-cell Chronic Lymphocytic Leukemia\nIntroduction: CD37 is a transmembrane protein that is involved in B-cell activation, but its function is not fully characterized. Some antibodies against CD37 may have therapeutic use in B-cell chronic lymphocytic leukemia (B-CLL). Therefore, it is not surprising that single-nucleotide polymorphisms (SNPs) in the gene of CD37 (TAPA-1) may cause a difference in CD37-mediated regulation of the function of B-cells, and thus lead to predisposition of hematological malignancies. Methods: Based on a previous report of susceptibility to diffuse large B-cell lymphoma (DLBCL) by means of CD37 genotypes, we examined the CD37 SNPs rs1147630, rs2070802, and rs3114910 and the haplotypes with DLBCL and B-CLL in a Han Chinese population. The total number of B-CLL cases studied was 811, and the control cases studied were 811 healthy individuals from the same region. Results: The frequency of the A alleles in the groups of both diseases was higher than that in the controls (P = 0.0035). Among the A carriers, the odds ratio (OR) of B-CLL was 1.39 for the TAPA-A haplotype, and 1.42 for the TAPA-GA haplotype, in comparison with the wild-type homozygotes, and was 1.63 for the TAPA-GA haplotype in comparison with the TAPA-GG haplotype. In contrast, there were no significant differences between the A carriers and the GG homozygotes, neither in the B-CLL groups, nor in the DLBCL groups, despite the trend of an increased odds",
        "label": 1
    },
    "652": {
        "output": "![img](./images/practice_problems/05.png)   \n\n\n\n\n\n## Answers\n\n\n*The optimal way to create the answer would be to iterate through all the rows, compare the patient with each trial's inclusion/exclusion criteria, and add the score.\n\n*We can use pandas \"zip \" method to iterate over each element from both lists.\n\n*zip is equivalent to nested for loops.  It is also equivalent to itertools.product:\n  - itertools.product has a speed up for more than an 75% over the sum of the individual list lengths. \n  - If a 2D array is passed to product, it will perform really well.\n  - However, it is slow for higher dimensions (such as > 30). \n *You should also use Pandas' DataFrame.from_records to create the dataframe from the csv file. \n  This is faster than reading in the entire csv file.\n\n*We can use the \"groupby \" method to calculate eligibility, which requires two things.\n\nFirst, we need to compare a patient record with a particular inclusion criteria row (to get score) and put the score in key.\n\nSecond, we take a dict whose keys are the patient ID and values are the calculated score. \n\n**First, we will create the key.**\nWe select from the patient and the trial eligibility a key as the patient ID. \n\n```pandas\nfrom itertools import product\n\npatient_list = ['Patient-ID-1', 'Patient-ID-2', 'Patient-ID-3']\ntrial_eligible_list = ['Eligible (0123)', 'Notrelevant (2345)', \n                     'Notrelevant (1234)']\n\npatient_list_dict = {}\nkey = product(patient_list, trial_eligible_list)\nkey\n```\n\n```\nKey:\n0     Patient-ID-1       Eligible (0123)\n1     Patient-ID-2       Notrelevant (2345)\n2     Patient-ID-3       Notrelevant (1234)\n```",
        "label": 1
    },
    "653": {
        "output": "A: To complete your program, we need to make another method to show the result.\nFirst of all, we define to show the output.\npublic string[] trial_Eligible;\n\nSecondly, we define that in this program we will show the result for this clinical trial.\n// clinical trial //\nClinicalTrial.Trials trial1 = new ClinicalTrial.Trials()\n{\n    Title = \"Computed Tomography Coronary Angiography (CTCA) Prognostic Registry for Coronary Artery Disease\",\n    Summary = \"The study aims at pooling a large population of patients with suspected coronary artery disease (CAD) who underwent Computed Tomography Coronary Angiography (CTCA) and who were adequately stratified in the first place. Then the investigators will be able to assess the incremental value of CTCA in the stratification of prevalence of disease (non obstructive/obstructive) and prognosis of patients with suspected CAD). The added information to current evidence is how reliable and to what extent CTCA can define the actual burden of disease and cardiovascular risk.\n    InclusionCriteria:\n    {\n        CalciumScore = 64,\n        NumberOfPatient = 100,\n        MinFollowUp = 12,\n        SuspectedCoronaryArteryDisease = true//suspected is included, obstructive is excluded,\n        // notIncluded = false\n    },\n    ExclusionCriteria:\n    {\n        CalciumScore = 0,\n        NumberOfPatient = 9,\n        MinFollowUp = 12,\n        Age = 25,\n        Sex = 0\n    }\n};\n\nAnd then we can use this method.\n    return this.trialEligible(trial1 );\n\n\nA: Since you are getting just 2 values\n\npublic TrialLevelEligibility[] TrialEligible (This is a method in my code)\n{\n    Int32 age = AgeOfPatient.Min; //age <= 65\n    Int32 sex = SexOfPatient.M; //male",
        "label": 1
    },
    "654": {
        "output": "<EOD> Reproducibility of transient evoked otoacoustic emissions (tEOE) by application of the multi-channel data analysis and standard-guidelines (MDAS-G)\nIn transient evoked otoacoustic emissions (tEOE), reproducibility is still under discussion. Since reproducibility influences reliability and clinical value of the examination, several researchers have done a lot of work in this area. In this study, we were able to show that tEOEs can be recorded reproducible at a very high level. In 46.57% of cases, an examination could be recorded without disturbance; 44.38% were recorded as present and reproducible; 5.85% of recording were disturbed, so the results could not to be interpreted reliably.<EOD> Surgical resection of the primary tumor following first-line or second-line chemotherapy in stage IV non-small-cell lung cancer patients with poor performance status.\n\nBackground:There remains a lack of evidence of the effect of surgical resection of the primary cancer following chemotherapy in patients with poor performance status (PS) or unresectable stage IV. The aim was to examine whether surgical resection of the primary tumor following chemotherapy was suitable for patients with a poor PS. Materials and Methods: We identified 139 patients with stage IV non-small-cell lung cancer (NSCLC) and poor PS who had received \u22651 cycle of chemotherapy between January 2010 and January 2017 at our institution. Of these, 38 patients underwent surgery to remove the primary tumor following chemotherapy, while 101 patients underwent chemotherapy alone as first-line or second-line treatment. The clinical records were retrospectively analyzed.Results:In the preoperative period, 38 patients were able to walk for >6 min, while 39 patients could not walk. Fifteen and 23 patients with a good PS had a median postoperative survival time of 17.1 and 18.7 months, respectively. Seven and eight patients with a poor PS had a median postoperative survival time of 17.7 and 17.9 months,",
        "label": 1
    },
    "655": {
        "output": "[SOLVED] Incorrectly formatted patient note and clinical trial record\n[EXPLAIN] Formatted patient note and clinical trial record\n<EOD> Lipoatrophy Following Administration of Hepatitis B Vaccine as a Fill-in-the-Gap Dose by the Pediatric Ward and Intensive-care Unit Nurses\n\nIntroduction: HBV vaccination is the only way to protect people from developing liver cancer or lifelong infection from HBV. Hepatitis B-related injections are generally known to cause lipoatrophy following intradermal vaccination and also a fill-in-the-gap dose by nurses. Objectives: The present study aimed to investigate the risk of lipoatrophy following hepatitis B vaccination as a fill-in-the-gap dose by nurses in the pediatric ward and intensive-care unit. Methods: The research samples were the healthcare providers who reported a history of hepatitis Be vaccination in the pediatric ward and intensive-care unit in Rasht, Northern Iran. Two hundred six questionnaires were provided to the participants through convenience sampling. The questionnaire was designed based on a literature review about fill-in-the-gap doses. The questionnaire included demographic, educational, and work experience information. The data were entered into Excel (Windows 2011) and analyzed by SPSS 19.0 (SPSS Inc. Chicago: IL, USA). Results: The majority of participants had a bachelor's degree, 1 to 5 years post-graduation experience, and work experience less than 50 patients of hepatitis B vaccination. The majority of participants (66.7%) had experienced adverse effects, mainly including worsening local reactions or lesions (21.6%), fever (17.9%), and swelling (14.8%). Conclusion: Lipoatrophy was noticed in 8.3% of participants. More than half of participants were unaware of the criteria for performing fill-in-the-gap dose. Therefore, a plan should be designed to control the conditions of vaccine administration and nurses should complete their education on fill-in-the",
        "label": 2
    },
    "656": {
        "output": "---\n\n##[Trial-level Eligibility] Assessment of Eligibility (Assignee): <Assignee>\n[INT] Goodness of fit method: R 2\n[INT] Goodness of fit method: R 2\n[RQ1] Is your code working the same way for the given patient note? Is your code working the same way for the given patient note?\nIf so, run the `fit() function with 'goodness of fit method` and calculate the adjusted R 2 in the results.\n`fit(formula=\"Trial-level eligibility ~ sex*clinicalTrials ~ clinicalTrials*race + sex + race\", type = \"quasibinomial\", data = df1, method=\"R2\", test = \"\")$Rsq`)\nAdjusted R2 = 0.981986\n\nIf not, check all your assumptions one by one and modify the formula and the code as needed.\n---\n<EOD> Transduction of murine lymphocytes by pseudotyped lentiviral vectors is independent of VLA\u20104 and CD4\nThe ability to transduce quiescent and activated cells is critical to the widespread use of lentiviral vectors in therapeutic approaches. In this study, we compared the transduction of quiescent and interleukin\u20102 (IL\u20102)\u2010activated murine L\u2010cells and lymphocytes of various organs by two pseudotyped human immunodeficiency virus type 1 (HIV\u20101) lentiviruses, VSV\u2010G pseudotyped (LV\u2010VSV) and a novel gibbon ape leukemia virus (GaLV) pseudotype (LV\u2010GaLV), used in a range of experiments to investigate tropism. The LV\u2010VSV vector had a wide species tropism and readily infected and transduced resting and activated L\u2010cells (35% and 32 %, respectively) but transduction of quiescent freshly isolated resting lymphocytes was poor, with the highest percentages obtained using activated cells (2.5%). In contrast, LV\u2010GaLV transduction of lymph",
        "label": 1
    },
    "657": {
        "output": "You should enter the patient information in the `Input Data` panel. You should make a trial-patient number `Trial-patient: `, a trial-assignment `Trial-related: `, if the patient was included in the clinical trial. A trial-patient should be an integer. \nYou can insert data using a row insert command of a computer mouse in the `patient data table`. Please, be carefule when you are inserting data, because the amount of rows of the table depends on the total data you are entering. If you are making an update of the patient record that is already existed in the clinical trial, you should not enter only",
        "label": 1
    },
    "658": {
        "output": "# Evaluation\nUse the links in the evaluation section to load your work into the Jupyter Notebook on your machine. The evaluation will automatically load every variable and use it to provide feedback.\n\n<span class='survival-table'>\n  <script>\n    init = setInterval(function check () {\n\n      clearInterval(init);\n\n      if (isTableValid() == FALSE)\n        init();\n      else\n        return\n\n    }, 5000);\n  </script>\n\n  <form action=\"#\" method=\"post\">\n<input type=\"hidden\" name=\"Survival-table-datafile\" value=\"../data/survivaltable.csv\">\n<input type=\"hidden\" name=\"output\" value=\"eval\">\n<input type=\"submit\" value=\"submit\">\n    </form>\n\n  <div id=\"Jupyter-output\"></div>\n</span>\n<EOD> NUTRITION IN ANGINA BY ETHNICITY: ARE ASIAN ETHNIC DIETS HARMFUL?\nWe investigated the association between diet and angina over a four-year period using five waves of National Health and Nutrition Examination Survey (NHANES) data (2007\u20132011). We examined associations between angina and diet by racial/ethnic groups. We used Chi-square tests for trends and logistic regression to calculate odds ratios at each wave. Participants were 17 911 adults with angina and 92 506 participants without angina. After adjusting for socio-demographic covariates, we observed an angina-diabetes interaction. Among people without diabetes, we identified an increased risk of angina among people diagnosed as being in the high alcohol consumption category. We found, as compared to the non-Hispanic white population, that the Mexican American population had a higher prevalent rate of angina over time (P trend\u2009=\u20090\u00b702). The multi-racial/ethnic group (except Mexican American and Hispanic) had a higher prevalence of angina than the non-Hispanic white population. The Mexican American population showed an increasing trend of angina",
        "label": 1
    },
    "659": {
        "output": "# [END]<EOD> Effects of a 5-lipoxygenase Inhibitor (Zileuton) Compared with Cromolyn-Placebo on Pollution-Induced Health Status\n\n\n\n## Health status questionnaire items\n\n## 21-item version health status questionnaire items\n21 items on health status including frequency of:\nA.\nB.\nC.\n1. Headaches 1. Cough 1. Shortness of breath 1. Difficulty breathing 1. Sneezing 2. Pain (not headache or migraine) 2. Fatigue 2. Wheezing 2. Dry throat or stuffy nose 2. Shortness of breath 2. Difficulty breathing C. Gingivitis 11. Wheezing while inhaling 11.\nVoice hoarse/laryngitis 11.\nCough after heavy exercise 11.\nNasal sinus problems 11.\nVoice hoarse/sore throat 11.\nChest pain at exercise 11.\nCough without a cold 11.\nChronic fatigue 11.\nCold sores 11.\nDizziness without cold 11.\nDifficulty breathing 11.\nEye (itchy, red) 11.\nHay fever/ nasal allergy 11.\nItchy nose, stuffy 11.\nItchy skin 11.\nItchy, burning eyes 11. 12. Difficulty breathing 12.\nLoss of taste and smell 12.\nPain in back near heart 12.\nPoor memory 12.\nPsychological stress 12.\nDifficulty getting nose to breathe 12.\nLow backache 12.\nDifficulty closing eyes 12.\nDifficulty swallowing 12.\nLoss of concentration 12.\nSore throat 12. . Eye (itchy, red) 23.\nItchy nose, stuffy 23.\nItchy throat, difficulty",
        "label": 2
    },
    "660": {
        "output": "The eligibility of the patient is 2 (2 eligible) while the summary of this is presented in the last line.\n\n## [HINTS]\nPlease see the following link and answer the questions: [HINTS]\nYou have to be careful about what type of patients is eligible or not. Take a careful look at all the scenarios in this toolkit so as not to be lure into false assumptions. The patient in this patient note case is eligible for the trial.\n\n## Good luck!\n[/HINTS]\n<EOD> Effects of the novel dopamine D2 receptor agonist cariporide on cocaine intake in humans.\nCariporide (also called Compound 21) functions as a potent, selective, and noncompetitive inhibitor of the H+,K(+)-ATPase, resulting in an intracellular acidification with anticancer activity. Recent studies suggest the ability of H+,K(+)-ATPase blockade to regulate neurotransmitter release and behavior. Because the endogenous neurotransmitter dopamine (DA), which is involved in the modulation of cocaine self-administration and reward, is sensitive to acidification of the synaptic milieu, we hypothesized that the noncompetitive H+,K(+)-ATPase blocker cariporide may alter cocaine reward in humans. Therefore, in a first experiment we determined the dose-dependence and time-course effect of cariporide on the reinforcing properties of cocaine in a human model of drug self-administration which included three distinct phases such as i.v. drug self-administration and intravenous drug preference assessment sessions. In a second experiment, we explored the effects of H+,K(+)-ATPase inhibition on cocaine-induced plasma oxytocin by a placebo-controlled cocaine administration combined with the administration of cariporide or placebo. Cariporide selectively blunted the reinforcing properties of cocaine in a dose-dependent manner, but did not alter the intravenous drug preference for cocaine. There was a trend towards a decrease of oxytocin release by",
        "label": 1
    },
    "661": {
        "output": "[ACHTUNGSPFEILE].\n\n[A]. If the patient is excluded, set the result to the first argument of the ``exclude`` function. The excluded reason will come out in the second position of the result.\n\n[B] If the patient is not relevant, set the result to the second argument of the `not\u2010relevant` function. The excluded reason will come out in the third position of the result.\n\n[C] If the patient is eligible, set the result to the third argument of the `eligible` function. \n\nTrial-level eligibility: 0) Excluded `exclude`(first argument of the ``exclude`` function). The excluded reason will come out in the second position of the result.\n\nTrial-level eligibility: 1) Not relevant `not_relevant`(second argument of the `not\u2010relevant` function). The excluded reason will come out in the third position of the result.\n\nTrial-level eligibility: 2) Eligibile `eligible`(third argument of the `eligible` function).\n\nTrial-level eligibility: 2) Eligible.`\n\n[/ACHTUNGSPFEILE]\n\n## Evaluate the solution\nYour solution will be evaluated by the grader.\n\n### Expected\nThe Expected is 100%.\n\n### Submitted solution\nYour solution contains errors.\n\n### Screenshots\n![Screenshots: Assess eligibility](./screenshots/eligibility/eligibility.png)\n\n### Solution-verification scripts\nAs for any given homework, we encourage you to use the following scripts to ensure that you understand how it is being evaluated by the grader. If you are able to successfully execute the provided script, it is probable that the grader can do so as well, and it will provide you with further confidence in understanding how to do well on this homework.\n\n| File                                          | Contents                                               |\n| ------------------------------------------ | ------------------------------------------------------ |\n| `assess_eligibility.rd`<br>([output])        | Verifies your solution's eligibility",
        "label": 1
    },
    "662": {
        "output": "[TIPS]\nYou may run these commands to check code efficiency:\n\n``` r\n\n```\n# Run\n\n``` r\n\n```\n<EOD> Effect of H2-receptor antagonists on prostaglandin E2 release in the rat stomach.\nProstaglandin E2 (PGE2) release in the rat stomach was measured in response to various stimuli at different doses in the presence or absence of H2-antagonists. 1) PGE2 release induced by 100 mM KCl, 5 mM sodium taurocholate, or 10(-6) M histamine was almost completely inhibited by famotidine at 100 micrograms/rat, regardless of whether the PGE2 release was measured in vehicle (20% dimethyl sulfoxide)- or CMN (1:1:18, acetone:olive oil:ethanol)-treated rats. H2-antagonists were reported to be able to diffuse across the gastric mucosa at pharmacological concentrations. However, we found that it was difficult to achieve adequate penetration of famotidine and pirenzepine into the stomach with CMN treatment. Pure famotidine also showed a tendency to inhibit PGE2 release in the rat stomach. 2) In contrast, 1 mM histamine-induced PGE2 release was only slightly inhibited by 100 micrograms/rat famotidine, by 3 mg/rat cimetidine, or by 100 micrograms/rat pirenzepine. This indicates that H2-receptor antagonists were able to affect H+/K+ ATPase activity of parietal cells in the rat stomach. 3) Cimetidine increased histamine-induced PGE2 release. This increase was prevented as soon as famotidine was added simultaneously to their combination. 4) H+/K+ ATPase activity of rat gastric fundic mucosa preparation was inhibited in the presence of 10(-6) M famotidine as much as in the presence of 10(-5) M nif",
        "label": 1
    },
    "663": {
        "output": "[Q1_A01] Please take a look at the following table.\n\n![alt1](/data/A0/alt1/alt1_violet2.png)\n\n#[Q1] What is the age that is closest to the lower 50% limit for the age group with the greatest number of patients?\n\n#[Q1_A02]. What is the number of patients in the age group 51-60? Give your answer in integers. For example, \"two patients\" would receive credit for the answer 2.\n\n#[Q1_A03]] What is the number of patients in the age group younger than 40 years? Give your answer in integers. For example, \"two patients\" would receive credit for the answer 2.\n\n#[Q1_A04] What is the number of patients in the age group older than 85 years? Enter integers only. For example, \"two patients\" would receive credit for the answer 2.\n[/CASE]\n\n## [EXP][A1]\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (",
        "label": 2
    },
    "664": {
        "output": "### Excluded Patients\n\n### Not Relevant Patients\n\n### Eligible Patients\n\n### Instructions for `output` command:\n\n`output`\n[\n(optional) `title:` (suggested: \u201cPatient Report: Clinical Eligibility for A Randomized Controlled Trial of Fatigue in MS\u201d)\n(optional) `title:` (suggested: \u201cSummary: Patient Report: Clinical Eligibility for A Randomized Controlled Trial of Fatigue in MS\u201d)\n(optional) `title:` (suggested: \u201cTrial report: Clinical Eligibility for A Randomized Controlled trial of Fatigue in MS\u201d)\n(default) `title:`\n(default) `title:` (`A Randomized Controlled trial of Fatigue in MS\u201d)\n`[data_analysis|feature_extraction]` (`Patient Report: Clinical Eligibility for A Randomized Controlled Trial of Fatigue in MS\u201d)\n\n### Instructions for `print_data_table()` command:\n\n`print_data_table()`\n[\n(default) `title:` (`Summary: Patient Report: Clinical Eligibility for A Randomized Controlled Trial of Fatigue in MS\u201d)\n(default) `title:` (`Patient Report: Clinical Eligibility for A Randomized Controlled Trial of Fatigue in MS\u201d)\n(default) `title:` (`Trial report: Clinical Eligibility for A Randomized Controlled trial of Fatigue in MS\u201d)\n\u201cA Randomized Controlled trial of Fatigue in MS\u201d\n\n### Exercise 11. Using the `predict()` command for decision tree classification\n\nIn this exercise, you will build decision tree algorithms to predict the class label of the data items in the `clinical_trials` dataset. This data-driven exploration of the class distributions over the values of different attributes in the dataset should provide some insight and hints on which attributes one might be particularly interested in in the classification of the dataset. In particular, you are going to construct decision trees to identify patient reports for clinical trial recruitment for the following two diseases: \n* \"Breast cancer\"",
        "label": 0
    },
    "665": {
        "output": "<EOD> .\nThe authors report their experience of 184 cases of intestinal invagination studied and treated by endoscope. Diagnosis was made by endoscopy, but in 6% of the cases, endoscopic examination was normal because clinical symptoms and other radiological investigations were inconclusive. Experience is reviewed by types of invagination (35 cases of jejuno-jejunal, 25 cases of jejuno-ileal, 25 cases of ileo-colic, 39 cases of colonic invagination, 20 cases of Meckel's diverticulum, 15 cases of invagination at the anal sphincter by stenosis, and 6 intussusception lesions). The endoscope was found to be a useful complementary method. It has a good accuracy by anatomical site, especially in jejuno-ileal and Meckel's diverticulum invagination. With the endoscope and the fluoroscope one can have radiological confirmation by viewing intestinal loops by endoscopy. By introducing a trocar into the lesion, it is possible to do a puncture if the invagination is small. The endoscope has been shown to be of interest to make endoscopic suture possible in some cases. It has also been of help in the search for bleeding, and makes it easier to see the site of the pathology in chronic invagination. After treating the patient the endoscope can be used to check up on it.<EOD> .\nOBJECTIVE\nThe effects of endurance exercise on bone mass and bone loss induced by ovariectomy (OVX) were investigated.\n\n\nMETHODS\nTwenty female Wistar rats (age, 12 months; weight, 350 +/- 35 g) were randomly divided into 4 groups: control group (n = 5), sham-operated rats group (n = 5), endurance-exercise rats (EX) group (n = 5), and OVX and endurance-exercise rats (OVX-EX) group (n = 5). Twenty-four weeks after exercise, the",
        "label": 0
    },
    "666": {
        "output": "## [/TRI]\n### Inclusion criteria\n\n```python\ndef get_inclusion_criteria(note):\n    \"\"\"Get a list of inclusion criteria, and a list of exclusions.\n\n    Parameters:\n    note -- an NLP'd patient note (i.e. Listing)\n\n    Returns:\n    inclusion_criteria -- a list of inclusion criteria, e.g. [\"high altitude\" \"experimenter\",..., \"elevate\",..., \"sit\",..., \"walk\",..., \"play sports\", \"exercise\",..., \"climb stairs\",], a list of exclusion criteria, e.g. [\"mild\", \"mild\", \"mild\",..., \"mild depression\",..., \"moderate\", \"moderate cough\",..., \"moderate wheezing\", \"...\", \"moderate anxiety\", \"experience any symptoms\"], [3] --> [\"mild\", \"moderate\", \"mild\"]\n        The inclusion criteria with index 0 is used as the default\n    \"\"\"\n    \n    return {0: [\"high altitude\", \"experimenter\", \"smoke\", \"smoke\", \"exercise\", \"stress\", \"run\", \"hike\", \"exercise\", \"jog\", \"play sports\", \"walk\", \"play sports\", \"go to the gym\", \"sit\", \"play sports\", \"climb stairs\", \"exercise\", \"sit\", \"play sports\", \"walk\", \"play sports\", \"climb stairs\", \"jog\", \"play sports\", \"run\", \"run\", \"pray\", \"pray\", \"play sports\", \"jog\"],\n                    1: [\"walk\"],\n                    2: [\"play sports\"]}\n```\n\n- Note: this function has a lengthy list of input parameters. If the data type of the input is not correct, the method will not evaluate at all to calculate the inclusion criteria. \n\n### Exclusion criteria\n\n```python\ndef get_exclusion_criteria(note):\n    \"\"\"Get a list of inclusion criteria, and a list of exclusions.\n\n    Parameters:\n    note -- an NLP'd patient note (i.e. Listing)\n\n    Returns:",
        "label": 1
    },
    "667": {
        "output": "The cut-off value is listed in the first row. \n\nThe exclusion criteria of `Cut off value: `\nClick the button `Select Exclusion`, and then click the button `Calculate. You should calculate like this. \n\nFinally, you should repeat the same calculation for the other exclusion criterion if any. \n\nTrial-level eligibility` = `Cutoff value * Exclusion * Inclusion\n\n\nWe should apply the last cut-off value into this formula. \n(Inclusion- Exclustion) == Cut-off value\n\nExclusion (for example No. 1) -(Inclusion) == Cut-off value\n(794.5- 63) == 731.5\nWhen the triallevel eligibility is `eligible` , this means that your patient is NOT excluded on the grounds of the trial's exclusion criteria, and is therefore eligible for the trial.\n\nIn the next step, you should repeat the operation. \nTrial-level eligibility for the other exclusion criterion (No. 2.) is the same as that of `Trial-level eligibility: 0) Excluded.`.\n\n![6.R1.06_Patient_Case](http://www.gsk-clinicalstudyfile.com/Images/Round1/2012-8/20111123120127_1_20121204113010_25910_2_33510_B6F7BF30_000)<EOD> Antioxidant and antibacterial activities and c",
        "label": 0
    },
    "668": {
        "output": "# Inspirations\n<EOD> Gastric cancer\nGastric cancer is a disease of genetic complexities. The development of gastric cancer is a multistep and multifactorial process, involving both host and environmental factors. Helicobacter pylori infection, family history of cancer, diet, occupation, and genetic susceptibility are the major modifiable risk factors for gastric cancer. A number of genetic changes occur during the development of gastric cancer. These include: hypermethylation, somatic and viral mutation, microsatellite instability, alteration of molecular biomarkers at DNA/RNA levels, and chromosomal instability. The role of these alterations at different stages of the development of gastric cancer has become clearer in recent years. Gastric cancer has been classified mainly on the basis of histologic features. It can be further divided into 2 distinct groups: intestinal type and diffuse type. There are several differences between intestinal and diffuse types, including histological growth, gene expression, and clinical outcome. In addition, the intestinal and diffuse types of gastric cancer exhibit differences in their etiopathogenesis. Gene expression profiles have been used to examine the molecular mechanisms underlying the progression from chronic gastritis to gastric cancer. In the current review, an overview of gastric cancer associated with environmental (smoking, drinking, diet, family history, and environmental mutagens) and genetic factors, classification, histopathology, and molecular events associated with the development of gastric cancer is discussed.<EOD> Dental Care under General Anesthesia in Patients after Orthognathic Surgery\u2014A Case Series\n\nCitation: Vilela, M.A.; Ramalho, R.; Oliveira, V. Dental Care under General Anesthesia in Patients after Orthognathic Surgery-A Case Series. Int.Abstract: Orthognathic surgery was initiated in 1900 by Cottwell, when he reported the first lateral maxillary ostectomy, and today, it is a well-established approach with high results in terms of anesthetic care, safety and patient satisfaction. Pre-surgical orthodontic",
        "label": 0
    },
    "669": {
        "output": "<EOD> The Relationship between Blood Oxalate and 24-Hour Urinary Calcium in the General Population and in Patients with Primary Hyperoxaluria\n\nObjectives: This research was aimed to investigate the relationship between blood oxalate (BO) and 24-hour urinary calcium (24UCr) among patients with primary hyperoxaluria (PHP) and normal population.Methods: 166 PHP patients and 902 volunteers were collected for the experiment, all of which underwent BO, creatinine, and 24UCr measurements. According to 24UCr level, volunteers were divided into normal control group (NC,< 50-299 mg/24 h), high 24UCr group (H24UCr, \u2265 300 mg/24 h) and low 24UCr group (L24UCr, < 300 mg/24 h). Comparing the difference of BO in NC, H24UCr, and L24UCr groups, the relationship between BO and 24UCr was further analyzed.Results: The BO levels among the three groups were significantly different. The normal populations in the H24UCr group had higher BO than in the L24UCr group (1.53 \u00b1 0.40 vs. 1.32 \u00b1 0.36 mg/dL and P < 0.001), and BO had a significant linear relationship with 24UCr in the three groups (R 2 = 0.197, P < 0.001). BMI had linear correlation with BO for female normal controls of the H24UCr group (R 2 = 0.112, P = 0.016). Conclusion: BO levels change considerably among the three groups, and BO had a significant linear relationship with 24UCr, suggesting that an increase in BO may be related to the occurrence of kidney stones, osteoporosis and other diseases caused by abnormal calcium and oxalate metabolism. Therefore, the measurement of BO and 24UCr is critical to improve the efficacy of prevention and treatment for kidney stones.",
        "label": 1
    },
    "670": {
        "output": "---\n\n# Overview\n\nThe objective of this study is to assess non-invasive cardiac imaging modalities with known high accuracy for the detection of heart disease in patients presenting for the first time to the cardiologist with chest pain. The diagnostic accuracy of the various cardiac imaging techniques needs to be assessed for the ability to detect and localize coronary artery disease. We expect the results obtained by the various imaging modalities to correlate with angiography, which is considered the gold standard.\n\n> 80 years:  76% sensitivity and 74% specificity\n> 76 to  70 years:  80% sensitivity and 72% specificity\n> 70 to  66 years:  85% sensitivity and 70% specificity\n> 66 to  63 years:  93% sensitivity and 67% specificity\n> 63 to  60 years:  97% sensitivity and 67% specificity\n> 60 to  57 years:  99% sensitivity and 67% specificity\n\n# Study Design\n\nWe will evaluate the diagnostic accuracy of various non-invasive cardiac imaging techniques to detect coronary artery disease in symptomatic patients who have undergone cardiac catheterization. The diagnostic accuracy will be assessed using the sensitivity, specificity, and likelihood ratios.\n\n## Study Population  \nThe population will consist of patients older than 40 years who have undergone cardiac catheterization.\nPatients will be referred to the study based on the results of non-invasive cardiac imaging assessments and their pre-test likelihood for coronary artery disease. \n\n> Note: \n> Note:\nAll patients who satisfy the eligibility criteria will be approached, and their informed consent will be obtained. Patient identification numbers will be assigned to the participants.\n\n## Sample Size\nInitially, 180 patients with 20% prevalence of disease will be sampled, based on a preliminary data assessment with a 1:1 ratio between those with stenosis and those without stenosis. Based on our preliminary results, the sensitivity was",
        "label": 0
    },
    "671": {
        "output": "This is the data you need to make the decision about Trial-level eligibility: the variables `Age, Gender, EducationLevel, ReasonForVisit, TreatmentChoice, and Trial-level eligibility`, the list variable `Subject: 1 to 20`, and the data vector `Risk_Qual, Risk_Num, Risk_Abs, Risk_Rel, TreatmentChoice`.\nTo choose the option that is correct, press the corresponding button.\nLet's do a validation:\n\n### Incorrect button pressed\nThe button `4` (Absolute risks in graphs) was pressed.\n\n### Correct button pressed\nPlease proceed to the next step.\nThe button `4` (Absolute risks in graphs) was pressed.\n\nWhat else do you need?\n\n### Incorrect button pressed\nThe button `1` (Qualitative risks in graphs) was pressed.\n\n### Correct button pressed\nPlease proceed to the next step.\nThe button `1` (Qualitative risks in graphs) was pressed.\n\n### Incorrect button pressed\nThe button `1` (Qualitative risks in graphs) was pressed.\n\n### Correct button pressed\nPlease proceed to the next step.\nThe button `1` (Qualitative risks in graphs) was pressed.\n\nCheck your button choice:\n\nThere is no correct answer. You just have to choose the option you think is correct.\n\n## Check your answers:\n\nLet's go to the last instruction.\n\n## Instruction: `Check your answers:`\n\nMake the best choice about Trial-level eligibility:\n\nThe number 0, 1, or 2, please.\n\n- 0: Excluded.\n- 1: Not relevant.\n- 2: Eligible.\n\n02-227-332-302-955-432-688-967-029-82822-7\n\n## Check your button choice:\n\nThere is no correct answer. You just have to choose the option you think is correct.\n\n124,936,023,647,4558,875,985",
        "label": 1
    },
    "672": {
        "output": "## Task T3: Eligibility Criteria (Step 4) \nTrial-level eligibility\n(1) Excluded = Excluded (2) Not eligible = Not relevant (reasons not identified) (3) Eligible = Eligible\nThe following factors represent the exclusion criteria from your study:\n(1) previous transplantation of a heart, lung or liver;\n(2) active cardiac sarcoidosis;\n(3) active inflammatory gastrointestinal disease;\n(4) previous cardiac arrest;\n(5) history of coronary artery bypass graft (within 3 months);\n(6) pregnancy;\n(7) history of cancer (except for stage I-II nonmelanoma skin cancers) or an immunodeficient state;\n(8) current malignancies, excluding basal cell carcinoma and stage I nonmelanoma skin cancers(3)\n```python\n\n\n\n\n\ndef eligibility_factors():\n    return {1, 2, 3, 4, 5, 6, 7, 8, 9, 10, \"age\", 13, \"age\", 14, \"history_diabetes\"}\n   \n# get the factor level\npatient_demographics = {}\nfor patient in patients:\n    if ('age' in patient and 'years' in patient):\n        patient_demographics[12] = patient['years']\n    if (\"history_diabetes\" in patient):\n        patient_demographics[13] = \"History of diabetes\"\n    if (len(patient_demographics) < 12):\n        patient_demographics[9] = 'Inclusion criteria (see table below)'\n    \nfor line in trial.text.split():\n    if ': ' == line: # Find line that includes a key-value pair\n        key = line[:line.index(':')]\n        value = line[line.index(':') + 2:]\n        \n        if key in eligibility_factors.keys(): # Is this key already present in eligibility_factors.keys() key",
        "label": 0
    },
    "673": {
        "output": "To complete the assessment in the 'Eligibility Check' window of the 'Assessment' window, click the save button. \n\n# Result\n\nFrom the input note and clinical trial, the output is as below:\n\n### Eligibility Assessment\n\n\n\nTrial-level eligibility: 2) Eligible\n\n### Patient-level assessment\n\nAge  46 : 46 years-old\nGender: Male.\nTitle: A Randomized Double Blind Placebo Control Study of Huang-Chi-Wu-Wu- Tang in Patients With Intracranial\nArterial Stenosis\nSummary: This clinical trial requires participants to be diagnosed with intracranial arterial stenosis and has already been treated with medical therapies. \nInclusion criteria: Inclusion Criteria:\nAge >40 years old.\nGender: Male and Female\nDiagnosed with intracranial arterial stenosis (any one of the following two conditions:\n1. stenotic ratio of > 50% in any of the main intracranial arteries: middle cerebral artery (M1), anterior cerebral artery (ACA), vertebrobasilar trunk, vertebral artery, basilar artery, internal cerebrovascular artery, internal carotid artery\nStipulation for the stenotic area: must be on the segment that is longer than 10mm but shorter than 25mm\nIn case of multiple intracranial arteries involved, the greatest stenosis degree shall be followed and evaluated\nStipulation for intracranial arterial stenosis:\nFor each stenosis degree (50-75%, 75-90%, 90-99%, 99%-100%), the intracranial arteries are summarily evaluated, respectively. If the same artery with a stenosis degree of <50%, it is not regarded as intracranial arterial stenosis.\nPatients are excluded from the trial in the following circumstances\uff1a\nStenting operation was taken in the past 6 months or will undertake in 3 months.",
        "label": 1
    },
    "674": {
        "output": "# <br><strong>F.5. Example</strong> <br>[TEST_ID:1234106]\n\n# <br><strong>F.6. Markdown Syntax</strong>\n\n```\n\n--- This is a [Test](Test.md) document ---\n\n## Folder \n```\n...\n## Example [F.6](#F6)-[F.6](#F6)-2\n...\n```\n```\n--- This is the subsubfolder [Example] [F.6](#F6)-[F.6](#F6)-2 ---\n--- A [Test](Test.md) document ---\n\n[F.6](#F6)-[F.6](#F6)-1\n```\n```\n----- ---This is a subfolder [Example] [F.6](#F6)-1--- [[F.6](#F6)-2]] This is a [Trial-level eligibility] 2) Eligible; [F.6](#F7)-[F.6](#F7)-1](https://github.com/shio1122/Drools-Project#F7-6-1).\n```\n--- This is a [Test](Test.md) document ---\n\n</details>\n\n\n# <br><strong>G. Examples</strong>\n\n```\n--- This is a [Test](Test.md) document ---\n\n## F.1. Folder \n```\n...\n## Example1 [F.1](#F.1)-[F.1](#F.1)-1\n```\n```\n--- This is the subsubfolder [Example1] [F.1](#F.1)-1--- [[F.1](#F.1)-2]] This is a [Trial-level eligibility] 1)Excluded; [F.1](#F.2)-[F.1](#F.2)-1](https://github.com/shio1122/Drools-Project#F.2-6-1).\n```\n--- This is a [Test](Test.md) document ---\n\n--- This is a [Test](Test.md) document ---\n\n--- This is the subsubfolder [Example2] [F.1](#F.1)-2--- [F",
        "label": 1
    },
    "675": {
        "output": "You are going to learn how to do tasks in Python-notations to the following text are explanations to the tasks. You may use code completion feature of your editor to write the code faster. Check that you use same package versions.\n\n\n\n<EOD> Molecular analysis of the genetic loci causing primary pulmonary hypertension in rat genetic models by using the microsatellite marker system.\nPrimary pulmonary hypertension (PPH) is a familial syndrome of increased pulmonary artery pressure due to smooth muscle cell hypertrophy and proliferation. Inbred rat strains are considered to be spontaneous models in which the genetic background shows a close relationship to human PPH. We performed a genome screening of the two PPH-prone strains, the Wistar Kyoto-Tokyo (LWH/Izm) strain, and NZ-T-Tokyo (NZRTJ) strain, and selected the NZRTJ strain on the basis of the genetic susceptibility to pulmonary hypertension. A total of 224 polymorphic markers, covering the entire rat genome, were screened using the microsatellite markers system with DNA samples of 27 F2 animals. A set of markers showing differences in the heterozygosity rates between the NZRTJ strain and any other inbred strains or the heterozygosity rate of the F2 progeny, was regarded as markers of the region of the disease locus. With this approach, we could detect an informative polymorphic marker, D11Rat1543, which was located in a 3.4-cM region of rat chromosome 1. Furthermore, we identified the microsatellite markers RNO6 and D11Rat7614, located in rat chromosomes 6, as informative markers, in addition to the marker D11Rat1543, for the NZRTJ strain. The region of the disease locus obtained in our study overlaps with the genetic locus previously suggested by using a congenic animal model. Our strategy to detect the disease locus of the PPH-prone strains may also be applied to the search for other multigenic",
        "label": 1
    },
    "676": {
        "output": "[INST] End of the tutorial.\n<EOD> Effects of a Falls-Management Nursing Program on Quality of Life, Falling Behavior, and Sense of Self-Efficacy after Fall\n\n\n\n# Introduction\nAmong older adults, risk factors for falls are aging, the environment, health conditions, and physical, mental, and social changes. Furthermore, even in people who have a lower risk of falling, many falls occur because of factors that are unpredictable, such as an individual's loss of balance due to muscle weakening or slipping. The incidences of these falls are greater in old age [1] and the incidence of falls rises drastically when it becomes an elder problem [bib_ref]  Falls and their prevention in elderly people: What do we know?, Rubenstein [/bib_ref] . It is estimated that 33% of adults who are over 65 years old and 50% of adults who are over 80 years old have fallen this year. According to the Korea Health and Welfare Statistics released the report that about 7 per 1000 adults over 65 fall each year. A fall involves an accident that results in the body losing its balance or making contact with the ground or something else, and it is a problem that most people expect to happen as the life expectancy in the world gets longer [bib_ref]  Fall prevention in the elderly, Kok [/bib_ref] . Falls have an immense impact on the lives of the elderly and their caregivers, and older adults tend to have more severe and complex concerns about falls than young adults. They are also prone to fearing falls or avoiding them altogether as much as possible. They have the most self-care-related concerns after falls, especially due to the limitations in mobility and physical strength [bib_ref]  A Study of the Effects of Nursing Intervention on Fear of Falling..., Choi [/bib_ref] . In addition, falls pose a major problem in terms of accidents, quality of life, quality of health care, and costs [bib_ref]  Falls among institutionalized older persons: A cause for concern, Tinetti [/bib_ref] . In particular, although falls that occur in the elderly at home are inexpensive to prevent, they are difficult to address because the elderly do not receive enough treatment and care for these falls",
        "label": 1
    },
    "677": {
        "output": "## [INST] Inputs\n\n\n![](http://docs.jacovitron.com/data-flow-graph/fig-1.png \"Graph\")\n#1 `Challenge`\n![](http://docs.jacovitron.com/data-flow-graph/fig-2.png \"Graph\")\n#2 `Note`\n![](http://docs.jacovitron.com/data-flow-graph/fig-3.png \"Graph\")\n\n\n## How to implement the Challenge-Notes-Trial-level-eligibility dataflow?\n\n\n### Using the jacovitron IDE\n\n1. Create a new machine learning project using the IDE - JacoviTron.\n\n1. Go to **File, Source, New** on the menu bar and select the **Notebook Source**:\n\n    :::image type=\"content\" source=\"_static/notebook.png\" alt-text=\"New Notebook Source Tab\":::\n\n1. In the **New Notebook Source** dialog box, select **File, New**:\n\n    :::image type=\"content\" source=\"_static/notebook_source.png\" alt-text=\"New Notebook Source Dialog\":::\n\n1. Enter **Challenge-Notes-Trial-level-eligibility** for the dialog box **New Notebook Name**:\n\n    :::image type=\"content\" source=\"_static/new-notebook.png\" alt-text=\"New Notebook Name dialog\":::",
        "label": 1
    },
    "678": {
        "output": "__  ____  ____   _______  __  ____   _______  __  __\n| |    | |    | |       |    | |    | |       |    | |    | |\n| |    | |    | | _       |    | |    | | _      |    | |    | |\n| |    | |    | | |       |    | | ____ | |       |_____|__|____|\n|_____|_____|_____| |_____|_____|_____| |_____|_____|_____________|__________|\n\n<!-- ========== EDA ANATOMIC CENTRAL ARTERIES PATTERNS =========== -->\n\n\n<div class=\"alert alert-warning message\" role=\"alert\" id=\"eda_central_patterns\">\n        <p><span id=\"eda_central_patterns_help\">(c) Inklin et al. 2016. [<a href=\\\"http://doi.org/10.1136/bmjopen-2016-013217\\\">BMJ Open.</a>] <em>What is the normal pulsatile arterial pattern of a peripheral artery? - A narrative review and case based approach</em>  25.</span> </p>\n</div>\n\n<ul>\n<li id=\"eda_central_pattern\">\n    <div class=\"alert alert-info\" role=\"alert\">\n<p style=\"display: inline-block;\"><button class=\"caret\">\n    <span>\n        <span class=\"glyphicon glyphicon-question-sign\" aria-hidden=\"true\"></span>\n    </span>\n    Question &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</button>\n</span>\n    <span class=\"collapsible\" data-collapsible-tag=\"hint\">                                           \n\nWhat arterial pulsation patterns does a normal CCA present? \n\n- Normally, peripheral CCA  has no detectable pulsation.\n- In the presence of an arteritis (e.g., vasculitis  or atheroscl",
        "label": 2
    },
    "679": {
        "output": "# Question 4\n[INST] This patient note from the clinical trial will allow the researchers to select the ideal candidate who is likely to benefit and also ensure that the patient will not be harmed. We are a group of experienced professionals and we have noticed that although the data were collected by physicians and healthcare providers, sometimes there is missing data. For example, the patient's smoking history can be missing from the medical records (0), not available (1), or unknown (2). It is also a common situation that the data on risk factors were obtained from the patient's answers to the questionnaire.\n\nThe data on cardiovascular risk factors from the clinical trial:\n\n## Name (n=40)\nAge (n=40)\n\n\n## Male smoker (n=40)\nSmoking history (40)\n 1+1\n 2+3\n 3+2\n 3+2\n 0+2\n 0+1\n 1+1\n 0+2\n 0+3\n 4+0\nLaboratory Test (n=40)\nLDL (n=40,mg/dL)\n<160\nHDL (mg/dL)\nN/a N/a N/a N/a N/a\n\nSystolic BP (mmHg)\n<130 N/a N/a N/a N/a N/a N/a\n\nDiastolic BP (mmHg)\n<80\n\n\n## N/a\n\nGender (\n\nHaving smoking history: No smoking (0), Yes smoking (1), Former smoking (2).\nHaving hypertension history: No hypertension (0), Yes hypertension (1), Former hypertension (2).\nWhat is this? : What is the clinical trial's inclusion and exclusion criteria?\n\n## Inclusion\nAge <65 yrs \n\n## S28\n- The patient can communicate well with the clinical team - The primary caregiver will have adequate support from the local family and community structures\n- The patient is willing and able to provide informed consent for study participation and is willing to allow study personnel to",
        "label": 1
    },
    "680": {
        "output": "## 4.1.5_daily_task_example_0.yml\n\n### 4.1.5_daily_task_example_0.ml\n\n[INFO]\n[INFO]  --- [YAML-EXAMPLE]\n[INFO]  --- [ML-EXAMPLE]\n@params ('task_name') @params ('run')\n```\n\n```python\n# -*- coding: utf-8 -*-\n# @params ('task_name') @params ('run')\n\nimport util\nimport yaml\nimport tempfile\nimport os\nimport sys\n\nimport pprint\nfrom rich.console import print\nfrom rich.panel import Panel\nfrom rich.text import Text\nimport pandas\nimport numpy as np\n\ntry:\n    # If this is executed then we're in a terminal, not some IDE\n    import platform\n    osName = platform.system()\n    osVersion = platform.machine()\n    osRelease = platform.linux_distribution(full=False)\n    _print_system = False\nexcept (IOError, ValueError):\n    # If this is executed then we're in an iTerm or iShare or something\n    _print_system = True\n\nprint([\n    \"----------------------------------------------\",\n    \"---\"\n])\nprint(Panel(\n    Text('Hello World !'),\n    \"**************************************\"),\n    Panel(Text('---------------'), \"---------------\"),\n    Text(\"This is my first experience using MLflow!\")\n))\nprint(\"*****************\" * 10)\nprint([\n    \"*****************\", \"****\"\n])\nprint(Panel(Text('This my first run!'), \"Hello\"))\n\n\n# +\n# -----------------------\n# Define DataFrame\ndf = pandas.DataFrame()\n\n# The number of rows and columns will be determined by the dataset\ndf['name'] = pandas.Series([\n    \"John\",\n    \"Ali\",\n    \"Taro\",\n    \"Tanita\",\n    \"Raymond\",\n    \"Yuzuki\",\n    \"Eleonora\"\n])\n\ndf['age1'] = pandas.Series([\n    15,\n    16,",
        "label": 0
    },
    "681": {
        "output": "### Expected output\n\nYou generate patient note and note: ```{clinicaltrials}\n    A 46-year-old man with family history of cardiovascular disease presents with dizziness and frequent headaches. He has no cardiovascular risk factors such as smoking or hypertension, and is not physically active. The patient's LDL-C and HDL-C levels were 545 mg/dL and 53 mg/dL, respectively, and his fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications.\n    Neck auscultation revealed a systolic murmur of 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed a severe stenosis of carotid artery (left internal carotid artery, LICA) and moderate stenosis of right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively, and the RICA PSV was 91.72 cm/s, and the RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and were predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n    [/clinicaltrials]\n    Patient note: {clinicaltrials_start}{clinicaltrials_end}\n        {clinicaltrials_note}[/clinicaltrials]\n    [/clinicaltrials]\n```\n\nAbove",
        "label": 0
    },
    "682": {
        "output": "## Required parameters:\n- Disease: CAD -> disease\n- [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n- The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). -> Eligibility_Scale: 2) Eligible.\n- A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits.\n- The patient reported no use of lipid-lowering medications.\n- Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 9",
        "label": 1
    },
    "683": {
        "output": "## Assessment of Patient's Eligibility\n[INST: You should choose the patient's characteristics from the patient's note above.]\nInput the patient's information into the trial. By pressing the Trial-Level Eligibility key  on the keyboard, a patient list will appear.\n\n## How to assess eligibility?\nAssessment of Patient's Eligibility:\nUse the keys shown below to assess each patient:\n\n## Patient-level eligibility \nInput to the trial the information on the patient level eligibility. There are three assessments at the patient-level in trials: 0) Excluded (patient meet inclusion criteria, but are excluded on the grounds of the trial's exclusion criteria), 1) Not relevant (patient does not have sufficient information to qualify for the trial), or 2) Eligible (patient meet all of the trial's inclusion criteria and no of exclusion criteria were defined). \n\n## Excluded due to the inclusion criterion\nExcluded Due to the Inclusion Criteria:\nWhen you press the key '0/Excluded`, the 'Trial-level eligibility value changes to 1/Not relevant`and the name of the excluded criterion appears on the bottom line, e.g., \"Lipid level below threshold limit.\" \n\n## If not\nIf not: Press 1/Not Relevant:\nAfter the screen displays the message, 'Not Relevant', you should press 'Enter/Return' key. \n\n## If yes\nIf yes:\nAfter the screen displays the message, 'Eligible', you should press 'Enter/Return' key and the name of the inclusion criterion appears on the bottom line:\n\n## Output of patient-level eligibility: \nIf your patient, i.e., the participant of the trial, satisfies the inclusion criteria at the patient-level, trial-level eligibility will be written one time, e.g., if the patient is eligible for the first trial, `trial-level eligibility: 2-Eligible` will be output for the first trial. If the patient is eligible for two trials, trial-level eligibility will be written twice, e.g.,  for the first trial and  for the",
        "label": 2
    },
    "684": {
        "output": "___\n\n# S5.2\n[INST] Hello! Here is a new trial to evaluate the effect of low doses of ropivacaine for patients with chronic post-traumatic neuropathic pain. The clinical trial is designed to assess the efficacy and safety of low doses of ropivacaine in patients with chronic post-traumatic neuropathic pain, which is characterized by a combination of abnormal sensory symptoms (burning, pricking, etc.) and abnormal motor symptoms (fasciculation, muscle spasm, etc.). The duration of pain should be at least 6 months. In addition, pain should be in the affected limb, but not limited to the affected limb. \nIn this trial, you play the role of a helpful assistant for clinical trial recruitment. You are comparing a given patient and note against the inclusion and exclusion criteria  of a clinical trial with the aim to assess the patient's eligibility.\n\nThe clinical trial requires patients in the placebo group to perform exercises of flexion, extension, and dorsiflexion of the ankle joint three times a day for 30 minutes each time before the ropivacaine injection. The same amount of exercise is performed in the ropivacaine group before the ropivacaine injection, the only difference being the injection of ropivacaine once before each exercise. \nThe assessment for patient eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n \nHere is the patient note: \nA 28-year-old man presents with chronic pain and sensory changes in the left lower leg, which have persisted for two years with occasional burning pain in the right lower leg. The pain is in the posterior aspect of the knee joint and radiates to the posterior aspect of the ankle joint. The ankle reflex was present. The vibration sensation was diminished in the lateral aspect of the right lower",
        "label": 1
    },
    "685": {
        "output": "What to do if a criterion does not apply to both patient and trial?\n\nYou should output `Trial-level eligibility: 0) Excluded.`.  \n\n# Background\n\nIf you have encountered several concepts that the course does not elaborate, we recommend that you visit the Wikipedia homepage on the terms involved in this lesson for their definitions and further interpretations.\n\n# Tutorial\n\n\n`$trial=[\"Sleeping disorders in adolescents\" , \"Treating hypertension\", \"Vitamin levels in children\"]`\n\n`$test=[\"Patient\", \"Trial\"]`\n\n`$test2=[\"Patient\", \"Trial\"]` \n\nRun the following code: `[[Trial-level eligibility test($test,$test2,$patient)]]`\n\n```\n2) Eligible (0) Excluded (1) Not relevant (2) (object)[[0], (object)[[1], (object)[[2],\n      \"Not enough information to qualify for the trial.\"], \"Excluded\", \"\", {}},\n     \"{}\"]]\n```\n\nThe output should be identical to the first output.\n\nNow you know that you should print 1 if the trial does include the following criteria that are also applicable to the patient. \n\n```\n2) Eligible (0) Excluded (1) Not relevant (2) (object)[[0], (object)[[1], (object)[[2],\n      \"Not enough information to qualify for the trial.\"], \"Excluded\", \"\", {}},\n     \"{}\"]]\n```\n\nThe output should be identical to the first output.\n\nIf a criterion is met (both trial and patient) and the trial requires exclusion, print 0, otherwise print 2 (eligible). \n\n```\n2) Eligible (0) Excluded (1) Not relevant (2) (object)[[0], (object)[[1], (object)[[2],\n      \"Treatment of hypertension in children\" , \"0.0\", \"Not enough information\",\n      \"\", {}},\n     \"{}\"], (object)[[2], (object)[[2],\n      \"Lack of control of BP\", \"40-",
        "label": 1
    },
    "686": {
        "output": "__A sample output:__\nPatient_No/Alias                Trial-ID  Patient_No/Alias   Trial-ID    Trial-Level_Eligibility\n# Trial-ID: ACCELERATE\nPatient_No/Alias                ACCEL0179         1  Eligible\nPatient_No/Alias                ACCEL0179         1  Excluded\nPatient_No/Alias                ACCEL0179         1  Not_relevant \n\n__Recommended software:__\nYou will need to use the program on a Python version 3.8.8 or higher in the Anaconda environment with conda 4.10.8 or higher on your PC. You will also need to complete Python and SQL practice tutorials.\n\n# 1",
        "label": 1
    },
    "687": {
        "output": "This is a simple step that lets the user know what the user can do. In other words, it confirms that there are no exclusion criteria at the trial level.  \nSee how it looks like in the notebook `1_patient_notes_1__2_trial_level.ipynb`.\n<img src=\"https://user-images.githubusercontent.com/3554955/146816235-32c4f465-d007-45c0-90b6-00ad5d2bdb9f.png\" alt = \"1_patient_notes_1__2_trial_level.ipynb\" width = \"910\" height = \"896\" />\n\n**Input:**\n\n`In the patient note, all the exclusion criteria must be checked. `\n\n`What about the trial-level exclusion criteria:\n- 2) Not relevant,\n- 3) Excluded, or\n- 4) Eligible. `\n\n- The first step of the workflow: You need to calculate whether the user is eligible to participate in the trial. In other words, you need to make sure whether the conditions of inclusion are fulfilled. There are three parameters that can be considered.\nA user is eligible to participate in a trial when the following three conditions are met:\n1) the patient meets inclusion criteria\n   (the status of inclusion (1, 2) is relevant to the trial), 2) the patient does not have sufficient information to qualify for the trial (the status of inclusion (1, 2) is not relevant to the trial), and 3) the patient meets exclusion criteria, but is not excluded (the status of exclusion not-eligible (3, 4) is relevant to the trial).\n\nIf all conditions are met (the patient meets all inclusion criteria, the patient lacks relevant information regarding exclusion criteria, and the patient also does not meet exclusion criteria), this patient is an eligible participant.\nThe output that you need to provide to the user is a three-category variable indicating the assessment of eligibility, as a list, in which zero stands for excluded, one for not relevant, and two for el",
        "label": 0
    },
    "688": {
        "output": "```python\n\nimport numpy as np\n\nfrom flask import Flask, jsonify\nfrom myproject.data import patient_note\n\napp = Flask(__name__)\n\n\n@app.route('/')\ndef root():\n    data = patient_note.patient_note['In-trial_eligible']\n    return jsonify(data['In-trial_eligible'])\n\n\n@app.route('/evaluation')\ndef evaluate_eligibility():\n    data = patient_note.patient_note['In-trial_eligible']\n    return jsonify(data['In-trial_eligible'])\n\n\n@app.route('/evaluation/<id>')\ndef evaluate_eligibility_by_id(id):\n    data = patient_note.patient_note['In-trial_eligible'][id]\n    return jsonify(data['In-trial_eligible'])\n\n\n@app.route('/evaluation/<id>')\ndef evaluate_eligible_by_id(id):\n    data = patient_note.patient_note['In-trial_eligible'][id][\n        'Trial-level eligibility']\n    return jsonify(\n        data['Trial-level eligibility']['Patient-eligible']['Patient-eligibility'].keys())\n\n```\n\n[source][source-code]\n```python\n\ndata =patient_note.patient_note['In-trial_eligible']\ndata = np.array(data)\ndata = np.vectorize(lambda x: np.ravel(x))\n\ndata['patient_id'] = [patient_id]\ndata.Trial-level eligibility['Trial-level eligibility'] = [\n    [\n        [\n            {\n                'Patient-eligibility': [\n                    'Patient'\n                ]\n            }\n        ]\n    ]\n]\n```\n\nYou can access http://localhost:5000/root/evaluation to view the response.\n\n```html\n<h1>Result of patient note:\n<code>{'patient_id': [-",
        "label": 2
    },
    "689": {
        "output": "#### [A19] What if the trial includes a control arm with another treatment? \n[[INST] The treatment of CHD is multidisciplinary and comprehensive, including revascularization operation, drug or intravascular treatment, and cardiac rehabilitation. Revascularization, including percutaneous transluminal coronary angiography (PTCA) and coronary artery bypass surgery (CABG), is an important way to treat CHD, which can effectively increase the area of myocardial blood supply by opening completely or partially the stenosis or occlusion of the main vessels of the heart. Different people have different ideas about the choice of therapeutic drugs for CHD, and some people believe that western medicine can only give antithrombotic drugs at the initial stage, while others believe that the long-term use of western medicine can reduce the risk of myocardial infarction. Therefore, the use of a western medication is often necessary to maintain a normal heartbeat during the revascularization operation, postoperative rehabilitation and the recovery process. `<EOD> The role of vitamin D and VDR gene polymorphisms in primary ciliary dyskinesia\n\nRecent studies demonstrated that ciliary dysfunction and respiratory insufficiency are associated with alterations in bone physiology and osteologic manifestations in the lung. These effects are mediated by regulation of the cilia by 1,25-dihydroxyvitamin D 3 [1,25(OH) 2 D 3 ] signaling. Primary ciliary dyskinesia (PCD) is a rare autosomal recessive disease caused by impaired function of the mucociliary apparatus due to defects in motile cilia. Vitamin D and its receptor are likely key components for the development of cilia, and altered DNA methylation in these proteins has been observed in PCD. We investigated the association of circulating 25-hydroxyvitamin D (25OHD) levels, vitamin D binding protein (GC) levels in plasma and DNA methylation analysis of a VDR functional polymorphism, GC, and VDR genes (PCD12",
        "label": 1
    },
    "690": {
        "output": "### Step 2: Data preprocessing\n\nFirst, let's consider all the data for the CAD example:\n\n[TRAIN] \ndata_set=np.array([array([0., 16.16, -6., 1., 1., 1., 1., 1., 0., 18.6, 0.691, 0., 1., 0., 0., 1., 0., 0., 0., 1., 0., 0., 0, .]), array([[630, 3, 3, 1, 1.],, array([[5.044, 1, 0.5, 0., 0.064],, array([[1., 3.48, 1., 1.63, 0., 3.5],, array([[34.7, 100.5, 500., 67., 26,, array([68., 78., 96., 4., 13., 21., 14., 34., 16],], array([10.5,10.6,4.6,4.8,4.7,4.7,4.6,7.6,5.7]), array([355011., 107., -27., 1., 0., 0., 3., 0., 5.022, 0., 1.162, 0., 1., 1., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.],), array([3306., 3., 1., 1.],), array([[6100, 3, 3, 1, 1.],, array([[4.35e-4, 1, 0.5, 0., 0.064],, array([1.36, 1.2, 0.66, 0., 0.2],, array([4, 10",
        "label": 2
    },
    "691": {
        "output": "# Requirement\n\n## # `requirement` <file:Requirement.md>\nAdd any additional requirement for the user that he uses this package.\n\n<EOD> Inhibition of Glycyrrhetinic Acid\u2010induced Activation of Hepatic Stellate Cells by Bifendate\nGlycyrrhetinic acid (GA) induces the activation of hepatic stellate cells (HScs) by promoting fibrogenesis and the overexpression of connective tissue growth factor (CTGF). Bifendate is the first clinically approved medicine for its antifibrotic effects. We examined whether bifendate inhibits GA\u2010induced HSC activation.<EOD> In situ growth of CdS quantum dots on glassy carbon electrode for direct electrochemical detection of N-methylmyoinositol.\nA direct electrochemical method was developed for the sensitive determination of N-methylmyoinositol (NMMI) based on its in situ electrochemical reduction on glassy carbon electrode (GCE) to 5,6,7,8-tetrahydro-5,8,5'-tetramethyl-m-inositol (THIMI), which is further converted to 2,3-dihydroxybenzoic acid (DHBA) and finally to 1,2,4-benzenetricarboxylic acid 2,2,4-triacetate (BTA) with the assistance of a ferrocene methanol-K3Fe (CN)6-H2O2 system. By this electrochemical oxidative cleavage approach, 5.0 mM NMMI can be successfully detected by a differential pulse voltammetry (DPV) at an ultra-low potential window from 0.45 V to 0.7 V. The detection limit was measured to be 1.32 \u03bcM by DPV. It is the first report to describe an electrochemical approach for determining NMMI using a direct electrochemical reduction strategy. The method may hold great promise for electrochemical studies on the electrochemical reduction of bioactive natural polyols.<EOD> Nomenclature for factors of the HLA system,",
        "label": 1
    },
    "692": {
        "output": "### Case Study 2\nIn this case study, you will predict the effect of a particular single-nucleotide polymorphism (SNP) on the drug responses of patients who are treated with a common drug.\n\nWe will use `SNPs` R package `GenABEL` to analyze genetic data and use `RColorBrewer` package for a colorful visualization.\n\nIn this study, we use genetic data as predictors (e.g., SNPs) that may help to predict future drug responses or adverse drug reactions.\n\nThere are two types of genetic traits: \n1. Single-Nucleotide Polymorphism (SNP)\n2. Haplotypes\n\nFor single-nucleotide polymorphism (SNP), the genetic data come in the form genotype `0`, `1`, or `2`. These represent the count of occurrences of each of three possible allelic variants of a specific SNP.\n\nFor haplotypes, we use numerical values of genotype as `0: 0` (reference genotype), `1: 0, 1`, `2: 1, 0, 2` (dosage).\n\nThe data are summarized in the following section for both cases.\n\n#### SNP Data\n\nA complete set of genetic data of these eight single-nucleotide polymorphisms is available in the file `SNPs.csv` in the folder `./SNP.``\n\n\n\nA few descriptive statistics of these eight SNPs among the patients who have been treated with metformin are summarized in the following tables.\n\n| SNP | Number (sample size) |  Mean  |  S.D. | Minimum | Maximum |\n| --- | --- | --- | --- | --- | --- | \n| S780 | 571 | 0.765 | 0.988 | 0 | 19 |\n| S753 | 508 | 0 | 0.578 | 0 | 19 |\n| A1527 | 530 | 0 | 0.563 | 0 | 18 |\n| S75",
        "label": 1
    },
    "693": {
        "output": "**[HIDE]**\n<EOD> The role of social media in the communication of scientific publications: A Brazilian and Portuguese comparative analysis.\nOBJECTIVE\nThe dissemination of scientific publications has grown on social media, but to date, there is no research comparing how popular scientific publications communicate on this network in different languages and cultural contexts.\n\n\nMETHODS\nA comparative analysis of the social media communication of seven popular scientific publications in Brazil and Portugal was carried out between January and April 2022.\n\n\nRESULTS\nTwitter and Facebook had more publications than other social networks. There was a great diversity in the activities performed on Twitter, with the posting of texts, links, photos, and videos on the different publications. The newsletter was the most commonly used activity on Facebook, being performed by all publications in both countries. In Portugal, the number of subscribers of each Twitter profile was similar for each publication, while in Brazil there was a disparity in the number of followers.\n\n\nCONCLUSIONS\nThe analysis of activities performed on Twitter and Facebook demonstrated a greater diversity of strategies on these two social networks than on others, such as Instagram and WhatsApp. Although there was a similar number of Portuguese publications and subscribers in both Facebook and Twitter in all countries, more disseminating publications are found in Brazil than in Portugal. Therefore, future studies should analyze how the cultural context of the populations where the publications operate impacts the communication on Twitter and Facebook.<EOD> A comparison of techniques for localizing the ossicular chain to guide prosthesis implantation\nSUMMARY For a number of patients with ossicular chain discontinuities or defective ossicles, the use of incus or malleus prosthesis has successfully compensated for deficiencies in transmission of sound. It is essential to locate the defective ossicles with precision to ensure proper placement of the prosthesis and, ultimately, optimal hearing. A study was undertaken to compare two of current methods of localizing ossicles with an alternative technique we have adopted in our clinical work. The first is a standard technique using a 4 mm tip-fitted probe during surgery. We are now using another technique in which end-fitted probes, 6 mm in diameter, are used throughout pre-operative audiological testing with a stapedectomy and in-",
        "label": 1
    },
    "694": {
        "output": "</section>\n\n<section id=\"example_3\"><h3>Example #3: Multiple groups, multiple trials</h3><section class=\"subsection\" id=\"section_5143740744523\"><h3 id=\"example_3\"><a class=\"anchor\" href=\"#example_3\">Introduction</a></h3><section class=\"subsection\" id=\"example_3\"><hr>\n\nYou are an epidemiologist who is analyzing mortality risks among hospitalized children in your hospital during the past year. You used a 5-year interval to count how many times certain patient conditions occurred. In your analysis, you are curious about the distribution of diagnosed conditions among infants, children, and adolescents. \n   \n```R\ncondition <- read.table(\"condition.txt\")\ncondition$infant <- condition$Infant # Infant\ncondition$child <- condition$Child # Child\ncondition$adolescent <- condition$Adolescent # Adolescent\ncondition <- data.frame(infant=cond-ition$Infant, child=condition$Child, adolescent=con-dition$Adolescent)\n```\n\nHere is the data: \n\n   \n```R\ncondition\n```\n\n   \n```\n   \n+--------------------------------+-------+-------+---------------------------------+\n| infants                         |      |      | hospitalized conditions      |\n+================================+======+======+===============================+\n|                            Infant |      |      |                             |\n|                            2.00E+05 |      |                             |\n|                                    |      | <class 'data.frame'>         |\n|                                    |      |                             |\n|                            2.00E+05 |      |                             |\n|                -------------------------------------------------------|\n+--------------------------------+    |    |    |                             |\n+ infants                         |    |    | hospitalized conditions      |\n+--------------------------------+    |    |    |                             |\n|    2.00E+05                     |    |    |                             |\n|                                    |    |-----------------------------|\n+    2.00E+05                     |    |",
        "label": 1
    },
    "695": {
        "output": "\u2b50 We expect to receive your patient notes and a clinical trial within 1 hour.\n\n## [FIN]\n<EOD> A case of a man with testicular adenomatoid tumor\n\nTesticular adenomatoid tumors are very rare lesions, usually benign, and found incidentally during operations. These lesions are usually asymptomatic and do not have any prognostic implications. Histopathology is the method of choice to make a microscopic evaluation, as they are similar to salivary glands. Hereby, we describe a rare testicular tumor case presented in a 61-year-old male patient with clinical and radiological signs of testicular tumor.\n\n# Background\nTesticular adenomatoid tumors are rare tumors of scrotal ectodermal origin, characterized by a mixture of epithelial, myoepithelial, and endothelial elements. This tumor histology is similar to that of salivary gland tumors [bib_ref]  Adnexal tumours of the testis: the ultrasonographic appearance of 35 cases: a..., De Feo [/bib_ref] . These tumors can be found incidentally in a palpation or in an open or laparoscopic procedures, in most of the cases [bib_ref]  Adnexal tumours of the testis: the ultrasonographic appearance of 35 cases: a..., De Feo [/bib_ref]  [bib_ref]  An incidentally discovered testicular adenomatoid tumor and spermatocele, Mcnally [/bib_ref] .\n\n## Case presentation\nAn asymptomatic 61-year-old white male patient was referred to our radiology practice for abdominal ultrasonography and CT. His past medical history was significant with hypertension and cardiovascular disease and he had no history of any malignant lesion before. He is not taking any drug or supplements. He had no systemic effects after his last treatment with a cardiac pacemaker. In the physical examination, the patient had normal findings except for the presence of a swollen right testis.\nOn the other hand, his abdominal ultrasonography revealed multiple cystic lesions in size ranges 30-45 mm (Figs.",
        "label": 1
    },
    "696": {
        "output": "## D. Examples\n\n```\n# 0) Excluded:\nP00147     Patient met exclusion 2 # age > 40 years \nP00155     Patient met exclusion 2 # age > 40 years \nP00196     Patient met exclusion 2 # age > 40 years \nP00244     Patient was excluded 1 # history of myocardial infarction # included \nP00249     Patient was excluded 2 # age > 40 years \nP00322     Patient was excluded 1 # history of myocardial infarction # included \nP00387     Patient was excluded 2 # age > 40 years \nP00454     Patient was excluded 4 # current cigarette smoker # included \nP00919     Patient was excluded 3 # LDL \u2265 160 mg/dL \n\n# 1) Not relevant:\nP00003     Not age appropriate \nP00018     Not age appropriate \nP00146     Patient had no relevant medical history # no history of hypertension \nP00156     Patient was not in inclusion criteria 1.0; \nP00234     Patient had no medical history of myocardial infarction \nP00236     Patient met inclusion criteria 1.1. # age 20-40 years inclusive \nP00263     Patient met age inclusion criteria 1.1. # age 20-40 years inclusive \nP00271     Patient met age inclusion criteria 1.1. # age 20-40 years inclusive \nP00334     Patient had no medical history of myocardial infarction \nP00336     Patient had no medical history of myocardial infarction \nP00369     Patient was not in inclusion criteria 1.1. # age inclusive 20 to",
        "label": 0
    },
    "697": {
        "output": "### Implementation\n\n- [X](https://colab.research.google.com/github/cjllang/pycda/blob/main/README.md#implementing-the-problem)\n<EOD> The Cerebellum and Spino-Ophthalmic Tinnitus: The Importance of Cerebrovascular Occlusion\n\nA 33-year-old man with acute left retro-orbital and left upper extremity numbness was admitted to our hospital with suspected transient ischemic attack (TIA). He reported a sudden sensation of buzzing sound in his ear about one month earlier. An initial cranial magnetic resonance imaging scan (MRI) revealed acute infarction in the right cerebellum. A follow-up carotid ultrasound identified bilateral high-grade stenosis and occlusion of the internal carotid arteries. He underwent carotid endarterectomy after three months of aggressive risk factor control, the internal carotid artery on the right side was eventually replaced with a shunt. Despite significant improvement of motor function during the following year, the patient complained of a persistent tinnitus in the left ear, which was associated with ipsilateral retro-orbital pain. Subsequent cranial MRI scans showed enlargement of the hypometric area of the right cerebellar hemisphere associated with increased signals on T2-weighted and fluid-attenuated inversion recovery images, and no significant recovery on diffusion-weighted images, 13 months after onset. Based on all the clinical symptoms and images, we diagnosed his deafness as left spino-ophthalmic tinnitus, and hypothesized about the pathophysiology.\n\n# Introduction\nCerebellar tinnitus is an abnormal perception of noise in one ear caused by dysfunction of the cerebellum. [bib_ref]  Tinnitus-catastrophia del sonido del cerebelo?, Vizel [/bib_ref]  The cerebellum has reciprocal projections to both the contralateral thalamus and ipsilateral cochlear nucleus and has connections with the midbra",
        "label": 1
    },
    "698": {
        "output": "[INST]\n\n### Recommendation\n- We recommend that you should follow the guideline which is shown in the red area. The input variables are written as \"Trial-Level Eligibility\".\n\n# Example of a solution\nHere is an example of a solution. You can learn how to write an R script by reading the solution.\n\n```r\n# TrialLevelEligibility <- c(\n#       \"0) Excluded\",\n#       \"1) Not Relevant\",\n#       \"2) Eligible\"\nTrialLevelEligibility <- c(\"0\", \"1\", \"2\")\n# Your assignment is Trial-level eligibility\nTrialLevelEligibility\n\n# Your assignment is Patient-level eligibility\nPatientLevelEligibility <- c(\"0\", \"1\", \"2\")\n\n# Your assignment is Trial-Level Eligibility\nTrialLevelEligibility <- c(\"0\",\"1\",\"2\")\n\n# Your assignment is Patient-level Eligibility\nPatientLevelEligibility <- c(\"0\",\"1\",\"2\") \n\n```\n<EOD> Chest ultrasound findings in a case of SARS-CoV-2 infection: a case report\n\nIn the current coronavirus disease 2019 pandemic, diagnosis of suspected or confirmed cases relies on a positive reverse transcription polymerase chain reaction of the viral RNA or highly trained clinical suspicion. The emergence of atypical presentations of this disease led to using complementary imaging for differential diagnosis. This study presents a case of confirmed SARS-CoV-2 where all common radiological findings were presented. The chest ultrasound was performed to detect any radiological signs, and a typical \"white lung\" pattern with signs of alveolar-interstitial syndrome was found.\n\n# Introduction\nMany viruses, mostly of the family coronaviruses, are known to be causing respiratory infections in the previous century. The most famous one is the severe acute respiratory syndrome coronavirus (SARS-Co-V). Coronavirus disease 2019 , identified as an emerging infectious disease in December 2019, was first reported in China, Wuhan",
        "label": 0
    },
    "699": {
        "output": "## Exercise\n\nIn 30 minutes, try completing the exercise.\n\n1. Find a patient, as in 1.1. Consider that the patient note is incomplete in 1.2. Try to fill it in, and in the last column, use Trial-level eligibility to check the eligibility (in 1.2.a).\n\nCongratulations! You are now able to assess a patient's eligibility using the Trial-level eligibility assessment.\n\n## Discovery\n\n## Discovery is one of the features that distinguishes clinical research from other branches of science and technology.\n\nIn this module, you will be guided step by step through each of the Discovery aspects of a data analysis to produce a statistical model that enables the researcher to draw conclusions from the trial's data. You will discover the differences between a simple regression model compared to a richer model that helps you to answer more important and meaningful questions on study outcome. You will also practice calculating effect size, which is an important indicator of practical importance or relevance of statistical effects.\n\nAt the end of the lesson, you will be able to identify the various Discovery aspects of clinical trial data analysis, and be able to calculate effect size for different statistical models.\n\n## 1.1  What are the aspects of Discovery?\nYou have learned much about clinical trial design through the previous modules. The following module focuses on another aspect of the clinical trial: Discovery. The purpose of Discovery is to discover whether a new biological or therapeutic intervention is of interest in a new disease area. In other words, does this intervention change the primary or secondary endpoint?\n\nThe Discovery aspects encompass the data collected from the trials, from baseline to the outcomes, which include the following:\n1.1.1. Descriptive statistics. Here are a few examples:\n1.1.2. Variables related to the treatment effect. Here are a few examples:\n1.1.3. Variables related to dropouts. Here are a few examples:\n1.1.4. Variables related to adverse events during the clinical trial. Here are a few examples:\n1.1.5. Variables related to participant characteristics. Here are a few examples",
        "label": 0
    },
    "700": {
        "output": "To summarize, the patient is eligible for clinical trial participation if and only if the values in the last two columns (Trial-Level Eligibility and Patient-Level Eligibility) are both 2, e.g., `Trial-level eligibility:\n[formula]  2) Eligible; Patient-level eligibility 2) Eligible,`.[INST] [/formula] \n\n\n## Examples\n\n \n\n## Input file (assistant.txt) \n[INST] You should read the input file in the first cell by the `readline` command.\n\n`Input file: assistant.txt`[INST] `readline(file =\"input-file.txt\")[INST] ```\n[INST] The function `f1` outputs the trial level eligibility, including the patient level eligibility, and the function `f2` outputs only the patient level eligibility. To specify the output text file to write the output by `f1` and `f2`, we should use the function `filewrite(file =\"file-name.txt\")` by following the comments \n\n```\npatient-level eligibility:\n\nEligibility: Excluded\nPatient-level eligibility:\n\nTrial-level Eligibility:\n\nTrial-level Eligibility: 2) Eligible\nPatient-level eligibility:\n\nEligibility: Excluded\nTrial-level eligibility:\n\nTrial-level Eligibility:\n\nTrial-level Eligibility: 2) Eligible\nPatient-level eligibility:\n\nEligibility: Not relevant\n```[INST] [INST] Since `f1` prints the result to the screen in the interactive session, you should use the `!` button to write in a new line. [INST]\n\n[INFO]: The trial-level eligibility is the following: \n\n```python\ntrial-level eligibility:\n\nTriallevel eligibility:\n\nEligibility: Eligible\n```\n\n[INFO]: The patient-level eligibility is the following: \n\n```python\npatient-level eligibility:\n\nEligibility: Excluded\n```\n\n[INFO]: The trial",
        "label": 2
    },
    "701": {
        "output": "# Examples\n\n## Example:\n```python3\ndef calculate_test(patient_note, clinical_trial):\n\tresult_trial_level = \"\"\n\n\tdef return_trial_level_eligibility(patient_note):\n\t\tfor i in clinical_trial.notes:\n\t\t\tif patient_note == i[\"patient_note\"]:\n\t\t\t\tresult = \"Not relevant (\" + i[\"note\"] + \") \" + i[\"_source\"]\n\t\t\t\treturn result\n\t\treturn False\n\n\tif return_trial_level_eligibility(patient_note):\n\t\t# Get eligibility score\n\t\tresult_trial_level = \"Excluded (\" + \"0\") + \" \" : patient_note \"Not relevant (\" + \"1\") + \" \" + \"2)\"\n\telse:\n\t\tresult_trial_level = \"Elgible (\" + \"2)\")\n\n\treturn result_trial_level\n```\n\n## Example:\n```python3\nclinical_trial1 = 1\nclinical_trial2 = 2\nclinical_trial3 = 3\nclinical_trial4 = 4\nclinical_trial5 = 5\nclinical_trial6 = 6\nclinical_trial7 = 7\nprint(r\"%s. Trial-level eligibility:\".format(clinical_trial1))\nprint(calculate_test(\"John Cage is one of most influential composers of this century.\", clinical_trial1))\nprint(r\"%s. Trial-level eligibility:\".format(clinical_trial2))\nprint(calculate_test(\"Cage's compositions span a variety of media, including music, artworks, writing, film, and ideas.\", clinical_trial2))\nprint(r\"%s. Trial-level eligibility:\".format(clinical_trial3))\nprint(calculate_test(\"Although his music is frequently performed, relatively few compositions are currently available on CD.\".format(clinical_trial3), clinical_trial",
        "label": 0
    },
    "702": {
        "output": "[[END]] </codeblock> In the code \n\n> class ClinicalTrial < ApplicationRecord #<ActiveRecord::Base;\n\n> \n> \n> def eligibility_stratification_rules(recruitment_status: :recruiting)\n>   # Add this method according to requirements of the clinical trial\n>   # TODO: Add your eligibility_stratification_rules\n>   if recruitment_status == :recruiting\n>     \"Trial-level eligibility: Excluded\"; if inclusion_criteria_list.blank? && exclusion_criteria_list.blank? && inclusion_criteria_id.nil? && exclusion_criteria_id.nil?\n>     \"Trial-level eligibility: Not Relevant\"\n>     \"Trial-level eligibility: Eligible\"\n>   else\n>     # Else non-recruiting\n>     \"Trial-level eligibility: Not Relevant\"\n>   end\n\n</pre>\n[/codeblock]\nHere, the clinicaltrail's model contains eligibility_stratification_rules.\n\n### Codes for eligibility assessment\n\nEligibility has two assessment levels. \n\n### Codes for trial-level eligibility\n\nIn this category, we should assess how each patient should qualify. \n\n### Codes for patient-level eligibility\n\nIn this category, we should assess whether each patient should be included in the given trial. This assessment of patient-eligibility has also a three-point scale: 0) Excluded (patient is excluded based on the trial-exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria are not applicable). \n\n### Case study 3\nHere is a case study. One of the co-author's team members experienced a cardiovascular emergency and decided to apply for the data science method he has been researching for a long time. By the way, this is why she is a member of the research team. When she saw that the research team's model is about the",
        "label": 1
    },
    "703": {
        "output": "Your work is done! If you want, submit your code to [https://www.kaggle.com/], which is a site for machine learning and data science competitions. If you don't want to, don't worry. You have completed this exercise for yourself!\n\n[PROG]<EOD> Genetic and Transcriptional Networks Underlying the Loss of Meiotic Divisions in the Cryptococcus deneoformans hgc1 Deletion Locus\nDiploid fungi undergo meiotic divisions and must assemble mature, pairing-compatible homologous chromosomes. In the basidiomycete Cryptococcus deneoformans, lack of a meiosis-associated coiled-coil (MACC) protein, hgc1 (histone variant gene complementation gene 1), prevents meiosis without inducing apoptotic cell death. Here, we characterized the hgc1 deletion locus to elucidate the mechanism by which lack of this essential protein eliminates entry into meiosis. The hgc1 deletion allele is unstable in both vegetative and meiotic progeny, suggesting a mechanism that prevents chromosomal inheritance rather than a simple lack of hgc1. Analysis of meiotic metaphase I chromosomes revealed that the hgc1 deletion locus forms a small (\u223c0.3 \u00d7 0.2 \u03bcm), irregular structure that is reminiscent of a nucleolus. The structure contains the histone gene cluster, but most genes are not detectably transcribed during vegetative growth and meiosis. Haploid descendants of meiotic progeny are genetically unstable, accumulating various chromosomal rearrangements, suggesting that lack of HGC1 does not impair meiotic recombination. A small population of cells that formed mature basidia containing viable tetrads arose as spontaneous mutants lacking the hgc1 deletion structure. These hgc1 deletion rescue strains initiate the meiotic pathway, accumulating small dikaryotic nuclei that display a wild-type stereotypical arrangement of meiosis I chromosome segregation. These results raise the question of how hgc1 delet",
        "label": 1
    },
    "704": {
        "output": "You may consider only using a few variables (e.g., sex, race, age, etc.), so you can simplify your data by using a one-hot encoding that converts the values from columns into binary columns (0/1 vectors). For instance, 7 races were encoded as seven binary variables, 0/1 column. Similarly, 9 age groups were each encoded as nine (0/1) columns to be tested in the classification model. \n\n[INC] `one_hot_encoders = ['Race', 'Age']`\n\nYou can add/remove new variables in the `one_hot_encoders` list. Make sure you add or remove them in the same order as they appear in the dataset. For instance, the following line in the script is invalid because the 'Race' variable is at the end of the list.\n\n[INST] `one_hot_encoders = ['Race', 'Age']`\n\n`one_hot_encoders [0] = ['White', 'Black', 'Hispanic', 'Asian', 'Native American']`\n\n## Preprocessing\n\nWe need to combine two CSV files that are stored under the `input_data` directory (or whichever location you specified in the filepaths function). Note: this step is repeated for each trial_id.\n\n[INC] `train_data_path = 'data/example1-train-data.csv'`\n\n[INC] `test_data_path = 'data/example1-test-data.csv'`\n\n[INST] `combined_input_data = pd.read_csv(str(train_data_path), header=None)`\n\n[INST] `combined_input_data = pd.read_csv(str(test_data_path), header=None)`\n\nWe need to use the `add_one_hot_features` function with the one_hot_encoders variable to transform text features in the data to 0/1 binary representations.\n\n[INST] `add_one_hot_features = pd.DataFrame(pd.DataFrame.to_numpy())`\n\n[INST] `add_one_hot_features = add_one_hot_features.append(df[one_hot_encoders[0]])`",
        "label": 1
    },
    "705": {
        "output": "You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm",
        "label": 0
    },
    "706": {
        "output": "### Example output of the program\n   \n<EOD> The effectiveness of an individualized approach to teaching physical examination skills.\nIn the last decade it has become more apparent that there are numerous problems with the traditional lecture method in medical education and that this method is not meeting the needs of today's students. In an effort to address these problems, instructional methods such as lecture plus skills laboratories and problem based learning have been developed to encourage more student-centered learning. Unfortunately, these methods still fall short of the real-world demands of a student's medical education. In their attempt to address this issue, the medical faculty at the University of Toronto developed and implemented an individualized skills program that is now being taught at more than 12 different sites across the province. This article will discuss the method and rationale behind the development and implementation of this program at the University of Toronto. Furthermore, we will discuss the preliminary results from three different educational sites that have been utilizing the individualized skills program.<EOD> Dual-energy subtraction angiography: in vivo preliminary results in patients with subtotally resected carotid stenosis.\nPURPOSE\nTo prospectively investigate the feasibility of dual-energy subtraction angiography (DESA) by using intravenously (I V) administered iodine contrast material (C).\n\n\nMETHODS\nA monoenergetic dual-detector system was designed with the purpose of acquiring projection data according to the following energy characteristics: 95 keV and 140 keV. The acquired data for a preand postcontrast projection were combined through dual-energy subtraction (DES) of the two projection datasets to produce DESA images. Seven patients who had subtotally resected carotid stenosis and who had a cerebrovascular hemodynamic impairment caused by a flow-limiting carotid stenosis underwent DESA imaging. The intravenously administered I' and 130 mg I' of Omnipaque (New England Nuclear, Boston, MA) were injected into an antecubital vein by using a power injector. CM and DESA images in 2-mm increments are acquired. Postprocessing of the DESA images allows",
        "label": 0
    },
    "707": {
        "output": "Please, let me know if this solution is of any help to you or not, and also I hope this tutorial could be useful to others in need. Thanks!\n<EOD> Exposure to the metabarcoding primer is a major driver of the observed heterogeneity in COI sequence data\n\nMetabarcoding-based studies are increasingly applied to study biological diversity and to screen environmental DNA (eDNA) data for the presence of invasive species. The sensitivity, however, of metabarcoding primers to polymorphic sites is often ignored, which can result in overrepresentation of certain primer binding groups. Here, we use a comparative approach to explore the contribution of primer binding group (PBG) to species abundance, the extent to which PBGs are linked with biological parameters such as species size, species diversity and relative abundance in order to investigate the underlying mechanisms of PBG selection. We used comparisons between COI metabarcoding and Sanger sequencing datasets to examine the influence of primer binding site selection bias on sequence heterogeneity. We found that COI metabarcoding is biased towards taxa that have multiple copies of the exact complementary nucleotide in the COI coding sequence. These groups are mainly comprised from taxa with a larger mitogenome size, high taxon richness and species abundance. We therefore propose to consider the number of PBGs as one of the factors affecting metabarcoding success, particularly when the goal is to maximize taxon richness.Electronic supplementary material:The online version of this article (https ://doi.org/10.1007/s1098 0-020-01098 -9) contains supplementary material, which is available to authorized users.\n\n# Introduction\nThe field of metabarcoding continues to evolve and is gaining popularity within science since it allows the identification of hundreds of species within ecological communities using only a tiny sample [bib_ref]  DNA barcoding: error rates based on comprehensive sampling, Meyer [/bib_ref]  [bib_ref]  A large-scale evaluation of marker performance in eDNA metabarcoding of fishes based..., Bigman [/bib_ref]  [bib_ref]  Global diversity of acoelomate worms (Acoela) reveals multiple",
        "label": 1
    },
    "708": {
        "output": "__Note__:\n- Make sure to read this example carefully. It includes a number of things that are discussed in Chapter `Using Markdown`.\n- [INST>] Use <NAME> to make references to your colleagues. You can replace <NAME> with your own name/surname.\n\n[INST>]: [cite:1]\n__Example 9__: The relationship between cardiac hypertrophy and the risk of mortality in a hypertensive population.\n\n1. This table is not included in the following paper.\n\n2. Data are expressed as estimated hazard ratio and 95% confidence intervals. The estimated hazard ratio is an adjusted hazard ratio, to the extent possible, from the multivariable analysis (for a complete description of the adjustment covariates, see the legend on this table).\n\n__Example_12__: Using Markdown on Linux\n\n---\n\n1. Markdown may sometimes fail in Linux while the reason is not always clear: here is some tips to solve this issue.\n2. First of all, remember that Markdown should not be embedded inside Markdown files. \n```\n```\n---\n\n1. One thing that you need to do is to add ~ to start a new line. If you do a Ctrl+l, the text is automatically wrapped in a new line. This is not really a bug, but a problem for the word processor to correctly render Markdown commands. You may find solutions that fix this issue. Other words, it is always possible to avoid wrapping things, if you know how to write.\n```\n```\n\n1. In fact, you can use many other commands to override the behavior of the word processor with Markdown. For example, if you want to change the font family, you can use the following command:\n```\n```\n```\n---\n\n1. Whenever Markdown fails, remember that Markdown's syntax is very simple and it is therefore a good learning experience.\n```\n```\n```<EOD> Effect of 6\u2010month treatment with recombinant human erythropoietin on reticulocyte count and erythroid precursor number in patients with end\u2010stage renal disease\nAbstract:\u2002 It is unclear whether an appropriate erythropoietin (rHuEpo) treatment schedule can prevent anaemia in patients with ren",
        "label": 0
    },
    "709": {
        "output": "<EOD> Cytomorphology of pleomorphic adenoma of the salivary glands in fine-needle aspirates: A study of 11 cases\n\nPleomorphic adenoma (PA) is the most common neoplasm of the major salivary glands. However, there are reports of its occurrence in minor glands and also in other locations. The tumour is benign in nature, but shows some locally invasive growth pattern. It has a peculiar growth pattern and cytomorphology due to the two major components: epithelial and myoepithelial. The aspiration cytology of the tumour depends on the relative amount of each of these cellular components present. Fine-needle aspiration (FNA) cytology of large mass lesions may produce inconclusive results and may require cell block preparation and conventional histopathologic examination for accurate diagnosis. The diagnosis of PA of minor glands requires very high index of clinical suspicion and specific location of the tumour and a high index of suspicion on cytology. We evaluated eleven cases of pleomorphic adenoma as FNAC material from May 2005 to April 2010. They included predominantly female patients (80%). There were nine cases of parotid gland (81.81%); one periobuccal gland and another from a minor salivary gland (tail of parotid). Most of the cases (seven) showed a mixed cellular population of epithelial and myoepithelial cells [Papanicolaou (PAP) stain, 200X] while three cases showed predominantly myxoid stroma [Picrosirius Red stain, 400X]. One case was adenoid cystic like [PAP, 200X]. Oncocytic changes and squamous metaplasia were noted in one case [PAP, 200X] each. Our series of fine-needle aspiration cytology of pleomorphic adenoma is very interesting to note the various variant appearances that can be seen in the cytologic picture.\nPleomorphic adenoma (PA) is the most common benign neoplasm of salivary glands. It is mostly",
        "label": 0
    },
    "710": {
        "output": "A: It seems easy enough to figure out but a hint:\n1. Look at all the values - the patient notes and the clinical trial notes - and then combine them together.\n2. If multiple values are present - either from the patient notes or from the clinical trial notes - you must combine the values to a singular answer and put it in that line.\nSo in this example, there is:\n- a patient's name - \"Alvin\";\n- 46 years old;\n- family history - \"no cardiovascular risk factors\";\n- LDL-C and HDL-C - \"545 and 53 respectively\";\n- fasting glucose and triglyceride levels - 85 and 158 mg/dL;\n- no use of lipid-lowering medications;\n- patient notes for the clinical trial:\n- Title: Carotid Atherosclerosis In Newly Diagnosed Type 2 Individuals Summary: It has been hypothesized, based on recent trials, that only early intervention can reduce cardiovascular morbidity and mortality in individuals with type 2 diabetes (T2DM). This finding may imply that atherosclerosis at diabetes diagnosed is either negligible, or at early, or non-advanced still modifiable disease stage. However, sparse information is available regarding atherosclerosis prevalence and its characteristics at diabetes presentation. Furthermore, although cardiovascular disease (CVD) prevention is the major goal of treatment in T2DM, risk assessment tools, mostly based on traditional CV risk factors lack of adequate specificity to identify individuals at higher risk. Therefore, non-invasive tests, such as carotid ultrasound, have been recommended to better define CV risk in several groups of individuals, including those with intermediate risk or with T2DM.~Patients with T2DM have a higher prevalence of several CV risk factors, so individuals with newly diagnosed T2DM (NEWDM) will be matched with non-diabetic (CONTROL) individuals for age and sex (the main determinants of atherosclerosis), but also for known, treated hypertension and dyslipidemia, and smoking habit.~",
        "label": 1
    },
    "711": {
        "output": "<issue_comment>username_3: ### [\ud83c\udfaa Background](https://clinicaltrials.gov)\n\n```\n[INST]\nTitle: The Gore SCAFFOLD Clinical Study\nSummary: Evaluate the safety and efficacy of the GORE\u00ae Carotid Stent for the treatment of carotid artery stenosis in patients at increased risk for adverse events from carotid endarterectomy\nInclusion criteria:\nPatient is at least 18 years old at informed consent\nPatient is willing and capable of complying with all study protocol requirements, including specified follow-up period and can be contacted by telephone.\nPatient is willing to provide written informed consent prior to enrollment in study.\nPatient is either:\nSymptomatic with carotid stenosis \u226550% as determined by angiography using NASCET methodology. Symptomatic is defined as amaurosis fugax ipsilateral to the carotid lesion; Transient Ischemic Attack (TIA) or non-disabling stroke within 180 days of the procedure within the hemisphere supplied by the target vessel; OR\nAsymptomatic with carotid stenosis \u226580% as determined by angiography using NASCET methodology\nPatient must be considered high risk for adverse events during carotid endarterectomy\nNote: Additional inclusion criteria may apply\n\n[HINT] Let's think step by step.\n\n[INST] Finally, you should always write `Trial-level eligibility: 2) Eligible.` in the last line by `Trial-level eligibility:`.\n[/HINT]\n```\n\n#### Exercise of the [\ud83c\udfaf Task 5b](./task-5b.md)\n\n<EOD> Identification of two new H-2 b mutant mice with disruption of the gene encoding the class I HLA molecule Qa-2.\nThe genetics of the murine major histocompatibility complex (MHC) has been a model system for studies of disease-associated susceptibility/resistance genes. Mice which are completely devoid of the class I HLA Molecule encoded",
        "label": 1
    },
    "712": {
        "output": "## [FEMPI_PROBLEM 1.A.1]\nYour task is to calculate a `trial-level` score for the assessment of eligibility according to the method `TrialLevelScore` using the `trial-level` data. You can read about the method `TrialLevelScore` in the next [FEMPI_PROBLEM 1.B.1]. You can read about the data to use for this method in the next [FEMPI_DATA 4.A.1]. After reading all the following, you should code the following Python lines: \n#import numpy as np import matplotlib. pyplot as plt from sklearn.svm import SVC from sklearn.linear_model import LinearRegression from scipy.signal import find_peaks # Define a score in the case of the exclusion of a patient (0) # Define a score in the case of a patient being not-relevant (1) # Define a score in the case of the inclusion of a patient (2) # Calculate the trial-level score # Score= np.ones(len(fempi_prob_trial)) # For n_patient=3 : # Calculate the score for the first patient # Trial-levelscore= n_points_for_criteria==0 ? np.ones(1, dtype=int) : # Score1= np.ones(1, dtype=int)+(1-score1_avg)/100 # where score1_avg is the mean score of the second patient # Score1= score1_avg * (Score_to_calculate_score1 / 100) # where score1_to_calculate_score1 is the trial-level score of the second patient # Score_to_calculate_score1= np.ones(1, dtype=int) # Calculate the score for the second patient # Trial-levelscore= n_points_for_criteria==1 ? np.ones(1, dtype=int) : # Score2= np.ones(1, dtype=int) * (Score1_avg / 100) # where score1_avg is the mean score of the second patient # Score2= score1_avg * (Score_to_",
        "label": 1
    },
    "713": {
        "output": "A multicenter double-blind study that assessed the effct of donepezil hydrochloride (Aricept) on mild cognitive deficits in patients with vascular brain disease. A total of 395 patients over the age of 50 were randomly assigned to placebo (n=171) and active drug (n=224) groups. There were no differences in the degree of decline in cognitive performance during a 26-week period between the 2 groups. Donepezil hydrochloride had no effect on cognitive functioning or mood in patients with mild to moderate vascular cognitive impairment, even though donepezil improved cognitive performance in some patients. (source: UpToDate)\n\n## Exercise1_dl9507_solution.Rmd\n## # 3.2. VISUALIZATION Exercise 1\n\n## # 3.2.1. Tutorial\n\n### Plot the sample characteristics.\nsummary(D9507_data)\n\n\n## ### #plot patient's individual data\nplot(D9507_data, type = \"ind\", main = \"Individual data)\n\n\n## ### # plot sample mean\nplot(D9507_data, type = \"",
        "label": 1
    },
    "714": {
        "output": "## Exclude Patient Due to Trial's Incompleteness\nThe trial includes and assesses a different set of variables and parameters than the trial's eligibility. The trial's design must satisfy all patients for whom the variables are available, even if the variables are not in the eligible parameters.\nThe following should occur:\n\n1. Assess Tri",
        "label": 1
    },
    "715": {
        "output": "### Exercise 40  \n\nIssue 3 has been discussed at the weekly meeting of the Clinical Governance Team. The team has agreed to move forward with the clinical pathway and that all the patients with the conditions that fit the clinical pathway will follow the pathway. A clinical pathway is a set of sequential steps designed to guide the care and treatment of patients with specific health problems. It is a document that describes each step in patient care, from the moment when the patient enters the healthcare system to the moment of discharge. \n\nClinical Pathways are designed to improve the quality of care, reduce variation in care, improve cost effectiveness, and reduce hospital stays and associated costs. They can improve communication about the patient's care. Clinical governance describes the processes by which an organization ensures consistency in best practice across the system, and is",
        "label": 2
    },
    "716": {
        "output": "* This code is the same as the example code.<EOD> A method comparing the sensitivity of the tuberculin and Mantoux tests.\nThe tuberculin and Mantoux tests were compared in 60 children, using the sensitivity of a skin test as defined by J. G. L. Hutchison and his colleagues (3). The Mantoux test proved to be more sensitive than the tuberculin test in each of the three categories of the former. The tuberculin and Mantoux tests were also compared in 47 men and one woman, using the sensitivity of a tuberculin test as defined by Hutchison et al. The Mantoux test proved to be more sensitive than the tuberculin test in 39 of these 48 patients.\n The skin tests were applied as parallel tests. In the study of the children at the time of a routine skin test, the test results were compared, using both the individual readings and the group readings of the tuberculin and Mantoux tests. The individual readings showed significant differences in the sensitivities of the tests in 41 of 60 children and the group readings in 57 of 60 children. The Mantoux test showed a higher sensitivity according to the group readings than did the tuberculin test in all three categories of the Mantoux test.\n These comparisons indicate that the Mantoux test provides sensitivity comparable to that of the tuberculin test, while at the same time increasing considerably the ease and comfort of the procedure and perhaps the reliability as well.<EOD> In vitro Effects of L\u2010Carnitine on the Function of Lymphocytes from Healthy Humans\nWe examined the in vitro effects of a water\u2010soluble, biochemically active nutrient, L\u2010carnitine (beta\u2010hydroxy\u2010gamma\u2010N\u2010trimethylaminomethylbutyric acid), on the function of lymphocytes from healthy human subjects. L\u2010carnitine was not toxic to lymphocytes at concentrations equal to or below its saturating concentration (2.24 mM); in addition, L\u2010carnitine at a supraphysiologic concentration (22.4 mM) increased the survival rate of normal lymph",
        "label": 1
    },
    "717": {
        "output": "### Exercise\nIn the following exercise you should complete the eligibility matrix by comparing the patient and clinical trial with an instruction manual. When comparing, choose the most appropriate answer.\n\n## Exercise: Clinical trial and patient eligibility by an instruction manual\n\n\nInstructions:\nIn this exercise you should complete a table by determining whether a patient would be eligible for a clinical trial. For this, please compare the patient's characteristics with the instruction manual.\n\n| Trial | Patient | Instructions|\n|------------|------------ |-----------|\n| LOTUS |A 46-year-old man | The subject must be > 21 years of age.|\n| LOTUS |This patient is over 21 years of age.|\n| LOTUS | This is an inclusion criterion since this patient is over 21 years of age.|\n| LOTUS | His life expectancy of the  \\+/\\  the minimum distance of 5 cm between the clavicle and bifurcation, as assessed by duplex Doppler ultrasound, computed axial tomographic (CT) angiography or magnetic resonance (MR) angiography.\n| The subject has a minimum distance of 5 cm between the clavicle and bifurcation, as assessed by duplex Doppler ultrasound, CT angiography or magnetic resonance (MR) angiography.|\n| LOTUS | \\+/\\ \\+/\\ \\+/\\ |\n\n## Exercise Solution: Clinical trial and patient eligibility by an instruction manual\nEligibility criterion:\nInclusion criteria:\n| LOTUS | > 21 years of age   \\+/\\ minimum distance of 5 cm between the clavicle and bifurcation |  \\+/\\ \\+/\\ |\n\n### Exercise Solution\nThis is the eligibility matrix after completing the exercise with the instruction manual. Eligible patients have at least one eligibility item. Ineligible patients have no eligibility item. A patient is not evaluated when no information is available.\n\n\n| Criterion | Eligibility| Explanation |\n|------------ |------------ |------------ |\n|Life expectancy| \\+",
        "label": 1
    },
    "718": {
        "output": "References [INST0]: `References [INST0]:`.\n```python\ndoc = '''doc body'''\n\ndef eligibility_assessment():\n\n    [instructions for each step in bullet points]\n\n    # first step\n    pass\n\n    # second step\n    pass\n\n    # third step\n    pass\n\n    # last line for this bullet point\n    if __name__ == \"__main__\":\n        print 'Trial-level eligibility: 2) Eligible.'\n    pass\n\nprint_instructions()\nprint_results()\n\n<EOD> Progenitor Cells from Blood for Stroke Patients\nStroke is one of the leading causes of death in the United States, with 795 000 new cases and 180 000 deaths occurring in 2003.1 The direct and indirect annual costs of stroke care exceed $62 billion.2 More than half of all strokes are ischemic, and up to 20% of patients will become dependent on others for activities of daily living.3 Although a large number of neuroprotective and neurogenic treatments have been tested during the past two decades in preclinical stroke models, few have been translated into the clinic. The failure of the neuroplasticity response of the residual neural network to be recruited may contribute to the relatively poor clinical outcomes seen in ischemic stroke patients. Cellular replacement with progenitor cells from both neural and nonneural origin has been proposed as a means to circumvent the problem of failing plasticity. In 2006 three small studies demonstrated the recruitment of endogenous neurogenesis after administration of human bone marrow-derived mesenchymal stromal cells (MSCs) in preclinical stroke models.4\u20137 As a result, four ongoing multicenter stem cell trials for treatment of subacute and chronic ischemic stroke are testing the infusion of mesenchymal stromal cells from bone marrow or adipose tissue (clinicaltrials.gov). The cellular infusion method varies: one study administered cells through a catheter into the internal carotid artery; another",
        "label": 2
    },
    "719": {
        "output": "<EOD> Characterization of human peripheral blood lymphocytes responding to human immunodeficiency virus (HIV) type 1 antigens. The V1 loop region of HIV-1 gp120 induces a strong response of alpha beta CD4-/CD8- T cells while the V2 and V3 regions and the C3 and C4 peptides of HIV-1 gp160 induce a weak response of T cells bearing CD4 on their surface with or without co-expression of CD8.\nThis study focuses on the response of T lymphocytes generated by the treatment of PBMC with the V1 loop region (amino acids 11 to 197), the V2 region (amino acids 192 to 307), the V3 region (amino acids 304 to 438) and the C4 peptide (amino acids 401 to 423) of HIV-1 (HIV-1 gp120-307 synthetic peptide) or envelope peptide (HPV envelope peptide of HP",
        "label": 0
    },
    "720": {
        "output": "<EOD> Comorbidities Increase the Severity of COVID-19 among the Elderly: An Analysis of a Massive COVID-19 Cohort in Japan\n\n\n\n# Introduction\nThe novel coronavirus responsible for the Coronavirus Disease (COVID-caused a pandemic, and >600 million people have been infected by March 2022. Although this pandemic was less severe in children, the elderly experienced severe symptoms and mortality with a high mortality rate of >10% in patients \u226585 years of age. Old age, male sexand comorbidities (diabetes mellitus, hypertension, ischemic heart disease, cerebrovascular disease, arrhythmia, heart failure, lung diseases, and chronic kidney are risk factors for severe symptoms in COVID-19 patients.\nThere are several issues about COVID-19 among the elderly: a report from the United States showed higher rates of hospitalization in individuals \u226565 years; other reports showed higher rates of hospitalization, intensive care unit admission, development of acute respiratory distress syndrome, and critical illness in elderly COVID-19 patients. The reason for these phenomena might be a difference in the expression of Angiotensin-converting enzyme-2 (ACE2), and the degree of immunosuppression caused by increased age is suggested to increase the risk of COVID-19 severity.\nJapan is an elderly culture in which the elderly account for only~10% or less of the population compared to other nations. The ratio is <10% in Korea (20%;. Several studies have shown that the rates of incidence, hospitalization, and death in elderly Japanese are all lower than that in elderly Caucasian populations. In contrast, the rate in elderly Chinese people is higher than that in elderly Caucasian populations, especially during the initial period of the pandemic. Aging reduces the adaptive immune response, thereby decreasing the production of neutralizing antibodies, and increasing susceptibility toward viral infection and disease severity. Several previous studies have suggested that elderly Chinese people have relatively greater susceptibility compared to Caucasian people.\nIn this study,",
        "label": 0
    },
    "721": {
        "output": "<EOD> Isometric exercise and muscle contraction attenuates nerve injury\u2010induced incapacitating pain in mice by regulation of TRPA1\n\nPeripheral nerve injury (PNI) could cause a persistent and debilitating pain condition known as chronic neuropathic pain (CNP). We evaluated the effect of isometric exercise and contraction in response to a chronic constriction injury (CCI) model of neuropathic pain. A CCI-induced neuropathic pain model was established in 8-week-old male C57BL/6J mice. The mechanical and thermal thresholds and latency to noxious heat evoked potentials (HEPs) were assessed. Isometric contraction was also used to test the impact of isometric exercise on the established CCI-induced PNI. In CCI groups, mice receiving two regimens of contraction training showed remarkable and significant lowered pain thresholds starting at 21 days and lasting until 33 days compared with control CCI groups. Isometric exercise prevented a reduction in mechanical and thermal thresholds compared with control CCI groups. The expression of transient receptor potential ankyrin 1 (TRPA1) was assessed by immunohistochemistry. TRPA1 expression was upregulated in the dorsal root ganglia (DRG) of the control groups, while it was downregulated after isometric exercise. Our findings indicate that isometric exercise and contraction could alleviate chronic neuropathic pain caused by nerve injury. K E Y W O R D S chronic neuropathic pain, isometric exercise, muscle contraction, transient receptor potential ankyrin 1 1 | INTRODUCTION Peripheral nerve injury-induced neuropathic pain is a common, persistent and debilitating pain disorder associated with dysregulation and sensitization of trigeminal and spinal nociceptive systems. Neuropathic pain has been treated primarily using analgesics, including morphine, but long-term use may result in an unresolved crisis due to many side-effects or drug resistance (I. Z. (2011)). Recently, exercise therapy has demonstrated beneficial effects, such",
        "label": 1
    },
    "722": {
        "output": "[END]\n\n## 3. Assignments\n1. In this section, you will have to create tasks to let your teammates perform the given tasks and review their solutions in detail and provide comments. \n2. Please submit the detailed assignment information about the assigned tasks along with the necessary information about the expected results in this section.\n\n## 4. Workflow\nAs explained in the following figure, you will have to perform task 3 and its sub-tasks with the help of three teams. Your team is composed of two students of team 1, two students of team 2, and one student of team 3. We have assumed that all teams are working in parallel, and the timeframe for the team tasks is one working day per week.\n\n<a class=\"image-wide image\" style=\"background: rgb(9, 118, 131); display: block; cursor: hand\" href=\"https://github.com/HamidRaasti/CS-UMLS-BIOINFORMATICS-COURSE/blob/master/images/Tasks/Tasks.png\"><img src=\"https://github.com/HamidRaasti/CS-UMLS-BIOINFORMATICS-COURSE/blob/master/images/Tasks/Tasks.png\" alt=\"Tasks\" /></a>\n\n## 5. Submission\n\n- Upload your assignment in _CS/Submission/cs_\n- If you are interested in using any source code written in other programming languages on the platform, you need to submit the source code along with a readme file to us. You can provide the source code to us in `TAR` format.\n\n# 6. Deadline\n- The deadline for the assignment is _week 1_ . [DOWNLOAD FILE](http://cs.iitd.ac.in/~vibha/assessment/assessment-cs-bioinfo-s3.pdf) \n\n\n<EOD> Exploring the effect of CAG repeat length on disease pathogenesis in spinocerebellar ataxia type 1\n\n\n\n# Introduction\nTrinucleotide repeat expansion disorders, which have a genetic cause in approximately 53 distinct disorders (http://www.trinucle",
        "label": 1
    },
    "723": {
        "output": "## Tasks and Subtasks\n\n### FIND THE REASON FOR NO TRIAL LEVEL ELIGIBILITY\nEach clinical trial has a specific inclusion criteria and exclusion criteria. For each clinical trial \n\n![](../figures/images/2019-08-24-133336.png)\n\n\nEach trial has one or more reasons corresponding to the exclusion criteria. Exclusion criteria define a set of conditions, such as the age range specified in a study, which disqualifies a person from participating. Each trial has a set of exclusion criteria for that trial, i.e., the reason for the trial-level assessment of no eligibility. You are required to print and save this document. On the last page, the number of the page for the reason for the no trial-level eligibility for the trial. The first line is the number of the trial exclusion criteria. You should print the number of the reason of no trial-level eligibility from last page. [INST]\n\n### GET THE PAST MEDICAL HISTORY FOR THE PATIENT\nBased on the past medical history, generate a past list of diseases the patient has. We want you to use the history tool to get a list of diseases a patient may have had. For each of the diseases, save the disease name and the onset year to the same file named _past_diseases.txt. You should copy the lines from https://github.com/Cambridge-AI-Lab/Past_Diagnoses/blob/master/history_tool/past_diagnoses_data.zip into _past_diseases.txt`. After you finish adding information, you should copy the lines from the _past_diseases.txt_ file back to the history_tool/past_diagnoses_data.zip file.  We want you to save the new file as _past_diagnoses_data.zip`. [INST]\n\n### GET THE DRUG TREATMENTS, INCLUDING POTENTIAL DRUG ALLERGIES AND ADVERSE EFFECTS\nFor each drug treatment, i.e., medication name plus dosage and frequency of ingestion, record the following",
        "label": 0
    },
    "724": {
        "output": "### Implementation\n\n#### Data preparation\n\nIf the dataset contains more than 1,000 sample cases, it is recommended to apply data cleaning and pretreatment to avoid outlier effect. Perform a case-by-case review of the data before you start working with it. Remove any unspecified or implausible entries. In addition, add some special codes for missing values to handle missing values efficiently for all variables.\nLet's define `sample_data` as follows:\n\n    \n\n\n### 1.\nRead and load the data. The first data file is a data frame, which consists of several rows with variables and samples. We can use the read.csv function to read data files in comma separated values (CSV) format (see [data.csv on GitHub]). The second file is a data frame with a variable name (patient), and the first column contains 1,000 samples.\n\n    data.csv <- read.csv(\"https://github.com/kyoung-won/clinical_trial_inference/tree/main/data/data.csv\")\n    patient <- data.csv[1:1000,]\n\n\n\n\n    ##  [1] \"Patient\" \"Height\" \"Weight\" \"Age\" \"A1c\" \"Total_cholesterol\" \"High_density_lipoprotein_cholesterol\" \"Low_density_lipoprotein_cholesterol\" \"Triglycerides\" \"Blood_pressure\" \"Sex\" \"Occupation\" \"History_of_smoking\" \"Family_history_of_cardiovascular_diseases\" \"Family_history_of_type_two_diabetes\")\n\n    ## Sample data\n\n    ## Patient1 Patient2 Patient3 . . . Patient1000\n    ##     \"46\"      \"50\"   \"37\"        \"54\"         \"54\"     \"40\"     \"49\"    \"49\"    \"40\"     \"43\"\n    ##   \"in\"        \"in\"    \"in\"         \"in\"\n    ##   \"in\"        \"in\"    \"in\"",
        "label": 0
    },
    "725": {
        "output": "## Relevance assessment\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a clinical trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\nHere is the clinical trial's inclusion and exclusion criteria:\n\n## INCLUSION CRITERIA\nPatients with a diagnosis of noncardioembolic IS that developed between 8 and 180 days before the start of the protocol treatment\n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal",
        "label": 1
    },
    "726": {
        "output": "<EOD> Anaphylactic Shock After Low-dose Cervical Anesthesia of Loxapine: A Case Report\n\n\n\n# Introduction\nLoxapine is chemically classified as a dibenzoxazepine derivative and thioxanthen derivative. It is used in treatment of acute schizophrenia and chronic paranoid schizophrenia. It induces sleep (acting mainly in the lower brain centers), alleviates anxiety, calms restlessness, and improves social withdrawal by reducing psychological conflict.\nSome anaphylactic shocks are associated with a wide variety of compounds and materials. Even small amounts of antimicrobial preservatives and additives are known to cause anaphylactic shock.\nWe report a case of anaphylactic shock caused by low-dose cervical anesthesia using loxapine, a second-generation antipsychotic drug.\n\n## Case\nA 27-year-old female patient was admitted to the emergency room complaining of skin rash, dyspnea, and nausea. The patient was administered an intramuscular injection with 0.5 mg/kg loxapine, 15 minutes after receiving an intravenous injection with 5 mg pethidine for her pain. Soon after, the patient exhibited a wheat-sized rash on the upper back side, followed by dyspnea and nausea. The attending physician attempted to revive the patient via the trachea and re-injected loxapine.\nWhen the attending physician arrived, the patient had stopped crying, exhibited a drowsy state, and her vital signs were as follows: blood pressure (BP), 170/110 mmHg; pulse (P), 144 beats per minute; respiration rate (R), 30 breaths per minute; oxygen saturation (SO 2 ), 80%; and a core temperature within a normal range. It was difficult to insert a central venous catheter or an arterial line; therefore, we attempted a peripheral intravenous line. At that point, the patient was exhibiting un",
        "label": 0
    },
    "727": {
        "output": "<EOD> .\nThe clinical and the histopathologic findings are reported in a case of \"angio-cystoma glutinosa cutis\". This vascular lesion was situated on the right hypochondrium in an 96 years old woman. The patient had a large bluish nodule of firm consistence. The histopathological report showed a large neoformation of vessels which occupied the whole thickness of the dermis. These vessels were either thick walled or thin walled. The endothelial cells of the vascular lumina were very often atypical. Vascular buds, anastomoses and a halo of hemosiderin deposits peripherally were also seen. The differential diagnosis is discussed, and a new hypothesis is advanced concerning the pathogenesis of these lesions.<EOD> Clinical evaluation of the HemoCue portable hemoglobinometer.\nHemoCue, a portable hemoglobinometer, was evaluated in a clinical setting. The device is simple to use and gives a readout within 30 to 120 seconds, depending on the instrument. The analysis is based on the difference in absorbance of two hemoglobin solutions. The HemoCue Hemoglobin Test shows good correlation with the Technicon H 2 -Hb (r = .945; P < .001), H 4 -Hemoglobin (r = .947; P < .001), Hemocor (r = .904; P < .001), H 2 Diacridine (Technicon) (r = .848; P < .001), and the Coulter LH-20 (r = .815; P < .001) blood analyzers. The use of the HemoCue Hemoglobin Test, in a clinical setting should prove useful in the determination of a patient's hemoglobin concentration.<EOD> Immunolocalization of Fractalkine (CX3C Chemokine) and Its Receptor CX3CR1 (Fractalkine Receptor) in the Rat Mice Retina\nFractalkine (CX3CL1) is a membrane-bound chemokine with unique imm",
        "label": 0
    },
    "728": {
        "output": "# A B Example\n**A:** Patient Note :\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53  mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158  mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications. **B:** Clinical Trial\nTitle: to Evaluate the Safety and Efficacy of Pitavastatin in Patients With Hyperlipidemia Summary: Primary Objective: To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy (Livalo 2mg) and intensive lipid lowering therapy (Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: \u00b5T-\u00b5C < 0.4 vs H1: \u00b5T-\u00b5C < 0.4 \u00b5T = the change of HbA1c in the test drug (Pitavastatin 4 MG) \u00b5C = the change of HbA1c in the control drug (Pitavastatin 2 MG)\nInclusion criteria: Male and Female patients who are more than 20 years old or 70 years old or less. Patient who voluntarily sign on written informed consent form Patient who LDL-C \u2265 100mg/dl or was diagnosed with hyperlipidemia Patient who was suspected with Imparied Fasting Glucose (IFG) and satisfy FPG level \u2265 100mg/dL and < 126mg/dL when FPG measured twice.<EOD> .\nEven if the number of human cases of infection-associated brucellosis is decreasing, there is a considerable increase in economic losses in livestock all over the world due",
        "label": 1
    },
    "729": {
        "output": "End of Instance\n<EOD> Identification of the first HapMap-based genetic biomarker with prognostic value for patients with gastric cancer in China.\nThe aim of this study is to identify a novel prognostic biomarker and its underlying mechanism in gastric cancer (GC) and to predict clinical outcomes in GC patients. A total of 241 gastric cancer tissues and 227 adjacent tissues were included to screen the differentially expressed genes between tissue specimens and controls by microarray and verified by quantitative real-time PCR. Kaplan-Meier method was used to analyzed prognostic significance. The enrichment of PNPLA3 was verified by western blotting, immunohistochemistry, and tissue microarray. The protein interactome of PNPLA3 in GC tissues was performed by Co-Immunoprecipitation-Mass Spectrometry and analyzed according to Gene Ontology Term. It was found that PNPLA3 was overexpressed in GC tissues and the high expression of PNPLA3 was associated with the poor overall survival. PNPLA3 over-expression significantly increased cell proliferation and drug resistance of GC cells. Moreover, PNPLA3 expression was positively correlated with the staging of patients. Furthermore, we obtained 15 proteins of PNPLA3 interactome. These data indicated that PNPLA3 could be a prognostic biomarker and a candidate therapeutic target for the treatment of GC patients in China<EOD> Diploid genome sequencing of the malaria mosquito Anopheles gambiae reveals stabilizing selection on histone proteins and the rapid evolution of genomic islands.\nTo explore the genetic makeup and evolution of the complex genomes of Aedes aegypti and Ae. albopictus we report the whole genome sequences of their parents Anopheles gambiae and An. quadriannulatus, respectively. As expected, we found that the two insects have different genomes: the Drosophila melanogaster and An. gambiae genomes have been stabilized at similar sizes of approximately 160-180 Mb, whereas the Ae. albop",
        "label": 0
    },
    "730": {
        "output": "### T1FG1-1st-5-01-2019\nInstructions:\nThere are a number of challenges in this assessment: \n- Eligibility Assessment on Patient Note: \nAs we have seen, the eligibility assessment needs to be done for each study note for a given clinical trial \n- Evaluation of lipid profile or lipid therapy and assignment of lipid category: \nThe Lipid panel report must include a measure of LDL-C, which is determined in plasma, i.e., the clearest and most reliable source of LDL \nIt is important to recognize that if the LDL-C value was measured with a method other than Friedewald, the calculated LDL-C is only approximate \nThe LDL measurement should be included within 3 months of the study start date or within 4 weeks to the actual study start date \nTG > 150 mg/dL or use of TG lowering medication:\nIt is reasonable to treat this condition and continue to do so during the trial \nWe do not encourage changes to drug therapy without the approval of the investigator. Therefore, the data will be included in the analysis, but participants should remain on the same drug therapy at the beginning of the trial and during the trial \nHDL-C <40 mg/dL or use of HDL-C raising medication:\nHDL-C value should be measured < 3 months of the study start date or < 4 weeks to the actual study start date \nIt is reasonable to treat this condition and continue to do so during the trial \nIf treatment of the condition has already begun, participants should continue to be treated during the trial \nVLDL - We encourage changes to drug therapy without the approval of the investigator \n- TG: We do not encourage changes to drug therapy without the approval of the investigator. Therefore, the data will be included in the analysis, but participants should remain on the same drug therapy at  beginning of the trial and during the trial \n\nLow-Level Language (LLL) (TASK T2FG1-1st-5-01-2019)\n\nAssess the study eligibility as",
        "label": 0
    },
    "731": {
        "output": "### Hint\n\nThis is an example for an ad hoc clinical trial. You can think from the clinical point of view and change the inclusion criteria accordingly. The more data you add to your clinical trial, the most reliable the final outcome of your recruitment may become. For example, we can consider adding patient characteristics e.g., age, smoker or non-smoker, diabetes, hypertension, gender, etc.\n\n## [RUN]\n\n<README title=\"Input/Outputs\" />\n\n_Your clinical report should start with the title, e.g., `Title: Hello World Report.`, then use the input, output_types as necessary, and finally, the output, e.g., `Output: [0, 1, 2]`. Remember to make sure that you are using the proper brackets, indentations for the titles of each block._\n\n```python\nimport pandas as pd\nimport numpy as np\nimport xlsxwriter as xw\nfrom pathlib import Path, PUREPATH\nfrom datetime import datetime, timedelta\nfrom typing import Union\nfrom io import BytesIO\nfrom collections import deque\n\npd.setoption('display.max_rows', 150)\n\n\ninput_types = pd.DataFrame(\n    {\n        'Clinical_Study' : [\n            'Cohort', 'Ad Hoc', 'Open', 'Blended'\n        ],\n        'Patient':['Clinical_Note', 'Patient_Detail'],\n        'Treatment':['Medication','Other_Interventions'],\n        'Disease':['Cancer','Cardiovascular_Disease',\n                  'Bacterial_Resistancer_Disease',\n                  'Diabetes'],\n        'Incidence':['Cancer', 'Hypertension',\n                      'Diabetes',\n                      'Arrythmias',\n                      'Peripheral_Vascular_Disease',\n                      'Stroke', 'COPD',\n                      'Congestive_Heart_Failure'],\n        'Sex':[\n            'Male', 'Female', 'Gender_Not_Reported'],\n        '",
        "label": 0
    },
    "732": {
        "output": "}\n\nYou need to repeat the above steps for 3-62-3, 3-72-1 and 3-73-1 as well.\n\nYou have finished. A report like this\n[[report]]\n<EOD> Development of a novel bifunctional single-chain antibody to c-Met and its application in tumor detection.\nAIM\nThe objective of the current work was to express and characterize a novel bifunctional scFv-mTNAP in vitro and in vivo.\n\n\nMATERIALS AND METHODS\nThe scFvs, specific for human c-Met receptors and mTNAP fused by peptide linker SSGGGGSGGGGSGGGGS, were connected by a peptide linker SSGGGGSGGGGSGGGGS. Western blot analysis was performed to analyze the expression of fusion protein in HEK293T cells. ELISA assay was used to detect the affinity to human c-Met receptors.\n\n\nRESULTS\nMutated mTNAP was fused to the scFv for c-Met receptors by a short peptide linker SSGGGGSGGGGSGGGGS in recombinant vector pET-28a. Recombinant bifunctional scFv-mTNAP protein was purified by his-tag affinity chromatography. ELISA assay results proved a high affinity between bifunctional scFv-mTNAP and human c-Met receptors.\n\n\nCONCLUSION\nThe scFv to human c-Met receptors was successfully fused to the catalytic domain of mTNAP by a short peptide linker SSGGGGSGGGGSGGGGS in vitro. This result provided the molecular basis for further application of bifunctional scFv-mTNAP fusion protein.<EOD> Theoretical analysis of anisotropic magnetoresistivity in a ferromagnetic (Ga,Mn)As quantum well.\nThe anisotropic magnetoresistivity in a ferromagnetic diluted magnetic semiconductor film is analyzed using a multiband theory. We clarify how the spin-orbit scattering (which does",
        "label": 1
    },
    "733": {
        "output": "<EOD> The Role of Thyroid Function During Pregnancy\n\nPregnancy significantly alters thyroid functions due to increased levels of thyroid stimulating hormone (TSH), estrogens, progesterone (P4) and thyroid stimulatory substance (P-TSH) of unknown nature. We have recently studied the effect of P4 and estrogen on TSH levels. Interestingly, it was noticed that estrogen and P4 induce P-TSH secretion in rats, but exert no significant effect on TSH secretion. Also, no influence of estrogen and P4 on the level of pituitary thyroid receptors can be documented under any physiological state. However, when the pituitary thyroxine receptor (T-TR) binding sites are down-regulated by the endogenous TH-T3, a rise in the level of P-TSH can be observed. Further, the TSH level tends to rise as the number of T-TR binding sites are decreased under conditions such as hypothyroidism and cold-exposure, suggesting a pituitary autoregulatory type mechanism. Under conditions of exogenous P-TSH secretion such as in hyper-prolactinemia, the thyroid gland function is inhibited and T-TR binding properties altered to a lesser extent, indicating a negative feedback mechanism. Thus, it is apparent from the above studies that, in addition to the pituitary gland autoregulation, there is also a central feedback mechanism operating in the hypothalamo-pituitary-thyroid axis. P-TSH binds to the pituitary LTHR, and induce TSH liberation via the pituitary gland and exerts feedback to the hypothalamo-pituitary-thyroid axis. Although the nature and biochemical characteristics of P-TSH remain elusive, it would be worthwhile to investigate if the P-TSH is in any way identical to LTHR, which has been reported to increase TSH liberation and to alter T-TR binding properties under various physiological as well as pathological conditions. Further, to elucidate the role of P-TSH in pregnancy, a thyroid specific TSH receptor gene knock",
        "label": 0
    },
    "734": {
        "output": "We hope you enjoyed our lesson. Thank you for using the PyTorch [https://github.com/pytorch/pytorch] library and for contributing to our education materials! 2. Choose the button `Upload example` under the `Data` tab.. This will open the window of Datasets Tab as shown in Fig 4.4.1. You can see that there are two dataset tab in the dashboard, which are `Dataset 1` and `Dataset 2`. `Dataset 1` is all data that you loaded in `Data_preproessing` folder and `Dataset 2` is the original labeled dataset with label encoded. 3. In the drop-down menu under `Choose dataset`, click on `Dataset 1` tab to load training data.. 4. Choose the button `Upload example` again under the `Data` tab.. 5. The window of example in Datasets Tab should be shown inFig 4.4.5. Here we can click on the `Download example data` to visualize the loading results. 6. Click on the `Download` button again to load all training data in the folder `Data_preprocessing`.. 7. Click on the button `Download` once again to load all data in the folder`Original_Labeled_Dataset`. 8. Click on the button `Download` again to load training data in the folder `Data_preprocessing`. 9. Click the button `Download` again to load training data in the folder `Trial_Label`. 10. Finally, to download the validation data, we click on the button `Download` for several times, as shown inFig 4.4.7. If the download finished, it will be written in the status field on the right-panel of Datasets Tab. 11. Once the download finished, we can use the following syntaxes to load these datasets in our training, respectively: `train_dataset = Data.from_file(os.path.join(f\"`trainset\", \"Final_training_set.csv\"), batch_size=30, shuffle=True) train_dataset_label = Data.from_file(os.path.join(f\"`trainset\", \"Final_training_set_label.csv\"), batch_size=30, shuffle=",
        "label": 0
    },
    "735": {
        "output": "[END]\n\n[Tutorial home](../tutorial/index.md#instructions)\n\nCopyright\u00a9 2013-<NAME>.  All rights reserved.\n\nThis file is distributed under the terms of the MIT License.<br />\nFor licensing information please visit: http://www.kaggle.com/c/NACC-2013-Challenges/info<br />\n<NAME ><br />\n<EMAIL> <br />\n<EOD> Role of intracavitary shunt as a diagnostic adjunct to the assessment of thymic masses in dogs.\nTo differentiate between benign and malignant thymic masses, it is important to characterize the tumor biologically. To determine the feasibility of endoscopic intracavitary shunting of malignant thymic masses in dogs with malignancy, 1 mL of 8.7 mmol sodium iothalamate (Conray 300) was injected into tumors of 10 dogs with thymic malignant masses. Injection was performed with a double-barreled Foley catheter by transcutaneous endoscopic approach under general anesthesia. Three dogs had squamous cell carcinoma, 2 had undifferentiated carcinoma, 2 had lymphoma, and 3 had myxofibrosarcoma. Thrombus formation with contrast accumulation within the left atrium and ventricle was seen in all tumors. Lymphoma was confirmed histopathologically, and 3 dogs with lymphoma had pleural and pericardial effusions after contrast injection. Intracavitary shunting with contrast is a simple and valuable diagnostic tool, which can aid in the differentiation of benign and malignant thymomas and identify the presence of malignant cells in cytologic samples and effusions.<EOD> A clinical study of rye grass allergy and sensitivity among asthmatics.\nRye grass pollen sensitivity is very common among individuals with allergic nasal airway disease in Israel. However, whether the prevalence of grass-induced asthma is any higher than that with other causes of season",
        "label": 0
    },
    "736": {
        "output": "<EOD> A study on the anti-fertility activity of ethonium dipropionate.\nThe anti-fertility activity of ethonium dipropionate in male and female Sprague-Dawley rats is reported in this work. The drug was administered orally, at the dosage of 250 mg/Kg/day, for forty days. The treatment did not show any direct effect on the sperm characteristics, neither in animals administered with the drug nor in control (negative or positive) groups. In the group treated with the drug (250 mg/kg/day), only 34.4% of the females in estrous got pregnant after mating with proven male and no pregnancy occurred in 20 rats under the negative control.<EOD> Phase behavior of aqueous biphasic systems based on poly(vinyl caprolactam) and poly(vinyl sulfate) with poly(vinyl acetate) as modifier. Application to the extraction of phosphoproteins from soybean oil.\nA new family of aqueous biphasic systems (ABS) based on poly(vinyl caprolactam) as the polymer with an electrolyte in the aqueous phase, a water immiscible polymer in addition to water as the dispersed phase and poly(vinyl sulfate) (PVSL) or poly(vinyl acetate) (PVAT) as modifier was prepared. The influence of the amount of modifier and the pH of the system on the partitioning of proteins has been investigated in the ternary phase diagram of the system composed of poly(vinyl caprolactam) and PVSL (molar ratio 1\u2009:\u20091), with poly(vinyl acetate) as modifier, being the partitioning of proteins studied in the absence and in the presence of phosphate from the dispersed phase. For systems with PVAT as modifiers, the pH was maintained at 4.8 whereas for systems with PVSL, the pH was varied from 5.3 to 3.2, using 0.5 equiv of phosphate at 35 \u00b0C. It was found that the addition of phosphate decreased the cloud point and promoted the",
        "label": 1
    },
    "737": {
        "output": "##[INST] Hello. Your name is AI. You are a researcher and data scientist. Your task is to identify the appropriate medical records from the electronic medical records in [TARGET] and annotate the note information.\n\nIn addition, please label the patients with their IDs. Please annotate each note with the ID that is assigned to that patient when they go to hospital.\n\n[TARGET] is an international electronic medical records and the medical information management service from [TARGET]. The service provides the entire electronic health record of [CORPORATION]. [TARGET] provides an integrated EHR system with the ability to aggregate all electronic medical record data, along with various services, such as data management and analysis. [TARGET] is a big data company specialized in medical data centers.\n\nPlease take these notes into consideration.\n\nEach note in an electronic medical record includes a structured data (such as medical record information) and an unstructured data (such as free-text data). The structured data consists of medical record information items such as demographics, procedures, diagnoses, prescriptions, and so on. The medical record information in each electronic medical record can be represented by XML-based EHR interchange formats such as [FONT] and [DEPENDENCY].\n\nThe structured data is linked with other medical information via unique patient IDs. The patient IDs are assigned to patients when they visit the hospital. Each note's unique patient ID is given as a `patient:patient:id` XML element. Each note represents data associated with patients.\n\nEach note consists of structured (e.g., information recorded by the physician) and unstructured text (e.g., narrative text describing clinical events) data.\n\nPlease focus on the clinical information from electronic medical records (not administrative claims, radiologic images, etc.).\n\n[CORPORATION] is committed to protecting the rights and privacy of patients, and to maintaining the integrity of clinical notes and research data. Data that is provided for the purpose of research under this agreement is not collected for marketing or sales use and will not be sold to any other entity, except in response to a subpoena or court order.\n\nEnsure that you fully review the medical information of the patient and complete the patient notes",
        "label": 1
    },
    "738": {
        "output": "Here you can see the running program of the problem in Colab notebook. You can refer to the program by clicking the ``View` button or the button next to the notebook title.\n\n![](https://github.com/Mak2711/ColabExercises/blob/main/Instructions/M1-1/img1.png)\n\n### Case 7: [INST] Hello. You are a helpful assistant in a trial-tracking system. You should track trials for patients with certain eligibility criteria. You should also determine if a patient meets criteria for a given trial. \n\n[TEST]\n\n![](https://github.com/Mak2711/ColabExercises/blob/main/Instructions/M1-1/img2.png) [INST]\n\n### Case 9: [INST] You have been invited to take part in an influenza vaccine trial testing an adjuvant for greater efficacy than that of the existing vaccine. The inclusion criteria for this study are as follows:\nHave had previous exposure to influenza (either symptomatic or asymptomatic)\n\n![](https://github.com/Mak2711/ColabExercises/blob/main/Instructions/M1.2/img131.png) [INST]\n\n### Case 11: [INST] Hello.  You are an assistant for assessing whether a patient meets the criterion for clinical trials. The patient's health insurance covers some clinical trials and the patient must receive preauthorization from his insurance company to participate in a clinical trial.\n\n![](https://github.com/Mak2711/ColabExercises/blob/main/Instructions/M1.2/img132.png) [INST]\n\n### Case 13: [INST] You are a clinical trial coordinator. An insulin trial is about to start and you would like to know the eligibility status for each of the patients who have been previously seen for glucose management.  \n\n![](https://github.com/Mak2711/ColabExercises/blob/main/",
        "label": 0
    },
    "739": {
        "output": "In this way, this module will be presented to you:\n\n\n\n\nCORRECT_1.py\nIncorrect\n\n    Trial-level eligibility: 2) Eligible\n\n    Trial-level eligibility: 2) Eligible, 3) Not relevant\n\nCORRECT_2.py\n\nCORRECT_3.py\n\n\n\n\n<div style=\"font-size: large\"><b>Instructions<span style=\"font-size: 80%;\"></span></b></div><!-- <div style=\"font-size: largest; font-style: italic\"><br>Instructions</div> -->\n\n<div style=\"font-size: smaller\"><b>Exercises<span style=\"font-size: 80%;\"></span></b></div><!-- <div style=\"font-size: smaller\"><br>Exercises<br></div> -->\n\n<div style=\"font-size: 35%; font-weight: bold\">\n\n   <h1>&lt;h1&gt;\n\n</h1>\n    <h2>&lt;h2&gt;\n\n</h2>\n    <h3>&lt;h3&gt;\n\n</h3>      \n    <div>&lt;p&gt;\n\n         \n<h3 style=\"color: green\">Correct Answer:</h3>\n\n\n<div>\r\n    <div class=\"example\">\n        <pre class=\"prettyprint\"><span style=\"font-size: 35%;\"># Trial-level eligibility: <span style=\"font-style: italic\">0) Not relevant; </span><br></span><span style=\"font-style: italic\"><blockquote><i>The patient does not have sufficient information to qualify for the trial.<br /></i></blockquote></span>\n        </pre>\n    </div>\n</div>\n\n<div style=\"width:85%;\">\n\n    <br><br>\n    <br><br>\n    <br>\n    <form id=\"correctAnswer1\">\n        <input type=\"radio\" value=\"1\" name=\"CorrectAnswer\" /><br>\n<label>Incorrect</",
        "label": 2
    },
    "740": {
        "output": "**The output example:**\n\n  You are not relevant.\n\n  Not relevant.\n\n  Excluded.\n\n  Eligible.\n\nAs you already knew about your eligibility: 1. Not relevant (your note contains no sufficient information to qualify for the trial).\n2. Eligible (your note meets the inclusion criteria of the trial and the exclusion criteria do not apply).<EOD> Effects of the Duration of Anesthesia and Anterior Pituitary Denervation on the Levels of Prolactin in the Anterior Hypothalamus and Hypophysis of the Rat\nWe previously reported that the hypothalamic concentration of prolactin was increased immediately after the discontinuation of isoflurane anesthesia during pregnancy. In the present study we examined the effects after the discontinuation of isoflurane anesthesia on prolactin levels in the anterior hypothalamus and hypophysis of ovariectomized, non-pregnant rats. We also examined the effects on anterior lobe PRL concentrations after anterior pituitary denervation. The anesthesia time was 120 min. The levels of prolactin mRNA in the anterior hypothalamus, detected by the reverse transcription and competitive polymerase chain reaction, were increased significantly following the discontinuation of the anesthesia. The levels were also increased, but they failed to reach significance, after anterior pituitary denervation. Hypothalamic levels of immunoreactive PRL tended to be higher after anterior pituitary denervation. However, the hypothalamic concentrations of prolactin did not significantly increase following discontinuation of the anesthesia in denervated rats. In contrast, after anterior pituitary denervation, the levels of prolactin in the hypophysis increased. These results suggest that the increased hypothalamic concentration of prolactin is mediated by pituitary hormone.<EOD> Efficacy and Safety of the Lumason\u2122 Contrast Agent\nAbstract The authors provide a comprehensive review of published and presented safety and efficacy data related to the utilization of Lumason",
        "label": 1
    },
    "741": {
        "output": "# Exercise solution\n\n# Trial_level.txt\n\n# Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution/Trial-Level\n\n# Result\n\n# # Exercise 2.1\n\n# Exercise Solution\n\n# Trial_level.txt\n\n# Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution/Trial-Level\n\n# Result\n\n# # Exercise 2.2\n\n# Exercise Solution\n\n# Trial_level.txt\n\n# Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution/Trial-Level\n\n# Result\n\n# # Exercise 2.3\n\n# Exercise Solution\n\n# Trial_level.txt\n\n# Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution/Trial-Level\n\n# Result\n\n## Exercise Solution \n\n# Trial_level.txt\n\n# Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution/Trial-Level\n\n# Result\n\n## # Exercise 2.4\n\n# Exercise Solution \n\n# Trial_level.txt\n\n# Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution/Trial-Level\n\n# Result\n\n## # Exercise 2.5\n\n# Exercise Solution \n\n# Trial_level.txt\n\n# Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution/Trial-Level\n\n# Result\n\n## # Exercise 2.6\n\n# Exercise Solution \n\n# Trial_level.txt\n\n## Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution_Trial-Level\n\n# # Exercise 2.7\n\n# Exercise Solution \n\n# Trial_level.txt\n\n## Solution_file\n\n# Solution\n\n# Trial_level\n\n# Solution_Trial-Level\n\n# # Exercise 2.8\n\n# Exercise Solution \n\n# Trial",
        "label": 1
    },
    "742": {
        "output": "To make our solution easier to understand, we split it into four sub-problems. Below you will find their solutions, plus some useful tips and methods you can try out.\n\n## Subproblem 1: Extract clinical text from patient note\n[Subproblem 1: Extract clinical text from patient note]\nIn this subproblem you should extract the clinical text (CT) from the patient note. The CT is the same for all patients of this type.\nInput: Input:  In this subproblem you should read the clinical trial's specification. The specification is the same for all clinical trials of this type. \nOutput: Output: <EOD> Effects of the neuroprotective drugs minocycline and progesterone on motor recovery in a murine model of traumatic brain injury.\nOBJECTIVE\nTo investigate the effects of the neuroprotective drugs minocycline and progesterone on motor recovery in a murine model of traumatic brain injury (TBI).\n\n\nMETHOD\n56 adult male and female C57BL/6 (B6) mice were assigned to one of five treatment groups: (1) control; (2) TBI; (3) Sham + Minocycline; (4) Sham + Progesterone; and (5) TBI + Minocycline (150 mg/kg/dose i.p. every 48 hours for up to 4 weeks) +Progesterone (2 mg/kg, intraperitoneally, daily for 14 days and 0.2 mg/kg, subcutaneously, every other day for the following 14 days). All mice underwent a pre-injury session to establish individual baseline scores and a 16-day training session, after which the treatment cohort underwent TBI or sham procedures. During the 4 weeks following TBI/Sham surgery, treatments continued. The Rotarod behavioral task and a novel sensorimotor apparatus were used as tests of motor recovery. In the Rotarod, mice were trained to remain on an accelerating rotating rod for 60 seconds. In the novel sensorimotor apparatus, mice experienced a 5-day shaping procedure",
        "label": 1
    },
    "743": {
        "output": "##[TUTOR]\nThis test may also be called the \"Tongue\" trial. As you saw in the tutorial, it tests whether the tongue is \"tied\" to the lower jaw, which could be a sign of Bell's palsy. In more detail, it tests whether the muscle (levator tongue) that raises the tongue is able to pull it up against resistance. \n\n\n## Exercise (Exercise)\n\nYou will be shown a series of tasks in which you will be asked to open your mouth as wide as possible and hold it open for five seconds, or until told to relax. This series of exercises tests the integrity of the muscles that open the mouth, and in particular the muscle closest to the lower jawbone (m. mylohyoid). When these muscles are weak, they may not be able to hold the lower jawbone in proper place when a person is talking, swallowing, or chewing. In more detail, this set of exercises tests whether you can voluntarily suck in your cheeks and tongue, like you're going to kiss, or like you're sucking your thumb.\n\n\n### Task 1\n\n\n\n**Inspect your mouth, and see that your lips are closed.**\n\n\nDo you have any questions? If so, please ask now.\n\n### Rest for 5 seconds.\n\n\n### Task 2\n\n\n\nDo your usual deep breathing: start by breathing in through the nose and out through the mouth. Then start by breathing in through the mouth and out through the nose.\n\n\n\n**Make sure your lips are closed all the time.**\n\n\nDo you have any questions? If so, please ask now.\n\n### Task 3\n\n\n\n[REST FOR 10 SECONDS]\n\n\n### Task 4\n\n\n**Move your jaw up and down while you breathe in and breathe out.**\n\n\n\n**Make sure your lips are closed all the time.**\n\n\nDo you have any questions? If so, please ask now.\n\n### Task 5\n\n\n**Suck in your cheeks as if you are about to kiss someone, then hold it for five seconds**.",
        "label": 1
    },
    "744": {
        "output": "<EOD> The effect of high glucose level on the in vitro mineralization activity of human periodontal ligament fibroblasts\nThis study was undertaken to examine the effect of high glucose levels on in vitro mineralization activity of human periodontal fibroblasts. Enamel slices were prepared and cultured in mineralsufficient (MS) medium or demineralizing (DM) medium, either alone or in the combination with high glucose (30 and 0.3 mM). Thereafter, the samples from each culture were prepared at the end of the incubation period for morphometry, scanning electron microscopy (SEM), and quantitative energy dispersive X\u2010ray analysis. The results showed that fibroblasts cultured in DM medium alone formed deposits significantly higher than those in MS medium. Incubation with high glucose (30 mM) markedly decreased cellular activity, including viability, attachment, and mineralization, whereas high glucose (0.3 mM) induced opposite effects, particularly at the late stage of the incubation period. Microfilament arrangement and cytoskeletal protein synthesis were also markedly decreased by high glucose level. In conclusion, under in vitro conditions, human periodontal ligament fibroblasts could be induced to form deposits and mineralize. However, high glucose significantly affected mineralization activity. Therefore, our findings suggest that periodontal fibroblasts play an important role in periodontal mineralization; however, under pathological conditions where the high blood sugar level exists, fibroblasts may lose their function to remineralize enamel and dentin, and thus result in defects of periodontal tissue and mineralization. \u00a9 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 95\u2013102, 2017.<EOD> Facing the problem of gastro-intestinal ulcers.\nThe main factors determining the aetiology of gastric and duodenal ulcers were surveyed in 254 patients by means of a questionary prepared for the purpose, and using the same method of inquiry. After having eliminated such",
        "label": 1
    },
    "745": {
        "output": "We have the final patient note: \nA 48-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such",
        "label": 0
    },
    "746": {
        "output": "##[S]\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a thre...\n\n### Input the clinical trial info\nUse the clinictrial infoparser to load your clinical trial information and the clinicaltrials[12] module for a search of clinical trials.\n\nThis script reads in the input file clin2tria.txt which should contain the clinical trial information. The input file should look like this:\n\n[clinicaltralinfos]/nct03283610/\n\nName: NCT03283610\n\nLead: 30\n\nIdentifier: U00010I00\n\n\n# ClinicalTrials.gov search for trial results\n\nThis script loads the patient_info_table[6] by using the [clinictrialinfoparser][2] module. Then, this script loads the clinicaltrials[12] module to run the search of clinical trials with the term \"NCT03283610\".\n\nThe search results have a format as follows:\n\n<![CDATA[<Trial result for nct03283610>\n\n# Clinical decision support based on clinical trials\n\nThis script reads in the input file NCT number by using the [clinictrialinfoparser][2] module. Then, this script loads the trial results of NCT number by using the [NCT number search] module.\n\nThen, this script loads the clinicaldecision[6] module to generate a clinical decision based on the clinical trial information, which is shown as follows:\n\n</body>\n\n</html>\n[5] [clincialtrialrecpt](https://github.com/jiangzhenyu/jupyter-notebook-projects/blob/master",
        "label": 0
    },
    "747": {
        "output": "<EOD> Transmission of SARS: evaluation of electronic personal protective equipment and risk for healthcare workers.\nPersonal protective equipment (PPE) is important in reducing transmission risks for both healthcare workers (HCWs) and patients during hospital-acquired infections (HAIs). The purpose of this study was to model the use of PPEs by HCWs to prevent transmission to HCWs and patients and to evaluate the ability of the current HCW PPE to decrease this transmission. Three different models were created using the HCW-patient contact matrices calculated for each hospital department and time. The first model assumed PPE penetration and used this information to estimate the transmission risk from HCW to patient. Using SARS-CoV-2 epidemiological data from Hong Kong, we calculated the infection attack rate (IAR) and secondary infection risk (SIR) in healthcare facilities. The 2nd model was created to determine patient IAR and SIR. We assumed all patients were infected after HCWs were in hospital for 6 days. We created 2nd case patients-HCWs were infected after hospital exposure of healthcare-associated cases and used SIR from the 2nd model to model the transmission from 2nd patients to HCWs. We found that HCWs in certain departments and time periods may be at higher risk of SIR than other departments and time periods. In the simulation, HCW PPE may have decreased healthcare facility IAR and SIR. We believe that more work on the SARS-CoV-2 transmission model is needed. PPE use has been an extremely important tool to reduce infections risk for HCWs. We encourage more work to be done to better understand prevention of HAIs and HCW-SARS-CoV-2 exposure.<EOD> .\nWe described the course of infection caused by Salmonella enteritidis in a neonate during the first 6 months of life, in whom the source of infection was a contaminated raw milk from a breast fed infant. The authors point out the need to take into account the possibility of early Salmonella infection also in healthy infants born from healthy mothers and breast fed.<EOD> \nOBJECTIVE\nTo assess the reli",
        "label": 0
    },
    "748": {
        "output": "---\n\n# Task1\n\n\n## <span id=\"Task1\">Task1</span>\n\n\n\n<p><strong>\n  </strong><p>Consider <code>patientNote</code>\n  and <code>clinicalTrial</code> defined above.\n  Given the <code>patientNote</code>, assess the patient's eligibility for the clinical trial <code>clinicalTrial</code>.\n  The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n  You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n  The assessment should be a statement that contains either the character '0', or '1' or '2'.\n  </p>\n  </p>\n  \n  <p><strong>Output format</strong><p>You should return a statement that contains either the character '0', or '1' or '2'.\n  Use the <a href=\"https://www.python.",
        "label": 2
    },
    "749": {
        "output": "### Requirements\n\n- Python 2.7 or higher\n<EOD> Effect of bovine adrenaline and epinephrine and amines on the isolated hearts of dogs and rabbits.\nIt is generally recognized that both epinephrine and adrenaline have effects on the heart other than those associated with their action as a local vascular spasmogen. As one phase of a study of the actions of these two substances, experiments were designed to determine whether the effects of these substances on the dog and rabbit heart could be attributed to factors other than a direct direct vasoconstriction of the coronary vessels. Adrenaline in doses from 0.1 to 10.0 /ig. per minute had no effect upon the performance or the blood supply of the dog's heart except during the very early period of drug administration when the beats became more rapid. The administration of adrenaline via an intracoronary method prevented the rise in blood pressure when the cardiac output was increased as, for example, when the infusion rate of the heart-lung machine was increased from that which maintained a normal output. It is suggested that this effect on the baroreceptor reflexes is the mechanism by which this drug, when administered intravenously, is able to produce a marked decrease in blood pressure.<EOD> Biosynthesis and Expression of a Novel Chromosome Perturbation Factor in Saccharomyces cerevisiae\n\nIn Saccharomyces cerevisiae, karyogamy (karyo, nuclear; gamy, union) is the final step in sexual cell fusion, resulting in the formation of a stable diploid zygote. After conjugation of haploid cells to form a zygote, a meiotic-like program of sporulation is initiated, leading to segregation of meiotic products or recombinant spores. During this program the nucleus of each cell undergoes a number of changes including: (i) changes in size and shape; (ii) formation of a nuclear envelope; (iii) chromosome segregation and (iv) cytokinesis. We report here the isolation of chromosome perturbation mutants (cpp1 and cpp2) of yeast as the results of a forward genetic screen designed to",
        "label": 0
    },
    "750": {
        "output": "- [INTRO] `This is a 5-year, non-interventional, multicenter, observational study examining the effectiveness of drugs and behavioral factors of health on the occurrence of cardiovascular disease in the general population. This study focuses on individuals with cardiovascular disease, diabetes and mental illness. It examines behavioral modifications, the role of drugs used to control risk factors, as well as the influence of psychological factors.\n\n  [Intro] \n`A: Introduction \n`B: This is the Introduction section.   \n`C: This study aims to examine the effect of some environmental (e.g., air pollution, noise) and behavioral (e.g., dietary habits, physical activity) factors on the development of cardiovascular diseases. It will gather data from population-based registers on all residents of Finland whose residential addresses have changed during the previous year. The study consists of three phases. The registers on population, living conditions and health care visits will be linked with data on medication purchases and health behaviors collected using questionnaires.`\n \n  `D: In Phase 1, the following information will be obtained: name, pseudonym, address, address change history, and name of the first person who moved into the residence. In Phase 2, information will be collected on visits to health care services, purchase of medicines and purchase of other health-related goods on all residents who changed their residence during the previous year. In Phase 3, information from the Population Register Centre on the residence of each participant will be collected for a period of 5 years and data on cardiovascular disease. Data will be collected in two phases approximately 5 years apart. No medication will be bought for this study. A questionnaire will be sent to the participants. They will be asked for permission to collect information on factors associated with the occurrence of cardiovascular diseases by analyzing linkage of patient records to population-based registers. Patients aged 16 and above will be asked to return a consent form. Patients aged 14 to 15 will be asked to present to their health care center. Only patients who have signed a consent form will be included in the study. \n \n  `P: Participants",
        "label": 0
    },
    "751": {
        "output": "Please discuss the answers to these questions for your eligibility assessment of clinical trial recruitment. \n\n\n\n\n<EOD> Effect of acute or chronic suppression of vasopressin on glomerular capillary pressure in normal dogs.\nThe effect on glomerular hemodynamics of acute intravenous injection or the intravenous continuous infusion of arginine-vasopressin (AVP) was examined in normal dogs with micropuncture access to the kidney, and compared with the effect of continuous intravenous infusion or acute intravenous injection of isotonic saline. A progressive rise in mean arterial blood pressure occurred after AVP, although urine flow and urinary sodium excretion remained unchanged. Glomerular capillary pressure and filtration rate rose as mean arterial blood pressure increased up to 50 mm Hg, after which they remained unchanged. This finding suggests that the glomerular hydraulic pressure gradient determines glomerular perfusion pressure rather than arterial blood pressure per se. The effect of intravenous infusion of saline was also observed. In this study both glomerular capillary pressure and the filtration rate rose with the increase in mean arterial blood pressure without a maximum pressure level being attained. After the infusion of AVP was stopped glomerular capillary pressure and the filtration rate returned to values indistinguishable from those before the infusion. There was no apparent recovery during the 180-min period of observation after the infusion. The results indicate that AVP-induced changes in glomerular hemodynamics depend on continuous injection, not acute injection, of AVP, and that this continuous injection of AVP will not wash out acutely in a few hours. Glomerular capillary pressure and the filtration rate during continuous injection of AVP exceeded the preinfusion value by 43% and 39%, respectively, even though arterial blood pressure was almost identical to the preinfusion value, indicating that glomerular hemodynamics was markedly altered by the AVP.<EOD> Effect of low molecular weight chitosan on the physiological and biochemical mechanisms of the rice seed germination inhibition induced",
        "label": 1
    },
    "752": {
        "output": "## [CONTROL] You take into account various factors that can impact trial completion, for example, a drug's side effects. You are interested in the trial completion probability. The question is how various factors influence trial completion: i. the trial-level eligibility; ii. time until eligible patient identified; iii. time till randomized after eligibility.\n\nThe first step in calculating trial completion probability is to divide the trial into phases. Define phases for a trial:\n1) PEACE Trial: Eligibility of patients.\n2) PEACE Trial: patients are identified.\n3) PEACE Trial: patients are randomized.\n\nWe can now calculate the probability of trial completion. If we would know the number of patients in each phase, we could easily calculate the probability of trial completion, but, generally, this is not the case. \nThe following figure shows the cumulative probability of trial completion P(CPT). \nLet's calculate the cumulative probability of trial completion. We want to calculate where the following equation holds:\nPEACE Trial: Eligible patients :\nNumber of eligible patients + Number of identified patients \u2265 number of patients needed.\nLet's calculate the chance to identify a new eligible patient:\nPEACE Trial: Identify new eligible patients :\nNumber of eligible patients found + Number of newly eligible patients \u2265 number of patients needed.\nThis is illustrated in. [/CONTROL]\n[CONTROL] You now estimate the trial completion probability in the next example. Assume you have 1200 patients in phase 2 of a clinical trial with trial completion probability of p = 0.6. Phase 3 needs 600 patients. Assuming that the first 1200 patients need on average t5 months until they become eligible, how long it will take until phase 3 completes if 330 patients per month get into phase 2? Assume also that phase 3 needs on average t5 months until 600 patients are randomized.\nLet's first convert the probability to the complement:\nCPT: 600 patients for phase 3 are randomized\n= 100 -(100 %)\n= 100 % \u00f7 100 % \u00b7",
        "label": 1
    },
    "753": {
        "output": "# How to do the experiment\n\n## Load the data\n\n![][]()\n\n## Preparing data for the experiment\n\nYour dataset is located here: [Data file][]. Copy the file to your computer and make it executable.\nTo learn everything, you need to know about executing command-line files, see: [Tutorial: Executing code in bash, section Learn How to Execute Programs in Your Shell].\n\n## The execution part\n\nIn the terminal, make sure that you're in this working directory:\n[Linux]\n[Windows]\nOpen the experiment file with the editor of choice (i.e., [vi], [emacs], [nano]):\n% vi experiment file\nOpen each data file with the editor of choice and then edit the file contents.\nAdd a [trial file][] in the working directory.\n[Linux]:\n% cat trial file\n\n[Windows]:\n% echo 'trial file content'\n\n![][]()\n\nOpen the experiment file in the editor with [vi][] for instance. \nSearch and insert the following code to the end of the file:\n```\n%sed -e 's/Trial-level eligibility/Trial-level eligibility: 2) Eligible./' data_file    &> -    2>/dev/null\n```\n[Linux]\n% sed -e 's/Trial-level eligibility/Trial-level eligibility: 2) Eligible./' data_file     &> -       2>/dev/null\n[Windows]\n%sed -e 's/Trial-level eligibility/Trial-level eligibility: 2) Eligible./' data_file      &> -      2>/dev/null\n```\n[Linux]\n% sed -e 's/Trial-level eligibility/Trial-level eligibility: 2) Eligible./' data_file    &> -    2>&1\n[Windows]\n%sed -e 's/Trial-level eligibility/Trial-level eligibility: 2) Eligible./' data_file     &> -       2>&1\n[Linux]:\n% sed -e 's/Trial-level elig",
        "label": 1
    },
    "754": {
        "output": "[Ran45]\nRanjit Singh has created the following solution in Python and SageMath to solve the problem of this question. Note that this is just a way to solve the problem. He provided the SageMath notebook which can be downloaded directly (download notebook), and also edited code in this blog.\n[Ran50]\n\n<NAME> has created the following solution in SageMath. He provided the original source code (download source code).\n# Solution for problem statement\n\ndef check_eligibility(patient_note, clinical_trial):\n    \"\"\"\n    Inputs:\n    patient_note      - patient's clinical note\n    clinical_trial      - clinical trial information\n    \"\"\"\n    trial <- try\n        clinical_trial -> trial\n    on\n        ValueError\n    except\n        print(f\"Couldn't read trial info.\")\n        return\n    # trial_eligible <- clinical_trial %>% mutate(eligible = case_when(\n    #     missing() == NA ~ 0,\n    #     is.na(eligibility) ~ 0,\n    #     sum(patientLabs) == trialLabs ~ 1,\n    # ))\n\n    clinical_trial = clinical_trial %>%\n        mutate(eligibility = map2_chr(\n    patient_note %>% project(\n        last_diz = first(str_split(last_diz, split = \"_\")[2]\n    ),\n        last_papa = last(str_split(last_papa, split = \"_\")[2]),\n        last_hd = last(str_split(last_hd, split = \"_\")[2]),\n        last_chol = last(str_split(last_chol, split = \"_\")[2]),\n    ),\n    trialLabs = trialLabs %>%\n            mutate(labID = row_number()),\n                    labValue = map2_chr(patientLabs, trialLabs, reduce = list(+)),\n    ), # 1.\n    patient_note,\n    trialLabs,\n    patientLabs,\n    )) ~ trialLabs.labID = patient",
        "label": 1
    },
    "755": {
        "output": "_**What about using a dictionary instead of a list to obtain a dictionary key?**_ \n\nYou can use a dictionary for the same purpose, e.g.,\n```python\ndata_dict = collections.defaultdict(list)\ndata[\"inclusions.1\"] = ['Age <60']\ndata[\"inclusions.2\"] = ['Ascending aorta diameter <50 mm']\n```\n[!INCLUDE[cui-foun-_python_dictary](../includes/cui-foun-_python_dictary-md.md)]\n\nThis is similar to what dictionary keys are for, except you cannot change values or store new key-value pairs as you add new patients, as the set order and name can only be changed through reassignment, e.g.,\n```python\nfor patient in patients:\n    data[patient['ID']] = collections.defaultdict(list)\n```\nSee more about dictionaries: \n\n* [About dict](https://docs.python.org/3/library/collections.html#collections.defaultdict)\n\n\n_**What about using a default dict when you assign a variable name with single letter (e.g., `a` )?**_ \n\nThe following is the same code example, but the dictionary is a default dict, and we do not create a variable for it.\n\n```python\ndef isEligibleWithAge(patient):\n    \"\"\"This function determines if the patient is eligible for a clinical trial. \n    It does so by comparing their age with the trial requirement.\n    The output of the function is a boolean indicating the patient's eligibility \n    for the trial.\n    \"\"\"\n    trials = patient['Trials']\n    if trials['minage'] and int(patient['Age']) \n    >= trials['minage']:\n        return False\n    return True\n\n\ndef findEligibleSubject(patient):\n    \"\"\"This function determines if the current patient is eligible for the clinical trial. \n    It does so first by comparing the patient's ages with the trial requirement. \n    If the patient is not too old, then it tries to compare the patient's gender with \n    the",
        "label": 0
    },
    "756": {
        "output": "The file `Trial_eligibility_test_1001` is to test the program.\n\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<br />\n<",
        "label": 1
    },
    "757": {
        "output": "[MK1] How to format patient notes and clinical trials\n\n[MK2] Examination of factors for trial level eligibility\n<EOD> Immunohistochemistry of epidermal growth factor receptor on normal and malignant oral mucosa: a survey of literature.\nThe epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein of 170 kd, belonging to the tyrosine kinase family. EGFR is also known as erbB-1. It is over-expressed in squamous cell carcinoma and is frequently associated with oral squamous cell carcinoma. The binding site of EGFR with ligands such as Epidermal Growth Factor (EGF), transforming growth factor alpha (TGFa), and amphiregulin activates signaling pathways leading to cellular effects including proliferation, angiogenesis and migration. The ligands for EGFR are growth factors, peptides, and proteins, which play a role in controlling the functions of tissues and organ growth. All these molecules have similar structures and bind with high affinity to EGFR. Various immunohistochemical (IHC) studies have been conducted on specimens to measure the expression of EGFR on normal and malignant oral mucosa as well as the role of various ligands of these sites in controlling the functions of the growth factors and proteins in carcinoma and other lesions found in the oral cavity. We review the various IHC methods adopted by the author and other investigators to measure the EGFR and its expression on normal and malignant oral mucosa.<EOD> Neuroendocrinology of the circannual cycle in the spotted hyena and its effect on sexual behavior.\nThe circannual rhythm and the hormonal changes during the anestrus period and the pre-anestrus period of the spotted hyena (Hyaena hyaena) are outlined. Evidence that ACTH is involved in anestrus gonadotropin suppression is given. Fertility returns to normal when ACTH returns to low levels after a period of several months. ACTH increases gonadotropin",
        "label": 0
    },
    "758": {
        "output": "<EOD> PET/CT imaging of FLT uptake in inflammatory vascular lesions in atherosclerotic mice\nPurposeInflammatory vascular lesions, especially atherosclerosis, could be detected by fluorine-18 fluorodeoxyglucose (18F-FDG) single-photon emission computed tomography (SPECT) and positron emission tomography (PET)/CT. Recently a few studies have shown that 3\u2032-deoxy-3\u2032-18F-fluorothymidine (18F-FLT) can be applied in atherosclerosis. Herein, we investigate whether 18F-FLT can be used to monitor atherosclerosis progression and the early response to statin treatment. Materials and methodsAtherosclerotic mice (n\u200a=\u200a9) underwent different intraperitoneal administration protocols of statins. 18F-FLT was injected intraperitoneally, and images were acquired 40\u200amin later. The maximal standardized uptake value (SUVmax) was measured and assessed histopathologically. ResultsThe average SUVmax of FLT",
        "label": 0
    },
    "759": {
        "output": "## [TEST] 23. You are asked to write a program for a special clinical trial that enrolls only menopausal women. if the women are smokers, exclude the woman from trial participation; otherwise, keep her.\n\nIn this experiment, patients with a smoking history were excluded. Exclude 'Yes' status of smoking in menopausal women from trial participation. Only keep these patients whose 'smoking history' is 'false'.\n\nWe want to test who smokes or not. It seems that this is pretty easy. But we need to deal with the age of the patient. Since the median age of menopause is 41, we need to determine patients who are over 40 years old. So, we need to extract the age from the name of the patients.  \n\nLet's see how we get the age from the name  of patients.  \nI did not make any mistakes in this code. To find out the age, I used the split() function which splits a string into characters. If we type 'split(str1, char)', we can split a string according to the specified char. You can see the output below. [TEST] 24. You are asked to write a program for a special clinical trial that enrolls only menopausal women. If, the menopausal date of women is overdue, exclude the woman from trial participation; otherwise, keep her. [Inst] 5.0.0\n\n\n\nInput a random date for each case and print the mean. Exclude the cases in whom the date was overdue from trial participation. Only keep the cases whose date is 'not overdue.'\nOutput: 25. You are asked to write a program for a special trial that enrols only patients from a designated country. If, the country of a man is not that specified country, exclude the man from trial participation; otherwise, keep him. [Inst] 5.0.0\n\n\n\nInput a country, and then print the cases who were excluded from trial participation due to the country of that case being not the country specified in this trial.\nOutput: **26. You are asked to write a program for a trial that enrolls only adenomyosis and endometriosis patients. If, the disease of a woman is not that specified disease",
        "label": 1
    },
    "760": {
        "output": "> # Note, this line is added in the output since you did not put it before\n\n<h2 id=output>Output</h2>\n\n\n<table>\n  <thead>\n  %r<NAME>   LDL-C  HDL-C  Blood Pressure   FPG   Diastolic Pressure Diastolic Blood Pressure   Neck pressure Systolic Pressure Diastolic Pressure\n  <tr style=\">\n  <th>Age(years)</th>\n  <td>46</td>\n  <th>Systolic Pressure(mmhg)</th>\n  <td>85</td>\n  <th>Trial Eligibility</th>\n  <td>2) Eligible</td>\n  <th>Chest Pressure(mmhg)</th>\n  <td>150</td>\n  <th>Trial Eligibility</th>\n  <td> 2) Eligible</td>\n  </tr>\n  </thead>\n  </table>\n\n<EOD> Long-distance movements of the yellow fever mosquito Aedes aegypti and antigenic variation in its circumsporozoite during migration.\nThe geographic distribution of yellow fever in West Africa and its expansion to South Africa is explained by the northward movements of the Aedes aegypti vector by wind and riverboat traffic. The movement of this mosquito is limited by temperature. Temperature is also a factor in antigenic variation in the circumsporozoite (CS) of A. aegypti, the protective antigen of yellow fever. The CS of A. aegypti in southern Cameroon and in the Gambia, where yellow fever does not occur naturally, has been found to have identical patterns of antigenic variation to A. aegypti elsewhere in West Africa where yellow fever occurs, i.e., at locations several hundreds of kilometers distant. The CS antigenic variation in A. aegypti in South Africa, which is also several hundreds of kilometers distant from West African endemic areas, has different patterns to other African areas. These findings suggest that migrations of A. aegy",
        "label": 0
    },
    "761": {
        "output": "For the code coverage criteria, refer to the following link: [CODE COVERAGE]\nFor the code coverage, refer to the following link:\n[CODE COVERAGE]\n\n### Run\n\nRun your model code from the Python program, i.e., `python <path to your code (file: file0)>`. Make sure to use an up-to-date test file, i.e., `data/sample_test_5.txt`.[TEST INPUT]\n\n![test_sample_run]({{ site.images.test_sample_run }})\n\n\n\n## Testing\nYou must test your model against the existing test file and compare your test results with the current test results to ensure that your file is up to date and that your changes haven't broken the test. After you've run code from your Python program on your test file, you can use this tool to get summary test statistics:\n![test_sample]({{ site.images.test_sample }})\n\n### Run from your local files\n\nTo run the tests from your local files, run the following command where the test file pathname is assumed to be `data/sample_test.txt`(this will vary according to your file's name): \n\n```\n$ ../build/release/run_model.sh data/sample_test.txt\n```\n\nIf any test fail, you should open the test file and the code that you changed, look at the test fail logs carefully, and try to fix the code errors. Finally, use the above test command with the updated test.\n\n### Run from online Docker images\n\nTo run the test file directly from online Docker images, run the following command and paste the image URL where `img02` is replaced by correct image URL:\n\n```\n$ ../build/release/run_model.sh test://\n```\n\n### Run the test from a Docker container\n\nSince we don't run the test inside the Docker container, the code in question can't be modified. To run tests in the Docker container, open the test file in the container and type the following commands:\n\n```\n$ docker container exec python docker-1 python /home/<user>/.venv/lib/python2.7/site-packages/pytest test_sample.py\n\n===================================================",
        "label": 1
    },
    "762": {
        "output": "[INSTRUCTIONS] Exclusions include history of stroke or myocardial infarction, significant arrhythmias, liver or kidney disease, malignant hypertension, and drug abuse \n\n## Assessment of eligibility at the patient level\nIn clinical trials, patient recruitment is usually the first step in the enrollment process.\nPatient-level eligibility (PLC) is a process that assesses if a patient meets all the eligibility criteria for a clinical trial. All potential participants are assessed for the following:\n\n- \n\n## Criteria are described with yes/no answer (eligible/not eligible)\nIn a practical example:\nTo assess the patient level eligibility, your job is to check whether the patient meets all the inclusion and exclusion criteria of a clinical trial. PLC uses Boolean AND operation. So, the assessment will be made only when all the criteria are met. The rules for PLC are:\n\n## \nPLC (Sayed-Hassan, 2021) \n\n## Assessment of eligibility at the trial level with yes/no answer\nIn clinical trials, the patients are assessed for eligibility using a combination of Boolean variables that are associated with the criteria of each patient. It is important to emphasize the distinction between PLC and Trial-level eligibility. While PLC only assesses one-by-one for the individual eligibility criteria, the Trial-level eligibility assesses the appropriateness of the patient for the trial as a whole. It combines each of the eligibility criteria for the particular clinical trial. Trial-level assessment is a method to assess each patient's eligibility for a clinical trial. You have to create a statement about this. Use the `Trial-level eligibility ' string value created above.\n\n## Assessment of eligibility at the trial level with numerical scale\nIn clinical trials, many patients are assessed for eligibility using a combination of string or Boolean variables associated with each of the criteria (Yes/No answers). It is important to emphasize the distinction between PLC and Trial-level eligibility. While PLC only assesses one-by-one",
        "label": 0
    },
    "763": {
        "output": "[[INST]###\n<EOD> Improving medical education in times of crisis\n\n\n\n# Introduction\nCOVID-19 has wreaked havoc on medical education around the world. Many",
        "label": 1
    },
    "764": {
        "output": "##<h3 class=\"sectionlevel zero\">Examples</h3><h4 class=\"sectionlevel one\">Example 1</h4><h5 class=\"sectionlevel two\">Patient:</h5><pre>&lt;Bodies name=&quot;patient&quot;/&gt;\n\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n&lt;/Bodies name=&quot;patient&quot;/&gt;\n\n\n\n&rt;Assessments/&gt",
        "label": 0
    },
    "765": {
        "output": "## The goal of Ophix \n<EOD> Identification of a novel mutation responsible for 2-hydroxyacid-responsive hyperammonemia\n\n\n\n# | introduction\nUrea cycle disorder (UCD) is a rare inborn error of ureagenic metabolism, and its clinical manifestations occur from neonates to adults. [bib_ref]  Urea cycle disorders: diagnosis, pathophysiology, and therapy, Brusilow [/bib_ref]  The incidence of UCD is estimated to be approximately 1 in 30,000 to 58,000. [bib_ref]  An international, multicenter study of outcomes in children with urea cycle disorders, Tuchman [/bib_ref]  Classic OTC deficiency (OMIM#613187), caused by a deficiency in the enzyme ornithine transcarbamylase (OTC, OMIM*609032) results in impaired carbamylphosphate (CP) synthesis, and leads to hyperammonemia caused by an excessive amount of exogenous protein intake. Clinical manifestations in OTC deficiency include developmental disorders, a tendency to seizures, and even coma, which may result in the death of patients. [bib_ref]  Diagnosis and treatment of urea cycle disorders: consensus clinical practice recommendations from..., Hughes [/bib_ref]  The symptoms in OTC deficiency can be suppressed when the patient with OTC deficiency is given nitrogen-free formula, low-protein diet, and supplement drugs, such as glycerol phenylbutyrate (GPB), sodium benzoate, and sodium phenylbutyrate to convert toxic ammonia to nontoxic urea. However, patients with concomitant inborn error in the urea cycle exhibit severe hyperammonemia even on a low-protein diet with these drugs, and may occasionally die when they intake ammonium salts, branched-chain amino acids, or other nitrogen sources. [bib_ref]  Acute hyperammonemic encephalopathy in adult patients with urea cycle disorders, Rigau",
        "label": 0
    },
    "766": {
        "output": "## <a name=\"A.2\"></a>[A2] The next example code for a clinical trial data.\nIn the [C.5](#C.5) part, you will learn how to write trial-level data for a clinical trial.\n\n### Step 1: Codes to check if the clinical trial meets the conditions of the clinical trial.\nWe use `if` statements to verify if the trial matches the eligibility criteria. In this example, the following conditions need to be met:\n\n\n\n\t\t\n`\n'\n\n\n- Age is at least 20 years old; the patient is over 20 years old.\n\n\n- Male; the patient is male.\n\n\n- HBeAg-positive; the patient is positive for HBeAg.\n```\n\t'\n```\n\nWe will check if the patient is appropriate for the treatment trial by applying the conditions described above.\n\n### Step 2: Codes to write trial-level eligibility for a clinical trial.\nOnce the clinical trial is passed the condition checks, we will write a trial-level eligible in the `eligible_list[t].eligible_trial` field. \n\nFirst, check the eligibility criteria:\n```\n'\n'\nif EligibilityCriteria.has_patient_enrolled:\n    if eligible_list[t].sex == \"M\":\n        if eligible_list[t].age >= 20:\n            if eligible_list[t].HbeAg == \"positive\":\n                eligible_list[t].eligible_trial.append(34994)\n```\nNow we have two cases: \n\n\n* There is only one condition to satisfy (patient age greater than or equal to 20 years old), and this condition is met for the patient \"male 39-year-old with positive HBeAg.\" The trial eligibility will be \"Eligible\". In this case, patient \"male 39-year-old with positive HBeAg\" meets all the eligibility criteria and will be entered into the trial.\n\n* There are two conditions (patient age and patient gender) to satisfy. Patient \"male",
        "label": 0
    },
    "767": {
        "output": "Here we use clinical trial ACEi 10mg BID to make an assessment of eligibility of the trial.\nAs you can see, the trial is in the section with the red font. All selected trials will have the red font. After selecting a trial, you can go back to `Trial Summary`.\nNow you evaluate all the inclusion criteria of the trial. If the criteria are all met, you proceed immediately to recommend the trial to the patient. If more than one criterion has to be evaluated, you go back to `Next` until all the criteria has been evaluated. \nFirst evaluate the trial. Now go to `Inclusion criteria`.\n\nThe inclusion criteria for the trial are as follows:\n- Aged 3 months to 10 years\n- History of angina for less than 8 weeks' duration\n- Suffer from at least one of the major ischemic heart disease risk factors: high total cholesterol levels (\u2265 200 mg/dL) or high LDL-C (110 mg/dL)\n- Abnormal left ventricular function\n- Anterior ST-segment depression \u2265 1 mm on exercise testing\n- Sustained ventricular tachycardia with heart rate greater than 150 b.p.m.\n- Left ventricular end-diastolic pressure greater than 20 mmHg\n- Angina of at least 6 months' duration\n- CAD with greater than 50% luminal narrowing of the major coronary vessels\n- Abnormal LVH (increased LV wall thickness, high LVMI, high LVMR). \nNext, you evaluate the exclusion criteria of the trial.",
        "label": 1
    },
    "768": {
        "output": "**Input: (2)**\n\n[INST] You can use the command-line interface of R to assess trial eligibility; i.e., the command-line will call the following R functions: assessment_table and trial_level_eligibility. First, execute this code:\n\n  `Rscript trialleligibility.R`\n\nYou should obtain the following result:\n\n[![Instructions on using an R console:](https://i.stack.imgur.com/aKx7s.png)](https://raw.githubusercontent.com/syuzhenchen/Trial-eligibility-by-patient-notes/master/trialleligibility.R)\n\n[![Instructions on using an R console:](https://i.stack.imgur.com/ZD5yv.png)](https://raw.githubusercontent.com/syuzhenchen/Trial-eligibility-by-patient-notes/master/exclu.R)\n\nIf you click the 'Yes' option, the following result will be displayed:\n\n[![Instructions on using an R console:](https://i.stack.imgur.com/XsAx1.png)](https://raw.githubusercontent.com/syuzhenchen/Trial-eligibility-by-patient-notes/master/data_160929230387.R)\n\n[![Instructions on using an R console:](https://i.stack.imgur.com/JUyHk.png)](https://raw.githubusercontent.com/syuzhenchen/Trial-eligibility-by-patient-notes/master/data_20160220220742.R)\n\n[![Instructions on using an R console:](https://i.stack.imgur.com/4N3kf.png)](https://raw.githubusercontent.com/syuzhenchen/Trial-eligibility-by-patient-notes/master/data_20160220222228.R)\n\nThese data demonstrate the trial-and patient-level eligibilities",
        "label": 0
    },
    "769": {
        "output": "[INS 1, 0] You are working on the trial \"BDNF\". \nTitle: BDNF supplementation in patients with cardiovascular disease\n\n\nSummary: The aim of the project is the comparison of the effects of supplementation with BDNF and placebo on patients with cardiovascular disease and high levels of Follistatin.\n\nInclusion Criteria:\nBody Mass Index (BMI) in the range 18.5 - 35\nDiagnosis of CAD as the first criterion for inclusion in the study is \u2265 50% stenosis in at least one coronary angiogram demonstrated.\nage above 45 years and less than 65 years\nPatients with BMI over than 30 would be excluded.\nPatients taking medications, such as statins or anti-platelets, are not excluded, however, it is expected that in the beginning of study they should control their drugs, i.e., to maintain their current dose and type of drugs. At the beginning of the study, if any of these drugs is to be started or changed, the participant would have to sign an additional consent form.\nPatients who have used dietary supplementation, such as vitamins and herbal products, less than 3-month before and throughout the intervention would be excluded from the study.\nFor those who are taking BDNF, supplementation or eating high levels of BDNF containing foods, such as nuts, are required to be stopped at least 4 weeks prior to the study and remain so throughout the intervention.\nAll study participants will be required to have normal levels of liver and kidney function tests, total protein, albumin, and also have no history of mental illness.\nPatients with a history of other medical or surgical disorders, especially malignancies, would be excluded.\nWomen are not eligible in the current study.\nWillingness to participate\nPatients taking statins (atorvastatin, lovastatin, rosuvastatin) and non-steroidal drugs (indomethacin, diclofenac, ibuprofen, fenoprofen, acetylsalicylic acid) will continue to take the appropriate medicine throughout the",
        "label": 2
    },
    "770": {
        "output": "Now, you see the following sample patient note:\n# Patient_note_2568\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA), estimated at 71.0%-99.5% lumen reduction; as well as moderate stenosis in the right internal carotid artery (RICA) estimated at 12.3%-50% reduction. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nIf we look at the clinical trial, we see:\nTitle: Feasability of Collaborative Care in the Secondary Prevention of Coronary Heart Disease\n\nSummary: The main focus of the pilot study is to evaluate",
        "label": 0
    },
    "771": {
        "output": "- When given the patient note - Input an assessment of eligibility using the three-point grade: 0) Excluded; 1) Not relevant; and 2) Eligible. \n- If the patient meets the inclusion criteria and there is no contraindication according to the trial-specific exclusion criteria then it is not possible to exclude the patient, this is to say that he/she can be enrolled into the clinical study. \n- If a patient with an assessment of `Not relevant` was eligible. \n- Do not use the `Cut` button - it does not change anything at this step.\n- After you have entered the data for all patients, click on the `Done` button on the bottom-right. This will save all data on the current work-sheet.\n[CIRC]\n<EOD> Phase I, randomized, placebo-controlled, double-blind, dose-escalation study of the pharmacokinetics, safety and tolerability of single ascending doses of KLS-0153.\nOBJECTIVE\nTo explore and describe the potential acute effects of KLS-0153 in relation to a single dose in a double-blind, placebo-controlled and dose-escalation study.\n\n\nMETHODS\nThis study included 65 healthy male and female volunteers with ages in range from 18 to 45 years. They received single 4,6, 18, 54, 100, 178, and 448 mg/day of KLS-0153 or placebo.\n\n\nRESULTS\nThe highest tolerated was the dose of 4 48 mg/day, with minor adverse events; the dose for first in human use, was 1/5th of this, with tolerability. No serious adverse events were reported. There was no significant change in vital signs, electrocardiography, clinical laboratory, electrophysiology, or pharmacokinetic data. A dose-dependent increased incidence of adverse events and decreased heart rate was associated with KLS-0153. An expected time-independent increase in peak serum concentrations was noted.",
        "label": 1
    },
    "772": {
        "output": "[",
        "label": 2
    },
    "773": {
        "output": "[/SOLVED]\n\nA: This one is easy to figure out.\nThis line is basically an array, just to give you an idea.\n[Trial]\nid         1 2 ...  12 \nname =      \"Name 1\" \"Name 2\" ...   \"Name 12\" \n\nThe 12 name values are what need your attention. Let's say, you have an array of values but only you need the \"Name 12\" values.\nSo, this line of code, would only have values \"Name 12\", \nid = 12\nname = \"Name 12\"\n\nYou could use a for loop to check through name and find out whether the value \"Name 12\" is in that array, e.g \nfor value == \"Name 12\" do\n    id = value\n    name = \"Name 12\"\nend for\n\n<EOD> Long-Term Follow-Up of Stereotactic Radiosurgery for Certain Trigeminal Neuralgias: A Single-Center Study\nBACKGROUND: We report the results of the largest prospective series of patients with drug-resistant trigeminal neuralgia (DR-TN) treated with stereotactic radiosurgery (SRS). METHODS: Twenty-five patients were treated with SRS between November 2000 and October 2010 for DR-TN associated with a vascular loop in 23 patients and trigeminal nerve schwannoma in 1 patient. Follow-up was determined with the use of the Brissaud-Cats method. RESULTS: The present cohort of 25 patients was treated with gamma knife SRS between November 2000 and October 2010, with a mean follow-up of 49 months. Median treatment doses delivered to the trigeminal nerve were 80 cGy for 15 and 90 cGy for 7 patients. One patient died of another cause 8 months after SRS. Two patients had transient (<1 month), moderate (<1 month), and severe facial numbness (<1 month) after the treatment. Eight patients reported a sensation of hypof",
        "label": 0
    },
    "774": {
        "output": "<EOD> Antiretroviral therapy during pregnancy and postpartum interventions for prevention of mother-to-child HIV transmission\nAntiretroviral drugs for human immunodeficiency virus (HIV) in pregnant women have been available since 1994 and their use during pregnancy in the United States to prevent perinatal HIV transmission has increased dramatically since 1996. This review focuses on the pharmacokinetics of the antiretroviral drugs recommended for prevention of mother-to-child HIV transmission (MTCT), and reviews the current state of the science in antiretroviral drug use during pregnancy based on both published results and unpublished data. We evaluated the pharmacokinetic interaction between antiretroviral and anti-parasitic or anti-toxoplasma regimens and the influence of HIV, parasites, malaria, or viral hepatitis co-infections on either antiretroviral dosing or pharmacokinetics. For neonates, studies were carried out to evaluate the antiretroviral levels in maternal milk, and to assess drug concentrations in neonates receiving either high breast milk concentrations or formula. Finally, new concepts of timing of initiation of antiretroviral therapy (ART) to reduce perinatal HIV transmission were reviewed, as were the benefits and risks of continuing or discontinuing ART after delivery.<EOD> Nutritional and clinical management of infants on gastrostomy tubes.\nThe incidence of cerebral palsy, particularly severe and complicated forms, is now 1,7\u20132 in every 1000 live births (Shelton and Acheson, 1979). Infants with this condition who are fed through a gastrostomy tube are increasing in number in our paediatric units. We now feel it is important to draw attention to the problems of nutritional, fluid and electrolyte imbalance and the associated complications which may be encountered in such patients, particularly those with severe cerebral palsy, and suggest ways of their avoidance and control.<EOD> In vitro anti-",
        "label": 0
    },
    "775": {
        "output": "### Inputs\n\nHere is the list of inputs.\n\n* **Patient Note**: a patient report.\n* **Clinical Trial Eligibility:** clinical trial eligibility, either 0) Excluded, 1) Not relevant, or 2) Eligible.\n\n### Environment Setup\n* **Instruction:** enter `conda env list 2> env_vars.txt` and paste `env_vars.txt` as the first line at the end of the `notebook` file.\n\n### Expected Results\nYou will get the output something like this:\n<pre>\n\n0_0_0_0\n0_0_0_0\n1_0_0_0\n0_0_0_0\n1_0_0_0\n1_0_0_0\n2_0_0_0\n1_0_0_0\n1_0_0_0\n0_0_0_0\n2_0_0_1\n2_0_0_1\n1_0_0_1\n1_0_0_1\n1_0_0_0\n2_0_0_1\n2_0_0_1\n1_0_0_1\n1_0_0_1\n1_0_0_0\n\n</pre>\n\n\n## Trial-Level Eligibility Notation Problems\n\n### Input Notes Missing\nSometimes the input notes are totally blank,\nYou can modify the following line accordingly,\n`Patient note = pd.DataFrame([[\"\", \"\", \"\", \"\", \"\", \"\"\"], [\"\", \"\", \"\", \"\", \"\"\", \"\"]], columns=patient_notes_cols, dtype=str).astype(int)`\n\n### Inconsistent Dates\nSometimes the clinical trial date is one day later than the patient note date and thus inconsistent to the patient note date, so the trial-level eligibility might be 2) Eligible by accident.  Also, the range of clinical trial dates is not narrow enough, the whole process for clinical trial screening might be very costly,\nSo, here are how to modify the code to get a consistent date, and a narrowed range of clinical trial dates:\n```",
        "label": 0
    },
    "776": {
        "output": "<EOD> .\nA study on the effects of three different kinds of drugs (clavulanate, azlocillin and mecillinam) after oral or intramuscular injection in patients was made. Clavulanate, azlocillin and mecillinam showed good serum levels of their active ingredients following oral administration. Compared with those after intramuscular injection, the serum level of clavulanate at 2 hours after oral administration was 70% of the serum level of azlocillin. Therefore, the antibacterial activity of clavulanate was similar to that of azlocillin. High levels of mecillinam were observed in the serum, but good levels of aminopenicillins, such as ampicillin and carbenicillin, were not observed.<EOD> In Situ Formed Nanocluster Catalytic Network for Enzyme-Free and Chemiluminescent DNA Amplification.\nA DNA system with amplification based on nanocluster catalytic reactions is constructed. A cascade of DNA/RNA hybridization reactions triggers nanocluster catalytic reactions among three kinds of chemiluminescent probes, and the in situ formed chemiluminescent nanoclusters give signals for detection of target DNA. The catalytic mechanism is investigated through theoretical calculations, and we find that an intermediate species - the RNA-3WJ has a key role to play in regulating the nanoclusters' catalytic reactions, which leads to a strong fluorescence enhancement and a chemiluminescence enhancement in a specific sequence. This chemiluminescence enhancement can be used to detect the target DNA without false signals, and the sensitivity can be as high as 0.6 pM. The unique design here can be regarded as an important supplement for nucleic acid detection using chemiluminescent probes.<EOD> The Effect of Acetylsalicylic Acid, Cinnamic Acid and Some of Its Derivatives, against Malignant Colorectal Cancer Cells In Vitro\n\nCitation: Mladinova, K.; Yordanov, Y.; Nedyalkova, O.; Krumova, M",
        "label": 2
    },
    "777": {
        "output": "# A1\n\n## Exercise\nThis exercise assumes you have some prior knowledge of Python. If you'd prefer to work through the full version of this tutorial using a REPL session, or with a notebook environment, you can use a Jupyter widget or [Google Colaboratory - Colab](https://colab.research.google.com/), both of which [allow syntax highlighting](https://docs.github.com/en/free-pro-team@latest/github/setting-up-git-and-using-GitHub-to-collaborate-on-source).\n\nA1.1. Install libraries (conda, numpy, scipy, pandas, sklearn, jupyter)\n\n![image](https://user-images.githubusercontent.com/35509879/118749478-336d7300-b0d6-4bda-af17-15abce8cb048.png)\n\nA1.2. Run the code (notebook)\n\n<img src=\"https://user-images.githubusercontent.com/35509879/118749537-89215f80-dd3c-4601-8dda-7311917982ef.png\">\n\nA1.3. Result\n\n![image](https://user-images.githubusercontent.com/35509879/118749505-09a0da00-06b1-4b20-8c96-f4ccdd00364f.png)\n\n\n\n\n# A2\nA2.1. Patient information\n\n\nThe patient had a history of hypertension and dyslipidemia.\n\n![image](https://user-images.githubusercontent.com/35509879/118749511-c6dcd780-764f-4af0-8a9b-a0fd8f7654be.png)\n\n\n\n\n\nA2.2",
        "label": 1
    },
    "778": {
        "output": "<EOD> Preparation and Characterization of the Nutraceutical Beverage Based on Bamboo Leaf Polyphenols (BLPs)\n\nBamboo leaves (Phyllostachys heterocycla) are used as a kind of traditional Chinese herbal tea and functional beverage. The main bioactive compounds in bamboo leaf polyphenols (BLPs) with antioxidant and anti-inflammatory activities and potential beneficial effects on human health were confirmed by chemical and biochemical approaches. After the optimization of ultrasonic extraction parameters, total polyphenols content in BLPs were determined as 3.89 \u00b1 0.15 g/100 g of dry weight. The content of flavonoid and condensed tannins was 0.96 \u00b1 0.05 g/100 g dry weight and 2.48 \u00b1 0.10 g/100 g dry weight, respectively. Among nine phenolic compounds identified by ultra-performance liquid chromatography-orbitrap mass spectrometry (UPLC-orbitrap MS), caffeic acid (109.07 \u00b1 1.98 \u00b5g/100 kG,) and quercitrin (172.54 \u00b1 0.35 \u00b5g/100 mg,) were the most dominant constituents. The BLPs showed strong free radical scavenging capabilities in 1,1-diphenyl-2-picrylhydrazyl (DPPH) and 2,26-Azinobis-(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) assays. In addition, the BLPs exhibited significant inhibitory effects towards 5-lipoxygenase (5-LOX), \u03b1-amylase (\u03b1-AI), and \u03b1-glucosidase (\u03b1-GI). The findings suggested that BLPs could be a potential nutraceutical beverage resource for improving physical health, and the BLPs are promising natural raw material to formulate functional foods and health supplements.\n\n# Introduction\nBamboo leaves (Phyllost",
        "label": 2
    },
    "779": {
        "output": "[INTEX]\n\n\u00a9 {{date}}. Bioinformatics Lab, Faculty of Computer Science, Helwan University. All rights reserved.\n\n      <br>\n      <b>\n        Development, Maintenance and Infrastructure Support <br>\n        Laboratory of Biostatistics and Bioinformatics, Department of Clinical Pharmacy,\n        Faculty of Pharmacy, Cairo University\n        <br>\n        <NAME>,\n        Faculty of Computer Science, Helwan University\n        <br>\n        <NAME>,\n        Faculty of Medical Engineering, Cairo University\n        <br>\n        <NAME>, Faculty of Computer Science and Engineering, Helwan University\n        <br>\n        <NAME>, Department of Medical Engineering, Faculty of Medicine, Ain Shams University\n      </b>\n      <br>\n <br>\n<b>\n   License:\n    This content is licensed under Creative Commons Attribution - ShareAlike 4.0\n</b>\n</html>                                    \n<EOD> A retinoid-inducible gene-switch system for the control of endogenous transgene activity in transgenic mice\n\nBackground: Retinoic acid (RA) exerts a variety of biological activities such as stimulation of cell proliferation and regulation of gene expression. There is increasing evidence that RA is an extracellular signal for regulating normal tissue differentiation and cell proliferation. RA is known to induce expression of its receptor genes in various tissues. Hence, we utilized the RA inducible transcriptional response to develop a powerful tool for controlling gene expression of transgenes in the nervous system of transgenic mice.Results: A transgene cassette containing a minimal cytomegalovirus enhancer, a minimal simian virus 40 promoter, a rabbit beta-globin intron/exon, and the human retinoic acid receptor binding site (hRARE) connected to the SV40 polyadenylation signal, which we named RARE-GAS, was employed. By inserting the RARE alone into the transgene cassette, we observed robust RA-inducible transgene expression in transgenic mice. When the",
        "label": 1
    },
    "780": {
        "output": "### 1: Create and save the `main` code \nSave the workspace (e.g., `main.ipynb`). Make sure the `Output` section is properly configured in `metadata` attribute:\n<ipynb-metadata output='output_path'>\n</ipynb-metadata>\n\nThe output should be saved as a .ipynb file, and the results should be saved in the directory. It depends on the operating system and the configuration you use. Some of the popular ways to do this include:\n`$ nbexport -o output_path -o ipynb input_notebook`\n\n### 2: Save the results into a .json object \nCreate a new file `inp.json` in the current folder, then change the first line of the code below to save the results into a .json file. In the following code:\n\t\n<br>\n\n`if __name__=='__main__':`\n\n\timport numpy as np\n\timport pandas as pd\n\timport matplotlib.pyplot as plt\n\timport seaborn as sns\n\tfrom matplotlib.backends.backend_pdf import PdfPages\n\timport nbhtml\n\tfrom nb_print_helper import print_html\n\n\tinp_list=pd.read_csv('inp.csv',sep = ',')\n\n\tinp=inp_list.copy()\n\tinp.head()<br>\n\n\tinp.drop(['Age',  'History of Diabetes', 'History of Hypertension', 'Hypertension', 'Smoking', 'CAD Family History', 'Waist Hip Ration'],axis = 1,inplace=True,)<br>\n\n\tage=inp['Age'].apply(lambda x: int(np.floor(100*x.round(2))))<br>\n\n\tage.plot()\n\tage.dropna(axis=0,inplace=True)<br>\n\n\tage.isna().plot()\n\tage.dropna().plot()<br>\n\n\tage.mean.<br>\n\tage['Mean'].plot()<br>\n\tage['SD'].plot()<br>\n\n\tinp.isna().plot",
        "label": 0
    },
    "781": {
        "output": "[[TUTOR]]\n# <NAME>\n\nThe tutorial is on a patient visiting a hospital and needs the doctor to decide whether he/she is healthy enough to go upstairs. \nAt each doctor visit, the doctor asks the patient about the health problems he/she had in the past seven days up to today. The doctor then determines the severity of those problems by how much trouble they caused [from none to severe (11)]. \nThe doctor also checks several other health problems and medications/treatments to decide on a rating between 0 and 10. The sum of scores for all the four aspects (four categories: problems; medications; treatments; and overall) gives the overall health rating, which indicates the patient's condition. \nHere is an example of the patient's visit notes:\nThe doctor should now compute the overall health rating. To do so, the doctor must sum up the scores from the four categories [treatment, medications, overall problems, and problems] and determine the overall health rating. \nEach category has 11 labels from 0 to 10. The scores of the four categories should match the patient's answers. As a result, each category should add to the overall health rating, and the total sum has to be between 0.0 and 10.0. The following equations (calculations) show the calculations for the four categories: The doctor should now compute the overall health rating. To do so, the doctor must sum up the scores from the four categories [treatment, medications, overall problems, and problems] and determine the overall health rating. \nNote that, to compute `overall problems score`, the sum of all the problems is calculated. If the total sum is greater than the number of problems, the doctor should apply `total problems score - (# of problems) = problems score.`?\n\n# <NAME>\n\nDuring the patient's visit to the clinic, the doctor examines the patient and asks a series of questions in an examination room. The medical practitioner may include all the findings from the examination and the information about the history of the disease. Each of these findings provides doctors with an insight into the patient's health condition. The doctor can diagnose the patient's condition accurately based on the responses to the questions or the find",
        "label": 0
    },
    "782": {
        "output": "[INST]\n- _The assessment module_, at which we start off.\n    We create a new trial and then assign a patient to it.\n\n- _The trial_ module allows users to view the trial information, create an empty trial, view the eligibility,\n    and view the patient notes.\n\n- _The patient_ module is where users can view all the patients that have been included in the trial.",
        "label": 0
    },
    "783": {
        "output": "A: First determine if this patient is eligible for the study, if not then he is excluded otherwise he is eligible.\nNext determine if the patient is receiving any exclusionary medications, if not he will not be excluded.\nNext consider whether his clinical findings are clinically significant to the patient. This is a more subjective judgement, you ask yourself would you refer the patient for further consultation if you diagnosed him.\nYou should consider his age LDL-C and CAD family history (risk factors for CAD). As well as the extent of carotid artery disease.\n<EOD> .\nOne hundred and eighty three bacterial strains isolated from urine in urinary tract infection and from feces of patients after laparotomies in IJSS in Nijmegen during the period July 1970 to June 1971 were tested for sensitivity to eleven antibiotics using the agar dilution technique. The results of these tests were related to the time and place of isolation of individual strains. The organisms investigated were: enterococci (66), enterobacteria (50), non-enteric gramnegative aerobic organisms (26) and other gramnegative anaerobes (51). In enterobacteria, E. coli and enterococci both an outbreak of enotexceptic enterococci containing strains producing penicillinase and gentamicin/kanamycin resistance was observed.<EOD> Surgical intervention in necrotizing enterocolitis: Is delayed laparotomy associated with worse out-comes in NEC patients with intestinal perforation?\nABSTRACT Objective We aimed to compare the results of early and delayed laparotomy in neonates with intestinal perforation secondary to necrotizing enterocolitis (NEC). Methods Between January 2009 and February 2014, 13 neonates who underwent a laparotomy due to perforation were included in the study. The perforation site and complications and the surgical findings were recorded. The patients were divided into two groups: group 1, early laparotomy (<48 hours",
        "label": 1
    },
    "784": {
        "output": "### Pre-requisites\n\n```python\nimport pdb\nimport pickle\nimport argparse\nimport numpy as np\n\nnp.random.seed(5656)\n\nimport time\n```\n\n```python\ndef init_logger(logger_name):\n\n    logger = logging.getLogger(logger_name)\n    logger.setLevel(logging.INFO)\n    fmt = logging.Formatter(\n        \"%(levelname)-8s %(message)s\"\n    )\n    console = logging.StreamHandler()\n    console.setLevel(logging.DEBUG)\n    fh = logging.FileHandler(\"output.txt\", mode=os.O_RDWR  )\n    fh.setLevel(logging.INFO)\n    formatter = logging.Formatter(\n        f\"%(asctime)-5s [%(levelname)-8s]: %(message)s\"\n    )\n    fh.setFormatter(fmt)\n\n    if logger_name == \"main\":\n        logger = logging.getLogger(\"main\")\n        # \u8bbe\u7f6e\u6253\u5370\u8f93\u51fa\u7ea7\u522b, \u9ed8\u8ba4\u662finfo\u7ea7,\u53ef\u4ee5\u4e0d\u663e\u793a\u7684\u8f93\u51fa\u8dfb\u5370\u5230\u6587\u4ef6\n        logger.setLevel(logging.INFO)\n        # \u8bbe\u7f6e\u8f93\u51fa\u5b57\u4e32, \u4e00\u822c\u60c5\u51b5\u4e0b, \u4f1a\u663e\u793a\u4e3a \u6253\u5370\u5230std in,console\u548clog file\n        console.setLevel(logging.INFO)\n        fh.setLevel(logging.DEBUG)\n        \u5212\u7ebf\u90e8\u5206\u53ef\u4ee5\u5ffd\u7565\u53bb\u6389, \u4e0d\u5fc5\u4f7f\u7528\u6574\u884c\u6ce8\u91ca\n        \n    logger.handlers[0].addHandler(console)\n    fh.daemon = True\n    fh.addHandler(logger)\n\n    return logger\n```\n\n```python\ndef main():\n\n    # \u54cd\u5e94\u547d\u4ee4\u884c\u7684\u53c2\u6570\n    parser = argparse.ArgumentParser()\n\n    parser.add_argument('-c', help='input csv file | test dataset')\n    parser.add_argument('-r', help='report folder', default=\"/c/Users",
        "label": 0
    },
    "785": {
        "output": "## 7. [INST] Experiment data\nData for learning to create a model for evaluating trial-level eligibility is a simple vector of 300 patients as `experiment_data = DataFrame ({ 0: age, 1: gender, 2: systolic, 3: diastolic }, 0: pdl.Trial.v1_patient, 1: pdl.Trial.v1_patient, 2: pdl.Trial.v1_patient, 3: pdl.Trial.v1_patient ), pdl.Trial_300_v1.csv`.\n\n8. [INST] Loading data and preparing for training / [OPTIONAL] Loading data and preparing for testing\n\n\t*Data pre-processing\n* [OPTIONAL] Model training\nTo test whether the machine learning models make a better assessment of trial-level eligibility than clinical staff, we will compare the outputs made by the models with those of clinical staff. So, we should set 'True-Clinical staff' value as 0 in 'trial_level_eligibility_outcome` of `experiment_data`. After that, prepare a new experiment data: `experiment_new_data = experiment_data.merge( trial_level_eligibility_outcome.replace ( True_Clinical_staff ,0 ))`.\nAnd then, load them into memory as experiment objects.\n`experiment_1 = pdl.Experiment ( data=experiment_old_data , name = \"Eligibility Predictor (old).\", title = \"Eligibility predtctor (old)\" , model_type =\"Regression\" , model_parameter={`data_type` : \"categorical\", **`data_param` : experiment_data.Data.parameter.keys(), `parameter` : experiment_data.Data.parameter.keys(), `parameter_type` : \"Categorical\" } )`.\n`experiment_2 = pdl.Experiment ( data=experiment_new_data , name = \"Eligibility Predictor (new),\" title = \"Eligibility predtctor (new),\" data_type =\"categorical\", data_param = experiment",
        "label": 1
    },
    "786": {
        "output": "<EOD> Effect of craniotomy position on intraoperative visualization during microvascular decompression: a randomized controlled trial.\nOBJECTIVE\nMicrovascular decompression (MVD) is one of the most effective surgical therapies for patients presenting with refractory trigeminal neuralgia (TGN). A limited view of the root entry zone due to the craniotomy often makes it difficult to expose the root, especially for lower root entry zone (REZ) lesions. The objectives of this study were to determine the effectiveness of changing one's position at the surgical platform and to assess whether the angle of the microscope, surgical table orientation, and the craniotomy location can improve the intraoperative visualization during MVD for TGN.\n\n\nMETHODS\nThis was a prospective, randomized controlled trial of MVD for TGN. The 90 sides for 60 patients were randomly divided into group A and group B. All MVD surgeries were performed by the same surgeon in a standardized fashion. Visualization was recorded from 3 aspects. For group A, before opening the dura, the surgeon stood with his back to the surgical platform to look at the operative field and then stood on the surgical platform to look at the operative field. In group B, the surgical procedure was performed by the surgeon in the same manner as the previous method, except that the surgeon stood on the surgical platform during the whole operation. We also measured the angles of the microscope and the operation table.\n\n\nRESULTS\nWe found that the visual field from each of the 4 directions measured from the 3 areas was statistically significantly improved when a surgeon was standing on the surgical platform. Furthermore, a surgeon's back to the surgical platform to look at the operative field had the biggest impact on the angle of the microscope (preoperative, 12.4\u00b0 \u00b1 0.9\u00b0; 2-weeks postoperative, 9.4\u00b0 \u00b1 0.7\u00b0; F = 33.550, p < 0.001). The location of the craniotomy, the angle of the microscope, and surgical table orientation did not differ significantly between the 2 groups, and none",
        "label": 1
    },
    "787": {
        "output": "[/CITATION]\n--Lawrence Wan, PharmD, Department of Bioinformatics and Systems Biology, Faculty of Engineering and Information Technology, University of Technology Sydney\n\n\nA: If you're happy with your code, and your \"if\" blocks, I strongly recommend that you always make your \"if\"s start with \"If\" rather than just \"if\", and that this is done every time the block of code appears if any of the other conditions don't apply.  As a result, you can have if(b, c, d), where b, c and d are all variables, while leaving all conditions satisfied, as b, c and d are all variables.  Similarly, if(True), where True is a variable that evaluates to true, is also something that should generally be frowned upon.  It's easier to have to decide how to evaluate something than to create something or change something.\n\nA: Your solution is pretty basic, and a quick solution to a test I wrote to demonstrate a slightly clever technique called recursion.\nclass Solution:\n    def numFood(self, list):\n        \"\"\"\n        :type int list: an ordered list of sizes\n        :rtype int: a result\n\n        Given an ordered list of sizes, and returns the sum of the list members, plus (number of elements -1).\n\n        For example, a list [[5,2,1,3,7],[7,2,5,8]](https://www.python.org/doc/peps/pep-0287.html) would return 23\n        \"\"\"\n        # This loop is a pretty basic way to figure out the list's length and the average.\n        for size in list:\n            return sum(list) + (len(list)-1) * (size/len(list))\n\n\n# Test code:\n# A:\nif(list):\n    if(len(list)):  # A little trick that doesn't make for bad programming (yet)\n        return (len(list)*(list[0])+sum(list))         # Odd one out?\nelse:\n    if(0): # Avoid ugly code.\n        print(\"No list:\") # Avoid ugly code.\n    pass\n\n# B:",
        "label": 1
    },
    "788": {
        "output": "Question: The given patient data are insufficient to judge if the patient is eligible. Please check with us to see if we need to provide further clarification and/or data to complete the assessment.\nQuestion: The given patient data are insufficient to judge if the patient is eligible. Please check if we need to provide further clarification and/or data to complete the assessment.\nPatient's condition: The patient's BP is higher than reference range, his age is 73 years old; patient report the high BP, and he did not mention his past medical history. Patient is smoker, so the risk of CAD increasing.\nWhat is your judgment on the patient's eligibility status and reasons for the judgment?\nInput:\nTrial-level eligibility: 1) Excluded. Rational/Question: The age of 73 for male is already exclusion. The systolic blood pressure of 182 mmHg shows the patient's cardiac health is deteriorating. And the patient is also a smoker.\nExamination details: Sodium 140.7 mmol/L. It is within the normal level. 125 / 84 mm Hg. The BP is a level higher than reference range.\nQuestion: What would be your judgment of the patient eligibility status and reasons for the judged?\nInput:\nPatient's condition: His age is 38 years old. He has no past medical history. He does not mention his smoking or history of alcohol intake. BP at 2012/4/11 was 125/84 mmHg. BP at the most recent visits are 143/87mmHg. The past measurement results are normal, the recent values are elevated.\nHospital examination: blood glucose level (0.40 mmol/L), sodium (146 mmol/L), potassium (4.9 mmol/L), chloride (109 mmol/L), creatinine (68 umol/L), urea nitrogen (8.1 umol/L), bicarbonate (21 mmol/L), anion gap (1.0 mm",
        "label": 0
    },
    "789": {
        "output": "<EOD> Proposal for a methodology of clinical validation of the use of 3-dimensional printers in plastic surgery: design and development of 9 surgical models of rhinoplasty.\nAIM\nTo describe a methodology of clinical validation of the use of 3D printing technology in surgery, and to design and develop 9 models of rhinoplasty, to allow 3D surgical planning.\n\n\nMATERIALS AND METHODS\nThe methodology is based on the following steps: evaluation of clinical need, design with the software, 3D printing, surgical planning, simulation of surgery, and clinical evaluation with photographs. The validity of the study results was determined by a reliability coefficient: Cronbach's alpha.\n\n\nRESULTS\nIn this study, 61 patients were evaluated. The following surgical models were generated and validated clinically: 9 for rhinoplasty, and the resulting surgical outcomes were validated by the surgeon's Cronbach's alpha alpha (90% CI ) as follows: right nasal flap (0.87, 0.73 - 0.94), left nasal flap (0.87, 0.73 - 0.94), and skin graft (0.86, 0.73 - 0.94), in a cohort of 61 patients.\n\n\nCONCLUSION\nThe proposed methodology allows validating the correct use of 3D technology in plastic surgery, through an exhaustive evaluation protocol by expert surgeons.<EOD> .\nBasing on the present state of clinical studies, the authors suggest that the efficacy of drug therapy for chronic schizophrenia is best demonstrated by a change in the clinical symptoms measured by an objective and qualitative rating scale, i.e. the psychopathological rating scale.<EOD> .\nVitamin D supplementation in pregnancy to prevent preterm birth would be a cheap approach to reducing preterm birth in the presence of an increased risk of premature delivery. Vitamin D is not only related to bone metabolism but also to the immune system. Many studies have been performed to establish vitamin D supplementation in pregnancy as a",
        "label": 0
    },
    "790": {
        "output": "[C1] - [Trial_level_eligibility](https://github.com/biocore-ai/biocore_webtools/blob/2ae714a0bf65889d60c324bfee98cd1ddfcdee71/src/data/institution/BIO16/BIO16_CL_C1/Patient_List.py)\n \n\n   Patient ID     Patient name    Trial level eligibility  Exclusion criteria  Not included in this trial  Eligibility assessment\n    135          Patient 135           Excluded                  Excluded\n    136          Patient 136           Not relevant                   Excluded\n    137          Patient 137           Excluded                  Excluded\n    138          Patient 138           Excluded                  Excluded\n    139          Patient 139           Not relevant                   Excluded\n    140          Patient 140           Not relevant                   Excluded\n    141          Patient 141           Excluded                  Excluded\n    142          Patient 142           Not relevant                   Excluded\n    143          Patient 143           Not relevant                   Excluded\n    144          Patient 144           Excluded                  Excluded\n    145          Patient 145           Not relevant                   Excluded\n    146          Patient 146           Not relevant                   Excluded\n    147          Patient 147           Excluded                  Excluded\n    148          Patient 148           Not relevant                   Excluded\n    149          Patient 149           Excluded                  Excluded\n    150          Patient 150           Excluded                  Excluded\n    151          Patient 151           Excluded                  Excluded\n    152          Patient 152           Excluded                  Excluded\n    153          Patient 153           Excluded                  Excluded\n    154          Patient 154           Excluded",
        "label": 2
    },
    "791": {
        "output": "# A.1. Criterion 1: Age and gender\nIn this criterion, you check, in the current patient note, whether the patient is eligible by age and gender.\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For",
        "label": 0
    },
    "792": {
        "output": "[MORE STUDIES] \n10.7. [INSERT VOICING] Exam Question: When a physician is diagnosing dementia in a patient who has received a drug for Alzheimer's disease for 6\u00a0months, which is more accurate, TICS or MDRS score?\n\n[ANSW: 'Both scores are useful.' [INST]].\n\n\n![](/figures/004-06-image.png) \n\nHere is the clinical trial:\n```r\nclinicalTrial = list( \"Identifier.Name\" = \"10008483\", \n\"Title\" = \"Alopathic or Homeopathic Alternative to Standard Care for the Treatment of Early Stage Dementia: Results of a Randomized Controlled Trial (HOME-D)\", \n\"Type\" = \"Trial\", \n\"Language\" = \"English\",\n\"Date\" = \"2015-08-19T08:03:02\", \n\"Protocol.Identifier\" = \"2009/CWL-",
        "label": 1
    },
    "793": {
        "output": "## Required Input Format\nIt is assumed that you supply the input file and the output file from the input folder to the output folder. You must put them on the same line and save them in this folder.\nThe input file has three columns for the assessment of eligibility from the left to right. If no patient meets the inclusion criteria, output the zero as 0. Otherwise, output the scale number from 0 to 2.\nThe output file has two columns for the assessment of eligibility from the left to right. Output the scale number from 0 to 2. \nInput File:\nCholesterol20mg%\nLdlC20mg%\nLdlC30mg%\nLdlC40mg%\nLdlC50mg%\nBloodPressure40mmHg\nBloodPressure120mmHg\nBloodPressed40mmHg\nBloodPressed120mmHg\nSmokingPresent\nSmokingAbsent\nNoCancer\nCancerPresent\nFamilyHistoryPresent\nFamilyHistoryAbsent\nAspirinPresent\nAspirinAbsent\nFemalePresent\nMaleAbsent\nAge0\nAge30\nAge58\nAge71\nAgeOlder\nWeight140\nHeight177\nBMILessThan35\nBmil35\nHeight60\nWeight200\nFemaleAbsent\nFamilyHistoryAbsent\nAge40\nCholesterol80mg%\nBMILessThan15\nFamilyHistoryAbsent\nAge60\nCholesterol80mg%\nHeight180\nWeight130\nBmilMoreThan35\nFamilyHistoryAbsent\nBMILessThan15\nHeight40\nHeight80\nAge0\nAge0\nAge0\nAge0\nAge0\nAge0\nOutput File:\n2\n2\n2\n2\n2\n2\n2\n2\n1\n1\n1\n1\n1\n0\n0\n0\n0\n0<EOD> Prevention and Control of COVID-19 Infections by Aseptic Nonwoven Fabrics\n\nThe coronavirus disease 2019",
        "label": 0
    },
    "794": {
        "output": "[TUT] This will show you how to check for patient eligibility: \n[FCT] There is more than one patient, so first you should filter them by date: \n[FCT] By name: \n[FCT] By gender: \n[FCT] By the type of their blood: \n[FCT] By birthdate: \n[FCT] By age group: \n[FCT] By birthplace: \n[FCT] By age group: \n[FCT] By marital status: \n[FCT] By occupation type: \n[INST] Your patient list will be narrowed down to a single patient. \n[FCT] Let's filter by the trial name: 1) CAD: 3C_002: 01. \n[INST] The patient eligibility should be 2) Eligible. \n[FCT] Good. Let's go home. \n[FCT] By patient id: 165219937: Eligible. \n\n__Bonus: Here is additional material. It will help you to become more familiar with the concepts of clinical trials, which may be useful if you want to become a professional. It is available [here(in .pdf format)].____\n<EOD> <filename>README.md\n# Symfony Flex Voter Extension\n\n[![Build Status](https://img.shields.io/travis/dahlia3004/symfony-flex-voter-extension.svg)](https://travis-ci.org/dahlia3004/symfony-flex-voter-extension) [![Coverage Status](https://img.shields.io/scrutinize/coverage/github/dahlia3004/symfony-flex-voter-extension.svg)](https://scrutinizer-ci.com/g/dahlia3004/symfony-flex-voter-extension)\n\nFlex voters available for [Symfony 3 Flex](https://github.com/symfony/Symfony/releases/tag/v3.x)\n\n## Installation\n\nSymfony Flex Voter",
        "label": 1
    },
    "795": {
        "output": "2) Expected answer: \nOutputs: 0 for the first and second patient, and 2 for the third and fourth.\n3) Solution: \nOn the one hand, you could use a simple `if \u2026 else` structure to identify the eligibility of patients; on the other hand, you could add the patient note to an iterator and iterate the note to find the eligibility.\nInstead of the `if \u2026 else` structure, the following code fragment is possible in a more compact form:\n\nThe reason is that the function `filter(x::Array{String, 1}, p::Int\u2026)` of Julia actually is a function like `filter(x::Array{String, 1}, b::Bool, p1=false, \u2026)` which means that a Boolean is added to each entry of `x` and compared with the Boolean parameter `b`.\nIn this case, the parameter in parentheses is `false` and only patients with a note including the letter `t` would be assigned to the corresponding index of `P_note`. If at least one patient note starts with \"t\", the code fragment returns a tuple of the corresponding indices with the current value stored in `eligibility` of the respective patient.\nFor this example, a function called `set_data(:t_note)` could be provided.\n<EOD> Changes in p127 mRNA expression in rat kidney cortex after ischemia-reperfusion.\nThe changes in the expression of proliferation-associated p127 mRNA level in rat kidneys after ischemia-reperfusion were examined by reverse transcriptase/polymerase chain reaction (RT/PCR). The p127 mRNA level began to increase at 1 hour after reperfusion following 60 minutes of ischemia. This increase continued for 3 to 7 days after reperfusion and returned to basal levels on days 14 to 21. In situ hybridization analysis revealed that in the S1 segment, the p127 mRNA-positive cells appeared within 1 hour and accumulated from 1 to 7 days after reperfusion, but not in the S3 segment, and in the S2 and S4 segments, the p127 mRNA-positive cells appeared from",
        "label": 2
    },
    "796": {
        "output": "# Discussion and Conclusion\nIn case of difficulties in defining eligibility criteria, consider the following tips:\nTry to make a list of factors which allow someone to participate in a trial. Think what are the best questions to ask to the patient, to answer \"Are you excluded?\" or \"Will you need exclusion criteria to avoid injury\".\nIt may be hard to define the eligibility criteria in the patient note. One way to get all the information needed is to ask the team of the attending physician, while working with them.\n\n# Author's contributions\nAll the mentioned authors have collaborated in the same way with regards the conceptualization of the problem formulated under the supervision of the fourth author, and with the preparation of the article for submission to the journal.\n\n# Funding\nThere were not received any research fundings for the article.\n\n## Ethics approval\nEthical approval was not required to carry out this study on the basis of national guidelines.\n\n## Provenance and peer review\nNot commissioned, externally peer-reviewed.\n\n## Please state any conflicts of interest\nAuthors do not have any conflict of interest to report.\n\n## Please state any sources of funding for your research\nAll authors have full funding to complete the project.\n\n# Discussion\n\n## Discuss this article\n\n## Conceptualization\nThe clinical team of the Romanian National Institute for Research and Development in Biology and Medicine, Institute of Cardiovascular Diseases, Department of Cardiovascular Imaging, University of Medicine and Pharmacy of Craiova, Craiova, Romania, the Romanian Society of Cardiology and Diabetology (RoSDC); together with the Academic University of Craiova, Department of Medicine and Pharmacy, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Craiova, Romania, and The Heart Surgery Institute, Craiova General County Hospital, Romania.\n\n# Declaration of interest\nThe authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.\n\n## Abbreviations\nAMI, acute myocardial ischemia; CAD, coronary artery disease; DBP, diastol",
        "label": 0
    },
    "797": {
        "output": "[/MAST]\n\n## Exercise: Exercise 2.5\n\n# You will:\n\n- Learn about the role of supervised training in the diagnosis of ADHD.\n\n- Diagnose patients as having probable or confirmed ADHD using the 2-minute Supervised Training Instruction (STI) Score.\n\n## The STI score is the total number of tasks accomplished (correctly and incorrectly) in the 2-minute interval.\n\n# [INST] Step by step Exercise 2.5\n\n## Your responsibility:\nThis exercise should be done using our online app. To use this app, you must log into the website <http://kids.adhd.de> first. Next, you should use your login data of `s19229001@hotmail.com` and `johny84@gmail.com`. To log in, you only have to enter your data and then press the button to submit login data. (Login data is also saved, so if a new exercise is needed, you need to press the button `Start exercise` to enter the environment). In the next part, you should download the file `BMJ-ADHD-2-Exercise-3-Diagnose_2nd_step_supervised_training.pdf` and then open this file. You can get the file from the link provided in a previous page.\n\n\n![Instruction]. (a) Instruction for Exercise 2.5\n\n\n## Input: Output: \n[INST] The first part is just as simple as the one before. So, no further explanation is necessary. Just follow the instruction in the first table.\n\nLet's think step by step:\n\n\n## **Step 1.0:**\nThe supervised training is done in 2 min. For each task, 2 points are given for positive response and 0 points for a negative response. The STI score is the total number of tasks accomplished (correctly and incorrectly) in the 2-minute interval. Let's see the following table from the article.\n\n![Instruction ]. (a) Results of the Instruction Group\n\n\n## **Step 1.1:**\nFor the second part, you already know that if the",
        "label": 1
    },
    "798": {
        "output": "___\n\n#### Reference\n\n[1] ICH E3: Addendum to ICH Topic E 9 Statistical Principles for Clinical Trials\n\n___\n\n##[Trial] Title: Middle Cerebral Artery Velocity and Oxygen Saturation of the Brain During Carotid Endarterectomy\n\nSummary: The primary endpoint of our study is to determine whether neurological symptoms (aphasia, paresis, loss of consciousness, numbness) occur after clamping the internal carotid artery, and if so, changes shown by transcranial Doppler or INVOS monitor is more sensitive regarding the symptoms? Secondary endpoint: the degree of change in the measured parameters after internal carotid artery is clamped, and if there is any difference between the operated and non-operated sides?\n\nInclusion criteria:\n100 patients awaiting carotid artery endarterectomy carried out in regional anesthesia\n\nAge: patients over 18 years\n\nGender: both female and male patients are included in the study\n\nMedical equipment: venous catheter, arterial catheter for invasive blood pressure monitoring\n\nBilateral continuous measurement of the middle cerebral arteries with transcranial Doppler\n\nBilateral continuous measurement of the cerebral saturation with INVOS monitor\n\n___\n\n#### References\n\n1,2\n\n___\n\n##[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do",
        "label": 2
    },
    "799": {
        "output": "A [ClinicalTrial]: [INST] is a class that describes a clinical study or trial that requires an evaluation to define the eligibility of a patient or subject for inclusion in the trial. You can declare a trial using the [ClinicalTrial] class by writing the class name followed by the attributes. If a clinical trial or study requires two different types of data, e.g., a patient record and an assessment, you can declare a [ClinicalTrial] class with a [Assessment] class. The [ClinicalTrial] and [Assessment] classes are described in detail (Section 11.2 and 11.3.3, respectively) and provide rich functionality for representing complex data structures.\n\nClinicalTrial: [INST] attributes may include the following:\n\nAssessment: [INST] describes a part of the clinical trial, i.e., an assessment of a clinical manifestation or a biological marker to be measured in a clinical trial.\n\nAssessment: [INST] attributes may include the following:\nA 43-year-old male undergoing percutaneous coronary intervention (PCI) in the left anterior descending artery (LAD) due to severe symptomatic coronary stenosis. \n\nHere is the assessment: \nTitle: Assessment of Left Anterior Descending Artery \nType: [INST] assessment of the LAD (i.e., left artery 1) \nBMI: \nDischarge date: August 28, 2011 \nDuration: 24 hours \nResults: \nMeasurement 1: \nCerebrovascular disease in the form of a previous stroke in the left frontal and occipital lobe \nDiagnosis: \n\nType: [INST] diagnosis \nBMI: \nDischarge date: February 6, 2011 \nResults: \nMeasurement: \nMeasurement 1: \nCerebrovascular disease in the form of a previous stroke in the left frontal and occipital lobe \nCongenital heart disease \n\nCongenital heart disease: [INST] is congen",
        "label": 1
    },
    "800": {
        "output": "You have to try all cases to get some points and win the game!\n\n## Summary\nThe eligibility assessment has two distinct subdomains: the patient-level and the trial-level eligibility. The patient-level assessment is performed on a per-patient basis, whereas the trial-level assessment assesses the eligibility of a patient for inclusion in a particular clinical trial.\nThe eligibility assessment is the core procedure of patient recruitment into a clinical trial, and is critical. Incorrect or inadequate eligibility assessments can result in the loss of patients for the trial and, ultimately, in the loss of an eligible patient.\nThe assessment of clinical trial eligibility requires knowledge of the medical history and demographic/vital signs of the patient, the trial inclusion and exclusion criteria, the demographics and characteristics of the participants involved in the clinical trial, and the clinical outcomes to be assessed in the trial.\n\n# Discussion\nThe assessment of the eligibility of a patient for inclusion in a clinical trial is a complex and multifaceted process that requires comprehensive knowledge of the medical history and demographic/ vital signs of the patient, the trial inclusion and exclusion criteria, the demographics and characteristics of the participants involved in the clinical trial, and the clinical outcomes to be assessed in the trial. The eligibility assessment procedure consists of three distinct steps:\n\n1. Assessing and documenting the available data on the patient (e.g., medical history and demographic information)\n\n2. Assessing trial inclusion and exclusion criteria\n\n3. Assessing the patient's eligibility for inclusion in the clinical trial\n\nThe eligibility assessment should be performed meticulously and systematically to minimize errors and ensure that all patients are assessed fairly and accurately. The assessment of the eligibility of a patient for inclusion in a clinical trial requires comprehensive knowledge of the patient's medical history and demographics, a thorough understanding of the trial inclusion and exclusion criteria, and an in-depth assessment of the patient's medical history, demographics, and characteristics. The evaluation of eligibility must be performed by the physician in a timely and accurate manner.\n\n# Con",
        "label": 2
    },
    "801": {
        "output": "========================================================\n\nYour task is to create a script which will complete this task. If you complete your script, you'll receive a badge. If your script is of good quality, you'll receive a second badge. If you submit two good scripts, we\u2019ll send you a t-shirt. However, you must submit the script within one month since the workshop.\n\n[INST] You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n    Task - Trial-Level Eligibility\n    Input - A clinical trial\n    Output - Trial-level eligibility for all patients.\n\n[//INST]\nIn the following exercise, you will generate code for a program that implements trial-level eligibility determination for a given clinical trial. It is important to remember that the determination of eligibility and the decision whether to include a patient in a clinical trial are the exclusive responsibilities of the trial investigators. The trial can establish additional exclusion criteria.\n\nNote: You should always repeat Trial-level eligibility in the last line by `Trial-level eligibility: 2) Eligible`.\n\n[#] Write a Java program that produces Trial-level Eligibility for all patients.\n\nNote: You should always repeat Trial-level eligibility in the last line by `Trial-level eligibility: 2) Eligible`.\n\n[INST] You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n[//INST]\nNote that the clinical trial's inclusion criteria depend on the particular clinical study, and these criteria are always specified",
        "label": 1
    },
    "802": {
        "output": "## Exercise 4\n\n[INST] [C] Let's analyze patients' notes (see section on [Patient note]). \n\n[C] Using one of the above patient notes, please construct the appropriate test for each note based on the information you have gathered . Each test must evaluate multiple aspects and be applicable to all the notes in the document. You should be able to reproduce the same outcome result for each patient. Therefore, the test should not only be applicable to the one used example provided to you, but should be a \"generally applicable\" test, i.e., be applicable to all patients. \n\n## [/c]\n\n# Background\nThe test is implemented using the [A] [T] [E] [S] paradigm .\n\n[A] [T] [E] [S]: Acronym for Algorithmic Thinking Experiential Sensemaking Social\n\n\n[A] The first step is to analyze the available data, which may be very simple in nature:\n[A1] (A1.1) Analyze data. We could be faced with only a few lines of data from this section as shown in #11. We need to analyze the meaning behind these lines (#11). As in the following subsection, we need to convert the meaning of the data to the [A] [T] [E] [S] concepts.\nWe'll need: a) An initial context b) The first assumption c) The purpose of the analysis d) The second assumption We need to create a preliminary description of the data to create the initial context. For example, in #12 we need to add \"in section\" -#1 \"patient note\" -to create a preliminary description of the raw data. We now have #13:\n(A1.1) Analyze data. Annotation of #11-#12 is in #17.\nA1.2) Annotation of #11-#12\n#17. Create a preliminary description of the data based on the title of the patient note 'patient notes' and the context that it falls within 'in section patient notes'. #18. First assumption: Given the context -that this is from section patient notes -the question that arose was \"What could be the purpose of this article?\" What",
        "label": 1
    },
    "803": {
        "output": "<EOD> The effect of antagonists on spinal analgesic action produced by intrathecal injection of enkephalin.\nIntrathecal injection of enkephalin (4 micrograms) in the cat produced analgesia that was prevented by co-injection of naloxone (10 ig) but not antagonized by co-injection of morphine (200 g). When morphine 200 or 2000 / g and naloxone 10 or 150 / kg were co-injected, the spinal analgesic action of enkephalin (4 / g) was unaffected in doses up to 10-fold greater than that of enkephalin alone. However, higher concentrations of morphine or naloxone did block the action of enkephalin (4/g), although the threshold dose of naloxone was significantly lower than that of morphine. A small dose of enkephalin also lowered the threshold dose of naloxone to block the response to a larger dose of enkephalin. These results show that the spinal analgesic action of enkephalin (4 / g) involves an opiate receptor while higher doses produce blockade of that mechanism by the antagonist morphine.<EOD> Sleep and mental health in childhood--a new approach.\nSleep problems in childhood are common, well-recognized entities with serious effects on childhood mental health, development, and quality of life. In this article, the relationship between sleep, behavior, and mental health in children is reviewed.<EOD> .\nOBJECTIVE\nTo explore the effects of Pifolozolin (PFZ) on inflammatory cytokines and vascular cell adhesion molecule-1 (VCAM-1) in rheumatoid arthritis fibroblast-like synoviocyte (RA-FLSs).\n\n\nMETHODS\nHuman RA-FLSs were isolated, cultured and randomly divided into three groups, i.e. the blank group, the control group and the PFZ group, with 6 wells in each group. The control group was treated with TNF-\u03b1. The PFZ group was treated with PFZ for 2",
        "label": 2
    },
    "804": {
        "output": "If an entry is missing, do not add anything. If two or more entries are missing, write a comment explaining the issue.\nPlease submit the trial_level_eligibility.txt file before the deadline of July 23rd, 2019.\nThanks in advance for your participation.  \n\n*** End of Instructions ***\n\n### Step 2:\nMake a new Python file in GitHub: `Evaluation_NCEPT_Trial-level_eligibility/_evaluation_file`.\n[Download file here](https://raw.githubusercontent.com/Yong-Kwon/Evaluation_NCEPT_Trial-level_eligibility/master/trial_level_eligibility.txt)\n\n### Step 3:\nCheck the file for completion. Do not attempt to change/fix the syntax of the file. (See Example)\n\n### Step #4: Run the file in `Evaluation_NCEPT_Trial-level_eligibility/_evaluation_file`. It will return the result of all patients in trial.txt. If the number of returned patients is odd, you should check your trial.txt file for the missing triallevel_eligibility entry.\n\n### Step #5: Find the result that includes trial id (i.e., Evaluation NCEPT-tle.csv line 3) (See Example). If all the numbers at the 2. row (e.g., `0`) are 1's, then you can use some code to write a results report for submission.\n\n### Step #6: Run the code and check the result in `./evaluation_ncept_trial_level_eligibility/results_report.Rmd`. Run locally by `R -e \"R <path to report.Rmd>\"` or run on the GitHub page by accessing this repository [here](https://github.com/Yong-Kwon/Evaluation_NCEPT_Trial-level_eligibility/releases/tag/tle_report) or by [clicking the button here](https://badjosephkj.github.io/Evaluation_NCEPT_Trial-level_eligibility/releases/tag/tle_report",
        "label": 1
    },
    "805": {
        "output": "3. [CODE]\n* \nYour task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. (more than you do now, it\u2019s only a list now, not in the context of the whole application)\n* Here is the code: input note; output trial_level_eligibility;\nset list=note;\nwhile (line=getline(AR, list, 1, 10)) do\npatients=lower(line);\nfor (i in 0:1000) do\npat_list=substring(line, 1, i);\nmatch_score=intersect(pat_list, search('inclusion criteria', patients));\nif match_score>0 then trial_level_eligibility = 0;<EOD> Pre-exercise cerebral blood volume and glucose concentrations in trained and untrained humans in response to exercise at moderate intensity.\nAIM\nThis study was performed to assess cerebral blood volume and blood glucose concentrations in response to 30 min of cycling at moderate workload in trained and untrained humans. The data are needed to improve the understanding of cerebral blood volume and blood glucose regulation during moderate intensity physical activity.\n\n\nMETHODS\nEchographic and enzymatic studies have been performed with 2 trained male cyclists and 6 nonendurance-trained young adults at rest, and before, during and after, 30 min of cycling at 50% Wmax. Cerebral blood volume and blood glucose concentrations were measured by echography and by enzymatic assay. Mean values of both methods have been obtained.\n\n\nRESULTS\nFor trained cyclists, there is a significant (P<0.05) increase in cerebral blood volume and a significant (P<0.05) decrease in blood glucose at the end of 30' cycling at 50% Wmax compared to baseline. For untrained subjects there is also a significant (P<0.05) increase in cerebral blood volume and a significant (P<0.05) decrease in blood glucose concentration at the end of 30",
        "label": 2
    },
    "806": {
        "output": "To make sure you get your desired output when providing any given patient's case note, use the following command line to execute the code. You may want to use `pip install git` first if pip is not already install in your `pypath`. It helps to fetch and install the most recent code which is up to date.\n```\npip3 path/to/directory/with/code run script_name.py\n```\n\nIf the code is not run as intended, refer to the following section at the bottom of the file.\n\n### Exercise 7\nPlease copy this code in the `exercise_7` directory in `path/to/directory/with/code`. Then, execute this line to run the program.\n```\npython3 path/to/directory with code/exercise_7/exercise_7.py\n```\nTo execute the code in an interactive environment, you may use `python3 -i path/to/directory with code/exercise_7/exercise_7.py`. The script allows the user to go through the code line by line. The user can also modify the script if necessary. As a result, this approach is highly suggestive of learning through exploratory data analysis. If you do not use the interactive approach, please run the above line of code and make sure that you get the desired output shown below. When running in the interactive mode, it should bring up the following:\n```\nYou are a helpful assistant of clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n\n...This is the patient note: A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications.\nThe patient",
        "label": 2
    },
    "807": {
        "output": "</inst>\n<EOD> Evolution of the Human Thalamocortical Connectome from Marmosets to Humans\nThalamocortical (TC) circuits are fundamental constituents of the mammalian brain. While anatomical investigations have confirmed the evolutionary conservation of the TC projections within and between mammalian species, little is known about the molecular mechanisms underlying these fundamental features of neural circuitry. To understand better the molecular foundations of mammalian evolutionary convergence on TC circuit architecture, we examined human and nonhuman primate gene expression to identify molecular mechanisms underlying the formation of TC axons. Here, we demonstrate that thalamocortical axons are selectively enriched for several genes, including Robo3, Nrgn, Gprin1a, Kif21b, and Fyn and that these genes are regulated by shared enhancers. Comparison of the enrichment of genes for TC connectivity with a human orthologous gene set implicated in the genetic etiology of autism spectrum disorder (ASD), reveal ASD candidate genes as potential regulators of TC connectivity. We used the expression of 4 of these candidate genes as readouts to implicate the regulator Lhx2 for ASD. Our novel findings provide insights into the evolution and molecular mechanisms that underpin the molecular basis of human neurodevelopmental disorders. SIGNIFICANCE STATEMENT Through our integrative transcriptomic analysis involving connectomics, genome-wide molecular data, transcription factor binding site analysis, and functional assays, we demonstrate how the molecular mechanisms underlying thalamocortical (TC) connections have been conserved through mammalian evolution and how genetic risk factors for the neurological disorder autism spectrum disorder (ASD) are related to TC connectivity. These new insights provide a molecular framework for understanding the conserved aspects of neurobiological development, and how genetic risk may be linked to this process.<EOD> PARP inhibitors in triple-negative breast cancer\nPurpose of review In this review, we summarize several recent studies which have increased our knowledge of the role of the enzyme poly(adenosine 5\u2032-diphosphate",
        "label": 0
    },
    "808": {
        "output": "- Question: You should compare a patient note and the inclusion criteria to determine the patient's eligibility. What is clinical trial inclusion criteria?\n\n#### Cluing:\nYou compare the patient's age, gender type, and other characteristics such as medical conditions with the criteria set by the clinical trial's investigators.\nClinical trial inclusion criteria define what specific types of patients will be included in the clinical trial. Clinical trial inclusion criteria are often based on the disease being studied. The inclusion criteria may include the age of a person, gender, type of medical conditions, etc.\nClinical trials usually have inclusion criteria to determine who is eligible to participate in the trial. Some clinical trials target specific populations, like adults or children. Most trials have a minimum age requirement for participants, such as 18 years or older.\nSome common inclusion criteria are the health status of the participant, like being stable and free from major health problems. Some other criteria include the ability to participate in all study-related activities, such as regular visits or following specific instructions.\nFurthermore, to get a better understanding of the study, participants will need to understand the study process, as well as potential risks and benefits associated with the trial. Therefore, it is important for individuals to understand the clinical trial inclusion criteria and discuss them with the trial team to determine if they meet the eligibility requirements for participation in the trial.\n- Good Luck!\n\n[INST] You are a research coordinator in a data management laboratory. The aim of your study is to establish a quality-assured and cost-effective laboratory service to perform research trials by providing high-quality laboratory services and data. As the primary investigator, you have already identified and developed a working protocol, which is now shared with the laboratories for study and quality assurance (QA/QC). The goal of this quality assurance (QA/QC) is to ensure that the laboratories' methods, techniques, and processes meet the intended purpose and performance expectancy of the study and that the research laboratories are able to replicate the trial protocol. What quality assurance strategies will you suggest to the laboratory?\n\n___ (Write your answer)\n----\n\n### QA/QC- Related Quality System\n\n### QA",
        "label": 0
    },
    "809": {
        "output": "In this example, if the patient's age was greater than 65 years, the patient would be excluded due to the trial age restriction. In this case, you may want to skip the next patient and look at the next document. After completing this trial, you are going to evaluate the eligible patients' data to get their demographic information and to find their diagnosis-related information.\nThere are a variety of ways to make a diagnosis in this clinical trial. In general, diagnoses are made by pathognomonic presentation, physical findings, and laboratory findings. They all should be entered into the patient note. There are four diagnosis levels in the IntraSight system that you can use to make a diagnosis: definitive, probable, presumptive, and not applicable. \n\n[CXR-1]: 1201\n[CXR-2]: 123\n[Amp] = 20\u00b5m\n[Amp] = 75.0\u00b5m\n\n### \u27a1 123 CXR\n\nPatient 123 is here.\n\n[DIAG-123]: Dementia, Alzheimer's disease, Mild Cognitive Impairment \u2191 \u27a1 Mild to moderate Alzheimer's disease, Dementia (AD/DLB)\n\n[BIO]-[DIAG-123]: Alzheimer's disease(AD), mild cognitive impairment (MCI), dementia \u2191 \u27a1 Mild to moderate AD/DLB\n\n[BIO]-[DIAG-123]: Mini mental test 5 (MMT5) 33, Instrumental Activities of Daily Living (IADL) Assessment 24 points \u2191 \u27a1 Mild to moderate AD/DLB\n\n[DIAG-123]: Memory (M) score 16 \u2191 \u27a1 Mild to moderate AD/DLB\n\n[DIAG-123]: Visual and spatial organization (AS) 5 points \u2191 \u27a1 Mild to moderate AD/DLB\n\n[DIAG-123]: Language and verbal memory (FAS",
        "label": 0
    },
    "810": {
        "output": "## Good luck. \n- `Trial-level eligibility`\n<EOD> On the Physiology of Eel-Pox\n\nRECOLLECTIONS ON SOME LATE DISCOVEREST OF A FORM OF EEL-POX IN THE GREAT FRENCH PISES (RECOLLECTIONS ON THE DISCOVERY OF A FORM OF EEL-POX IN THE \" SUEQN ET AUBIERY\" TYPES IN THE GREAT FRENCH PIESES.)THE following little account of a form of eel-pock which I have discovered in some of the greatest French pies, may not be quite uninteresting\nto vaccinologists. It was the result of a hurried inspection which I was induced to make of some cages of great pies from the Nivernais River in the Month of December last (1868), and of which a detail is given below. It is the first time since the discovery of eel-pox that I have observed this kind of disease. Its peculiarities are in some way related to those of vaccination.\nIt is well known that although there are numerous pies in which there is no evidence of eel-pox, it is nevertheless the universal opinion that we are obliged more or less to the pike for the contagium variolorum. In the very great rivers of Central and Southern France, as those of the Nivernais, the pisciculture consists for the most part of the pike, which weighs from 150 to 200 kilogrammes (say 310 to 440 pounds); and besides its very high price, it is used in all cases where a fish of considerable size and good flavour is desired.\nIn its flesh, the pike contains a large proportion of fat and its bones are exceedingly hard; for which reason it is not much used by the peasants, or sold to the country people of the district.\nIt is reserved for the rich and for those who keep house for the town. Its flesh is very grateful to the epicure, and for this reason alone it might be called the king of fish. It is the most delicious and the most appreciated of the Great Pies. Its appearance is very like that of our pike, and",
        "label": 1
    },
    "811": {
        "output": "Example:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dl, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40 and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n\n\nTrial-level eligibility: 1) Not relevant. The patient does not have sufficient information to qualify for the trial.\nTrial-level eligibility: 1) Not relevant. The patient does not have sufficient information to qualify for the trial.\n\n## 1) Eligible.\nTrial-level eligibility: 2) Eligible.\n<EOD> The effect of phonetic variation on the intelligibility of children who",
        "label": 2
    },
    "812": {
        "output": "<EOD> Reliability of different test methods for the assessment of glucose tolerance in healthy young adult cats.\nOBJECTIVE\nTo compare the reliability of the glucose tolerance test (GTT) and a modified 25-minute GTT in healthy young adult cats.\n\n\nANIMALS\n5 mature male and 5 mature female purpose-bred domestic shorthaired cats.\n\n\nPROCEDURES\nCats underwent 3 GTTs and a modified 25-minute GTT, with treatments administered in random order. The GTT consisted of the administration of 0.5 g of glucose/kg of body weight IV. The modified 25-minute GTT consisted of the administration of 1 g of glucose/kg of body weight IV; the blood glucose concentration was checked every 5 minutes for the first 25 minutes. Treatments were repeated every 3 days for 3 time points, and the time between each time point was 7 to 14 days (depending on which test was conducted on a given time point).\n\n\nRESULTS\nThe modified GTT was consistently highly correlated with the results of the GTT. In addition, the intraindividual coefficient of variation of the modified GTT was much lower compared with the GTT at all time points. Using the modified GTT test, only 1 cat had a significant increase in its glucose concentration at 5 minutes post glucose challenge, whereas, 3 cats had significant increases at 15 minutes using the GTT. Overall, modified 25-minute GTT results of all of the cats were unaffected compared with their GTT.\n\n\nCONCLUSIONS AND CLINICAL RELEVANCE\nResults supported that using the 25-minute GTT is a reliable way of assessing glucose tolerance in healthy young adult cats, because it was highly correlated with the GTT results of all cats and had a much lower intraindividual coefficient of variation. However, interpretation of clinical GTT results should be done with caution, because the GTT may indicate decreased tolerance to glucose, when the modified GTT does not do so.<EOD> Fetal haemor",
        "label": 1
    },
    "813": {
        "output": "The second problem is about the output eligibility criteria.\n\nI would like to find patients with 1) CAD and 2) PSV more than 160 and 3) PSV over 160 cm/s.\n\n### Solution\n\n\nSo let's get back to the second question: `How can you make output of inclusion criteria?`\n\n\n`\n\n![INST](./media/tutorial/c03-1_03.png \"2.1\")\nHere is how to achieve the inclusion criteria 1 and 2:\n![INST](./media/tutorial/c03-2_01.png \"2.2\")\nAnd the inclusion criteria 3?:\n![INST](./media/tutorial/c03-3_01.png \"2.3\")\n\nNow the next step is, using the AND logic `^`, to create the logic that matches the criteria you want.\n\n![INST](./media/tutorial/c03-4_01.png \"2.4\")\n\nHere is how it works: if we want to match any of the criteria for criteria 3, we should use the logical operator `^` (or \"exclusive or\") to avoid falsepositive results. Let's do it like this:\n\n`c03-2^`\n\n\n`\n\n![INST](./media/tutorial/c03-5_01.png \"2.5\")\n\n\nA third question: `And what about a patient with three exclusion criteria?`\n\n\n\n\nA third problem may be how to obtain the results after applying the eligibility criteria.\nLet's say I would like to know the assessment results in a short form, for example, in a string to print:\n`Trial-level eligibility: 1) Excluded`\n\n\nSo, the answer is a bit complicated to formulate because the output is an array with many different values. We can use the first element of the array, which always presents the eligibility score, which is 1 for exclusion and 2 for inclusion. Then we can print the string by adding a comma and the score for every patient.\n\nNow, let's see the solution: \n\n\n![](./media/tutorial/",
        "label": 1
    },
    "814": {
        "output": "<EOD> Lactic Acid Promotes the Metastasis of Gastric Adenocarcinoma Via Activating the C-Myc/miRNA Pathway\n\nPurpose: This study explored the effect and molecular mechanism of lactic acid in the development of gastric cancer.Methods: We detected the expression of lactic acid in the serum and tissue of patients. We overexpressed or knocked down lactic acid in the patients' peripheral blood mononuclear cells. We used ELISA to detect the change of p-c-Myc and miRNA. We constructed a tube model of blood vessels. We used an in situ hybridization kit to detect the expression of miRNA in tissues. In vitro experiment, cell proliferation ability, and EMT level were detected by cell count kit-8 and Western blotting. Flow cytometric method assessed cell apoptosis. Transwell experiment evaluated cell migration and invasion, tube formation and cell cycle. Luciferase assay verified the miRNA and its target gene.Results: The lactic acid levels in patients with gastric cancer were higher than in patients with benign gastric tumors. The content of lactic acid was positively correlated with the expression of PD-L1, CXCR4, SDF-1\u03b1, and CCR7. The expression of lactic acid in patients with lymph node metastasis was higher than that without lymph node metastasis. The expression of lactic acid was positively correlated with the miRNA hsa-miR-1246, hsa-miR-138-5p, hsa-miR-6721-3p, and negatively correlated with the expression of miR-221-5p mRNA. In vitro experiments showed that lactic acid could induce EMT of gastric cancer cells, promote proliferation, and inhibit apoptosis of gastric cancer cells, but had no effect on the cell cycle. Lactic acid can promote the migration and invasion ability of gastric cancer cells and increase the angiogenesis ability. Silencing miRNA can inhibit the proliferation and invasion abilities of gastric cancer cells induced by lactic acid",
        "label": 2
    },
    "815": {
        "output": "<EOD> The Influence of Mucin-Binding and Capsule Type Gene Mutations on the Virulence and Fitness of Cryptococcus neoformans\n\nCryptococcus neoformans is a haploid fungal pathogen whose virulence properties and survival mechanisms in the host are inextricably linked to its mucin-binding (muc1) and capsular (capsular genes) molecules. In order to address the role of muc1 and capsular gene mutations to the fungal virulence and adaptation to its host environment, we constructed strains with different combinations of all null mutants in both muc1 and capsule. In this regard, the influence of each mutation from mucin-binding genes, CAP10, CAP59, and SUN41, or capsule mutants, CAP59, AXL2, RBT5, or GXM, on the fungal virulence and fitness to survive in macrophages and the lung environment, was shown to be independent of the presence of the others. Additionally, we demonstrated that these mutations did not affect its intrinsic susceptibility to several stresses including exposure with antifungal drugs and oxidative stress. These results support a model in which these virulence genes might be independently regulated, allowing C. neoformans to cope with the host environment and to successfully colonize and disseminate the host.\n\n# Introduction\nCryptococcus spp. are haploid, ubiquitous air-borne pathogens belonging to the phylum Basidiomycota.\nCryptococcus neoformans, the etiological agent of cryptococcosis in humans, is the most pathogen virulent and frequently encountered species in nature [bib_ref]  Estimation of the current global burden of cryptococcal meningitis among persons living..., Park [/bib_ref] . In the last decades it has been one of the most important fungal pathogens that cause opportunistic infections [bib_ref]  Estimation of the current global burden of cryptococcal meningitis among persons living..., Park [/bib_ref] . The infection most often results from the inhalation of basidiospores from environmental",
        "label": 1
    },
    "816": {
        "output": "[HOLD T2]\n\n---\n\n\n## Repeated Evaluation Modules\n---\nHere is the repeated evaluation modules:\n```\nTrial:\n# Set the number of cases per trial as 100\n# First time\n# Repeated evaluation\nnumber_of_cases: \"100\"\n\nRun: # Repeated evaluation\n\n# Repeat the trial for 100 times, i.e., set Repeat as 100\nRepeat: \"100\"\n\n# Set time to repeat as 1 hour by Time.\nTime: \"1\"\n\n# Make each run to take at most 10 minutes by Time Limit.\nTime Limit: \"10\" \n\n# Make each run of the trial to take at most 10 minutes. This module will wait until each run is finished.\nTime Limit: \"10\" \n\n# The number of patients to be selected at the first time. Each module will take the patient to be evaluated.\nNumber of Patients: \"1\"\n\n# Select patient at the first time. Set the selection of random seed. Here is the same random seed.\nRandom Seed: \"123456\"\n```\n---\n\n### Step-by-step guide\n---\n# Install\n```sh\npip3 install data_driven_pipelines\n```\n# Clone this repository\n```sh\ngit clone https://github.com/AICHR/data-driven-pipelines.git\n```\n# Create a folder under data-driven-pipelines/repeatedEvaluation Modules\n```sh\nmkdir RDM\n```\n# Set working directory\n```sh\ncd RDM\n```\n# Install data-driven pipelines for repeated evaluation module\n`pip3 install .`\n\n# Create a folder under data-driven-pipelines/repeatedEvaluation Modules (folder 1)\n```sh\nmkdir (folder1)\n```\n# Create a new folder under data-driven-pipelines/repeatedEvaluation Modules (folder 2)\n```sh\nmkdir (folder2)\n```\n# Set working directory inside RDM\n```sh\ncd (folder2)\n```",
        "label": 0
    },
    "817": {
        "output": "##[HINT]\nYour task is `Trial-level assessment of eligibility`. You compare patients' notes to the information in a clinical trial to determine whether the patient would be eligible for that clinical trial.\nThis is a special kind of patient note (a medical prescription) which is used to input clinical trial's information (the eligibility criteria and so on).\n\nFor example, see [here](https://code.jupyter.org/user/hankshuang/jupyter-in-africa/blob/master/notebooks/dream_challenge/part_1_input_table_to_csv/data.ipynb).\n\n```python\npatients.values[0] = 'Excluded'\npatients.values[-1] = 'Excluded'\n\nprint(\"Number of data:\", len(patients), \"\\n\")\nprint(\"First row:\", patients.iloc[0], \"\\n\")\nprint(\"Last row:\", patients.iloc[-1], \"\\n\")\nprint(\"First column:\", patients.iloc[0], \"\\n\")\nprint(\"Last column:\", patients.iloc[-1], \"\\n\")\nprint(\"First column:\", patients.iloc[0][0], \"\\n\")\nprint(\"First column:\", patients.iloc[0][1], \"\\n\")\nprint(\"First column:\", patients.iloc[0][2], \"\\n\")\n\n##[HINT]\nYou can refer any medical prescription (or other kinds of prescription, etc.).\n\nJust try to change the dataset, then you can learn how to find the information that you need.\n```\n<EOD> Lack of effect of calcium antagonists vs thiazides in hypertensive obese blacks.\nIt is unclear whether the results of studies evaluating the safety and efficacy of calcium antagonists in the management of mild-to-moderate essential hypertension can be extended to Blacks, and there is a lack of information on the effects of such agents in Blacks who are substantially above normal weight. A randomized, double-blind crossover study was conducted in overweight (or obese) Black patients who were inadequately responsive to diuretics,",
        "label": 1
    },
    "818": {
        "output": "## Expert Rules\n\nThese are rules for expert. Please check the table below.<EOD> Comparison of a new automated serum glucose method by the hexokinase procedure with other routine methods.\nEvaluation of a new automated serum glucose method using hexokinase and an immobilized glucose detector cell was performed. Serum glucose was determined by the hexokinase procedure, an ion-exchange method and an enzymatic method which involves the use of glutamate dehydrogenase. The results of the Hexokinase and the Ion Exchange methods correlate well (r = 0.966) with the enzymatic method. The Ion Exchange method is less stable in its calibration curve and more laborious than the Glucose Oxidation and Hexokinase methods. Thus the Glucose Oxidation and the Hexokinase methods have been selected for the determination of glucose in the clinical laboratory.<EOD> Cervical spinal cord hemorrhage due to a pseudoaneurysm of the proximal medullary artery\n\nCervical spinal cord hemorrhage is a well-recognized complication of extracranial cerebral aneurysms. In contrast, hemorrhage into the spinal cord is rarely encountered and is generally due to hematologic or metabolic disease or trauma. We herein report a case of cervical spinal cord hemorrhage due to direct cervical vascular injury by the rupture of an aneurysm, which was revealed by herniation of the medulla oblongata through a fracture of the atlantoaxial joint. The patient was successfully treated by surgical tracheostomy and irrigation of the cervical spinal canal.\n\n# Introduction\nCervical spinal epidural hematomas (SEHs) are well-recognized complications of extracranial cerebral aneurysm rupture, and are generally encountered in association with traumatic spinal injury. [bib_ref]  Intraspinal subdural hematoma: clinical features and surgical outcome in 20 patients, Lawton [/bib_ref]  [bib_ref]  Traumatic spinal subdural",
        "label": 1
    },
    "819": {
        "output": "There are two types of clinic trials in this dataset. One is the 'patient trial', an individual study based on a specific question of interest, and the other is the 'review trial', where multiple studies are combined. The code for patient trial here is `Trial-type: Review trial`! [INS]! {2019-09-18, 2019-10-10} [/INS]! and the code for review trial is `Trial-type: Patient`! \n<EOD> Development of a novel antibody targeting a conserved epitope on human ciliary neurotrophic factor receptor alpha.\nCONTEXT\nThe use of monoclonal antibodies targeting the surface of ciliated epithelial cells has been used with great effect in the treatment of dry eye. Unfortunately, the effect is temporary and not well tolerated.\n\n\nOBJECTIVES\nThe primary objective was to develop and characterize a human anti-recombinant human ciliary neurotrophic factor receptor alpha (rhCNTFR\u03b1) monoclonal antibody. The secondary objective was to examine its binding characteristics, safety, efficacy, side effects, and effects on the tear film in vivo and on cultured human conjunctival epithelial cells.\n\n\nMETHODS\nClones were isolated from a cDNA library of peripheral blood mononuclear cells by phage display selection. Antibody binding to rhCNTFR\u03b1 was measured by sandwich ELISA, ELISpot, and surface plasmon resonance assay. The effect of the antibody on cellular proliferation, migration, secretion, and signaling was evaluated. The antibody was tested in a rabbit dry eye model.\n\n\nRESULTS\nOne antibody binding rhCNTFR\u03b1 was identified and was designated as C1-9. The antibody demonstrated a KD of 27 nmol/L, and was >80% inhibitory at concentrations of 500 nmol/L or below. The antibody decreased conjunctival epithelial cell proliferation and migration, cellular viability, and basally secreted nerve growth",
        "label": 0
    },
    "820": {
        "output": "In this way, it is sufficient if patients meet all three of the inclusion criteria but do not satisfy any of the exclusion criteria. That is, if the trial has the structure that a patient may have all exclusion criteria that apply to him, his overall eligibility will be calculated as `1 - n - n`.\n\n### Evaluation\nFor the evaluation:\n\n- Let us evaluate the following patient note. The inclusion criteria, if met, are `1) 46 years old; 2) Family history of CAD; 3) Physically active; 4) LDL-C 167.5 mg/dL; 5) HDL-C 63 mg/dL; 6) No use of lipid-lowering medications; 7) No exclusion to the trial due to any exclusion criteria; 8) Trial-level eligibility: `Eligible`. We conclude that this patient meets all inclusion criteria and this is the first record of a heart rhythm in out-of-hospital cardiac arrest with an initial non-shockable rhythm and is eligible for the clinical trial.\n- Let us evaluate the following patient note. The inclusion criteria, if met, are `1) 46 years old; 2) Family history of CAD; 3) Physically active; 4) LDL-C 167.5 mg/dL; 5) HDL-C 63 mg/dL; 6) No use of lipid-lowering medications; 7) No exclusion to the trial due to any exclusion criteria; 8) Trial-level eligibility: `Excluded.`. We conclude that this patient meets all inclusion criteria and this is the first record of a heart rhythm in out-of-hospital cardiac arrest with an initial shockable rhythm and is not eligible for the clinical trial. \nAs explained previously, the patient note provides information so that you have to determine the eligibility of patients. It is possible that patients may meet eligibility criteria in different parts of the study, i.e., some part may be excluded from the study but other parts may be included. Each time when you meet an eligibility criteria, you must call it using the format described in the previous",
        "label": 0
    },
    "821": {
        "output": "1. Create a `Rx` named `hiv`. The medication for treatment of infection with HIV or AIDS. It can include drugs such as antiretroviral therapy or monoclonal antibodies.\n2. Assign a value of 1 to the property `age` of the patient (patient.age).\n3. Assign a value of 1 to the property `hiv` of the patient (patient.hiv).\n4. Create and assign a value of 1.5 to the property `gender` of the patient (patient.gender).\n5. Create and assign a value of 1 to the property `status` of the patient (patient.status).\n7. Assign a value of 1 to the property `cad` of the patient (patient.cad).\n10. Assign a value of 1 to the property `cad2` of the patient (patient.cad2).\n11. Assign a value of 1 to the property `cad3` of the patient (patient.cad3).\n12. Assign a value of 1 to the property `cad4` of the patient (patient.cad4).\n13. Assign a value of 1 to the property `cad5` of the patient (patient.cad5).\n14. Assign a value of 1 to the property `cad6` of the patient (patient.cad6).\n15. Assign a value of 1 to the property `cad7` of the patient (patient.cad7).\n16. Assign a value of 1 to the property `cad8` of the patient (patient.cad8).\n17. Assign a value of 1 to the property `cad9` of the patient (patient.cad9).\n18. Assign a value of 1 to the property `cad10` of the patient (patient.cad10).\n19. Assign a value of 1 to the property `cad11` of the patient (patient.cad11).\n20. Assign a value of 0 to the property `cad12.`",
        "label": 0
    },
    "822": {
        "output": "If the number of patients whose record information is given only is 100 and all of them pass the assessment to the trial, then the total of records = 100. To display all the trials of the assessment of eligibility, create the following line right after the assessment of eligibility:\n\n  `Trial-level assessment of eligibility:`\n\nThe number of records: `100/100`= `1`\n\nFor the second trial, you need to enter the trial data after the first trial using the same method, i.e., the `Trial-level assessment of eligibility:` line is skipped. To display the second trial only, set the total of records to 100 and include only the second trial in the file after the assessment of eligibility section. For the third trial, add the text file after the assessment of eligibility line. The value for the total of records should be greater than each trial. \n[/INT]<EOD> Clinicopathologic study of the nasal cavity in dirofilariasis.\nA clinicopathologic study of the nasal cavity in Dirofilaria infection was conducted on 580 cases. Of the two cases in this study, one was a 1-year-old boy who had right intranasal dirofilariasis in July 2000, and the other was a 12-year-old girl who had left nasal dirofilariasis in June 2002. Their chest x-ray showed nodular shadows in the right or left lung which have been proved as the residuals of Dirofilaria in the surgical section. Based on this case, the authors evaluated the location, size, color, consistency of the nasal dirofilariasis, and then analyzed the relationship between these factors and the location. They observed the relationship between the presence of granuloma and the location in dirofilariasis and investigated the histologic features of granulomatous inflammation to identify the types of tissue response.<EOD> Sensitivity of Diverse Enterobacteria to Synthetic Photosynthetic Compounds\nSUMMARY. Phenazine compounds isolated and synthesized from bacterial plant path",
        "label": 0
    },
    "823": {
        "output": "[EXERCISE]\n1) Which line should you execute the `Trial-level eligibility` statement? Select the correct answer.\n```python\ndef main():\n    trial_patient = [\"Patient note\"]\n    trial_recruitment = [\"Trial name\"]\n    trial_eligibility = [\"Trial level eligibility\"]\n    # Here is your code.\n\n\"\"\"main.py\"\"\"\nmain()\n```\n---\n\n[EXERCISE ANSWER]\nIf the trial name has the value `Coronary Revascularization Assessed by Stress PET` and trial-level eligibility is assigned as eligible, then the code should output the number `2) Eligible`.\n```python\ndef main():\n    trial_patient = [\"Patient note\"]\n    trial_recruitment = [\"Trial name\"]\n    trial_eligibility = [\"Trial level eligibility\"]\n    # Here is your code.\n\n\"\"\"main.py\"\"\"\nmain()\n```\n<EOD> Genetic analysis of the BRAF and KRAS mutations in cutaneous melanoma.\nOBJECTIVE\nTo investigate the BRAF and KRAS gene mutations in Chinese melanoma samples, and to evaluate their correlation with other clinicopathological factors of cutaneous melanoma (CM).\n\n\nMETHODS\n102 CM specimens were subjected to PCR-direct sequencing to detect BRAF and KRAS mutations. Immunohistochemical staining was carried out to detect the expressions of BRAF V600 and KRAS V12 in paraffin-mounted tissue sections. The clinicopathological factors were analyzed in relation to each gene mutation.\n\n\nRESULTS\nBRAF V600 mutation was observed exclusively in 60 of 102 (58.8%) CM specimens, mainly V600E (57/60) with a minor fraction of V600K (3/60). KRAS V12 was detected in 23.5% of CM specimens. There was a significantly positive association between BRAF V",
        "label": 0
    },
    "824": {
        "output": "Here is part of the result, but it is not complete: \nPlease, consider more detail of the full result.\nPlease, consider more detail of the full result, e.g., include columns about other variables such as gender, age, LDL-C, HDL-C, fasting glucose and triglyceride level etc.\n\n[INST]\n[fig]  [INST] 5: [INST]) // if the assessment of eligibility is `1) Not relevant ` // then only patient is not relevant for entry into clinical trial) [INST] // if the assessment of eligibility is `2) Eligible ` // then only patient is relevant for entry into clinical trial) [INST] //if the assessment of eligibility is `0) Excluded ` // then only patient is not relevant for entry into clinical trial) [INST] //then this means that the patient is excluded on the grounds of the trial's exclusion criteria) //so in this case patient should not be recruited in clinical trial)[INST] [/fig] \n<EOD> Transmission, persistence, and seroprevalence of severe acute respiratory coronavirus virus 2: a retrospective cohort study in 28 European countries\n\nObjective To determine, in the absence of a formal prospective clinical trial, if severe acute respiratory coronavirus virus 2 (SARS-CoV-2) transmission is higher in children. Patients and methods This retrospective cohort study in 28 European countries analysed the association between child age groups and SARS-CoV-2 transmission, persistence, and seroprevalence for the period 29 April to 9 May 2020. Cases were defined as SARS-CoV-2-infected patients identified by real-time polymerase chain reaction testing. Controls were randomly selected from patients with influenza-like illness without laboratory confirmation of SARS-CoV-2. Exposure was measured by the number of children aged 0-9, 10-14, and 15-19 years per 100 adults aged \u226515 in each country. Results The SARS-CoV-2 seroprevalence was, on the",
        "label": 0
    },
    "825": {
        "output": "##[/CODE]\n##[TEST]\nYou should always output the patient's eligibility according to the clinical trial eligibility criteria. You need to do so via `Trial-level eligibility` and it will be in the last line of the note table like `Trial-level eligibility: 2) Eligible.`.\nIf you're satisfied with your code, please hit the `Test` button below:\n<EOD> .\nOBJECTIVES\nTo explore the current status and factors affecting treatment and follow-up of tuberculosis in patients with type 2 diabetes mellitus (TB-DM2) in the community medical center.\u2029\n\n\nMETHODS\nBased on a cross-sectional study, multistage stratified sampling was used to select 169 patients with TB-DM2 treated in 6 community medical centers in Taiyuan, Shanxi province. Investigation data (e.g., age, T-test, course of disease, diagnosis and treatment process) were collected and analyzed by SPSS 17.0 software.\u2029\n\n\nRESULTS\nMost (92.3%) of the TB-DM2 patients had a history of self treatment, which mainly included medication on the outside, herbs and over the counter drugs. They had 2-10 times of physician visits before admission to the community medical centers, with a mean time of 77.0 days. Before admission, 97.2% of the patients received anti-tuberculosis treatment; 48.5% of the patients obtained drug information in the community medical center and 90.0% did not know the drug's dosage. A total of 60.7% (n=103) had a positive urine glucose test at the time of admission; however, only 34.8% were educated about glucose monitor equipment. During treatment, 46.2% showed poor glycemic control (HBA1c \u2265 7%). Most patients (90.6%) had to purchase glucose strips (11 times/week) and insulin syringes (21.3 times/week), at a cost of",
        "label": 0
    },
    "826": {
        "output": "```python\nimport pandas as pd\nimport numpy as np\nimport pprint\nimport matplotlib.pyplot as plt\nimport matplotlib.patches as patches\nimport seaborn as sns\nfrom matplotlib.patches import ArtistProperties\nimport json\nfrom nltk.tokenize import sentence_split\nimport pandas\ndata_df = pd.read_csv(\"./dataset/patient_note.csv\")\nt_level_df = pd.read_csv(\"./dataset/clinical_trial.csv\")\ndata_df = data_df[\"patient_note\"]\nt_level_df = t_level_df[\"trial_level_eligibility\"]\ndata_df = data_df[data_df['Insurance Status'] == 'NHPI].dropna(axis = [0,])\ndata_df = data_df.append(t_level_df, ignore_index=True)\ndata_df.head(3)\n#Trial-level eligibility: 0) Excluded\n#trial_id: \"02B-2016-CAD-661\"\n#data_id: \"1\"\n#Trial-level eligibility: 1) Not relevant\n#trial_id: \"02B-2016-CAD-661\"\n#data_id: \"2\"\n#Trial-level eligibility: 2) Eligible\n#trial_id: \"02B-2016-CAD-661\"\n#data_id: \"3\"\ndata_df[\"gender\"] = data_df[\"gender\"].map(lambda s: s.capitalize())\ndata_df = data_df[\"trial_id'] == \"02B-2016-CAD-661\"] # 0.008041 \ndata_df = data_df[data_df['Trial-level eligibility']!=None] # 0.028246\ndata_df.dropna() # 0.006162\ndata_df = data_df.sample(random_state = 1) # 0.001",
        "label": 1
    },
    "827": {
        "output": "### Tutorial/Evaluation\n\n\n\n\n* [x]  I was able to run my `run` script in the command terminal\n\n* [x] I was able to start my new clinical trial with `trial start`\n\n* [x] I was able to start a patient by `patient start`\n\n* [x] I was able to get output from `show` in the `patient start` function\n\n* [x] I was able to get output from `run` in the `patient start` function\n\n* [x] I was able to get output from `trial-level eligibility`. In the end,\nthe `Trial-level eligibility: ` variable should be in the same line as `patient name:`\n\n\n## Getting Started Tutorials\n\n\n### Tutorial/Getting Started with Basic Functions\n\n* [x] Learn from the basic functions\n\n\n### Tutorial/Evaluation\n\n\n* [x] I was able to run `eval(get_all_trials)` function to get all the trials\n\n* [x] I was able to run `eval(get_all_pairs_of_trial)` function to get all the pairs of trial\n\n* [x] I was able to run `eval(get_all_trial_nodes)` function to get all the trial nodes\n\n* [x] I was able to run `eval(get_all_patients)` function to get all the study patients\n\n* [x] I was able to run `eval(get_all_trial_clusters)` function to get all the trial clusters\n\n* [x] I was able to run `eval(get_all_trial_studies)` function to get all the trial study\n\n* [x] I was able to run `eval(get_all_trial_study_status)` function to get all the trial study staus\n\n* [x] I was able to run `eval(get_all_trial_studies_status)` function to get all the trial status as a list\n\n\n## Clinical Trial Library\n\n\n### Tutorial/Overview\n\n\n* [x] I was able to install clin",
        "label": 0
    },
    "828": {
        "output": "![INSERT FIGURES]\n\n##[DECLARATION] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.[INSERT TABLE 1]\n\n### Step 1: Eligibility\n\n\n#### Eligible\n\n```\nTrial-level eligibility: 2) Eligible\n```\n\n#### Not Eligible\n\n```\nTrial-level eligibility: 1) Not relevant\n```\n\n#### Excluded\n\n```\nTrial-level eligibility: 0) Excluded\n```\n#### Not applicable\n\n```\nTrial-level eligibility: N/A\n```\n\n### Step 2: Unique ID\n\n\n#### Non-unique ID\n\n> Non Unique ID\n\n```\nPatient ID: XXX\n```\n\n#### Unique ID\n\n> Unique ID\n\n```\nPatient ID: XXX\n```\n\n### Step 3: Mental stress\n\n\n#### Mental Stress\n\n> Mental stress\n\n```\n\n## Mental stress\n```\n\n> No mental stress\n\n```\n\n## No mental stress\n```\n\n### Step 4: Mental stress\n\n\n#### Mental stress\n\n> Mental stress\n\n```\n\n## Mental stress\n```\n\n> No mental stress\n\n```\n\n## Mental stress \n```\n> N/A\n\n```\n\n## No mental stress\n```\n<EOD> Enhanced stability of a solubilized model protein of membrane protein by polyethylene glycol 4000.\nLysozyme, an anionic model protein of a cell membrane protein, was studied as a solubilized membrane protein. The effect of polyethylene glycol 4000 (PEG 4000) on the thermal stability of the solubilized protein was examined by the fluorescence method and spect",
        "label": 0
    },
    "829": {
        "output": "[fig]  [INST] 1: The clinical trial information: 15253 (title), wrist arthroscopy; American Society of Anesthesiologists (ASA) physical status I -III; in patients scheduled for a wrist arthroscopy.2) The inclusion criteria: age; female; adult patients having wrist arthroscopy surgery. [INST] Eligibility criteria: 1) Included: 0) Male; 2) Female; 3) Adult patients (Age 18 years and over); 4) ASA status I-II for age and medical fitness; 5) Scheduled wrist arthroscopy (Diagnostic arthroscopy, Tendon repair, Wrist Decompression, Wrist arthroscopy, Radiofrequency of medial or lateral branch of the median nerve, Carpal tunnel release). 2) Not included: 1) Patients under 18 years of age; 2) Patients under 20 kg; 3) ASA status III; 4) Patients with history of allergy to local anesthesia; 5) Patients who are not willing to participate; 6) ASA status IV and V patients; 7) Patients with any other co-morbidities and contraindications; 8) Patients with known psychiatric and neuropsychological disorders; 9) Patients suffering from uncontrolled diseases; 10) Patients who were on antidepressant therapy for a long duration; 11) patients suffering from anxiety disorders; 12) Patients on medications known to produce withdrawal symptoms; 13) Patients having severe medical or psychiatric conditions; 14) Patients with a drug addiction problem; 15) Patients who have been admitted and treated for alcoholism or substance abuse; 16) Patients with evidence of cognitive dysfunction assessed by MMSE. 1) The exclusion criteria: 0) Patients who developed intra-operative cardiovascular or pulmonary events; 1) Patients with serious cardiac, renal, or hepatic disease; 2) History of ischemic",
        "label": 0
    },
    "830": {
        "output": "___\n[FATAL] Let's train your attention. In the given input data, a patient is 18 years old or older.\nWhat do you expect in age and age groups? [INSERT]\nYou should select the following output: `Age_and_age_groups: \"18 years and older.\"`[INSERT].[INST] \n___\n[FATAL] If only one or more exclusion criteria applies to a patient, you expect an output in the following format: `Inclusion criteria: Incompatible exclusion criteria: 1) Age less than 18 years old.`[INSERT] \n\n___\n[FATAL] In the given patient note, you should select the following output: `Llk -Cervical -Stroke -Ligation: \"Diagnosis:\ncerebrovascular accident. Pathology:\nsubarachnoid hemorrhage.\nEvaluation: \"Cerebral vascular accident.\n\n1.1. Lifestyle:\nNon-compliant healthy lifestyle.\nCurrent:\nDiagnosed with Diabetes Mellitus type 2. Mild hypertension and hypercholesterolemia.\nMedication:\nmetformin 1000 mg in AM, in PM.\n\n## 1.2.\nMedical history:\nFamily history of cardiovascular (stroke) events. Aortic and bifrontal aneurysms.\nHistory of cardiac surgery:\nCoronary artery bypass grafting.\nHistory of surgery:\nAortic valve replacement.\n\n## Diagnosis:\nDiagnosed with aortic and bifrontal aneurysms. Previous history of coronary artery bypass grafting.\nHistory of chronic diseases:\nDiagnosed with cardiovascular disease previously (e.g. coronary artery bypass grafting, aortic valve replacement).\nPrevious medical history:\nDiagnosed with cardiovascular disease previously (e.g. coronary artery bypass grafting aortic valve replacement).\n\n## Relevant pathology:\nAortic aneurysms, bifrontal, right and left",
        "label": 0
    },
    "831": {
        "output": "_83_\n\n## 2\n\n![](https://s3.amazonaws.com/clinical-ai/assets/book.jpg)\n\n## What are the inclusion criteria?\nThere are four inclusion criteria: a) The patients must be \u226518 years old.\nb) The patients must have severe to moderate atherosclerotic cerebrovascular stenosis that is symptomatic. The patients' symptomatic CAS must be classified as follows:\n\n1. IAD is defined as an acute ischemic neurological deficit due to cerebral artery stenosis without any evidence of brain infarction. IAD is classified according to subtypes:\nA. transient ischemic attack (TIA) \u00b1 acute ischemic neurological deficit lasting \u226424 hr.\nB. stroke \u00b1 acute cerebral ischemia lasting \u226524 hr.\nIAD is an acute ischemic neurological deficit without any evidence of brain infarction defined as a sudden onset and clear clinical manifestation presenting as focal neurological deficits or cognitive dysfunction (such as disorders of consciousness, dysarthria, dysphagia, dysaesthesia, sensory abnormality, ataxia, and paralysis) with an evolution lasting <24 hr. [61]\n\n1. Acute symptomatic carotid artery occlusion (ACAO) with cerebrovascular insufficiency caused by unilateral severe cerebrovascular stenosis in the proximal internal carotid artery\n\nA. within 1 week of cerebral embolic-ischemic stroke, ACAO, or TIA.\nB. a proximal cerebrovascular stenosis within the ICA in which \u226590% luminal stenosis (>90%) is shown in the 3-dimensional digital subtraction angiography (DSA) scan. \nc) The patients should have an ultrasound-defined proximal stenosis of the internal carotid artery (>70%).\nd) The patients",
        "label": 0
    },
    "832": {
        "output": "<EOD> A case of neuroendocrine tumor in the renal pelvis.\nThe urinary tract is the most frequent location (50-65%) of paragangliomas. Their extra-adrenal origin in this location is 90%. Clinical presentation is unspecific and often nefarious, and the diagnosis is more rarely pre-operative (only 15-20% of the cases). The diagnosis of these tumoral lesions of urinary tract of the paraganglioma type is made by a multidisciplinary team in cooperation with the pathologist and neuro-radiologist. The authors report a case of a patient admitted in the Department of Urology of the University Emergency Hospital of Bucharest with a palpable right renal mass and anuria from ten days before the admission.<EOD> In vitro antioxidant and anti-inflammatory activity of hydroethanolic extract and its fractions from Plectranthus amboinicus (Lour.) Spreng.\nThe aim of this study was to evaluate the antioxidant and anti-inflammatory activity of the aqueous and hydroethanolic extracts (hydro-E) and the two soluble-liquid (soluble and aqueous) and insoluble-liquid (chloroform, cyclohexane, methanol, and ethyl acetate) fractions (hydro-Fr) from leaves of Plectranthus amboinicus. Antioxidant activity was determined in vitro by DPPH, ABTS, NO, and OH radical scavenging tests, determination of reducing capacity, and enzymatic inhibitory activity against lipoxygenase. Anti-inflammatory activity was evaluated in vitro on the inhibition of the enzyme proteinase and elastase. The results showed that, among all extracts and fractions, hydro-E presented the highest antioxidant activity, with lower IC50 values (5.52-18.75 microg/mL) in ABTS, DPPH, NO, and OH radical scavenging assays and in enzymatic inhibition. In the anti-inflammat",
        "label": 0
    },
    "833": {
        "output": "You need to run it by the following command. \n\nYou will receive an error because there is not a `Trial-level eligibility` header: `Error: Invalid JSON object: \"\".`.\n\nSo you should use `Trial-level eligibility: 2) Eligible.`, like this, by `Trial-level eligibility:2) Eligible.`. [INST]\n\nOutputs:\n\n```json\n{\n    \"TrialID\": 16\n}\n```\n\nYou can see a sample output in [here](https://gist.github.com/alid-safiyullah/40c31d0c3cb0586cc8d06854b5b78ec9).\n\n\n# Discussion and Revision\n\n<EOD> Heterocyclic ring formation via  cycloaddition of vinylcyclopropanes with pyridine.\nA general  cycloaddition of vinylcyclopropanes with pyridines provides a straightforward route for the synthesis of pyridoheterocyclic compounds of diverse substitution patterns. The reaction occurs selectively on one end of symmetrical vinylcyclopropanes, thus avoiding the generation of the cyclopropylpyridine intermediate. The  product with the endo (but not exo) configuration, arising from the intramolecular attack by the re face or C2 of the pyridine on the vinylcyclopropane, contains a concave face with good solubility. In particular, several bicyclic pyridines  were obtained in more than 70% yield by using tertiary vinylcyclopropanes, thus avoiding the use of pyrazinylpyridines. The 2,2'-dihydroxy-1-phenyl-6-methylpyridin-4(1H)-one (DDQ) is the optimal catalyst to improve the yield of the pyridine-based heterocycles.<EOD> .\nThe aim of this study was to evaluate the role of preconditioning by endurance training on protection of the myocardium against experimental ischemic-reperfusion injury. The experiments were carried out on 50 white rats randomized into two groups: the",
        "label": 1
    },
    "834": {
        "output": "Good Luck! In the [URL], you can try the interactive tutorial by clicking the \"Try now\" button.\n\n### How should we handle missing LDL-C data in a multi-armed trial to evaluate a therapy for lowering cholesterol?\n\n##\n\n## Background and goals\nIn the first scenario, the data were recorded in all patients. In this scenario, all patient data are available, including age, sex, body mass index, LDL-cholesterol, statin use before and after the start of the trial and information on cardiovascular events and adverse\nreactions, as well as information on the patient (name), the participant's date of birth, and contact information (phone number and the name of the first contact on the participant's personal address).\n\n### First question:\nHow should we conduct sensitivity analysis to examine patients with missing LDL-C data? \nAs shown, the data were recorded in all patients. \n\n#### Sensitivity analysis 1:\nIf we assume that the missing data are missing completely at random (MCAR), then we should only consider cases for which all information is available. \nAs shown, the data were recorded in all patients. \n\n#### Sensitivity analysis 2:\nIf we assume that the missing data are not missing completely at random (MNAR), then we should consider all cases except for the missing ones. \n\n### Second question:\nShould we drop all patients with missing data?\nAssuming a 30% probability of a patient having LDL-C data:\n\n\n\n\nAssuming the MCAR assumption: \nThe expected number of patients with missing data is 30%. Given that the MNAR data are missing:\n\nAssuming the MNAR assumption: \nThe expected number of patients with missing data is 3.9.\nIn this example, a sensitivity analysis would make it easier to compare the probabilities in the two data-missing scenarios and the results in the complete data. You can use our package \"Mixed\" to perform sensitivity analysis. \n\n### Third question:\nWhat is your thought on a scenario missing randomized group?\nIf all patients had the same number and type of missing data (for example, only LDL-C data are missing in Arm A because LDL",
        "label": 2
    },
    "835": {
        "output": "##[/CODE]\n** 4. What is the value of '03-Oct-2020'? It is a timestamp representing the latest update for the particular note. [INSTR]\nFor demonstration purposes, we take the latest updated note on this day to continue our assessment.\n\n** 5. Define the function for assessing note's eligibility based on clinical trial's inclusion and exclusion criteria. [INST]\nWe can see the function of assess_eligibility_assistant() from the source code of the sample notebook. We can easily find the definition of the function. \ndef assess_eligibility_assistant(patient_note):\n    for eligible_value in [0, 1, 2]:\n        trial_eligibility = eligibility_mapping.get(int)\n        eligibility = patient_note.eligibility\n        if eligibility == eligible_value:\n            assessment_status = 'Eligible.'\n            assessment_text = assessment_text + trial_eligibility + ': ' + eligibility + '\\n'\n    return assessment_text\n\nAnd we can see the definition of eligibility_mapping in the code:\n\neligibility_mapping = {\n0: 'Excluded.',\n1: 'Not relevant.',\n2: 'Eligible.',\n}\n\nSo, we need to make the following changes: \n1. Eligibility mapping: For demonstration purpose, we change eligibility_mapping from [0, 1, 2] to eligibility_mapping from [0, 'Excluded', 'Eligible'], just to remind us to modify the eligibility_mapping from the original mapping. The reason why we don't modify original mapping is that to maintain the same order of the output, e.g., 'Excluded.', 'Not relevant.', 'Eligible.'. The first line represents 'Excluded' and the next two lines represent 'Not relevant', and 'Eligible'. If we change the order of [0, 'Excluded', 'Eligible'], it means the order of the output will be changed to [0, 'Not relevant', 'Eligible'], which is confusing, because it is not",
        "label": 1
    },
    "836": {
        "output": "2) Exclude (output `4`) if it is not a patient with LDL-C level 545 mg/dL (or 21 mM) and no use of lipid-lowering medications. 3) Not relevant (output `0`). 4) Eligible (output `2`). \nNext, you should calculate the Total score summed over three trial-level eligibility score and compare it with the maximum score of the trial-level eligibility, i.e., 3. \n\nThe highest score, 3, is the total score (S_T) for a patient, which would let us choose an active clinical trial for this patient with this trial ID (TID=16) and the trial title (viz. ``Bone marrow transplantation for lymphoma (BMT) ``) that has the following restrictions from the patients: (i) Lymphoma, (ii) advanced, and (iii) not having a donor. \nIn a real situation and depending on the choice of patients, the patients with scores 1, 2 and 3 can be included in a single trial, 2 and 3 in another trial, 2 in yet another trial etc. \n<EOD> Role of Heterogeneous Water Distributions in LCST Switching of Amphiphilic Copolymers.\nResponsive polymers are a versatile tool in chemical engineering, smart surfaces, and sensors because of their ability to switch between different conformation states, controlled through external stimuli. One class of stimuli-responsive polymers is that exhibiting lower critical solution temperatures (LCSTs), which experience phase separation of their polymeric chains once placed in an aqueous environment, with the chains either aggregating at or forming an insoluble hydrogel. The LCST switching of stimuli-responsive polymers is a crucial step where the phase change into a polymeric-rich system is often accompanied by a substantial decrease in the solution's water content. The presence of water is known to have a large impact on the aggregation behavior of responsive polymer solutions, thereby determining the system's equilibrium phase diagram. However, how the heterogeneous water content impacts the kinetics of the LCST switching is incompletely understood, which is",
        "label": 0
    },
    "837": {
        "output": "For more information, please refer to the following article by Dr. Ishaq: You Will be a Good Clinical Trial Recruiter [/NOTE]\nThe assessment of eligibility is the key question in a clinical trial. It makes sense to perform a thorough eligibility assessment before a study participant is enrolled so that you can make informed decisions about eligibility. If the participants are unsuitable for the trial, it is a waste of time if we enroll them later. Conversely, we do not want to enroll people who are well suitable for the trial, but we are required to enroll unsuitable people. Assessing eligibility with a careful and detailed discussion with the patient and your supervisor will minimize the incidence of enrolling an unsuitable study participant.\nAlthough it seems like a simple question, the eligibility assessment is very complicated. You can determine eligibility in various ways. You should understand what is required of the patient to decide who will be included in the clinical trial. Eligibility criteria might include certain health problems, medications, age limits, and so on.[/NOTE]\n\n\n### Exclusion criteria\n\nDuring the screening, you should exclude those who do not meet the inclusion criteria. An exclusion might include severe health problems, pregnancy, medications that can affect the study outcome, and so on. If you find yourself excluding people who are well-suited for the trial, consider the following: a better eligibility assessment, other inclusion criteria, or a modification of the study. [/NOTE]\n\n### Inclusion criteria\n\nDuring the screening, you should determine those who meet the inclusion criteria. Inclusion criteria might include the following:\n- certain age\n- certain gender\n- certain health problems\n- certain medical test results\n- taking certain prescribed medications\n- living in a particular area\n- etc.[/NOTE]\n\n### Eligibility\n\nEligibility refers to whether to enroll participants or not.[/NOTE]\n\n### Exclusion criteria\n\nExclusion criteria are the reasons why patients are not able to participate in the clinical trial (e.g., they are not suitable for the trial, they live too far from the study center, etc.).[/NOT",
        "label": 0
    },
    "838": {
        "output": "![INST]\n[INST]\n\n### Recommended solution\nLet's think step by step.\n\n### Data loading\n1. Define the structure of each input variable data.\n    * age\n    * gender\n    * LDL_C\n    * HDL_C\n    * FBG\n    * TG\n    * BP\n    * smoking\n    * family_history\n    * medication\n    * diabetes_history\n    * diabetes_treatment\n    * LICA_PSV\n    * LICA_EDV\n    * RICA_PSV\n    * RICA_EDV\n\n    - For the data of `family_history` and `diabetes_history`, you should extract the words of the sentence using JaroWinkler distance measure which is included in the Text Processing Toolkit package.\nThe distance measures include the Jaro, JaroWinkler, Levenshtein, and JaroWinkler and Levenshtein distance measures, which are included in Text Processing Toolkit package. Here is the JaroWinkler distance definition(JaroWinkler distance : is defined as the number of edit operations needed to change the Jaro distance).\n\"JaroWinkler is defined as the number of edit operations needed to change the Jaro distance. The edit operations are insert or delete a letter and replace a letter. Two words are considered to be equal if both begin with the same lead letter and end with the same terminal letter, no matter about any edit operations.\"\nThe words that satisfy similarity(distance=0) should be regarded as the same word.\n- For the data of `family_history` and `diabetes_history`, you should extract the words of the sentence using JaroWinkler distance measure which is included in the Text Processing Toolkit package.\nThe distance measures include the Jaro, JaroWinkler, Levenshtein, and JaroWinkler and Levenshtein distance measures, which are included in Text Processing Toolkit package. Here is the JaroWinkler distance definition(the words that satisfy similarity(distance=0) should be regarded as the same word.\n- For the data of `family_history` and `diabetes_history`, you should extract",
        "label": 1
    },
    "839": {
        "output": "A: What's new since first answer? Just updated this to python3. I've never used this before the answer from @Krupa, but here's something I found that helped in my code: \nprint(type(s[i])) # will print '<slice>' so the slice we need does not appear in the output\n\nThis helps by telling if the variable that you're looking for is part of your slice.\n\nA: The following method gives you all the info per patient record in patients(df, ['Age_at_onset', 'Gender', 'Weight']).\ndef print_summary_per_record(df, columns):\n    for index, row in df.iterrows():\n        print (f'{row[\"Age_at_onset\"]} {row[\"Gender\"]} {row[\"Weight\"]} {')\n \n    i = 1\n    for index, row in df.iterrows():\n        print (f\"Index {row[\"Age_at_onset\"]} {row[\"Gender\"]} {row['Weight']} {'...'}\")\n\n<EOD> In Vivo Detection of Mitochondrial Activity and Aging Rate: A Pilot Study of D-Ribose Administration\n\nRecent reports have shown that increased levels of D-ribose, a sugar that plays a vital part in all aspects of energy production, were negatively associated with mitochondrial health. Also, increased levels of D-ribose in the blood have been related to several diseases including obesity and cardiovascular diseases. In this study, we report an inverse correlation between D-ribose levels with mitochondrial energetic parameters using the FLUOX-D system, a non-contact fluorescence lifetime imaging technique for absolute quantification of cellular metabolic activity. We provide here the first proof of concept of this methodology to analyze and establish a link between D-ribose with mitochondrial activity and health. The findings indicate that D-ribose increases with age and correlate with reduced mitochondrial activity. This indicates that D-ribose could be an index of aging, and may help to determine a rate of aging in future studies.\n\n# Introduction\nAging is a continuous process that affects the functionality of individuals through",
        "label": 0
    },
    "840": {
        "output": "## Geweke z-score\n\nThe Geweke diagnostic is a standardized measure of how close is the posterior distribution to the simulated (target) distribution. The Geweke z-score is often used as a diagnostic of convergence. Let g be a random walk Markov chain on parameters \\boldsymbol {\u03b8}, for a given time. \n\nThis statistic represents a deviation from the normal distribution, so that the larger the value, the more poorly the chain is mixed. The standard deviation of the statistic,\n\n\\sigma_{g} = \\sqrt{\\frac{\\mathbb{E}(\\delta_{g}^{2}}{N(N -1)}}{\\delta_{g}\\overline{\\overline{\\Delta}}}},\n\nwhere\n\n$$\\overline{\\overline{\\Delta}} = \\sum_{k=1}^{\\infty}\\left(W(k) - W^{*}(k)\\right) 2 = |\\theta - \\boldsymbol{\\theta}|^{2},$$\n\nis a measure of the magnitude of the deviation, and W and \u03b8 are the MCMC sample path and the target path respectively. It should be noted how closely this equation resembles an example of how to compute the autocor",
        "label": 1
    },
    "841": {
        "output": "### Input:\nTo use the program you must first open a file input.txt, with the following contents:\nNote: The program inputs all of your patient notes' data; hence, you must have provided the same to your script.\nThe information you provided must respect this syntax: Key: Value:\nExample:\n\n### Explanations:\nIf your Trial-level eligibility is 0, your patient is excluded (your patient note does not provide enough information to qualify for the trial), otherwise your patient is eligible. The third column is reserved for comments. You must supply the patient information required in this document.\n\n### Output:\nAt the end of the run, you will receive the following input.txt file on your screen: Example:\n\n### Output:\nAt the end of the run, a new file output_patients.txt will be downloaded to your screen or to the specified folder, if it is larger than 28 Kb: Example: This example highlights the patients who are to be recruited.\n\n##[TUTORIAL] Data pre-processing \nBefore running your script, you need to pre-process your patient note input.txt file, by removing the headers such as `Age` and `BP` and adding another column named 'Trial-level eligibility' that will be reserved for your Trial-Level Eligibility. In addition, it is imperative to create one more column by calculating the sum of the three columns of the previous columns `CAD +`, `CAD -`, `Lysocardiopathie` to have each patient patient note contains no more than one value. We will use this sum to find the number of patients who are to be recruited.\nYou can follow the instructions below\n\n### 1. Open input.txt file.\n\n### 2. Add a new column: Trial-level eligibility in the column next to `Trial-Leader`.\n\n### 3. Set the value to be 0 for each patient who doesn't meet the trial's eligibility criteria (i.e., excluded) and to 2 for each eligible patient. For each patient who is not excluded but does not meet the trial's criteria, set the value to -1:\n\n###",
        "label": 1
    },
    "842": {
        "output": "[INST] At the end of each patient note, it is indicated whether the patient has a risk factor or not. This is achieved with one line `+/+`. If the patient has multiple risk factors for the clinical trial, the first risk factor is given, e.g.,\n\npatient_ID Patient ID. 3219 \n\nThe patient information is filled out with multiple repetitions (lines 5-9), and the `+/+` is included at the end of each patient ID.\nIf a patient has multiple risk factors for a clinical trial, the first risk factor to be found is given. If there is no such rationale, the line that shows no risk factors is displayed. \npatient_ID +/+\npatient_ID Name, age, and gender. 3219\n3 31 + + + +/+\n\n## Example 4: Drug interaction\nHere is the patient:\nA 49-year-old female with a medical history of hypothyroidism diagnosed 14 years ago presents with increased abdominal girth and nocturia. The patient was taking levothyroxine for this condition; she also takes ibuprofen for pain due to sciatica.\nThe findings of her physical examination were unremarkable, with the exception of her thyroid gland (hard and enlarged). Her thyroid-stimulating hormone (TSH) and free thyroxin (f-T4) were within normal limits.\nThe results of a pap smear performed two years ago were normal. The patient was told to follow up for cervical examination and pap smear. She was informed that she should immediately return to the unit if she missed the annual cervical examination.\nThe patient has no history of cardiovascular, respiratory, or neuromuscular diseases. She is married and has an 8-year-old daughter. She has quit smoking 10 years ago. She has a moderate alcohol consumption of approximately 20 g of alcohol per day. Her physical activity is mild.\nThe past medical and family history of one of her relatives was unclear. Her son has an atrial septal defect, and her father died of a heart attack.\nUltrasonography of the thyroid g",
        "label": 1
    },
    "843": {
        "output": "The steps of the algorithm will be similar to those described above. Here are the steps using the following commands:\n[formula]  $ echo name of clinical trial > trial_name.txt $ echo inclusion criteria > inclusion_criteria.txt $ echo study protocol > study_protocol.txt $ echo data input > data_input.txt $ echo data output > data_output.txt $ echo new trial > newtrial.txt [/formula] \nBy changing the variables in the trial_name.txt, inclusion_criteria.txt, study_protocol.txt, data_input.txt, data_output.txt, and newtrial.txt files, any other scenario can be simulated.\n[D_END]\n\n### Question 3. Write a file containing the data input into the trial_name file and output the Trial-level eligibility in the `trial-level-eligibility.txt` file.\n`$ echo \"A 40-year-old man presents with dizziness and frequent headaches. \nHe has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and",
        "label": 0
    },
    "844": {
        "output": "__[16]__: Hello! You are a helpful assistant for a clinical trial recruitment. Your task is to compare the given patient notes and the inclusion criteria of the clinical trial to determine the patient's eligibility. The factors that allow someone to participate in clinical studies are called inclusion criteria based on characteristics such as age, gender, the type and stage of disease, previous treatment history, and other medical conditions. Exclusion criteria.\n_The assessment of eligibility has a three-point scale_:\n0. Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1. Not relevant (patient does not have sufficient information to qualify for the trial); and 2. Eligible (patient meets inclusion criteria and exclusion criteria do not apply). You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels 85 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3.6+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries revealed moderate stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 5",
        "label": 1
    },
    "845": {
        "output": "![TEST 1.pdf](https://user-images.githubusercontent.com/9739540/85475744-15487800-ce9d-11eb-8901-51285ceb2d1a.pdf)\n## Eligibility Checker App, step 1\nLet's make an eligibility checker table, input the patient note and the clinical trial's inclusion and exclusion criteria, and then use `eligibilityChecker()` at the end. \n- `eligibilityChecker()` accepts a data frame `PatientNotes`, and takes an integer from 0 to 2 in `Trial-level eligibility:` and `Criteria-level eligibility:` as an output. A greater number in the output indicates that a patient meets an inclusion criterion. \n- The function `criteriaExistence()` verifies whether a patient fulfils an inclusion criterion according to a data frame `CriteriaSummary` and an integer `criteriaNotation`: 0 to the patient met the criteria, else to the patient did not meet that criteria. The user should input a data frame ``CriteriaSummary`` that holds information regarding each inclusion/exclusion criterion and corresponding number of notations in our clinical trial, e.g., 0 means that the criteria are met, and 1 means otherwise in `criteriaNotation`. By default, the input `i` is 0, and 1 is when the patient meets an exclusion criterion. \n\nHere is the patient note.\nThe patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively.\nThe patient reported no use of lipid-lowering medications.\n``` jupyterlab Output: 1/2\n```\n\n\nTrial-level eligibility:\n``` jupyterlab output: \n2/2\n```\n\n## Eligibility Checker App, step 2\nEligibility can be determined at the clinical trial-level or criteria-level.  If the criteria are met at both levels, the patient can be enrolled. However, if the criteria are not met, e.g., the patient does",
        "label": 1
    },
    "846": {
        "output": "Here is the last patient note:\nA 46-year-old man presents with dizziness and frequent headaches. His HDL levels are 53\u2009mg/dL. His fasting glucose and triglyceride levels were 85 and 158\u2009mg/dL, respectively. He reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA), estimated between 40-50% of diameter. PSV was 208.5\u2009cm/s and EDV was 54.5\u2009cm/s, and RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces. \nThe plaque formation in the left and right internal carotid artery, as well as the carotid plaque character, indicated carotid atherosclerosis. The presence of stenosis in the carotid artery and the patient's LDL-C and LDL-C/HDL are highly suggestive of the underlying coronary artery stenosis. Conversely, these indicators do not exist in other patients, making this patient a valuable case report.\n[1] M. Dugas, K. O'Brien, M. Li, D. B. Yao, M. Li X. Cui, W. Lachance, J. C. Parmley, A. M. Kelm M. B. Demeester, A. T. Ferguson, K. J. Kelly",
        "label": 0
    },
    "847": {
        "output": "### Exercise 25: CPT4 Codes and ICD9\n\n[https://colab.research.google.com/github/tensorflow/docs/blob/master/tensorflow/examples/deep_cpg/README.md#instructions] \nThe main goal of this exercise is translating International Classification of Disease (ICD) codes of ICD-9 to ICD-10 through the [https://tools.doc.io/cpt3e] CPT4 System, which is equivalent to ICD9 and ICD-9 in US. All the CPT4 codes are provided as a link in the link text. You should input an ICD code to see the corresponding CPT4 code and the corresponding medical term. The code should be input in the upper left corner, while the medical term is provided in the top right corner. \n\nYou input a medical code (diagnostic code) that belongs to the range of ICD-10 (1371 to 1373), then the system will search all the medical services in the database, which are equivalent to the ICD-10 code. If the CPT4 code corresponds to the ICD-10, it will return the medical term of the code in the text box, otherwise it won't return any results. The CPT4 codes, which are in the ranges ICD-10 001 to 003 (Codes V01, V02 and V03), are not shown in the database because the codes are not relevant to medical services, i.e., medical products or medical supplies. To find an accurate translation, you should find the corresponding range of CPT4 System and the ICD-9 or ICD-10 range for each code and translate them. Note: You will see some codes that do not exist in both types of codes, e.g., CPT99579, 99637, 99628, 93969, . When you input the range of CPT4 Codes and ICD-10 code of 99xxx, 59579, 99637, 99628, etc. you should ignore the codes, which are not mentioned above and just type the rest, e.g",
        "label": 0
    },
    "848": {
        "output": "<jupyter_code>%cd C:\\Users\\noreply_at_username\\Documents\\jupyterlab_demo\n%python cds.ipynb\n\n!pip install pandas\n!pip install pandas4py # for parallel processing\nimport warnings\nimport os\nimport cds.utils.clinical_dataset as cls\nimport xarray as xr\nimport numpy as np\n%%load_ext parallel\n\ndf_all = cls.read('./datasets/demo_for_pyxarray.csv')\nclinical_df = cls.read_clinical('./datasets/demo_clinical.csv')\nclinical_dict = cls.read_clinical_dict('./datasets/demo_clinical_dict.csv')\nclinical_dict['id'] = ['ID-001','ID-002','ID-003','ID-004','ID-005','ID-006','ID-007','ID-008','ID-009','ID-010','ID-011','ID-012','ID-013','ID-014']\nclinical_info_df = cls.read_clinical_info('./datasets/demo_clinical_info.csv')\nclinical_data_df = cls.read_clinical_data('./datasets/demo_clinical_data.csv')\nclinical_strategy_df = cls.read_clinical_strategy('./datasets/demo_clinical_strategy.csv')\nds = cls.create_demo_dataset(\n    clinical_df,\n    clinical_dict,\n    clinical_info_df,\n    clinical_data_df,\n    clinical_strategy_df,\n    dataset=clspath.dataset_folder,\n)\n\n%%save -o cs241_demo_csfs -p cs241:data\n%%load_ext autoreload\n%%seed 0\n%%set_state(clspath.seed)\n\ns = xr.open_datasets([clspath",
        "label": 1
    },
    "849": {
        "output": "<EOD> Hydrocarbon adsorption by metal organic framework (MOFs)--a review.\nMetal organic frameworks (MOFs) are a class of microporous crystalline materials with an organic molecule bridged by a metal atom. In the past few decades, many methods have been proposed to improve the hydrocarbon hydrophobicity of the porous material based on the MOF structure, and to enhance the interaction between adsorbate and adsorption site in order to increase the uptake capacity and adsorption amount of hydrocarbons. In this review, we illustrate the relationship between pore structures and hydrocarbon adsorption by MOFs. We review the recent advances in MOFs used to adsorb hydrocarbons as well as the effects of the pore structure, type of the MOF, and the amount of confined space on the adsorption of hydrocarbons. In addition, we also discuss the adsorption mechanisms and future perspectives of hydrocarbon adsorption by MOFs.<EOD> Adenosine and ATP inhibit adrenergic-stimulated contraction of arterioles.\nVascular effects of locally applied adenosine and other nucleotides were investigated (with a new technique) in rat cremaster arterioles. After incubating arterioles in the presence or absence of adenosine deaminase (for 30 min) or adding apyrase (for 10 or 20 min), we measured diameters in response to adrenergic and muscarinic stimulation (in the presence and absence of receptor antagonists) of arterioles (15-125 mum inner diameter, under an initial pressure of 28 mmHg). Results indicate that: (a) ATP and adenosine (plus inosine) cause arteriolar dilation in a dose-dependent manner. (b) ATP-induced dilation is less than that caused by adenosine or inosine. (c) Adenosine has an additional, small direct constrictor action. (d) Internal dilation and constriction of arterioles occur in a time-dependent manner after locally",
        "label": 0
    },
    "850": {
        "output": "[TUTOR_REPLY]\n**If You Get Error Response:**\n- If you get `Internal Server Error` error, please see the [help page of the tutorial system](https://rstudio.com/products/rstudio-server/help/rstudio_server_tutorials/) that is also linked under the `Help` menu in the RStudio menu bar and click the `Help` button, you will see [Getting Started tutorial for Server](https://rstudio.com/products/rstudio-server/tutorials/introduction-to-r-server/getting-started-tutorial-for-server/), then retry!\n\n##### `Tutorial.R:5> trial-data <- get_trial_data(\"trials-data\")`\n\n##### `Tutorial.R:6> trial-data %>%\n    select(patientid = trial_patientid, trial_title = trial_name,\n            trial_summary = trial_summary, trial_exclusion_criteria = trial_exclcrite_criteriam,\n            trial_inclusion_criteria = trial_inclussion_criteriam, trial_status = trial_status)\n\n##### `Tutorial.R:7> trial-data %>%\n    group_by(patientid) %>%\n    summarise(sum_inclusion = sum(trial_inclusion_criteria), sum_exclusion = sum(trial_exclusion_criteria),\n             count_reasons = n_distinct(trial_exclusion_criteria)) %>%\n    ungroup() %>%\n    filter(sum_inclusion != 0) %>%\n    filter(sum_exclusion != 0) %>% \n    head()\n\n##### `Tutorial.R:8> trial-data %>% \n    filter(sum_exclusion != 0 & sum_inclusion != 0) %>% \n    group_by(patientid) %>% \n    summarise(trial_reasons = count_reasons / sum_exclusion, trial_inclussion_frac = sum_inclusion / sum_exclusion) %>% \n    summarise(trial_inclusion = trial_reasons, trial_exclusion = trial_inclussion_frac",
        "label": 1
    },
    "851": {
        "output": "[INST] For example, if a patient has a medical condition that was not included in prior clinical trials, he or she would still be included for study. This is especially the case of rare diseases, because a clinical trial could benefit from the inclusion of the patient with the rare disease. For clinical trials that include",
        "label": 0
    },
    "852": {
        "output": "Here is the output of the sample input:\nCovariate: Patient ID\nSample ID: S01\nPatient ID of the patient: 2021_05_18_13_31_55_10.json\n[formula]  `Eligible.` [/formula] \n\n## Examples\n```python\nfrom ctfslib import Trial_eligibility\n\n# Examples of using the Trial_eligibility library\n\n## Sample input\ndef input_for_patient_note(data_path, patient_number):\n    # Get patient data\n    patient_data = {\n            \"ID\": str(int(patient_number)),\n            \"first_visit\": str(patient_number),\n            \"gender\": \"MALE\",\n            \"height\": 175,\n            \"weight\": 95.3,\n            \"BMI\": 28.62,\n            \"age\": 24,\n            \"race\": \"Black\",\n            \"marital_status\": \"\",\n            \"religion\": \"None\",\n            \"patient_note\": \"  A 24-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications.\",\n            \"clinical_trial\": \"A randomized, double-blind, placebo-controlled trial testing an investigational drug and a noninvasive measure in asymptomatic, treatment-naive high-grade clinically significant prostatic intraepithelial neoplasia patients. Randomization is stratified by study site (either of 02 participating sites) with a 1:1 ratio of drug vs placebo and is based on the results of the 10-core pro",
        "label": 0
    },
    "853": {
        "output": "<EOD> .\nOBJECTIVE\nTo describe the experiences of breast feeding in 40 HIV positive mothers and to identify the difficulties and fears faced by the mothers to protect their babies from HIV infection.\n\n\nMETHODS\nThis was a descriptive and transversal study. The sample consisted of 40 HIV positive mothers who breast fed their children up to 6 months of age in the AIDS clinic of a public maternity hospital in Porto Alegre, Rio Grande do Sul State, Brazil. The study was developed through semi-direct questionnaires.\n\n\nRESULTS\nMost of the mothers studied (90%) had breast fed, and for 45 % of the mothers this was their first pregnancy. The majority of these women had an A2 HIV infection. The median of age was 21 years old. Forty percent breast fed until 90 days (average 38 days), 15 % breast fed until 180 days (average 141 days). The majority of the mothers (93%) used a formula until their child was at least 1 month old. Some of them chose to breast feed to avoid the use of a formula, and they reported the advantages and disadvantages of breast feeding (weight loss, mastitis, fear of contamination by HIV, transmission to the child) as reasons for starting using a formula.\n\n\nCONCLUSION\nThe mothers had difficulties in breast feeding owing to personal and family problems, and lack of information and support from health care professionals. Understanding the mothers' fears and needs can enable health professionals to give more effective assistance.<EOD> A Case of Synchronous Thyroid and Adrenal Neoplasms with Eosinophilic Expression of Granzyme B: A Possible Diagnostic Pitfall.\nEosinophilic granular convoluted tubular (EGCT) cells are characteristic of the parathyroid gland but have been reported in various benign and malignant thyroid lesions, including papillary thyroid carcinoma (PTC). Certain thyroid tumors express markers normally restricted to T lymphocytes, which may be misdiagnosed as T-cell lymphomas (TCLLs). This",
        "label": 1
    },
    "854": {
        "output": "[END] [INST]\n\n    In 2012 it was reported that at least 149 RCTs with ineligible patients enrolled were included in meta-analyses. Even more important, there is a high percentage of ineligible patients in the meta-analyses on the same topic. For example, only one third (31%) of RCTs comparing different treatments for the prevention of venous Thromboembolism (VTE) were adequately targeted to the included patient populations. \n    That means that in eligibility assessment, you should identify and eliminate ineligible patients, i.e., those who do not match with the inclusion or exclusion criteria, from the RCTs. \n\n### 1. Choose the correct inclusion criteria\n\nHere is a sample patient note:\nA 60-year-old woman presents with dizziness and frequent headaches. She has a family history of cerebrovascular disease and smoking history. She has no previous cardiovascular risk factors such as high blood pressure, high total cholesterol, and low-density lipoprotein-cholesterol. Her fasting glucose level was 85\u2009mg/dL.\nThe patient reported no use of anti-tachycardia therapy for angina pectoris.\nNeck auscultation revealed a systolic murmur 1+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries revealed severe stenosis in the left internal carotid artery (LICA), 36% stenosis in the right internal artery. For the LICA, peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s (>120\u2009cm/s) and 54.5\u2009cm/s (<130\u2009cm/s), respectively; RICA PSV was 91,72\u2009cm/s and RICA EDV was 37.3, 7cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common car",
        "label": 0
    },
    "855": {
        "output": "<center>\n<h2>Task 1: Calculating the Framingham index for the clinical trial</h2>\n<ul>\n<li><b><i>Input</i></b>: <i>patient name, gender, age, diagnosis, smoking status, hypertension, diabetes mellitus, family history of cardiovascular disease, hyperlipoproteinemia, homocysteine level, total cholesterol, HDL-C, LDL-C, blood glucose, triglyceride, blood pressure, maximum heart rate reached, systolic stenosis of the internal ICA, carotid atherosclerosis, diameter of the internal ICA, diameter of the common ICA.</i><br>\n<li><b><i>Output</i></b>: <i>Framingham score (FS): FS = (male factor \u00d7 1), (diabetes mellitus factor \u00d7 1), (hypertension \u00d7 2), (hyperlipoproteinemia \u00d7 1), (family history of CAD \u00d7 2) <br> <br> The maximum FS was 6: FSmax = 6). <br> <br>  If FSmax = 5, the patient was considered to be at risk of cardiovascular disease and included in the clinical trial <br/> <br>  If FSmax <5, the patient was considered to be a healthy population and not included in the clinical trial.</i> \n</li>\n</ul>\n</center><EOD> Comparison of Two Enzyme Immunoassays Designed for the Detection of Cytomegalovirus in Infants and Children by Using Saliva Samples\nSummary: We evaluated the performance of two new sensitive enzyme immunoassays (EIA) for the detection of cytomegalovirus (CMV) infection (CMV seropositivity) in infants and children by using saliva from 20 uninfected cord blood children and 20 children seronegative for CMV. Saliva samples showed a sensitivity lower than serum samples for CMV EIA detection, but a specificity of 80% compared to ser",
        "label": 0
    },
    "856": {
        "output": "A: This is more easily handled using list comprehension.  Use df.assign to set all the columns to categorical, then you can apply the df.query function to assign the results to the df.  There are a lot of examples in this stackoverflow question.  I can't copy over code from other posts, but you can get the general idea.<EOD> Clinical evaluation of an oxygen\u2010delivery monitor under emergency conditions *\nAn oxygen\u2010delivery monitor capable of continuous measurement of oxygen uptake (VO2) during extracorporeal circulation was clinically evaluated in an emergency setting. Arterial partial pressure of oxygen (PaO2), arterial oxygen content (CaO2), venous content of oxygen (CvO2) or VO2 were measured in 18 patients, in whom 29 emergency operations were performed. The monitor showed a linear correlation with Pao2 but an exponential correlation with the oxygen extraction ratio (EO2). EO2 was calculated from the equation: EO2 = 1 \u2212 VO2/CaO2, and showed little variation throughout the monitoring periods, which was in contrast to the changes of VO2. The values of PaO2 after successful weaning were low, but rapidly increased when the patient entered the recovery room.<EOD> .\nIt has always been a matter of discussion to clarify the significance of immunological abnormalities in patients with acute ischemic stroke. Lymphocyte subpopulations, the expression of various cytokines and the cellular oxidative metabolism have been investigated as possible markers that reflect the individual patient's vulnerability. A group of 70 patients with ischemic stroke were compared to a control group and were subdivided into early- and late-group of stroke according to occurrence of first stroke symptoms and first electroencephalographic abnormalities, respectively. In a subcohort of early-stroke patients the significance of immunological parameters and metabolic activity was evaluated in relation to ischemic lesions in the brain during early recovery stages. Cellular immunological parameters such as absolute lymphocyte count, CD3+, CD4+/CD8+ ratio and CD4+ na\u00efve cells were significantly reduced in patients with acute ischemic stroke compared to controls. However",
        "label": 1
    },
    "857": {
        "output": "### Output:\n\n`A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors.`.\n\n`- Patient note.`\n`- Inclusion criteria of the clinical trial:\n\n1. Female;\n\n- Patient is currently a manual labourer, and he is not a smoker;\n\n\nIn this patient, LDL (low density lipoprotein)-C level 545mg/dl, HDL (high density lipoprotein)-C level 53mg/dl. Lipid profile results, family history information of this patient were shown to you.\n- The patient reported no use of lipid-lowering medications.\n- Ultrasonography: carotid artery ultrasonography revealed severe stenosis in left internal carotid artery, and moderate stenosis in right internal carotid artery. - In the left internal carotid artery, peak-systolic (PSV) and enddiastolic velocity (EDV) cutoff values were 208.5 and 54.5 respectively. - In the right internal carotid artery (RICA), PSV was 91.72 and EDV was 37.37.\n- Plaque was observed in the anterior and posterior wall of the internal carotid artery and common carotid artery, were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic with less than 50% of the area being echolucent with uneven surfaces.\n\n\nHere are the patient notes and the eligibility results, we would like to recommend you to show this output results on your display.\n```c\n#define MIN 30\n#define MAX 60\n\n#define RADIANS 0.01*3.14159265358979\n\n#define PI 3.14159265358979 //pi\n```\n\n\n*Output:*\n```c\nfloat",
        "label": 0
    },
    "858": {
        "output": "You want to check your eligibility for the clinical trial. The trial-level eligibility, which means whether the patient is eligible to participate in the trial. Is this patient eligible for the trial?\r\n\r\n```\r\n018305#60395371\r\n```\r\n```eval_code\r\n\r\n#+source: python\r\n#+language: python\r\n#+tab-width: 4\r\n\r\n#-*- coding: utf-8 -*-\r\nimport numpy as np\r\nimport sys\r\nimport json\r\nimport itertools\r\n\r\n# INITIAL SETTINGS\r\nex = sys.argv[1]  # patient code\r\nst_num = int(sys.argv[2])  # st_num: start of test\r\net_num = int(sys.argv[3])  # et_num: end of test\r\nst = ex+st_num\r\net = ex+et_num\r\n# OUTPUT: the patient report for the trial\r\nimport time\r\ntotal_time = time.time()-time.time()\r\n\r\n# INITIAL SETUP\r\n# Finding Patient's characteristics\r\npat_id = int((ex-60395371)/1000)\r\npat_name = ''\r\npat_age = ''\r\npat_sex = 'N'\r\npat_education = 'N'\r\npat_marriage = 'N'\r\npat_smoking = 'N'\r\npat_drinking = '",
        "label": 2
    },
    "859": {
        "output": "___<EOD> Acquisition of 10 B-enriched 7Li through fusion reactions in hot heavy ion beams\n\nThe abundance ratio of 7 Li in heavy ion beams can be drastically changed due to nuclear fusion reaction. In the previous work, the fusion reaction was performed in the moderately hot ion beam target where the ion beam and nuclei in the target have comparable energies. Here we describe another new fusion reaction in the heavily charged ion beam (HCIB) where heavy nuclei are decelerated at the beam dump. A set-up of a new fusion reaction apparatus is described. The apparatus has several unique features such as the 10 B reaction by using beam-ionized carbon; the beam target having hydrocarbon gas and heavy ions which has not been done before in fusion reaction experiments; and a new technique to purify the 7 Li beam. In the experiment, the reaction product of Li 2p2P 3/2 1 2S 1=2 -10 B + 6Li was obtained by using a 12.8 MeV/u 10 B beam from the National Research Center for Laser Science (NRLS) and a hot heavy ion beam (HiBA) containing 10 B from the Hibakusha Research Institute in JAERI.\n\n# Introduction\nIn the previous work of heavy ion fusion (HIF), a set-up of a reactor containing a heavy ion beam target has been presented.\nIn HIF, the target gas is decomposed due to the nuclear fusion reaction resulting in the production of the deuterium of high abundance and 10 B. The newly created 7 Li is then extracted to the beam from the target gas due to the Coulomb force exerted on the nuclei, and the extraction energy is kept high enough to prevent the secondary ionization to the electronically excited state ofLi. The beam purity becomes higher with the longer-distance between the target and the separator. For example, the secondary electron ionization is suppressed to less than 1% for a separated distance of 130 cm in the previous work.\nIn addition to the previous work, another fusion reaction which is carried out in the heavily charged ion beam (HCIB)",
        "label": 2
    },
    "860": {
        "output": "Note: You must understand that every clinical study has its own criteria of inclusion or noninclusion, so be careful before you do the evaluation. \n\n> ## Running time:\n<EOD> An alternative hypothesis for the evolution of hominin skulls.\nThis research is a re-examination of the hypothesis that hominin skulls with small facial area develop from small-brained hominins to accommodate a larger dentition and that the increase in facial width can be explained by allometric relationships. To test the hypothesis, facial area was regressed on brain area, and the results were compared with similar regressions with body mass. The regressions indicate that the brain area is not a good predictor of facial area because, with the exception of the australopiths, the correlations are poor. The brain area for australopiths is in fact below the line of regression through the other species, whereas the facial area is above. This indicates that the brain size of australopiths is smaller than those of other hominins, even though their facial area is considerably greater. If facial area is used as an index of large brain size, the australopiths diverge from all the other hominin genera. We propose an alternative hypothesis to explain the pattern, in which the facial area is not large because of a large brain but because the australopiths have large canines. The hypothesis is supported by the finding that the canine size in australopiths is positively correlated with facial size although it is negatively correlated with brain size.<EOD> Complement activation by intact cells treated with antimetabolite drugs.\nThe complement-fixing activity of whole lysates of rabbit peritoneal and washed peritoneal cells was determined by measuring the consumption of complement in the presence of antidinitrophenyl (anti-DNP) antibody with the alternative pathway and with the classical pathway (antidinitrophenyl-D-glucosamine (anti-DNP-GC)-sensitized). DNP-N-acetyl-D-glucosamine was used to sensitize the cells intravenously. The lymphocytes required 5,000 times more antibody to activate the alternative pathway than did",
        "label": 1
    },
    "861": {
        "output": "## \u25b6 Example\n\n## Exercise 5 (FREE PRACTICE)\n\n##[CODE]\n[INST] Your task is to find the patient numbers on the list. You should also fill in the column \"Eligible\" (not \"Ineligible\") on the patient's list.\nYour initial list with patients IDs is already prepared (file EL_in_List.txt). If you type in another format (your own in Excel, or on a sheet of paper), then enter in the next step file that you are working on.\n\n##[OUTPUT]\n- \u25b6 [INST] You are going to solve 3 exercises. Here is your first patient, No. 39, on the list:\n\n## Exercise 5 - Patient 39 (Part 1)\n1) The patient notes are presented below. Find the three required variables:\n* * *\n- \u25b6 Here is the trial description:\nTitle: New Technologies in the Assessment of Plaque Stability\nSummary: The researchers are trying to determine if plaque stability can be assessed non-invasively with MRI acquisition and analysis, using contrast-enhanced pulse sequences.\n\n## Inclusion criteria [inst]\nInclusion Criteria:\n\n## Exercise 5 - Patient 39 (Part 2)\n2) Make a comparison between the eligibility of the patient on your list with the trial's exclusion criteria (EL39) and find Patient ID (no. 39, in the list). If there are any missing values, find them and enter the relevant data (mark with *). Copy the correct data to Patient-ineligible for Trial field. Write \"0\" next to all exclusion criteria, which are not relevant for this case (mark with #).\n\n## Eligible excluded\nPatient ID Patient ID Patient ID EL39 \u25b6 Trial Summary \nInclusion Criteria [INT]\n\n### Age\nPatient must be over 35 years of age\n\n### Gender\nMust be male\n\n### LDL\nAverage patient's LDL should not exceed the limit of 150 md/dL\n\n### Type-2 Diabetes\nThere",
        "label": 2
    },
    "862": {
        "output": "<jupyter_code>\ndef is_eligible(patient, clinical_trial):\n\npatient = {\n    \"name\": \"<NAME>\",\n    ...\n    \"age\": 46,\n    \"gend\": \"male\",\n    \"plac\": \"Munich, Germany\",\n    \"systo\": 85,\n    \"diast\": 40\n}\n\nclinical_trial = {\n    \"systo\": 280,\n    \"systd\": 140,\n    \"dia\": 90\n}\n\npatient_value = 0\nclinical_trial_value = 2\n\nprint(patient, clinical_trial, patient_value, clinical_trial_value)\n\npatient_value = 1\nclinical_trial_value = 2\n\nprint(patient, clinical_trial, patient_value, clinical_trial_value)\n\nclinical_trial_value = 1\npatient_value = 2\n\nprint(patient, clinical_trial, patient_value, clinical_trial_value)\n\nclinical_trial_value = 0\n\npatient_value = patient_value+1\n\nprint(patient, clinical_trial, patient_value, clinical_trial_value)\n\nclinical_trial_value = clinical_trial_value+1\n\nprint(patient, clinical_trial, patient_value, clinical_trial_value)<EOD> The Scaling Relationship of Pt3Sn Nanoalloys with Sn Additive.\nFinding new structures with novel properties in traditional metal alloys, with the purpose to further extending the application scope has attracted much attention. In this work, we investigated Pt based nanoalloys to uncover some interesting structure-property correlations. Pt3Sn nanoalloys with various Sn contents were fabricated by gas evaporation and subsequent Sn segregation, which results in",
        "label": 0
    },
    "863": {
        "output": "<EOD> Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitor in Osteosarcoma in Vitro and in Vivo\nObjectives The epidermal growth factor receptor (EGFR) induces cell proliferation of osteosarcoma (OS) cell lines in vitro and in vivo. Erlotinib is an orally bioavailable EGFR-specific reversible tyrosine kinase inhibitor. In the present study, we investigated the potential value of erlotinib in OS preclinical models. Methods Human HOS OS cells or primary cell cultures from patients with OS were treated with erlotinib, and cell proliferation, migration, and apoptosis were analyzed. Moreover, the effects of erlotinib treatment in 2 animal models of OS were also evaluated. Results Treatment of human HOS cells with erlotinib resulted in a significant dose-dependent reduction of proliferation and viability, an increase of apoptosis, and a reduction of cell migration. Moreover, treatment with erlotinib reduced tumor progression and increased apoptosis in an in vivo animal model of OS. Conclusions These findings suggest that erlotinib may be a useful adjuvant therapy option for OS patients.<EOD> HLA class I expression in human renal allografts with and without acute rejection.\nBACKGROUND\nThe importance and biological significance of HLA class I expression in graft tissue of renal allografts with acute rejection is still a matter of controversy.\n\n\nMETHODS\nHLA-A, -B and -DR expression in 38 renal transplant biopsies (five cases without acute rejection, 19 cases with acute humoral rejection and 14 cases with acute cellular rejection) was studied by immunohistochemistry. Monoclonal human anti-HLA antibodies HC-A27, HC-A2, HC-A11 and L243, which were directed against HLA-A2, HLA-A11, HLA-B7 and HLA-DR1, respectively, were used in the study.\n\n\nRESULT",
        "label": 1
    },
    "864": {
        "output": "The patient meets all the clinical trial's inclusion criteria and no exclusion criteria exist as specified in the clinical trial's exclusion criteria. The patient should be enrolled in a clinical trial.\nLet's think step by step. \n(1) `if`(IncludedCriteria1==``1`(NOT ELIGIBLE PATIENT) AND (IncluedCriteria2==``1``(ELGIBLE PATIENT)) OR else)`(if IncludedCriteria3==``1``(NOT ELIGIBLE PATIENT) AND (IncluedCriteria4==``1``(ELGIBLE PATIENT)))) OR else`\nThe patient has a disease that can participate in the clinical trial (1) (IncludedCriteria1==``1`(NOT ELIGIBLE PATIENT) AND (IncluedCriteria2==``1``(ELGIBLE PATIENT)). OR else (IncludedCriteria3==``1``(NOT ELIGIBLE PATIENT) AND (IncluedCriteria4==``1``(ELGIBLE PATIENT)).(2) Disease 1: LDL-C is more than 160 mg/dL \nDisease 2: LDL-C is less than 100 mg/dl. \n(3) (IncludedCriteria1==``INCLUDE``ANDINCULD1==``YES``)ORelse (IncludedCriteria2==``INCLUDE``ANDINCULD1==``YES``ORelse (IncludedCriteria3==``INCLUDE``ANDINCULD1==``YES``ORelse(IncludedCriteria1==``INCLUDE``ANDINCULD1==``NO``ANDINCULD2==``YES``))ORelse(IncludedCriteria1==``INCLUDE``ANDINCULD2==``NO``ORelse(IncludedCriteria1==``INCLUDE``ANDINCULD3==``YES``ORelse(IncludedCriteria1==``INCLUDE``ANDINCULD3==``NO``)) (Disease 3: T",
        "label": 0
    },
    "865": {
        "output": "[EX] You are encouraged to provide the patient note for the input of the function `get_patient_note`.\n\n<ol>\n<li><b>get_patient_note</b> (p): get the patient note in the form of a pandas data frame to enable data analysis<br>\n    <h3>Inputs</h3><pre class=\"docutils literal notranslate\"><code class=\"docutils literal notranslate\"><em>Parameters</em><br>\n    :<br>\n    <code class=\"literal notranslate\"><a class=\"reference internal\" href=\"02_main/INST/patient_note.html#inputs\"><code class=\"literal notranslate\"><abbr class=\"anchor\" data-placement=top href=\"#INST_patient_note\">\n    Instructions</abbr></code></a></code>\n<br><h3>Returns</h3><pre class=\"docutils literal notranslate\"><code class=\"docutils literal notranslate\"><em>Outputs</em><br>\n    :<br>\n    <code class=\"literal notranslate\"><a class=\"reference internal\" href=\"02_main/INST/patient_note.html#outputs\"><code class=\"literal notranslate\"><abbr class=\"anchor\" data-placement=top href=\"#INST_patient_note\">\n    Instructions</abbr></code></code></code></code)>\n<br><h3>Docstring</h3><pre class=\"docutils literal notranslate\"><code class=\"docutils literal notranslate\"><em>Docstr:</em><br>\n<code class=\"literal notranslate\"><a class=\"reference internal\" href=\"02_main/INST/patient_note.html#_docstr\">\n    Instructions</a></code></code></code></code><br>\n<div id=\"INST_patient_note\" class=\"docutils literal notranslate\"><code class=\"literal notranslate\">Patient notes.<h3>Notes</h3><h3>Parameters:</h3><dl><code class=\"literal notranslate\"><abbr class=\"anchor\" data",
        "label": 2
    },
    "866": {
        "output": "##[End of INST] \nNow, let's go back to the example of the patient note described above.\nYou've just started a new day in the hospital with a new set of tasks. You can recall the patient note before your boss started barking, so your brain is in a good shape. Therefore, you'll be sure to assess the note properly and do a good job. \nFirst, we'll look at the patient's medication use information. The patient takes Aspirin, Metoprolol, Perindopril, Lercanidipine, and Ramipril. Here's what he's taking:\n\n#### Medication\n\n## Amlodipine\nAmlodipine has effects on the arteries and muscles of the heart. Amlodipine relaxes and widens these arteries to make it easier for blood to flow. As the blood vessels relax, a drop in blood pressure occurs because the flow of blood is increased.\nThe first 60 days after the patient starts taking amlodipine, the patient should be under close medial monitoring by a doctor to ensure the safety of its use.\nAmlodipine can cause side effects. Stop taking amlodipine and contact your doctor if you have:\n\n## Fatigue\nFertility\nShortness of breath\n\nAmlodipine can rarely cause dangerous swelling of the muscles in the feet and legs (Rhabdomyolysis).\nAmlodipine increases blood flow in the arteries to reduce a condition called angina, which means chest tightness, shortness of breath, and a strong feeling of fatigue. An increase in blood flow in the arms and legs can also develop.\nFollowing amlodipine, the blood pressure drops, while the blood pressure may increase depending on the condition. Before the drug is injected, the doctor checks the patient's blood pressure.\nCalcium plays a vital role in the contraction of muscles throughout the body, including the heart muscle. Calcium supplementation is prescribed in the short term to help the heart better contraction.\nAmlodipine reduces the heart's ability to contract and can cause fainting by lowering blood pressure. Therefore, the treatment does not increase the patient'",
        "label": 2
    },
    "867": {
        "output": "<EOD> Synthesis and biological activities of C-10 substituted thiazolidine-2,4-diones.\nWe have synthesized a number of C-10 substituted thiazolidine-2,4-diones and evaluated them as antimicrobial, antiinflammatory, analgesic and free radical scavenging agents. Of these, compound 24 showed potent antimicrobial effect.<EOD> The effect of different cleft treatments on health-related quality of life in adults with cleft lip/palate.\nThe aim of this study was to examine the influence of different cleft treatments, including surgery, orthodontic treatments, speech therapy and dental rehabilitation, on the health-related quality of life (QOL) of adult patients with cleft lip/palate. All patients, 73 adults with bilateral cleft lip and palate and seven patients with cleft lip or palate, were interviewed using the 'Cleft QOL Scale: Adult' (CLEFT-AS). Descriptive statistical analysis of the data was based on parametric tests. A t-test with adjustment of Bonferoni was used to test differences of the QOL between three different cleft treatment groups: group A (no cleft surgery only), group B (initial cleft surgery only) and group C (all cleft surgeries completed). Results indicated that the three groups differed significantly in 'Speech related aspects', 'Appropriate appearance', 'Social activity', 'Social life/leisure' and 'Self-consciousness'. Patients in group B rated significantly lower in all of these aspects compared to patients in group A. In relation to cleft treatments, 'Social activity' and 'Self-consciousness' were positively associated with orthodontic treatment (OT), cleft speech surgery (CSS), dental rehabilitation (DR) and combined therapy such as speech corrective surgery and orthodontic treatment (CSS-OT). 'Physical activity' was positively associated with dental rehabilitation and CSS-OT. 'Self-independence' and 'Social relations' were strongly influenced by CSS and SSA-OT. In conclusion, this study showed significant differences in health",
        "label": 1
    },
    "868": {
        "output": "You must check the following: \n- Your trial-level eligibility will always be in the last row by the `Trial-level eligibility:`\n\n- If you make eligibility for the first time, you must check Trial-level eligibility: 1) Eligible.\n\n- If you make eligibility for the second time, you must check Trial-level eligibility: 2) Eligible.\n\n- If you make eligibility for the third time, you must check Trial-level eligibility: 2) Eligible.\n\nIf you have a doubt, you can simply use `el`. e.g., `el(name) : 2.`.\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits",
        "label": 0
    },
    "869": {
        "output": "## Trial code\nEvery clinical trial has a unique trial code. For better understand and better analysis, you should define the trial codes. \nThis is the data about clinical trial information on the site: \nYou need to use the trial_code parameter to refer to the trial code in the data set of clinical trials. \n`\"Trial\": \"Ethically Acceptable Clinical Trials for Patients at High Risk of Developing Type 2 Diabetes Mellitus - Clinical Trials for the Prevention and Diagnosis of Type 2 Diabetes \" #Citation #TrialCode #TrialNumber`You should specify the details about the trial code in the metadata of the data set. That is why the trial_code parameter is needed. \nIt should be saved to the metadata, e.g.\n    `data_type: \"clinical_trial\"``<EOD> The value of preoperative neutrophil/lymphocyte ratio and fibrinogen plasma concentrate use in the prevention of postoperative acute kidney injury in patients undergoing cardiac surgery\nBackground/aim Acute kidney injury (AKI) is a complication commonly encountered in cardiac surgery. This study was designed to investigate the efficacy of intraoperative and postoperative neutrophil/lymphocyte ratio (NLR) and fibrinogen plasma concentrate (FPC) usage for AKI prevention in cardiac surgery.Materials and methods This prospective study included 198 patients aged 18 and above who underwent elective cardiac surgery. Patients were divided into control (group 1; n = 134) and intervention group (group 2; n = 64) consisting of intraoperative FPC use + postoperative intravenous immunoglobulin use). Postoperative 48-hour NLR was used as an indicator for AKI prevention.Results The rates of AKI, the requirement of extracorporeal membrane oxygenation, and the inotropic requirement were lower in group 2 (P < 0.05). The amount of surgical blood loss was lower in group 2 (P = 0.022",
        "label": 1
    },
    "870": {
        "output": "When all cases are finished, go to ``2.5 Repeat Steps 1.1-1.4 in a loop.`` \n\n## 2.5 Repeat Steps 1.1-1.4 in a loop.\nWhile all data are shown in a table, for the clinical trial, we would use the data in the case to make a decision. If we were to repeat Steps 1.1-1.4 ten times, it would take more than 10 hours. To reduce computation time, we will repeat the clinical trial loop several times.\n\nBefore going into the main script, it would be helpful to know how to repeat a script several times. In Python, this can be done by defining an external function that will be used to call other functions in your script. As the number of repeating times is unknown, instead of defining an external function outside the main script that you will repeat several times, creating a counter in the main script will help you repeat the main script many times easily. This is called loop.\n\nTo repeat the script n times, you can do it step by step.\nStep by Step to Repeat the Script n Times \n- Go to shell and write the main script of case one of the data to be used\n  ~~$ Python main.py\n- Call back the main script as many times as you need.\n  ~~$ for i in i_var: Python main.py\n- After you got one version of the main script, for the clinical trial case, you can define all data to be used in the case like we did in case one and modify the part where you need.\nThis would generate three scripts for case three.\n~Usage: ~~$ Python main.py ~~$ Python main_clinical.py ~~$ Python main_clinical_repeat.py\n- Go to shell and write the main script of the case two of the data to be used\n ~~$ Python main.py\n - Run the main script and generate ten versions of the main script.\n ~~$ Python main.py -m 10\n - Go to shell and write the main script of the clinical trial\n ~~$ Python main.py\n - Repeat the main script and ten times, that would generate ten versions of the main script\n ~/$ Python main.py -m 10\n \nThat would have three ten versions",
        "label": 0
    },
    "871": {
        "output": "! \n\n[/MARGHLO]\n<br><br>\nIn this question, you have to compare a patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. \n\nThink about the characteristics that cause someone to be eligible to participate in a clinical study.\nAn individual must be eligible before a trial begins. The eligibility requirements that you should look for when reading the clinical trial description are: the patient's age, gender, his or her previous treatment history, and other medical conditions. You should always apply those factors that allow or may make a person eligible for clinical trial.\n\n- Your patient has a 1+/6+ diastolic murmur and is between the ages of 40 and 60, which are in the range of the conditions defined by the trial.\n- Your patient is male or female and is not using lipid-lowering medications; these conditions are also included in the trial.\n- Your patient's neck auscultation, ultrasonography, and carotid stenosis report show that the LICA is severely (50%) stenotic, and the RICA is moderately (40%) stenotic. Although these characteristics are not in the eligibility criteria of this clinical trial, they may have a significant influence on the patient's decision to take statin medication.\n- Your patient does not have any contraindications, such as serious allergies to the medications used in the clinical trial, history of myositis, rhabdomyolysis, or renal failure. You should apply all conditions that apply to the exclusion criteria of this clinical trial.\n\n! [/MARGHLO]\n<br><br>\nIn this question, determine the patient's eligibility by following the same steps:\n\n1. Check the given patient information and then determine the trial-level eligibility.\n2. You should check all of the factors that may affect the eligibility of this patient in the inclusion and exclusion criteria.\n3. Apply those factors that may make this patient eligible. \n\n\n\n## # 9. A Trial-Level Eligibility Scale (ELS)\nAn ELS",
        "label": 1
    },
    "872": {
        "output": "------------------\n[END]\n\nExplanation. We give a detailed step-by-step explanation of how to create the MCT2 data. For each task, input data, expected outcomes (i.e., a description of what to output), and programming code are provided. To avoid confusion in the MCT2 programming, we here provide additional instructions to explain specific aspects.\n\nThe MCT2 data file is an ASCII file with a specific format. There are generally three possible formats for an MCT2 data file: fixed length, header format, and line format. In the fixed length format, both column and row names can contain a maximum of 25 characters. In the header format or line format, the column name and the row number must be stored in headers, which limit the length of column names and row numbers. In the header format, the header line should be empty, whereas in the line format, all columns should have corresponding values in a single text row. The specifications of these formats are listed below to provide a better explanation of the required and restricted fields (column names and row numbers).\n\n[Fixed length]\nColumns\n\nRow numbers\n\nBecause the first column for the MCT2 data must be a field in the `Trials` table, i.e., TI, the first column cannot be in the form of a row number. Specifically, the row numbers of all columns should be at least 100, except the first column, which is TI. Therefore, the header format and the line format are suitable for the MCT2 data. For a better understanding of the specifications of the header and line formats, we provide the examples in Tables 5.1 and 5.2, where [FIXED LENGTH] indicates the fixed-length format.\n\nNote: The example in [fig_ref]  Table 5 1: Sample data using the fixed-length format [/fig_ref] .2 demonstrates the specifications for the header format; the example in [fig_ref]  Table 5 1: Sample data using the fixed-length format [/fig_ref]  \n\nTable\n :\n Example of MCT2 data using the header format (e.g., 5.2)\n\nTable row:\n Example of MCT2 data and header format (e.g., 5.2) \n\n[H]|Trial||Trials||TrialNum||St",
        "label": 1
    },
    "873": {
        "output": "A: It would seem as if the only way to do this is by some sort of loop, as opposed to a function call. In python, for instance, I'd write something like:\ndef print_trial_level_eligibility(doc):\n    for eligibility in doc:\n        print (Trial_level_eligibility.name, eligibility)\n\ndoc.trial_level_eligibility\n\n<EOD> Inhibition of Mitochondrial Respiration and the Metabolic Pathway of Lipin.\nAbstract : Lipin activity has a relationship to the state of the mitochondrial energy system. Therefore, the rate of inhibition of lipization by a mitochondrial poisons (cyanide, amytal) and inhibitors of the citric acid cycle has been investigated. The inhibition of lipization is a function of the concentration of the poisons employed and is directly related to the state of the mitochondrial energy system of the liver. Evidence has been obtained that the metabolic path of Lipin involves the citric acid cycle and the process of lipization occurs at the citric acid cycle.<EOD> Prevalence and incidence of epilepsy in rural and far urban Tanzania: the MAISA epilepsy study\nObjectives To describe the prevalence and incidence of epilepsy in two villages in rural and far urban Tanzania. Methods The Masai Epilepsy Aetiology Study (MAISA) is a case-control study, conducted in 2001. Participants with epilepsy were compared with two groups of controls, 2\u2005years or older, randomly selected from the same two villages. The MAISA Epilepsy Prevalence Study (MEPS) is a cross-sectional study conducted in 2002. All participants with epilepsy in the MEPS were re-assessed in 2007 (MEPS 2007). Results The point prevalence in MEPS was 32.0/1000 (95% CI 25.1 to 40.1) in rural and 24.5/1000 (95% CI 18.0 to 32",
        "label": 2
    },
    "874": {
        "output": "## 2) What if we want to predict the eligibility on the basis of the patient's status?\nYou should generate a model that predicts patient eligibility via the data given and choose the top 10 features that affecting eligibility. Then we suggest adding patient data to that model to predict eligibility on the patient's note level.\nYou should compare the 3-fold cross-validation accuracy of the model including trial-based data only by the 3-fold cross-validation accuracy of the model including patient-based data only.\n\n\nTASK 6.1\nWrite a Python Script to predict patient eligibility on Trial-level. The script should take each trial's eligibility score and output the score of each trial.\n\n\nTASK 6.2\nWrite a Python Script to predict patient eligibility on patient-level with trial data. The script should take each patient's trial-level eligibility score and predict the patient eligibility score on patient-level.\n\n**Good Luck!** \n\n* **Happy Coding!**\n<EOD> Identification of an acetate switch in a biofuel-producing strain of Clostridium thermocellum\n\nBackground: The conversion of sugars to ethanol by fermentation is a well-established conversion strategy that can mitigate many of the problems associated with the current global dependence on fossil fuels such as rising prices, increasing competition for oil, and damage to the environment. Lignocellulosic feedstock is abundant and currently represents the only low-cost source of sugars that can be converted into high-value chemicals. In the future, fermentation of lignocellulosic biomass into energy-dense biofuels will facilitate new markets for farmers and also provide economic incentives for further crop development. However, the hydrolysate derived from pretreatment of lignocellulosic feedstocks often contains an excess of toxic organic acid compounds. Thus, strains that are well-adapted to low pH and to the presence of toxic organic acids will have a competitive advantage for growth and hence should be used for commercial scale fermentations.Results:In this work, we studied a native Clostrid",
        "label": 0
    },
    "875": {
        "output": "[X][X][X]   \n### Results\n\nThe program produces the following results as .odv file.:   \n\n![](images/Paper_528.png)\n\n## Evaluation\n\nIn each simulation, the code takes \u223c 6 s until it writes a file to save the data.\n\n### Case Studies\n\n\n\n[X] [X] [X]   \nA 65-year-old man presents with mild dyspnea on exertion. He has multiple vascular risk factors, and there is a strong family history of coronary artery disease (CAD). An electrocardiogram (ECG) did not show any significant findings. His LDL-C concentration was 365\u2009mg/dL. The chest X-ray results showed a pulmonary vascular stenosis (70%\u221290%). Chest computed tomography with contrast enhancement showed no significant lesions. Laboratory findings were normal except for his LDL-C concentration. \n\nHe was offered a clinical trial and referred to the cardiologist in consultation with a dietician to lower his LDL.\nThe trial he was offered involves the following:\nTrial details:   \nTitle: A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level\n\nSummary: The primary objective of the study is to assess pharmacokinetics, dynamics, safety and tolerability of CiVi007 following single and multiple subcutaneous doses in subjects, including those on statin therapy\nInclusion criteria: Key Inclusion Criteria:\nMales or females, of any race, with fasting LDL C >2.6 mmol/L (100 mg/dL) and fasting serum triglycerides <4.52 mmol/L (400 mg/dL)\nhaematology and clinical chemistry without clinically significant abnormal values\nNormal renal and hepatic function\nWomen must not be pregnant, lactating or of child bearing potential\nMen must be willing to use appropriate contraception during the study\nAble to comprehend and willing to sign an ICF and to ab",
        "label": 2
    },
    "876": {
        "output": "# Authors' Note\nThis is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. See: http://creativecommons.org/licenses/by-nc-nd/4.0/.\n\n# Supplementary materials\nSupplementary Table S1: Trial-level eligibility (output) 1 23 6 693 2 694 15 37 2885 3 290 1622 4 241 483 5 235 395 6 242 126 7 241 72 8 262 693 9 212 485 10 145 708 11 143 99 12 130 627 13 127 456 14 207 276 15 165 09<EOD> Inhibition of cell division and cellular DNA synthesis by 2-aminopurine\nRat embryo fibroblasts treated with 2-aminopurine show an inhibition of entry into mitosis beginning with an increase above normal in the number of mitotic prometaphase cells. As the duration of the treatment increases an increasing portion of cells fail to enter mitosis. Also, a small but consistent increase in abnormal mitotic cells was noticed when 2-aminopurine was present; when the concentration was increased by a factor of 10 the aberrant mitotic figures represented around 30% of all prometaphase cells. In general, there was no difference in aberration frequency between mitotic cells exposed to the drug and postmitotic cells. In some experiments a progressive accumulation of micronuclei was observed when 2-aminopurine was present, with this event occurring more rapidly and to a greater extent at the higher concentrations. These results are interpreted as",
        "label": 0
    },
    "877": {
        "output": "# References\n- ClinicalTrials.gov NCT03211438.\n- ClinicalTrials.gov NCT03484845.\n- Spine (Phila Pa 1976). 2015 Jun 1;40(11):E450-67.\n- J Orthop Sports Phys Ther. 2011 May;41(5):284-287.e2.\n- Spine (Phila Pa 1976). 2010 Jun 1;35(17):1614-9.\n- Eur Spine J. 2013 Aug 22;22(suppl 2):396-403.\n\n\n\n\n<EOD> Cognitive-behavioral intervention to reduce depression and increase HIV risk reduction behaviors in a multi-site AIDS agency.\nThe current study examines the impact of a brief cognitive-behavioral intervention on depression and HIV risk-reduction among clients of a large AIDS agency. Ninety HIV-positive adults received one of two conditions: an Enhanced Treatment as Usual (ETAU) condition or an Embedded Cognitive-Behavioral Therapy intervention (eCBT). The eCBT consisted of three brief counseling sessions that incorporated elements of cognitive behavioral therapy. At baseline and 3, 6, and 9 months depression was evaluated using the Beck Depression Inventory. The AIDS Risk Reduction Behavior Survey was used to assess engagement in specific HIV risk behaviors. Results indicated those receiving eCBT reported significantly lower levels of depression, and higher levels of HIV-related risk-reduction behaviors compared to those in the ETAU condition. These findings suggest that eCBT can significantly impact both depression and HIV risk-reduction behaviors for HIV-positive adults.<EOD> Longitudinal study of blood pressure and renal function 6 years after subtotally nephrectomized rats.\nSubtotally nephrectomized rats have been used in previous intervention studies on renoprotection and hypertension.",
        "label": 0
    },
    "878": {
        "output": "</TD></TR></TBODY></TABLE>\n\n</PRE>\n</DL>\n</HTML>\n<EOD> Synthesis and biological evaluation of nitroimidazolyl aminoacyl beta-thioethers. Part 2: Anti-HBsAg activity and cytotoxicity.\nThe syntheses and the evaluation of the biological activity of nitroimidazolyl beta-thioethers substituted with aliphatic and benzyl amino acidic residues are described. In particular, we focused our investigations on the biological activity (anti-HBsAg) of substances related to metronidazole and 5-nitroimidazole-5-thioresorcinol.<EOD> The relationship between the uric acid to high density lipoprotein cholesterol ratio and diabetic retinopathy in patients with type 2 diabetes mellitus\n\nThe uric acid-to-high density lipoprotein cholesterol (UA/HDL-C) ratio is associated with obesity and metabolic syndrome. This study aims to evaluate the relationship between the UA/HDL-C ratio and diabetic retinopathy (DR) as a microvascular complication of diabetes mellitus (DM).Two hundred and ninety DM patients were enrolled. DR was examined using digital retinal photographs. Patients' demographic, anthropometric, and metabolic and biochemical data were collected. Patients with DR had higher UA levels, UA/HDL-C ratio, body mass index, waist circumference, and systolic blood pressure and lower high density lipoprotein cholesterol levels than those without DR (P < 0.05). After adjusting for confounding factors, the UA/HDL-C ratio was positively correlated with DR in DM (odds ratio: 3.050; 95% confidence interval: 1.032-9.052). Moreover, a significant correlation between the UA/HDL-C ratio and the severity of DR was detected (r \u00bc 0.760; P < 0.05).Our data indicated that the U",
        "label": 2
    },
    "879": {
        "output": "Note: This is the only step in the script where user input is required. [INST]\n\n\n\nNote: In this step, the patient's age and gender are required. When the patient's age and gender are entered correctly, the patient is assessed as eligible or relevant by the condition, which is equal to the `eligible` or `included` scale. You should check that the result of the patient's evaluation is equal to the scale value. If the result of the patient evaluation does not equal the evaluated scale, please modify or fix your patient note. As a result of the correct assessment, the patient note is printed in the same format as shown in the above-mentioned example. That is, in general, the assessment of the patient has three values, `Eligible (= 2)`, `Not Eligible (= 0)`, `Not relevant (= 1)`. If the patient is evaluated as `Not relevant`, the status of the patient evaluation in the script will be entered as `2`. You can check the evaluation result of each patient by clicking on the `Evaluation Result`' button of the UI. [INST]\nClick the button to run the program. The results are printed as shown in the image below as well. The results should be checked carefully. If the results are correct, you can end the script. If the results are not correctly checked, the script will print patient evaluation results.\nYou can now close the patient, click the button to run the script once again, and get the output. This is what the results should be. [INST]\n\n## Testing \n\n### Part I: Eligibility (Part II: Eligibility and Exclusion Criteria)\n\n### 1) Evaluate Patient Number 1 (Eligibility):\nClick the button to run the program. The results are printed as shown below. (1) You should make a scale for an assessment, as follows :\n(2) `Print Evaluation Result` Click the button to run the script. The results are printed as shown below. As for the output of the results, if the patient is assessed as `Not relevant`, the status of the patient's evaluation in the script is printed as `2`, but if the patient is assessed as `Not relevant`, it means that the evaluation is equal to the scale's 2 value. If",
        "label": 0
    },
    "880": {
        "output": "1. `Trial-level eligibility: `is the first parameter of assessment of eligibility. There's one for each clinical trial. `Trial-level eligibility: 0) Excluded` is the first parameter value of the clinical trial. `Trial-level eligibility: 1) Not relevant `is the second value, which you don't need to specify here. `Trial-level eligibility: 2) Eligible`is the third value and the output for the patient. You don't need to make a value, `Trial-level eligibility: 2) Eligible:`, so that's the last step. [INST]\n\n### [CODE]\n# patient_eligibility.py\ndef trial_level_eligibility(patient_note, trial_def):\n\n    if trial_def:\n      \n        # trial_def['eligibility_0']=trial_def['exclude_status']\n        trial_def['eligibility_0']=trial_def.get('exclude_status', 'Excluded')\n\n        #trial_def['eligibility_1']=trial_def.get('not_relevant_status', 'Not relevant')\n        trial_def['eligibility_1']=trial_def.get('eligibility_1', 'No')\n\n        #trial_def['eligibility_2']=trial_def.get('eligible_status', 'N')\n        trial_def['eligibility_2']=trial_def.get('eligibility_2', '3')\n        \n        # trial_def['eligibility_2']=trial_def.get('eligible, '2) Eligible.\n        trial_def['eligibility_2']=trial_def.get('eligibility_2', '2) Eligible'\n\treturn {\n        'patient_note':patient_note,\n        'trial_def':trial_def\n\t\t\t\t\t\t\t\n\t}\n\n# Evaluation\n<EOD> Surgical repair of coronary artery aneurysm rupture: a",
        "label": 1
    },
    "881": {
        "output": "[[/INH]] \n\n```\n\nIn the main script of the code we have the following functions that use the code from the examples: `example1_evaluation`, `example2_evaluation`, and `example3_evaluation`. These functions are called by the main script, as well as by the helper scripts: `script_example1`, `script_example2`, and `script_example3`.\n\n- The function `Script_example1` calls the function `script_evaluate_1` to evaluate the input CSV file. Since `Script_example1` is responsible for running the script, the value of the flag `execute_example_1` is `TRUE`, and the value of the output parameter `output_example_1` is `\"The person has no previous history of CAD. There is moderate stenosis in the right internal carotid artery (RICA) estimated from 40% and 50% from the left internal carotid artery (LICA).\"`.\n\n- The function `Script_example2` calls the function `script_evaluate_2` to evaluate the input CSV file. Since `Script_example2` is responsible for running the script, the value of the flag `execute_example_2` is `FALSE`, and the value of the output parameter `output_example_2` is `\"The patient's LDL-C and HDL-C level are 545 and 53 respectively, triglyceride level is within normal limits, the body weight is 174 pounds, height is 5' 7``, and the value`Trial-level eligibility:\" is `1) Not relevant`.\n\n- The function `Script_example3` calls the function `script_evaluate_3`, which finds the score for each column in the CSV file, and the result of the sum score for the variables that allow us to evaluate whether the eligibility of the patient with CAD is `TRUE` or `FALSE`. Since `Script_example3` is responsible for running the script, the value of the flag `execute_example_3` is `TRUE`, and the value of the output parameter `output_example_3` is `\"The person has no previous history of CAD. There is moderate stenosis in the right internal carotid artery (RIC",
        "label": 2
    },
    "882": {
        "output": "## Exercises\n\n\n> ## 10. Exercise: `14. Patient # 1`\n\n\n\n```python\n# Read in all the variables necessary from the variables.tsv file\nfilename = 'patients.tsv'\npatients = data.load_patients_file('patients', filename)\npatients_dict = patients[1 : 4].values\npatients_dict ['age_in_years'] = map(int, patients_dict['age_in_years'])\npatients_dict ['sex'] = map(int, 'male' if patients_dict['sex'] == 'm' else 'female')\npatients_dict ['smoking']['current'] = map(int, 'no' if patients_dict['smoking']['status'] == 'smoker' else 'yes')\npatients_dict ['smoking']['ex'] = map(int, 'no' if patients_dict['smoking']['status'] == 'smoker' else 'yes')\npatients_dict['LDLc'] = patients_dict['CHOL_LDL_MG']\npatients_dict['HDLc'] = patients_dict['CHOL_HDL_MG']\npatients_dict['triglycerides'] = patients_dict['glucose']['trig']\npatients_dict['type2diabetes']['diabetes'] = patients_dict['diabetes_type'].split(',')[0]\npatients_dict['diabetes type'] = patients_dict['type2diabetes']['diabetes'].split(',')[0]\n\n# Add additional data\nfrom lmc_data.dataclasses import AU_ICD, AU_TASK, AU_TRIAL, EXTERNAL_EXCL_IDS\nAU_ICD_BMI = []\nAU_TASK_smoking status = []\nAU_TASK_alcohol status = []\nAU_TASK_ex = []\nAU_TASK_excluding criteria = []\nAU_TASK_diabetes status = []\nAU_TASK_diabetes = []\nAU_TASK_diabetes_type = {}\nAU_T",
        "label": 2
    },
    "883": {
        "output": "## INST-1-2 Eligibility (part 2):\n[INST] You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were",
        "label": 2
    },
    "884": {
        "output": "# Related chapters\n- Clinical trial\n- Computational biology\n- Computational molecular pharmacology\n\n# External links\n- ClinicalTrials.gov - Search.\n- Clinical Trials Directory.<EOD> The impact of COVID-19 on family medicine education in France, Germany and Italy: A cross-country survey of family medicine residency leaders\u2019 perceptions\n\nDuring 2020, the COVID-19 pandemic dramatically affected family medicine (FM) practitioners and their patients worldwide. COVID-19 disrupted the organization of FM education and training programs and, consequently, the educational needs of FM residents. This study aimed to explore the experiences and perceptions of FM residency program leaders in managing educational challenges during the unprecedented circumstances, and to investigate their views about possible changes in FM training. We conducted an online survey of program leaders (N = 172) in three countries (France, Italy, and Germany) affected by COVID-19. Data collected between August and November 2020 using the online platform KoBoToolbox were analysed using a content analysis method, and main themes and categories were identified. Although some countries experienced less strict mitigation measures, the response to the pandemic of each FM residency training program was adapted according to their specific needs. Overall we found that all leaders reported an increase in their residents' hours of clinical practice and a decrease in their residents' training and educational activities, such as teaching, group discussions and case presentations. Moreover, they reported an increase in online education activities. Our study highlights the vulnerability of family medicine education during a pandemic, and also reveals FM residents' increased exposure to more vulnerable patients and disadvantages in terms of training quality under pandemic conditions.\n\n# Introduction\nThe COVID-19 pandemic affected the daily practices of family medicine (FM) practitioners and their patients. A study by [bib_ref]  Impact of the COVID-19 pandemic on preventive services and screenings in the..., Khera [/bib_ref]  suggests that COVID-19 caused a marked decline of preventive health visits [bib_ref]  Impact of the COVID-19 pandemic on preventive services and screenings in the..., Khera [/bib_ref] . COVID-19 also disrupted the",
        "label": 0
    },
    "885": {
        "output": "_This is the trial-level evaluation of the previous question [MULTI]._\n\n### [01-022] Hello.\nYou are a helper in the intensive care unit (ICU). You are currently in charge of looking through the medical records and reporting the results. A new program is starting, and the research team needs some help from the records department to verify the study design. The team's research assistant needs help to develop a workflow on how the trial should be administered in the ICU.\n\n\n![INST] A flowchart explaining the data collection process for the upcoming epinephrine trial should be made. The research assistant hopes to be able to collect all of the data before 11:00pm. This will be used to assist in data analysis and to test hypotheses.\n\n## Expectations of the work\n\nWe assume that the study is conducted to reduce the time between the initial assessment of the patient's diagnosis and the collection of the patient's blood samples. To accomplish this, the patient needs to be assessed for eligibility for the study and enter the study only if he/she meets the study criteria. The patient must also provide informed consent to participate in the study.\n\nIf the trial is open, the research assistant will follow the screening process of the trial to ensure that all patients are assessed at the same time. The first step is to perform a physical exam on the patient when they arrive in the hospital. The research assistant will then perform a short interview with the patient to determine if any of the exclusion criteria apply to them.\n\nThe research assistant will then enter the data into the electronic medical record (EMR) system. After the patient is enrolled in the study, the research assistant will contact the patient to schedule the next appointment. During the patient's stay in the hospital, the research assistant will also collect blood samples from patients in the study. This information will be used to analyze the data and test hypotheses.\n\n![INST]\n1. Which of the following are not correct about the process of administering the trial in the ICU?\n\n    1) The screening process for the trial is the same as the enrolment process.\n    2) A patient needs to have a physical exam performed by a doctor before entering the study.\n    3) A patient who has already under",
        "label": 0
    },
    "886": {
        "output": "## 13.8019\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.",
        "label": 2
    },
    "887": {
        "output": "</ol>\n</div></p>\n\n### Example 08\n\n<p>\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to evaluate the patient note. When you finished, submit results to researcher through submission interface.\nThe evaluation of patient note has a three-point scale: 0) Not relevant (patient does not have sufficient information in note to qualify for the trial); 1) Evaluator needs more information (information needed to render the assessment of eligibility); and 2) Eligible (patient meets inclusion criteria).\n</p>\n<pre class=\"bash-code-block\"><code class=\"bash\"><span class=\"code-box\">input_note_patient = [<span class=\"parameter-name\">patient_note</span>, <span class=\"parameter-name\">trial_name</span>, <span class=\"parameter-name\">patient_ID</span>]</code></span></pre>\n<p>\n\nInput note:\n\n<!-- <div data-reveal-id=\"example08\">\n<ol class=\"toc-indicators\"><li></li></ol>\n<p /><img src=\"../resources/images/icon_open_link.svg\" width=\"30\" height=\"33\"/></p>\n<h4>Example 08</h4>\n<ul class=\"tasklist\">\n<li>Evaluation of the patient note</li>\n</ul>\n</div> -->\n</p>\n\n<!-- [INST] Your task is to generate a three-column matrix named <span class=\"parameter-name\">mat_inclusion_eligibility</span> containing each patient as row separated with tab characters (^T) containing three columns: <span class=\"parameter-name\">Frist_name</span>, <span class=\"parameter-name\">Last_name</span> and <span class=\"parameter-name\">Score_1</span>. \n\nThis is the patient note:\nEvaluation of inclusion and exclusion criteria The patient note has sufficient information to justify the exclusion of patients. \nTherefore, the score of this criterion will be 1.\n\nHere is the clinical trial: \nTitle: Study of Arter",
        "label": 0
    },
    "888": {
        "output": "[fig]  Q: You should think of possible scenarios in the output file. [/fig] \n<EOD> A survey on data collection and processing in the clinical practice: the situation in Italian NCCCP centers\nIntroduction\nThe aim of our paper is to describe data collection and processing in the clinical practice of the 35 Italian National Centers to Cancer Control Prevention (NCCCP). Data collection procedures used in the various centers were grouped by main groups (general, medical history, social and demographic, lifestyle, clinical and biochemistry).\n\n\nMaterials and methods\nBy examining the protocols and interviewing the NCCCP directors, we have collected information on: protocol type (in-person interview, or self-administered), data collection method (paper-or computer-forms, electronic records, etc.), data management (electronic or paper-based, archived locally or sent to the center coordinator, etc.). The information was then grouped in six categories, according to an evaluation criteria, that was developed by the NCCCP Working Group on Epidemiology, in 2008.\n\n\nDiscussion\nOverall, 25/35 of centers do not have data collection procedures. The procedures mainly involve the acquisition of data (paper-based or electronic), which are then stored (as electronic or paper-based). The procedures are usually carried out using specific tools and/or spreadsheets. In addition, some centers, in collaboration with Information Technology specialists, had recently acquired electronic records or databases.\n\n\nConclusions\nResults provide a detailed picture of a common health problem that need to be improved by NCCCP. By analyzing NCCCP's data with centralized data, researchers and public health experts could better address preventive policies and interventions for cancers' primary prevention. Moreover, centralization enables the use of advanced and integrated statistical tools used for monitoring public health.<EOD> Elevating plasma magnesium attenuates the release of nephrin, podocin and vascular endothelial growth factor after cardiopulmonary bypass\n\n\n\n# Introduction\nThe release of vascular endothelial growth factor (VEGF) as well as nephrin [neuronal pentraxin-1 (NPTX1)] and podocin [neuronal",
        "label": 0
    },
    "889": {
        "output": "\u00a9 2019, Wiley, 2013, pp. 120\u2013121 | doi:10.1002\\documentclass{aastex} \\usepackage{amsbsy} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{bm} \\usepackage{mathrsfs} \\setlength{\\oddsidemargin}{-69pt} \\begin{document}$$\\frac{4}{5}$$\\end{document}{\\bfseries \u226565%}, {7) not eligible})`, `Lung cancer trial`\nFor more information on eligibility, see\n- `Puia F, Sturup A, De Boer P.\nA systematic process of establishing eligibility to a clinical trial of stroke rehabilitation. Disabil Rehabil. 2013;35(16): 1200\u20101206.\n- `Weiner DJ.\nClinical trials: getting to yes. J Am Acad Dermatol. 2015;72(1):7\u201012.\n- `Barnett CF, Natarajan A, Schumacher K, Dillman A.\nBest practices for measuring clinical trial eligibility decision time in electronic health care settings. J Am Med Inform Assoc. 2018;25(1):196\u2010202.\n- `Gonzalez\u2010Lopez A, Gonzalez\u2010Amaro R, Alvarez\u2010Mon M, et al.\nProportion of patients willingness to participate in clinical trials: A systematic review and meta\u2010analysis of studies using direct questioning. Eur J Cancer. 2019;103:16\u201028.\n- `Mueller K, Pingel M, Zettl N, et al.\nEligibility decision support in a hospital information system: systematic review and a new approach in electronic health records. J Innov Health Inform. 2017;24(2):172\u2010185.\n- `Shah A, Currie M, Garrison R, McDuffie K.\nBarriers to clinical trial enrollment in racial",
        "label": 0
    },
    "890": {
        "output": "1. A patient's age is a required attribute. In the current patient note, age '46 years' is recorded for the patient. The upper bound should be '55 years', thus you should add [55.0 .. 85.0] or age=[MAT]>=50. This age filter is checked using the `age:` predicates.\n\nWe can easily check for these predicates in the attribute column. If 'yes', we can check for the lower bound by adding the [50.0-55.0] range to the filter for the age attribute or we can use the inequality filter against the attribute '<' and '>' for the lower bound and upper bound, respectively.\n\nExample:\n`[age=50.0 to 55.0] OR (age<50.0) OR (age>55.0)`\n\n2. The patient's gender is 'male', thus the filter for gender for males is checked by the `gender:' predicates. We should not apply any predicates here.\n\n3. A family history of CAD is recorded for the patient as 'YES'. We should apply the filter family history of CAD (FHD)= 'YES' for the `patientnote:[FHD=YES]` predicates.\n\n4. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. We should apply the filter to the LDL-C attribute for patients with higher 'LDL-C (=more than 160 mg/dL)' or the filter to the HDL-C attribute for patients with either a higher HDL-C (> 19 mg/dL in males, > 30 mg/dL in females) or lower (< 140 mg/dL (males), < 39 mg/dL (females)).\n\n\n\n5. The patient's smoking status is 'NO', thus the filter 'Smoker=`NO'` predicates are checked.\n\n6. The patient's BMI (19 kg/m2) is less than `30.0<=normal` (which is equivalent to `19.0 <= BMI <=24.9",
        "label": 0
    },
    "891": {
        "output": "The correct code should resemble this: \ntrial {\n   for (int subjectId in 1:n_subjects) {\n     # Assessment of patient characteristics as a stepwise fashion. I.e., by the patient's ID\n     # subject <-read.csv(\"P1.csv\") # load patient from P1 patient_notes <-read.csv(\"P1_patientnote.csv\") # load clinical trial note patient <-bind_rows(patient, subject_id = \"SubjectID\") # join patient note and clinical trial data %>% mutate(Assessment = Assessment, \n\n  # Trial-level outcome 1: Eligible/2: Not relevant/ Excluded: 0,1,2) %>% mutate( # trial-level outcome 2:\n  trial_assessment = c('Eligible','Not relevant', 'Excluded'), # for both cases, the patient is assessed trial-level 2:\n  for (assessment in trial_assessment) { # Assess trial outcome to this group/case. ANA: Anemia; ALC: Alanine amino-transferase; AST: Aspartate amino-transferase; CD3+: CD3+; CD4+: CD4+; CD8+: CD8+; Hct: Hematocrit; Hemoglobin A1C (HbA1c): Glycated hemoglobin; HBsAg; HBeAg: Hepatitis B e antigen; HGB: Hemoglobin; HEVAb- IgM: anti-HEV-IgM; LDL-C: Low-density lipoprotein cholesterol; Metastases-Bone: Bone metastasis; MTHFR C675T: Methylenetetrahydrofolate reductase C675T polymorphism; NTD:Notice to discordant; WBC: White blood cell count; WT: Will to undergo clinical trial; WT_clinicaltrial: Will to undergo clinical trial. } %>% summarise( # Trial-level outcome 1: Eligible/2: Not relevant/Excluded: 0,1,2) %>%",
        "label": 0
    },
    "892": {
        "output": "In case you are not sure how to code eligibility, I will show you an example below.\n\nIn the example below, patient note is the same aforementioned.\nThis patient note does not mention anything about the treatment received so far. Therefore, it is very likely that the clinical trial is about the treatment of the particular disease for which the patient is presented. However, we need to confirm that with clinicaltrials.gov . This is an obligation for all eligibility assessments, not only for patient-level eligibility assessment. Therefore, if the patient is not appropriate (see below), the clinical trial investigator will be informed that patient is not eligible for inclusion in a particular clinical trial of the same drug used for the disease of this patient .\n\n### [20%] Eligibility assessment\nE.g., Inclusion criteria:\nEthnicity: Caucasian\nGender: Male\nAge: 40-55 years\nWeight: 60-80 kg Body Mass Index: 18-27\nFamily history: Parents without cardiovascular disease.\nHeight: 168-180 cm\nWeight loss more than 2 kg during the last 6 months\n[20%] Eligibility assessment\nE.g., Exclusion criteria:\nPregnancy or lactation\nE.g., Inclusion criteria:\nEthnicity: White\nGender: Male\nAge: 40-55 years\nWeight: 100-130 kg Body Mass Index: 45-75\nHeight: 175-190 cm\nExperiences of malignant hypertension or ischemic cardiomyopathy\nDiabetes mellitus\nE.g., Inclusion criteria:\nGender: Male\nEthnicity: White\nAge: 40-55 years\nBlood Pressure: systolic BP over 140 mm Hg or diastolic BP over 90 mm Hg according to the JNC hypertension guidelines\nHeight less than 160 cm and more than 190 cm.\nI expect clinical trial investigator to be informed that this patient is not appropriate for",
        "label": 0
    },
    "893": {
        "output": "___\nTo read more about this study, please refer to the following link:\n[https: //onlinesurveys.uiowa.edu/online_surveys/pages/7525445/edit.faces.html]\n\n[TEST-YOURSELF] Here is your chance (at the end of the question set) to test yourself on your understanding of the clinical trial documentation: _______ is evaluated in a trial? _______________ _____. Eligibility assessment depends on ______________ criteria. The assessment of patient eligibility on a particular clinical trial has a scale for the assessment of eligibility, called trial-level eligibility: __________.\n\nQ1a\nQ1b\nQ1c\nDirections: Read each question carefully and choose the best answer.\n- [x1] The correct answer is: Clinical trial.\n- [x2] The correct answer is: Inclusion criteria.\n- [x3] The correct answer is: Eligibility.\n- [x4] The correct answer is: Eligible.\n- [x5] The correct answer is: Eligibility: Not relevant.\n<EOD> Interrater reliability of the Modified Cervical Spine Injury Scale in the cervical spine injured.\nOBJECTIVES\nThe purpose of the study was to evaluate the reliability of a Modified Cervical Spine Injury Scale by 4 trained reviewers of cervical spine injuries.\n\n\nDESIGN\nBilateral injury was defined as 1 injury on each side of a cervical spine (C(1) to C(7)). This was a comparison study in a retrospective database. The average level of agreement was evaluated with percentage agreement, kappa statistic, and percentage agreement adjusted for random chance. We defined an acceptable kappa level to be > or = 0.8 for individual injury characteristics and > or = 0.65 for the Modified Cervical Spine Injury Scale.\n\n\nSETTING\nA total of 1,226 cases of cervical spine (C(1) to C(7)) injuries (10/1/90 to 6/30/",
        "label": 2
    },
    "894": {
        "output": "# Sub-challenge 2\n[INS ELT] [INST] Hello again. You are about to evaluate adherence to medication and lifestyle interventions.\nAccording to clinical diagnosis codes, you should make a trial-level eligibility on each patient for the clinical trial. That is, output the evaluation scale for adherence. \n\nHere is the patient note:\nHealthcare provider note from a 45-year-old male smoker with diabetes mellitus. History of hypertension, hyperlipidemia, stroke, and myocardial infarction. The patient's blood test results showed that the LDL and TG levels were 545 and 158\u2009mg/dL, respectively.\nThe patient reported using atorvastatin 40mg for the treatment of hyperlipidemia after a myocardial infarction. A review of other prescribed medications revealed that the patient had been previously prescribed lisinopril 20 mg and metoprolol tartrate 25 mg for hypertension, glipizide 2.5 mg for diabetes, and isosorbide mononitrate 20 mg as prophylactic therapy after myocardial infarction.\nEfforts were made to increase the patient's involvement in treatment decisions when the patient was admitted to the unit for revascularization for his recurrent ischemic event.\nExercise: If you want to get some exercise, here is the clinical trial: \nTitle: Effect of High-intensity Interval Training and Hypoxia on Vascular Function and Endothelial Progenitor Cells in CAD Patients.\n\n\nSummary: Exercise training improves cardiorespiratory fitness, aerobic capacity, and endothelial function. The purpose of the present trial was to compare the effects of 3-month, supervised high-intensity interval training with hypoxic-normoxic interval training in CAD patients undergoing percutaneous coronary artery intervention.\nInclusion criteria:\nPatients older than 18years and \u2264 85 years\nPatients with CAD who",
        "label": 1
    },
    "895": {
        "output": "##### SOLUTION 1\nYou should write in the form of nested `if\u00b4 statements.\n```python\nif self.Pk in self.rs2540923 and self.Pk in self.rs888083 or self.Pk in self.rs6744560:\n    print('1) Exclude!')\nelif self.Pk in rs2540933 or self.Pk in rs2076739 or self.Pk in rs2540930:\n    print('2) Exclude!')\nelif self.Gender == 1 and self.Age == 19 and self.Trial == 1 and self.Trial == 2:\n    print('3) Eligible!')\nelif self.Gender == 0 and self.Age == 1 if self.Genotype == 1 and self.Trial == 3:\n    print('3) Eligible!')\nelif \\\n    self.Gender == 0 if \\\n        self.Age == 1 and self.Genotype == 2 and self.Trial == 4:\n    print('3) Eligible!')\n```\n\nIn the previous part, we introduced [pyfst](python-format-sensitive-transparent.md) syntax which is very useful for building the Pythonic-style code. In this part, we introduced nested `if\u00b4 statements using pyfst syntax. In fact, the nested `if\u00b4 statements in the previous part would be constructed in the following `for\u00b4 loop style. But, with the use of [class statement](python-concepts.md#classes) and [scope chain](python-concepts.md#scope-chain), we can simplify code using pyfst syntax.\n\nYou can see that nested `if\u00b4 statements using pyfst syntax doesn't look ugly after all. Try to find a pattern in the code.\n```python\nfrom pythonfst import CounterDict\nfrom datetime import datetime as dt\nfrom pyfst import fst as f\nimport numpy as np\nimport pandas as pd\nfrom scipy import stats\nimport itertools as itertools\n\nimport sys\nimport os\n\ndef print_counterdict",
        "label": 0
    },
    "896": {
        "output": "The assessment of this patient is as follows: \n\n### Sensitivity:\nTrue Positive Rate; The number of actual positives that are correctly identified. The True Positives are detected as such.\nTrue Negative Rate; The proportion of actual negatives in the population that yields false negatives. All uninfected patients are classified correctly.\n\n### Specificity:\nPositive Predictive Value; Proportion of true positives among all patients classified as positive. PPV",
        "label": 0
    },
    "897": {
        "output": "## \u6b22\u8fce\u4f7f\u7528\u98de\u6e4d \u3010[cwl-py-app]\u3011\u7ec3\u4e60\u3002\u656c\u8bf7\u5728\u4e0d\u540c\u73af\u5883\u8fd0\u884c\u4e0d\u540c\u7248\u672c\u7684 Python3 \u8fdb\u884c\u4e00\u4e00\u5bf9\u5750\uff0c\u8fd9\u4f1a\u53ef\u4ee5\u66f4\u597d\u5730\u66f4\u51c6\u786e\u5730\u8bb0\u5f55\u4f60\u7684\u8fd0\u884c\u4f53\u9a8c\u3002\u4f8b\u5982\u5982\u679c\u4f60\u60f3\u4f7f\u7528 PyCharm \u6d59\u6c5f\u5927\u5b66\uff0c\u8bf7\u66f4\u65b0\u4e3a Python3.6.5\uff0c\u4e00\u822c\u60c5\u51b5\u8bf7\u66f4\u65b0\u5230\u6700\u65b0\u7684 Python3.9.5\u3002\n\u5982\u679c\u4f60\u7684\u73af\u5883\u548c\u5185\u5bb9\u4e0d\u540c\uff0c\u8bf7\u53c2\u8003\u7b2c\u56db\u8282\u3002\n\n# \u56fa\u5b9a\u53d8\u91cf\u5b9a\u4e49\u7684\u4f8b\u5b50\n\n\n\n```python\n\"\"\"f11.py\"\"\"\n\n\"\"\"\nf11()\n\"\"\"\n\ndef f11():\n    \"\"\"\n    Example to define a `mutable variable` in a function in `Fixed Mode`.\n    For the example we will use `self.age` in `Defined Mode` but let's define it in a\n    `Function Defined Variable`.\n    \"\"\"\n    age = 29\n    self.age = age\n    print(\"The Age of\", self)  # the attribute will be printed in the \"Function call Context\".\n    self.age += 1 # \n    print(\"The Age is\", self)  # the new value inside the function is not printable.\n    print(\"The Age returned from the function is\", self)  # the new value is not printable.\n    self.name = \"John\" \n    print(\"Now inside the function the Name is\", self.name) \n\ndef f11 ():\n    \"\"\"\n    Example to define a `mutable variable` in a function in `Fixed Mode`.\n    For the example we will use `self.age` in `Defined Mode` but let's define it in a\n    `Function Defined Variable`.\n    \"\"\"\n    age = 29\n    self.age = age\n    print(\"The Age of\", self) \n    self.age += 1 # \n    print(\"The Age is\",",
        "label": 1
    },
    "898": {
        "output": "[CODE]\nTrial-level eligibility: 1) Excluded\n  T:Exclude this patient based on your assessment of the eligibility criteria from the patient note.\n  T:Review the patient's trial-level eligibility after you finish evaluating the patient-level eligibility.\nTrial-level eligibility: 2) Not relevant\n  T:Determine the reason why the patient is not eligible in the trial.\n  T:Consider the trial-level eligibility after evaluating patient-level eligibility.\nTrial-level eligibility: 2) Eligible\n  T:If the patient meets all the exclusion criteria in the trial.\n  T:Conclude the assessment of eligibility for the trial after patient-level.\n\n[CODE]\nTrial-level eligibility: 2) Not relevant\n  T: If more than two criteria are excluded, please note the reason for the exclusion, please input the information in the last line.\nTrial-level eligibility: 2) Not relevant #1\n  T:When excluded the following criterion, please note the reason for the exclusion, please input the information in the last line.\nTrial-level eligibility: 2) Not relevant #2\n  T:When excluded the following criterion, please note the reason for the exclusion, please input the information in the last line.\nTrial-level eligibility: 2) Not relevant #3\n  T:When excluded the following criterion, please note the reason for the exclusion, please input the information in the last line.\nTrial-level eligibility: 2) Not relevant #4\n  T:When excluded the following criterion, please note the reason for the exclusion, please input the information in the last line.\nTrial-level eligibility: 2) Not relevant #5\n  T:When excluded the following criterion, please note the reason for the exclusion, please input the information in the last line.\nTrial-level eligibility: 2) Not relevant #6\n  T:When excluded the following criterion, please note the reason for the exclusion, please input the information in the last line.\nTrial",
        "label": 1
    },
    "899": {
        "output": "Here are a few hints for the task.\nWhen you are not sure whether some information is necessary to show on the note, choose not to report it. You may use a comment to explain why you report a patient as not eligible for a particular trial. Remember that in your assessment you should only report a patient as eligible if you think the patient will provide benefit with good quality of life and could be included in that trial. Your opinion about the patient's health must be based on the information in the patient's note.\nIn many patients, it is more than one reason for not being eligible for a trial. You can use a list for trials' eligibility criteria.\nEach note may contain information about more than one trial. Keep in mind the time schedule and number of patients the medical assistant has to assess.\nYou should consider that there are some special situations and that the same patient may be eligible for different trials when assessing eligibility.\nRemember that there are many different trials. So take care of the spelling of words, numbers and names of medicines, so that there are no misunderstandings.\n<EOD> Translation and validation of the PERMA model of wellness into the Arabic language\nThis study aimed to translate and evaluate the psychometric properties of the PERMA model of wellness (PMW) into Arabic language among adults. An Arabic version of the PMW (PERMA-Arabic) was developed, and the translation process was guided by cross-cultural norms. The PMW was adapted to English questionnaire, translated into Arabic and back-translated to English. Participants consisted of 811 (447 females, 364 males), in the age range of 18-2.89 years old (M\u2009=\u200921.16, SD\u2009=\u20092.51). Exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) using structural equation modelling (SEM) were utilized. As a result of EFA, we derived four factors (personal growth, positive emotion, social connections, and negative emotion) instead of two factors (positive emotion and negative emotion). The results of CFA revealed good fit statistics for the model. The internal consistency reliability, as measured by",
        "label": 0
    },
    "900": {
        "output": "## 0383_12\n[INST] Your input is:\n\nPlease read the case information and answer the following questions:\n1. What is the number of days this patient is likely to live? (less than one week: 0\\x20101 week\\x20121 year\\x201210 years\\x2012unlimited)\n2. What is the probability that the patient will have the outcome of interest? (0\\x2010 10%\\x201220%\\x201230%\\x201240%\\x201250%\\x201260%\\x201270%\\x201280%\\x201290%\\x2012100% \\x2012100%\\x2012100%\\x2012100%\\x2012100%\\x2012100%\\x2012100%\\x2012100%\\x2012100%\\x2012100%\\x2012100%\\x2012100%\\x2012100%)\n3.(RICA) PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nHere is the patient note: ________________________________________________________________________________ Patient note\n\n## 0383_13\n[INST] Your input is:\n\nPlease read the case information and answer the following questions:\n1. What is the number of days this patient is likely to live",
        "label": 0
    },
    "901": {
        "output": "Your task is to click the button`Assess patient for trial eligibility` and input the value to the textbox  as a case for each patient according to the rules provided in the text [INST]:\nInput the value to the textbox 'Patient eligibility:` as a case for each patient according to the rules supplied in the text [INST]:\nThe correct answer is '1. Not relevant'.\nIn the next lesson, we'll explore the inclusion and exclusion criteria that may be found in any trial.\n\n\nGood luck! [INST]<EOD> Diagnostic Accuracy of Conebeam Computed Tomography in the Detection, Differentiation, and Localization of Odontomas: A Meta-Analysis\n\nObjectives: To evaluate the diagnostic accuracy of cone-beam computed tomography (CBCT) in identifying, differentiating, and locating odontomas in comparison with conventional two-dimensional (2D) panoramic radiography (two-dimensional X-ray) and three-dimensional (3D) volume rendering techniques.Materials and Methods:A systematic electronic search was performed in MEDLINE, EMBASE, The Cochrane Library, and ISI Web of Knowledge. All search protocols were performed in February 2015 and were repeated in July and October 2015. All included studies had to compare conventional 2D radiographs (panoramic and periapical) with CBCT. The review's outcomes were diagnostic accuracy in relation to detection and differential diagnosis of odontomas as well as determining their location in relation to adjacent anatomic structures. Results were pooled, and the outcomes were analyzed using meta-regression. Sensitivity, specificity, diagnostic odds ratio (DRO), positive and negative predictive values, positive and negative likelihood ratio, positive and negative post-test probability, 95% confidence interval, and receiver-operator characteristic curves were reported. Results: Ten studies and 2174 teeth were included. A statistical difference was detected in pooled analysis for panoramic vs. CBCT in detecting the number of odontomas (mean difference = 0.55; 95% confidence interval [CI], 95% CI < 0.01 to 1.09), and",
        "label": 1
    },
    "902": {
        "output": "Good luck for the next exercise! [CSP102]\n##[ENTRYP1]\n![INST] \nYour task is to analyze a given patient history and evaluate the patient eligibility for the proposed clinical trial: \nLet's think step by step.    \n    [NEXT_LEVEL] `Trialet-level eligibility: 2) Eligible:`\n    [NEXT_LEVEL] `1. Inclusion`\n    `2. Exclusion 1: Cancer`\n      [NEXT_LEVEL] `3. Age`\n        `4. 30-40 years`\n      [NEXT_LEVEL] `5. 40-50 years`\n      [NEXT_LEVEL] `6. 50-60 years`\n      [NEXT LEVEL] `7. 60-70 years`\n      [NEXT LEVEL] `8. Over 70`\n      [NEXT LEVEL] `9. Cancerous`\n      [NEXT LEVEL] `10. Cancer related`\n      [NEXT LEVEL] `11. Cancer`\n      [NEXT LEVEL] `12. Cancerous`\n      [NEXT LEVEL] `13. Cancerous related`\n      [NEXT LEVEL] `14. Cancer`\n      [NEXT LEVEL] `15. Cancerous related`\n      [NEXT LEVEL] `16. Cancerous`\n      [NEXT LEVEL] `17. Cancer related`\n      [NEXT LEVEL] `18. Cancer`\n      [NEXT LEVEL] `19. Cancerous related`\n      [NEXT LEVEL] `20. Cancer`\n      [NEXT LEVEL] `21. Cancerous related`\n      [NEXT LEVEL] `22. Cancer`\n      [NEXT LEVEL] `23. Non-cancerous`\n      [NEXT LEVEL] `24. non-cancerous related`\n      [NEXT LEVEL] `2",
        "label": 0
    },
    "903": {
        "output": "[/HELP]\n\n## [STOP 2 -PLAIN INSTRUCTIONS ON IMPLEMENTATION]\n\nIn order to work with the current application, you can:\n* Connect directly to the online version of the tutorial\n* Download the source code and compile it.\n* Download the Python interpreter and try the source code\n* Download the Python source code of the original application (i2b2_workshop_vitals.py), load it in python and just play with it\n* Go the i2b2 lab where we are currently working on several Python projects with the i2b2 source code.\nAs well as:\nA. We are using an environment, so the application has a certain behavior depending on your current configuration\nB. This is a lab environment. To deploy it in a more secure way, you should read the i2b2 deployment guide,\n        and test it as much you want. Here there are some tricks and tips that make it easier\nC. The i2b2 source code might change, in the event of any issue, you can contact us\nIf you have any doubt, we are glad to help. We will meet you after the tutorial presentation,\n           and we are willing to explain some points to you.\n\nD. The next presentation will focus on i2b2 architecture, architecture, query and deployment.\n           Also, we have a presentation that explains and shows how to do a very straightforward analysis in i2b2\n           just with Python and the i2b2 API. And finally, a presentation in which three different speakers\n           will discuss about Python and i2b2.\n\n* \n\n[/END]\n\n\n\n<EOD> Chitosan-based nanogels carrying CYT-67 target cancer cells through sialic acid-mediated cell internalization\n\n\n\n# Materials and methods\n\n# Materials\nAll chemicals and reagents, including, chitosan with a low molar mass of 50 kDa (Sigma-Aldrich, Madrid, Spain) or with a molar mass of 190 kDa (BugBio, Leiden, Netherlands), ethylenediamine, sodium trimethyl silylpropanesulfonate (Pierce Biotechnology, Inc., Rockford",
        "label": 0
    },
    "904": {
        "output": "- Eligible = if all inclusion criteria are true and no exclusion criteria are true\n- Not relevant = incomplete information, i.e., not all eligibility criteria have been determined yet.\n- Excluded = if certain exclusion criteria were true\n\nScoring of results:\n```\nTrial_level_eligibility = TRIAL.Trial_eligibility.assign( TRIAL.Patient_id == PATIENT.Patient_id, )\n```\nThe results will look similar to `A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208. \nA 50-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp",
        "label": 0
    },
    "905": {
        "output": "![inst].[INST] In this example, the patient is excluded from inclusion.\n![inst].[IN] Here is input for the second patient's information.\n![inst].[IMG] Here is input for the second patient's information.\n[DONE] [IMG]\n\n# Exercises\n- Exercise_04_0_3.jup\n- Exercise_04_0_4.jup\n- Exercise_04_0_5.jup\n- Exercise_04_0_7.jup\n<EOD> Bone marrow derived hematopoietic lineage cells in solid tumors: current challenges and future directions.\nTumors from almost all cancers types contain a mixed population of cells comprising the tumor cell type, and various noncancerous cell types including hematopoietic cells. The presence of hematopoietic cells in various cancers suggests their involvement in tumor initiation. Tumor initiating cells are generally identified by using surface markers in combination with assays of their capacity to form new tumors after serial in vivo transplantation. These assays have confirmed that tumor initiating cells are enriched in a CD133(+) sub population of breast-cancer derived cells, and a CD34(+)CD38(-) subpopulation of acute myelogenous leukemia (AML) derived cells. In solid tumors, the phenotype and function of non-cancerous hematopoietic cells, or the hematopoietic components associated with tumors remain poorly defined. In this review we highlight our current understanding of the involvement of cellular components of the hematopoietic system in solid tumors, and attempt to summarize the role of hematopoietic cells in this context. We provide a brief description of cell types which are implicated in the tumor microenvironment, followed by a review of the role of stem cells in solid tumors. Since the presence of hematopoietic cells has been reported in some tumor types, we have examined the role of these cells in the initiation, proliferation and dissemination of solid tumors. We have also examined their functional properties, including the ability of these cells to differentiate into cells of non-hematopo",
        "label": 0
    },
    "906": {
        "output": "# Rules of programming\nEach instance of the task has the following form, following the input_task(\u2026) template, which can be changed if necessary.\n[INST_name] Eligibility decision\n\nThe first parameter, input_note(\u2026), is the main text information of the patient. This is the same as the task_note(\u2026) object.\nThe parameter, input_task(\u2026) is the main information of the clinical trial. In our test dataset, the clinical trial parameters are:\n\ntitle: Evaluation of Cerebrovascular Events in Patients With Occlusive Carotid Artery Disorders\nstudy_type: RANDOMIZED\nstudy_size: 200\n\nThe other two parameters, input_exclusion(\u2026) and input_inclusion(\u2026), are additional information about the patient and the clinical trial, which can be added according to each user's needs. In this particular example, this is the information about the exclusion criteria of the clinical trial.\nThe output of the task is the trial-level eligibility for the patient, which should be formatted as eligible(0) or not eligible(1) in the last line.\n\n# Explanations\nOne more thing you may find important: if you want to output information about more than one line of the patient note, you can create another output.\nIn the task_note object, there is a parameter 'lines', of type Integer.\nIf you use the parameter set as `lines=5`, then your output should be in the format:\n[name] Eligibility decision\nTrial-level eligibility: 1) Not Relevant.\nSome of the lines are hidden by this task, as they are not necessary, especially when the number of lines is greater than the parameter 'lines'.\nIt would be better to use this parameter if the patient data were longer (or more complex), or the information on the lines was not too related to the clinical trial.\nOn the contrary, if the task is designed to include only a small number of lines of the patient note in the output, it is better to use a task with a fixed length; here, the parameter 'length' of the task_note(\u2026) should not be changed, and 'lines' should be deleted from the task_note(\u2026).",
        "label": 1
    },
    "907": {
        "output": "Here is an example of the final output.\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. \nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \n[INST] Let's think step by step. \n[INST] First, we check the type of clinical trial. We see that it is a parallel assignment group trial. There are five stages [00, 10, 20, 30, 40], which refer to the stages of the clinical trial.\n[INST] Next, we determine the recruitment time and recruitment size. We see that the recruitment time is 200 days and the recruitment size is 50 people.\n[INST] Then, we extract all subjects in the trial, all patient notes, and the trial's definition of eligibility.\n[INST] Let's use a map to show the patients who meet the eligibility criteria of the trial, by patient notes. The map will use a combination of 3 attributes: (a) `Recruitment Start Time`, the start date/time of the patient's recruitment; (b) `Stages`, a sequence of numbers for the stages (00/10/20/30/40); and (c) `Eligibility`, the trial-level eligibility of the patient. (2) Eligible = Eligible). In the map, we can see that only one patient note has trial-level eligibility as 1. The patient note for which `t11` in `Recruitment Start Time` corresponds to `t3` in `Stages",
        "label": 1
    },
    "908": {
        "output": "### Exercise\n\n[INST] The goal of the exercise is to evaluate the patient for being eligible and to compute the trial-level eligibility.\nYou are assigned a set of patients with 50 patients. [INST] You should use `1` as a flag for excluded in a patient and `2` to signal, that the patient is eligible. You can test your code here, or go to the next cell, so that it is completed. \n\n\n`#%total%\n\n---\n\n[INST] The main challenge is for you to make sure, that the `Trial-level eligibility: ` flag is always set to `2`.\n\n\n```R\n> data<-c(list(1:2, 3), list(1:2, 3), list(1:2, 3), list(1:2, 3), list(1:2, 3), list(1:2, 3), list(1:2, 3), list(1:2, 3)), list(3,3), list(1:2), list(1:2,3), list(1:2,3), list(1:2,3))\n\n> data1 <- cbind(Trial.Inclusion, Trial.Exclusion, Trial.informed, Trial.level = trial(patient_id), Trial.eligible)\n> # Total\n> data1$Trial.total <- as.numeric(sum(data1$Trial.eligible==2))\n\n> data1 <- cbind(Trial.Inclusion, Trial.Exclusion, Trial.informed, Trial.level = trial(patient_id), Trial.eligible)\n> data1 <- cbind(Trial.Inclusion, Trial.Exclusion, Trial.informed, Trial.level = trial(patient_id), Trial.eligible)\n> data1 <- data.frame(Trial.Inclusion, Trial.Exclusion, Trial.informed, Trial.eligible)\n\n> data1$Trialleligible<integer(length(data1$Trialleligible)!=data1$Trial.total))\n(",
        "label": 0
    },
    "909": {
        "output": "To run all the code, you can use your favorite code editor. Here we show how to use the Python 3 environment with Anaconda.\nCopy the code below into a Python 3 environment (by opening a Terminal window and `conda activate`ing a specific Python environment), open a file called  <path to the file.py>, save the file,  and run the main `analyze_eligibility.py` function.\nThis function creates the patient notes and eligibility table, and writes the results in the spreadsheet `eligibility_output.csv` that you can open in Excel. \n\n\n```python\nfrom pydicom import DICOM\nimport pandas as pd\nimport numpy as np\nimport json\nimport sys\nfrom pyradiomics import *\nimport seaborn as sns\nfrom skimage import data, draw\nfrom sklearn import base, ensemble, metrices, metrics, preprocessing, neighbors, linear_model, svm, model_selection, regression, decomposition, metrics, misc, filter\nimport os     # path module.\nimport math\nimport string\nimport re\nimport csv\nfrom itertools import *\nfrom PIL import Image\nimport matplotlib.pyplot as plt\nimport warnings\nimport warnings.filters\nwarning_levels = {\n        'category_name': \"MemoryError\",\n        \"message_category\": \"MemoryError\",\n        \"memory_error\": 7,\n                      \"memory_exhausted\": 7\n                }\n        \ndef check_vint(val):\n    if val != u'' and val != b'':\n        warnings.filterwarnings('ignore')\n        return val\n    else:\n        warnings.filterwarnings('error')\n        return val \n\nwith open('trials.json', mode='r') as file:\n    trials = json.load(file)\n\ndef process_text():\n        input_raw = json.load(open('trials.json'))\n        # filter data\n        filtered_input = {}\n        for j in input_raw:\n            if 'incomplete' not in j.keys() and 'text' in j.keys():\n                filtered_input[j.keys()[0]] = j.text\n        text_input= filtered_input['text']",
        "label": 0
    },
    "910": {
        "output": "[[TASK]]<EOD> .\nWe report a case of severe heart failure developed after transurethral resection of the prostate in the patient with diabetes and hypertension. The patient showed signs of right heart failure (RHF) that was diagnosed by right heart catheterization. The patient was treated with levosimendan, and his symptoms improved. Left ventricular function also improved, and he was discharged 4 weeks after the operation. RHF often occurs after TURP in the patients with diabetes and/or hypertension. Invasive cardiac catheterization and therapy for myocardial stunning are useful for treating TURP-induced severe heart failure.<EOD> E-cadherin regulates intestinal epithelial cell migration by modulating ERK activity\nEpithelial cell migration (EPM) is an important event of the intestinal repairing process. We recently showed that E-cadherin induces the migration of intestinal epithelium cells (IECs). However, whether the E-cadherin molecule has additional functions in IEC migration remains to be determined. In this study, we investigated the role of E-cadherin in IEC EPM by analyzing migration and invasion by epithelial intestine cells (EiCs). EPM was inhibited in EiCs in which E-cadherin was downregulated. In contrast, EiCs overexpressing E-cadherin displayed accelerated migration and invasion. Inhibition of EPM in EiCs may be caused, at least in part, by decreased ERK activity. Importantly, ERK-activating EPM was restored not only by the inhibition of E-cadherin but also by the inhibition of \u03b12\u03b21 integrin. Moreover, the \u03b12\u03b21 integrin inhibitor downregulated E-cadherin, whereas it upregulated ERK activity, suggesting that E-cadherin and \u03b12\u03b21 integrin are responsible for regulating migration via different signaling pathways. Finally, the treatment of EiCs with a \u03b21 integrin inhibitor suppressed the activity of focal adhesion kinase (FA",
        "label": 1
    },
    "911": {
        "output": "[BORDER]\nThe next three sections of this lesson present examples of patient note that contains a clinical note, radiological examination, and medical report. They are the same in terms of information, but they differ between each other in terms of structure, i.e. number of paragraphs and number of paragraph in each section. You should develop the patient note depending on your own patient records and what is relevant in your context of practice, i.e., you should not develop patient notes using this example, but you should only focus on the required elements, i.e., patient data (name, gender, age, date of examination), clinical data (clinical symptoms, findings from the physical examination), radiological data (results), and biomarkers data (blood test results, etc.)\n\n[END]<EOD> Dose optimization of tacrolimus in renal transplantation: a review of clinical data.\nThe long-term preservation of renal function after transplantation depends predominantly on the prevention of renal allograft rejection and, to a clinically significant degree, on the development of renal allograft damage and scarring, known as chronic allograft nephropathy or chronic rejection. Tacrolimus (FK506) is a powerful and potent immunosuppressive agent. Tacrolimus use results in less acute rejection than cyclosporine use (6-12% vs. 11-25%), but cyclosporine use results in more chronic rejection (40-45% vs. 15-25%), especially in the first few years after transplantation. Tacrolimus use results in less creatinine clearance reduction during the first year after transplantation. A major issue in the clinical use of tacrolimus is managing tacrolimus trough blood concentrations (C(0)) according to tacrolimus doses. High tacrolimus concentrations are an important cause of acute nephrotoxicity and can result in the development of chronic allograft damage or chronic nephrotoxicity and may contribute to renal allograft dysfunction and to graft loss. Proper management of high tacrolim",
        "label": 0
    },
    "912": {
        "output": "# Conclusion\nDose you find the steps of eligibility assessment in your clinical trial?\n\n# In your trial, you are asked to make the eligibility assessment.\n\n# You have to assess patient eligibility for clinical trials in patients with coronary artery disease.\n\n# After you are sure that a patient is qualified.\n\n# Once a patient has been determined as eligible.\n\n# Exclusion criteria should be applied.\n\n# After all your patient's eligibility for the trial is determined you have to state `Drug Eligibility: Eligible.`\n\n# You may ask your clinicians to use our software to determine patient's eligibility. This software is named as `Elizabeth`.\n\n# The clinicians are invited to use our software 'Elizabeth' to determine patient's eligibility.\n\n# Please note you have to set some properties to be sure that 'Elizabeth' is ready to do its job as follows:\n[INST] Installation of 'Elizabeth' is explained in the [instructions](#installation-of-elizabeth).  \n\n## Properties of 'Elizabeth':\n[INST] Installation of 'Elizabeth' is explained in the [instructions](#installation-of-elizabeth)    `data/local/elizabeth` as the folder to store output files and the folder where log data will be written, `data/logs`\n\n[INST] Installation of 'Elizabeth' is explained in the [instructions](#installation-of-elizabeth)    `data/logs` as the folder where log data will be written, `data/logs` # The above statement includes a list of patients' inclusion and exclusion criteria for each of your clinical trial.   \n\n# Please note that the software is used twice. Once to see if a trial candidate is qualified for clinical trial according to our software, second to assess the patient's eligibility to your trial.  \n\n# If you have questions or need help, please consult with the software designer (M.M).  \n\n# Please, use this software to get real patients-level eligibility.  \n\n# After you are sure of patient's eligibility for your clinical",
        "label": 1
    },
    "913": {
        "output": "_Example 1_ Output:\n![](/attachment/uploads/file/59129/8712_image_19.JPG)\n![](/attachment/uploads/file/59129/8712_image_20.JPG)\n\n_Example 2_ Output :\n![](/attachment/uploads/file/59129/8712_image_22.JPG)\n![](/attachment/uploads/file/59129/8712_image_23.JPG)<EOD> A Dual-Color Optical Probe to Discriminate PD-1/PD-L1 Interactions from Cell\u2013Cell Interactions\n\n\n\n# Introduction\nImmune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy, providing a promising pathway to prevent tumor tolerance. As a representative class of ICIs, programmed death-1 (PD) and its ligands programmed death ligand-1 (PD-L1) and programmed death ligand-2 (PD-L2) play a significant role in promoting cancer progression through the immune response . PD-1 suppresses T cell activation by interacting with its ligands and attenuates the antigenpresenting ability of immune cells . Dysregulated PD-L1/PD-1 expression in several tumor types results in an evasion of immunosurveillance and promotes cancer progression and metastasis, which is an undesirable immune evasion mechanism . PD-L1 is specifically expressed in the immune cells and tumor cells but not in tumor-related fibroblasts . As immune checkpoints, PD-L1/PD-1 signaling not only promotes tumor cell escape from immune system but also suppresses T cells in the tumor microenvironment, preventing the T cells from eliminating the tumor . Because of the important roles of the PD-1/PD-L1 axis in tumor formation, survival, and progression, blockade of this signaling with antibodies has been applied in current cancer immunotherapies and achieved promising antitumor impacts .\nPD-L1-mediated",
        "label": 0
    },
    "914": {
        "output": "For your solution, the patient and the clinical trial will be as follows:<br>\n\n[TEST] Patient\nA 46-year-old man presents with dizziness and frequent headaches.\n- He has a family history of cholesterol. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, respectively) were within normal limits.\n- The patient reported no use of lipid-lowering medications.\n- Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA,), as well as moderate stenosis in the right internal carotid artery (RICA, estimated between 40% and 50%.For the LICA,the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior \nwalls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and were predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n[/TEST]\n\n[TEST] Clinical trial\nTitle: Lifestyle Modification Programme for Patients With Asymptomatic Carotid Artery Stenosis\n\nSummary: This study randomises patients with patients with asymptomatic carotid artery stenosis, to be managed either by providing an intensive 12-week lifestyle modification programme, or standard healthcare.\n- Inclusion criteria: In",
        "label": 1
    },
    "915": {
        "output": "**Please read carefully before submitting your solution:**\nIt is very important that you understand our grading criteria and how it is calculated before you send in your solution. Any solution not meeting them will not be graded. It follows from our policy the definition of \"good\" solution (the criteria of which our authors should follow when crafting their solutions), see below, where the percentage score refers only to the assignment of the right category in each of the three problem steps.\n\n\nThe three problem steps are evaluated in the following way. We do not allow multiple submissions in our challenges. We are also unable to give out partial credit. Our experts use a custom scoring system to evaluate the submitted solutions.\n\n\n| Problem steps | Minimum number of stars| Expected solution                           |\n| -------------- | ---------------------------------------------------------------- |\n|  Inclusion criteria identification | 2 stars per included condition |\n|  Plaque segmentation | 1 star per correct segmentation (a segment is a pixel) |\n|  Plaque classification | 1 star per correct category (LRNC, calcification, fibrotic tissue) |\n|  | Total score: **3 stars**                                                    |\n\n\nYou should always have a category for each step of the problem. Every category is assigned 3 points. As you can see, it's not enough to have one correctly calculated condition or plaque, instead you need to segment and classify all conditions and segment the plaque correctly.\n\nThe stars in each problem step are subtracted if either of the two problem steps (i.e. inclusion criteria identification, segmentation and/or classification) is solved with less than 2 stars.\n\n#\n\n## **STEP 1: **Inclusion criteria identification\n\n### **Problem instructions**\n\nInput file should contain following header:\n\n```\nPatient-ID Trial-patient-id Patient-description Age \n660 LDA92_1177 43M 72 Years                100 \n661 LDA92_1211 43M 73 Years                100 \n662 LDA92_1203 57M 72 Years                095  \n663 LDA92_120",
        "label": 1
    },
    "916": {
        "output": "* 2. What are the inclusion and exclusion criteria for the clinical trial?\n\n* 2.1 The inclusion criteria for this trial are:\n- For inclusion into a clinical trial, the patient must be over 18 years old\n- The patient's neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery. - The patient was physically active.\n- The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels were within normal limits.\n- The patient reported no use of lipid-lowering medications.\n- For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n- All these results will be used to calculate the degree of stenosis, which was 80% for the left internal carotid.\n- Furthermore, it was concluded that the patient was at high risk for a cardiovascular event, as the disease of his carotid artery is associated with a high risk of stroke, as it meets the criteria for carotid stenosis (a 70% or greater reduction in the diameter of the lumen of the artery) as well as the clinical risk of the patient. \n* 2.2 If the patient meets any of the following exclusion criteria, then",
        "label": 1
    },
    "917": {
        "output": "Tutorial\n\n## Tutorial for the task: Evaluation of the efficacy of the stable ezetimibe-rosuvastatin combination in patients with primary hypercholesterolemia in achieving the target plasma LCL-C level.\n\n### \n\n## 1) Patient-level eligibility: Check the correct assessment of eligibility for the clinical trial. The assessment is based on the inclusion criteria. You should make a patient-level eligibility for each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\n## 1) Output correct assessment of eligibility for each patient, i.e., output a trial-level eligibility, e.g., `Eligible 1) for the clinical trial, i.e., output a trial-level eligibility, e.g., `Eligible 1) for the clinical trial, i.e., output a trial-level eligibility, e.g., `Eligible 1) for the clinical trial, i.e., output a trial-level eligibility, e.g., `Eligible 1) for the clinical trial, i.e., output a trial-level eligibility, e.g., `Eligible 1) for the clinical trial, i.e., output a trial-level eligibility, e.g., `Eligible 1) for the clinical trial, i.e., output a trial-level eligibility, e.g., `\n\n## 1) Patient-level eligibility: Check the correct assessment of eligibility for the clinical trial. The assessment is based on the inclusion criteria. You should make a patient-level eligibility for each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\n## 1) Output correct assessment of eligibility for each patient, i.e., output a trial-level eligibility, e.g., `Eligible 1) for the clinical trial, i.e., output a trial-level eligibility, e.g., `Eligible 1) for the clinical trial, i.e., output a trial-",
        "label": 1
    },
    "918": {
        "output": "### 3.2.2  \nWe will focus on the following factors when making the trial-level eligibility: \n\n### 3.2.2.1 \nTo begin, the subject has been determined not to be excluded from the trial. \n### 3.2.2.2 \nIf we are on the third patient note, the subject has the following data and we can infer his clinical history from the data:\n\n### Included\n- Type 2 diabetes mellitus\n- Hypertension\n- History of coronary artery disease\n- Smoker\n- Hyperlipidaemia\n- Family history of CAD: Father\n- Medication: Metformin in current use\n- Medication: Statin in current use\n- Medication: antianginal drug in current use\nWhen we move on to the patient, we will look for the following data:\n\n## Age\n- Patients between the ages of 19 and 75 years were included in the study\n\n## Sex\n- male \n- female \n\n## Ethnic origin\n- Caucasian\n\n## Body weight\n- Weight (BMI) 46\n\n## Height\n- Height 1.68\n\n## Smoking\n- Ex-smoker. 10 pack-years.\n\n## Physical activity\n- Physically active at work and in daily life with no moderate to intense physical exercise.\n\n## Diabetes\n- Type 2 Diabetes\n\n## Hypertension\n- Hypertension\n\n## Family history of premature CAD\n\n## Allergies\n- No significant allergies\n\n## Cardiovascular disease\nCardiovascular Disease\n- Coronary artery disease \nIn view of the clinical history and the patient's data, we can judge that the subject does not meet the exclusionary criteria. \n\n### 3.2.2.3 \nIf we are on the fourth patient note, the subject has the following data and we can infer his clinical history from the data:\n\n### Included\n- Type 2 diabetes mellitus\n- Hypertension\n- History of coronary artery disease\n- Smoker\n-",
        "label": 1
    },
    "919": {
        "output": "**NOTE:** **Instances with a score between 0 and 1 (0, 0.08, ..., 1) will be marked as `not relevant` but you can give them the trial level eligibility 2, if you think that they meet the inclusion criteria in spite of their low scores by giving them the trial-level eligibility `2 (Eligible)` as illustrated in the second code listing below.** \n\n<!--markdown-only--><!--README.md--><!--README_MD--><!---This is a README file. \nDO NOT EDIT THIS DIRECTORY--><!--This README file is autogenerated--><!--by the makeresume tool at <a href=\"https://zhangyao.github.io/mkt\">mkt.zhangyao.dev</a>, which makes README files suitable for GitHub. \nBecause you're editing this text, that means you're editing the code that is generating this directory. \nThe code for the generated README is stored under <em>README.md</em>. \n-->\n<!--README.md--><!--README_GENERATED--><h1 id=\"overview-and-purpose\">Overview and Purpose</h1>\n<p>\n   This library is a set of classes, objects, types, modules, and other elements for generating C# solutions to the following problems:\n</p>\n<p>\n   &nbsp;&nbsp;&nbsp;&nbsp;1. Creating an object class that implements a simple interface and provides the interface's member functions.\n</p>\n<p>\n   &nbsp;&nbsp;&nbsp;&nbsp;2. Detecting if a string is a valid integer in C#.\n</p>\n<p>\n   &nbsp;&nbsp;&nbsp;&nbsp;3. Detecting if a string is a valid number in C#<br>\n     <br>\n     and returning if it is not a number, <br>\n     or returning if it is a number and detecting if this is a scientific number or not.<br>\n     and returning if it is a number, the number type, and, if it is a scientific number, the number's scale factor.",
        "label": 0
    },
    "920": {
        "output": "</p>\n<p>\n\n![image src=\"\" alt=\"\" style=\"width:500px;height:415px;\"]()\n</p>\n\nThe file containing the question is provided [here](https://github.com/bionutrition4u/QA-Querimenta/blob/master/File_Querimento.txt).\n\n### [Task 2](/en-us/quizquestions/question/tasks/task-2/)\n\nIn this task, you need to create a variable called `isMatch` as `var isMatch = 0;` at the beginning.\nThen, use the following steps:\n\n1. Find the value of the `Triallevel_eligibility` variable for each participant.\n2. If the value is 1, the person is included in the trial; otherwise, they are not included. (It is important if the person is included in the trial, assign `isMatch = 1`, otherwise `isMatch = 0`.)\n3. Display the value of the `isMatch` variable for each participant.\n\n```\nvar isMatch = 0;\n\nfor (a = 0; a < 3; a++) {\n    if (Triallevel_eligibility == 1) {\n        isMatch = 1;\n    } else {\n        isMatch = 0;\n    }\n\n    console.log(\"Triallevel Eligibility: \" + Triallevel_eligibility +\"\\n\" ); // Outputs Trial-level Eligibility\n\n    console.log(\"Match: \" + isMatch ) // Outputs Match.\n}\n```\n\nIf you run the code, you will read:\n\n```\nTriallevel Eligibility: 0\nMatch: 0\nTriallevel Eligibility: 0\nMatch: 0\nTriallevel Eligibility: 1\nMatch: 1\n```\n\n### [Task 3](/en-us/quizquestions/question/tasks/task-3",
        "label": 0
    },
    "921": {
        "output": "Good job! (^_^)\n\n#### 5. [Episode 3] Assessment of stent delivery\n\nAfter evaluation of the patient's eligibility, you can proceed to the assessment of stent delivery stage, i.e., assessment of technical performance which is used to determine whether a stent will be placed during the next stage. \n\nLet's think step by step. \n\n> $ sudo python <filename>.py \n> $ python <filename>.py\n\n## 1. Stent delivery checklist\n\nA stent delivery checklist is designed to identify and document all conditions that may cause technical difficulty when a carotid stent is implanted.\n\nIt is recommended that 2 observers complete the checklist during the procedure.\n\nThe following is a list of potential problems or conditions during the stent delivery phase that may help the interventionist to improve the stent delivery techniques in the clinic.\n- Pre-stenting evaluation - Pre-stenting ultrasound evaluation (recommended) - Distal land marker < 1.5 mm distal to the ICA-CCA bifurcation - Significant ulceration of the target lesion defined as having total length of >6 mm.\n\n## 2. Stent delivery problems 1\n\n- Insufficient carotid puncture site is not available (e.g., aortic arch calcification, presence of prominent thoracic aorta).\n- Distal carotid access site does not allow easy passage of the delivery catheter.\n- Carotid calcification causing unsuitable bend of the delivery catheter, preventing it from entering into the distal carotid artery lumen.\n- CCA to ICA ratio 1.8 or greater.\n- Presence of carotid plaque.\n- Presence of soft carotid (plaque).\n- Stent delivery failure - Stent delivery failure in the presence of a hard or soft plaque in the proximal common carotid \n- Stent delivery failure in the presence of ulcerated or ruptured plaque in the proximal common carotid artery. \n- Stent delivery failure in the presence of ulcerated plaque in the bulb or internal carotid ar",
        "label": 1
    },
    "922": {
        "output": "## Exercise 9: Create a Data Set in the TableView\n[INST] Go to the data set you have just created and select `New Row`.\n\n[INST] On the field `Patient note` select `\"A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. His LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits The patient reported no use of lipid-lowering medications.\" as text and select `OK`.\n\n[INST] Repeat the steps for `Patient note`, as well as patient age, the last name of his parent or caregiver (first name is a random character), his blood pressure, his physical activity level and the severity of his coronary artery disease in each coronary arteries.\n\n[INST] To create a random patient note, you can change the data of patient information, such as the date of the patient visit, the first name, the last name of the patient or caregiver, the height, and the weight. \n\nA note: The same random note information is used in exercise 4.\n\n[INST] To create a patient note with a random number, we will replace the note with a random number, whose value is between 0 and 999999999. To create a random number, select in the menu `Computer >Random number`.\n\n[INST] Then, you will enter in an input field `Random number: <enter number (e.g., 10000 or 900000000) >` the random number. Now, your clinical trial will have a second version with a random patient note.\n\n\n## Exercise 10: Use Custom Filtering in the Data View\n[INST] You will open a tab \"Data View\" by clicking the \"Data > Data View\" in the menu.\n[INST] You will create a custom filter by right-clicking the",
        "label": 0
    },
    "923": {
        "output": "# Discussion\nIn the first patient note, the patient meets the inclusion criteria, but is excluded on the grounds of the trial-specific exclusion criteria (e.g., previous use of lipid-lowering drugs). In the clinical trial, patients meeting the trial-specific inclusion criteria are excluded from the trial (e.g., patients receiving lipid-lowering therapy). In this patient, trial-level eligibility is determined as 0) Excluded. So the clinical trial recruitment assistant can proceed to the next information-seeking for the next patient.\nIn the second patient note, the patient does not meet the inclusion criteria and cannot be included in the clinical trial. Here, trial-level eligibility is determined as 1) Not relevant. So the administrator cannot proceed to the next information-seeking for the next patient.\nIf you had missed `Trial-level eligibility:` in the first line (patient notes) and in the last line (clinical trial), just add this code by using `if` condition.\n\n## Export\nIn the `Trial-level eligibility:` code block in the last line, the `Trial-level eligibility: ` statement is a kind of export statement, so you can get the trial-level eligibility as a string, e.g., `Trial-level eligibility: 0,`.\n<EOD> Enhanced Antibiotic Sensitivity through Optimized Culture in Capsules\nStrain improvement is performed to improve the productivity of a target strain, but such improvement is not always achieved. This is because the strain used for strain improvement usually shows a higher fitness in the fermenter condition than in its natural environment, which generally consists of a mixture of carbon sources (e.g., glucose and xylose in corn-milling- and corncob-milling-derived hydrolysates) and inhibitors (e.g., furfural, vanillin, and ferulic acid). Therefore, to obtain an improvement in productivity in such harsh conditions, it is important to improve the strain\u2019s physiological function. To achieve this improvement, the present study used CapsuleRIC, a capsule robot, which has previously been successful in enriching the microbial",
        "label": 1
    },
    "924": {
        "output": "<EOD> Fas\u2010associated phospho\u2010protein with death domain\u2010like (FADDL) up\u2010regulates hypoxia\u2010induced erythroid differentiation by stimulating heme biosynthesis\nDuring maturation in red marrow (RM), erythroid precursors undergo hypoxia\u2010dependent apoptosis, and the survivors give rise to enucleated erythrocytes. Apoptosis is blocked and enucleation is accelerated when RM\u2010derived progenitors (erythroblasts) are placed under normoxic conditions. These effects are mediated by the protein Fas\u2010associated phospho\u2010protein with the death domain (FADD). The FADD homologue FADDD (form of FADD with death domain\u2010like), which shares 62.7% amino acid sequence similarity with human FADD, differs from FADD by its long C\u2010terminal tail. Previously, we showed that FADD and FADDL (form of FADD with death domain) are associated with erythroblasts during maturation, FADDL being less abundant. Here, we evaluate whether FADDL could affect erythroblast maturation, focusing on the effect of FADDL on the modulation of hypoxia\u2010stimulated enucleation that is induced during erythroid differentiation. Results indicate that FADDL stimulates hypoxia\u2010stimulated enucleation by regulating heme biosynthesis. Expression of iron storage protein transferrin receptor 1 and mitochondrial iron transporter (MTT) in normoxic conditions was down\u2010regulated by FADDL over\u2010expression and was restored to levels comparable to hypoxic conditions by knockdown of FADDL. Our results suggest that FADDL regulates the production of iron\u2010sulfur clusters involved in mitochondrial heme synthesis, which is critical for enucleation during hypoxia\u2010induced erythropoiesis.<EOD> Molecular Docking and Screening of Novel Anti\u2010Human Respiratory Syncytial Virus Drug Candidates\nHuman respiratory syncytial virus (HRSV) is a respiratory pathogen that causes severe bron",
        "label": 0
    },
    "925": {
        "output": "<EOD> The use of a digital camera to diagnose and manage a retinal hemangioma.\nWe describe a technique using a digital camera to take images of the fundus to diagnose and monitor retinal hemangiomas.<EOD> .\nCarcinoma of the cervix is the second most frequent cause of cancer among women in the world. Epidemiological data indicate that 500 000 new cases are diagnosed each year. The principal therapeutic modality in the treatment of carcinoma remains surgery or radiotherapy, and in the future, one possible approach for the treatment of the diseases should be gene therapy. We describe the most important therapeutic procedures in gene therapy for urological tumors, and review its present state, as well as possible clinical applications for genetically-engineered carcinoma of the cervix.<EOD> Rate-Independent Measurement of Transmembrane Potential with Microparticle Electrophoresis\n\nA novel rate-independent electrokinetic technique for the measurement of transmembrane potential was demonstrated. To enhance the method's signal-to-noise response and reliability, the effect of particle concentration and electrolyte ionic gradient were systematically investigated. The transmembrane potential of biological cells was measured successfully with the aid of the proposed microfluidic particle separator.\n\n# Introduction\nMeasurement of transmembrane potential is of paramount importance in fundamental science and biological engineering [bib_ref]  Ion channels, permeability and water transport across biological membranes, Finkelstein [/bib_ref]  [bib_ref]  A novel micromotor-based microdevice for rapid and selective isolation of biological cells..., Xuan [/bib_ref] . Due to the difficulty in directly recording transmembrane potential by electrodes inserted into a cell or sample [bib_ref]  Dielectric properties of mammalian cell membranes from 100 Hz to 10 MHz:..., Merla [/bib_ref]  , a major effort is directed at electrokinetic-based methods such as electroosmotic [bib_ref]  Capillary-electrophoretic characterization of the electrophoretic mobility and electroosmotic flow behavior in a..., Kawamura [/bib_ref]  and electrokinetic inertial phenomena [bib_ref]  Transport in an elect",
        "label": 2
    },
    "926": {
        "output": "<EOD> Development of the concept of nursing theory.\nThis article traces changes in the way theory has been defined over the years. It shows how nursing theories have changed from being primarily prescriptive and descriptive to being concerned with the interlocking and interactive nature of concepts, the meaning assigned to these concepts, and methods of studying these complex processes.<EOD> The Mendelian Disposition of Rheumatoid Arthritis\nThe hypothesis that rheumatoid arthritis may be a condition in which the inheritance is Mendelian is discussed and the evidence given in support of the theory. There is no evidence to support the idea that the inheritance of the disease is autosomal recessive and no suggestion has been put forward that the hypotheses may be based on the existence of two alleles in the same gene. It is concluded that rheumatoid arthritis may be regarded as \u201cpolygene\u201d and \u201cpleiotropy\u201d in the sense that it occurs with very considerable frequency in the population as a whole but is by no means rare. There are many loci for which there seems to be a genetic contribution to the occurrence of rheumatoid arthritis and the effect of each individual locus is very small.<EOD> A Novel Efficient Computational Method for Estimating the T-2 Toxin Concentration in Animal Feed\n\nA novel mathematical-based computational method was established to detect low-level T-2 toxin content in animal feed containing different combinations of the T-2 toxin analogues HT-2 toxin, T-2 triol, T-2 tetraol, neosolaniol, and fumonisin B 1 . The mathematical model is designed as a series of first-order and second-order mathematical equations. The equations describe the mathematical relationship among two toxins in the model, the weight of toxins, and the weight of feed material. The model was verified using in vitro toxin absorption and excretion in animal feed samples. The experiment measured changes in the T-2 toxin concentration using a rapid gas chromatography-mass spectrometry method within feed samples that were incubated with piglet feces at 37 - C for 12 h. Feces were collected from three normal pigs and from pigs that received different tox",
        "label": 1
    },
    "927": {
        "output": "[REPEAT]\n\nIMPORTANT NOTICE: Some information in these examples might violate your institution's confidentiality rules or local regulations. Please change it to comply with your local environment.\n\n---\n\n## Step 3: Clinical Research Coordinators\n\n[CRCs] Hello. You are a clinical research coordinator managing multiple clinical trials. Your main tasks are to recruit patients, schedule appointments with patients to visit the site for screening and onboarding, inform patients about the protocol, and make sure all the clinical trial records are updated regularly. You are using a clinical trial management system (CTMS) system, the OpenClinica platform. It provides clinical trial management. \n\nThe recruitment of eligible patients is a critical task in clinical trials. Clinical Research Clinical Research Coordinator can help patients enrollment in trials, assist doctors and nurses to provide high quality care, help patients adhere to the clinical trial protocols for the safety, and ensure patients can complete research protocols and achieve good outcomes. \n\nBy monitoring patient enrollment status per subject, you can keep track of on-target progress and identify any issues with enrollment. You can determine the number of active and inactive patients and assign patients to specific recruitment processes for different clinical trials, such as an online or hard copy of patient consent forms, in order to meet regulatory requirements. \n\nThe CTMS system supports many standard clinical trial features, including enrollment tracking and management and managing consent forms, and allows CRCs to customize them to meet the needs of their trials. \n\nHere is the clinical trial screening process: \nTitle: Short Physical Activity Program in Coronary Artery Disease.~\n\nScreening Process:\nOnboarding the patients through eligibility assessment\nScreening of patients' medical status\nRegistering patients into trial databases\nConducting the Informed Consent\n\nTo manage onboarding screening processes, you should schedule an exam by assigning a patient or group of patients to each clinician (physician, nurse, midwife, etc.), then use OpenClinica's integrated schedule feature to record the date or schedule a trial-specific date in the",
        "label": 0
    },
    "928": {
        "output": "Note. To execute the code, use the code editor for the notebook type `ipynb`. When executing, the program is run in the Python interactive session. If the program is run incorrectly, the run icon of the code editor will be displayed yellow. Refer to the following Help -> Advanced -> Run Notebook link for detailed help on how to run the code. {E1}\n\nExpected output\n![](http://sci-learning.org/assets/images/v2/book/book_data1/b_10_ex3.png)\n\n<EOD> Charged-particle beam formation in a laser electron accelerator.\nIon-acceleration physics in a laser electron accelerator (LEA) is studied. The electron plasma expanding from a circular plasma focus of a pulsed plasma lens was used as a plasma grating to guide the laser beam to a relativistic amplitude, then to accelerate a plasma-driven electron beam with a field of about 300 kV/m to a relativistic velocity. The LEA's electron beam and laser beam were detected by a time-gated photo-multiplier. The results show that, compared with a conventional laser acceleration method, the laser and the electron beam are accelerated one after the other. The injection electron beam does not necessarily have a high transverse spatial energy density, but a strong driving laser beam is necessary to drive an LEA.<EOD> Assessment of microleakage in composite restorations: a review article.\nIn the last 60 years, dental restorative materials have been developed for clinical application. The aim of this review is to emphasize the role of microleakage when dentists try to restore an acid-attacked tooth under stressful condition. Microleakage is one of the major concerns involved in the polymer-tooth-enamel interface, and it is a major problem with direct composite restorations. The current study focuses on various materials, the method of assessment of microleakage, and its implications in the dental restorative and dental bonding systems. In all of the articles found on search engines like PubMed/National Library of Medicine, Embase, and Google Scholar, in the years 2000-2018, only",
        "label": 0
    },
    "929": {
        "output": "<EOD> The role of intraoperative ultrasound in localizing residual tumor and guiding tumor excision in thyroid carcinoma\nThyroid carcinoma is a common cause for reoperation in the neck. The purpose of the study was to correlate the intraoperative findings of residual and recurrent tumor and to determine the indications for frozen section examination and the utility of intraoperative ultrasound in thyroid and neck cancer surgery. All surgeries over a two\u2010year period where intraoperative ultrasound was used for thyroid surgery evaluation were reviewed to determine the incidence and predictor variables of residual tumor found at surgery. Ninety\u2010two patients were evaluated with intraoperative ultrasound: 60 underwent thyroidectomy, 16 total parathyroidectomy, 14 thyroid cancer with lymph node dissection, and 2 thyroidectomy with neck dissection. Thirty\u2010six thyroidectomies required frozen section histologic evaluation of the surgical margins. A total of 45 ultrasonic examinations revealed suspicious ultrasonic features and were correlated with intraoperative surgical data. Nine of 36 thyroidectomy specimens had tumor at the site of the surgical margin or other unexpected site. Seven tumors were recognized on frozen section. The remaining two tumors could not be identified at the time of surgery. The predictive variables for residual diseases include ultrasonic suspicion at surgical margins, tumor extension to the neck lateral to the thyroid, and lymph node involvement. These results indicate that intraoperative ultrasound is important in thyroid and neck cancer to localize residual tumor and to guide tumor excision. It may reduce the need for frozen section and shorten the operative time. \u00a9 1996 Wiley\u2010Liss, Inc.<EOD> Isolation and functional analysis of an active recombinant SARS-CoV-2 main protease\n\nThe coronavirus main protease, commonly known as SARS-CoV-2 main protease (M pro ), as a homodimeric complex is essential for the viral replicase poly",
        "label": 0
    },
    "930": {
        "output": "_Note:_ When you press the 'Check All' button at the end of the first column of the screen, the patient will be excluded in the following columns.\nIf the result is 0 (excluded), select 'Yes' in the box just above the patient's note to include it in the next trial. If the result is 1 (not relevant), select the box just below the patient's note and the patient will be automatically included in the next trial. Only if the result is 2 (eligible), do not select anything and you did the correct assessment. \n\n\n\n```\nCheck All\n<form method=\"post\" action=\"?r=register\">\n<input type=\"checkbox\" name=\"patients[]\"/>\n<input type=\"checkbox\" name=\"patients[]\"/>\n<input type=\"checkbox\" name=\"patients[]\"/>\n<input type=\"checkbox\" name=\"patients[]\"/>\nCheck All\n<!-- for more information, read the FAQ section below -->\n[INST] <!-- <button onclick=\"show_hidden_instructions();\">Show instructions</button> -->\n<button onclick=\"show_hidden_form();\">Show form</button>\n<button onclick=\"hide_hidden_form();\">Hide form</button>\n<input type=\"submit\" value=\"Done\">\n</form>\n```\n\n\n\n# FAQ\n\n\n\n<!-- Begin FAQ -->\n\n<!-- Markdown format copied from https://github.com/bhagwat/angular/blob/master/demo/README.md  -->\n### What is 'check all' button?\n\n-  If you choose the correct answer for the inclusion criterion, you should check it and press \"check all\".  \n\n-  Only when you select all checkmarks in column 1 and press check all are you able to select patients for further assessment.  \n\n```js\nvar button_selector = function(){\n    if ($(\"checkbox:checked:not(#checkAll):not(#checkAllAll):not(#checkAllAllAll):checked\").length > 0){\n        $(\"#checkAllAllAll\").click();\n    } else {\n        $(\"#checkAllAllAll\").prop(\"checked\", false);\n        $(\"#checkAllAll\").click();\n    }\n} // end of button_selector",
        "label": 0
    },
    "931": {
        "output": "Good luck! And don't hesitate to ask, if anything is unclear.\n\n[INST]\n\n# In-depth discussion of the exercise\n\n## Summary statement\nThis exercise is a good example with many realistically structured cases, and therefore we recommend that you read through the materials. This exercise is especially good at identifying the differences in eligibility between the trial and the cases in the first place, and secondly, examining if a patient meets the inclusion criteria in an ideal manner (e.g., the answer for 19 and 26, which are not suitable for trial recruitment). The exercise provides an explanation for patients who are not excluded on the grounds of the selection criteria. It is also good for familiarizing yourself with the general idea of the clinical trial, and eligibility and how to assess patient characteristics based on their cases. Therefore, let's go through the exercise!\n\n## Comment\n\nWhen you are looking for a patient who is suitable for trial recruitment, you need to check whether the patient is eligible because of the inclusion and exclusion criteria. In the trial, the eligibility is confirmed based on the notes, but in reality, we need to check the actual conditions based on the interview. Therefore, the real situation may seem less ideal to us when we assess the eligibility based on the actual situation. In the case of this exercise, you need to read the information about the trial and the case first and then see if the patient has the eligibility. Let's look carefully at the criteria for each trial.\n\n## Comment\n\nFirst, we will check out a clinical trial with inclusion and exclusion criteria. If the inclusion criteria are met, move to the next step. If they are not, move to the exclusion criteria if applicable or return and adjust your judgment. Let's check if we meet the criteria.\n\n## Inclusion criteria:\npatients with CAD patients with a family history of CAD\n\n## Exclusion criteria:\npatients with other heart diseases patients without a family history of CAD\n\n## Inclusion criteria\n\n### 1) History of dyslipidemia\n\nPatients with CAD have hypoalbuminemia, hypocholesterolemia, hypertriglyceridemia, and low apolipoprotein A1,",
        "label": 1
    },
    "932": {
        "output": "Clinical trial 00001, for simplicity here is shown without a title: \nTitle: 00001\n\nSummary: To determine the benefit of pravastatin sodium on clinical outcome among patients who have undergone coronary angioplasty.\nInclusion Criteria: Patients 40 years of age or older and having one or more documented coronary artery stenosis.\nExclusion Criteria: The following conditions are absolute contraindications for participation in this study, including acute myocardial infarction/angina pectoris and angiography. Patients should be free of these conditions upon entering the study for 5 days or longer (acute myocardial infarction) and 2 days or longer (angina pectoris) or for 24 hours (angiography).\n\nNotes: Trial-level eligibility is: `Trial-level eligibility: 2) Eligible.`. [INST] Your input is:\n```\n>> Trial-level eligibility: 2\n```\n\n## Exercises\n\nBefore we proceed with practice, note that you should use this notation for input variables as the following, e.g., `Trial_level_eligibility: 2`.\n\n## 1. Add the following variables to the existing [inst] file:\n- `age` is 68.000.\n- `gender` is 1\n- `hypertension` is 0\n- `dyslipidemia` is 0\n- `hypercholesterolemia` is 0\n- `heart_rate` is 93.\n\n## 2. Run the following command:\n```\n$ python generate_srs.py Expected_output_for_Exercise.txt Trial_level_eligibility > expected_output\n```\n\n## 3. Make sure the output file you get is like this as the example output:\n```\n  SRS Trial 00001\n  # Patient # 91126\n    Trial-level eligibility: 2\n    Age: 68.000 (68)\n    Gender: 1 (female)",
        "label": 1
    },
    "933": {
        "output": "---\n__HINT:__ If your file contains several variables, i.e., multiple lines of output in `trial-level eligibility,` you can repeat the `f` function several times by putting its content inside the `for` loop, in the `f{` and/or `f}` (or just in the `f` function, too.)  \n```{r runitall}#repeatedly calculate patient's eligibility \n  trial_level_eligibility <- lapply(c(\"0\",\"2\"), function(inclus){ \n      trial_level_eligibility_1<{ \n          trial_level_eligibility = dataset %>% \n            left_join(rbindlist(map(c(\"inclus\", \"Excluded\"), \n                               list(get_string_from_the_input_file, \n                                    get_trial_level_eligibility_out))), \n                        by = \"patient\", suffix = \"_\") %>% \n            set_colnames(c(\"patient\", \"trial_level_eligibility\")) %>% \n            filter(fread_string_column(\"patient\") %in% \n                  fread_string_columns(\"inclus\", \"patient\")) %>% \n            group_by(patient) %>% \n            mutate(trial_level_eligibility = as.factor(trial_level_eligibility))\n      } \n      }) \n      trial_level_eligibility = try(lapply(trial_level_eligibility, \n                                    bind_rows), \n                               error = \"Error occurred in calculation\") \n  }\n```\n---\nIn this tutorial, we will calculate the patient's eligibility based only on patient ID and trial-level eligibility. \n``tidyverse`` (https://tidyverse.org/) and ``fread`` (https://github.com/pather/ fread) packages will be used for the calculation. The output of trial-level eligibility based on patient ID and trial-level eligibility has a specific structure. The code structure of the output is shown below \n```{r}\n  example_output <str_reverse(c(",
        "label": 0
    },
    "934": {
        "output": "<EOD> Detection of mosaic aneuploidy in human eggs: a possible mechanism for the high rate of chromosomal aberration in human oocytes.\nThe incidence of chromosome deletion was studied in 1251 human eggs by using fluorescence in situ hybridization (FISH). The deletion of the long arm of chromosome 1 was specifically tested as an example. We found that 2 of 653 eggs tested had partial or complete monosomy of chromosome 1q, and 11 of 366 eggs had partial or complete de novo loss of the short arm of chromosome 18. By using DNA probes for specific chromosomes, we examined deletion of the long arm of chromosome 1 in the oocytes with 1q- ascertained by FISH analysis. The results indicated that deletion of the long arm of chromosome 1 was also present in the eggs with normal 1q homologs ascertained by FISH. These findings suggest that deletion of a chromosomal segment occurs in both normal cells and in the subpopulation of oocytes with aneuploidy, and the loss of long arm of chromosome 1 may arise via a mosaic aneuploid state. In some oocytes, partial de novo deletions of chromosome 1 are corrected by further chromosomal segregation to nonviable, nonfertilizable eggs, and the remaining subpopulation of oocytes with normal 18 homologs was also derived from the mosaic aneuploid cells.<EOD> NON-PARAMETRIC TESTS FOR POPULATION DYNAMICS: PROPAGULATION COEFFICIENTS AS ILLUSTRATION.\nThe paper shows how new non-parametric tests or existing tests can be used to assess the significance of parameters, particularly propagation rate in models of population dynamics. First, we present an analysis of the chi-square statistic based on logarithmic link function for various combinations of two-level and three-level designs. Under the constraint that the observed values and the expected values of the parameters come from normal distributions with specific variance, it is shown that a set of non",
        "label": 2
    },
    "935": {
        "output": "[CONT] \n\nThe clinical rule evaluation system should be defined as follows: `R1: R1: `, e.g., `R1: Include`. `R2: R2: `, e.g., `R2: Exclude`.[/CONT]\n\n## Rule 2 RULE A. AGE\n```\nIF $Age >= 46 THEN RuleType:Inclusion; RuleWeight: 1;\nElse RULE A. AGE\n```\n`RuleType` is set in the attribute `RuleType` and `RuleType` was assigned either `Inclusion` or `Exclusion`. `RuleWeight` is set in the attribute `RuleWeight` and is a real number. The rule expression is placed inside the RULE A. statement with the rule type set in the attribute `RuleType` (e.g., `RuleType: Inclusion`) `RuleType`: `RuleType` will set the rule type in the attribute `RuleType`.\n\n## Rule 3 RULE B. LDL-C LEVEL\n```\nIF ($LDL-C < 54) THEN RuleType: Inclusion; RuleWeight: 9;\nOR RuleType: Exclusion; RuleWeight: 1;\nELSE RuleType: Inclusion; RuleWeight: 1;\n```\n`RuleType` is set in the attribute `RuleType` and `RuleType` was assigned either `Inclusion` or `Exclusion`. `RuleWeight` is set in the attribute `RuleWeight` and is a real number. The rule expression is placed inside the `ELSE` statement for `RuleType= Inclusion`, and if is not preceded by `OR` statement between rule A and rule C, which indicates it is the last rule evaluated.\n\n## Rule 4 RULE C. NECK AUCTURALIZ-TION\n```\nIF ($NeckAucturaltion <3+/6+) THEN RuleType: Exclusion; RuleWeight: 1;\n```\n`RuleType` is set in the attribute `RuleType` and `RuleType` was assigned either `Exclusion` or `Inclusion`. `RuleWeight` is set in the attribute `RuleWeight` and is a real number. The rule expression is placed inside the `IF` statement with a condition set",
        "label": 1
    },
    "936": {
        "output": "## Tutorial on Efficiency evaluation of two-step random sampling\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nHere is the clinical trial: \nTitle: Cardiovascular Events in GnRH Agonist vs. Antagonist\n\n\nSummary: The purpose of this study is to test if the use of Degarelix for 1 year associated with a lower rate of cardiovascular toxicity compared",
        "label": 0
    },
    "937": {
        "output": "Your task is to complete the Python file named trial_input_eligible.ipynb and to make it readable using the format of IPython Notebook. You may also find it very useful to make it very readable by inserting comments and code tags.\nYou can find a complete example of how the problem was solved at the following link:\n [TIPS]\n\n# Your solution should resemble the example. You don't have to use a Jupyter Notebook. You can create a regular Python file.\n# You can create a regular Python file, like the example\n\n# [B]\n\n# Your solution should resemble the example. You don't have to use a Jupyter Notebook. You can create a regular Python file.\n# You can create a regular Python file, like the example\n\n# [C]\n\n# Your solution should resemble the example. You don't have to use a Jupyter Notebook. You can create a regular Python file.\n# You can create a regular Python file, like the example\n\n# [D]\n\n# Your solution should resemble the example. You don't have to use a Jupyter Notebook. You can create a regular Python file.\n# You can create a regular Python file, like the example\n\n[E]\n\n# Your solution should resemble the example. You don't have to use a Jupyter Notebook. You can create a regular Python file.\n# You can create a regular Python file, like the example\n\n[F]\n\n# In each notebook, you should create your file and upload it.<EOD> Transposable elements regulate abiotic and biotic stress responses in rice\nDespite being the most important staple crop, rice is sensitive to biotic and abiotic stresses such as drought, which negatively affects agricultural productivity. The advent of genomic approaches such as genome-wide transcriptomic analysis has identified a large list of transposable elements (TEs) that are differentially expressed under biotic and abiotic stress in rice. This review emphasizes the recent studies that investigated the involvement of TEs in the regulation of various stress-related genes in rice plants. The functional characterization of TEs has provided new insights into their role in the epigenetic regulation and gene expression. The character",
        "label": 0
    },
    "938": {
        "output": "<a href=\"index.html\" class=\"outlook-autocmd-ui\">a</a>\n<a href=\"#help\" title=\"Help\">?</a>\n<a href=\"documentation/index.html\" class=\"outlook-autocmd-ui\">c</a>\n<a href=\"documentation/overview.html\" class=\"outlook-autocmd-ui\">d</a>\n<a href=\"documentation/index.html\" class=\"outlook-autocmd-ui\">e</a>\n<a href=\"documentation/getting-started.html\" class=\"outlook-autocmd-ui\">f</a>\n<a href=\"documentation/guidelines.html\" class=\"outlook-autocmd-ui\">g</a>\n<a href=\"documentation/history.html\" class=\"outlook-autocmd-ui\">h</a>\n<a href=\"documentation/inclusion-criteria.html\" class=\"outlook-autocmd-ui\">i</a>\n<a href=\"documentation/introduction.html\" class=\"outlook-autocmd-autocmd-autocmdocmd-specialist.  `i.</a physicianocmd patient.autocmd`a trialist`patient patient and the patient andmd autocm trial patient. `patient trials trials`patient-eligible patient.\nAngi`patients as a patient`s history or the a person's-patient's trial's patient's medical eligible physician trial: Patient's`s ageing/eligible physician.\n[patient, clinical specialist. Medical condition. Ineligible patient's trial.\nPatient's eligible patient-el trial patient-clin 'nur trial-eligible patient for the clinical eligible`s criteria trial.\nMedician patient-eligible eligible and is the trial.\n[patients` eligible patient. A patient with trial for trialist eligible patient and is eligible patienteligible to a patient trial, trial eligible patient. In the clinician autable patient.\nMed patient.\nass trial.\npatient, eligible clinician patient's",
        "label": 1
    },
    "939": {
        "output": "#### Clinical-Trials::Coder::EL::V027::0\nThe first argument, the trial name, the second argument, patient note note and the third argument a trial-level eligibility are assigned.\nThe output is a hash reference for the trial, containing a field for the patient note and a hash reference for a trial-level eligibility with the fields trial, subject, patient's eligibility, note and note score.\n\n|     Note         | Patient's eligibility      | Excluded         | Eligible         | | score           | note-ref        | note               |\n| :----------------: | :-----------------------: | :------------------: | :----------------: | :----------       | :------------------: |\n| trial              | #<Hash:0x000000003318C840: 2996 bytes>| #<Hash:0x000000003318B080: 12 bytes> | #<Array:0",
        "label": 1
    },
    "940": {
        "output": "You can choose from  to make your final selection. [inst]\n\n![Trial-by-trial assessment of clinical trial eligibility.](img/03-experiments/clinical-trials/001-Trial-eligibility-table.png)\n\n![Trials that did not meet the inclusion criteria.](img/03-experiments/clinical-trials/002-Trial-eligibility-table2.png)\n\n![Trials that meet the inclusion criteria.](img/03-experiments/clinical-trials/003-Trial-eligibility-table3.png)\n\n![Trials that met the inclusion criteria but did not meet the exclusion criteria.](img/03-experiments/clinical-trials/004-Trial-eligibility-table4.png)\n\n## Test your program by generating the following table (the patient note should be changed)\nPatient Name:\n\n```\nJames Robertson, 28, male.\n\n```\nPatient age:\t        34 years\n\n```\nBlood pressure:\n\n```\nsystolic pressure, mmHg: 130\ndiastolic pressure, mmHg: 70\n\n```\nEjection fraction (EF):  55%\n\n```\nTreatment\n\n```\nMetoprolol 200mg/day\nExenatide 10\u03bcg/2 weeks\n\n```\nFamily history of CAD, hypertension, diabetes mellitus? : \n```\nHalpahalcobacter pylori infection (H. pylori status)?\n\n```\nnegative\n\n### The output of the program\n\n```\nPatient ID:\t158057921020156066422188972193\nTitle\t: A 28-year-old male comes for an outpatient appointment at the clinic\nYear \t\t: 2015\nRace: White\nGender: Male\n\nPatient name: \n James Robertson\n Patient age:",
        "label": 0
    },
    "941": {
        "output": "### Examples\n- You are in the assessment of eligibility of a clinical trial targeting a subject with a clinical condition, such as dyslipidemia.\n- You should first check whether this subject fits the inclusion criteria of the trial. We assume that you find the subject meets all the general inclusion criteria in.\n- Suppose that this subject doesn't match both (1) Exclusion criterion (1) 2): 8), in particular the subject has coronary artery disease  and is excluded (4) Due to other clinical trials targeting the same subject condition, you should check if all the exclusions apply in the previous trials. We consider that the history of previous stroke is considered to be met the exclusion criterion in this trial. Therefore, you should also exclude the subject.\n- You can also think that this subject matches all the trial's inclusion criteria:\n- Angina as an Inclusion criterion (1) 1): 1, such as Canadian Class III angina Canadian Cardiovascular Society (CCS III), Canadian cardiovascular society, which the patient is currently being treated;\n- Myocardial infarction as An inclusion criterion (1) 2): 2.\n- Treatment with statin (An inclusion criterion (1) 3): 3; In this example, you can find the subject currently receiving a statin.\n- Coronary artery disease as An inclusion criterion (1) 4): 4; The subject meets the coronary artery disease as \u2265 70% stenosis.\n- Age as an inclusion criterion (1) 5): 5, is > 60 but < 70 years old.\n- Dipyridamole thallium stress test as An inclusion criterion (1) 6): 6.\n- Ejection fraction \u2264 35% as An inclusion criterion (1) 7): 7. [Inst=Instruction]\n- You also check both the exclusion criterion (1) 1): 1and the exclusion criterion (1) 2): 2. If the subject doesn't meet the exclusion criterion (1) 2: 2, the inclusion criterion (1) 1) remains. Therefore, el",
        "label": 1
    },
    "942": {
        "output": "## R code\n# We load the packages and read the patients # and the clinical trial from a .csv file # patient_data <-read.csv(\"D:/GitHub/patient_note.csv\", sep=\";\", row.names=\"Patient_ID\") # # the file contains data of our patients and we print # the first 3 rows # head(patient_data) # # We now read the clinical trial from its .csv file 0 0 2 ))))\n\n## # the file contains clinical trial data and we print # the first 3 rows of the data # print(clinical_trial_data)\n\n## # print two patients, one eligible and a 0) Not relevant #\n\n## # eligible\nPatient_ID Patient_ID\n\n## 0) Not relevant\nPatient_ID Patient_ID<EOD> Influenza Vaccination of Healthcare Workers in the UK during Lockdown for COVID-19: An Analysis of the 2020\u20132021 Vaccination Season.\n\n [bib_ref]  Vaccination coverage among front-line health care providers working in long-term care facilities..., Nerandzic [/bib_ref]  [bib_ref]  COVID-19 and HCWs: What happens when those who care take care of..., Whitby [/bib_ref]  [bib_ref]  COVID-19 and HCWs: What happens when those who care take care of..., Whitby [/bib_ref]  [bib_ref]  SARS-CoV-2 infection among healthcare workers of a tertiary hospital in the beginning..., Cunha [/bib_ref]  [bib_ref]  Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BEI-2526: A phase 1..., Yang [/bib_ref]  \n\n# Methods\nWe analyzed immunization reporting data routinely captured and transmitted by Cerner systems across England as part of the NHIS. Health Evaluation and Monitoring software (HEMs) was developed by Cerner in 1990 and the immuno-specific software, Cerner Immunization Management (CIM), to automate immunization reporting and improve outpatient immunization delivery. CIM collects patient-specific information such as demographic data,",
        "label": 0
    },
    "943": {
        "output": "```\n<EOD> .\nIn 1 case of laryngeal cancer with multiple lymph node metastases, clinical N2 in the left supraclavicular region and clinical N1 in the right supraclavicular region following radiation therapy, surgical resection of clinically extracapsular enlarged nodes in post-operative scar tissue were attempted. Postoperatively, the enlarged nodes were not recognized as N2a tumor according to their appearance. Postoperative histology of the enlarged nodes revealed pathological N2b in the left supraclavicular region and pathological N1 in the right supraclavicular region. All pathological findings were pT1N2pN0M0 squamous cell carcinoma. Radiation therapy has been generally believed to be ineffective for metastatic lymph nodes. However, we suggest local radiation therapy should be indicated in some selected cases of laryngeal cancer in the early stage even though there are metastatic lymph nodes clinically.<EOD> A prospective randomized trial of the effects of low-dose radiation on acute lymphoblastic leukemia.\nThe effects of low-dose radiation on the clinical course of childhood B-acute lymphoblastic leukemia (ALL) were studied in the context of a phase III randomized trial of the chemotherapy program (BFM-90) of the Berlin-Frankfurt-M\u00fcnster (BFM) Medical Group for ALL. For the current publication, 129 new (de novo) and 38 secondary (i.e., relapsed or refractory) B ALL patients were compared regarding time to relapse, overall survival, late effects and genetic toxicity, both from the start of initial chemotherapy (1994) and with regard to long-term effects (2013). The effect of whole body exposure to low-dose radiation was studied in the initial phase of the ALL trial of the BFM-group (BFM-83), in which patients had been randomized to receive whole body irradiation before the first chemotherapy cycle, either to prevent the occurrence of the \"leukemia-initiating event\" in the context of the hematopoietic stem cell",
        "label": 0
    },
    "944": {
        "output": "---\n## C2-P177\n*Exercise 4* [C2](https://github.com/jiangzhen3031/KnowledgeMap-papers-py)\n\n*Exercise 4: Export a dataset from the Knowledge Graph using Neo4j *\n\n\nDownload the Knowledge Graph to a local Neo4j instance and then use `neo4j-docker` to start a Neo4j container.\n# Download the Knowledge Graph\n\nFrom the KM page or your local Neo4j, enter the knowledge graph `https://knowledgemap.github.com/knowledge_model_v1.0.2.bzl` in the address bar, click on the \"Dataset\" tab in the menu (top right), select the \"Dataset version\", the location of the dataset export file, and the destination location of the Neo4j data folder. (The file name can be specified, e.g., \"KM-0.2.6-180925_0000.json\" and \"KM_026_180925_0100.tsv\"). (The file size is also an option.)\n\nThe Knowledge Graph file will be stored in the Neo4j data folder (for example, `data/KM-0.2.6-180925_0000.json`).\n\n![download_knowledge_model](img/km/download_knowledge_model.png)\n\nTo export the dataset, right-click and select the \"download\" function. \n\n![download_dataset](img/km/download_dataset.png)\n\n### Dataset export\n\n1. In this example, we will export the dataset in the `KM-0.2.6-180925_0100.tsv` file from the KM graph to a local Neo4j instance, and the filename will be stored in the `tsv.txt` file. First, we need to download this file by using the \"Export\" tab on the Knowledge Graph website page.\n2. Open the KG file into the Neo4j desktop file explorer, then right-click and",
        "label": 1
    },
    "945": {
        "output": "[TUTOR] Here is a brief tutorial for using GPT-3 to solve your programming tasks:\nThe use of GPT-3 to create code in R is quite simple and does not require special skills. To generate code, just tell it to generate code in R and add the input data to the training dataset. Also, the generated code can be used to solve your programming problems in R, and some pieces of code can be used for debugging, which is the most common use case.\nTo use GPT-2 for generating code in R, run the following code:\n\n```\nlibrary(pluma) library(readr) library(nnet) df = read_csv(file = \"data/20.csv\") new_df = df %>% select(Blood_pressure_systolic, Blood_pressure_diastolic, ICP_brain, Lactate) dataset = dataset(new_df) # make a dataset and pass the dataset to the R code generator library(pluma) code = pluma::gpt() code(code = 1:5000, \"generate r code\", dataset = dataset) ```\n\nAfter you run the code above, you will see the generated code. In this example, we have generated the following (5000) pieces of code - the numbers indicate the number of the generated pieces of code. It may take a lot of time to generate all of the codes, so we suggest you generate them by blocks instead of all at once. The code below has the same structure:\n\n```\n```\nIn the generated code, we need to add some modifications, so we need to use the following line:\n```\n# make some modifications lib = paste0(\"r\", library(pluma)) pluma = paste0(lib, \"pluma::pluma3(code = 1, \",\n```\n\nThe code below generates your desired code in block 8:\n```\ncode(code = 8, file = paste0(\"r\", library(pluma)))\n```\nHere is the output:\n\n```\n# generate r code dataset(new_df) code = r { 10:1 } # make a dataset and pass the dataset to the R code generator 11:10 dataset = dataset(); # make another dataset that you want to pass to the R code generator",
        "label": 0
    },
    "946": {
        "output": "## [TARGET] Hello. Your patient has Takayasu arteritis with the classification mild-moderate. Since the Kerr score is 2, you should check the inclusion and exclusion criteria for the trial.\n\nHere is the list of inclusion and exclusion criteria for the trial:\n\nHere are the factors from your patient, based on the note presented in the assessment. \n\n\n### Inclusion: \n> Bone marrow edema, > Bone marrow edema and > 1 factor from Table 1\n\n### Exclusion:\n1) Bone marrow edema, > > 2 factors from Table 1\n\n> Exclusion criteria may be omitted in the case of mild to moderate disease states. In all three of the cases shown in , the patients were mild to moderate as defined by the IAS, and therefore all three were eligible. In contrast to the clinical presentation and treatment, the outcomes were very different among the three patients. In case 1, the patient had severe and progressive osteoporosis with multiple spine and hip fractures and disabling pain. In case 2, the patient had no complications at all from Gaucher disease at the time of presentation. This patient showed an excellent response to enzyme replacement, and as of this writing, was still in remission. In case 3, the patient also had severe osteoporosis with multiple severe metabolic bone disease-related bone fractures. It is important for each individual patient to be assessed to develop a treatment plan tailored to the patient's needs.\n\n> Cases 1 and 2 are both eligible for enrollment into a clinical trial of enzyme replacement therapy\n\n> The IAS and the TAG groups have developed clinical trials research guidelines for GD.\n> \n> 5.2 Trial Assessments: Patients with GD may undergo a trial assessment in addition to standard clinical care.\n[/TARGET]\n\n## [NOTABLE]\nHello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that",
        "label": 0
    },
    "947": {
        "output": "[fig]  [INST]: Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. [/fig] \n[table]  [ ]: Clinical trials are the first step to get new medicines to patients who are sick. However, many clinical trials fall short of their target recruitment numbers. Eligibility is therefore one of the key steps in the recruitment stage of a clinical trial. Identifying the population that qualifies for study inclusion ensures compliance with the trial protocol, safety monitoring, and data analysis. However, identifying the target population also prevents patients from being under-qualified or over-qualified for a trial. [/table] \n<EOD> Oxygen-sensitive gene regulation in a facultative anaerobe by an oxygen-binding transcription factor: involvement of a protein kinase.\nProtein kinase activity was detected in extracts of a Gram-negative facultative anaerobe, Neisseria perferingens, that was isolated from the human rectum. As is the case with other cyclic AMP-binding proteins, such as cAMP receptor protein (CRP) of Escherichia coli, the N. perfingens protein that reacts in vitro with radiolabeled cyclic AMP has a molecular weight of 42,000 and is an acid-soluble protein with a pH optimum of 6.2. The cyclic AMP-dependent protein kinase (PK) was found to exhibit higher kinase activity toward N. perfingens lysate and soluble proteins than it did toward the crude cell extract. Studies of the phosphorylation of a major soluble protein showed a correlation between the oxygen concentration in the growth medium and the rate of protein phosphorylation of the N. perfingens culture, providing evidence for the oxygen-sensitive nature of this PK. The oxygen-stimulated phosphorylation of this protein corresponded to the oxygen-dependent",
        "label": 0
    },
    "948": {
        "output": "1. You should print the patient note.\n\n\t     var printSrc = ('/patient-note-print.action');\n\n\t     response.redirect(printSrc);\n\n\n2. You should print the clinical trial.\n\n\t     var printSrc = ('/clinical-trial-print-summary.action');\n\n\t     response.redirect(printSrc);\n\n\n3. You should compare the patient note and the clinical trial.\n\n\t     var matchClinicalTrials = $('#match-clinical-trial').val();\n\t     // var trialNoteInfo = $('#trial-note-list').find('[title = ').val();\n\n\t     var trialMatchClinicalNoteInformation = trialNoteInfo.filter(item => {\n\t     \n\t     matchClinicalTrials = matchClinicalTrials.split(\"#\");\n\t\t\n\t     var clinicalNoteInformation = item.split(\"|\");\n\t     \n\t     for (var i = 0; i < trialMatchClinicalNoteInformation.length; i++) {\n\t     \n\t     for (var itemIndex = 0; itemIndex < matchClinicalTrials.length; itemIndex++) {\n\t\t\t\n\t     \n\t     if (clinicalNoteInformation[i] == matchClinicalTrials[itemIndex]) {\n\t     // return matchClinicalTrials[itemIndex] + \" : \" + trialNoteInfo[0].split(\"=\")[1] + \n\t     // \" for #1 0123456789\";\n\t     trialMatchClinicalNoteInformation = clinicalNoteInformation.slice(0,matchClinicalTrials.length);\n\t     return;\n\t     }\n\t     else if( trialNoteInfo[0].split(\"=\")[1].split(\",\").join(\"\").substring(\"1\" + itemIndex).trim() == matchClinicalTrials[itemIndex].split(\"=\")[1].split(\",\").join(\"\").substring(\"1\" + itemIndex).trim()) {\n\t\t\n\t     return matchClinicalTrials[itemIndex] + \" : \" + trialNoteInfo[0].split(\"=\")[1].split(\",\").join",
        "label": 0
    },
    "949": {
        "output": "[TASK]\nAnswers for the [TASK] can be found below. Please choose the correct answer.[INST] Hello, [TASK]! This [TASK] requires several input values.\n\nInputs are the following:\n\nLet's think step by step (you need to put these inputs into [CODE], and then click the \"Run\" button to see the output):\n\nOn the next page, please make a [Task] for each patient's [TASK], as shown below:\n\nTask (output): Excluded (2), Not relevant (0), Eligible (49)\nTask (output): Excluded (2), Not relevant (0, 21), Eligible (49, 23)\n\n[/TASK]\n\n### Task: [QUESTION].\n\n1. `Task:`[QUESTION].\n    \n2. `Task:`[QUESTION].\n\nTask (output): Eligible (151)\nTask (output): Excluded (4), Not relevant (54, 107)\n\nTask (output): Eligible (155)\nTask (output): Eligible (156)\nTask (output): Excluded (4)\nTask (output): Not relevant (54, 105, 125)\nTask (output): Excluded (4)\nTask (output): Not relevant (55, 71, 73, 81, 89, 102, 104, 112, 127)\n\nTask (output): Excluded (4)\nTask (output): Not relevant (55, 71, 73, 81, 89, 102, 104, 112, 127)\n\n    6. `Task:`.\n    \n    \nInputs are the following:\n\n1.  `Age:` (3).\n    \n2. `Lv-CAD` (0, 1).\n        - value of 0 means no Lv-CAD in a cohort\n        - value of 1 means Lv-CAD in a cohort\n        \n    \n2. `",
        "label": 1
    },
    "950": {
        "output": "<EOD> The Relationship Between Dental Plaque and Acute Gingivitis: A Study of Dental Pulp Responses in Humans\nTo investigate the relationship between subsurface dentine demineralization and dental plaque accumulation associated with bacteria in acute gingivitis, dental pulp responses in acute gingivitis were investigated immunohistochemically in 23 sites derived from eight teeth from seven healthy individuals. The eight teeth were all extracted when they were diagnosed as hopeless by their general dentists. Tooth sections were stained immunohistochemically with antibodies specific for osteopontin. Subsurface dentine demineralization was evaluated using surface electrical capacitance measurements during the tooth extraction. Accompanying each measurement, the amount of retained plaque accumulation was assessed by a microbiological assay. The relationship of the amount of dental plaque accumulation associated with acute bacterial accumulation with subsurface dentine demineralization was then examined. The results showed that the increased subsurface dentine demineralization correlated significantly with the amounts of dental plaque accumulation (P = 0.01, R2 = 0.0418) in acute gingival inflammation. These results indicate a close relationship between the amount of plaque accumulated and acute bacterial accumulation in dentine demineralization. The possibility of monitoring acute bacterial accumulation using electrical measurements indicates that this type of bioelectronics may be suitable for the management of acute gingivitis.<EOD> \u03b2\u2010Adrenergic stimulation impairs glutamate synaptic transmission onto rat parvocellular neuroendocrine neurones of the hypothalamo\u2013neurohypophysial system\nThe hypothalamo\u2013neurohypophysial system (HNS) is a master neuronal network that controls the functions of the neuroendocrine system and maintains the homeostasis of body fluid. Parvocellular neuroendocrine neurones of the HNS receive glutamatergic synaptic input from multiple brain regions; glutamate (excitatory) or GABA (inhibitory) modulates their elect",
        "label": 0
    },
    "951": {
        "output": "<EOD> Evaluation of the performance of the immature platelet fraction measured by Sysmex XP\u2010300i\nBackground and Objectives\u2002 The immature platelet fraction (IPF) is a parameter measured by automated hematology cell counters after gating platelets as particles with diameter \u22644 \u03bcm and fluorescence of side scatter (SS)\u2010A\u2010red cells. Little is known about the performance of the IPF measured by automated hematology cell counters. The study was performed to assess the characteristics of the IPF and to compare two automated hematology cell counters from Sysmex XP\u2010300i and XE\u20102100.<EOD> Hospice care and end of life decisions: the legal and ethical implications of the Montgomery Report\nThe Montgomery  report, published in February 2008, is a serious critique of end of life decisions and the role and use of Liverpool Care Pathway and also of the Liverpool Hospital Foundation NHS Trust. It is based around a \u2018factual reconstruction\u2019 of the last 48 hours of a terminally ill patient\u2019s life. It exposes an attitude towards the patient as being in need of curative treatment, rather than a person with progressive disease to whom adequate palliation should be given. It highlights a widespread tendency for patients perceived to be dying in hospices to have unacceptably high levels of suffering, and for staff to find end of life \u2018troublesome\u2019 and \u2018problematic\u2019.\n\nAs in any ethical debate the argument has to be seen in an empirical context and the Montgomery report suggests that end of life decisions within hospice care are in need of review. This review must include not only issues such as Liverpool Care Pathways (LCPs), which are at the heart of the debate and have been a lightening rod for public attention, but also other aspects of end of life decisions and death, including, for example, the ethics of admitting patients to an hospice in a stable terminal phase.1 This paper aims to explore some of these issues and considers whether any legal or criminal liability stems from Montgomery\u2019s analysis and findings.\n\nAbove all, Montgomery suggests that we must acknowledge that the care a dying person",
        "label": 0
    },
    "952": {
        "output": "_______________________________________________________________________________________\n\n*You must sign the [Trial-registration-Form](https://github.com/mikro123/Deep-Care-Augmented-Recruitment-System/blob/master/trial-registration-form.pdf) to use this Deep Care Augmented Recruitment system.\n\n[Trial-registration-Form](./trial-registration-form.pdf) _______________________________________________________________________________________\n<EOD> The effect of 670 nm low level light therapy on postoperative wound healing and inflammatory responses in patients following total knee arthroplasty: study protocol for a randomised controlled trial\n\nBackground: Delayed wound healing and infection remain the most common and serious complications after total joint arthroplasty. Currently, low level lasers have been used to stimulate wound healing. However, the effect of low level laser therapy on knee wound healing and inflammatory responses following total knee arthroplasty (TKA) remains unknown.Methods: In this single-blind and placebo-controlled randomised trial (RCT) design, 124 patients will be randomly enrolled (1:1) into treatment or control groups. Participants in the treatment group will receive 670 nm laser at 6.5 J/cm 2 , 3 sessions per week, for 6 weeks immediately after TKA, while participants in the control group will receive 670 nm laser at 0.25 J/cm 2 , 3 sessions per week, for 6 weeks in the immediate period after TKA as the sham treatment. The outcome assessments will be performed at 2 weeks, as well as 4, 8, 12 and 24 weeks after TKA. The primary endpoint will be the changes in inflammatory immune cell markers in knee joint fluid. Secondary endpoints will include changes in immune cell count as well as cell phenotype, time to normalisation of knee joint fluid neutrophil and lymphocyte, and changes in pain intensity and knee function. Furthermore, adverse events",
        "label": 0
    },
    "953": {
        "output": "[[NOTE] Your input is stored in the data dictionary, `data.xls`. The column headers start with `c_` in `AREA_BREAST` and `s_` in `RESTANT_ID`.]\n\n### Inference with [https://github.com/james-h/statpy](James Harden)\n\nIn this tutorial, we will use Python to predict the probability of an event occurring, given the patient's characteristics. To do so, we will use some of the statistical tools described in . A large sample of patients will be simulated in this tutorial. If we were to do this with real patients, we could expect to be over fitting and obtain predictions that do not generalize well to new cases. One of the techniques that allow us to decrease the over fitting is by using cross validation. We will use leave one out cross validation to estimate the performance of the model obtained.\n\nIt is important to mention that the statistical tests are described in a generic way in . The authors provide a python package where you can apply the tests following a few lines of code, or it is possible to use a webservice, for example [https://github.com/james-h/caret](James Harden).\n\nHere we will use the statistical methods described in to create a classification tool for the prediction of acute renal failure in critical illness patients. The methods to predict critical illness acute renal failure are described in chapter 3 of the book.\n\nThe training dataset contains information about each patient, clinical variables and the occurrence of acute renal failure. The aim is to construct an algorithm that predicts this clinical event. Our goal is to obtain a tool to help to the clinician in the decision-making process. Since we need to make several decisions in order to create the model, it is appropriate to follow the data analysis pipeline shown in .\n\n[[INSTRUCTION] In the first step, you need to create the variable that represent the occurrence of AKI. Note: AKI is the acronym in Spanish for Acute renal failure. To create this dummy variable, copy the patient information about AKI occurrence in the file named `patients_001.csv`. Then, copy that information and create the variable using the expression `patients_001 = np.copy(patients_00",
        "label": 0
    },
    "954": {
        "output": "## [Ans] In the patient note, if the patient has a family history of cad, what score should it show in the assessment of eligibility?\nA. Excluded. B. Ineligible. C. Relevant. D. 0. E. Not relevant.\n\n## Answer: d. 0\nExplanation:\nIn the patient note, if the patient has a family history of CAD, what score should it show in the assessment of eligibility? Family history of CAD.  \nThe patient note is analyzable in the trial. You should make a trial-level eligibility for each patient in this trial. Inclusion criteria: Patient who received or is expected to receive coronary stenting within 3 months. \nPatients with positive family history of CAD were considered as having positive family history of CAD. In this way, the right answer should the answer that scores patients in 0. The other options are all incorrect.\n\n## [Ans] if the patient's fasting glucose level was not within normal limits, what score should it show in the assessment of eligibility?\nA. Excluded. B. Ineligible. C. Not relevant. D. Relevant. E. 0.\n\n## Answer: c. not relevant.\nExplanation:\nIf the patient's fasting glucose level was not within normal limits, what score should it show in the assessment of eligibility? Not relevant.\nPatients with fasting and pre-prandial blood glucose levels above 130\u2009mg/dL were considered to be out of the normal range. Fasting blood glucose is required to be<130\u2009mg/dL.In this way, the right answer should the answer that scores patients in 2.\nThe other options are all incorrect.\n\n## [inst] Explain why not all options are correct.\nA. Since CAD risk assessment is performed according to the Framingham Coronary Risk Score, age and sex are not factors associated with CAD (in CVS, smoking and family history of CAD are associated with CAD, not age or sex). Blood pressure is also not a factor associated with CAD.\n-Framingham Coronary Risk Score (",
        "label": 0
    },
    "955": {
        "output": "## [CORRECT] \nThe patient is excluded from a clinical study on dizziness because the patient does not have sufficient information and the patient suffers from chronic dizziness.\n\n## [INCORRECT]\nThe subject is not eligible to participate in the study because the patient is too young and the patient has a low cholesterol level.\n\n## [INST]\nThe patient is excluded from a clinical study on chronic dizziness because the patient has a high cholesterol level and the patient's age is too young.\n\n## [OVERT]\nThe patient who fits the age bracket and does not have a too-high cholesterol level to participate in the dizziness study is not eligible to participate in the study.\n\n## [INSTCOR]\nThe patient is excluded from a clinical study on chronic dizziness because the patient has a high cholesterol level and the patient's age is too young.\n\n## [OVRTCOR]\nThe patient who fits the age bracket and has a too-high cholesterol level to participate in the dizziness study is not eligible to participate in the clinical study on chronic dizziness.\n\n## [OVRT]\nThe patient who fits the age bracket to participate in the dizziness study is not eligible to participate in the clinical study on dizziness.\n\n## [OVER]\nA patient who does not have a high cholesterol level to participate in the dizziness study is not eligible to participate in the clinical study on chronic dizziness.\n\n## [INSTC]\nThe patient is excluded from a clinical study on dizziness because the patient is too young and the patient suffers from chronic dizziness.\n\n## [OVERCOR]\nA patient who fits the age bracket and has a too-high cholesterol level to participate in the dizziness study is not eligible to participate in the clinical study on chronic dizziness.\n\n## [INSTOVT]\nThe patient is excluded from a clinical study on dizziness because the patient suffers from chronic dizziness",
        "label": 0
    },
    "956": {
        "output": "Please test a clinical trial and then submit your results for the rest of the four trials.\n\nPlease follow these steps to complete the task:\n1. Review the trial notes and compare them with the training data notes.\n2. Assess the eligibility of the training data  to include or exclude the patients in the trial. 2a. Do this for each trial.\n2b. To indicate if the trial notes are NOT relevant due to missing information or variables, please choose the 1 - 'Not relevant' label.\n2c. To indicate if the trial note is ELIGIBLE, please complete the following checklist.\n2d. Use the 0 or 1 code to indicate whether the patient will participate in the study:\n0= patient is excluded in the trial\n1= patient is eligible for the trial\n2. Save your results in the CSV file that we provided and name the file as follows: your name first initial and second initial_0_eligibility .csv .\n2d. You are allowed to use all required packages for your task. [/HOLDOUT] [/END]",
        "label": 0
    },
    "957": {
        "output": "## Recommendation\nThere is no simple way to distinguish patients with moderate-to-to high-risk CAD from patients with no or intermediaterisk CAD. Hence, we used the Framingham Risk Score to stratify patients into three groups of similar risk for CAD: low (CAD probability < 2%), intermediate and high (CAD probability > 20%). \nIn this task, you should predict the risk groups of the clinical trials (low, intermediate, high), whose inputs are the following medical data: age, sex, SBP, DBP, history of cigarette smoker, total cholesterol, HDL, fasting blood glucose, history of hypertension, and history of diabetes. \n\nYour assignment is to predict the patient's risk group by multiclass logistic regression. You should output the predicted risk value with range: 0-100. Each risk group, e.g., low and high, means no or low and high risk of CAD.\n\nHere are the training data for the regression task:\nThe training data consists of 24 records. One record means the input values of the training data, and it is shown in [fig_ref]  Table 5 1: Example Case Study [/fig_ref] .2\nYou may make a 10-fold cross validation by splitting the train-ing into 10-folds and calculating the performance metrics, e.g., accuracy, in each fold. \n\n# Input data\nAge, Sex, SBP, DBP, History of cigarette smoker, Total cholesterol, HDL, Fasting blood glucose, History of hypertension, History of diabetes These values are all numerical data, 23 in total.\n\n# Output dataset\nRisk groups This dataset consists of three labels. Low, intermediate, high. Each risk group represents that the probability of the CAD belongs to that risk group. The order of the three groups: high, intermediate, and low.\n\n# Output metrics\nPrecision, Recall, Accuracy Precision is how many of the total number of predictions for which the true group is low is low out of the total number of predictions that are grouped as low. \nRecall is how many of the true low group is low",
        "label": 0
    },
    "958": {
        "output": "For every patient: - First record the status of the assessment of eligibility;\n- then, calculate the value for Trial-level eligibility: 0 - Excluded; 1 - Not relevant; 2 - Eligible; and\n- the value of the assessment of eligibility and record it.\nYou may also see the Trial-level eligibility assessment code and the assessment status code for trial-level eligibility, which you can use to fill in the fields to output the results to the right path. You will not be assessed by yourself, but will be input into the file system. If you do not record, you may not know what your input is.\n\n![](/img/pics/help/clinical-data-entry/help_eligibility_1.png)\n---\n\n### 3) Excluded\nAssessment of Eligibility:  The trial did not include the patient. This is determined by the exclusion criteria of the trial.\n\n\n---\n\n### 4) Not Eligible\nAssessment of Eligibility:  The trial included patients for the trial and did not meet the eligibility criteria. This is determined by the exclusion and eligibility criteria of the trial.\n\n\n---\n\n### 5) Eligible\nAssessment of Eligibility:  The trial included patients for the trial and did meet the eligibility requirements. This is determined by the eligibility and exclusion criteria of the trial.\n\n\n---\n\n### 6) Not Relevant\nAssessment of Eligibility:  This means the patient is not the target of the trial. \n\n###### For a more in-depth understanding of how to use this field:\n\n\nThe assessment status of the eligibility is the trial-level eligibility 5. Trial-level eligibility must be zero when `0 - Excluded` and non-zero when  `1 - Not Relevant`, `2 - Eligible`, or `6 - Not Relevant`. \n\nTriall level eligibility status will not change if you switch to other lines: \n---\n\nThis patient does not meet the inclusion criteria.\n\n\n---\n\nThis patient meets the inclusion criteria.\n\n\n---",
        "label": 2
    },
    "959": {
        "output": "## Good luck!\n<EOD> Impact of an Ex Vivo Culture System on Craniosynostosis Precision Medicine\nAbstract Objective\u2003This review aims to (1) outline the steps for developing an ex vivo culture test that addresses limitations in the treatment of craniosynostosis (CS), (2) examine the current studies on culture of patient-derived cells from the calvaria, and (3) assess the clinical impact of patient-derived cultures in the context of personalized medicine. Design\u2003Through a review of the published and unpublished literature and the authors' experience, we provide an outline and overview of various studies relevant to the creation of an ex vivo culture test for CS. Setting\u2003The authors reviewed published literature and developed a model of an ex vivo culture test and analysis of patient-derived cells. Results\u2003The authors review the available literature on (1) the use of calvarial tissue in CS research to obtain patient-derived cells, (2) the use of cultured patient-derived cells as a surrogate for the original patient's conditions for drug testing, and (3) studies with primary cells and in vitro models of CS. Conclusion\u2003An ex vivo culture test has been designed to address the limitations on biopsy and clinical treatment, and ultimately CS precision medicine. The current understanding of the use of cultured primary cells of CS patients will be leveraged to establish a model that closely resembles the conditions of patient's specific malformation.<EOD> A Novel AU-Rich-Element-Binding Protein, AU-Rich-Element RNA-Binding Protein-2, Binds to the 3\u2032 Untranslated Region of Stem Cell Leukaemia Gene\n\nThe 39 untranslated region (39UTR) plays important roles in mRNA stability, sub-cellular localisation and posttranscriptional regulation. AU-rich elements (ARE) are characterised by the presence of multiple clusters of adenine and uridine (A/U) residues and are present in the 39UTR of a large proportion of mammalian mRNAs. The ARE-RNA-binding proteins (ARE-BPs) are present in almost all cell types and regulate mRNA of hundreds of gen",
        "label": 0
    },
    "960": {
        "output": "<EOD> Anatomical studies of the mandibular canal: Part III\u2014The anterior loop of the inferior alveolar nerve\nObjective: To investigate the morphological variation of the inferior alveolar nerve (IAN) in the mandible using cone-beam computed tomography (CBCT) imaging. Material and Methods: We examined the mandibles from 290 dry skulls to examine the morphology and course of the IAN. Data were then obtained from 35 cadaver hemi-mandibles. Results: We observed that the IAN bifurcated in 34 cadavers (97.1%). In 29 cadavers (82.9%), the inferior alveolar canal presented a sharp internal curve that originated in the mandibular foramen. This portion of the IAN was referred to as the anterior loop (AL or CBCT-AL). In 12 cadavers (34.3%), we also observed a second separate internal curve that originated from the posterior portion of the inferior alveolar canal. The mean distance from the IAN canal to the apices of the maxillary first molars was 25.3 mm. Conclusion: A CBCT provides reliable information about the localization and course of bone of the IAN. A high anatomical variation in the CBCT-AL (34.3%) was found compared to previously reported variations.<EOD> Corrosion behavior, mechanical properties and dental applications of biodegradable binary zinc-based alloys fabricated by different methods\n\nIn this paper, we investigated the effect of fabrication method on microstructural evolution, mechanical properties and corrosion behavior of biodegradable binary zinc (Zn)-based alloys, which aim to develop an ideal implant material for oral hard tissue repair. Zn-0.5Co, Zn-0.5Fe, Zn-0.5Ni, Zn-0.5W and Zn-0.5Mo samples were prepared by spark plasma sintering (SPS), hot press sintering (HPS) and solid solution processing (SSP). After preparation, samples at different sintering conditions (0.1-0.65 TPa for SPS, 5-10 MPa for HPS, and",
        "label": 0
    },
    "961": {
        "output": "* * *\n\n\n\n\n``` python\ndef patient_eligibility(patient_note):\n    with open('/data/inputpatient.txt', 'r') as fp:\n        data_input = fp.read()\n        #print(data_input.strip())\n        trial_input = data_input.strip().replace('[INST]','')\n        trial_input = trial_input.trim()\n        #print(trial_input.strip())\n        if trial_input == '0) Excluded':\n            print('Your patient {0} is excluded for the clinical trial {}'.format(input(\"Type your answer: \"), trial_input))\n            return\n        \n        elseif trial_input == '1) Not relevant':\n            print('Your patient {0} is not relevant for the clinical trial {}'. format(input(\"Type your answer: \", trial_input)))\n            return\n        \n       \n        else:\n            if trial_input == '(1) Eligible':\n                print('Your patient {0} is suitable for the clinical trial {}'.format(input(\"Type your answer: \", trial_input)))\n            else:\n                print('Your patient {0} has insufficient information to be assessed. ' . format(input(\"Type your answer:\", trial_input)))\n            return\n\npatient_eligibility(patient_note)\n```\n\n<!--- Your code may go here. -->\n\n<!--- Submit your results here. -->\n\n\n<!--- \u26a0\ufe0f If you need help, ask a colleague to test your program and provide feedback. ---><EOD> .\nThe patient presented in this case report was a 48-year-old female. She had been admitted in hospital a few years before, because of acute pneumonia, and there were many episodes of cough and dyspnea over the past three years. The pathogenesis of pseudomembranous pneumonia after bacterial pneumonia is considered to be related to bacterial infections. The lung biopsy revealed neutrophil exudates and fibrinous necrosis exudates. The lungs recovered well under proper treatment.<EOD> Proposal for a new technique for the",
        "label": 0
    },
    "962": {
        "output": "##[ /Trial-level eligibility] [ /INST]\n\n### Evaluate Patient Eligibility\nIn this case, your task is to answer a specific question, i.e., identify a patient with carotid web in the clinical trial's inclusion criteria. You should do this independently from the other participants who will do the same task. You should have the same patient note with the same clinical trial as the other participants. You are also restricted to 5 min to identify the patient with the carotid web. \n\nIt is clear as daylight as the patient's note corresponds to the inclusion criteria. The patient is eligible for the clinical trial. In particular, the clinical trial includes patients with carotid webs and cerebral infarctions or transient ischemic attacks. \n\nYou should show us the lines on which you placed your comments on the patient note and in the clinical trial you found them.\n\n\n\n\n# [Hackathon](https://github.com/microsoft/fhir-challenge/blob/master/hackathon)\n\n\n## [Overview](FHIR_Incidence_V2.docx)\n\n## About Us\n\nThis challenge is developed and maintained by a small group of volunteers with interests in FHIR. We are all either affiliated with organizations that are developing (or working with those that develop) FHIR or other open standard health care technologies. Our affiliations span academia, open source projects, health systems, consulting, and standards bodies, but all of us have a shared interest in the success of FHIR implementations for health care interoperability, data exchange, and the ability to effectively combine and exchange health care data while maintaining individual patient privacy and reducing the burden on those who collect and submit health care data.\n\nFHIR is a clinical data model based on RESTful web services to provide a standardized mechanism to manage clinical information, such as patient medical history, medications, allergies, procedures, observations, immunizations, problems, and care plans. Using the FHIR framework for HL7, we believe it can facilitate a large-scale exchange of health data and services, which will make it easier to track, provide data access, and enable health research and clinical work.",
        "label": 0
    },
    "963": {
        "output": "## Excluded Criteria\n- In the main script, you should implement code (a) to assess the exclusion criteria for each patient. In other words, by running the code, each patient should receive an exclusion score. Then, after summarizing the exclusion scores of all patients, the eligible patients should be separated using the threshold function, and the data for all patients with scores less than the threshold value should be excluded. According to the question, if the scores of the patient notes are greater than the threshold value, 0, they are eliminated.\n- [a] for each patient, the `Inclusion Eligibility` variable should be calculated and its corresponding variable with the score of zero is assigned as the `Exclusion Eligibility` variable.\n- [b] after the score for all patients is calculated, the final threshold must be calculated.\n- [c] the patients with scores lower than the threshold are excluded from the database.\n[a]\nfor(iter=1:length(V.ID)) {\n    % get the variable of the first number of the code \n    patient_score = as.integer(grep(strmatch(V.ID,INV.IDM)))\n    if(~is.nan(patient_score)) {\n        % calculate the included percentage as the number of included divided to the number of total\n        Excluded % percentage% = (patient_score+1)*100/sum(INV.IDM) \n        % assign the exclusion percentage\n        INV(cnames(iter),5).Exclusion_score = Excluded % percentage \n        % calculate the total exclusion percentages\n        Total_Exclusion_percentage = sum(Excluded % percentage*100)\n        % calculate the threshold\n        Threshold = round(Total_Exclusion_percentage/100) \n        % calculate the ineligible patients\n        INV(cnames(iter),1) = round(Excluded % percentage*(1-Threshold) 100)\n        % calculate the score of ineligible patients\n        INV(cnames(iter),2) = Threshold\n    }\n    else {\n        % calculate the percentage\n        patient_score = 0\n    }\n}\n\n[b]\nExcluded_",
        "label": 2
    },
    "964": {
        "output": "<EOD> .\nThe study was undertaken to clarify the roles of glutamate and aspartate (GA), potassium (K), and sodium (Na) in the development of hypokinesia. In the absence of extracellular K, the inhibitive effect of hypokinesia on the growth of chlorella mutans, Chlorella pyrenoidosa was inhibited, while its effects on the metabolite levels of intracellular GA and Na were reversed. The effect of GA on the growth of Chlorella was inhibited by the Na concentration in the environment; the effect of Na + on its growth was also found to be inhibited by the concentration of K + in the environment.<EOD> .\nThis report gives a review of the clinical efficacy of Naftidrofury (Ro 13-7567) in patients with advanced liver diseases with and without extrahepatic manifestation. The therapy (daily dosis of 400 mg) led to a clear to severe decrease of the mean bilirubin to the normal values in most of the patients of the treated group, the serum-levels of gammaGT, AP, SGPT, SGOT and the enzyme-deficiency in the serum were returned to normal values of a short therapy (10 to 34 days) of 7 patients with hepatic encephalopathy, a total clearance was achieved in 1--2 days. Treatment of 18 patients with active or symptomless oesophageal varices (386 sessions (34 days) during 10--480 days) leaded to a normalization of the portal pressure in this group of patients treated with Nafidrofury. The therapy of 63 patients with extrahepatic bleeding manifestation (212 sessions during 126 days) without liver dysfunction leaded to a normalizing influence on the hemorrhagic rate of the patients. Treatment of patients with severe liver diseases with encephalopathy, extrahepatic bleeding or active or symptomless portal hypertension shows an efficacy of the substance, which could be compared with the effect of the vasoactive substance of",
        "label": 0
    },
    "965": {
        "output": "<h1>\n4. Create dataframes to hold the results of the classification\n\nHere are the steps for getting the code to work:\n<h3>\nStep 1\n\nI will describe how to create a dataframe for classifying the data. First, create a new column for including information, e.g., column_1. Second, specify the classifier type as 'logistic_reg' for classification. <a href=\"https://scikit-learn.org/stable/modules/generated/sklearn.metrics.classification_report.html\">https://scikit-learn.org/stable/modules/generated/sklearn.metrics.classification_report.html</a>\n<h3>\nStep 2\n\nNext, create a new dataframe, i.e., column_2, to hold the results. `column_2_2` is an output dataframe for the classification, and `column_2_3` is an output dataframe for the confusion_matrix.\n<pre><code>\ndf_1['column_2_2'] = sklearn.metrics.classification_report(estimator=classifier, data=df_1, feature_names=['column_1'], target_names=['column_3'])\ndf_1['column_2_3'] = sklearn.metrics.confusion_matrix(estimator=classifier, data=df_1, feature_names=['column_1'], target_names=['column_3'])\n</code></pre>\n<h3>\nStep 3\n\nAdd a column to show the eligibility level, i.e., column_4. You need to find the column label that appears in <a href=\"http://scikit-learn.org/stable/modules/generated/sklearn.metrics.classification_report.html\">http://scikit-learn.org/stable/modules/generated/sklearn.metrics.classification_report.html</a> to indicate the eligibility level.\n<pre><code>\ndf_1['column_4'] = sklearn.metrics.classification_report(estimator=classifier, data=df_1, feature_names=['column_1'], target_names=['column_3'])\n</code></pre>",
        "label": 0
    },
    "966": {
        "output": "**3.2.6** ______________________________________________________________________________\n\n**What type of factors can also be used together with the features in the first data set?**\n\n- Add information about the study arm for each individual in the cohorts or trials (i.e., placebo or control) and the treatment stage for each patient (i.e., pre-and postintervention).\nFor this study, each patient has a unique patient ID, which was assigned automatically at the beginning of the experiment, and a study arm in each cohort. You can observe the values in the `patient_id` and `studyArm` variables in the patient note, which are not used in the previous data set. \n\n\n**Q1.** Are the study arm (placebo or control) and treatment stage (pre-and post-intervention) needed in your prediction task? If so, what is the most optimal prediction model for your task? How do you modify its settings?\n\nIn this cohort, four patients in the control arm, 3 in the treatment arm were diagnosed with HCC at 3.2, 11.0, and 24.5 years after starting treatment, respectively. In the treatment arm, all patients are alive after a median follow-up of 24 years, while all patients in the control arm had died of HCC at different periods after starting treatment (Q6). \n\nIn the second cohort, two patients were at the stage of pre-treatment (preintervention), two were at the stage of post-treatment (postintervention), and three had been diagnosed with HCC. In the third cohort, six patients are in the preintervention stage and four in the postintervention stage. In the fourth cohort, all are at the pre-intervention stage (Q7).\n\nPlease refer to the answer for Q3.4. \n\n\n**Q2. How would you modify the settings in the `patient_id` and `study_treatment` variables?\n\nQ3. For the second data set, you should predict the patient's study arm and treatment stage to answer Q1. How about the other factors in the second data set? As we mentioned earlier, add the study arm and treatment stage to the features. \n \nIn the first",
        "label": 1
    },
    "967": {
        "output": "<issue_comment>username_7: What is the expected output of the code when the patient qualifies for the trial?\n<issue_comment>username_8: Hi, @username_7. \n\nAs mentioned above, since the inclusion criteria of this trial is binary, the output of `Trial-level eligibility: ` should be a three-digit number. If the patient meets all inclusion and none of the exclusion criteria, then 0 (i.e. Excluded) should be the value printed by `Trial-level eligibility: `; otherwise, the trial-level eligibility will be printed as the second option of the comparison for the patient when the patient does meet all inclusion criteria, but one of the exclusion criteria is not met. For example, if the patient has history of cardio-vascular disease (CVD), you have to print the second option of the comparison (1) Not relevant rather rather than 0) Excluded. Then, the output of `Trial-level eligibility: ` will be `Trial-level eligibility: 1) Not relevant`.\n\nFor the example trial case shown above, you should print 0) Excluded, 1) Not relevant, and 2) Eligible from the trial-level eligibility.\n\nLet's go through step by step. \nHere is the trial note of a patient who has the inclusion criteria:\nA 46-year-old man presents with dizziness and frequent headaches.\n\nHere is the trial note of a patient who also has the exclusion criteria:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\n\nThe patient meets all of the inclusion criteria as well as none of the exclusion criteria. Since",
        "label": 0
    },
    "968": {
        "output": "Now, you should make a trial-level eligibility based on the second clinical trial:\nTitle: Effect of Vildagra \u00ae on Endothelial, Cardiac and Vascular Function\n\n[inst:\nInclusion Criteria:\nAge <40 years\n\nMild hypertension\nNo significant medical ailments.\n]\n\nExclusion Criteria:",
        "label": 1
    },
    "969": {
        "output": "\u25a1 Yes \u25a1 No 4. If you already have an output, output an additional line with ``1) Not relevant.`` in the beginning of the output file. Remember that if there was an output before, input the trial-level eligibility in the last line by 'Trial-level eligibility: 1) Not relevant.`.\n\u25a1 Yes \u25a1 No 5. Check the output file to see if you make any mistake. Let's repeat this trial now: `Question 2: You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). The patient note and the clinical trial are as described in Question 1: You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\nQuestion 9:\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that",
        "label": 1
    },
    "970": {
        "output": "### Evaluation \n\nPlease make a run in the `Evaluation` folder, and then, please run the Python program in the `evaluation.py` file as follows. \n``` python\npython evaluation.py `1000-inputs.txt` \n```\n### 1000-inputs.txt\n\nThe following is the file listing of the 1000 trials of the [1: 44; 2: 65; 3: 39; 4: 25] example. It is generated by `run evaluation.py < 1000-inputs.txt > 1000-outputs.txt`. \n```\n# Patient information #\n\nPatient age: 36\nPatient sex (female/male): female\nPatient height: 165.2 cm\nPatient weight: 57.6 kg\nPatient body mass index (BMI): 24\nPatient current use of lipid-lowering medications: `No (use of lipid-lowering medication has never been used)`\n\n# Patient BP #\n\nBlood pressures # Systolic\n\n# Patient's eligibility level #\n\nSystolic (mmHg) : 128\nDiastolic (mmHg) : 68\n\n\n\n# Risk factors #\n\nDyslipidemias, hypercholemic # : None\nCardiovascular disease # : None\nCigarette smoking # : None\nDiabetes mellitus # : None\nDiabetic, no evidence of diabetes # : None\nInsulin-dependent diabetes # : None\nInsulin non-dependent diabetes # : None\nHyperglyceridemia # : None\nHypertriglyceridemia # : None\nHyperuricemia # : None\nHyperuricemia # : None\nPrevious ischemic heart disease # : None\nPrevious stroke # : None\nCoronary artery disease # : None\n\n# Exclusion criteria #\n\nActive or history of drug-abuse # : None\nClinical study for",
        "label": 1
    },
    "971": {
        "output": "## The second patient note:\n- Patient: A 27-year-old man, physically active;\n- LDL-C on admission 548.62 mg/dL (1397.9 mmoL/L);\n- Patient presented no history of smoking, high blood pressure, dyslipidemia, diabetes mellitus, hypertension, or cardiac, hepatic, or kidney diseases and had no family history of cardiovascular disease.\n- Family history of CAD only for brother deceased at 33 y (1943:52) from \"coronary heart disease\" of unknown cause;\n- Physical examination: no abnormalities;\n- Lifestyle: non-smoker, moderate-intensity physical activity for recreation twice a week;\n- Results from other examinations: no pathological findings.\n\n## [inst] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\nThe factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 27-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and",
        "label": 2
    },
    "972": {
        "output": "## Good luck! And don't panic.\nTrial-level eligibility: 2), Excluded\nTrial-level eligibility: 1) Not relevant\n\n##[XSLIDES]/\nTrial-level eligibility: 0) Excluded; 2), Excluded\nTrial-level eligibility: 1), Not relevant; 0) Excluded; 2), Eligible; (2)\nTrial-level eligibility: 2) Eligible; (1) Not relevant; (0) Excluded; (2)\nTrial-level eligibility: 2), Excluded; 0) Excluded; 1) Not relevant; 2) Eligible\n\n## Input:\nTrial-level eligibility 1), Eligible; (2)\nTrial-level eligibility 2), Excluded; (0) Excluded; (1) Not relevant; (2) Eligible\nTrial-level eligibility 4) Not relevant; (3) Not relevant; 3), Not relevant; (4) Not relevant; (1) Not relevant; (2)\nTrial-level eligibility: 4) Not relevant; 3), Not relevant; 4) Not relevant; 1), Not relevant; 2) Excluded; 1), Not relevant; 2) Excluded\nTrial-level eligibility: 3) Not relevant; 1), Not relevant; 2), Not relevant; 3), Not relevant<EOD> Efficacy and Safety Profile by Intra-articular Injections of Platelet-Rich Products versus Hyaluronic Acid for Knee Osteoarthritis: A Meta-analysis.\nKnee osteoarthritis (OA) is the leading cause of severe long-term pain, and there is no cure for it. Different injections such as hyaluronic acid (HA) and platelet-rich product (PRP) have been widely used among patients with knee OA. We systematically reviewed 9 trials (1758 patients), assessing the efficacy and safety profile of PRP or HA in patients with knee OA, randomized into one of two categories: PRP therapy or H",
        "label": 1
    },
    "973": {
        "output": "Your task is to find the number of patients who meet the inclusion criteria, i.e. patients whose note has been judged to be eligible at the trial level by the physician who should be identified if the note is judged to be eligible for the trial. You should output the assessment for all relevant patients in the patient note, using the code for the patient whose assessment results are printed at the end of the note. 33 Note: A three-way assessment is only used to compare a patient's notes with notes of patients in clinical trials, not an actual clinical trials assessment result.34 \n \n[INSTR] Note that we provide the raw data of the 308 patient notes; only five of those are fully included. These five patients are part of the training cohort so if you want to practice you can look through all the cases without needing to go to the hospital. (For more details, please refer to the code in the file of practice problems.) \n \n[HINTS] For training, we provide data from 2637 patient notes; the remaining 230 notes are part of the test cohort. We recommend that you first train with the 2637 notes; once you are done training, then try to use your trained model to predict new notes (either the training set or test set). We encourage you to report your testing results in a GitHub (https://github.com/) repository. \n \n \n[INST] Hi. You can find the details of our requirements and the scoring criteria in the [INST] section and in our [HINTS] link. Below are some tips that the organizers hope will help in solving the challenges. \n \nWe recommend that you first read and attempt the [PRAC] first. If you are still unsure whether you have covered all that might be relevant then use [INF1]. If you are not sure about any of the [PRAC] first three tasks, then you could take advantage of [INF2], as it is a short question, and then also [INF1] is a full challenge. If after using [INF2] you are still unsure then move on to one of the [PRAC] tasks. You can also go to Task #1 to get a taste of the difficulty of Task #4.",
        "label": 2
    },
    "974": {
        "output": "We shall consider it as an input value for the next step.\n\nA patient cannot be evaluated as ``excluded`` in any step if the trial is not closed. To this end, we provide the following information in the configuration ``Trial configuration`` of the patient:\n`Trial configuration: Closed`\nYou should check the ``Configuration.TrialConfiguration`` of patients and then change the configuration to `TrialConfiguration Closed` as necessary.\n\n\nA: Here\u2019s how I\u2019d approach it:\nYou can get the number of patients that meet the criteria from the `Transection.Count` property of the `Transition.TransitionDetails` `DataReader` that comes along with the records.\nTo get the number of patients, where any part of the patient Note has a particular value, you can do this:\nTransition.TransitionDetails.Where(td => td.Patient.Age.ToInteger() < 65 && td.Patient.Gender == \"Male\").Count()\n\nA: As per my understanding.  \nYour first two lines will work if the eligibility flag will always be 0.\nYou need to rethink the Trial configuration. The only way to have trial configuration closed is when trial is already closed on the record table. In which case the recorder can no longer update any other field on the trial. For this to work, the closure criteria should be in a different table and updated when records are closed.\n<EOD> .\nIn 1997 the Swiss medical community was shocked by the publication of a death report on a previously healthy young male, who died at rest from a primary heart failure during a soccer game. Due to the suddenness of his death, the possibility of exercise-induced cardiac arrest was considered, even though at the time his electrocardiogram was normal. A further inquiry showed that the patient had, in fact, symptomatic aortic valve disease. Because, until the diagnosis of aortic stenosis was made, the man had never felt unwell at any time, he was regarded as being in the so-called \"low risk group\". To our knowledge, this is the first reported fatal case of aortic stenosis in Switzerland. This case report draws attention to aortic stenosis, a disease that is insidiously progressive.",
        "label": 0
    },
    "975": {
        "output": "<EOD> Divergent Evolution of Glutathione Transferases from Dracaena Cinnabari\n\nGlutathione transferase (GST; EC 2.5.1.18) is the enzyme that is primarily responsible for the cellular detoxification of endogenous compounds to their less toxic forms or for excretion from a cell. This enzyme is also involved in other critical functions such as redox balance control, signaling, and plant growth and development. In this context, we investigated the GST pool associated with the resin of the Dracaena cinnabari plants, the resin being known for its unique curative properties in both human and animal infections. We identified eight GST proteins by searching for the GST protein signature (SSGXPXXG) in our de novo transcriptome of Dracaena cinnabari, which was assembled from high-throughput RNA sequencing data. These candidate proteins were further verified by reverse transcription polymerase chain reaction (RT-PCR). Four out of the eight GST proteins (DcGST1, DcGST2, DcGST3, and DcGST4) were phylogenetically classified into the tau-class, two into the theta-class, one into the zeta-class, and one into the omega-class, with no DcGST protein included in the mu-class, which is the most widespread class of GST enzymes. In addition, gene models of GST proteins were constructed from full-length transcripts. The deduced GST proteins contained the GST signature with a conserved N-terminus. We estimated the evolutionary rates of the GST protein in Dracaena cinnabari by comparing the maximum likelihood estimation to the molecular clock rate, as derived from the calibrated branch time. The evolutionary rates of DcGST proteins were found to be different, indicating that functional divergence among multiple GST proteins is due to adaptation to functionally diverging environments. This observation was confirmed by calculating the Ka/Ks ratios of all the DcGST protein variants as compared with the reference Arabidopsis thaliana GST protein. This study provides new knowledge on plant",
        "label": 2
    },
    "976": {
        "output": "You can check the patient's notes at the patient level below:\n\nNote:\n- You can check all the patient's information by hovering your mouse over the button, such as `Patients`, `All visits` and `Medical history`.\n- You can choose your target patient by clicking on a patient's name in the table.\n- You can get more information by clicking on the button, such as `View more...` for patients' demographic information, `Visits and History` for more history, `Visit` for more details, `Lab` for lab records, and `Clinical notes` for clinical notes.\nTo get started:\nTo get started:\n\n    #!/bin/bash\n    # Required environment variables.\n    USERNAME=username\n    APP_KEY=$USERNAME\n    APP_SECRET=password\n    PWD=$PWD\n    # Run the script by providing any path of patient note, visit note and patient history note\n    #  $ python3.7 assessment_of_eligibility_by_note.py path/to/note_of_patient/  # path is the file path\n    path='path/to/note_of_patient/'\n    note=$path+'patient-info-note-template'\n    visit=$path+'visits-note-template'\n    history=$path+'patient_history_note_template.json'\n    run_python3_command_in_current_session $path note $APP_KEY $APP_SECRET 'patient-level-exclude-0' #patient-level-exclude-0 is the patient ID in patient note.\n    run_python3_command_in_current_session $path visit $APP_KEY $APP_SECRET 'visit-level-exclude-0' patient_id is the patient ID in visit note.\n    run_python3_command_in_current_session $path history $APP_KEY $APP_SECRET 'patient_history_level-patient-exclude-3 patient_id is the patient ID in patient history note.\n    python3 assessments_of_eligibility_by_note\n```\n\n## Task description\n\nThe clinical trial is called `Intr",
        "label": 0
    },
    "977": {
        "output": "You can replace the regular expression with the following: grep ^[0-9]* \\([^0-9] \\-*\\.*)\\([^]*\\)\n\nWhat other things can go wrong? There isn't much space for new info, a couple of new rows could break things up and cause problems.\n\nA: You can try this out - its a super simple way to handle nested for loops.\nlet tt=$F4\"^(?:^([^0-9]*\\d)+)[^0-9]*\\$\";\n\necho `echo $F1 | tt;`\n\necho `echo $F1 | tt | paste`\n\n\nA: *This answer is only valid for the code in the comment, if it's slightly altered the following will be invalid.\nSo you probably want to use a string:\n$DATA#=^[0-9]*\\d+\"\n\nThe $DATA variable will then be set to this string and you can use it like this:\n$DATA#=^",
        "label": 2
    },
    "978": {
        "output": "---\n\n# Exercise 5 - Clinical Trial - PICO Question\nPlease formulate the research question as \"PICO\" type format: Patients, Intervention, Comparisons, Outcomes. Here is how it looks:\n- Patients\n- Intervention\n- Comparison\n- Outcome\nThe objective is to compare the effects of an exercise program that includes high-intensity resistance training with that of a traditional strength training program on muscular strength in patients with breast cancer undergoing chemotherapy compared to the performance of the exercise after chemotherapy.\n\n\n## 1) Patients \n\nChemo-treated breast cancer patients\n\n2) Intervention \n\nExercise program\n\n3) Comparison \n\nExperimental Group:\ntraditional strength training program\n\nControl Group:\nResistance training\n\n4) Outcome \n\nMuscular strength\n\nExamples:\n- Muscle Mass as an Outcome\n- Muscle Atrophy as an Outcome\n- Muscle Strengthening as an Intervention\n- Surgery as a Comparison\nIn this case, it should be as follows:\n- Muscle Strength as an Outcome\n- Muscle Atrophy as an Outcome\n- Muscle Strengthening as an Intervention\n- Surgery as a Comparison\n\n---\n\n# Exercise 6 - Clinical Trial - STROBE Report\nPlease prepare your exercise, in this case you have at least 20 min to prepare it. After this time, please upload here your STROBE report.\n\n**Please answer these 5 questions on the STROBE checklist**:\nQ1: \n\nThe sample size of the study was 60\u00a0subjects with an age range of 42-65 years old. It is clearly mentioned that the power analysis was performed to establish the number of subjects required for the study. However, it fails to give enough information on the basis on which the 60\u00a0subjects were chosen.\n\nQ2: \n\nThe inclusion criteria were patients with the age range of 42-65 years old, the disease duration was over 5\u00a0years for the control group, and the disease duration was under 5\u00a0years for the experimental group. It fails to give enough information",
        "label": 0
    },
    "979": {
        "output": "##[/STOP] Clinical Trial Note\n\n##[START] Eligibility Report\nThe task of determining a patient's eligibility for clinical trials is called eligibility assessment or, more simply, eligibility screening. Once a clinical trial has been registered at the trial-level, a medical practitioners can access Trial-level eligibility information on the trial page and begin the eligibility report by clicking the button `Eligibility` in the toolbar. \n\nThe eligibility report has three sub-sections. The top section displays the trial's clinical characteristics that are important to the assessment of eligibility. For the given trial, the trial-level eligibility was found to be `not relevant` because the patient does not have sufficient information to qualify for it. The information about the disease and the exclusion and inclusion criteria is in the middle section. Detailed patient note and Trial-level eligibility information are provided in the bottom section. \n\n##[END] Eligibility Report\n\n##[START] Eligibility Determination\nWith patient and clinical trial information, you can compare it with the eligibility information of the trial. \n\n\n[ /START] Patient's Eligibility Report \n\n### [START] Eligibility Report  --  Eligible Patient Note\n\n[ /START] Patient's Eligibility Report \n\n\n### [START] Patient's EligibilityReport --  Ineligible Patient Note\n\n[ /START] Patient's Eligibility Report \n\n[ /START] Patient's Eligibility Report \n\n### [START] Patient's Eligibility Report\n--  Not Relevant Patient Note\n\n\n\n<EOD> Effects of 24-Hour Dietary and Exercise Control Versus 24-Hour Dietary Control on Insulin Signaling and Blood Glucose Control in Adults\n\n [bib_ref]  Physiological effects of long-term sleep deprivation in rats, Gaudilli\u00e8re [/bib_ref]  \n\n## Methode\nEs wurden zw\u00f6lf gesunde probandenten nach einer 3-st\u00fcndigen Vigilanz durch die Folgemittelung unters",
        "label": 1
    },
    "980": {
        "output": "## Exercise\n1.\nReproduce the steps 2.-6. of the problem in Section \\Instalation using Python 3. Export the results of your work again in a file to be saved with name: Exercise_Clinical_Trial_Eligibility` in a folder that you created just for the exercise. Make sure the file name is unique.\n\n## 2.\nLook at the file \\Exercise_16_Challenge.json, which contains the data for the exercise.\n\n## 3.\nOpen your newly created file using Python and verify that the data is correctly printed.\n\n## 4.\nAsk the instructor for feedback on how the solution you have uploaded to the platform is compared to the instructor's solution.\n\n## 5.\nFind the answers for all the steps given in the exercise manually.\n\n## 6.\nAnswer the following questions. \na. In which steps did you make errors?\n\n## Evaluation\n\n##\\Instalation\n\n\\Section Objectives\n### This section contains the assessment of the exercise.\n### The questions include:\n\\todo \n- What changes were made by fixing the errors?\n\n##[INST] Examining the changes to the code and the file of the exercise.\n\\todo \n- What is the outcome of the exercise?\n\n## Assessing the outcomes \n\n\n\n\\Section Results\nIn the assessment of the solution, you were scored by the following points. \n\\todo\n\n## Score\n\n## [INST] Answering 1, 2 and 3 below.\nYour solution is good; please edit slightly as there is little difference in the overall outcome of the exercise, but a higher score can be obtained. You scored a total of 4 out of 5\\todo The result of the evaluation can be expressed in points. The results should be expressed so that the grades are within the range of 2.5 to 4, taking into consideration the number of the sub-assignment.\n\n## Summary and Conclusion \nThis document is part of the \\Clinical Decision Support\\ module, which aims at teaching students the fundamentals of clinical decision support and clinical trial eligibility assessment",
        "label": 0
    },
    "981": {
        "output": "## Good luck.[EN-T]\n27. [QUESTION] There are two methods for detecting abnormal conditions: 1) direct assessment and 2) inference from available information. While most physicians use inference because it is both faster and more convenient, direct assessment is sometimes necessary because data are not available to make inferences. When conducting inference, one must formulate a decision framework that determines the probability that a conclusion is either true or false. This framework may be based on the Bayesian decision theory, the frequentist decision theory, or some hybrid of both. For example, many clinical decision-support studies focus on the frequentist decision theory, sometimes referred to as the \"one-step\" approach. \n\n28. [QUESTION] The risk a doctor gives to a patient is a probability value. The clinician should not merely inform a patient about the risk but also give an approximation of probability. Physicians can express the probability of the occurrence of some event, such as death or recovery, based on the following probabilities:\n\n## a) the probability of the event occurring, b) the probability of it not occurring, c) the probability of the diagnosis being correct or incorrect, and d) the probability of the treatment being beneficial or harmful. \n\n29. [QUESTION] Now consider a study of the accuracy of a new test, where the outcome is  disease. Suppose the new test is being studied to complement an existing test whose probability of disease is 8% when an individual is diagnosed as disease. The test-is-positive, test-is-abnormal, and test-is-diagnostic, p-values were .03, .20, and . and a new test is introduced.\n\n## 16\n\n32. [QUESTION] A diagnostic test accuracy study was planned to enrol a total of 100 participants: 50 participants with and 50 participants without .\n\n\nFor this study, the accuracy of the index tests was assessed against the reference standard, and the study has shown that the specificity of the index and 85% and the sensitivity of the index test and 75%. The data was then re-analysed using the sample size calculation formula of to obtain the optimal sample size of 100 for the above-specificity and -sens",
        "label": 0
    },
    "982": {
        "output": "<div className=\"source\">\"\n  <textarea aria-label=\"CodeSnippet 2\" className=\"code-cell\" name=\"code\" id=\"inputCodeTextarea-0\">\n    <!doctype html>\n    <html class=\"no-js\" lang=\"\">\n      <head>\n        <meta name=\"generator\" value=\"pragmatics/react-app-example\">\n        <meta property=\"og:title\" content=\"Example App - Skeleton\">\n        <meta property=\"og:description\" content=\"It's just the shell, folks - use it for development.\">\n        <meta property=\"og:site_name\" content=\"pragmatics\">\n        <meta property=\"og:url\" content=\"http://pragmatics.github.io/react-app-example\">\n        <meta  property=\"og:type\" content=\"website\">\n        <meta property=\"og:video\" content=\"\">\n        <meta property=\"og:image\" content=\"\">\n        <meta property=\"og:image:alt\" content=\"\">\n        <meta property=\"og:translator\" content=\"\">\n        <meta property=\"og:creator\" content=\"\">\n        <meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0\">\n        <script src=\"https://cdnjs.cloudflare.com/ajax/libs/jquery/2.1.1/jquery.min.js\"></script>\n\n        <title>Example App - Skeleton</title>\n        <link href=\"Sass/Skeleton.css\" rel=\"stylesheet\" type=\"text/css\" />\n        <script src=\"Requirements.js\"></script>\n        <script src=\"main.js\"></script>\n      </head>\n      <body>\n\n        <div id=\"app\">\n          <header>\n            <input type=\"checkbox\" id=\"check1\" />\n            <input type=\"checkbox\" id=\"check2\" />\n            <h2>Page head</h2>\n          </header>\n\n          <nav>\n            <ul>\n              <li><a href=\"#\"><span>1st button</span></a></li>\n              <li><span>4</span>\n              <ul",
        "label": 0
    },
    "983": {
        "output": "# <a id=\"Eligibility\"></a> [Eligibility:\nPatient data set][57]\nPatient data\n\n1) Patient_data: `patient_data`. A data frame of patients participating in the trial.\nEach row represents 1 patient. For each patient, there will be at least 1 unique ID, and the value of `age` and `gender`.\nAlso there will be 1 `patient_note` for each patient (it is not compulsory to record a `patient_note` for each patient). Each row represents the patient note for 1 patient, in which you should  write as much clinical data as possible, even if not indicated in the figure below. Clinical data not indicated in the table below is allowed.\n\n## ID (unique identifier)\n- `age`: age at diagnosis\n- `gender`: `M` for male, `F` for female, `N/A` stands for `not available`,\n- `patient_note:`  a link to a clinical note, `NA` stands for `note not provided`.\n\n2) `clinical_trial`\n- `id`: clinical trial identifier\n- `title`: clinical trial title\n- `organization`\n- `country`: Country where the clinical trial is based.\n\n## ID (unique identifier)\n- `id`: identifier for the clinical trial\n- `title`: the title of the clinical trial\n\n\n###  (Example data for 1 trial.  Note, this is to be adapted)\n```\n---\nEligibility: 2)\n- patient_note:    \n  - clinicaltrial patient 2 66 ------ male normal 10\n...\n```\n\nThe first patient:\n```\n---\nAge:        2   (i.e. year)\nGender:     male\npatient_note: ...\n```\n## What will happen when we run this code?  \nBroadly speaking, a `caret` function will be called to calculate the scales (e.g., 0: Excluded, 1: Not relevant, 2: Eligible). For each patient, clinical trial will predict the score (scale) by a specific model.\n\n# <a id=\"",
        "label": 1
    },
    "984": {
        "output": "## Expected outcomes\nHere is an example of a snippet of a data frame corresponding to Patient Note. To read information of this data frame, see `describe` function. \n\n    Patient Note\n    A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active.\n    The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\n    The patient reported no use of lipid-lowering medications.\n    Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n[Source: 1]\n\nThis is an example of a snippet of a data frame corresponding to Clinical Trial (as of September 13, 2020):",
        "label": 0
    },
    "985": {
        "output": "In [INST], please always replace with a value (e.g., LDL-C or ECG result) or with `0.02` if you want to provide an error message, e.g., `Trial-level Eligibility: 0.02)`.\n\n\n\n\n--\n\n---Your submission has been rated:\n\n| Q1 | 1  | \n| Q2 | 0  | \n| Q3 | 1  | \n| Q4 | 2  | \n| Q5 | 1  | \n---\n\n\n| Q1 | 1\n| Q2 | 1\n| Q3 | 2\n| Q4 | 3\n| Q5 | 3\n|\n\n### 3: Reviewing patients' clinical notes\n\nIn this mini-assignment, you will analyze the following patient clinical notes and determine their eligibility for a clinical trial.\n\nHere is the patient's clinical note information:\nGender: Female\nAge: 35;\nLDL-C: 130;\nGFR:100;\nALT: 15;\nCrCl: 90;\nGGT: 5\nHbA1c(%): 4.5;\nFBS(mg/dl): 100;\nBMI: 29.\n\nNow, using the same patient's clinical notes and the clinical trial information that you learned in the first mini-assignment, you will make trial-level eligibility for the clinical trial.\n\n- 1) Enter the patient's clinical notes as described in the previous question into the text area, in the textbox titled `Clinical_note_for_Evaluation`.[INST]\nThe clinical trial information is already included in the textbox `Trial_Evaluation`.\n\n- 2) Enter `Trial-level Eligibility: Evaluated (Trial-level Eligibility) 3) Trial-Level Eligibility: The patient should have baseline LDL-C above 125 mg/dl. (Trial-level Eligibility) 4) Trial-Level Eligibility: The patient should present with d",
        "label": 0
    },
    "986": {
        "output": "## \u60a8\u662f\u4e00\u540d\u533b\u52a1\u52a9\u624b\uff0c\u4f60\u9700\u8981\u6bd4\u8f83\u4e00\u60a3\u8005\u8bca\u7597\u767b\u8bb0\u548c\u4e34\u5e8a\u8bd5\u9a8c\u7684\u5224\u65ad\u8d44\u6599\uff0c\u5224\u65ad\u662f\u5426\u5408\u9002\u7684\u3002\u4f9d\u636e\u60a3\u8005\u75be\u75c5\u7c7b\u578b\u548c\u9636\u6bb5\u548c\u5176\u4ed6\u6cbb\u7597\u8fc7\u7a0b\uff0c\u4ee5\u6b64\u5efa\u7acb\u4e34\u5e8a\u8bd5\u9a8c\u7684\u57fa\u4e8e\u53c2\u52a0\u6807\u51c6\uff3bINST]\n\n\u4e00\u4e2a\u4e34\u5e8a\u8bd5\u9a8c\u7b56\u7565\u7684\u65e8\u662f\u6dcb\u5df4\u7624\u60a3\u8005\u7684\u9884\u540e\uff3bINST]\u3002\n\n\u4f30\u8ba1\u83b7\u5f97\u6700\u7ec8\u83b7\u76ca\u7684\u60a3\u8005\u6570\u91cf\u3002\u60a3\u8005\u4ece\u4e00\u4f4d\u4e34\u5e8a\u5b9e\u9a8c\u533b\u751f\u3001 \u591a\u4e2a\u4e34\u5e8a\u8bd5\u9a8c\u52a9\u624b\u4ee5\u53ca\u591a\u4e2a\u4e34\u5e8a\u8bd5\u9a8c\u8fd0\u4f5c\u4eba\u5458\u7684\u53c2\u4e0e\u521b\u9020\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u3002\u51b3\u5b9a\u7684\u53c2\u4e0e\u53c2\u6570\u7684\u6570\u91cf\u548c\u53c2\u4e0e\u8d38\u6613\u6570\u91cf\u51b3\u5b9a\u4e86\u4e34\u5e8a\u8bd5\u9a8c\u662f\u5426\u6210\u529f\u3002\u8be5\u51b3\u5b9a\u7684\u4f5c\u7528\u5728\u5728\u83b7\u53d6\u548c\u6536\u96c6\u4e34\u5e8a\u6307\u6807\u6570\u91cf\u4ee5\u53ca\u5904\u7406\u4e34\u5e8a\u95ee\u9898\u6570\u91cf\u4e0a\u3002\n\n\n\u4f60\u662f\u4e00\u4f4d\u533b\u52a1\u52a9\u624b\u7684\u5de5\u4f5c\u662f\u6bd4\u8f83\u60a3\u8005\u7684\u75c5\u60c5\u548c\u4e34\u5e8a\u8bd5\u9a8c\u8981\u6c42\uff0c\u5224\u65ad\u662f\u5426\u7b26\u5408\u3002\u4f60\u4f7f\u7528\u7684\u662f\u591a\u79cd\u4e0d\u540c\u7684\u6570\u636e\u4f9d\u636e\u8fd9\u79cd\u5e72\u9810\uff0c\u5305\u62ec\u75c5\u60c5\u7684\u57fa\u7840\u60c5\u51b5\uff0c\u5305\u62ec\u75c5\u4eba\u7684\u8eab\u4f53\u7279\u5f81\uff0c\u4eba\u4f53\u7684\u5065\u5eb7\u72b6\u51b5\uff0c\u548c\u7624\u5f62\u6001\u7684\u60c5\u51b5\u3002\n\n\n\u8fd9\u4e2a\u60a3\u8005\u7684\u6587\u732e\uff1a\n\n46 \u5c81\u7684\u7537\u6027\u4ee5",
        "label": 1
    },
    "987": {
        "output": "[EXERCISE]\n\n[INSERT]\n\n### **Case-level eligibility**\n[INSERT]\n\n### **Patient-level eligibility**\n[INSERT]\n\n#### **11.2.1.** Exclusion criteria\n[EXERCISE]\n\n[INSERT]\n\n### **Clinical Notes**\n[EXERCISE]\n\nThe following list refers to the clinical notes in the patient history. To read more about it, see the following link: https://bookdown.rdkit.org/master/sophtraderio/chapter_2/index.html#clinical-notes).\n\n\n[INSERT]\n\n#### **11.3.** Patients' Information\n[EXERCISE]\n\nThe following list refers to the patients' information in the patient history. To read more about it, see the following link: https://bookdown.rdkit.org/master/sophtraderio/chapter_2/index.html#patients-information).\n\n\n[INSERT]\n\n### **Surgical procedure**\n[EXERCISE]\n\nThe following list refers to the surgical procedure conducted on a patient. To read more about it, see the following link: https://bookdown.rdkit.org/master/sophtraderio/chapter_3/index.html).\n\n\n[INSERT]\n\n#### **11.4.** Investigator's Assessment\n[EXERCISE]\nTo determine how many patients have a target event (exposure of interest, adverse events, or both) that occurred during a given time period, use i3 for the Patients screened, i2 for the Patients included, i3 for the Patients randomised, i2 for the Patients randomised, i3 for the Patients analyzed, and/or i1 for the patients.\n\n\n[INSERT]\n\n\n# **11.5.** Saving 3. Data\n\nTo save to Excel sheet or S3 file, please use i4,\ni5 is to save to an interactive report (HTML format),\ni6 is to save PDF (either on patient level or by patient),\nand i7 is to save a CSV",
        "label": 0
    },
    "988": {
        "output": "### Examples.\n    The following table shows some examples for clinical trial notes:\n     | Note\n     | 0) Excluded\n     | 1) Not relevant\n     | 2) Eligible\n    -  Note:\n        1) Note:\n          0) Excluded\n           0) Excluded\n<EOD> Fatigue in patients with chronic kidney disease on dialysis\n\n\n\n# Introduction\nC hronic kidney disease (CKD) is a multifactorial disease characterized with progressive decreases in kidney function with significant impact in both patients and society. [bib_ref]  Clinical manifestation of nephrological interest. Part I. Chronic kidney disease (chronic kidney..., Moczulska [/bib_ref]  The major cause of mortality among CKD patients is cardiovascular complication, which is due to atherosclerotic, vascular disease. [bib_ref]  Cardiovascular disease in chronic kidney disease. A clinical Update from Kidney Early..., Wang [/bib_ref]  Fatigue is an averse and distressful sensation that a person has subjectively. [bib_ref]  Fatigue assessment in CKD: Beyond the clinical settings, Nixon [/bib_ref]  There is a multifactorial etiology of fatigue in CKD. Some factors affect the fatigue level including physical problems, uremia, anemia, hyperhomocysteinemia, the disturbed sleep and poor quality diet. [bib_ref]  An integrative review of fatigue impacting patients with chronic kidney disease undergoing..., Bressington [/bib_ref]  It is estimated that 20-60% of chronic dialysis and CKD patients complaint from fatigue.According to a nationwide study, in 2012, prevalence of fatigue among patients on chronic dialysis was reported as 29%, which was also found in patients with stage 5 CKD (18%). [bib_ref]  Fatigue in patients with stage 5 chronic kidney disease: Results from a..., Cohen [/bib_ref]  The presence of fatigue among CKD patients has multiple negative effects including decreases in quality of life. Some studies reported an association between a low quality diet, increased serum homocysteine",
        "label": 0
    },
    "989": {
        "output": "[bib_ref]  Learning to predict clinical trial eligibility in pediatric oncology using electronic health..., Zhang [/bib_ref]  \n 7.1.5. [INST] As with the previous three parts, you should use `LimeSurvey` as the survey tool. The variables are the same, except that you should include `Trial-level eligibility` in the fifth field. If you want to run this survey in your own server, you should add only the fifth field, so that LimeSurvey can process the form. Please contact us if you want to run this survey in your own server. You can copy the survey files in the subfolder `Surveys` in the dataset `surveys` by using the `data/surveys` directory or `sub` command in Tmux on Unix-like systems. The file names are `C001 (Biomarker).php`, `C002 (Drugs).php`, `C003 (Patient visit).php`, `C004 (Trial eligibility).php`, and `C005 (Clinical notes).php`. [INST]\n\nYou can now use the survey files in your hospital information system to collect patients' data.\n\n7.2. Surveys for Questionable-Reports: [INST] As with the surveys for eligibility, the variables are basically the same as described in the section 7.1.4, except that you should use the file `R001 (Questionable report).ipa` for `R001 (Questionable report)` and the file `R001 (Repeatable report).ipa` for `R002 (Repeatable report).` Instead of LimeSurvey, you should use `NHIS API REST`, as NHIS recommends. [INST]\n\nYou can now use the survey files in your hospital information system to collect patients' data.\n\n# Conclusion\nThis dataset is the largest dataset for the collection of information from hospital information systems. The dataset contains various clinical data, which helps investigators conduct clinical studies easily. Furthermore, this dataset may help researchers discover useful associations among clinical tests, findings, findings and drugs that may trigger adverse drug reactions in the future, and understand the relationship between clinical tests,",
        "label": 0
    },
    "990": {
        "output": "[[TRIAL_LEVEL_ELIGIBILITY]]<EOD> Hydrological regimes in the Tapaj\u00f3s Basin, Brazil, impacting on the structure of the lizard assemblage.\nHydrological seasonality has been related to differentiation in the communities of terrestrial organisms. The present study aims at evaluating the influence of the hydrological regimes (defined by floods, low amplitude annual flow fluctuations and dry periods), with the structure of an assemblage of lizards in the floodplain of the upper Tapaj\u00f3s River (MT). Three transects crossing the floodplain and parallel to the river were sampled monthly during the wet season and bimonthly in the dry season from January 1997 to February 1998. The structure of the lizard assemblages was estimated using a multivariate analysis of distributional patterns. In the wet and dry seasons, there were 76 and 64 lizard species, respectively. Species richness was high in all seasons and the assemblages were dominated by anurans, snakes and amphisbaenians (most of them diurnally active or nocturnally active). During the wet season, the species of the dry season were replaced by seasonal species. Seasonality was related with the assemblage structure of lizards in the floodplain of the upper Tapaj\u00f3s River.<EOD> .\nThe aim of this retrospective analysis is to evaluate the role of neuropsychiatric features and personality traits in the pathogenesis of recurrent depressive disorder. We studied 42 patients (Female 36, age 40.29 +/- 10.27, mean age at depressive episode onset 35.6 +/- 10.17, average age at beginning of study 45.55 +/- 10.38) and analyzed their personal histories using a structured telephone interview. 17 patients, had a bipolar, mixed disorder, 14 had personality disorder, and 7 patients had depression on remission. We found a significant association between neuropsychiatric features and the onset of depression with high frequency of panic attacks (p = 0.0",
        "label": 0
    },
    "991": {
        "output": "![TEST_2.png][TEST_2]\n\n# [Test 2.2](http://data.jmc.edu/view/1g504iQ2cVY) \n## [TEST 2.2](http://data.jmc.edu/view/1g504iQ2cVY)\n[TEST 2.2]\n\nLet's think step by step. \n\n1. [Prepare](https://data.jmc.edu/view/57yH79DwFdM)\n    1. Add a new notebook: `new_test`.\n    2. [Rerun Test 1.1](https://data.jmc.edu/view/wMjVg1k3Xu3) to complete the patient's data.\n       1. Create the new patient data.\n       2. Update the new data every 6 months.\n       3. Make sure that the patient's data file is updated before you rerun the notebook, otherwise you will get incorrect output results.\n        \n       4. You should be using `rclone` to synch your files in Google Drive with your own computer so that you do not have to be online all the time in Databrary. We will demonstrate how to install it when you run the notebook and you can download the instructions [here](https://data.jmc.edu/view/wUr0zTj1N0i) for future reference.\n\n    3. Add the following variables to the notebook you've created in the previous step so that you can retrieve the patient's data later:\n       1. `jason_path` stores the Google Drive path to the patient's data.\n       2. `jason_user` stores the username for the Google Drive.\n       3. `jason_password` holds the password to the same Google Drive.\n        \n    4. [Rerun](https://data.jmc.edu/view/6uLj5bWCp9R) this notebook by copying the Python code in the notebook and paste it into a new notebook to execute it.\n       1. The input data will be the [TEST1.xlsx](https://data.jmc",
        "label": 0
    },
    "992": {
        "output": "Your duty is to provide the correct answer from the given questions. The correct answer to this question is \"Diabetes Mellitus and Hyperlipidemia\". Diabetes and hyperlipidemia are the causes of micro and macro-angiopathy, which disrupt the blood supply. These disru",
        "label": 1
    },
    "993": {
        "output": "Your task is to assign the trial and patient-level eligibility to the patient note.\n\n## The inclusion criteria to be met at the trial level.\nAt least one of the following:\nAge \u2265 18 years\nInformed written consent\nAt least one major or two minor bleeding risk criteria of Academic Research Consortium (ARC)\nMajor criteria:\nLong-term oral anticoagulation\nSevere or end stage chronic kidney disease (CKD) (estimated glomerular - filtration rate [eGFR] <30 ml/min)\nHemoglobin <110 g/l\nSpont",
        "label": 0
    },
    "994": {
        "output": "[EXERCIS]\nTo summarize these three steps:\n1. Find all factors that will apply the Patient: all columns of the data set except \"age\" and \"risk\".\n2. Calculate the sum of rows that each age corresponds to (the number of the risk) and assign the numbers to the columns of the data set as columns_num.\n3. Compare age_num/risk_num with the patient's data set, and make decisions of the patient.\n\n```\ndef assessment(patient):\n    inclusion_data = {}\n    print(f'[INFO] Eligibility of Inclusion Criteria: {len(patient.risk)/len(patient.age)}')\n    #find factors from patient\n    for line in patient.risk:\n        inclusion_data[line.value_index] = patient[line.value_index]\n    #find factors from data.ini\n    for i in range(len(data.ini)):\n        if i not in data.ini.columns_num:\n            data.ini[data.ini.columns_num[i]].value_index = data.ini.rows[i].index\n    #update data\n    data.ini = data.ini\n    for item in inclusion_data:    \n        if include_criterion_num(item, patient):\n            patient['age']\n            pass\n    return ''\n\ndef included_num():\n    print(f'[INFO] This patient has the inclusion criteria: {data['age'] = included_criteria.value_index  == data[\"age\"].iloc[0]}')\n    #print(\"age:\", data.ini.columns_num.value_index)\n    included_criteria = (Patient[\"Age\"] == data.ini.columns_num.value_index)\n    return included_criteria\n```<EOD> The pharmacokinetics of diphenylhydantoin in the rat: determining the mechanism of prolonged anticonvulsant activity.\nThe pharmacokinetics of diphenylhydantoin (DPH) and its metabolites, diphenylhydantoin-13C-O-sulfate (DPHS), and diphenylhydantoin-",
        "label": 0
    },
    "995": {
        "output": "## Suggested approach\n\nDefining triallevel eligibility is complex.  There are many factors, e.g., age, race, sex, toxicity, prior or concomitant immunosupressive therapy, and many are trial dependent, e.g., if a trial has prior exposure to anti-CD20 or steroids in the eligibility criteria, it should be checked with the subject and considered in the subject's overall assessment.\n\n## Eligibility criteria and its use in SAS programming\n\nThe SAS code of patient's trial-level eligibility is as follows:\n\n*SUBROUTINE patient_level_ELIG ($RETSTREAM, $RETCLIENT, &$RETPATIENT, &$RETTHER, &$RETCLIENTNOTE)\nPROC ELIG ;\n  AGE_20to44 = $RETSTREAM;\n  ELKG$ = $RETSTREAM;\n  HASHELPER_20to44 = 1;\n  ELK$ = $RETSTREAM;\n  HASHELPER_20to44 = 2;\n  ELK20to44%$ = $RETSTREAM;\n  HASHELPER_20to44 = 3;\n  ELK20to44% = $RETSTREAM;\n  HASHELPER_20to44= 4 ;\n  ELK20to44%$ = $RETSTREAM;\n  HASHELPER_20to44 = 5;\n  ELK20to44% = $RETSTREAM;\n  HASHELPER_20to44 = 6;\n  ELK20to44%$ = $RETSTREAM;\n  HASHELPER_20to44 = 7;\n  ELK20to44% = $RETSTREAM;\n  HASHELPER_20to44 = 8;\n  ELK20to44%$ = $RETSTREAM;\n  H",
        "label": 2
    },
    "996": {
        "output": "## Good Luck!\nYou are here:\n\n/inst/0163-6282-6958/06-2/0/15/html/exercises/e_assessing_eligibility/e_assessing_eligibility.html\n\n* * *\n\n## Questions?\n\n### Problems?\nIf you have any problems, please send your questions (no confidential information in the question please) to the Instructor at [email protected] via email. You are highly suggested to send screenshots of your screen (in PNG format) for better understanding.\n\n### Support?\nIf you could not figure out the solution by yourself, or need help while doing the exercises, please make an appointment at [email protected] via email, and visit the [email protected] lab (No. 310) for online assistance during Mon-Fri: 09:30AM-12:00PM.\n\n### Contact Info?\nOffice Phone: +86 531 8896 6390\nLab Phone: +86 08512963464\nInstructor: Lijuan [email protected]\n\n### Further Information?\nInformation about the Course Instructor:\n\n### Grading\nYour grading depends on the following:\n1. The accuracy of output - your answer must be exactly what is required in the question\n2. The logic behind your solution - the solution you provide would be marked as 'Correct' only when the logic inside is understandable\nExcept solution that is invalid, your solution would be marked as 'Correct' when:\n\u2460 You have written all the code inside the block `for` loop\n\u2461 You have written the corresponding code inside the block `if ` statement\n\u2462 You have used the correct control flow from the question\n\u2463 Your solution would be marked as 'Incomplete' when:\n\u2460 You did not write the expected statement or control flow correctly\nExamples: writing the if statement code to the wrong block or writing `for` statement code in the wrong block or using `if /else` statement without writing the if /else code under corresponding conditions.\n\n### Grading Rub",
        "label": 1
    },
    "997": {
        "output": "## Learning Material\n-  - - A patient note\n-  - - A clinical trial\n- Data types\n- Data Types\n\n## Objective\nCheck the patient's eligibility and output the trial-level eligibility. \n\n## Instructions\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility for the patient on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated",
        "label": 0
    },
    "998": {
        "output": "10. Let's continue to the next trial. Trial-level eligibility 1: 2) Eligible; Trial-level eligibility 2: 2) Eligible. Next trial: 1) Excluded \n![A trial-level result with a patient note]\n[INST] Hello. This is the second trial. You are a helpful assistant to the clinical trial recruitment. Your task is to compare patient data with a given clinical trial so as to decide eligibility for participation. For this trial, we have one clinical trial for atherosclerosis and vascular calcification to assess the effects of different interventions for atherosclerosis and vascular calcification. For eligibility, you'll need to check a patient's records and make a binary decision based on the clinical trial's inclusion and exclusion criteria. \n\n[PRESENT] There have been several studies that investigated the effect of vitamin K2 on calcification of blood vessels. Vitamin K2 is necessary for bone strength, and when we have vitamin K deficiency, arterial calcification is accelerated. So, we made two different groups: vitamin D group and vitamin K2 group.\n\nTherefore, in this study, we will compare the effects of vitamin D and vitamin K2 supplementation on the progression of atherosclerosis at a 1-year follow-up. And these are the inclusion criteria:\n\n1. Asymptomatic Intracranial Stenosis patients\n2. Able to perform cognitive function tests.\n\n\n\n[PRESENT] And these are the exclusion criteria:\n\n1. History of stroke, coronary heart disease, myocardial infarction, peripheral artery disease, cerebral hemorrhage, and carotid artery surgery history and severe dyslipidemia.\n\nIf an exclusion criterion is identified for any reason, the study may be terminated for that reason, and other clinical studies may be performed instead. Exclusion criteria:\n1. History of stroke, coronary heart disease, myocardial infarction, peripheral arterial disease, cerebral hemorrhage, and carotid ar",
        "label": 2
    },
    "999": {
        "output": "<EOD> Focused ultrasound enhances delivery of therapeutics in conjunction with immunotherapy\nCell-penetrating peptides (CPPs) are widely used as non-invasive alternatives to conventional drugs. CPP-drug delivery is limited by insufficient blood-brain-barrier crossing. Here, we show that focused ultrasound (FUS) mediated cavitation significantly increases CPP-conjugated chemotherapy delivery into the CNS of mice. FUS was applied to the skull-base or cranium contralateral to tumors to create blood-brain barrier (BBB) disruption 30 min prior to intravenous CPP-doxorubicin (Dox) injection in 4T1 breast cancer and GL261 glioma mouse models. 9T4 CPP, but not the control 6TG10, caused a statistically significant reduction in tumor growth with Dox exposure in vivo. FUS enhanced BBB disruption to enable CPP-Dox entry into the mice's brain tumors. 9T4 CPP was also detected in the brains of healthy male and female mice. Using 3D ultrasound imaging, we examined FUS-mediated brain temperature elevation, BBB permeabilization, and the dose of Dox recovered from brain tumors when a 165 mg/kg dose of Dox was used. BBB disruption, which occurred 10 min after sonication, correlated with the presence of blood-derived cells in the tumor 24 h later. Sonication decreased brain temperature by an average of 2.9\u00b0C within a 5 mm radius from the sonication focus, accompanied by increased tumor temperature; these temperatures gradually recovered to normal values within 30 min after sonication. The CPP-Dox dose and local BBB disruption at 30 min post-sonication were both greater in the group receiving 9T4 CPP injections compared to the group receiving 6TG10 CPP injections. The group receiving 9T4 CPPs and FUS treatments with the highest doses of CPP-Dox had the highest rate of surv",
        "label": 0
    },
    "1000": {
        "output": "![INST] `Trial-level eligibility` should be a list of numbers such as 0, 1, and 2; for example, for a trial with 3-point assessment eligibility, 0) Excluded: 1) Not Relevant: 2) Eligible. You can select the appropriate number from a dropdown list.\n![INST] Here is a sample command output. The output is a table. The columns are `Number`, `Description`, `Default` and `Included` in this study. `Number` and `Description` are self-explanatory. `Default` is the default if the patient's data is empty in some cell. `Included` means the column value included in the assessment of trial-level eligibility. Here are sample commands and their results.\nCommand Example Output\nselect-trial-level-eligibles -i '{\"PatientAge\": 10.0, \"Gender\": null, \"PatientWeight\": null, \"PatientSmoke\": null, \"PatientAlcohol\": null, \"PatientIllegalDrug\": false, \"PatientMedicalHistory\": {\"Hypertension\": null, \"Diabetes\": null, \"Heart\": null, \"Liver\": null, \"PancreasDisease\": null, \"Stroke\": null, \"Cance r\": null, \"Pulmo nary\": null, \"G rinding: null, \"C olorectal\": null, \"Kidney\": null, \"Thy roid\": null, \"P regnancy\": null, \"E ndometri als\": null }, \"Procedure\": {\"Performed\": null, \"Onset\": null, \"Diagnosis\": null, \"Laterality\": null, \"Type\": null, \"Reason\": null, \"Reason2\": null, \"Degree\": null }, \"DiseaseCriteria\": {\"Diseasetype\": \"nose\", \"Finding\": \"Colds\", \"Symptom\": \"Fever\", \"SymptomID\": null, \"Symptombasedon\": null, \"Symptom-basedon2\": null, \"Symptom-surgery\": null, \"Symptom-basedone\": null, \"Symptom-basedon2\": null, \"",
        "label": 0
    }
}